{"50a11dd8962db94c572aa008f73a229b77b2edea": [["Central Message: Pandemic planning must include an objective triage of our patients needs with reallocation of resources, while acknowledging the limits of available data, and subsequent predictive models.", [["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83]]]], "PMC6818116": [["IntroductionPorcine reproductive and respiratory syndrome virus (PRRSV), a severe pathogen belonging to the Arteriviridae family that affects the global swine industry, is a positive-strand RNA virus with a genome of approximately 15 kb [1].", [["IntroductionPorcine reproductive and respiratory syndrome", "DISEASE", 0, 57], ["IntroductionPorcine reproductive and respiratory syndrome virus", "ORGANISM", 0, 63], ["PRRSV", "ORGANISM", 65, 70], ["PRRSV", "SPECIES", 65, 70], ["swine", "SPECIES", 153, 158], ["PRRSV", "SPECIES", 65, 70], ["swine", "SPECIES", 153, 158], ["IntroductionPorcine reproductive", "PROBLEM", 0, 32], ["respiratory syndrome virus", "PROBLEM", 37, 63], ["a severe pathogen", "PROBLEM", 73, 90], ["a positive-strand RNA virus", "PROBLEM", 172, 199], ["respiratory syndrome", "OBSERVATION", 37, 57], ["severe", "OBSERVATION_MODIFIER", 75, 81]]], ["The genomic RNA encodes RNA replicases (ORF1a and ORF1b), glycoproteins GP 2 to GP 5, the integral membrane protein M, and the nucleocapsid protein N (ORFs 2\u20137) [1].", [["ORF1a", "GENE_OR_GENE_PRODUCT", 40, 45], ["ORF1b", "GENE_OR_GENE_PRODUCT", 50, 55], ["glycoproteins GP 2", "GENE_OR_GENE_PRODUCT", 58, 76], ["GP 5", "GENE_OR_GENE_PRODUCT", 80, 84], ["integral membrane protein M", "GENE_OR_GENE_PRODUCT", 90, 117], ["nucleocapsid protein N (ORFs 2\u20137)", "GENE_OR_GENE_PRODUCT", 127, 160], ["genomic RNA", "RNA", 4, 15], ["RNA replicases", "PROTEIN", 24, 38], ["ORF1a", "PROTEIN", 40, 45], ["ORF1b", "PROTEIN", 50, 55], ["glycoproteins GP 2", "PROTEIN", 58, 76], ["GP 5", "PROTEIN", 80, 84], ["integral membrane protein M", "PROTEIN", 90, 117], ["nucleocapsid protein N", "PROTEIN", 127, 149], ["ORFs 2\u20137", "PROTEIN", 151, 159], ["RNA replicases", "TEST", 24, 38], ["ORF1a", "TEST", 40, 45], ["glycoproteins GP", "TEST", 58, 74], ["GP", "TEST", 80, 82], ["the integral membrane protein M", "TEST", 86, 117], ["the nucleocapsid protein N", "TEST", 123, 149], ["ORFs", "TEST", 151, 155], ["genomic RNA", "OBSERVATION", 4, 15]]], ["ORFs 2\u20137 have been extensively investigated [1\u20133], and an increasing number of studies have focused on ORF1a and ORF1b, which encode polyproteins that are processed into smaller protein products designated as nonstructural proteins (Nsps).", [["2\u20137", "GENE_OR_GENE_PRODUCT", 5, 8], ["ORF1a", "GENE_OR_GENE_PRODUCT", 103, 108], ["ORF1b", "GENE_OR_GENE_PRODUCT", 113, 118], ["Nsps", "GENE_OR_GENE_PRODUCT", 233, 237], ["ORFs 2\u20137", "DNA", 0, 8], ["ORF1a", "PROTEIN", 103, 108], ["ORF1b", "PROTEIN", 113, 118], ["protein products", "PROTEIN", 178, 194], ["nonstructural proteins", "PROTEIN", 209, 231], ["Nsps", "PROTEIN", 233, 237], ["ORFs", "TEST", 0, 4], ["ORF1a", "TREATMENT", 103, 108], ["ORF1b", "TREATMENT", 113, 118], ["encode polyproteins", "PROBLEM", 126, 145], ["smaller protein products", "TREATMENT", 170, 194]]], ["The roles for most Nsps in PRRSV have been explored to date, and Nsp1\u03b1/\u03b2, Nsp2, Nsp4 and Nsp11 have been implicated in modulating host immune responses to PRRSV infection [4\u20139].", [["PRRSV infection", "DISEASE", 155, 170], ["Nsps", "GENE_OR_GENE_PRODUCT", 19, 23], ["PRRSV", "ORGANISM", 27, 32], ["Nsp1\u03b1", "GENE_OR_GENE_PRODUCT", 65, 70], ["\u03b2", "GENE_OR_GENE_PRODUCT", 71, 72], ["Nsp2", "GENE_OR_GENE_PRODUCT", 74, 78], ["Nsp4", "GENE_OR_GENE_PRODUCT", 80, 84], ["Nsp11", "GENE_OR_GENE_PRODUCT", 89, 94], ["PRRSV", "ORGANISM", 155, 160], ["Nsps", "PROTEIN", 19, 23], ["Nsp1\u03b1", "PROTEIN", 65, 70], ["\u03b2", "PROTEIN", 71, 72], ["Nsp2", "PROTEIN", 74, 78], ["Nsp4", "PROTEIN", 80, 84], ["Nsp11", "PROTEIN", 89, 94], ["PRRSV", "SPECIES", 27, 32], ["PRRSV", "SPECIES", 27, 32], ["PRRSV", "SPECIES", 155, 160], ["most Nsps in PRRSV", "PROBLEM", 14, 32], ["Nsp1", "TEST", 65, 69], ["Nsp2", "PROBLEM", 74, 78], ["Nsp4", "PROBLEM", 80, 84], ["PRRSV infection", "PROBLEM", 155, 170]]], ["In addition, Nsp1 function is related to subgenomic mRNA synthesis regulation [10], and Nsp2 and Nsp3 are involved in inducing replication-associated membrane rearrangement [11,12].", [["membrane", "ANATOMY", 150, 158], ["Nsp1", "GENE_OR_GENE_PRODUCT", 13, 17], ["Nsp2", "GENE_OR_GENE_PRODUCT", 88, 92], ["Nsp3", "GENE_OR_GENE_PRODUCT", 97, 101], ["membrane", "CELLULAR_COMPONENT", 150, 158], ["Nsp1", "PROTEIN", 13, 17], ["subgenomic mRNA", "RNA", 41, 56], ["Nsp2", "PROTEIN", 88, 92], ["Nsp3", "PROTEIN", 97, 101], ["Nsp1 function", "PROBLEM", 13, 26], ["subgenomic mRNA synthesis regulation", "TREATMENT", 41, 77], ["Nsp2", "PROBLEM", 88, 92], ["Nsp3", "PROBLEM", 97, 101], ["Nsp1 function", "OBSERVATION", 13, 26], ["membrane rearrangement", "OBSERVATION", 150, 172]]], ["Moreover, the Nsp9 RNA polymerase and Nsp10 helicase are key enzymes for arterivirus RNA synthesis and are reportedly responsible for the virulence of highly pathogenic PRRSV [13].", [["Nsp9", "GENE_OR_GENE_PRODUCT", 14, 18], ["Nsp10", "GENE_OR_GENE_PRODUCT", 38, 43], ["PRRSV", "ORGANISM", 169, 174], ["Nsp9 RNA polymerase", "PROTEIN", 14, 33], ["Nsp10 helicase", "PROTEIN", 38, 52], ["arterivirus RNA", "RNA", 73, 88], ["PRRSV", "SPECIES", 169, 174], ["PRRSV", "SPECIES", 169, 174], ["the Nsp9 RNA polymerase", "TEST", 10, 33], ["Nsp10 helicase", "TREATMENT", 38, 52], ["key enzymes", "TEST", 57, 68], ["arterivirus RNA synthesis", "PROBLEM", 73, 98], ["highly pathogenic PRRSV", "PROBLEM", 151, 174]]], ["The roles of Nsps in viral pathogenesis and host immunity are also being explored.IntroductionAlthough many Nsp functions have been discovered, information about the biological role of PRRSV Nsp12 is limited.", [["Nsps", "GENE_OR_GENE_PRODUCT", 13, 17], ["Nsp", "GENE_OR_GENE_PRODUCT", 108, 111], ["PRRSV", "ORGANISM", 185, 190], ["Nsp12", "GENE_OR_GENE_PRODUCT", 191, 196], ["Nsps", "PROTEIN", 13, 17], ["Nsp", "PROTEIN", 108, 111], ["PRRSV Nsp12", "PROTEIN", 185, 196], ["PRRSV", "SPECIES", 185, 190], ["Nsps", "OBSERVATION_MODIFIER", 13, 17], ["viral pathogenesis", "OBSERVATION", 21, 39]]], ["Dong et al. investigated the Nsp12 interactome with cellular proteins, verified the interaction between the cellular chaperone HSP70 and Nsp12, and demonstrated that Nsp12 recruits HSP70 to maintain its own stability and promote viral replication [14].", [["cellular", "ANATOMY", 52, 60], ["cellular", "ANATOMY", 108, 116], ["Nsp12", "GENE_OR_GENE_PRODUCT", 29, 34], ["cellular", "CELL", 52, 60], ["cellular", "CELL", 108, 116], ["HSP70", "GENE_OR_GENE_PRODUCT", 127, 132], ["Nsp12", "GENE_OR_GENE_PRODUCT", 137, 142], ["Nsp12", "GENE_OR_GENE_PRODUCT", 166, 171], ["HSP70", "GENE_OR_GENE_PRODUCT", 181, 186], ["Nsp12", "PROTEIN", 29, 34], ["cellular proteins", "PROTEIN", 52, 69], ["cellular chaperone", "PROTEIN", 108, 126], ["HSP70", "PROTEIN", 127, 132], ["Nsp12", "PROTEIN", 137, 142], ["Nsp12", "PROTEIN", 166, 171], ["HSP70", "PROTEIN", 181, 186], ["HSP70", "TEST", 181, 186], ["viral replication", "OBSERVATION", 229, 246]]], ["Recently, Li et al. reported that porcine galectin-3 (GAL3) interacts with Nsp12 and showed that GAL3 overexpression significantly suppresses the replication of type 1 and 2 PRRSV strains [15].", [["Li", "CHEMICAL", 10, 12], ["porcine", "ORGANISM", 34, 41], ["galectin-3", "GENE_OR_GENE_PRODUCT", 42, 52], ["GAL3", "GENE_OR_GENE_PRODUCT", 54, 58], ["Nsp12", "GENE_OR_GENE_PRODUCT", 75, 80], ["GAL3", "GENE_OR_GENE_PRODUCT", 97, 101], ["porcine galectin-3", "PROTEIN", 34, 52], ["GAL3", "PROTEIN", 54, 58], ["Nsp12", "PROTEIN", 75, 80], ["GAL3", "PROTEIN", 97, 101], ["PRRSV", "SPECIES", 174, 179], ["porcine galectin", "TEST", 34, 50], ["GAL3 overexpression", "PROBLEM", 97, 116], ["type 1 and 2 PRRSV strains", "PROBLEM", 161, 187]]], ["Nsp12 was also found to induce the phosphorylation of signal transducer and activator of transcription 1 (STAT1) and the expression of proinflammatory cytokines and chemokines, including IL-1\u03b2, IL-8, chemokine ligand 2 (CCL2) and chemokine (C-X-C motif) ligand 10 (CXCL10), which may contribute to PRRSV pathogenesis [16].", [["Nsp12", "CHEMICAL", 0, 5], ["Nsp12", "GENE_OR_GENE_PRODUCT", 0, 5], ["signal transducer and activator of transcription 1", "GENE_OR_GENE_PRODUCT", 54, 104], ["STAT1", "GENE_OR_GENE_PRODUCT", 106, 111], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 187, 192], ["IL-8", "GENE_OR_GENE_PRODUCT", 194, 198], ["chemokine ligand 2", "GENE_OR_GENE_PRODUCT", 200, 218], ["CCL2", "GENE_OR_GENE_PRODUCT", 220, 224], ["C-X-C motif) ligand 10", "GENE_OR_GENE_PRODUCT", 241, 263], ["CXCL10", "GENE_OR_GENE_PRODUCT", 265, 271], ["PRRSV", "ORGANISM", 298, 303], ["Nsp12", "PROTEIN", 0, 5], ["signal transducer and activator of transcription 1", "PROTEIN", 54, 104], ["STAT1", "PROTEIN", 106, 111], ["proinflammatory cytokines", "PROTEIN", 135, 160], ["chemokines", "PROTEIN", 165, 175], ["IL-1\u03b2", "PROTEIN", 187, 192], ["IL-8", "PROTEIN", 194, 198], ["chemokine ligand 2", "PROTEIN", 200, 218], ["CCL2", "PROTEIN", 220, 224], ["chemokine", "PROTEIN", 230, 239], ["CXCL10", "PROTEIN", 265, 271], ["PRRSV", "SPECIES", 298, 303], ["Nsp12", "TEST", 0, 5], ["activator of transcription", "TREATMENT", 76, 102], ["proinflammatory cytokines", "TEST", 135, 160], ["chemokines", "TEST", 165, 175], ["IL", "TEST", 187, 189], ["IL", "TEST", 194, 196], ["chemokine ligand", "TEST", 200, 216], ["CCL2", "TEST", 220, 224], ["chemokine (C-X-C motif) ligand", "TREATMENT", 230, 260], ["CXCL10", "TEST", 265, 271], ["PRRSV pathogenesis", "PROBLEM", 298, 316], ["proinflammatory cytokines", "OBSERVATION", 135, 160]]], ["However, all of these studies focused on the interaction of host proteins with Nsp12, but no information describes how Nsp12 participates in the replication phase of the PRRSV lifecycle.", [["Nsp12", "GENE_OR_GENE_PRODUCT", 79, 84], ["Nsp12", "GENE_OR_GENE_PRODUCT", 119, 124], ["PRRSV", "ORGANISM", 170, 175], ["host proteins", "PROTEIN", 60, 73], ["Nsp12", "PROTEIN", 79, 84], ["Nsp12", "PROTEIN", 119, 124], ["PRRSV", "SPECIES", 170, 175], ["these studies", "TEST", 16, 29], ["Nsp12", "TREATMENT", 79, 84]]], ["A recent study attempting to explore the interaction network involving most PRRSV Nsps demonstrated that Nsp12 may serve as a hub of the Nsp interactome along with Nsp9 [17]; this study also indicated that Nsp12 may be a major component of the replication and transcription complexes (RTCs) [17].IntroductionHere, we investigate the biochemical properties of Nsp12 and further identify Nsp12 as a key component of PRRSV replication.", [["Nsp12", "CHEMICAL", 105, 110], ["Nsp12", "CHEMICAL", 206, 211], ["PRRSV", "ORGANISM", 76, 81], ["Nsps", "GENE_OR_GENE_PRODUCT", 82, 86], ["Nsp12", "GENE_OR_GENE_PRODUCT", 105, 110], ["Nsp", "GENE_OR_GENE_PRODUCT", 137, 140], ["Nsp9 [17]", "GENE_OR_GENE_PRODUCT", 164, 173], ["Nsp12", "GENE_OR_GENE_PRODUCT", 206, 211], ["Nsp12", "GENE_OR_GENE_PRODUCT", 359, 364], ["Nsp12", "GENE_OR_GENE_PRODUCT", 386, 391], ["PRRSV", "ORGANISM", 414, 419], ["PRRSV Nsps", "PROTEIN", 76, 86], ["Nsp12", "PROTEIN", 105, 110], ["Nsp12", "PROTEIN", 206, 211], ["transcription complexes", "PROTEIN", 260, 283], ["RTCs", "PROTEIN", 285, 289], ["Nsp12", "PROTEIN", 359, 364], ["Nsp12", "PROTEIN", 386, 391], ["PRRSV", "SPECIES", 76, 81], ["PRRSV", "SPECIES", 414, 419], ["A recent study", "TEST", 0, 14], ["this study", "TEST", 175, 185], ["Nsp12", "TREATMENT", 359, 364], ["Nsp12", "TREATMENT", 386, 391], ["PRRSV replication", "TREATMENT", 414, 431], ["PRRSV replication", "OBSERVATION", 414, 431]]], ["Notably, we demonstrate for the first time that Nsp12 is involved in viral subgenomic mRNA (sgmRNA) synthesis but not in minus-strand genomic RNA (-gRNA) synthesis.Plasmids and PRRSV infectious clones ::: Materials and methodsNsp12 was cloned from the HuN4 infectious cDNA clone and expressed as a fusion protein with an HA tag at its N-terminus using the expression vector pCMV-HA (Clontech, USA).", [["N", "CHEMICAL", 335, 336], ["Nsp12", "GENE_OR_GENE_PRODUCT", 48, 53], ["sgmRNA", "GENE_OR_GENE_PRODUCT", 92, 98], ["PRRSV", "ORGANISM", 177, 182], ["Nsp12", "GENE_OR_GENE_PRODUCT", 226, 231], ["Nsp12", "PROTEIN", 48, 53], ["viral subgenomic mRNA", "RNA", 69, 90], ["sgmRNA", "RNA", 92, 98], ["minus-strand genomic RNA", "RNA", 121, 145], ["PRRSV infectious clones", "CELL_LINE", 177, 200], ["Nsp12", "DNA", 226, 231], ["HuN4 infectious cDNA clone", "DNA", 252, 278], ["fusion protein", "PROTEIN", 298, 312], ["N-terminus", "PROTEIN", 335, 345], ["pCMV", "PROTEIN", 374, 378], ["HA", "PROTEIN", 379, 381], ["PRRSV", "SPECIES", 177, 182], ["PRRSV", "SPECIES", 177, 182], ["viral subgenomic mRNA (sgmRNA) synthesis", "PROBLEM", 69, 109], ["strand genomic RNA", "PROBLEM", 127, 145], ["a fusion protein", "TREATMENT", 296, 312], ["an HA tag", "PROBLEM", 318, 327], ["HA", "PROBLEM", 379, 381], ["viral subgenomic mRNA", "OBSERVATION", 69, 90], ["strand genomic RNA", "OBSERVATION", 127, 145], ["PRRSV", "OBSERVATION", 177, 182], ["infectious clones", "OBSERVATION", 183, 200]]], ["A series of plasmids expressing Nsp12 substitution mutations was constructed.", [["plasmids", "ANATOMY", 12, 20], ["Nsp12", "GENE_OR_GENE_PRODUCT", 32, 37], ["plasmids", "DNA", 12, 20], ["Nsp12", "PROTEIN", 32, 37], ["A series of plasmids", "TREATMENT", 0, 20], ["Nsp12 substitution mutations", "TREATMENT", 32, 60]]], ["Mutagenesis PCR was used to create mutations at three cysteine sites.", [["cysteine", "CHEMICAL", 54, 62], ["Mutagenesis PCR", "TEST", 0, 15], ["mutations at three cysteine sites", "PROBLEM", 35, 68]]], ["The C29A mutant was generated using the C29A forward primer and the C29A reverse primer, and the C35A and C79A mutants were constructed using the C35A and C79A forward and reverse primers, respectively.", [["C29A", "GENE_OR_GENE_PRODUCT", 4, 8], ["C35A", "GENE_OR_GENE_PRODUCT", 97, 101], ["C79A", "GENE_OR_GENE_PRODUCT", 106, 110], ["C29A mutant", "PROTEIN", 4, 15], ["C29A forward primer", "DNA", 40, 59], ["C29A reverse primer", "DNA", 68, 87], ["C35A and C79A mutants", "DNA", 97, 118], ["C35A and C79A forward and reverse primers", "DNA", 146, 187]]], ["For site-specific mutation of the PRRSV infectious clone (PRRSV HuN4-F5) [18], the Nsp9 to Nsp12 regions were cloned into the pUC57 vector; after mutation of the indicated site, this region was religated to the infectious clone using the NheI and AscI sites.", [["PRRSV", "ORGANISM", 34, 39], ["PRRSV", "ORGANISM", 58, 63], ["HuN4-F5) [18", "GENE_OR_GENE_PRODUCT", 64, 76], ["Nsp9", "GENE_OR_GENE_PRODUCT", 83, 87], ["Nsp12", "GENE_OR_GENE_PRODUCT", 91, 96], ["pUC57", "GENE_OR_GENE_PRODUCT", 126, 131], ["clone", "CELL", 222, 227], ["NheI", "GENE_OR_GENE_PRODUCT", 238, 242], ["AscI", "GENE_OR_GENE_PRODUCT", 247, 251], ["PRRSV infectious clone", "DNA", 34, 56], ["F5", "DNA", 69, 71], ["Nsp9 to Nsp12 regions", "DNA", 83, 104], ["pUC57 vector", "DNA", 126, 138], ["NheI and AscI sites", "DNA", 238, 257], ["PRRSV", "SPECIES", 34, 39], ["PRRSV", "SPECIES", 58, 63], ["the PRRSV infectious clone", "PROBLEM", 30, 56], ["the Nsp9 to Nsp12 regions", "TREATMENT", 79, 104], ["the infectious clone", "PROBLEM", 207, 227], ["the NheI and AscI sites", "TREATMENT", 234, 257], ["PRRSV", "OBSERVATION", 34, 39], ["infectious clone", "OBSERVATION", 40, 56], ["infectious", "OBSERVATION", 211, 221]]], ["All constructed mutants were confirmed by DNA sequencing.", [["DNA", "CELLULAR_COMPONENT", 42, 45]]], ["The sequences of the PCR primers are provided in Table 1.", [["PCR primers", "DNA", 21, 32], ["the PCR primers", "TEST", 17, 32]]]], "8684262586dc9538d9346212e54e833669c776c3": [["This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.", [["this version", "TREATMENT", 136, 148]]]], "4264ac54f0b410c2d961e5917c289c47f9f03390": [["Clinical caseyear-old woman known for type 1 diabetes presented to the emergency room with back pain, diffuse myalgia, asthenia, and fever (38.5 \u00b0C) .", [["back", "ANATOMY", 91, 95], ["type 1 diabetes", "DISEASE", 38, 53], ["back pain", "DISEASE", 91, 100], ["myalgia", "DISEASE", 110, 117], ["asthenia", "DISEASE", 119, 127], ["fever", "DISEASE", 133, 138], ["woman", "ORGANISM", 22, 27], ["woman", "SPECIES", 22, 27], ["type 1 diabetes", "PROBLEM", 38, 53], ["back pain", "PROBLEM", 91, 100], ["diffuse myalgia", "PROBLEM", 102, 117], ["asthenia", "PROBLEM", 119, 127], ["fever", "PROBLEM", 133, 138], ["diabetes", "OBSERVATION", 45, 53], ["back", "ANATOMY", 91, 95], ["diffuse", "OBSERVATION_MODIFIER", 102, 109], ["myalgia", "OBSERVATION", 110, 117], ["asthenia", "OBSERVATION", 119, 127]]], ["She had been taking nonsteroidal anti-inflammatory medication for 5 days following a trauma of the left ankle.", [["nonsteroidal", "ANATOMY", 20, 32], ["left ankle", "ANATOMY", 99, 109], ["trauma", "DISEASE", 85, 91], ["ankle", "ORGANISM_SUBDIVISION", 104, 109], ["nonsteroidal anti-inflammatory medication", "TREATMENT", 20, 61], ["a trauma of the left ankle", "PROBLEM", 83, 109], ["left", "ANATOMY_MODIFIER", 99, 103], ["ankle", "ANATOMY", 104, 109]]], ["Physical examination showed hypotension with arterial blood pressure of 70/30 mmHg.", [["arterial", "ANATOMY", 45, 53], ["blood", "ANATOMY", 54, 59], ["hypotension", "DISEASE", 28, 39], ["arterial", "MULTI-TISSUE_STRUCTURE", 45, 53], ["blood", "ORGANISM_SUBSTANCE", 54, 59], ["Physical examination", "TEST", 0, 20], ["hypotension", "PROBLEM", 28, 39], ["arterial blood pressure", "TEST", 45, 68], ["hypotension", "OBSERVATION", 28, 39], ["arterial", "ANATOMY_MODIFIER", 45, 53], ["70/30 mmHg", "OBSERVATION", 72, 82]]], ["The patient remained hypotensive despite fluid resuscitation with crystalloids and required continuous norepinephrine infusion.", [["fluid", "ANATOMY", 41, 46], ["hypotensive", "DISEASE", 21, 32], ["norepinephrine", "CHEMICAL", 103, 117], ["norepinephrine", "CHEMICAL", 103, 117], ["patient", "ORGANISM", 4, 11], ["fluid", "ORGANISM_SUBSTANCE", 41, 46], ["crystalloids", "ORGANISM_SUBSTANCE", 66, 78], ["norepinephrine", "SIMPLE_CHEMICAL", 103, 117], ["patient", "SPECIES", 4, 11], ["hypotensive", "PROBLEM", 21, 32], ["fluid resuscitation", "TREATMENT", 41, 60], ["crystalloids", "TREATMENT", 66, 78], ["continuous norepinephrine infusion", "TREATMENT", 92, 126], ["hypotensive", "OBSERVATION", 21, 32], ["fluid resuscitation", "OBSERVATION", 41, 60]]], ["At the time of admission, the patient complained of important pain in the left limb, although this was associated with a normal clinical examination.", [["left limb", "ANATOMY", 74, 83], ["pain", "DISEASE", 62, 66], ["patient", "ORGANISM", 30, 37], ["left limb", "ORGANISM_SUBDIVISION", 74, 83], ["patient", "SPECIES", 30, 37], ["important pain in the left limb", "PROBLEM", 52, 83], ["pain", "OBSERVATION", 62, 66], ["left", "ANATOMY_MODIFIER", 74, 78], ["limb", "ANATOMY", 79, 83]]], ["A small skin defect on the left ankle in relationship with the initial trauma was, however, noted.", [["skin", "ANATOMY", 8, 12], ["left ankle", "ANATOMY", 27, 37], ["trauma", "DISEASE", 71, 77], ["skin", "ORGAN", 8, 12], ["ankle", "ORGANISM_SUBDIVISION", 32, 37], ["A small skin defect on the left ankle", "PROBLEM", 0, 37], ["the initial trauma", "PROBLEM", 59, 77], ["small", "OBSERVATION_MODIFIER", 2, 7], ["skin", "ANATOMY", 8, 12], ["defect", "OBSERVATION", 13, 19], ["left", "ANATOMY_MODIFIER", 27, 31], ["ankle", "ANATOMY", 32, 37], ["trauma", "OBSERVATION", 71, 77]]], ["The gynecologic examination was normal.", [["gynecologic", "ANATOMY", 4, 15], ["The gynecologic examination", "TEST", 0, 27], ["gynecologic", "ANATOMY", 4, 15], ["normal", "OBSERVATION", 32, 38]]], ["Laboratory tests on admission showed elevated plasma C-reactive protein and procalcitonin levels (320 mg/L and 23 \u03bcg/L, respectively), an estimated glomerular filtration rate of 15 mL/ min/1.73 m 2 , an absolute neutrophil count of 1.4 G/L with increased band forms, thrombocytopenia (63 G/L), increased thromboplastin time, and very elevated creatine kinase levels (143,000 U/L).", [["plasma", "ANATOMY", 46, 52], ["glomerular", "ANATOMY", 148, 158], ["neutrophil", "ANATOMY", 212, 222], ["thrombocytopenia", "DISEASE", 267, 283], ["creatine", "CHEMICAL", 343, 351], ["creatine", "CHEMICAL", 343, 351], ["plasma", "ORGANISM_SUBSTANCE", 46, 52], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 53, 71], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 76, 89], ["glomerular", "TISSUE", 148, 158], ["neutrophil", "CELL", 212, 222], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 304, 318], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 343, 358], ["plasma C-reactive protein", "PROTEIN", 46, 71], ["procalcitonin", "PROTEIN", 76, 89], ["thromboplastin", "PROTEIN", 304, 318], ["creatine kinase", "PROTEIN", 343, 358], ["Laboratory tests", "TEST", 0, 16], ["elevated plasma C", "PROBLEM", 37, 54], ["reactive protein", "TEST", 55, 71], ["procalcitonin levels", "TEST", 76, 96], ["an estimated glomerular filtration rate", "TEST", 135, 174], ["an absolute neutrophil count", "TEST", 200, 228], ["increased band forms", "PROBLEM", 245, 265], ["thrombocytopenia", "PROBLEM", 267, 283], ["increased thromboplastin time", "PROBLEM", 294, 323], ["very elevated creatine kinase levels", "PROBLEM", 329, 365], ["reactive protein", "OBSERVATION", 55, 71], ["glomerular", "OBSERVATION", 148, 158], ["neutrophil count", "OBSERVATION", 212, 228], ["thrombocytopenia", "OBSERVATION", 267, 283], ["increased", "OBSERVATION_MODIFIER", 294, 303], ["thromboplastin", "OBSERVATION", 304, 318], ["very", "OBSERVATION_MODIFIER", 329, 333], ["elevated", "OBSERVATION", 334, 342]]], ["The patient was admitted to the intensive care unit (ICU) with the diagnosis of septic shock, and empiric antibiotic therapy was initiated with piperacillin/tazobactam plus clindamycin.", [["septic shock", "DISEASE", 80, 92], ["piperacillin/tazobactam", "CHEMICAL", 144, 167], ["clindamycin", "CHEMICAL", 173, 184], ["piperacillin", "CHEMICAL", 144, 156], ["tazobactam", "CHEMICAL", 157, 167], ["clindamycin", "CHEMICAL", 173, 184], ["patient", "ORGANISM", 4, 11], ["piperacillin/tazobactam", "SIMPLE_CHEMICAL", 144, 167], ["clindamycin", "SIMPLE_CHEMICAL", 173, 184], ["patient", "SPECIES", 4, 11], ["septic shock", "PROBLEM", 80, 92], ["empiric antibiotic therapy", "TREATMENT", 98, 124], ["piperacillin", "TREATMENT", 144, 156], ["tazobactam", "TREATMENT", 157, 167], ["clindamycin", "TREATMENT", 173, 184], ["septic shock", "OBSERVATION", 80, 92]]], ["A CT scan of the limb did not show radiologic signs of necrotizing fasciitis, but the patient subsequently rapidly developed signs of arthritis of both ankles plus the right elbow, which required surgical lavage.", [["limb", "ANATOMY", 17, 21], ["ankles", "ANATOMY", 152, 158], ["right elbow", "ANATOMY", 168, 179], ["necrotizing fasciitis", "DISEASE", 55, 76], ["arthritis", "DISEASE", 134, 143], ["limb", "ORGANISM_SUBDIVISION", 17, 21], ["patient", "ORGANISM", 86, 93], ["ankles", "ORGANISM_SUBDIVISION", 152, 158], ["elbow", "ORGANISM_SUBDIVISION", 174, 179], ["patient", "SPECIES", 86, 93], ["A CT scan of the limb", "TEST", 0, 21], ["necrotizing fasciitis", "PROBLEM", 55, 76], ["arthritis of both ankles plus the right elbow", "PROBLEM", 134, 179], ["surgical lavage", "TREATMENT", 196, 211], ["limb", "ANATOMY", 17, 21], ["necrotizing", "OBSERVATION_MODIFIER", 55, 66], ["fasciitis", "OBSERVATION", 67, 76], ["arthritis", "OBSERVATION", 134, 143], ["both", "ANATOMY_MODIFIER", 147, 151], ["ankles", "ANATOMY", 152, 158], ["right", "ANATOMY_MODIFIER", 168, 173], ["elbow", "ANATOMY", 174, 179], ["surgical lavage", "OBSERVATION", 196, 211]]], ["Synovial fluid and blood cultures came back positive with group A streptococcus (S. pyogenes), and the antibiotic therapy was deescalated for high-dose IV penicillin G. In spite of the initial acute renal failure and rhadomyolysis, the patient did not need renal support therapy during the ICU stay, could be transferred to the ward after 6 days, and recovered without sequelae.", [["Synovial fluid", "ANATOMY", 0, 14], ["blood cultures", "ANATOMY", 19, 33], ["renal", "ANATOMY", 199, 204], ["renal", "ANATOMY", 257, 262], ["penicillin", "CHEMICAL", 155, 165], ["acute renal failure", "DISEASE", 193, 212], ["rhadomyolysis", "DISEASE", 217, 230], ["penicillin G", "CHEMICAL", 155, 167], ["Synovial fluid", "ORGANISM_SUBSTANCE", 0, 14], ["blood cultures", "ORGANISM_SUBSTANCE", 19, 33], ["S. pyogenes", "ORGANISM", 81, 92], ["penicillin G", "SIMPLE_CHEMICAL", 155, 167], ["renal", "ORGAN", 199, 204], ["patient", "ORGANISM", 236, 243], ["renal", "ORGAN", 257, 262], ["S. pyogenes", "SPECIES", 81, 92], ["patient", "SPECIES", 236, 243], ["S. pyogenes", "SPECIES", 81, 92], ["Synovial fluid", "TEST", 0, 14], ["blood cultures", "TEST", 19, 33], ["group A streptococcus", "PROBLEM", 58, 79], ["S. pyogenes", "PROBLEM", 81, 92], ["the antibiotic therapy", "TREATMENT", 99, 121], ["high-dose IV penicillin G", "TREATMENT", 142, 167], ["the initial acute renal failure", "PROBLEM", 181, 212], ["rhadomyolysis", "PROBLEM", 217, 230], ["renal support therapy", "TREATMENT", 257, 278], ["sequelae", "PROBLEM", 369, 377], ["fluid", "OBSERVATION", 9, 14], ["acute", "OBSERVATION_MODIFIER", 193, 198], ["renal", "ANATOMY", 199, 204], ["failure", "OBSERVATION", 205, 212], ["renal", "ANATOMY", 257, 262], ["support", "OBSERVATION", 263, 270]]], ["The final diagnosis was a toxic shock syndrome due to group A streptococcus with septic oligoarthritis, most probably originating from a skin lesion and a left ankle trauma, in young woman with type 1 diabetes.IntroductionStreptococcal toxic shock syndrome (STSS) is a severe life-threatening condition complicating invasive infections by streptococci, mainly group A streptococcus (GAS, S. pyogenes) [1] .", [["skin lesion", "ANATOMY", 137, 148], ["left ankle", "ANATOMY", 155, 165], ["toxic shock syndrome", "DISEASE", 26, 46], ["group A streptococcus", "DISEASE", 54, 75], ["septic oligoarthritis", "DISEASE", 81, 102], ["skin lesion", "DISEASE", 137, 148], ["left ankle trauma", "DISEASE", 155, 172], ["type 1 diabetes", "DISEASE", 194, 209], ["toxic shock syndrome", "DISEASE", 236, 256], ["STSS", "DISEASE", 258, 262], ["infections", "DISEASE", 325, 335], ["group A streptococcus", "DISEASE", 360, 381], ["skin", "ORGAN", 137, 141], ["ankle", "ORGANISM_SUBDIVISION", 160, 165], ["woman", "ORGANISM", 183, 188], ["group A streptococcus", "ORGANISM", 360, 381], ["S. pyogenes", "ORGANISM", 388, 399], ["woman", "SPECIES", 183, 188], ["S. pyogenes", "SPECIES", 388, 399], ["S. pyogenes", "SPECIES", 388, 399], ["a toxic shock syndrome", "PROBLEM", 24, 46], ["group A streptococcus", "PROBLEM", 54, 75], ["septic oligoarthritis", "PROBLEM", 81, 102], ["a skin lesion", "PROBLEM", 135, 148], ["a left ankle trauma", "PROBLEM", 153, 172], ["type 1 diabetes", "PROBLEM", 194, 209], ["IntroductionStreptococcal toxic shock syndrome", "PROBLEM", 210, 256], ["a severe life-threatening condition", "PROBLEM", 267, 302], ["invasive infections", "PROBLEM", 316, 335], ["streptococci", "PROBLEM", 339, 351], ["toxic shock syndrome", "OBSERVATION", 26, 46], ["streptococcus", "OBSERVATION", 62, 75], ["septic", "OBSERVATION_MODIFIER", 81, 87], ["oligoarthritis", "OBSERVATION", 88, 102], ["most probably", "UNCERTAINTY", 104, 117], ["skin", "ANATOMY", 137, 141], ["lesion", "OBSERVATION", 142, 148], ["left", "ANATOMY_MODIFIER", 155, 159], ["ankle", "ANATOMY", 160, 165], ["trauma", "OBSERVATION", 166, 172], ["diabetes", "OBSERVATION", 201, 209], ["toxic", "OBSERVATION_MODIFIER", 236, 241], ["shock syndrome", "OBSERVATION", 242, 256], ["severe", "OBSERVATION_MODIFIER", 269, 275], ["invasive", "OBSERVATION_MODIFIER", 316, 324], ["infections", "OBSERVATION", 325, 335]]], ["Streptococcal infections are frequent and can lead to a broad range of diseases from Open Access *Correspondence: jerome.pugin@unige.ch 1 Division of Intensive Care, Faculty of Medicine Geneva, University Hospitals of Geneva, University of Geneva, Rue Gabrielle-Perret-Gentil 4, 1211 Geneva 14, Switzerland Full list of author information is available at the end of the article self-limited pharyngitis to severe diseases: bacteremia, pneumonia, meningitis, endocarditis, arthritis, sinusitis, and deep soft tissues infection, such as necrotizing fasciitis and myositis [2] .", [["soft tissues", "ANATOMY", 503, 515], ["Streptococcal infections", "DISEASE", 0, 24], ["pharyngitis", "DISEASE", 391, 402], ["bacteremia", "DISEASE", 423, 433], ["pneumonia", "DISEASE", 435, 444], ["meningitis", "DISEASE", 446, 456], ["endocarditis", "DISEASE", 458, 470], ["arthritis", "DISEASE", 472, 481], ["sinusitis", "DISEASE", 483, 492], ["soft tissues infection", "DISEASE", 503, 525], ["necrotizing fasciitis", "DISEASE", 535, 556], ["myositis", "DISEASE", 561, 569], ["soft tissues", "TISSUE", 503, 515], ["Streptococcal infections", "PROBLEM", 0, 24], ["a broad range of diseases", "PROBLEM", 54, 79], ["limited pharyngitis", "PROBLEM", 383, 402], ["severe diseases", "PROBLEM", 406, 421], ["bacteremia", "PROBLEM", 423, 433], ["pneumonia", "PROBLEM", 435, 444], ["meningitis", "PROBLEM", 446, 456], ["endocarditis", "PROBLEM", 458, 470], ["arthritis", "PROBLEM", 472, 481], ["sinusitis", "PROBLEM", 483, 492], ["deep soft tissues infection", "PROBLEM", 498, 525], ["necrotizing fasciitis", "PROBLEM", 535, 556], ["myositis", "PROBLEM", 561, 569], ["infections", "OBSERVATION", 14, 24], ["pharyngitis", "OBSERVATION", 391, 402], ["severe", "OBSERVATION_MODIFIER", 406, 412], ["diseases", "OBSERVATION", 413, 421], ["bacteremia", "OBSERVATION", 423, 433], ["pneumonia", "OBSERVATION", 435, 444], ["meningitis", "OBSERVATION", 446, 456], ["endocarditis", "OBSERVATION", 458, 470], ["arthritis", "OBSERVATION", 472, 481], ["sinusitis", "OBSERVATION", 483, 492], ["deep", "ANATOMY_MODIFIER", 498, 502], ["soft tissues", "ANATOMY", 503, 515], ["infection", "OBSERVATION", 516, 525], ["necrotizing", "OBSERVATION_MODIFIER", 535, 546], ["fasciitis", "OBSERVATION", 547, 556], ["myositis", "OBSERVATION", 561, 569]]], ["The STSS represents a severe complication of (mainly invasive) group A streptococcal infections, and less frequently due to other streptococcal species [3, 4] .IntroductionSevere invasive GAS infections have been known for a long time, but GAS infections associated with shock and multiple organ failure have been first reported in the beginning of the 1990s after the description princeps of the staphylococcal toxic shock syndrome in 1978 [5] [6] [7] [8] [9] .", [["organ", "ANATOMY", 290, 295], ["STSS", "DISEASE", 4, 8], ["streptococcal infections", "DISEASE", 71, 95], ["GAS infections", "DISEASE", 188, 202], ["infections", "DISEASE", 244, 254], ["shock", "DISEASE", 271, 276], ["multiple organ failure", "DISEASE", 281, 303], ["staphylococcal toxic shock", "DISEASE", 397, 423], ["syndrome", "DISEASE", 424, 432], ["organ", "ORGAN", 290, 295], ["5] [6] [7] [8] [9]", "SIMPLE_CHEMICAL", 442, 460], ["a severe complication", "PROBLEM", 20, 41], ["group A streptococcal infections", "PROBLEM", 63, 95], ["other streptococcal species", "PROBLEM", 124, 151], ["Severe invasive GAS infections", "PROBLEM", 172, 202], ["GAS infections", "PROBLEM", 240, 254], ["shock", "PROBLEM", 271, 276], ["multiple organ failure", "PROBLEM", 281, 303], ["the staphylococcal toxic shock syndrome", "PROBLEM", 393, 432], ["severe", "OBSERVATION_MODIFIER", 22, 28], ["complication", "OBSERVATION", 29, 41], ["invasive", "OBSERVATION_MODIFIER", 53, 61], ["streptococcal", "OBSERVATION_MODIFIER", 71, 84], ["infections", "OBSERVATION", 85, 95], ["Severe", "OBSERVATION_MODIFIER", 172, 178], ["invasive", "OBSERVATION_MODIFIER", 179, 187], ["GAS infections", "OBSERVATION", 188, 202], ["organ", "ANATOMY", 290, 295], ["failure", "OBSERVATION", 296, 303], ["staphylococcal", "OBSERVATION_MODIFIER", 397, 411], ["toxic shock syndrome", "OBSERVATION", 412, 432]]], ["In 1989, Steven et al. [1] reported a \"toxic shock-like syndrome\" among patients with scarlet fever associated with GAS.", [["toxic shock", "DISEASE", 39, 50], ["scarlet fever", "DISEASE", 86, 99], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["a \"toxic shock", "PROBLEM", 36, 50], ["syndrome", "PROBLEM", 56, 64], ["scarlet fever", "PROBLEM", 86, 99]]], ["The term streptococcal toxic shock syndrome was further coined, in analogy to the staphylococcal toxic shock syndrome.", [["streptococcal toxic shock syndrome", "DISEASE", 9, 43], ["staphylococcal toxic shock syndrome", "DISEASE", 82, 117], ["The term streptococcal toxic shock syndrome", "PROBLEM", 0, 43], ["the staphylococcal toxic shock syndrome", "PROBLEM", 78, 117], ["streptococcal", "OBSERVATION_MODIFIER", 9, 22], ["toxic shock syndrome", "OBSERVATION", 23, 43], ["staphylococcal", "OBSERVATION_MODIFIER", 82, 96], ["toxic shock syndrome", "OBSERVATION", 97, 117]]], ["A similar but distinct entity of STSS, caused by nongroup A streptococci, was also reported [10, 11] .IntroductionThe exact mechanism of STSS is not entirely understood but has to do with a combination of the effect of streptococcal toxins-enterotoxins with superantigen activity-other streptococcal enzymes and toxins, and the host response to streptococcal infection, a complex interplay between host immunity and pathogen virulence [12] .IntroductionAdmission to the ICU is usually necessary for patients with STSS.", [["STSS", "DISEASE", 33, 37], ["STSS", "DISEASE", 137, 141], ["streptococcal infection", "DISEASE", 345, 368], ["STSS", "DISEASE", 513, 517], ["STSS", "CANCER", 33, 37], ["STSS", "CANCER", 137, 141], ["patients", "ORGANISM", 499, 507], ["superantigen", "PROTEIN", 258, 270], ["streptococcal enzymes", "PROTEIN", 286, 307], ["patients", "SPECIES", 499, 507], ["STSS", "PROBLEM", 33, 37], ["nongroup A streptococci", "PROBLEM", 49, 72], ["STSS", "PROBLEM", 137, 141], ["streptococcal toxins", "PROBLEM", 219, 239], ["enterotoxins", "PROBLEM", 240, 252], ["superantigen activity", "PROBLEM", 258, 279], ["other streptococcal enzymes", "TEST", 280, 307], ["toxins", "PROBLEM", 312, 318], ["streptococcal infection", "PROBLEM", 345, 368], ["STSS", "PROBLEM", 513, 517], ["distinct", "OBSERVATION_MODIFIER", 14, 22], ["STSS", "OBSERVATION", 33, 37], ["streptococci", "OBSERVATION", 60, 72], ["streptococcal", "OBSERVATION_MODIFIER", 345, 358], ["infection", "OBSERVATION", 359, 368]]], ["Treatment usually requires the control of the infectious source, which is particularly important in patients with myositis and/or necrotizing fasciitis, as well as the support of failing organs.", [["organs", "ANATOMY", 187, 193], ["myositis", "DISEASE", 114, 122], ["necrotizing fasciitis", "DISEASE", 130, 151], ["patients", "ORGANISM", 100, 108], ["organs", "ORGAN", 187, 193], ["patients", "SPECIES", 100, 108], ["Treatment", "TREATMENT", 0, 9], ["the infectious source", "PROBLEM", 42, 63], ["myositis", "PROBLEM", 114, 122], ["necrotizing fasciitis", "PROBLEM", 130, 151], ["failing organs", "PROBLEM", 179, 193], ["infectious", "OBSERVATION", 46, 56], ["myositis", "OBSERVATION", 114, 122], ["necrotizing", "OBSERVATION_MODIFIER", 130, 141], ["fasciitis", "OBSERVATION", 142, 151]]], ["There is controversy as to whether patients with STSS and multiple organ failure should be treated with polyclonal intravenous immunoglobulins (IVIG).", [["organ", "ANATOMY", 67, 72], ["intravenous", "ANATOMY", 115, 126], ["STSS", "DISEASE", 49, 53], ["multiple organ failure", "DISEASE", 58, 80], ["patients", "ORGANISM", 35, 43], ["organ", "ORGAN", 67, 72], ["intravenous immunoglobulins", "SIMPLE_CHEMICAL", 115, 142], ["IVIG", "SIMPLE_CHEMICAL", 144, 148], ["patients", "SPECIES", 35, 43], ["STSS", "PROBLEM", 49, 53], ["multiple organ failure", "PROBLEM", 58, 80], ["polyclonal intravenous immunoglobulins (IVIG", "TREATMENT", 104, 148], ["organ", "ANATOMY", 67, 72], ["failure", "OBSERVATION", 73, 80]]], ["A puzzling finding is that patients presenting with STSS have frequently taken NSAIDs, although the causal role of NSAIDs remains controversial.", [["STSS", "DISEASE", 52, 56], ["NSAIDs", "CHEMICAL", 115, 121], ["patients", "ORGANISM", 27, 35], ["NSAIDs", "SIMPLE_CHEMICAL", 115, 121], ["patients", "SPECIES", 27, 35], ["A puzzling finding", "PROBLEM", 0, 18], ["STSS", "PROBLEM", 52, 56], ["NSAIDs", "TREATMENT", 79, 85], ["NSAIDs", "TREATMENT", 115, 121]]], ["Herein, we review the current knowledge on the clinical presentation, and the treatment of STSS, which remains a severe, and frequently life-threatening condition in the ICU, sometimes requires debilitating surgical debridement.Epidemiology of streptococcal toxic shock syndromeGroup A steptococcus (S. pyogenes) is an aerobic grampositive bacterium characterized by its beta-hemolytic activity (complete hemolysis in blood agar culture plates).", [["blood", "ANATOMY", 418, 423], ["STSS", "DISEASE", 91, 95], ["streptococcal toxic shock", "DISEASE", 244, 269], ["hemolysis", "DISEASE", 405, 414], ["STSS", "CANCER", 91, 95], ["streptococcal toxic shock syndromeGroup A steptococcus", "ORGANISM", 244, 298], ["S. pyogenes", "ORGANISM", 300, 311], ["blood", "ORGANISM_SUBSTANCE", 418, 423], ["A steptococcus", "SPECIES", 284, 298], ["S. pyogenes", "SPECIES", 300, 311], ["A steptococcus", "SPECIES", 284, 298], ["S. pyogenes", "SPECIES", 300, 311], ["STSS", "PROBLEM", 91, 95], ["debilitating surgical debridement", "TREATMENT", 194, 227], ["streptococcal toxic shock syndromeGroup", "PROBLEM", 244, 283], ["A steptococcus (S. pyogenes", "PROBLEM", 284, 311], ["an aerobic grampositive bacterium", "PROBLEM", 316, 349], ["its beta-hemolytic activity", "PROBLEM", 367, 394], ["complete hemolysis", "PROBLEM", 396, 414], ["blood agar culture plates", "TEST", 418, 443], ["severe", "OBSERVATION_MODIFIER", 113, 119], ["debilitating", "OBSERVATION_MODIFIER", 194, 206], ["surgical debridement", "OBSERVATION", 207, 227], ["streptococcal", "OBSERVATION_MODIFIER", 244, 257], ["toxic", "OBSERVATION_MODIFIER", 258, 263], ["beta-hemolytic", "OBSERVATION_MODIFIER", 371, 385]]], ["Not all GAS strains carry genes and/or are able to release exotoxins with superantigen activity (see below).", [["exotoxins", "PROTEIN", 59, 68], ["superantigen", "PROTEIN", 74, 86]]], ["To establish the diagnosis of STSS, GAS need to be isolated from a sterile site [13] .", [["STSS", "DISEASE", 30, 34], ["GAS", "DNA", 36, 39], ["STSS", "PROBLEM", 30, 34], ["GAS", "PROBLEM", 36, 39], ["a sterile site", "TREATMENT", 65, 79], ["STSS", "OBSERVATION", 30, 34]]], ["Strains of GAS isolated from patients with invasive disease harbor predominantly types 1 and 3 M protein and secrete the pyrogenic exotoxin (superantigen) A, B or both.", [["invasive disease", "DISEASE", 43, 59], ["GAS", "ORGANISM", 11, 14], ["patients", "ORGANISM", 29, 37], ["exotoxin", "GENE_OR_GENE_PRODUCT", 131, 139], ["B", "CELL", 158, 159], ["GAS", "DNA", 11, 14], ["pyrogenic exotoxin", "PROTEIN", 121, 139], ["superantigen", "PROTEIN", 141, 153], ["patients", "SPECIES", 29, 37], ["Strains of GAS", "PROBLEM", 0, 14], ["invasive disease harbor", "PROBLEM", 43, 66], ["secrete the pyrogenic exotoxin (superantigen)", "TREATMENT", 109, 154], ["GAS isolated", "OBSERVATION", 11, 23]]], ["Nasopharyngeal mucosa and skin are the principal sites of asymptomatic GAS colonization.", [["Nasopharyngeal mucosa", "ANATOMY", 0, 21], ["skin", "ANATOMY", 26, 30], ["sites", "ANATOMY", 49, 54], ["Nasopharyngeal mucosa", "MULTI-TISSUE_STRUCTURE", 0, 21], ["skin", "ORGAN", 26, 30], ["Nasopharyngeal mucosa", "PROBLEM", 0, 21], ["asymptomatic GAS colonization", "PROBLEM", 58, 87], ["mucosa", "ANATOMY", 15, 21], ["skin", "ANATOMY", 26, 30], ["principal", "OBSERVATION_MODIFIER", 39, 48], ["asymptomatic", "OBSERVATION_MODIFIER", 58, 70], ["GAS colonization", "OBSERVATION", 71, 87]]], ["GAS are believed to enter into deeper tissues and the bloodstream by a rupture of an epithelial barrier, but has also the capacity to penetrate through intact membranes [12] .Epidemiology of streptococcal toxic shock syndromeStreptococcal toxic shock syndrome has been reported among children and adults all around the world, but remains a relatively rare disease.", [["tissues", "ANATOMY", 38, 45], ["bloodstream", "ANATOMY", 54, 65], ["epithelial barrier", "ANATOMY", 85, 103], ["membranes", "ANATOMY", 159, 168], ["streptococcal toxic shock", "DISEASE", 191, 216], ["toxic shock syndrome", "DISEASE", 239, 259], ["GAS", "GENE_OR_GENE_PRODUCT", 0, 3], ["tissues", "TISSUE", 38, 45], ["epithelial barrier", "TISSUE", 85, 103], ["membranes", "CELLULAR_COMPONENT", 159, 168], ["children", "ORGANISM", 284, 292], ["GAS", "DNA", 0, 3], ["children", "SPECIES", 284, 292], ["GAS", "PROBLEM", 0, 3], ["an epithelial barrier", "TREATMENT", 82, 103], ["streptococcal toxic shock syndromeStreptococcal toxic shock syndrome", "PROBLEM", 191, 259], ["a relatively rare disease", "PROBLEM", 338, 363], ["deeper tissues", "ANATOMY", 31, 45], ["bloodstream", "OBSERVATION_MODIFIER", 54, 65], ["rupture", "OBSERVATION", 71, 78], ["epithelial barrier", "OBSERVATION", 85, 103], ["streptococcal", "OBSERVATION_MODIFIER", 191, 204], ["toxic", "OBSERVATION_MODIFIER", 205, 210], ["toxic shock syndrome", "OBSERVATION", 239, 259], ["disease", "OBSERVATION", 356, 363]]], ["Whereas sporadic cases are the rule, some clusters and outbreaks of STSS in closed environments, such as hospital and nursing homes, and even families, have been reported [14, 15] .", [["STSS", "DISEASE", 68, 72]]], ["Transmission of GAS causing STSS among family members has also been described [16, 17] .Epidemiology of streptococcal toxic shock syndromeIn prospective population-based surveillance data from Europe and Australia, the incidence of invasive GAS infections was around 3 cases/100,000 inhabitants/year [17] .", [["STSS", "DISEASE", 28, 32], ["streptococcal toxic shock", "DISEASE", 104, 129], ["GAS infections", "DISEASE", 241, 255], ["GAS", "GENE_OR_GENE_PRODUCT", 16, 19], ["STSS", "CANCER", 28, 32], ["GAS", "DNA", 16, 19], ["STSS", "DNA", 28, 32], ["streptococcal toxic shock syndromeIn prospective population", "PROBLEM", 104, 163], ["surveillance data", "TEST", 170, 187], ["invasive GAS infections", "PROBLEM", 232, 255], ["GAS", "OBSERVATION", 16, 19], ["streptococcal", "OBSERVATION_MODIFIER", 104, 117], ["toxic", "OBSERVATION_MODIFIER", 118, 123], ["invasive", "OBSERVATION_MODIFIER", 232, 240], ["GAS infections", "OBSERVATION", 241, 255]]], ["Between 13 and 15% of patients presenting with invasive GAS infections develop STSS with a mortality rate ranging from 23 to 44% [16, 18] .", [["GAS infections", "DISEASE", 56, 70], ["STSS", "DISEASE", 79, 83], ["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["invasive GAS infections", "PROBLEM", 47, 70], ["STSS", "PROBLEM", 79, 83], ["a mortality rate", "TEST", 89, 105], ["infections", "OBSERVATION", 60, 70]]], ["Data from Center for Diseases Control (CDC) reported 309 cases of STSS infection, an incidence of 0.2 cases per 100,000 inhabitants/year, with a case fatality rate of 36% [18] .Epidemiology of streptococcal toxic shock syndromeIt is now well established that GAS infections, even when invasive, are associated with a low attributable mortality, unless they are invasive and meet the criteria for a toxic shock syndrome.", [["STSS infection", "DISEASE", 66, 80], ["streptococcal toxic shock syndrome", "DISEASE", 193, 227], ["GAS infections", "DISEASE", 259, 273], ["toxic shock syndrome", "DISEASE", 398, 418], ["STSS infection", "PROBLEM", 66, 80], ["a case fatality rate", "TEST", 143, 163], ["streptococcal toxic shock syndrome", "PROBLEM", 193, 227], ["GAS infections", "PROBLEM", 259, 273], ["a low attributable mortality", "PROBLEM", 315, 343], ["a toxic shock syndrome", "PROBLEM", 396, 418], ["infection", "OBSERVATION", 71, 80], ["streptococcal", "OBSERVATION_MODIFIER", 193, 206], ["toxic shock syndrome", "OBSERVATION", 207, 227], ["GAS", "OBSERVATION_MODIFIER", 259, 262], ["infections", "OBSERVATION", 263, 273], ["toxic", "OBSERVATION_MODIFIER", 398, 403], ["shock syndrome", "OBSERVATION", 404, 418]]], ["Streptococcal toxic shock syndrome mortality is mainly influenced by the patient's medical history, the site of infection, comorbidities, extremes of age, and the delay of diagnosis.", [["Streptococcal toxic shock syndrome", "DISEASE", 0, 34], ["infection", "DISEASE", 112, 121], ["patient", "ORGANISM", 73, 80], ["patient", "SPECIES", 73, 80], ["Streptococcal toxic shock syndrome mortality", "PROBLEM", 0, 44], ["infection", "PROBLEM", 112, 121], ["comorbidities", "PROBLEM", 123, 136], ["toxic", "OBSERVATION_MODIFIER", 14, 19], ["shock syndrome", "OBSERVATION", 20, 34], ["infection", "OBSERVATION", 112, 121]]], ["The morbidity associated with STSS can also be very significant, particularly when extensive surgical debridement is needed in cases with necrotizing fasciitis, and as a consequence of organ failure in shocked patients, some of them might be permanent, such as respiratory and renal insufficiency [19, 20] .Clinical presentation of streptococcal toxic shock syndromeThe CDC coined the definition of STSS in 2010 as \"a severe illness associated with noninvasive or more frequently with invasive group A streptococcal infections\" [13, 21] .", [["organ", "ANATOMY", 185, 190], ["respiratory", "ANATOMY", 261, 272], ["renal", "ANATOMY", 277, 282], ["STSS", "DISEASE", 30, 34], ["necrotizing fasciitis", "DISEASE", 138, 159], ["organ failure", "DISEASE", 185, 198], ["respiratory and renal insufficiency", "DISEASE", 261, 296], ["streptococcal toxic shock syndrome", "DISEASE", 332, 366], ["STSS", "DISEASE", 399, 403], ["illness", "DISEASE", 425, 432], ["streptococcal infections", "DISEASE", 502, 526], ["organ", "ORGAN", 185, 190], ["patients", "ORGANISM", 210, 218], ["renal", "ORGAN", 277, 282], ["patients", "SPECIES", 210, 218], ["The morbidity", "PROBLEM", 0, 13], ["STSS", "PROBLEM", 30, 34], ["extensive surgical debridement", "TREATMENT", 83, 113], ["necrotizing fasciitis", "PROBLEM", 138, 159], ["organ failure", "PROBLEM", 185, 198], ["respiratory and renal insufficiency", "PROBLEM", 261, 296], ["streptococcal toxic shock syndrome", "PROBLEM", 332, 366], ["a severe illness", "PROBLEM", 416, 432], ["invasive group A streptococcal infections", "PROBLEM", 485, 526], ["morbidity", "OBSERVATION", 4, 13], ["debridement", "OBSERVATION", 102, 113], ["necrotizing", "OBSERVATION_MODIFIER", 138, 149], ["fasciitis", "OBSERVATION", 150, 159], ["organ", "ANATOMY", 185, 190], ["failure", "OBSERVATION", 191, 198], ["renal", "ANATOMY", 277, 282], ["insufficiency", "OBSERVATION", 283, 296], ["streptococcal", "OBSERVATION_MODIFIER", 332, 345], ["toxic shock syndrome", "OBSERVATION", 346, 366]]], ["Patients with STSS usually present with a series of symptoms due to a combination of toxin secretion and the primary focus of infection.", [["STSS", "DISEASE", 14, 18], ["infection", "DISEASE", 126, 135], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["STSS", "PROBLEM", 14, 18], ["symptoms", "PROBLEM", 52, 60], ["toxin secretion", "PROBLEM", 85, 100], ["infection", "PROBLEM", 126, 135], ["infection", "OBSERVATION", 126, 135]]], ["Systemic symptoms of STSS are in great part related to the production and the secretion of GAS superantigen exotoxins, cross-linking the major histocompatibility class II and T cell receptors, present on antigen-presenting cells and T lymphocytes, respectively.", [["T cell", "ANATOMY", 175, 181], ["antigen-presenting cells", "ANATOMY", 204, 228], ["T lymphocytes", "ANATOMY", 233, 246], ["STSS", "DISEASE", 21, 25], ["GAS superantigen exotoxins", "GENE_OR_GENE_PRODUCT", 91, 117], ["histocompatibility class II", "GENE_OR_GENE_PRODUCT", 143, 170], ["T cell receptors", "GENE_OR_GENE_PRODUCT", 175, 191], ["cells", "CELL", 223, 228], ["T lymphocytes", "CELL", 233, 246], ["GAS superantigen exotoxins", "PROTEIN", 91, 117], ["major histocompatibility class II", "PROTEIN", 137, 170], ["T cell receptors", "PROTEIN", 175, 191], ["antigen-presenting cells", "CELL_TYPE", 204, 228], ["T lymphocytes", "CELL_TYPE", 233, 246], ["Systemic symptoms", "PROBLEM", 0, 17], ["STSS", "PROBLEM", 21, 25], ["the secretion of GAS superantigen exotoxins", "PROBLEM", 74, 117], ["T cell receptors", "TEST", 175, 191], ["STSS", "OBSERVATION", 21, 25]]], ["Symptoms are therefore closely related to the response of stimulated immune cells secreting proinflammatory cytokines and vasodilating mediators, resembling to those observed in \"classic\" septic shock, due to endotoxins, for example.", [["immune cells", "ANATOMY", 69, 81], ["septic shock", "DISEASE", 188, 200], ["immune cells", "CELL", 69, 81], ["stimulated immune cells", "CELL_TYPE", 58, 81], ["proinflammatory cytokines", "PROTEIN", 92, 117], ["Symptoms", "PROBLEM", 0, 8], ["stimulated immune cells", "TREATMENT", 58, 81], ["secreting proinflammatory cytokines", "PROBLEM", 82, 117], ["vasodilating mediators", "TREATMENT", 122, 144], ["classic\" septic shock", "PROBLEM", 179, 200], ["endotoxins", "PROBLEM", 209, 219], ["septic shock", "OBSERVATION", 188, 200]]], ["STSS may occur as a complication of GAS infections occurring at any site, but most frequently associated with soft tissue infections, such as cellulitis, myositis, and necrotizing fasciitis [22] .Clinical presentation of streptococcal toxic shock syndromeClassically, three phases are described for the clinical presentation of STSS [2] .", [["soft tissue", "ANATOMY", 110, 121], ["STSS", "DISEASE", 0, 4], ["infections", "DISEASE", 40, 50], ["soft tissue infections", "DISEASE", 110, 132], ["cellulitis", "DISEASE", 142, 152], ["myositis", "DISEASE", 154, 162], ["necrotizing fasciitis", "DISEASE", 168, 189], ["streptococcal toxic shock", "DISEASE", 221, 246], ["STSS", "DISEASE", 328, 332], ["soft tissue", "TISSUE", 110, 121], ["STSS", "PROBLEM", 0, 4], ["GAS infections", "PROBLEM", 36, 50], ["soft tissue infections", "PROBLEM", 110, 132], ["cellulitis", "PROBLEM", 142, 152], ["myositis", "PROBLEM", 154, 162], ["necrotizing fasciitis", "PROBLEM", 168, 189], ["streptococcal toxic shock syndromeClassically", "PROBLEM", 221, 266], ["GAS infections", "OBSERVATION", 36, 50], ["soft tissue", "OBSERVATION_MODIFIER", 110, 121], ["infections", "OBSERVATION", 122, 132], ["cellulitis", "OBSERVATION", 142, 152], ["myositis", "OBSERVATION", 154, 162], ["necrotizing", "OBSERVATION_MODIFIER", 168, 179], ["fasciitis", "OBSERVATION", 180, 189], ["streptococcal", "OBSERVATION_MODIFIER", 221, 234], ["toxic", "OBSERVATION_MODIFIER", 235, 240], ["shock syndromeClassically", "OBSERVATION", 241, 266]]], ["The first phase which precedes the onset of severe hypotension by 24-48 h. is a severe influenza-like illness characterized by high fever, myalgia, headaches, and chills.", [["hypotension", "DISEASE", 51, 62], ["influenza-like illness", "DISEASE", 87, 109], ["fever", "DISEASE", 132, 137], ["myalgia", "DISEASE", 139, 146], ["headaches", "DISEASE", 148, 157], ["chills", "DISEASE", 163, 169], ["severe hypotension", "PROBLEM", 44, 62], ["a severe influenza-like illness", "PROBLEM", 78, 109], ["high fever", "PROBLEM", 127, 137], ["myalgia", "PROBLEM", 139, 146], ["headaches", "PROBLEM", 148, 157], ["chills", "PROBLEM", 163, 169], ["severe", "OBSERVATION_MODIFIER", 44, 50], ["hypotension", "OBSERVATION", 51, 62], ["severe", "OBSERVATION_MODIFIER", 80, 86], ["influenza", "OBSERVATION", 87, 96], ["high", "OBSERVATION_MODIFIER", 127, 131], ["fever", "OBSERVATION", 132, 137], ["myalgia", "OBSERVATION", 139, 146], ["chills", "OBSERVATION", 163, 169]]], ["Nonspecific digestive symptoms such as nausea, vomiting, and diarrhea may also be present during this initial phase.", [["digestive", "ANATOMY", 12, 21], ["Nonspecific digestive symptoms", "DISEASE", 0, 30], ["nausea", "DISEASE", 39, 45], ["vomiting", "DISEASE", 47, 55], ["diarrhea", "DISEASE", 61, 69], ["digestive", "ORGAN", 12, 21], ["Nonspecific digestive symptoms", "PROBLEM", 0, 30], ["nausea", "PROBLEM", 39, 45], ["vomiting", "PROBLEM", 47, 55], ["diarrhea", "PROBLEM", 61, 69], ["diarrhea", "OBSERVATION", 61, 69]]], ["Alteration of the central nervous system with delirium is reported in roughly half of patients.", [["central nervous system", "ANATOMY", 18, 40], ["Alteration of the central nervous system", "DISEASE", 0, 40], ["delirium", "DISEASE", 46, 54], ["central nervous system", "ANATOMICAL_SYSTEM", 18, 40], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["delirium", "PROBLEM", 46, 54], ["central", "ANATOMY_MODIFIER", 18, 25], ["nervous system", "ANATOMY", 26, 40], ["delirium", "OBSERVATION", 46, 54]]], ["Skin lesions as possible streptococcal infection may be present.", [["Skin lesions", "ANATOMY", 0, 12], ["streptococcal infection", "DISEASE", 25, 48], ["Skin lesions", "PATHOLOGICAL_FORMATION", 0, 12], ["Skin lesions", "PROBLEM", 0, 12], ["streptococcal infection", "PROBLEM", 25, 48], ["lesions", "OBSERVATION", 5, 12], ["possible", "UNCERTAINTY", 16, 24], ["streptococcal", "OBSERVATION_MODIFIER", 25, 38], ["infection", "OBSERVATION", 39, 48]]], ["Examination of the skin and soft tissues is essential in the initial clinical evaluation of the patients, as well as during follow-up, up to four times per day, looking for tenderness, localized swelling, and erythema, or the more suggestive violaceous bullae, such as those observed in necrotizing fasciitis.", [["skin", "ANATOMY", 19, 23], ["soft tissues", "ANATOMY", 28, 40], ["bullae", "ANATOMY", 253, 259], ["tenderness", "DISEASE", 173, 183], ["swelling", "DISEASE", 195, 203], ["erythema", "DISEASE", 209, 217], ["bullae", "DISEASE", 253, 259], ["necrotizing fasciitis", "DISEASE", 287, 308], ["skin", "ORGAN", 19, 23], ["soft tissues", "TISSUE", 28, 40], ["patients", "ORGANISM", 96, 104], ["erythema", "PATHOLOGICAL_FORMATION", 209, 217], ["bullae", "PATHOLOGICAL_FORMATION", 253, 259], ["patients", "SPECIES", 96, 104], ["Examination of the skin and soft tissues", "TEST", 0, 40], ["the initial clinical evaluation", "TEST", 57, 88], ["tenderness", "PROBLEM", 173, 183], ["localized swelling", "PROBLEM", 185, 203], ["erythema", "PROBLEM", 209, 217], ["violaceous bullae", "PROBLEM", 242, 259], ["necrotizing fasciitis", "PROBLEM", 287, 308], ["skin", "ANATOMY", 19, 23], ["soft tissues", "ANATOMY", 28, 40], ["localized", "OBSERVATION_MODIFIER", 185, 194], ["swelling", "OBSERVATION", 195, 203], ["erythema", "OBSERVATION", 209, 217], ["violaceous", "OBSERVATION_MODIFIER", 242, 252], ["bullae", "OBSERVATION", 253, 259], ["necrotizing", "OBSERVATION_MODIFIER", 287, 298], ["fasciitis", "OBSERVATION", 299, 308]]], ["An early and transient macular rash may be present, predominating on the upper chest [23] .", [["macular", "ANATOMY", 23, 30], ["rash", "DISEASE", 31, 35], ["An early and transient macular rash", "PROBLEM", 0, 35], ["early", "OBSERVATION_MODIFIER", 3, 8], ["transient", "OBSERVATION_MODIFIER", 13, 22], ["macular rash", "OBSERVATION", 23, 35], ["may be", "UNCERTAINTY", 36, 42], ["upper", "ANATOMY_MODIFIER", 73, 78], ["chest", "ANATOMY", 79, 84]]], ["Palmar and plantar desquamation is classical in STSS, but does not occur in all patients and is usually observed only few days after the in initial symptoms ( Fig. 1 ) [23] .Clinical presentation of streptococcal toxic shock syndromeSoft tissues involved with GAS infections are usually very painful (hyperalgesia), frequently disproportionately compared to findings on clinical examination.", [["Palmar", "ANATOMY", 0, 6], ["plantar", "ANATOMY", 11, 18], ["Soft tissues", "ANATOMY", 233, 245], ["desquamation", "DISEASE", 19, 31], ["STSS", "DISEASE", 48, 52], ["streptococcal toxic shock syndrome", "DISEASE", 199, 233], ["infections", "DISEASE", 264, 274], ["hyperalgesia", "DISEASE", 301, 313], ["plantar", "ORGANISM_SUBDIVISION", 11, 18], ["STSS", "CANCER", 48, 52], ["patients", "ORGANISM", 80, 88], ["Soft tissues", "TISSUE", 233, 245], ["patients", "SPECIES", 80, 88], ["Palmar and plantar desquamation", "PROBLEM", 0, 31], ["streptococcal toxic shock syndrome", "PROBLEM", 199, 233], ["GAS infections", "PROBLEM", 260, 274], ["very painful", "PROBLEM", 287, 299], ["hyperalgesia", "PROBLEM", 301, 313], ["clinical examination", "TEST", 370, 390], ["plantar", "ANATOMY", 11, 18], ["desquamation", "OBSERVATION", 19, 31], ["streptococcal", "OBSERVATION_MODIFIER", 199, 212], ["toxic shock syndrome", "OBSERVATION", 213, 233], ["tissues", "ANATOMY", 238, 245], ["GAS infections", "OBSERVATION", 260, 274]]], ["Pain can be localized in a limb, but also on the abdomen, pelvis or thorax.", [["limb", "ANATOMY", 27, 31], ["abdomen", "ANATOMY", 49, 56], ["pelvis", "ANATOMY", 58, 64], ["thorax", "ANATOMY", 68, 74], ["Pain", "DISEASE", 0, 4], ["limb", "ORGANISM_SUBDIVISION", 27, 31], ["abdomen", "ORGAN", 49, 56], ["pelvis", "ORGAN", 58, 64], ["thorax", "ORGAN", 68, 74], ["Pain", "PROBLEM", 0, 4], ["limb", "ANATOMY", 27, 31], ["abdomen", "ANATOMY", 49, 56], ["pelvis", "ANATOMY", 58, 64], ["thorax", "ANATOMY", 68, 74]]], ["The discrepancy between the intensity of the pain reported by the patient, and a normal (or quasinormal) clinical examination should alert the clinician for the possibility of a STSS.", [["pain", "DISEASE", 45, 49], ["STSS", "DISEASE", 178, 182], ["patient", "ORGANISM", 66, 73], ["patient", "SPECIES", 66, 73], ["the pain", "PROBLEM", 41, 49], ["clinical examination", "TEST", 105, 125], ["a STSS", "PROBLEM", 176, 182], ["discrepancy", "OBSERVATION_MODIFIER", 4, 15], ["intensity", "OBSERVATION_MODIFIER", 28, 37]]], ["Changes in skin color and violaceous bullae are also highly suggestive of invasive S. pyogenes soft tissue infection.", [["skin", "ANATOMY", 11, 15], ["violaceous bullae", "ANATOMY", 26, 43], ["soft tissue", "ANATOMY", 95, 106], ["infection", "DISEASE", 107, 116], ["skin", "ORGAN", 11, 15], ["violaceous bullae", "PATHOLOGICAL_FORMATION", 26, 43], ["S. pyogenes", "ORGANISM", 83, 94], ["soft tissue", "TISSUE", 95, 106], ["S. pyogenes", "SPECIES", 83, 94], ["S. pyogenes", "SPECIES", 83, 94], ["Changes in skin color", "PROBLEM", 0, 21], ["violaceous bullae", "PROBLEM", 26, 43], ["invasive S. pyogenes soft tissue infection", "PROBLEM", 74, 116], ["skin", "ANATOMY", 11, 15], ["color", "OBSERVATION_MODIFIER", 16, 21], ["violaceous", "OBSERVATION_MODIFIER", 26, 36], ["bullae", "OBSERVATION", 37, 43], ["highly suggestive of", "UNCERTAINTY", 53, 73], ["invasive", "OBSERVATION_MODIFIER", 74, 82], ["pyogenes", "OBSERVATION_MODIFIER", 86, 94], ["soft tissue", "OBSERVATION_MODIFIER", 95, 106], ["infection", "OBSERVATION", 107, 116]]], ["The clinical evidence for deep invasive infection will become more obvious as the illness progresses.", [["infection", "DISEASE", 40, 49], ["deep invasive infection", "PROBLEM", 26, 49], ["evidence for", "UNCERTAINTY", 13, 25], ["deep", "OBSERVATION_MODIFIER", 26, 30], ["invasive", "OBSERVATION_MODIFIER", 31, 39], ["infection", "OBSERVATION", 40, 49]]], ["Erroneous diagnoses, depending on the localization, are frequent.", [["Erroneous diagnoses", "PROBLEM", 0, 19]]], ["Classical initial misdiagnoses are deep vein thrombosis, limb ischemia, gastroenteritis, peritonitis, acute coronary syndrome, pericarditis, and meningitis.Clinical presentation of streptococcal toxic shock syndromeIn some cases, a skin lesion suggestive of GAS entry is visible early in the development of an invasive GAS infection and should be thoroughly searched for.", [["deep vein", "ANATOMY", 35, 44], ["limb", "ANATOMY", 57, 61], ["coronary", "ANATOMY", 108, 116], ["skin lesion", "ANATOMY", 232, 243], ["deep vein thrombosis", "DISEASE", 35, 55], ["limb ischemia", "DISEASE", 57, 70], ["gastroenteritis", "DISEASE", 72, 87], ["peritonitis", "DISEASE", 89, 100], ["acute coronary syndrome", "DISEASE", 102, 125], ["pericarditis", "DISEASE", 127, 139], ["meningitis", "DISEASE", 145, 155], ["streptococcal toxic shock syndrome", "DISEASE", 181, 215], ["GAS infection", "DISEASE", 319, 332], ["deep vein", "MULTI-TISSUE_STRUCTURE", 35, 44], ["limb", "ORGANISM_SUBDIVISION", 57, 61], ["skin", "ORGAN", 232, 236], ["Classical initial misdiagnoses", "PROBLEM", 0, 30], ["deep vein thrombosis", "PROBLEM", 35, 55], ["limb ischemia", "PROBLEM", 57, 70], ["gastroenteritis", "PROBLEM", 72, 87], ["peritonitis", "PROBLEM", 89, 100], ["acute coronary syndrome", "PROBLEM", 102, 125], ["pericarditis", "PROBLEM", 127, 139], ["meningitis", "PROBLEM", 145, 155], ["streptococcal toxic shock syndrome", "PROBLEM", 181, 215], ["a skin lesion", "PROBLEM", 230, 243], ["GAS entry", "PROBLEM", 258, 267], ["an invasive GAS infection", "PROBLEM", 307, 332], ["deep vein thrombosis", "OBSERVATION", 35, 55], ["limb", "ANATOMY", 57, 61], ["ischemia", "OBSERVATION", 62, 70], ["gastroenteritis", "OBSERVATION", 72, 87], ["peritonitis", "OBSERVATION", 89, 100], ["acute", "OBSERVATION_MODIFIER", 102, 107], ["coronary", "ANATOMY", 108, 116], ["syndrome", "OBSERVATION", 117, 125], ["pericarditis", "OBSERVATION", 127, 139], ["meningitis", "OBSERVATION", 145, 155], ["streptococcal", "OBSERVATION_MODIFIER", 181, 194], ["toxic shock syndrome", "OBSERVATION", 195, 215], ["skin", "ANATOMY", 232, 236], ["lesion", "OBSERVATION", 237, 243], ["suggestive of", "UNCERTAINTY", 244, 257], ["GAS entry", "OBSERVATION", 258, 267], ["visible", "OBSERVATION_MODIFIER", 271, 278], ["invasive", "OBSERVATION_MODIFIER", 310, 318], ["GAS infection", "OBSERVATION", 319, 332]]], ["This lesion can be as insignificant as a skin abrasion, often associated with localized redness, edema, but also hematoma or bullae.", [["lesion", "ANATOMY", 5, 11], ["skin", "ANATOMY", 41, 45], ["edema", "ANATOMY", 97, 102], ["hematoma", "ANATOMY", 113, 121], ["bullae", "ANATOMY", 125, 131], ["skin abrasion", "DISEASE", 41, 54], ["redness", "DISEASE", 88, 95], ["edema", "DISEASE", 97, 102], ["hematoma", "DISEASE", 113, 121], ["bullae", "DISEASE", 125, 131], ["skin", "ORGAN", 41, 45], ["edema", "PATHOLOGICAL_FORMATION", 97, 102], ["hematoma", "PATHOLOGICAL_FORMATION", 113, 121], ["bullae", "PATHOLOGICAL_FORMATION", 125, 131], ["This lesion", "PROBLEM", 0, 11], ["a skin abrasion", "PROBLEM", 39, 54], ["localized redness", "PROBLEM", 78, 95], ["edema", "PROBLEM", 97, 102], ["hematoma", "PROBLEM", 113, 121], ["bullae", "PROBLEM", 125, 131], ["lesion", "OBSERVATION", 5, 11], ["insignificant", "OBSERVATION_MODIFIER", 22, 35], ["skin", "ANATOMY", 41, 45], ["abrasion", "OBSERVATION", 46, 54], ["localized", "OBSERVATION_MODIFIER", 78, 87], ["redness", "OBSERVATION", 88, 95], ["edema", "OBSERVATION", 97, 102], ["hematoma", "OBSERVATION", 113, 121], ["bullae", "OBSERVATION", 125, 131]]], ["However, in more than half of severe GAS infections with STSS, such skin lesions will not be found [2] .Clinical presentation of streptococcal toxic shock syndromeThe second phase of the STSS is characterized by systemic manifestations, such as tachycardia, tachypnea, and high fever.", [["skin lesions", "ANATOMY", 68, 80], ["infections", "DISEASE", 41, 51], ["STSS", "DISEASE", 57, 61], ["streptococcal toxic shock syndrome", "DISEASE", 129, 163], ["STSS", "DISEASE", 187, 191], ["tachycardia", "DISEASE", 245, 256], ["tachypnea", "DISEASE", 258, 267], ["fever", "DISEASE", 278, 283], ["skin lesions", "PATHOLOGICAL_FORMATION", 68, 80], ["severe GAS infections", "PROBLEM", 30, 51], ["STSS", "PROBLEM", 57, 61], ["such skin lesions", "PROBLEM", 63, 80], ["streptococcal toxic shock syndrome", "PROBLEM", 129, 163], ["the STSS", "TEST", 183, 191], ["systemic manifestations", "PROBLEM", 212, 235], ["tachycardia", "PROBLEM", 245, 256], ["tachypnea", "PROBLEM", 258, 267], ["high fever", "PROBLEM", 273, 283], ["severe", "OBSERVATION_MODIFIER", 30, 36], ["GAS", "OBSERVATION_MODIFIER", 37, 40], ["infections", "OBSERVATION", 41, 51], ["skin", "ANATOMY", 68, 72], ["lesions", "OBSERVATION", 73, 80], ["streptococcal", "OBSERVATION_MODIFIER", 129, 142], ["toxic shock syndrome", "OBSERVATION", 143, 163], ["second", "OBSERVATION_MODIFIER", 167, 173], ["phase", "OBSERVATION_MODIFIER", 174, 179], ["STSS", "OBSERVATION", 187, 191], ["systemic", "OBSERVATION_MODIFIER", 212, 220], ["manifestations", "OBSERVATION", 221, 235], ["tachycardia", "OBSERVATION", 245, 256], ["tachypnea", "OBSERVATION", 258, 267], ["high", "OBSERVATION_MODIFIER", 273, 277], ["fever", "OBSERVATION", 278, 283]]], ["As said previously, pain is usually present in a limb, in the abdomen or the thorax, and is disproportionate compared to the clinical findings, even with deep invasive infection, such as necrotizing fasciitis ( Fig. 2) .", [["limb", "ANATOMY", 49, 53], ["abdomen", "ANATOMY", 62, 69], ["thorax", "ANATOMY", 77, 83], ["pain", "DISEASE", 20, 24], ["infection", "DISEASE", 168, 177], ["necrotizing fasciitis", "DISEASE", 187, 208], ["limb", "ORGANISM_SUBDIVISION", 49, 53], ["abdomen", "ORGAN", 62, 69], ["thorax", "ORGAN", 77, 83], ["pain", "PROBLEM", 20, 24], ["deep invasive infection", "PROBLEM", 154, 177], ["necrotizing fasciitis", "PROBLEM", 187, 208], ["limb", "ANATOMY", 49, 53], ["abdomen", "ANATOMY", 62, 69], ["thorax", "ANATOMY", 77, 83], ["disproportionate", "OBSERVATION_MODIFIER", 92, 108], ["deep", "OBSERVATION_MODIFIER", 154, 158], ["invasive", "OBSERVATION_MODIFIER", 159, 167], ["infection", "OBSERVATION", 168, 177], ["necrotizing", "OBSERVATION_MODIFIER", 187, 198], ["fasciitis", "OBSERVATION", 199, 208]]], ["Other possible and more frequent causes of infectious occurrences of fever should be ruled out, such as pneumonia, abdominal infection, or meningitis in case of neurological impairment.", [["abdominal", "ANATOMY", 115, 124], ["neurological", "ANATOMY", 161, 173], ["fever", "DISEASE", 69, 74], ["pneumonia", "DISEASE", 104, 113], ["abdominal infection", "DISEASE", 115, 134], ["meningitis", "DISEASE", 139, 149], ["neurological impairment", "DISEASE", 161, 184], ["abdominal", "ORGANISM_SUBDIVISION", 115, 124], ["fever", "PROBLEM", 69, 74], ["pneumonia", "PROBLEM", 104, 113], ["abdominal infection", "PROBLEM", 115, 134], ["meningitis", "PROBLEM", 139, 149], ["neurological impairment", "PROBLEM", 161, 184], ["infectious", "OBSERVATION", 43, 53], ["fever", "OBSERVATION", 69, 74], ["pneumonia", "OBSERVATION", 104, 113], ["abdominal", "ANATOMY", 115, 124], ["infection", "OBSERVATION", 125, 134], ["meningitis", "OBSERVATION", 139, 149]]], ["At this stage, computed tomography (CT) scan and/or magnetic resonance imaging (MRI) exams are usually useful to evaluate the soft tissue source of GAS infection, as well as to make a difference between skin infection and fasciitis.", [["soft tissue", "ANATOMY", 126, 137], ["skin", "ANATOMY", 203, 207], ["infection", "DISEASE", 152, 161], ["skin infection", "DISEASE", 203, 217], ["fasciitis", "DISEASE", 222, 231], ["soft tissue", "TISSUE", 126, 137], ["skin", "ORGAN", 203, 207], ["computed tomography (CT) scan", "TEST", 15, 44], ["magnetic resonance imaging", "TEST", 52, 78], ["MRI) exams", "TEST", 80, 90], ["GAS infection", "PROBLEM", 148, 161], ["a difference between skin infection", "PROBLEM", 182, 217], ["fasciitis", "PROBLEM", 222, 231], ["soft tissue", "ANATOMY", 126, 137], ["GAS infection", "OBSERVATION", 148, 161], ["skin", "ANATOMY", 203, 207], ["infection", "OBSERVATION", 208, 217], ["fasciitis", "OBSERVATION", 222, 231]]], ["In case of doubt, surgical revision should be performed with biopsy of the fascia, and intensive lavage and debridement in case of infection and necrosis, respectively.Clinical presentation of streptococcal toxic shock syndromeThe third phase of clinical presentation is characterized by circulatory shock that can be sudden and profound, accompanied by multiple organ failure.", [["fascia", "ANATOMY", 75, 81], ["organ", "ANATOMY", 363, 368], ["infection", "DISEASE", 131, 140], ["necrosis", "DISEASE", 145, 153], ["streptococcal toxic shock syndrome", "DISEASE", 193, 227], ["circulatory shock", "DISEASE", 288, 305], ["organ failure", "DISEASE", 363, 376], ["fascia", "TISSUE", 75, 81], ["organ", "ORGAN", 363, 368], ["surgical revision", "TREATMENT", 18, 35], ["biopsy of the fascia", "TEST", 61, 81], ["intensive lavage", "TEST", 87, 103], ["debridement", "TREATMENT", 108, 119], ["infection", "PROBLEM", 131, 140], ["necrosis", "PROBLEM", 145, 153], ["streptococcal toxic shock syndrome", "PROBLEM", 193, 227], ["circulatory shock", "PROBLEM", 288, 305], ["multiple organ failure", "PROBLEM", 354, 376], ["surgical revision", "OBSERVATION", 18, 35], ["fascia", "ANATOMY", 75, 81], ["debridement", "OBSERVATION", 108, 119], ["infection", "OBSERVATION", 131, 140], ["necrosis", "OBSERVATION", 145, 153], ["streptococcal", "OBSERVATION_MODIFIER", 193, 206], ["toxic shock syndrome", "OBSERVATION", 207, 227], ["third", "OBSERVATION_MODIFIER", 231, 236], ["phase", "OBSERVATION_MODIFIER", 237, 242], ["circulatory shock", "OBSERVATION", 288, 305], ["multiple", "OBSERVATION_MODIFIER", 354, 362], ["organ", "ANATOMY", 363, 368], ["failure", "OBSERVATION", 369, 376]]], ["Despite aggressive therapy many patients will die within 24-48 h of hospitalization.", [["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["aggressive therapy", "TREATMENT", 8, 26]]], ["The clinical criteria defined by the CDC are shown in Table 1 and are based on signs of shock, organ dysfunction, and skin involvement.", [["organ", "ANATOMY", 95, 100], ["skin", "ANATOMY", 118, 122], ["shock", "DISEASE", 88, 93], ["organ dysfunction", "DISEASE", 95, 112], ["organ", "ORGAN", 95, 100], ["skin", "ORGAN", 118, 122], ["the CDC", "TEST", 33, 40], ["shock", "PROBLEM", 88, 93], ["organ dysfunction", "PROBLEM", 95, 112], ["skin involvement", "PROBLEM", 118, 134], ["shock", "OBSERVATION", 88, 93], ["organ", "ANATOMY", 95, 100], ["dysfunction", "OBSERVATION", 101, 112], ["skin", "ANATOMY", 118, 122]]], ["Although used widely, many of the CDC criteria are not specific for STSS and are observed in sepsis or septic shock associated with other bacteria.", [["STSS", "DISEASE", 68, 72], ["sepsis", "DISEASE", 93, 99], ["septic shock", "DISEASE", 103, 115], ["the CDC criteria", "TEST", 30, 46], ["STSS", "PROBLEM", 68, 72], ["sepsis", "PROBLEM", 93, 99], ["septic shock", "PROBLEM", 103, 115], ["other bacteria", "PROBLEM", 132, 146], ["sepsis", "OBSERVATION", 93, 99], ["septic shock", "OBSERVATION", 103, 115]]], ["Acute renal failure with elevated serum creatinine levels at the time of admission is, however, classical in STSS.", [["renal", "ANATOMY", 6, 11], ["serum", "ANATOMY", 34, 39], ["Acute renal failure", "DISEASE", 0, 19], ["creatinine", "CHEMICAL", 40, 50], ["STSS", "DISEASE", 109, 113], ["creatinine", "CHEMICAL", 40, 50], ["renal", "ORGAN", 6, 11], ["serum", "ORGANISM_SUBSTANCE", 34, 39], ["creatinine", "SIMPLE_CHEMICAL", 40, 50], ["STSS", "CANCER", 109, 113], ["Acute renal failure", "PROBLEM", 0, 19], ["elevated serum creatinine levels", "PROBLEM", 25, 57], ["renal", "ANATOMY", 6, 11], ["failure", "OBSERVATION", 12, 19], ["elevated", "OBSERVATION_MODIFIER", 25, 33], ["serum", "OBSERVATION_MODIFIER", 34, 39]]], ["In Table 2 are summarized symptoms, signs, and elements of clinical history suggestive of STSS reported in the literature.Clinical presentation of streptococcal toxic shock syndromeThe definition of \"probable\" and \"confirmed cases\" (CDC criteria) are the following [21] : A \"probable case\" is a case that meets the clinical case definition in the absence of another identified etiology for the illness, and with isolation of GAS from a non-sterile site.", [["STSS", "DISEASE", 90, 94], ["streptococcal toxic shock syndrome", "DISEASE", 147, 181], ["illness", "DISEASE", 394, 401], ["STSS", "CANCER", 90, 94], ["GAS", "DNA", 425, 428], ["summarized symptoms", "PROBLEM", 15, 34], ["signs", "PROBLEM", 36, 41], ["STSS", "PROBLEM", 90, 94], ["streptococcal toxic shock syndrome", "PROBLEM", 147, 181], ["the illness", "PROBLEM", 390, 401], ["GAS", "PROBLEM", 425, 428], ["a non-sterile site", "TREATMENT", 434, 452], ["STSS", "OBSERVATION", 90, 94], ["streptococcal", "OBSERVATION_MODIFIER", 147, 160], ["toxic shock syndrome", "OBSERVATION", 161, 181], ["GAS", "OBSERVATION", 425, 428]]], ["A \"confirmed case\" is a case that meets the clinical case definition and with isolation of group A streptococcus from a normally sterile site (e.g., blood, cerebrospinal, synovial, pleural or pericardial fluid).Laboratory investigations, microbiology, and imagingThe white blood cell count can be normal or only moderately elevated at the time of admission, usually accompanied by a marked elevation of circulating immature neutrophils (band forms).", [["site", "ANATOMY", 137, 141], ["blood", "ANATOMY", 149, 154], ["cerebrospinal", "ANATOMY", 156, 169], ["synovial", "ANATOMY", 171, 179], ["pleural", "ANATOMY", 181, 188], ["pericardial fluid", "ANATOMY", 192, 209], ["white blood cell", "ANATOMY", 267, 283], ["neutrophils", "ANATOMY", 424, 435], ["blood", "ORGANISM_SUBSTANCE", 149, 154], ["cerebrospinal", "ORGANISM_SUBSTANCE", 156, 169], ["synovial", "TISSUE", 171, 179], ["pleural", "MULTI-TISSUE_STRUCTURE", 181, 188], ["pericardial fluid", "MULTI-TISSUE_STRUCTURE", 192, 209], ["white blood cell", "CELL", 267, 283], ["neutrophils", "CELL", 424, 435], ["circulating immature neutrophils", "CELL_TYPE", 403, 435], ["group A streptococcus", "PROBLEM", 91, 112], ["blood, cerebrospinal, synovial, pleural or pericardial fluid", "PROBLEM", 149, 209], ["Laboratory investigations", "TEST", 211, 236], ["microbiology", "TEST", 238, 250], ["imaging", "TEST", 256, 263], ["The white blood cell count", "TEST", 263, 289], ["moderately elevated", "PROBLEM", 312, 331], ["a marked elevation of circulating immature neutrophils", "PROBLEM", 381, 435], ["cerebrospinal", "ANATOMY", 156, 169], ["synovial", "ANATOMY", 171, 179], ["pleural", "ANATOMY", 181, 188], ["pericardial", "ANATOMY", 192, 203], ["fluid", "OBSERVATION", 204, 209], ["normal", "OBSERVATION", 297, 303], ["moderately", "OBSERVATION_MODIFIER", 312, 322], ["elevated", "OBSERVATION_MODIFIER", 323, 331], ["marked", "OBSERVATION_MODIFIER", 383, 389], ["elevation", "OBSERVATION_MODIFIER", 390, 399], ["circulating immature neutrophils", "OBSERVATION", 403, 435]]], ["The diffuse capillary leak, together with IV fluid loading may contribute to low albumin levels.", [["capillary", "ANATOMY", 12, 21], ["fluid", "ANATOMY", 45, 50], ["capillary", "TISSUE", 12, 21], ["albumin", "GENE_OR_GENE_PRODUCT", 81, 88], ["albumin", "PROTEIN", 81, 88], ["The diffuse capillary leak", "PROBLEM", 0, 26], ["IV fluid loading", "TREATMENT", 42, 58], ["low albumin levels", "PROBLEM", 77, 95], ["diffuse", "OBSERVATION_MODIFIER", 4, 11], ["capillary leak", "OBSERVATION", 12, 26]]], ["Hemolysins produced by GAS may cause a hemolytic anemia.", [["Hemolysins", "CHEMICAL", 0, 10], ["hemolytic anemia", "DISEASE", 39, 55], ["Hemolysins", "GENE_OR_GENE_PRODUCT", 0, 10], ["GAS", "ORGANISM", 23, 26], ["Hemolysins", "PROBLEM", 0, 10], ["a hemolytic anemia", "PROBLEM", 37, 55], ["GAS", "OBSERVATION", 23, 26], ["may cause", "UNCERTAINTY", 27, 36], ["hemolytic", "OBSERVATION_MODIFIER", 39, 48], ["anemia", "OBSERVATION", 49, 55]]], ["A multiple organ dysfunction will reflect in organ-specific laboratory tests (increased creatinine in case of decreased renal function, low platelets and increased clotting times in case of coagulopathy, increased levels of transaminases for liver involvement, and hypoxemia in case of acute lung injury or ARDS) [2, 25, 26] .", [["organ", "ANATOMY", 11, 16], ["organ", "ANATOMY", 45, 50], ["renal", "ANATOMY", 120, 125], ["platelets", "ANATOMY", 140, 149], ["liver", "ANATOMY", 242, 247], ["lung", "ANATOMY", 292, 296], ["organ dysfunction", "DISEASE", 11, 28], ["creatinine", "CHEMICAL", 88, 98], ["coagulopathy", "DISEASE", 190, 202], ["liver involvement", "DISEASE", 242, 259], ["hypoxemia", "DISEASE", 265, 274], ["acute lung injury", "DISEASE", 286, 303], ["ARDS", "DISEASE", 307, 311], ["creatinine", "CHEMICAL", 88, 98], ["organ", "ORGAN", 11, 16], ["organ", "ORGAN", 45, 50], ["creatinine", "SIMPLE_CHEMICAL", 88, 98], ["renal", "ORGAN", 120, 125], ["platelets", "CELL", 140, 149], ["liver", "ORGAN", 242, 247], ["lung", "ORGAN", 292, 296], ["platelets", "CELL_TYPE", 140, 149], ["A multiple organ dysfunction", "PROBLEM", 0, 28], ["specific laboratory tests", "TEST", 51, 76], ["increased creatinine", "PROBLEM", 78, 98], ["decreased renal function", "PROBLEM", 110, 134], ["low platelets", "PROBLEM", 136, 149], ["increased clotting times", "PROBLEM", 154, 178], ["coagulopathy", "PROBLEM", 190, 202], ["increased levels of transaminases", "PROBLEM", 204, 237], ["liver involvement", "PROBLEM", 242, 259], ["hypoxemia", "PROBLEM", 265, 274], ["acute lung injury", "PROBLEM", 286, 303], ["ARDS", "PROBLEM", 307, 311], ["multiple", "OBSERVATION_MODIFIER", 2, 10], ["organ", "ANATOMY", 11, 16], ["dysfunction", "OBSERVATION", 17, 28], ["renal", "ANATOMY", 120, 125], ["low platelets", "OBSERVATION_MODIFIER", 136, 149], ["coagulopathy", "OBSERVATION", 190, 202], ["liver", "ANATOMY", 242, 247], ["hypoxemia", "OBSERVATION", 265, 274], ["acute", "OBSERVATION_MODIFIER", 286, 291], ["lung", "ANATOMY", 292, 296], ["injury", "OBSERVATION", 297, 303], ["ARDS", "OBSERVATION", 307, 311]]], ["Increased creatinine levels at the time of admission are suggestive of STSS due to GAS, and more frequently observed than in other cases of \"classical septic shock.", [["creatinine", "CHEMICAL", 10, 20], ["STSS", "DISEASE", 71, 75], ["septic shock", "DISEASE", 151, 163], ["creatinine", "CHEMICAL", 10, 20], ["creatinine", "GENE_OR_GENE_PRODUCT", 10, 20], ["Increased creatinine levels", "PROBLEM", 0, 27], ["STSS", "PROBLEM", 71, 75], ["GAS", "PROBLEM", 83, 86], ["classical septic shock", "PROBLEM", 141, 163], ["creatinine", "OBSERVATION", 10, 20], ["suggestive of", "UNCERTAINTY", 57, 70], ["STSS", "OBSERVATION", 71, 75], ["GAS", "OBSERVATION", 83, 86], ["septic shock", "OBSERVATION", 151, 163]]], ["\"Laboratory investigations, microbiology, and imagingA particular effort should be paid to seek for the presence of streptococci (GAS, essentially) from sterile Table 1 Clinical criteria for streptococcal toxic shock syndrome based on CDC definitions [13] a Clinical manifestations do not need to be detected within the first 48 h of hospitalization or illness, as specified in the 1996 case definition [24] .", [["streptococcal toxic shock syndrome", "DISEASE", 191, 225], ["illness", "DISEASE", 353, 360], ["Laboratory investigations", "TEST", 1, 26], ["microbiology", "TEST", 28, 40], ["imaging", "TEST", 46, 53], ["streptococci", "PROBLEM", 116, 128], ["streptococcal toxic shock syndrome", "PROBLEM", 191, 225], ["CDC definitions", "TEST", 235, 250], ["a Clinical manifestations", "PROBLEM", 256, 281], ["illness", "PROBLEM", 353, 360], ["streptococci", "OBSERVATION", 116, 128], ["toxic shock syndrome", "OBSERVATION", 205, 225]]], ["The specification of the 48-h time constraint was for the purpose of assessing whether the case was considered nosocomial, not whether it was a case or not Clinical criteria: An illness with the following clinical manifestations a Hypotension defined by a systolic blood pressure less than or equal to 90 mmHg for adults or less than the fifth percentile by age for children aged less than 16 years Multiple organ involvement characterized by two or more of the following Renal impairment: Creatinin \u2265 2 mg/dL (\u2265 177 \u00b5mol/L) for adults or \u2265 twice the upper limit of normal for age.", [["blood", "ANATOMY", 265, 270], ["organ", "ANATOMY", 408, 413], ["Renal", "ANATOMY", 472, 477], ["Hypotension", "DISEASE", 231, 242], ["Renal impairment", "DISEASE", 472, 488], ["blood", "ORGANISM_SUBSTANCE", 265, 270], ["children", "ORGANISM", 366, 374], ["organ", "ORGAN", 408, 413], ["Renal", "ORGAN", 472, 477], ["children", "SPECIES", 366, 374], ["nosocomial", "PROBLEM", 111, 121], ["An illness", "PROBLEM", 175, 185], ["a Hypotension", "PROBLEM", 229, 242], ["a systolic blood pressure", "TEST", 254, 279], ["Multiple organ involvement", "PROBLEM", 399, 425], ["Renal impairment", "PROBLEM", 472, 488], ["Creatinin", "TEST", 490, 499], ["illness", "OBSERVATION", 178, 185], ["Renal", "ANATOMY", 472, 477], ["impairment", "OBSERVATION", 478, 488], ["upper limit", "OBSERVATION_MODIFIER", 551, 562], ["normal", "OBSERVATION", 566, 572]]], ["In patients with preexisting renal disease, > twofold elevation baseline creatinine levels Coagulopathy: Platelets \u2264 100,000/mm 3 (\u2264 100 \u00d7 10 6 /L) and/or disseminated intravascular coagulation, defined by prolonged clotting times, low fibrinogen level, and the presence of fibrin degradation products Liver involvement: Alanine aminotransferase, aspartate aminotransferase, or total bilirubin levels \u2265 twice the upper limit of normal for the patient's age.", [["renal", "ANATOMY", 29, 34], ["Platelets", "ANATOMY", 105, 114], ["intravascular", "ANATOMY", 168, 181], ["Liver", "ANATOMY", 302, 307], ["renal disease", "DISEASE", 29, 42], ["creatinine", "CHEMICAL", 73, 83], ["Coagulopathy", "DISEASE", 91, 103], ["intravascular coagulation", "DISEASE", 168, 193], ["Alanine", "CHEMICAL", 321, 328], ["aspartate", "CHEMICAL", 347, 356], ["bilirubin", "CHEMICAL", 384, 393], ["creatinine", "CHEMICAL", 73, 83], ["Alanine", "CHEMICAL", 321, 328], ["aspartate", "CHEMICAL", 347, 356], ["bilirubin", "CHEMICAL", 384, 393], ["patients", "ORGANISM", 3, 11], ["renal", "ORGAN", 29, 34], ["creatinine", "SIMPLE_CHEMICAL", 73, 83], ["Platelets", "CELL", 105, 114], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 168, 181], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 236, 246], ["fibrin", "GENE_OR_GENE_PRODUCT", 274, 280], ["Liver", "ORGAN", 302, 307], ["Alanine", "AMINO_ACID", 321, 328], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 329, 345], ["aspartate", "SIMPLE_CHEMICAL", 347, 356], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 357, 373], ["bilirubin", "SIMPLE_CHEMICAL", 384, 393], ["patient", "ORGANISM", 443, 450], ["fibrinogen", "PROTEIN", 236, 246], ["fibrin", "PROTEIN", 274, 280], ["Alanine aminotransferase", "PROTEIN", 321, 345], ["aspartate aminotransferase", "PROTEIN", 347, 373], ["patients", "SPECIES", 3, 11], ["patient", "SPECIES", 443, 450], ["preexisting renal disease", "PROBLEM", 17, 42], ["twofold elevation baseline creatinine levels Coagulopathy", "PROBLEM", 46, 103], ["Platelets", "TEST", 105, 114], ["disseminated intravascular coagulation", "PROBLEM", 155, 193], ["prolonged clotting times", "PROBLEM", 206, 230], ["low fibrinogen level", "PROBLEM", 232, 252], ["fibrin degradation products", "PROBLEM", 274, 301], ["Alanine aminotransferase", "TEST", 321, 345], ["aspartate aminotransferase", "TEST", 347, 373], ["total bilirubin levels", "TEST", 378, 400], ["renal", "ANATOMY", 29, 34], ["disease", "OBSERVATION", 35, 42], ["elevation", "OBSERVATION_MODIFIER", 54, 63], ["disseminated", "OBSERVATION_MODIFIER", 155, 167], ["intravascular coagulation", "OBSERVATION", 168, 193], ["prolonged", "OBSERVATION_MODIFIER", 206, 215], ["clotting", "OBSERVATION", 216, 224], ["fibrin degradation", "OBSERVATION", 274, 292], ["Liver", "ANATOMY", 302, 307], ["upper limit", "OBSERVATION_MODIFIER", 413, 424], ["normal", "OBSERVATION", 428, 434]]], ["In patients with preexisting liver disease, a > twofold increase over baseline levels Multiple organ failure including two or more of the following: renal impairment, coagulopathy, liver involvement, acute respiratory distress syndrome since its presence defines \"confirmed\" cases of STSS (Table 1) .", [["liver", "ANATOMY", 29, 34], ["organ", "ANATOMY", 95, 100], ["renal", "ANATOMY", 149, 154], ["liver", "ANATOMY", 181, 186], ["respiratory", "ANATOMY", 206, 217], ["liver disease", "DISEASE", 29, 42], ["organ failure", "DISEASE", 95, 108], ["renal impairment", "DISEASE", 149, 165], ["coagulopathy", "DISEASE", 167, 179], ["liver involvement", "DISEASE", 181, 198], ["respiratory distress syndrome", "DISEASE", 206, 235], ["STSS", "DISEASE", 284, 288], ["patients", "ORGANISM", 3, 11], ["liver", "ORGAN", 29, 34], ["organ", "ORGAN", 95, 100], ["renal", "ORGAN", 149, 154], ["liver", "ORGAN", 181, 186], ["patients", "SPECIES", 3, 11], ["preexisting liver disease", "PROBLEM", 17, 42], ["a > twofold increase over baseline levels", "PROBLEM", 44, 85], ["Multiple organ failure", "PROBLEM", 86, 108], ["renal impairment", "PROBLEM", 149, 165], ["coagulopathy", "PROBLEM", 167, 179], ["liver involvement", "PROBLEM", 181, 198], ["acute respiratory distress syndrome", "PROBLEM", 200, 235], ["STSS", "PROBLEM", 284, 288], ["liver", "ANATOMY", 29, 34], ["disease", "OBSERVATION", 35, 42], ["increase", "OBSERVATION_MODIFIER", 56, 64], ["organ", "ANATOMY", 95, 100], ["failure", "OBSERVATION", 101, 108], ["renal", "ANATOMY", 149, 154], ["impairment", "OBSERVATION", 155, 165], ["coagulopathy", "OBSERVATION", 167, 179], ["liver", "ANATOMY", 181, 186], ["acute", "OBSERVATION_MODIFIER", 200, 205], ["respiratory distress", "OBSERVATION", 206, 226]]], ["The presence of GAS in non-sterile site defines \"probable\" cases in addition to clinical criteria.", [["GAS", "DNA", 16, 19], ["GAS in non-sterile site", "PROBLEM", 16, 39], ["GAS", "OBSERVATION", 16, 19], ["non-sterile site", "OBSERVATION_MODIFIER", 23, 39]]], ["Similar to other types of infections, bacterial cultures (including blood cultures) should be performed rapidly, and prior to the administration of antibiotics.", [["cultures", "ANATOMY", 48, 56], ["blood cultures", "ANATOMY", 68, 82], ["infections", "DISEASE", 26, 36], ["blood", "ORGANISM_SUBSTANCE", 68, 73], ["infections", "PROBLEM", 26, 36], ["bacterial cultures", "TEST", 38, 56], ["blood cultures", "TEST", 68, 82], ["antibiotics", "TREATMENT", 148, 159], ["infections", "OBSERVATION", 26, 36]]], ["Depending on the suspected source of infection, the following sites should also be cultures: skin, deep soft tissue, peritoneal fluid, urine, sputum, pharyngeal swab, and synovial fluid.", [["cultures", "ANATOMY", 83, 91], ["skin", "ANATOMY", 93, 97], ["soft tissue", "ANATOMY", 104, 115], ["peritoneal fluid", "ANATOMY", 117, 133], ["urine", "ANATOMY", 135, 140], ["sputum", "ANATOMY", 142, 148], ["pharyngeal swab", "ANATOMY", 150, 165], ["synovial fluid", "ANATOMY", 171, 185], ["infection", "DISEASE", 37, 46], ["skin", "ORGAN", 93, 97], ["deep soft tissue", "TISSUE", 99, 115], ["peritoneal fluid", "MULTI-TISSUE_STRUCTURE", 117, 133], ["urine", "ORGANISM_SUBSTANCE", 135, 140], ["sputum", "ORGANISM_SUBSTANCE", 142, 148], ["pharyngeal swab", "MULTI-TISSUE_STRUCTURE", 150, 165], ["synovial fluid", "ORGANISM_SUBSTANCE", 171, 185], ["infection", "PROBLEM", 37, 46], ["cultures", "TEST", 83, 91], ["skin, deep soft tissue, peritoneal fluid, urine, sputum, pharyngeal swab", "TEST", 93, 165], ["synovial fluid", "PROBLEM", 171, 185], ["infection", "OBSERVATION", 37, 46], ["skin", "ANATOMY", 93, 97], ["deep", "ANATOMY_MODIFIER", 99, 103], ["soft tissue", "ANATOMY", 104, 115], ["peritoneal", "ANATOMY", 117, 127], ["fluid", "OBSERVATION", 128, 133], ["pharyngeal swab", "ANATOMY", 150, 165], ["synovial", "ANATOMY", 171, 179], ["fluid", "OBSERVATION", 180, 185]]], ["Antibiotics must be administered as soon as possible, just after the first blood culture, in case of high suspicion of streptococcal invasive infection with or without shock.", [["blood", "ANATOMY", 75, 80], ["streptococcal invasive infection", "DISEASE", 119, 151], ["shock", "DISEASE", 168, 173], ["blood", "ORGANISM_SUBSTANCE", 75, 80], ["Antibiotics", "TREATMENT", 0, 11], ["the first blood culture", "TEST", 65, 88], ["streptococcal invasive infection", "PROBLEM", 119, 151], ["shock", "PROBLEM", 168, 173], ["streptococcal", "OBSERVATION_MODIFIER", 119, 132], ["invasive", "OBSERVATION_MODIFIER", 133, 141], ["infection", "OBSERVATION", 142, 151]]], ["Blood cultures will come back positive in about half of all cases with streptococcal STSS.", [["Blood cultures", "ANATOMY", 0, 14], ["streptococcal STSS", "DISEASE", 71, 89], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood cultures", "TEST", 0, 14], ["streptococcal STSS", "PROBLEM", 71, 89], ["streptococcal STSS", "OBSERVATION", 71, 89]]], ["Of note, staphylococcal toxic shock syndrome is rarely associated with positive blood cultures, being a \"purer\" toxin disease.", [["blood cultures", "ANATOMY", 80, 94], ["staphylococcal toxic shock syndrome", "DISEASE", 9, 44], ["blood", "ORGANISM_SUBSTANCE", 80, 85], ["staphylococcal toxic shock syndrome", "PROBLEM", 9, 44], ["positive blood cultures", "PROBLEM", 71, 94], ["a \"purer\" toxin disease", "PROBLEM", 102, 125], ["staphylococcal", "OBSERVATION_MODIFIER", 9, 23], ["toxic shock syndrome", "OBSERVATION", 24, 44]]], ["Laboratory criterion for STSS diagnosis is \"positive\" if GAS is isolated in any microbiological test from sterile sites.", [["GAS", "DNA", 57, 60], ["Laboratory criterion", "TEST", 0, 20], ["STSS diagnosis", "TEST", 25, 39], ["GAS", "PROBLEM", 57, 60], ["any microbiological test", "TEST", 76, 100]]], ["CT scans and MRI are helpful to identify the source of infection [27, 28] .", [["infection", "DISEASE", 55, 64], ["CT scans", "TEST", 0, 8], ["MRI", "TEST", 13, 16], ["infection", "PROBLEM", 55, 64], ["infection", "OBSERVATION", 55, 64]]], ["MRI is more sensitive than CT for diagnosing skin and soft tissue infections but is less specific and therefore tends to increase the number of \"false-positive\" findings.", [["skin", "ANATOMY", 45, 49], ["soft tissue", "ANATOMY", 54, 65], ["skin and soft tissue infections", "DISEASE", 45, 76], ["skin", "ORGAN", 45, 49], ["soft tissue", "TISSUE", 54, 65], ["MRI", "TEST", 0, 3], ["CT", "TEST", 27, 29], ["diagnosing skin", "TEST", 34, 49], ["soft tissue infections", "PROBLEM", 54, 76], ["\"false-positive\" findings", "PROBLEM", 144, 169], ["skin", "ANATOMY", 45, 49], ["soft tissue", "OBSERVATION_MODIFIER", 54, 65], ["infections", "OBSERVATION", 66, 76], ["less specific", "OBSERVATION_MODIFIER", 84, 97]]], ["The interpretation by the radiologist should always be taken with caution because radiological early signs might be benign: low local inflammation and no abscess formation, at least in the beginning, and absence of gas in the tissue, S. pyogenes does not produce gas [25] .", [["abscess", "ANATOMY", 154, 161], ["tissue", "ANATOMY", 226, 232], ["inflammation", "DISEASE", 134, 146], ["abscess", "DISEASE", 154, 161], ["abscess", "PATHOLOGICAL_FORMATION", 154, 161], ["tissue", "TISSUE", 226, 232], ["S. pyogenes", "ORGANISM", 234, 245], ["S. pyogenes", "SPECIES", 234, 245], ["S. pyogenes", "SPECIES", 234, 245], ["radiological early signs", "TEST", 82, 106], ["low local inflammation", "PROBLEM", 124, 146], ["abscess formation", "PROBLEM", 154, 171], ["gas in the tissue", "PROBLEM", 215, 232], ["S. pyogenes", "PROBLEM", 234, 245], ["benign", "OBSERVATION_MODIFIER", 116, 122], ["low local", "OBSERVATION_MODIFIER", 124, 133], ["inflammation", "OBSERVATION", 134, 146], ["no", "UNCERTAINTY", 151, 153], ["abscess", "OBSERVATION", 154, 161], ["gas", "OBSERVATION", 215, 218], ["tissue", "ANATOMY", 226, 232]]], ["A discordant radiological and surgical image is not infrequent at the early stage of fasciitis.", [["fasciitis", "DISEASE", 85, 94], ["A discordant radiological and surgical image", "PROBLEM", 0, 44], ["fasciitis", "PROBLEM", 85, 94], ["fasciitis", "OBSERVATION", 85, 94]]], ["The MRI is more specific for fasciitis.", [["fasciitis", "DISEASE", 29, 38], ["The MRI", "TEST", 0, 7], ["fasciitis", "PROBLEM", 29, 38], ["fasciitis", "OBSERVATION", 29, 38]]], ["The presence of a thick (> 3 mm) hyperintense signal in the deep fascia on fat-suppressed T2 weighted or short tau inversion-recovery images are important markers for necrotizing fasciitis [27] .", [["deep fascia", "ANATOMY", 60, 71], ["fat", "ANATOMY", 75, 78], ["necrotizing fasciitis", "DISEASE", 167, 188], ["fascia", "TISSUE", 65, 71], ["fat", "TISSUE", 75, 78], ["a thick (> 3 mm) hyperintense signal in the deep fascia", "PROBLEM", 16, 71], ["necrotizing fasciitis", "PROBLEM", 167, 188], ["thick", "OBSERVATION_MODIFIER", 18, 23], ["> 3 mm", "OBSERVATION_MODIFIER", 25, 31], ["hyperintense", "OBSERVATION_MODIFIER", 33, 45], ["deep", "ANATOMY_MODIFIER", 60, 64], ["fascia", "ANATOMY", 65, 71], ["necrotizing", "OBSERVATION_MODIFIER", 167, 178], ["fasciitis", "OBSERVATION", 179, 188]]], ["Although less predictive and informative, soft tissue echography can be useful in some cases since it can be performed at the bedside in the ICU unstable patient and can be frequently repeated [29] .", [["soft tissue", "ANATOMY", 42, 53], ["soft tissue", "TISSUE", 42, 53], ["patient", "ORGANISM", 154, 161], ["patient", "SPECIES", 154, 161], ["soft tissue echography", "TEST", 42, 64]]], ["An important message is that in case of a doubt, of a discordant radiological and clinical examination in a patient with systemic inflammation and/or shock, surgery should be considered without delay to evaluate the possibility of a necrotizing fasciitis, and surgical debridement with opening of the muscular fascias in cases of fasciitis.", [["muscular fascias", "ANATOMY", 301, 317], ["inflammation", "DISEASE", 130, 142], ["shock", "DISEASE", 150, 155], ["necrotizing fasciitis", "DISEASE", 233, 254], ["muscular fascias", "DISEASE", 301, 317], ["fasciitis", "DISEASE", 330, 339], ["patient", "ORGANISM", 108, 115], ["patient", "SPECIES", 108, 115], ["clinical examination", "TEST", 82, 102], ["systemic inflammation", "PROBLEM", 121, 142], ["shock", "PROBLEM", 150, 155], ["surgery", "TREATMENT", 157, 164], ["a necrotizing fasciitis", "PROBLEM", 231, 254], ["surgical debridement", "TREATMENT", 260, 280], ["opening of the muscular fascias", "TREATMENT", 286, 317], ["fasciitis", "PROBLEM", 330, 339], ["systemic", "OBSERVATION_MODIFIER", 121, 129], ["inflammation", "OBSERVATION", 130, 142], ["necrotizing", "OBSERVATION_MODIFIER", 233, 244], ["fasciitis", "OBSERVATION", 245, 254], ["debridement", "OBSERVATION", 269, 280], ["muscular fascias", "ANATOMY", 301, 317], ["fasciitis", "OBSERVATION", 330, 339]]], ["Surgical exploration is not only important for diagnosis (fasciitis remaining a diagnosis made by histopathology on a biopsy of a fascia [30] , but is a cornerstone of fasciitis treatment [31] .Laboratory investigations, microbiology, and imagingDifferential diagnosis of invasive GAS infections causing STSS include: gaseous gangrene, perineal Fournier's disease, staphylococcal soft tissue infections and cellulitis, and synergistic cellulitis.Pathophysiology and predisposing factorsThe pathophysiology of STSS is based on bacterial toxins.", [["fascia", "ANATOMY", 130, 136], ["soft tissue", "ANATOMY", 380, 391], ["fasciitis", "DISEASE", 58, 67], ["fasciitis", "DISEASE", 168, 177], ["infections", "DISEASE", 285, 295], ["STSS", "DISEASE", 304, 308], ["gaseous gangrene", "DISEASE", 318, 334], ["Fournier's disease", "DISEASE", 345, 363], ["staphylococcal soft tissue infections", "DISEASE", 365, 402], ["cellulitis", "DISEASE", 407, 417], ["cellulitis", "DISEASE", 435, 445], ["STSS", "DISEASE", 509, 513], ["fascia", "TISSUE", 130, 136], ["fasciitis", "PATHOLOGICAL_FORMATION", 168, 177], ["tissue", "TISSUE", 385, 391], ["predisposing factors", "PROTEIN", 466, 486], ["Surgical exploration", "TEST", 0, 20], ["fasciitis", "PROBLEM", 58, 67], ["a biopsy", "TEST", 116, 124], ["fasciitis treatment", "TREATMENT", 168, 187], ["Laboratory investigations", "TEST", 194, 219], ["microbiology", "TEST", 221, 233], ["imaging", "TEST", 239, 246], ["invasive GAS infections", "PROBLEM", 272, 295], ["STSS", "PROBLEM", 304, 308], ["gaseous gangrene", "PROBLEM", 318, 334], ["perineal Fournier's disease", "PROBLEM", 336, 363], ["staphylococcal soft tissue infections", "PROBLEM", 365, 402], ["cellulitis", "PROBLEM", 407, 417], ["synergistic cellulitis", "PROBLEM", 423, 445], ["predisposing factors", "PROBLEM", 466, 486], ["STSS", "PROBLEM", 509, 513], ["bacterial toxins", "PROBLEM", 526, 542], ["not only important", "UNCERTAINTY", 24, 42], ["fasciitis", "OBSERVATION", 58, 67], ["fascia", "ANATOMY", 130, 136], ["fasciitis", "OBSERVATION", 168, 177], ["invasive", "OBSERVATION_MODIFIER", 272, 280], ["GAS infections", "OBSERVATION", 281, 295], ["gaseous gangrene", "OBSERVATION", 318, 334], ["perineal", "ANATOMY", 336, 344], ["Fournier", "OBSERVATION", 345, 353], ["staphylococcal", "OBSERVATION_MODIFIER", 365, 379], ["soft tissue", "OBSERVATION_MODIFIER", 380, 391], ["infections", "OBSERVATION", 392, 402], ["cellulitis", "OBSERVATION", 407, 417], ["synergistic", "OBSERVATION_MODIFIER", 423, 434], ["cellulitis", "OBSERVATION", 435, 445], ["STSS", "OBSERVATION", 509, 513]]], ["Superantigens are proteins that share the ability to trigger excessive and nonspecific T cell activation, therefore generating the massive secretion pro-inflammatory cytokines and other mediators producing capillary leak and arterial hypotension [32] .Pathophysiology and predisposing factorsStaphylococci and streptococci are the two most common bacterial genera known to produce superantigens.", [["T cell", "ANATOMY", 87, 93], ["capillary", "ANATOMY", 206, 215], ["arterial", "ANATOMY", 225, 233], ["hypotension", "DISEASE", 234, 245], ["T cell", "CELL", 87, 93], ["capillary", "TISSUE", 206, 215], ["arterial", "MULTI-TISSUE_STRUCTURE", 225, 233], ["Superantigens", "PROTEIN", 0, 13], ["pro-inflammatory cytokines", "PROTEIN", 149, 175], ["superantigens", "PROTEIN", 381, 394], ["excessive and nonspecific T cell activation", "PROBLEM", 61, 104], ["the massive secretion pro-inflammatory cytokines", "PROBLEM", 127, 175], ["capillary leak", "PROBLEM", 206, 220], ["arterial hypotension", "PROBLEM", 225, 245], ["predisposing factorsStaphylococci", "PROBLEM", 272, 305], ["streptococci", "PROBLEM", 310, 322], ["common bacterial genera", "PROBLEM", 340, 363], ["superantigens", "PROBLEM", 381, 394], ["cell activation", "OBSERVATION", 89, 104], ["massive", "OBSERVATION_MODIFIER", 131, 138], ["secretion pro-inflammatory", "OBSERVATION", 139, 165], ["capillary leak", "OBSERVATION", 206, 220], ["arterial", "ANATOMY", 225, 233], ["hypotension", "OBSERVATION", 234, 245], ["factorsStaphylococci", "OBSERVATION", 285, 305]]], ["Among streptococci, Streptococcus pyogenes (group A streptococcus), S. dysgalactiae (group C streptococcus), and S. equis (group G streptococcus) can produce exotoxins with superantigen activity [12, 32, 33] .", [["Streptococcus pyogenes", "DISEASE", 20, 42], ["S. dysgalactiae", "DISEASE", 68, 83], ["Streptococcus pyogenes", "ORGANISM", 20, 42], ["group A streptococcus", "ORGANISM", 44, 65], ["S. dysgalactiae", "ORGANISM", 68, 83], ["group C streptococcus", "ORGANISM", 85, 106], ["S. equis", "ORGANISM", 113, 121], ["group G streptococcus", "ORGANISM", 123, 144], ["exotoxins", "PROTEIN", 158, 167], ["superantigen", "PROTEIN", 173, 185], ["Streptococcus pyogenes", "SPECIES", 20, 42], ["A streptococcus", "SPECIES", 50, 65], ["S. dysgalactiae", "SPECIES", 68, 83], ["C streptococcus", "SPECIES", 91, 106], ["S. equis", "SPECIES", 113, 121], ["G streptococcus", "SPECIES", 129, 144], ["Streptococcus pyogenes", "SPECIES", 20, 42], ["S. dysgalactiae", "SPECIES", 68, 83], ["S. equis", "SPECIES", 113, 121], ["Among streptococci", "TEST", 0, 18], ["Streptococcus pyogenes", "PROBLEM", 20, 42], ["group A streptococcus", "TEST", 44, 65], ["S. dysgalactiae", "TEST", 68, 83], ["group C streptococcus)", "TEST", 85, 107], ["S. equis (group G streptococcus", "PROBLEM", 113, 144], ["exotoxins", "PROBLEM", 158, 167], ["streptococci", "OBSERVATION", 6, 18], ["Streptococcus pyogenes", "OBSERVATION", 20, 42]]], ["The first streptococcal pyronegic toxin which appeared subsequently to be a superantigen was described in 1924 [34, 35] .", [["streptococcal pyronegic toxin", "PROTEIN", 10, 39], ["superantigen", "PROTEIN", 76, 88], ["The first streptococcal pyronegic toxin", "TEST", 0, 39]]], ["Eleven different streptococcal superantigens (also known as streptococcal pyrogenic enterotoxins, SPEs) have been identified to date in S. pyogenes.", [["streptococcal pyrogenic enterotoxins", "GENE_OR_GENE_PRODUCT", 60, 96], ["SPEs", "GENE_OR_GENE_PRODUCT", 98, 102], ["S. pyogenes", "ORGANISM", 136, 147], ["streptococcal superantigens", "PROTEIN", 17, 44], ["streptococcal pyrogenic enterotoxins", "PROTEIN", 60, 96], ["SPEs", "PROTEIN", 98, 102], ["S. pyogenes", "SPECIES", 136, 147], ["S. pyogenes", "SPECIES", 136, 147], ["Eleven different streptococcal superantigens", "PROBLEM", 0, 44], ["streptococcal pyrogenic enterotoxins", "PROBLEM", 60, 96], ["streptococcal superantigens", "OBSERVATION", 17, 44]]], ["Although they have different protein amino acid sequences and structures, they produce the same biological effects.", [["amino acid", "CHEMICAL", 37, 47], ["amino acid", "CHEMICAL", 37, 47], ["amino acid", "AMINO_ACID", 37, 47], ["protein amino acid sequences", "PROTEIN", 29, 57], ["different protein amino acid sequences", "TEST", 19, 57]]], ["They are single-chain proteins expressed as precursor molecules, which are then cleaved to release the functional extracellular toxin.", [["extracellular", "ANATOMY", 114, 127], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 114, 127], ["toxin", "SIMPLE_CHEMICAL", 128, 133], ["single-chain proteins", "PROTEIN", 9, 30], ["precursor molecules", "PROTEIN", 44, 63], ["extracellular toxin", "PROTEIN", 114, 133], ["single-chain proteins", "TREATMENT", 9, 30]]], ["They share sequence homologies in highly conserved regions called \u00abfamily signature motifs\u00bb [12, 36] .", [["\u00abfamily signature motifs", "DNA", 66, 90]]], ["The gene coding for superantigens can be present in streptococci, but may remain silent, with no expression of the toxin.", [["streptococci", "CELL", 52, 64], ["superantigens", "PROTEIN", 20, 33], ["toxin", "PROTEIN", 115, 120], ["superantigens", "PROBLEM", 20, 33], ["streptococci", "PROBLEM", 52, 64], ["the toxin", "PROBLEM", 111, 120]]], ["The human factors triggering the expression of superantigens are largely unknown.", [["human", "ORGANISM", 4, 9], ["human factors", "PROTEIN", 4, 17], ["superantigens", "PROTEIN", 47, 60], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["The human factors", "PROBLEM", 0, 17], ["superantigens", "PROBLEM", 47, 60]]], ["Experimental studies have shown that GAS was able to modify gene expression depending on its environment, expressing virulence factors (such as superantigens) promoting the transition from superficial to invasive disease [37] .Pathophysiology and predisposing factorsThe main characteristic of superantigens is their ability to bind to major histocompatibility (MHC) class II molecules outside of the antigen groove, and the V\u00df region of the T cell receptor, cross-linking those two receptors.", [["T cell", "ANATOMY", 442, 448], ["GAS", "GENE_OR_GENE_PRODUCT", 37, 40], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 442, 457], ["GAS", "DNA", 37, 40], ["virulence factors", "PROTEIN", 117, 134], ["superantigens", "PROTEIN", 144, 157], ["predisposing factors", "PROTEIN", 247, 267], ["superantigens", "PROTEIN", 294, 307], ["major histocompatibility (MHC) class II molecules", "PROTEIN", 336, 385], ["antigen groove", "PROTEIN", 401, 415], ["V\u00df region", "PROTEIN", 425, 434], ["T cell receptor", "PROTEIN", 442, 457], ["Experimental studies", "TEST", 0, 20], ["gene expression", "PROBLEM", 60, 75], ["expressing virulence factors", "PROBLEM", 106, 134], ["invasive disease", "PROBLEM", 204, 220], ["predisposing factors", "PROBLEM", 247, 267], ["the T cell receptor", "TREATMENT", 438, 457], ["superficial", "OBSERVATION_MODIFIER", 189, 200], ["invasive disease", "OBSERVATION", 204, 220], ["main", "OBSERVATION_MODIFIER", 271, 275], ["superantigens", "OBSERVATION", 294, 307], ["T cell", "OBSERVATION", 442, 448]]], ["This triggers the activation of both the antigen-presenting cell and the T lymphocyte, bypassing conventional mechanisms of MHC-limited antigen cell activation (Fig. 3) .", [["antigen-presenting cell", "ANATOMY", 41, 64], ["T lymphocyte", "ANATOMY", 73, 85], ["cell", "ANATOMY", 144, 148], ["cell", "CELL", 60, 64], ["T lymphocyte", "CELL", 73, 85], ["cell", "CELL", 144, 148], ["T lymphocyte", "CELL_TYPE", 73, 85], ["MHC", "PROTEIN", 124, 127], ["the T lymphocyte", "TEST", 69, 85], ["antigen cell activation", "OBSERVATION", 136, 159]]], ["Since immune cell activation is not restricted to cells expressing and recognizing a single antigen, but rather polyclonal, cell activation is massive and explains the systemic pro-inflammatory activity, arterial hypotension, and end-organ dysfunction due to shock in patients with STSS [12, 38, 39] .", [["immune cell", "ANATOMY", 6, 17], ["cells", "ANATOMY", 50, 55], ["cell", "ANATOMY", 124, 128], ["arterial", "ANATOMY", 204, 212], ["organ", "ANATOMY", 234, 239], ["arterial hypotension", "DISEASE", 204, 224], ["end-organ dysfunction", "DISEASE", 230, 251], ["shock", "DISEASE", 259, 264], ["STSS", "DISEASE", 282, 286], ["immune cell", "CELL", 6, 17], ["cells", "CELL", 50, 55], ["cell", "CELL", 124, 128], ["arterial", "MULTI-TISSUE_STRUCTURE", 204, 212], ["organ", "ORGAN", 234, 239], ["patients", "ORGANISM", 268, 276], ["patients", "SPECIES", 268, 276], ["immune cell activation", "PROBLEM", 6, 28], ["a single antigen", "PROBLEM", 83, 99], ["rather polyclonal, cell activation", "PROBLEM", 105, 139], ["the systemic pro-inflammatory activity", "PROBLEM", 164, 202], ["arterial hypotension", "PROBLEM", 204, 224], ["end-organ dysfunction", "PROBLEM", 230, 251], ["shock", "PROBLEM", 259, 264], ["STSS", "TEST", 282, 286], ["immune cell activation", "OBSERVATION", 6, 28], ["cell activation", "OBSERVATION", 124, 139], ["systemic", "OBSERVATION_MODIFIER", 168, 176], ["pro-inflammatory activity", "OBSERVATION", 177, 202], ["arterial", "ANATOMY", 204, 212], ["hypotension", "OBSERVATION", 213, 224], ["organ dysfunction", "OBSERVATION", 234, 251], ["shock", "OBSERVATION", 259, 264]]], ["The cross-linking of receptors by superantigens leads to the activation of up to 25% of lymphocytes as compared with < 0.1% for conventional antigen-triggered T-cell activation [40] [41] [42] .Pathophysiology and predisposing factorsAside from superantigens, S. pyogenes produces and secretes a wide variety of exotoxins and enzymes such as streptolysins, streptokinase, hyaluronidase, and DNAse such as streptodornase and chemokine proteases and toxic molecules that play undoubtedly an important pathogenic role in necrotizing fasciitis and STSS.", [["lymphocytes", "ANATOMY", 88, 99], ["T-cell", "ANATOMY", 159, 165], ["necrotizing fasciitis", "DISEASE", 517, 538], ["STSS", "DISEASE", 543, 547], ["lymphocytes", "CELL", 88, 99], ["T-cell", "CELL", 159, 165], ["S. pyogenes", "ORGANISM", 259, 270], ["streptolysins", "GENE_OR_GENE_PRODUCT", 341, 354], ["streptokinase", "GENE_OR_GENE_PRODUCT", 356, 369], ["hyaluronidase", "GENE_OR_GENE_PRODUCT", 371, 384], ["DNAse", "GENE_OR_GENE_PRODUCT", 390, 395], ["streptodornase", "GENE_OR_GENE_PRODUCT", 404, 418], ["superantigens", "PROTEIN", 34, 47], ["lymphocytes", "CELL_TYPE", 88, 99], ["predisposing factors", "PROTEIN", 213, 233], ["superantigens", "PROTEIN", 244, 257], ["exotoxins", "PROTEIN", 311, 320], ["enzymes", "PROTEIN", 325, 332], ["streptolysins", "PROTEIN", 341, 354], ["streptokinase", "PROTEIN", 356, 369], ["hyaluronidase", "PROTEIN", 371, 384], ["DNAse", "PROTEIN", 390, 395], ["streptodornase", "PROTEIN", 404, 418], ["chemokine proteases", "PROTEIN", 423, 442], ["toxic molecules", "PROTEIN", 447, 462], ["S. pyogenes", "SPECIES", 259, 270], ["S. pyogenes", "SPECIES", 259, 270], ["The cross-linking of receptors", "TREATMENT", 0, 30], ["lymphocytes", "TEST", 88, 99], ["conventional antigen", "TEST", 128, 148], ["predisposing factors", "PROBLEM", 213, 233], ["superantigens", "PROBLEM", 244, 257], ["S. pyogenes", "PROBLEM", 259, 270], ["exotoxins", "PROBLEM", 311, 320], ["enzymes", "TEST", 325, 332], ["streptolysins", "TREATMENT", 341, 354], ["streptokinase", "TREATMENT", 356, 369], ["hyaluronidase", "TREATMENT", 371, 384], ["DNAse", "TREATMENT", 390, 395], ["streptodornase", "TREATMENT", 404, 418], ["chemokine proteases", "TREATMENT", 423, 442], ["toxic molecules", "PROBLEM", 447, 462], ["necrotizing fasciitis", "PROBLEM", 517, 538], ["STSS", "PROBLEM", 543, 547], ["pyogenes", "OBSERVATION", 262, 270], ["necrotizing", "OBSERVATION_MODIFIER", 517, 528], ["fasciitis", "OBSERVATION", 529, 538]]], ["In addition, S. pyogenes expresses surface virulence factors such as the M-protein (inhibition of opsonisation and phagocytosis), lipoteichoic acid (Toll-like receptor-dependent immune cell activation), protein F (adhesion to host cells) that are also considered as virulence factors [12] .Pathophysiology and predisposing factorsInfants and elderly individuals carry the highest risk of invasive GAS infection.", [["surface", "ANATOMY", 35, 42], ["cell", "ANATOMY", 185, 189], ["cells", "ANATOMY", 231, 236], ["lipoteichoic acid", "CHEMICAL", 130, 147], ["GAS infection", "DISEASE", 397, 410], ["S. pyogenes", "ORGANISM", 13, 24], ["surface virulence factors", "GENE_OR_GENE_PRODUCT", 35, 60], ["M-protein", "GENE_OR_GENE_PRODUCT", 73, 82], ["lipoteichoic acid", "SIMPLE_CHEMICAL", 130, 147], ["Toll-like receptor", "GENE_OR_GENE_PRODUCT", 149, 167], ["immune cell", "CELL", 178, 189], ["protein F", "GENE_OR_GENE_PRODUCT", 203, 212], ["host cells", "CELL", 226, 236], ["Infants", "ORGANISM", 330, 337], ["individuals", "ORGANISM", 350, 361], ["surface virulence factors", "PROTEIN", 35, 60], ["M-protein", "PROTEIN", 73, 82], ["Toll-like receptor", "PROTEIN", 149, 167], ["protein F", "PROTEIN", 203, 212], ["host cells", "CELL_TYPE", 226, 236], ["virulence factors", "PROTEIN", 266, 283], ["predisposing factors", "PROTEIN", 310, 330], ["S. pyogenes", "SPECIES", 13, 24], ["Infants", "SPECIES", 330, 337], ["S. pyogenes", "SPECIES", 13, 24], ["S. pyogenes", "PROBLEM", 13, 24], ["surface virulence factors", "PROBLEM", 35, 60], ["the M-protein (inhibition of opsonisation", "TREATMENT", 69, 110], ["phagocytosis", "TEST", 115, 127], ["lipoteichoic acid", "TEST", 130, 147], ["receptor-dependent immune cell activation", "TREATMENT", 159, 200], ["protein F (adhesion to host cells", "PROBLEM", 203, 236], ["predisposing factors", "PROBLEM", 310, 330], ["invasive GAS infection", "PROBLEM", 388, 410], ["pyogenes", "OBSERVATION", 16, 24], ["immune cell", "OBSERVATION", 178, 189], ["invasive", "OBSERVATION_MODIFIER", 388, 396], ["GAS infection", "OBSERVATION", 397, 410]]], ["GAS is able to cause severe disease in otherwise healthy individuals, with between a fifth and a third of cases occurring in individuals with no predisposing risk factors to severe infection [19, 43] .Pathophysiology and predisposing factorsPreexisting skin lesions are the most frequently identified risk factor for invasive GAS infection.", [["skin lesions", "ANATOMY", 253, 265], ["infection", "DISEASE", 181, 190], ["skin lesions", "DISEASE", 253, 265], ["GAS infection", "DISEASE", 326, 339], ["GAS", "GENE_OR_GENE_PRODUCT", 0, 3], ["skin lesions", "PATHOLOGICAL_FORMATION", 253, 265], ["GAS", "DNA", 0, 3], ["predisposing factors", "PROTEIN", 221, 241], ["severe disease", "PROBLEM", 21, 35], ["severe infection", "PROBLEM", 174, 190], ["predisposing factors", "PROBLEM", 221, 241], ["Preexisting skin lesions", "PROBLEM", 241, 265], ["invasive GAS infection", "PROBLEM", 317, 339], ["severe", "OBSERVATION_MODIFIER", 21, 27], ["disease", "OBSERVATION", 28, 35], ["severe", "OBSERVATION_MODIFIER", 174, 180], ["infection", "OBSERVATION", 181, 190], ["skin", "ANATOMY", 253, 257], ["lesions", "OBSERVATION", 258, 265], ["most frequently", "OBSERVATION_MODIFIER", 274, 289], ["invasive", "OBSERVATION_MODIFIER", 317, 325], ["GAS infection", "OBSERVATION", 326, 339]]], ["Alcohol abuse, chronic lung disease, immunosuppression, intravenous drug use, heart disease, diabetes, cancer, varicella zoster virus infection, and recent child birth have also been identified as risk factors [44] .", [["lung", "ANATOMY", 23, 27], ["intravenous", "ANATOMY", 56, 67], ["heart", "ANATOMY", 78, 83], ["cancer", "ANATOMY", 103, 109], ["Alcohol abuse", "DISEASE", 0, 13], ["chronic lung disease", "DISEASE", 15, 35], ["heart disease", "DISEASE", 78, 91], ["diabetes", "DISEASE", 93, 101], ["cancer", "DISEASE", 103, 109], ["varicella zoster virus infection", "DISEASE", 111, 143], ["lung", "ORGAN", 23, 27], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 56, 67], ["heart", "ORGAN", 78, 83], ["cancer", "CANCER", 103, 109], ["varicella zoster virus", "ORGANISM", 111, 133], ["varicella zoster virus", "SPECIES", 111, 133], ["varicella zoster virus", "SPECIES", 111, 133], ["chronic lung disease", "PROBLEM", 15, 35], ["immunosuppression", "TREATMENT", 37, 54], ["heart disease", "PROBLEM", 78, 91], ["diabetes", "PROBLEM", 93, 101], ["cancer", "PROBLEM", 103, 109], ["varicella zoster virus infection", "PROBLEM", 111, 143], ["chronic", "OBSERVATION_MODIFIER", 15, 22], ["lung", "ANATOMY", 23, 27], ["disease", "OBSERVATION", 28, 35], ["heart", "ANATOMY", 78, 83], ["disease", "OBSERVATION", 84, 91], ["diabetes", "OBSERVATION", 93, 101], ["cancer", "OBSERVATION", 103, 109], ["varicella", "OBSERVATION_MODIFIER", 111, 120], ["zoster virus infection", "OBSERVATION", 121, 143]]], ["Interestingly, it has been demonstrated that MHC class II haplotypes influence the host susceptibility to develop STSS.", [["STSS", "DISEASE", 114, 118], ["STSS", "CANCER", 114, 118], ["MHC class II", "PROTEIN", 45, 57], ["STSS", "PROBLEM", 114, 118]]], ["The haplotype DR15/ DQ6 is less commonly associated with STSS disease than the haplotype DR14/DQ5, for example [45] [46] [47] .Pathophysiology and predisposing factorsRetrospective studies and case series describe the possible association between nonsteroidal anti-inflammatory drugs (NSAIDs) use and the development and/or the extension of serious invasive diseases due to GAS [48] .", [["nonsteroidal", "ANATOMY", 247, 259], ["NSAIDs", "CHEMICAL", 285, 291], ["DR15", "GENE_OR_GENE_PRODUCT", 14, 18], ["DQ6", "GENE_OR_GENE_PRODUCT", 20, 23], ["STSS", "CANCER", 57, 61], ["nonsteroidal anti-inflammatory drugs", "SIMPLE_CHEMICAL", 247, 283], ["NSAIDs", "SIMPLE_CHEMICAL", 285, 291], ["DR15", "DNA", 14, 18], ["DQ6", "DNA", 20, 23], ["DR14", "DNA", 89, 93], ["DQ5", "DNA", 94, 97], ["The haplotype DR15/ DQ6", "TREATMENT", 0, 23], ["STSS disease", "PROBLEM", 57, 69], ["Retrospective studies", "TEST", 167, 188], ["nonsteroidal anti-inflammatory drugs", "TREATMENT", 247, 283], ["NSAIDs)", "TREATMENT", 285, 292], ["serious invasive diseases", "PROBLEM", 341, 366]]], ["Where it is true that the association between NSAIDs consumption and STSS exists, it has been difficult until now to differentiate between a simple association (pain killer NSAIDs use in varicella, sore throat or because of pain in invasive GAS infection), and a causal effect or a participation of NSAIDs in the development of STSS.", [["NSAIDs", "CHEMICAL", 46, 52], ["STSS", "DISEASE", 69, 73], ["pain", "DISEASE", 161, 165], ["NSAIDs", "CHEMICAL", 173, 179], ["varicella", "DISEASE", 187, 196], ["sore throat", "DISEASE", 198, 209], ["pain", "DISEASE", 224, 228], ["GAS infection", "DISEASE", 241, 254], ["NSAIDs", "CHEMICAL", 299, 305], ["STSS", "DISEASE", 328, 332], ["NSAIDs", "SIMPLE_CHEMICAL", 46, 52], ["NSAIDs", "SIMPLE_CHEMICAL", 299, 305], ["STSS", "CANCER", 328, 332], ["NSAIDs consumption", "TREATMENT", 46, 64], ["STSS", "PROBLEM", 69, 73], ["a simple association", "PROBLEM", 139, 159], ["pain killer NSAIDs", "TREATMENT", 161, 179], ["varicella", "PROBLEM", 187, 196], ["sore throat", "PROBLEM", 198, 209], ["pain", "PROBLEM", 224, 228], ["invasive GAS infection", "PROBLEM", 232, 254], ["NSAIDs", "TREATMENT", 299, 305], ["STSS", "PROBLEM", 328, 332]]], ["The association could also be that NSAIDs use in invasive GAS infection may mask initial signs and symptoms, and delay diagnosis and adapted treatment of invasive infections.", [["NSAIDs", "CHEMICAL", 35, 41], ["infection", "DISEASE", 62, 71], ["infections", "DISEASE", 163, 173], ["NSAIDs", "SIMPLE_CHEMICAL", 35, 41], ["NSAIDs", "TREATMENT", 35, 41], ["invasive GAS infection", "PROBLEM", 49, 71], ["symptoms", "PROBLEM", 99, 107], ["invasive infections", "PROBLEM", 154, 173], ["could also be", "UNCERTAINTY", 16, 29], ["invasive", "OBSERVATION_MODIFIER", 154, 162], ["infections", "OBSERVATION", 163, 173]]], ["Others have argued though that NSAIDs is independently associated with an increased risk for development of streptococcal toxic shock syndrome.", [["NSAIDs", "CHEMICAL", 31, 37], ["streptococcal toxic shock syndrome", "DISEASE", 108, 142], ["NSAIDs", "SIMPLE_CHEMICAL", 31, 37], ["NSAIDs", "TREATMENT", 31, 37], ["streptococcal toxic shock syndrome", "PROBLEM", 108, 142], ["streptococcal", "OBSERVATION_MODIFIER", 108, 121], ["toxic shock syndrome", "OBSERVATION", 122, 142]]], ["Bryant et al. suggest that NSAIDs could delay muscle regeneration, induce cellular immunosuppression, and increase susceptibility to post-injury GAS infection.", [["muscle", "ANATOMY", 46, 52], ["cellular", "ANATOMY", 74, 82], ["NSAIDs", "CHEMICAL", 27, 33], ["muscle regeneration", "DISEASE", 46, 65], ["infection", "DISEASE", 149, 158], ["NSAIDs", "SIMPLE_CHEMICAL", 27, 33], ["muscle", "ORGAN", 46, 52], ["cellular", "CELL", 74, 82], ["NSAIDs", "TREATMENT", 27, 33], ["muscle regeneration", "PROBLEM", 46, 65], ["cellular immunosuppression", "TREATMENT", 74, 100], ["post-injury GAS infection", "PROBLEM", 133, 158], ["et al", "OBSERVATION", 7, 12], ["cellular immunosuppression", "OBSERVATION", 74, 100]]], ["NSAIDs may accelerate GAS disease progression in established soft tissue infection and could reduce antibiotic efficacy [49, 50] .", [["soft tissue", "ANATOMY", 61, 72], ["NSAIDs", "CHEMICAL", 0, 6], ["soft tissue infection", "DISEASE", 61, 82], ["NSAIDs", "SIMPLE_CHEMICAL", 0, 6], ["soft tissue", "TISSUE", 61, 72], ["NSAIDs", "TREATMENT", 0, 6], ["GAS disease progression", "PROBLEM", 22, 45], ["soft tissue infection", "PROBLEM", 61, 82], ["antibiotic efficacy", "TREATMENT", 100, 119], ["GAS disease", "OBSERVATION", 22, 33], ["soft tissue", "OBSERVATION_MODIFIER", 61, 72], ["infection", "OBSERVATION", 73, 82]]], ["It has also been shown that endotoxin-treated volunteers had elevated tumor necrosis factor (TNF) levels, and decreased neutrophil functions when they had taken NSAIDs, and this may also be true in toxin-induced streptococcal shock [51, 52] .TreatmentThe management of STSS requires a multidisciplinary team involving intensivists, specialists in infectious diseases, microbiologists, and surgeons.", [["neutrophil", "ANATOMY", 120, 130], ["endotoxin", "CHEMICAL", 28, 37], ["tumor", "DISEASE", 70, 75], ["necrosis", "DISEASE", 76, 84], ["NSAIDs", "CHEMICAL", 161, 167], ["streptococcal shock", "DISEASE", 212, 231], ["STSS", "DISEASE", 269, 273], ["infectious diseases", "DISEASE", 347, 366], ["endotoxin", "SIMPLE_CHEMICAL", 28, 37], ["volunteers", "ORGANISM", 46, 56], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 70, 91], ["TNF", "GENE_OR_GENE_PRODUCT", 93, 96], ["neutrophil", "CELL", 120, 130], ["NSAIDs", "SIMPLE_CHEMICAL", 161, 167], ["toxin", "SIMPLE_CHEMICAL", 198, 203], ["tumor necrosis factor", "PROTEIN", 70, 91], ["TNF", "PROTEIN", 93, 96], ["endotoxin-treated volunteers", "PROBLEM", 28, 56], ["elevated tumor necrosis factor", "PROBLEM", 61, 91], ["TNF) levels", "TEST", 93, 104], ["decreased neutrophil functions", "PROBLEM", 110, 140], ["NSAIDs", "TREATMENT", 161, 167], ["streptococcal shock", "PROBLEM", 212, 231], ["endotoxin", "OBSERVATION_MODIFIER", 28, 37], ["elevated", "OBSERVATION_MODIFIER", 61, 69], ["tumor", "OBSERVATION", 70, 75], ["necrosis", "OBSERVATION_MODIFIER", 76, 84], ["decreased", "OBSERVATION_MODIFIER", 110, 119], ["neutrophil functions", "OBSERVATION", 120, 140], ["streptococcal shock", "OBSERVATION", 212, 231]]], ["Early identification of the disease, as well as rapid treatment, is key to minimize both morbidity and mortality in this deadly disease.", [["the disease", "PROBLEM", 24, 35], ["rapid treatment", "TREATMENT", 48, 63], ["both morbidity", "PROBLEM", 84, 98], ["this deadly disease", "PROBLEM", 116, 135], ["disease", "OBSERVATION", 28, 35]]], ["Of extreme importance, a rapid source control and quick initiation of effective antibiotic therapy are both crucial.", [["a rapid source control", "TREATMENT", 23, 45], ["effective antibiotic therapy", "TREATMENT", 70, 98]]], ["In the case of STSS, the admission to the ICU, and the initiation of supportive treatment of several dysfunctional organs, is usually necessary.TreatmentWhen a patient presents with elevated and persistent fever, pain in soft tissues out of proportion with the clinical examination, and/or signs of shock, the multidisciplinary team should meet at the bedside, including a surgeon, discuss the investigation strategy, usually CT, MRI and/or surgical review of the painful region (or the site with radiological abnormalities).", [["organs", "ANATOMY", 115, 121], ["soft tissues", "ANATOMY", 221, 233], ["STSS", "DISEASE", 15, 19], ["fever", "DISEASE", 206, 211], ["pain", "DISEASE", 213, 217], ["shock", "DISEASE", 299, 304], ["organs", "ORGAN", 115, 121], ["patient", "ORGANISM", 160, 167], ["soft tissues", "TISSUE", 221, 233], ["patient", "SPECIES", 160, 167], ["supportive treatment", "TREATMENT", 69, 89], ["several dysfunctional organs", "PROBLEM", 93, 121], ["elevated and persistent fever", "PROBLEM", 182, 211], ["pain in soft tissues", "PROBLEM", 213, 233], ["the clinical examination", "TEST", 257, 281], ["shock", "PROBLEM", 299, 304], ["the investigation strategy", "TEST", 390, 416], ["usually CT", "TEST", 418, 428], ["MRI", "TEST", 430, 433], ["surgical review", "TEST", 441, 456], ["the painful region", "PROBLEM", 460, 478], ["radiological abnormalities", "TEST", 497, 523], ["persistent", "OBSERVATION_MODIFIER", 195, 205], ["fever", "OBSERVATION", 206, 211], ["soft tissues", "ANATOMY", 221, 233], ["shock", "OBSERVATION", 299, 304]]], ["The surgical approach has the advantage to look for fascia involvement visually, and to be able to perform a surgical biopsy and histopathology, deep bacteriological cultures, to open fascias if necessary, to check muscle viability underneath the fascia, and perform debridement of necrotic tissues.", [["fascia", "ANATOMY", 52, 58], ["fascias", "ANATOMY", 184, 191], ["muscle", "ANATOMY", 215, 221], ["fascia", "ANATOMY", 247, 253], ["necrotic tissues", "ANATOMY", 282, 298], ["necrotic", "DISEASE", 282, 290], ["fascia", "TISSUE", 52, 58], ["muscle", "TISSUE", 215, 221], ["fascia", "TISSUE", 247, 253], ["necrotic tissues", "TISSUE", 282, 298], ["The surgical approach", "TREATMENT", 0, 21], ["fascia involvement visually", "PROBLEM", 52, 79], ["a surgical biopsy", "TEST", 107, 124], ["histopathology", "TEST", 129, 143], ["deep bacteriological cultures", "TEST", 145, 174], ["debridement", "TREATMENT", 267, 278], ["necrotic tissues", "PROBLEM", 282, 298], ["surgical", "OBSERVATION", 4, 12], ["muscle", "ANATOMY", 215, 221], ["fascia", "ANATOMY", 247, 253], ["debridement", "OBSERVATION", 267, 278], ["necrotic tissues", "OBSERVATION", 282, 298]]], ["In case of necrotizing fasciitis and/or myositis, this aggressive surgical approach is the only one that may help stabilize the patient and save his life.", [["necrotizing fasciitis", "DISEASE", 11, 32], ["myositis", "DISEASE", 40, 48], ["patient", "ORGANISM", 128, 135], ["patient", "SPECIES", 128, 135], ["necrotizing fasciitis", "PROBLEM", 11, 32], ["myositis", "PROBLEM", 40, 48], ["this aggressive surgical approach", "TREATMENT", 50, 83], ["necrotizing", "OBSERVATION_MODIFIER", 11, 22], ["fasciitis", "OBSERVATION", 23, 32], ["myositis", "OBSERVATION", 40, 48]]], ["The more unstable is the patient (heavy requirement of norepinephrine), the more rapid should this assessment be, and surgical debridement be performed.TreatmentIn shocked patients, large volumes of crystalloids are usually required, together with significant doses Fig. 3 Schematic representation of T cell activation by a conventional peptide antigen (orange) and by a superantigen, binding unspecifically MHCII and T cell receptor, resulting to a massive, multiclonal release of T cell mediators and pro-inflammatory cytokines, in contrast to regulated, antigen-dependent inflammatory response during a conventional T cell activation, with activation of a single T cell clone.", [["T cell", "ANATOMY", 301, 307], ["T cell", "ANATOMY", 418, 424], ["T cell", "ANATOMY", 482, 488], ["T cell", "ANATOMY", 619, 625], ["T cell clone", "ANATOMY", 666, 678], ["norepinephrine", "CHEMICAL", 55, 69], ["norepinephrine", "CHEMICAL", 55, 69], ["patient", "ORGANISM", 25, 32], ["norepinephrine", "SIMPLE_CHEMICAL", 55, 69], ["patients", "ORGANISM", 172, 180], ["crystalloids", "ORGANISM_SUBSTANCE", 199, 211], ["T cell", "CELL", 301, 307], ["MHCII", "GENE_OR_GENE_PRODUCT", 408, 413], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 418, 433], ["T cell", "CELL", 482, 488], ["T cell", "CELL", 619, 625], ["T cell clone", "CELL", 666, 678], ["superantigen", "PROTEIN", 371, 383], ["MHCII", "PROTEIN", 408, 413], ["T cell receptor", "PROTEIN", 418, 433], ["T cell mediators", "PROTEIN", 482, 498], ["pro-inflammatory cytokines", "PROTEIN", 503, 529], ["T cell clone", "CELL_LINE", 666, 678], ["patient", "SPECIES", 25, 32], ["patients", "SPECIES", 172, 180], ["norepinephrine", "TREATMENT", 55, 69], ["this assessment", "TEST", 94, 109], ["surgical debridement", "TREATMENT", 118, 138], ["TreatmentIn", "TREATMENT", 152, 163], ["large volumes of crystalloids", "TREATMENT", 182, 211], ["significant doses Fig", "TREATMENT", 248, 269], ["T cell activation", "PROBLEM", 301, 318], ["a massive, multiclonal release of T cell mediators", "PROBLEM", 448, 498], ["pro-inflammatory cytokines", "PROBLEM", 503, 529], ["antigen-dependent inflammatory response", "PROBLEM", 557, 596], ["a conventional T cell activation", "TREATMENT", 604, 636], ["a single T cell clone", "TREATMENT", 657, 678], ["more", "OBSERVATION_MODIFIER", 4, 8], ["unstable", "OBSERVATION_MODIFIER", 9, 17], ["large", "OBSERVATION_MODIFIER", 182, 187], ["volumes", "OBSERVATION_MODIFIER", 188, 195], ["T cell activation", "OBSERVATION", 301, 318], ["massive", "OBSERVATION_MODIFIER", 450, 457], ["cell", "OBSERVATION", 484, 488], ["pro-inflammatory cytokines", "OBSERVATION", 503, 529], ["dependent", "OBSERVATION_MODIFIER", 565, 574], ["inflammatory", "OBSERVATION_MODIFIER", 575, 587], ["cell clone", "OBSERVATION", 668, 678]]], ["APC antigen-presenting cell, TcR T cell receptor, MHCII major histocompatibility class II molecule, TNF-\u03b1 tumor necrosis factor alpha, IFN-\u03b3 interferon gamma, IL interleukin of vasopressors.", [["cell", "ANATOMY", 23, 27], ["TcR T cell", "ANATOMY", 29, 39], ["tumor", "DISEASE", 106, 111], ["APC", "GENE_OR_GENE_PRODUCT", 0, 3], ["cell", "CELL", 23, 27], ["TcR T cell receptor", "GENE_OR_GENE_PRODUCT", 29, 48], ["MHCII major histocompatibility class II", "GENE_OR_GENE_PRODUCT", 50, 89], ["TNF-\u03b1 tumor necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 100, 133], ["IFN-\u03b3 interferon gamma", "GENE_OR_GENE_PRODUCT", 135, 157], ["IL interleukin", "GENE_OR_GENE_PRODUCT", 159, 173], ["APC antigen", "PROTEIN", 0, 11], ["TcR T cell receptor", "PROTEIN", 29, 48], ["MHCII major histocompatibility class II molecule", "PROTEIN", 50, 98], ["TNF-\u03b1 tumor necrosis factor alpha", "PROTEIN", 100, 133], ["IFN-\u03b3 interferon gamma", "PROTEIN", 135, 157], ["IL interleukin", "PROTEIN", 159, 173], ["APC antigen", "TEST", 0, 11], ["TNF", "TEST", 100, 103], ["tumor necrosis", "PROBLEM", 106, 120], ["alpha", "TEST", 128, 133], ["IFN", "TEST", 135, 138], ["interferon gamma", "TREATMENT", 141, 157], ["IL interleukin of vasopressors", "TREATMENT", 159, 189], ["TNF", "ANATOMY", 100, 103], ["tumor", "OBSERVATION_MODIFIER", 106, 111], ["necrosis", "OBSERVATION", 112, 120]]], ["Invasive hemodynamic monitoring is generally useful in those patients to guide fluid loading, vasopressor treatment, and the possible requirement of inotropic drugs.", [["fluid", "ANATOMY", 79, 84], ["patients", "ORGANISM", 61, 69], ["fluid", "ORGANISM_SUBSTANCE", 79, 84], ["patients", "SPECIES", 61, 69], ["Invasive hemodynamic monitoring", "TEST", 0, 31], ["fluid loading", "TREATMENT", 79, 92], ["vasopressor treatment", "TREATMENT", 94, 115], ["inotropic drugs", "TREATMENT", 149, 164]]], ["Virtually all patients with STSS need intubation and ventilatory support, frequently develop ARDS, as well as renal failure requiring renal replacement therapy [2] .", [["renal", "ANATOMY", 110, 115], ["renal", "ANATOMY", 134, 139], ["STSS", "DISEASE", 28, 32], ["ARDS", "DISEASE", 93, 97], ["renal failure", "DISEASE", 110, 123], ["patients", "ORGANISM", 14, 22], ["renal", "ORGAN", 110, 115], ["renal", "ORGAN", 134, 139], ["patients", "SPECIES", 14, 22], ["STSS", "PROBLEM", 28, 32], ["intubation", "TREATMENT", 38, 48], ["ventilatory support", "TREATMENT", 53, 72], ["ARDS", "PROBLEM", 93, 97], ["renal failure", "PROBLEM", 110, 123], ["renal replacement therapy", "TREATMENT", 134, 159], ["ARDS", "OBSERVATION", 93, 97], ["renal", "ANATOMY", 110, 115], ["failure", "OBSERVATION", 116, 123], ["renal", "ANATOMY", 134, 139], ["replacement", "OBSERVATION", 140, 151]]], ["Acute kidney injury with elevated creatinine at the time of admission is frequently found in severe GAS infections and STSS, and when present should make the clinician think of this disease.TreatmentAntibiotics Surprisingly, S. pyogenes remains universally susceptible to penicillin despite the widespread use of penicillin for over 7 decades [53] .", [["kidney", "ANATOMY", 6, 12], ["Acute kidney injury", "DISEASE", 0, 19], ["creatinine", "CHEMICAL", 34, 44], ["infections", "DISEASE", 104, 114], ["STSS", "DISEASE", 119, 123], ["penicillin", "CHEMICAL", 272, 282], ["penicillin", "CHEMICAL", 313, 323], ["creatinine", "CHEMICAL", 34, 44], ["penicillin", "CHEMICAL", 272, 282], ["penicillin", "CHEMICAL", 313, 323], ["kidney", "ORGAN", 6, 12], ["creatinine", "SIMPLE_CHEMICAL", 34, 44], ["S. pyogenes", "ORGANISM", 225, 236], ["penicillin", "SIMPLE_CHEMICAL", 272, 282], ["penicillin", "SIMPLE_CHEMICAL", 313, 323], ["S. pyogenes", "SPECIES", 225, 236], ["S. pyogenes", "SPECIES", 225, 236], ["Acute kidney injury", "PROBLEM", 0, 19], ["elevated creatinine", "PROBLEM", 25, 44], ["severe GAS infections", "PROBLEM", 93, 114], ["STSS", "PROBLEM", 119, 123], ["this disease", "PROBLEM", 177, 189], ["TreatmentAntibiotics", "TREATMENT", 190, 210], ["S. pyogenes", "PROBLEM", 225, 236], ["penicillin", "TREATMENT", 272, 282], ["penicillin", "TREATMENT", 313, 323], ["kidney", "ANATOMY", 6, 12], ["injury", "OBSERVATION", 13, 19], ["elevated", "OBSERVATION_MODIFIER", 25, 33], ["creatinine", "OBSERVATION", 34, 44], ["severe", "OBSERVATION_MODIFIER", 93, 99], ["GAS infections", "OBSERVATION", 100, 114]]], ["Some strains have, however, developed resistance to macrolides, tetracyclins and clindamycin.", [["macrolides", "CHEMICAL", 52, 62], ["tetracyclins", "CHEMICAL", 64, 76], ["clindamycin", "CHEMICAL", 81, 92], ["macrolides", "CHEMICAL", 52, 62], ["tetracyclins", "CHEMICAL", 64, 76], ["clindamycin", "CHEMICAL", 81, 92], ["macrolides", "SIMPLE_CHEMICAL", 52, 62], ["tetracyclins", "SIMPLE_CHEMICAL", 64, 76], ["clindamycin", "SIMPLE_CHEMICAL", 81, 92], ["Some strains", "PROBLEM", 0, 12], ["macrolides", "TREATMENT", 52, 62], ["tetracyclins", "TREATMENT", 64, 76], ["clindamycin", "TREATMENT", 81, 92], ["strains", "OBSERVATION", 5, 12]]], ["Penicillin G is bactericidal and remains, at high parenteral doses, the first-line treatment for infections due to SGA.", [["parenteral", "ANATOMY", 50, 60], ["Penicillin", "CHEMICAL", 0, 10], ["infections", "DISEASE", 97, 107], ["SGA", "DISEASE", 115, 118], ["Penicillin G", "CHEMICAL", 0, 12], ["Penicillin G", "SIMPLE_CHEMICAL", 0, 12], ["Penicillin G", "TREATMENT", 0, 12], ["bactericidal", "PROBLEM", 16, 28], ["high parenteral doses", "TREATMENT", 45, 66], ["the first-line treatment", "TREATMENT", 68, 92], ["infections", "PROBLEM", 97, 107], ["SGA", "PROBLEM", 115, 118], ["bactericidal", "OBSERVATION_MODIFIER", 16, 28]]], ["In vivo, the efficacy of penicillin might be affected by the inoculum size.", [["penicillin", "CHEMICAL", 25, 35], ["penicillin", "CHEMICAL", 25, 35], ["penicillin", "SIMPLE_CHEMICAL", 25, 35], ["penicillin", "TREATMENT", 25, 35], ["inoculum", "OBSERVATION_MODIFIER", 61, 69], ["size", "OBSERVATION_MODIFIER", 70, 74]]], ["Clinical failures of penicillin alone have been reported.", [["penicillin", "CHEMICAL", 21, 31], ["penicillin", "CHEMICAL", 21, 31], ["penicillin", "SIMPLE_CHEMICAL", 21, 31], ["Clinical failures", "PROBLEM", 0, 17], ["penicillin", "TREATMENT", 21, 31]]], ["Due to the inoculum and steady-state volume of distribution disturbance, maximal parenteral doses of penicillin G are required (e.g., 4 mio IU/4 h.).TreatmentClindamycin, a lincosamide antibiotic, is usually added to penicillin or aminopenicillin since it inhibits the protein synthesis by blocking the 50S sub-unit of the bacterial ribosome.", [["parenteral", "ANATOMY", 81, 91], ["ribosome", "ANATOMY", 333, 341], ["penicillin", "CHEMICAL", 101, 111], ["TreatmentClindamycin", "CHEMICAL", 149, 169], ["lincosamide", "CHEMICAL", 173, 184], ["penicillin", "CHEMICAL", 217, 227], ["aminopenicillin", "CHEMICAL", 231, 246], ["penicillin G", "CHEMICAL", 101, 113], ["TreatmentClindamycin", "CHEMICAL", 149, 169], ["lincosamide", "CHEMICAL", 173, 184], ["penicillin", "CHEMICAL", 217, 227], ["aminopenicillin", "CHEMICAL", 231, 246], ["penicillin G", "SIMPLE_CHEMICAL", 101, 113], ["TreatmentClindamycin", "SIMPLE_CHEMICAL", 149, 169], ["lincosamide", "SIMPLE_CHEMICAL", 173, 184], ["penicillin", "SIMPLE_CHEMICAL", 217, 227], ["aminopenicillin", "SIMPLE_CHEMICAL", 231, 246], ["bacterial ribosome", "CELLULAR_COMPONENT", 323, 341], ["50S sub-unit", "DNA", 303, 315], ["bacterial ribosome", "PROTEIN", 323, 341], ["the inoculum", "PROBLEM", 7, 19], ["distribution disturbance", "PROBLEM", 47, 71], ["maximal parenteral doses of penicillin G", "TREATMENT", 73, 113], ["TreatmentClindamycin", "TREATMENT", 149, 169], ["a lincosamide antibiotic", "TREATMENT", 171, 195], ["penicillin", "TREATMENT", 217, 227], ["aminopenicillin", "TREATMENT", 231, 246], ["the protein synthesis", "PROBLEM", 265, 286], ["the bacterial ribosome", "TREATMENT", 319, 341], ["inoculum", "OBSERVATION", 11, 19], ["bacterial ribosome", "OBSERVATION", 323, 341]]], ["It thus may therefore block the production of exotoxins such as the superantigens [54, 55] .", [["exotoxins", "PROTEIN", 46, 55], ["superantigens", "PROTEIN", 68, 81], ["exotoxins", "PROBLEM", 46, 55]]], ["The effect of decreased production of superantigens by clindamycin treatment has been demonstrated in animal studies [56] .", [["clindamycin", "CHEMICAL", 55, 66], ["clindamycin", "CHEMICAL", 55, 66], ["clindamycin", "SIMPLE_CHEMICAL", 55, 66], ["superantigens", "PROTEIN", 38, 51], ["decreased production of superantigens", "PROBLEM", 14, 51], ["clindamycin treatment", "TREATMENT", 55, 76], ["animal studies", "TEST", 102, 116], ["decreased", "OBSERVATION_MODIFIER", 14, 23], ["production", "OBSERVATION_MODIFIER", 24, 34]]], ["Interestingly, penicillin and clindamycin both inhibit in vitro the production of the streptococcus superantigen pyrogenic exotoxins A (SPEA) and B (SPEB) isolated in S. pyogenes strains implicated in toxic shock syndrome, but the inhibition by clindamycin was significantly more important [57, 58] .", [["penicillin", "CHEMICAL", 15, 25], ["clindamycin", "CHEMICAL", 30, 41], ["toxic shock syndrome", "DISEASE", 201, 221], ["clindamycin", "CHEMICAL", 245, 256], ["penicillin", "CHEMICAL", 15, 25], ["clindamycin", "CHEMICAL", 30, 41], ["clindamycin", "CHEMICAL", 245, 256], ["penicillin", "SIMPLE_CHEMICAL", 15, 25], ["clindamycin", "SIMPLE_CHEMICAL", 30, 41], ["pyrogenic exotoxins A", "GENE_OR_GENE_PRODUCT", 113, 134], ["SPEA", "GENE_OR_GENE_PRODUCT", 136, 140], ["B (SPEB)", "ORGANISM", 146, 154], ["S. pyogenes strains", "ORGANISM", 167, 186], ["clindamycin", "SIMPLE_CHEMICAL", 245, 256], ["streptococcus superantigen pyrogenic exotoxins A", "PROTEIN", 86, 134], ["SPEA", "PROTEIN", 136, 140], ["B", "PROTEIN", 146, 147], ["SPEB", "PROTEIN", 149, 153], ["S. pyogenes", "SPECIES", 167, 178], ["S. pyogenes", "SPECIES", 167, 178], ["penicillin", "TREATMENT", 15, 25], ["clindamycin", "TREATMENT", 30, 41], ["the streptococcus superantigen pyrogenic exotoxins", "TEST", 82, 132], ["B (SPEB)", "TEST", 146, 154], ["S. pyogenes strains", "PROBLEM", 167, 186], ["toxic shock syndrome", "PROBLEM", 201, 221], ["clindamycin", "TREATMENT", 245, 256], ["toxic shock syndrome", "OBSERVATION", 201, 221]]], ["Besides, the prolonged post-antibiotic activity and the lack of an inoculum effect (an increase in the minimal inhibitory concentration of an antibiotic when the number of organisms increases) may be desirable properties in the treatment of STSS.TreatmentThe addition of clindamycin to penicillin may improve patient outcomes and reduce mortality [59] .", [["STSS", "DISEASE", 241, 245], ["clindamycin", "CHEMICAL", 271, 282], ["penicillin", "CHEMICAL", 286, 296], ["clindamycin", "CHEMICAL", 271, 282], ["penicillin", "CHEMICAL", 286, 296], ["STSS", "CANCER", 241, 245], ["clindamycin", "SIMPLE_CHEMICAL", 271, 282], ["penicillin", "SIMPLE_CHEMICAL", 286, 296], ["patient", "ORGANISM", 309, 316], ["patient", "SPECIES", 309, 316], ["the prolonged post-antibiotic activity", "PROBLEM", 9, 47], ["an inoculum effect", "PROBLEM", 64, 82], ["the minimal inhibitory concentration", "TREATMENT", 99, 135], ["an antibiotic", "TREATMENT", 139, 152], ["STSS", "PROBLEM", 241, 245], ["Treatment", "TREATMENT", 246, 255], ["clindamycin", "TREATMENT", 271, 282], ["penicillin", "TREATMENT", 286, 296], ["inoculum effect", "OBSERVATION", 67, 82], ["increase", "OBSERVATION_MODIFIER", 87, 95]]], ["Concentrations of the SPEA toxin were significantly lower 1 h after treatment when clindamycin or linezolid was added to penicillin, compared with penicillin alone.", [["clindamycin", "CHEMICAL", 83, 94], ["linezolid", "CHEMICAL", 98, 107], ["penicillin", "CHEMICAL", 121, 131], ["penicillin", "CHEMICAL", 147, 157], ["clindamycin", "CHEMICAL", 83, 94], ["linezolid", "CHEMICAL", 98, 107], ["penicillin", "CHEMICAL", 121, 131], ["penicillin", "CHEMICAL", 147, 157], ["SPEA toxin", "SIMPLE_CHEMICAL", 22, 32], ["clindamycin", "SIMPLE_CHEMICAL", 83, 94], ["linezolid", "SIMPLE_CHEMICAL", 98, 107], ["penicillin", "SIMPLE_CHEMICAL", 121, 131], ["penicillin", "SIMPLE_CHEMICAL", 147, 157], ["SPEA toxin", "PROTEIN", 22, 32], ["the SPEA toxin", "TEST", 18, 32], ["treatment", "TREATMENT", 68, 77], ["clindamycin", "TREATMENT", 83, 94], ["linezolid", "TREATMENT", 98, 107], ["penicillin", "TREATMENT", 121, 131], ["penicillin", "TREATMENT", 147, 157]]], ["The mode of action of linezolid is similar to that of clindamycin, but its use in STSS is limited, and has no theoretical advantage over clindamycin [58] .", [["linezolid", "CHEMICAL", 22, 31], ["clindamycin", "CHEMICAL", 54, 65], ["STSS", "CHEMICAL", 82, 86], ["clindamycin", "CHEMICAL", 137, 148], ["linezolid", "CHEMICAL", 22, 31], ["clindamycin", "CHEMICAL", 54, 65], ["clindamycin", "CHEMICAL", 137, 148], ["linezolid", "SIMPLE_CHEMICAL", 22, 31], ["clindamycin", "SIMPLE_CHEMICAL", 54, 65], ["clindamycin", "SIMPLE_CHEMICAL", 137, 148], ["linezolid", "TREATMENT", 22, 31], ["clindamycin", "TREATMENT", 54, 65], ["clindamycin", "TREATMENT", 137, 148]]], ["The optimal duration of antibiotic treatment for STSS remains controversial and is usually guided by the clinical evolution, and by the need for recurrent surgical interventions.", [["STSS", "DISEASE", 49, 53], ["antibiotic treatment", "TREATMENT", 24, 44], ["STSS", "PROBLEM", 49, 53], ["recurrent surgical interventions", "TREATMENT", 145, 177]]], ["Duration of 2 weeks for the antibiotic therapy is often proposed, however, without any strong evidence supporting this duration of treatment.", [["the antibiotic therapy", "TREATMENT", 24, 46], ["treatment", "TREATMENT", 131, 140]]], ["Again, it is important to stress that antibiotic therapy alone is not sufficient to treat and cure STSS.", [["STSS", "DISEASE", 99, 103], ["antibiotic therapy", "TREATMENT", 38, 56]]], ["Antibiotic penetration into infected tissues, and sites of soft tissue and muscle necrosis is frequently very low, if not absent.", [["tissues", "ANATOMY", 37, 44], ["sites", "ANATOMY", 50, 55], ["soft tissue", "ANATOMY", 59, 70], ["muscle", "ANATOMY", 75, 81], ["muscle necrosis", "DISEASE", 75, 90], ["tissues", "TISSUE", 37, 44], ["soft tissue", "TISSUE", 59, 70], ["muscle", "ORGAN", 75, 81], ["Antibiotic penetration into infected tissues", "PROBLEM", 0, 44], ["soft tissue and muscle necrosis", "PROBLEM", 59, 90], ["penetration", "OBSERVATION_MODIFIER", 11, 22], ["infected tissues", "OBSERVATION", 28, 44], ["soft tissue", "ANATOMY", 59, 70], ["muscle", "ANATOMY", 75, 81], ["necrosis", "OBSERVATION", 82, 90]]], ["This is essentially due to the poor vascularization of these sites, partly due to infection-induced microvascular thrombosis.", [["sites", "ANATOMY", 61, 66], ["microvascular", "ANATOMY", 100, 113], ["infection", "DISEASE", 82, 91], ["microvascular thrombosis", "DISEASE", 100, 124], ["microvascular", "TISSUE", 100, 113], ["the poor vascularization of these sites", "PROBLEM", 27, 66], ["infection", "PROBLEM", 82, 91], ["microvascular thrombosis", "PROBLEM", 100, 124], ["essentially due to", "UNCERTAINTY", 8, 26], ["poor", "OBSERVATION_MODIFIER", 31, 35], ["vascularization", "OBSERVATION", 36, 51], ["partly due to", "UNCERTAINTY", 68, 81], ["infection", "OBSERVATION", 82, 91], ["microvascular thrombosis", "OBSERVATION", 100, 124]]], ["Only surgical debridement of infected and necrotic tissues associated with high-dose systemic antibiotic therapy may improve mortality.ImmunoglobulinLower levels of neutralizing antibodies against streptococcal toxins and the M-protein in patients' plasma are correlated with invasive diseases of GAS [60, 61] .", [["necrotic tissues", "ANATOMY", 42, 58], ["plasma", "ANATOMY", 249, 255], ["necrotic", "DISEASE", 42, 50], ["necrotic tissues", "TISSUE", 42, 58], ["antibodies against streptococcal toxins", "GENE_OR_GENE_PRODUCT", 178, 217], ["M-protein", "GENE_OR_GENE_PRODUCT", 226, 235], ["patients", "ORGANISM", 239, 247], ["plasma", "ORGANISM_SUBSTANCE", 249, 255], ["neutralizing antibodies", "PROTEIN", 165, 188], ["M-protein", "PROTEIN", 226, 235], ["patients", "SPECIES", 239, 247], ["surgical debridement", "TREATMENT", 5, 25], ["infected and necrotic tissues", "PROBLEM", 29, 58], ["high-dose systemic antibiotic therapy", "TREATMENT", 75, 112], ["ImmunoglobulinLower levels", "TEST", 135, 161], ["neutralizing antibodies", "TEST", 165, 188], ["streptococcal toxins", "PROBLEM", 197, 217], ["the M-protein", "TEST", 222, 235], ["invasive diseases of GAS", "PROBLEM", 276, 300], ["surgical", "OBSERVATION_MODIFIER", 5, 13], ["debridement", "OBSERVATION", 14, 25], ["infected", "OBSERVATION_MODIFIER", 29, 37], ["necrotic tissues", "OBSERVATION", 42, 58], ["high", "OBSERVATION_MODIFIER", 75, 79]]], ["Case reports in the 1990s described a lower mortality in patients with STSS who benefited from polyclonal immunoglobulins [62] [63] [64] .", [["STSS", "DISEASE", 71, 75], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["polyclonal immunoglobulins", "TEST", 95, 121]]], ["These findings pointed at possible importance of antibodies in the protection against invasive diseases and suggested that addition of IV polyclonal immunoglobulins (IVIG) to the treatment may be useful as an adjunctive therapy.", [["invasive diseases", "DISEASE", 86, 103], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 149, 164], ["IVIG", "SIMPLE_CHEMICAL", 166, 170], ["antibodies", "PROTEIN", 49, 59], ["IV polyclonal immunoglobulins", "PROTEIN", 135, 164], ["IVIG", "PROTEIN", 166, 170], ["antibodies", "TREATMENT", 49, 59], ["invasive diseases", "PROBLEM", 86, 103], ["IV polyclonal immunoglobulins (IVIG)", "TREATMENT", 135, 171], ["the treatment", "TREATMENT", 175, 188], ["an adjunctive therapy", "TREATMENT", 206, 227]]], ["Possible mechanisms of action of immunoglobulins in STSS are: neutralization of toxins, improvement in bacterial opsonization, phagocytosis, and killing, as well as a possible immunomodulatory effect mediated by the interaction of Fc receptors and immune cells [65, 66] .ImmunoglobulinThe first report suggesting a lower mortality in the group of patients with STSS treated with IVIG was reported in an observational cohort study [67] .", [["immune cells", "ANATOMY", 248, 260], ["STSS", "DISEASE", 52, 56], ["STSS", "DISEASE", 361, 365], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 33, 48], ["STSS", "SIMPLE_CHEMICAL", 52, 56], ["Fc receptors", "GENE_OR_GENE_PRODUCT", 231, 243], ["immune cells", "CELL", 248, 260], ["Immunoglobulin", "GENE_OR_GENE_PRODUCT", 271, 285], ["patients", "ORGANISM", 347, 355], ["STSS", "CANCER", 361, 365], ["IVIG", "SIMPLE_CHEMICAL", 379, 383], ["immunoglobulins", "PROTEIN", 33, 48], ["Fc receptors", "PROTEIN", 231, 243], ["immune cells", "CELL_TYPE", 248, 260], ["Immunoglobulin", "PROTEIN", 271, 285], ["patients", "SPECIES", 347, 355], ["immunoglobulins in STSS", "PROBLEM", 33, 56], ["toxins", "PROBLEM", 80, 86], ["bacterial opsonization", "PROBLEM", 103, 125], ["phagocytosis", "PROBLEM", 127, 139], ["killing", "PROBLEM", 145, 152], ["immunomodulatory effect", "PROBLEM", 176, 199], ["Fc receptors", "TEST", 231, 243], ["immune cells", "TEST", 248, 260], ["a lower mortality", "PROBLEM", 313, 330], ["STSS", "PROBLEM", 361, 365], ["IVIG", "TREATMENT", 379, 383], ["an observational cohort study", "TEST", 400, 429], ["bacterial opsonization", "OBSERVATION", 103, 125], ["lower", "OBSERVATION_MODIFIER", 315, 320]]], ["In a randomized, double-blind placebo-controlled study reported in 2003, patients with IVIG had a recovery of organ function significantly more rapid but no survival advantage [68] .", [["organ", "ANATOMY", 110, 115], ["patients", "ORGANISM", 73, 81], ["organ", "ORGAN", 110, 115], ["patients", "SPECIES", 73, 81], ["double-blind placebo", "TREATMENT", 17, 37], ["IVIG", "TREATMENT", 87, 91], ["organ function", "PROBLEM", 110, 124]]], ["This study was stopped prematurely because of a slow recruitment and was not powered to demonstrate the possible effect of IVIG on mortality.", [["IVIG", "CHEMICAL", 123, 127], ["IVIG", "SIMPLE_CHEMICAL", 123, 127], ["This study", "TEST", 0, 10], ["a slow recruitment", "PROBLEM", 46, 64], ["IVIG", "TREATMENT", 123, 127]]], ["A recent randomized double-blinded placebo-controlled trial tested the effect of IVIG in necrotizing soft tissue infections (INSTINCT trial) [69] .", [["soft tissue", "ANATOMY", 101, 112], ["necrotizing soft tissue infections", "DISEASE", 89, 123], ["IVIG", "SIMPLE_CHEMICAL", 81, 85], ["soft tissue", "TISSUE", 101, 112], ["A recent randomized double-blinded placebo", "TREATMENT", 0, 42], ["IVIG", "TREATMENT", 81, 85], ["necrotizing soft tissue infections", "PROBLEM", 89, 123], ["necrotizing", "OBSERVATION_MODIFIER", 89, 100], ["soft tissue", "ANATOMY", 101, 112], ["infections", "OBSERVATION", 113, 123]]], ["There was no statistically significant difference between placebo and the interventional groups concerning the primary outcome (functional status assessed by the physical component summary (PCS) score of the 36-item short-form health survey (SF-36) 6 months after randomization) and the secondary outcome (mortality and multiple organ failure) [69] .", [["organ", "ANATOMY", 329, 334], ["multiple organ failure", "DISEASE", 320, 342], ["organ", "ORGAN", 329, 334], ["placebo", "TREATMENT", 58, 65], ["multiple organ failure", "PROBLEM", 320, 342], ["no", "UNCERTAINTY", 10, 12], ["statistically", "OBSERVATION_MODIFIER", 13, 26], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["difference", "OBSERVATION", 39, 49], ["organ", "ANATOMY", 329, 334], ["failure", "OBSERVATION", 335, 342]]], ["However, patients suffering from documented STSS represented < 10% of the study population making it impossible to draw definite conclusions for this subgroup.", [["STSS", "DISEASE", 44, 48], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["documented STSS", "PROBLEM", 33, 48], ["the study", "TEST", 70, 79]]], ["Another recent retrospective study could not demonstrate a benefit of routine use of IVIG in necrotizing fasciitis [70] .", [["necrotizing fasciitis", "DISEASE", 93, 114], ["IVIG", "SIMPLE_CHEMICAL", 85, 89], ["Another recent retrospective study", "TEST", 0, 34], ["IVIG", "TREATMENT", 85, 89], ["necrotizing fasciitis", "PROBLEM", 93, 114], ["necrotizing", "OBSERVATION_MODIFIER", 93, 104], ["fasciitis", "OBSERVATION", 105, 114]]], ["Guidelines from the Infectious Disease Society of America (IDSA) state that additional studies testing the efficacy of IVIG in this indication are needed and also point to the fact that not all IVIG preparations are alike, in particular with the titers of neutralizing antibodies [71] .", [["Infectious Disease", "DISEASE", 20, 38], ["IVIG", "SIMPLE_CHEMICAL", 119, 123], ["neutralizing antibodies", "PROTEIN", 256, 279], ["additional studies testing", "TEST", 76, 102], ["IVIG", "TREATMENT", 119, 123], ["all IVIG preparations", "TREATMENT", 190, 211], ["neutralizing antibodies", "TEST", 256, 279], ["Infectious", "OBSERVATION_MODIFIER", 20, 30]]], ["Therefore, the use of IVIG in STSS cannot be routinely recommended and should be discussed on a case-by-case basis.", [["IVIG", "SIMPLE_CHEMICAL", 22, 26], ["STSS", "CANCER", 30, 34], ["IVIG", "TREATMENT", 22, 26]]], ["Plasmapheresis has been proposed, but level of evidence for its use is even smaller than that for IVIG, and only based on isolated cases reports [72] .PreventionChemoprophylaxis Secondary invasive GAS disease has been documented to occur in individuals in close contact with the index patient.", [["GAS disease", "DISEASE", 197, 208], ["patient", "ORGANISM", 285, 292], ["patient", "SPECIES", 285, 292], ["Plasmapheresis", "TREATMENT", 0, 14], ["IVIG", "TREATMENT", 98, 102], ["Chemoprophylaxis", "TREATMENT", 161, 177], ["invasive GAS disease", "PROBLEM", 188, 208], ["invasive", "OBSERVATION_MODIFIER", 188, 196], ["GAS disease", "OBSERVATION", 197, 208]]], ["Carapetis et al. [59] report an incidence rate of developing an invasive GAS infection 2011 times higher than in the general population in Australia (95% confidence interval, 413-5929).", [["GAS infection", "DISEASE", 73, 86], ["an invasive GAS infection", "PROBLEM", 61, 86], ["invasive", "OBSERVATION_MODIFIER", 64, 72], ["GAS", "OBSERVATION_MODIFIER", 73, 76], ["infection", "OBSERVATION", 77, 86]]], ["The effectiveness of antibiotic prophylaxis on the risk of development of secondary invasive GAS infections remains, however, unclear [73] [74] [75] .", [["infections", "DISEASE", 97, 107], ["antibiotic prophylaxis", "TREATMENT", 21, 43], ["secondary invasive GAS infections", "PROBLEM", 74, 107], ["secondary", "OBSERVATION_MODIFIER", 74, 83], ["invasive", "OBSERVATION_MODIFIER", 84, 92], ["GAS infections", "OBSERVATION", 93, 107]]], ["The CDC recommends prophylaxis for contacts who have risk factors for the disease [76] , and to advise contacts to rapidly search for medical help when presenting signs compatible with GAS infection.VaccinationGAS is responsible for a high morbidity and mortality with diverse clinical manifestations.", [["GAS infection", "DISEASE", 185, 198], ["prophylaxis", "TREATMENT", 19, 30], ["the disease", "PROBLEM", 70, 81], ["GAS infection", "PROBLEM", 185, 198], ["VaccinationGAS", "TEST", 199, 213], ["a high morbidity", "PROBLEM", 233, 249], ["diverse clinical manifestations", "PROBLEM", 269, 300], ["compatible with", "UNCERTAINTY", 169, 184], ["GAS infection", "OBSERVATION", 185, 198]]], ["A safe vaccine which would not induce autoimmune pathology and cover different GAS strains would be of great interest.", [["A safe vaccine", "TREATMENT", 0, 14], ["autoimmune pathology", "PROBLEM", 38, 58], ["different GAS strains", "PROBLEM", 69, 90], ["GAS strains", "OBSERVATION", 79, 90]]], ["Despite various efforts, such a vaccine could not be developed to date [77] [78] [79] [80] .Preventing transmissionTransmission of GAS infection from patients with STSS to other patients or household contacts has been reported in healthcare settings.", [["GAS infection", "DISEASE", 131, 144], ["STSS", "DISEASE", 164, 168], ["[77] [78] [79", "SIMPLE_CHEMICAL", 71, 84], ["GAS", "ORGANISM", 131, 134], ["patients", "ORGANISM", 150, 158], ["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 150, 158], ["patients", "SPECIES", 178, 186], ["a vaccine", "TREATMENT", 30, 39], ["GAS infection", "PROBLEM", 131, 144], ["GAS infection", "OBSERVATION", 131, 144]]], ["The CDC recommends contact and droplet plus standard precautions for the first 24 h of effective antimicrobial therapy in patients with severe GAS infection [81] .", [["GAS infection", "DISEASE", 143, 156], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["standard precautions", "TREATMENT", 44, 64], ["effective antimicrobial therapy", "TREATMENT", 87, 118], ["severe GAS infection", "PROBLEM", 136, 156], ["severe", "OBSERVATION_MODIFIER", 136, 142], ["GAS infection", "OBSERVATION", 143, 156]]], ["This recommendation is, however, not based on solid ground, and standard precautions are believed to be sufficient in many other institutions, including ours.", [["standard precautions", "TREATMENT", 64, 84]]], ["Routine screening and prophylactic treatment of household contacts are currently not recommended [82, 83] .ConclusionThe streptococcal toxic shock syndrome is an acute and severe systemic illness in part due to toxins with superantigen activity secreted by streptococci, mainly by group A streptococcus.", [["streptococcal toxic shock syndrome", "DISEASE", 121, 155], ["systemic illness", "DISEASE", 179, 195], ["group A streptococcus", "ORGANISM", 281, 302], ["Routine screening", "TEST", 0, 17], ["prophylactic treatment", "TREATMENT", 22, 44], ["The streptococcal toxic shock syndrome", "PROBLEM", 117, 155], ["an acute and severe systemic illness", "PROBLEM", 159, 195], ["toxins", "PROBLEM", 211, 217], ["superantigen activity secreted", "PROBLEM", 223, 253], ["streptococci", "PROBLEM", 257, 269], ["group A streptococcus", "PROBLEM", 281, 302], ["streptococcal", "OBSERVATION_MODIFIER", 121, 134], ["toxic shock syndrome", "OBSERVATION", 135, 155], ["acute", "OBSERVATION_MODIFIER", 162, 167], ["severe", "OBSERVATION_MODIFIER", 172, 178], ["systemic", "OBSERVATION_MODIFIER", 179, 187], ["illness", "OBSERVATION", 188, 195]]], ["The intensity, the rapidity of the development of shock and multiple organ failure on one hand, and cutaneous, fascia, and muscle necrosis, on the other hand, makes it essential to recognize and treat it rapidly.", [["organ", "ANATOMY", 69, 74], ["hand", "ANATOMY", 90, 94], ["cutaneous", "ANATOMY", 100, 109], ["fascia", "ANATOMY", 111, 117], ["muscle", "ANATOMY", 123, 129], ["shock", "DISEASE", 50, 55], ["organ failure", "DISEASE", 69, 82], ["muscle necrosis", "DISEASE", 123, 138], ["organ", "ORGAN", 69, 74], ["hand", "ORGANISM_SUBDIVISION", 90, 94], ["cutaneous", "ORGANISM_SUBDIVISION", 100, 109], ["fascia", "TISSUE", 111, 117], ["muscle", "ORGAN", 123, 129], ["shock", "PROBLEM", 50, 55], ["multiple organ failure", "PROBLEM", 60, 82], ["cutaneous, fascia", "PROBLEM", 100, 117], ["muscle necrosis", "PROBLEM", 123, 138], ["intensity", "OBSERVATION_MODIFIER", 4, 13], ["rapidity", "OBSERVATION_MODIFIER", 19, 27], ["shock", "OBSERVATION", 50, 55], ["multiple", "OBSERVATION_MODIFIER", 60, 68], ["organ", "ANATOMY", 69, 74], ["failure", "OBSERVATION", 75, 82], ["cutaneous", "ANATOMY", 100, 109], ["fascia", "ANATOMY", 111, 117], ["muscle", "ANATOMY", 123, 129], ["necrosis", "OBSERVATION", 130, 138]]], ["Surgical look and aggressive debridement of the infected site(s) is frequently required in necrotizing fasciitis.", [["site", "ANATOMY", 57, 61], ["necrotizing fasciitis", "DISEASE", 91, 112], ["Surgical", "TREATMENT", 0, 8], ["aggressive debridement", "TREATMENT", 18, 40], ["the infected site", "PROBLEM", 44, 61], ["necrotizing fasciitis", "PROBLEM", 91, 112], ["aggressive", "OBSERVATION_MODIFIER", 18, 28], ["debridement", "OBSERVATION", 29, 40], ["infected", "OBSERVATION", 48, 56], ["necrotizing", "OBSERVATION_MODIFIER", 91, 102], ["fasciitis", "OBSERVATION", 103, 112]]], ["Antibiotic therapy should be given rapidly, associating high doses of parenteral beta-lactams plus clindamycin for its \"anti-toxin\" effect.", [["beta-lactams", "CHEMICAL", 81, 93], ["clindamycin", "CHEMICAL", 99, 110], ["clindamycin", "CHEMICAL", 99, 110], ["parenteral beta-lactams", "SIMPLE_CHEMICAL", 70, 93], ["clindamycin", "SIMPLE_CHEMICAL", 99, 110], ["Antibiotic therapy", "TREATMENT", 0, 18], ["parenteral beta-lactams", "TREATMENT", 70, 93], ["clindamycin", "TREATMENT", 99, 110], ["its \"anti-toxin\" effect", "TREATMENT", 115, 138]]], ["Secondary surgery for lavage and debridement is also frequently needed to control STSS.", [["lavage", "ANATOMY", 22, 28], ["STSS", "DISEASE", 82, 86], ["Secondary surgery", "TREATMENT", 0, 17], ["lavage", "TREATMENT", 22, 28], ["debridement", "TREATMENT", 33, 44], ["lavage", "OBSERVATION", 22, 28], ["debridement", "OBSERVATION", 33, 44]]], ["Survival can be at the cost of impairment of limb function following muscle necrosis or amputations.ConclusionAbbreviations ICU: intensive care unit; STSS: streptococcal toxic shock syndrome; GAS: group A streptococcus; IVIG: polyclonal intravenous immunoglobulins; CT: computed tomography; MRI: magnetic resonance imaging; NSAIDs: nonsteroidal antiinflammatory drugs; IDSA: Infectious Disease Society of America; TNF-\u03b1: tumor necrosis factor alpha; SPE: streptococcus pyrogenic enterotoxin; MHC: major histocompatibility; CDC: center for diseases control; APC: antigen-presenting cell; TcR: T cell receptor; IFN-\u03b3: interferon gamma; IL: interleukin.", [["limb", "ANATOMY", 45, 49], ["muscle", "ANATOMY", 69, 75], ["intravenous", "ANATOMY", 237, 248], ["cell", "ANATOMY", 581, 585], ["T cell", "ANATOMY", 592, 598], ["impairment of limb function", "DISEASE", 31, 58], ["muscle necrosis", "DISEASE", 69, 84], ["amputations", "DISEASE", 88, 99], ["streptococcal toxic shock syndrome", "DISEASE", 156, 190], ["streptococcus", "DISEASE", 205, 218], ["Infectious Disease", "DISEASE", 375, 393], ["tumor", "DISEASE", 421, 426], ["necrosis", "DISEASE", 427, 435], ["limb", "ORGANISM_SUBDIVISION", 45, 49], ["muscle", "ORGAN", 69, 75], ["nonsteroidal antiinflammatory drugs", "SIMPLE_CHEMICAL", 332, 367], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 414, 419], ["tumor necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 421, 448], ["APC", "GENE_OR_GENE_PRODUCT", 557, 560], ["cell", "CELL", 581, 585], ["TcR", "GENE_OR_GENE_PRODUCT", 587, 590], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 592, 607], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 609, 614], ["interferon gamma", "GENE_OR_GENE_PRODUCT", 616, 632], ["IL", "GENE_OR_GENE_PRODUCT", 634, 636], ["interleukin", "GENE_OR_GENE_PRODUCT", 638, 649], ["TNF", "PROTEIN", 414, 417], ["tumor necrosis factor alpha", "PROTEIN", 421, 448], ["SPE: streptococcus pyrogenic enterotoxin", "PROTEIN", 450, 490], ["MHC", "PROTEIN", 492, 495], ["APC", "CELL_TYPE", 557, 560], ["antigen-presenting cell; TcR: T cell receptor", "PROTEIN", 562, 607], ["IFN", "PROTEIN", 609, 612], ["\u03b3", "PROTEIN", 613, 614], ["interferon gamma; IL: interleukin", "PROTEIN", 616, 649], ["Survival", "TREATMENT", 0, 8], ["limb function", "PROBLEM", 45, 58], ["muscle necrosis", "PROBLEM", 69, 84], ["amputations", "PROBLEM", 88, 99], ["streptococcal toxic shock syndrome", "PROBLEM", 156, 190], ["GAS", "TEST", 192, 195], ["group A streptococcus", "PROBLEM", 197, 218], ["IVIG", "TREATMENT", 220, 224], ["polyclonal intravenous immunoglobulins", "TREATMENT", 226, 264], ["computed tomography", "TEST", 270, 289], ["MRI", "TEST", 291, 294], ["magnetic resonance imaging", "TEST", 296, 322], ["NSAIDs", "TREATMENT", 324, 330], ["nonsteroidal antiinflammatory drugs", "TREATMENT", 332, 367], ["TNF", "TEST", 414, 417], ["tumor necrosis factor alpha", "PROBLEM", 421, 448], ["streptococcus pyrogenic enterotoxin", "PROBLEM", 455, 490], ["diseases control", "PROBLEM", 539, 555], ["APC", "TEST", 557, 560], ["antigen", "TEST", 562, 569], ["limb", "ANATOMY", 45, 49], ["muscle", "ANATOMY", 69, 75], ["necrosis", "OBSERVATION", 76, 84], ["amputations", "OBSERVATION", 88, 99], ["toxic shock syndrome", "OBSERVATION", 170, 190], ["Infectious", "OBSERVATION", 375, 385], ["tumor", "ANATOMY", 421, 426], ["necrosis", "OBSERVATION", 427, 435]]]], "PMC7461069": [["In practice, all material and human health resources were devoted exclusively to the fight against the pandemic, and all scheduled surgical activities were canceled.INTRODUCTIONThe Spanish Society of Cardiovascular and Endovascular Surgery (SECCE) reacted expeditiously to the new situation created by the pandemic and established a series of recommendations1to ensure care in different healthcare dimensions: emergencies, surgical prioritization of preferential patients, safe delay of elective patients, and adaptation of extracorporeal membrane oxygenation (ECMO) programs in the context of COVID\u201019.Ventricular assist devices\u2014heart transplant ::: CHALLENGESPretransplant circulatory support in Spain has traditionally been done with short\u2010term devices that enabled effective and sufficient support until the arrival of the organ in a matter of days, since the donation system by the Transplant National Organization (the \u201cSpanish Model\u201d) has achieved short waiting times.", [["Cardiovascular", "ANATOMY", 200, 214], ["extracorporeal membrane", "ANATOMY", 524, 547], ["Ventricular", "ANATOMY", 603, 614], ["organ", "ANATOMY", 827, 832], ["Cardiovascular and Endovascular Surgery", "DISEASE", 200, 239], ["human", "ORGANISM", 30, 35], ["patients", "ORGANISM", 463, 471], ["patients", "ORGANISM", 496, 504], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 524, 547], ["Ventricular", "MULTI-TISSUE_STRUCTURE", 603, 614], ["organ", "ORGAN", 827, 832], ["human", "SPECIES", 30, 35], ["patients", "SPECIES", 463, 471], ["patients", "SPECIES", 496, 504], ["human", "SPECIES", 30, 35], ["Endovascular Surgery", "TREATMENT", 219, 239], ["elective patients", "TREATMENT", 487, 504], ["extracorporeal membrane oxygenation", "TREATMENT", 524, 559], ["ECMO) programs", "TREATMENT", 561, 575], ["CHALLENGESPretransplant circulatory support", "TREATMENT", 651, 694], ["short\u2010term devices", "TREATMENT", 737, 755], ["circulatory support", "OBSERVATION", 675, 694], ["organ", "ANATOMY", 827, 832]]], ["The trade\u2010off is that long\u2010term circulatory support has had a slow development and a reduced experience in Spain in comparison with the surrounding countries, amounting to a total of 40 to 50 implants per year for all indications in recent years.Ventricular assist devices\u2014heart transplant ::: CHALLENGESIn this scenario, the impact of the coronavirus pandemic on ventricular assist devices has been minimal.", [["Ventricular", "ANATOMY", 246, 257], ["ventricular", "ANATOMY", 364, 375], ["coronavirus", "DISEASE", 340, 351], ["Ventricular", "MULTI-TISSUE_STRUCTURE", 246, 257], ["coronavirus", "ORGANISM", 340, 351], ["ventricular", "MULTI-TISSUE_STRUCTURE", 364, 375], ["long\u2010term circulatory support", "TREATMENT", 22, 51], ["Ventricular assist devices\u2014heart transplant", "TREATMENT", 246, 289], ["the coronavirus pandemic", "PROBLEM", 336, 360], ["ventricular assist devices", "TREATMENT", 364, 390], ["slow", "OBSERVATION_MODIFIER", 62, 66], ["reduced", "OBSERVATION_MODIFIER", 85, 92], ["transplant", "OBSERVATION", 279, 289], ["coronavirus", "OBSERVATION", 340, 351], ["ventricular", "ANATOMY", 364, 375], ["minimal", "OBSERVATION_MODIFIER", 400, 407]]], ["Excluding ECMO support to COVID\u201019 patients, emergency implants have only been performed in situations of cardiogenic shock and as urgent pretransplant support, and even in these cases, the devices used have been short\u2010term ones (Impella, ECMO).", [["cardiogenic shock", "DISEASE", 106, 123], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["ECMO support", "TREATMENT", 10, 22], ["emergency implants", "TREATMENT", 45, 63], ["cardiogenic shock", "PROBLEM", 106, 123], ["urgent pretransplant support", "TREATMENT", 131, 159], ["the devices", "TREATMENT", 186, 197], ["Impella", "TREATMENT", 230, 237], ["ECMO", "TREATMENT", 239, 243], ["cardiogenic shock", "OBSERVATION", 106, 123]]], ["Elective heart transplants were suspended in most of the Spanish groups for 2 months, so nonurgent patients, assisted with long\u2010term devices, remained on the waiting list.", [["heart", "ANATOMY", 9, 14], ["heart", "ORGAN", 9, 14], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["Elective heart transplants", "TREATMENT", 0, 26], ["long\u2010term devices", "TREATMENT", 123, 140], ["heart", "ANATOMY", 9, 14], ["transplants", "OBSERVATION", 15, 26]]], ["In the post\u2010COVID era, we should not expect major changes in both device indications and implantation strategy.Background ::: ECMO therapy ::: CHALLENGESThe need to treat critical COVID\u201019 patients has forced cardiovascular surgeons to decide whether or not to implant an ECMO system.", [["cardiovascular", "ANATOMY", 209, 223], ["patients", "ORGANISM", 189, 197], ["patients", "SPECIES", 189, 197], ["both device indications", "TREATMENT", 61, 84], ["implantation strategy", "TREATMENT", 89, 110], ["ECMO therapy", "TREATMENT", 126, 138], ["an ECMO system", "TREATMENT", 269, 283], ["ECMO", "OBSERVATION", 272, 276]]], ["As there is only scant and unsubstantiated evidence available hitherto, with only minor experiments conducted, limited to a few published cases from China2,3,4and some literature reviews, such as that of Savarimuthu et al,5the benefits of ECMO system implantation are not clear.Background ::: ECMO therapy ::: CHALLENGESTo add some confusion to the issue, doubts were raised about the possible deleterious effect of ECMO in this disease.", [["confusion", "DISEASE", 332, 341], ["ECMO system implantation", "TREATMENT", 239, 263], ["ECMO therapy", "TREATMENT", 293, 305], ["some confusion", "PROBLEM", 327, 341], ["ECMO", "TREATMENT", 416, 420], ["this disease", "PROBLEM", 424, 436], ["scant", "OBSERVATION_MODIFIER", 17, 22], ["ECMO", "OBSERVATION", 239, 243], ["clear", "OBSERVATION", 272, 277], ["ECMO", "OBSERVATION", 416, 420]]], ["Patients who die of COVID\u201019 have significantly lower lymphocyte counts and significantly higher interleukin\u20106 (IL\u20106) levels than survivors.", [["lymphocyte", "ANATOMY", 54, 64], ["Patients", "ORGANISM", 0, 8], ["lymphocyte", "CELL", 54, 64], ["interleukin\u20106", "GENE_OR_GENE_PRODUCT", 97, 110], ["IL\u20106", "GENE_OR_GENE_PRODUCT", 112, 116], ["interleukin\u20106", "PROTEIN", 97, 110], ["IL\u20106", "PROTEIN", 112, 116], ["Patients", "SPECIES", 0, 8], ["COVID", "TEST", 20, 25], ["significantly lower lymphocyte counts", "PROBLEM", 34, 71], ["lymphocyte counts", "OBSERVATION", 54, 71]]], ["It is a well\u2010known fact, that during ECMO support there are substantial decreases in the number and function of some lymphocyte populations, as well as consistently high IL\u20106 levels, which are inversely correlated with survival.6Elevated concentrations of IL\u20106 in the lungs, induced by starting ECMO, have also been shown to be associated with parenchymal damage in porcine models of veno\u2010venous (VV) ECMO.7", [["lymphocyte", "ANATOMY", 117, 127], ["lungs", "ANATOMY", 268, 273], ["parenchymal", "ANATOMY", 344, 355], ["parenchymal damage", "DISEASE", 344, 362], ["lymphocyte populations", "CELL", 117, 139], ["IL\u20106", "GENE_OR_GENE_PRODUCT", 170, 174], ["IL\u20106", "GENE_OR_GENE_PRODUCT", 256, 260], ["lungs", "ORGAN", 268, 273], ["parenchymal", "TISSUE", 344, 355], ["veno\u2010venous", "MULTI-TISSUE_STRUCTURE", 384, 395], ["lymphocyte populations", "CELL_TYPE", 117, 139], ["IL\u20106", "PROTEIN", 170, 174], ["IL\u20106", "PROTEIN", 256, 260], ["VV", "SPECIES", 397, 399], ["ECMO support", "TREATMENT", 37, 49], ["substantial decreases", "PROBLEM", 60, 81], ["some lymphocyte populations", "PROBLEM", 112, 139], ["Elevated concentrations of IL\u2010", "PROBLEM", 229, 259], ["ECMO", "TREATMENT", 295, 299], ["parenchymal damage", "PROBLEM", 344, 362], ["veno\u2010venous (VV) ECMO", "TREATMENT", 384, 405], ["substantial", "OBSERVATION_MODIFIER", 60, 71], ["decreases", "OBSERVATION_MODIFIER", 72, 81], ["number", "OBSERVATION_MODIFIER", 89, 95], ["some", "OBSERVATION_MODIFIER", 112, 116], ["lymphocyte populations", "OBSERVATION", 117, 139], ["high", "OBSERVATION_MODIFIER", 165, 169], ["concentrations", "OBSERVATION_MODIFIER", 238, 252], ["IL", "OBSERVATION_MODIFIER", 256, 258], ["lungs", "ANATOMY", 268, 273], ["parenchymal", "ANATOMY_MODIFIER", 344, 355], ["damage", "OBSERVATION", 356, 362]]]], "7fa6a89af06e588d737c868cdcebceaee14d7532": [["IntroductionInfectious diseases have been paramount among the threats to health and survival for most of human evolutionary history (Haldane 1949; Lederberg 1999; Harpending and Rogers 2000; Cooke and Hill 2001) .", [["IntroductionInfectious diseases", "DISEASE", 0, 31], ["human", "ORGANISM", 105, 110], ["human", "SPECIES", 105, 110], ["human", "SPECIES", 105, 110], ["IntroductionInfectious diseases", "PROBLEM", 0, 31]]], ["The interaction of the human host with a wide variety of pathogens has been accompanied by genetic adaptations to spatially and temporally fluctuating selective pressures imposed by the infectious agents.", [["human", "ORGANISM", 23, 28], ["human", "SPECIES", 23, 28], ["human", "SPECIES", 23, 28], ["a wide variety of pathogens", "PROBLEM", 39, 66], ["temporally fluctuating selective pressures", "PROBLEM", 128, 170], ["the infectious agents", "TREATMENT", 182, 203], ["infectious", "OBSERVATION", 186, 196]]], ["Numerous studies have sought the genetic imprint of natural selection imposed by pathogen pressures in human genes involved in immune response or, more generally, in host-pathogen interactions (Vallender and Lahn 2004) .", [["human", "ORGANISM", 103, 108], ["human genes", "DNA", 103, 114], ["human", "SPECIES", 103, 108], ["human", "SPECIES", 103, 108], ["Numerous studies", "TEST", 0, 16], ["natural selection", "TREATMENT", 52, 69], ["natural selection", "OBSERVATION", 52, 69], ["pressures", "OBSERVATION_MODIFIER", 90, 99], ["immune response", "OBSERVATION", 127, 142]]], ["For example, natural selection has acted on such genes as MHC, b-globin, G6PD, IL-2, IL-4, TNFSF5, the Duffy blood group genes, and CCR5 (Ohta 1991; Hughes et al. 1994; Flint et al. 1998; Hamblin and Di Rienzo 2000; Tishkoff et al. 2001; Bamshad et al. 2002; Sabeti et al. 2002; Verrelli et al. 2002) .", [["blood", "ANATOMY", 109, 114], ["MHC", "GENE_OR_GENE_PRODUCT", 58, 61], ["b-globin", "GENE_OR_GENE_PRODUCT", 63, 71], ["G6PD", "GENE_OR_GENE_PRODUCT", 73, 77], ["IL-2", "GENE_OR_GENE_PRODUCT", 79, 83], ["IL-4", "GENE_OR_GENE_PRODUCT", 85, 89], ["TNFSF5", "GENE_OR_GENE_PRODUCT", 91, 97], ["Duffy blood", "GENE_OR_GENE_PRODUCT", 103, 114], ["CCR5", "GENE_OR_GENE_PRODUCT", 132, 136], ["MHC", "DNA", 58, 61], ["b-globin, G6PD, IL-2", "DNA", 63, 83], ["IL-4", "DNA", 85, 89], ["TNFSF5", "DNA", 91, 97], ["Duffy blood group genes", "DNA", 103, 126], ["CCR5", "DNA", 132, 136], ["MHC", "TEST", 58, 61], ["b-globin", "TEST", 63, 71], ["G6PD", "TEST", 73, 77], ["IL", "TEST", 79, 81], ["IL", "TEST", 85, 87], ["TNFSF5", "TEST", 91, 97], ["globin", "ANATOMY", 65, 71], ["CCR5", "ANATOMY", 132, 136]]], ["However, little is known about genetic variation of genes involved in direct recognition of pathogens, or pathogens' products, and virtually no studies have investigated the extent to which pathogens have exerted selective pressures on the innate immune system.IntroductionThe phylogenetically ancient innate immune system governs the initial detection of pathogens and stimulates the first line of host defense (Medzhitov and Janeway 1998a Janeway and Medzhitov 2002) .", [["immune system", "ANATOMICAL_SYSTEM", 247, 260], ["pathogens", "PROBLEM", 92, 101], ["pathogens' products", "PROBLEM", 106, 125], ["pathogens", "PROBLEM", 356, 365], ["selective", "OBSERVATION_MODIFIER", 213, 222], ["pressures", "OBSERVATION_MODIFIER", 223, 232]]], ["Recognition of pathogens is mediated by phagocytic cells through germline-encoded receptors, known as \"pattern recognition receptors,\" which detect pathogenassociated molecular patterns that are characteristic products of microbial physiology (Kimbrell and Beutler 2001; Janeway and Medzhitov 2002) .", [["phagocytic cells", "ANATOMY", 40, 56], ["phagocytic cells", "CELL", 40, 56], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 103, 132], ["phagocytic cells", "CELL_TYPE", 40, 56], ["germline", "DNA", 65, 73], ["encoded receptors", "PROTEIN", 74, 91], ["pattern recognition receptors", "PROTEIN", 103, 132], ["pathogens", "PROBLEM", 15, 24], ["microbial physiology", "PROBLEM", 222, 242], ["pathogens", "OBSERVATION", 15, 24], ["microbial physiology", "OBSERVATION", 222, 242]]], ["This initial interaction is then translated into a set of endogenous signals that ultimately lead to the induction of the adaptive immune response (Medzhitov and Janeway 1998b) .IntroductionIn recent years, the C-type lectin receptors have re-Figure 1Scaled diagram of the CD209/CD209L genomic region.", [["C-type lectin receptors", "GENE_OR_GENE_PRODUCT", 211, 234], ["CD209", "GENE_OR_GENE_PRODUCT", 273, 278], ["C-type lectin receptors", "PROTEIN", 211, 234], ["CD209/CD209L genomic region", "DNA", 273, 300], ["the C-type lectin receptors", "TEST", 207, 234]]], ["For CD209, we sequenced a total of 5,500 bp per chromosome, and, for CD209L, 5,391 bp per chromosome.", [["chromosome", "ANATOMY", 48, 58], ["chromosome", "ANATOMY", 90, 100], ["CD209", "GENE_OR_GENE_PRODUCT", 4, 9], ["chromosome", "CELLULAR_COMPONENT", 48, 58], ["CD209L", "GENE_OR_GENE_PRODUCT", 69, 75], ["chromosome", "CELLULAR_COMPONENT", 90, 100], ["CD209", "DNA", 4, 9], ["CD209L", "DNA", 69, 75], ["5,391 bp per chromosome", "DNA", 77, 100], ["CD209L", "TEST", 69, 75], ["bp", "TEST", 83, 85]]], ["The neck region corresponding to exon 4 and composed of seven coding repeats is also shown. ceived much attention in the area of innate immunology, the results of which were novel functional insights into the primary interface between host and pathogens (Medzhitov 2001; Cook et al. 2003; Fujita et al. 2004; Geijtenbeek et al. 2004; McGreal et al. 2004) .", [["neck region", "ANATOMY", 4, 15], ["neck", "ORGAN", 4, 8], ["exon 4", "DNA", 33, 39], ["neck", "ANATOMY", 4, 8], ["region", "ANATOMY_MODIFIER", 9, 15]]], ["In this context, two prototypic members of the C-type lectinreceptor family are particularly interesting, since they can act as both cell-adhesion receptors and pathogenrecognition receptors.", [["cell", "ANATOMY", 133, 137], ["C-type lectinreceptor", "GENE_OR_GENE_PRODUCT", 47, 68], ["cell", "CELL", 133, 137], ["pathogenrecognition receptors", "GENE_OR_GENE_PRODUCT", 161, 190], ["C-type lectinreceptor family", "PROTEIN", 47, 75], ["cell-adhesion receptors", "PROTEIN", 133, 156], ["pathogenrecognition receptors", "PROTEIN", 161, 190]]], ["These lectins include CD209 (DC-SIGN: dendritic cell-specific ICAM-3 grabbing nonintegrin [MIM 604672]) and its close relative CD209L (L-SIGN: liver/lymph node-specific ICAM-3 grabbing nonintegrin [MIM 605872]) (Curtis et al. 1992; Geijtenbeek et al. 2000b Geijtenbeek et al. , 2004 Soilleux et al. 2000; Pohlmann et al. 2001 ).", [["DC", "ANATOMY", 29, 31], ["dendritic cell", "ANATOMY", 38, 52], ["liver", "ANATOMY", 143, 148], ["lymph node", "ANATOMY", 149, 159], ["CD209", "GENE_OR_GENE_PRODUCT", 22, 27], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 29, 36], ["dendritic cell-specific ICAM-3", "GENE_OR_GENE_PRODUCT", 38, 68], ["nonintegrin", "GENE_OR_GENE_PRODUCT", 78, 89], ["CD209L", "GENE_OR_GENE_PRODUCT", 127, 133], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 135, 141], ["liver", "ORGAN", 143, 148], ["lymph node", "MULTI-TISSUE_STRUCTURE", 149, 159], ["ICAM-3", "GENE_OR_GENE_PRODUCT", 169, 175], ["lectins", "PROTEIN", 6, 13], ["CD209", "PROTEIN", 22, 27], ["DC", "PROTEIN", 29, 31], ["SIGN", "PROTEIN", 32, 36], ["ICAM", "PROTEIN", 62, 66], ["nonintegrin", "PROTEIN", 78, 89], ["MIM 604672", "PROTEIN", 91, 101], ["CD209L", "PROTEIN", 127, 133], ["SIGN", "PROTEIN", 137, 141], ["ICAM", "PROTEIN", 169, 173], ["nonintegrin", "PROTEIN", 185, 196], ["These lectins", "TEST", 0, 13], ["CD209", "TEST", 22, 27], ["ICAM", "TEST", 62, 66], ["liver/lymph node", "PROBLEM", 143, 159], ["specific ICAM", "TEST", 160, 173], ["dendritic cell", "OBSERVATION", 38, 52], ["liver", "ANATOMY", 143, 148], ["lymph node", "OBSERVATION", 149, 159]]], ["These lectin-coding genes are located on chromosome 19p13.2-3, within an \u223c26-kb segment, and result from a duplication of an ancestral gene (Bashirova et al. 2003; Soilleux 2003 ).", [["lectin", "GENE_OR_GENE_PRODUCT", 6, 12], ["chromosome 19p13.2-3", "GENE_OR_GENE_PRODUCT", 41, 61], ["lectin-coding genes", "DNA", 6, 25], ["chromosome 19p13.2-3", "DNA", 41, 61], ["\u223c26-kb segment", "DNA", 73, 87], ["These lectin", "TEST", 0, 12], ["duplication", "OBSERVATION", 107, 118]]], ["An additional characteristic of both CD209 and CD209L is the presence of a neck region, primarily made up of seven highly conserved 23-aa repeats, that separates the carbohydrate-recognition domain involved in pathogen binding from the transmembrane region.", [["neck region", "ANATOMY", 75, 86], ["transmembrane region", "ANATOMY", 236, 256], ["carbohydrate", "CHEMICAL", 166, 178], ["CD209", "GENE_OR_GENE_PRODUCT", 37, 42], ["CD209L", "GENE_OR_GENE_PRODUCT", 47, 53], ["CD209", "PROTEIN", 37, 42], ["CD209L", "PROTEIN", 47, 53], ["23-aa repeats", "DNA", 132, 145], ["carbohydrate-recognition domain", "PROTEIN", 166, 197], ["transmembrane region", "PROTEIN", 236, 256], ["a neck region", "PROBLEM", 73, 86], ["both", "OBSERVATION_MODIFIER", 32, 36], ["CD209", "OBSERVATION", 37, 42], ["neck", "ANATOMY", 75, 79], ["region", "ANATOMY_MODIFIER", 80, 86], ["pathogen binding", "OBSERVATION", 210, 226], ["transmembrane", "ANATOMY_MODIFIER", 236, 249]]], ["This neck region presents high nucleotide identity between repeats, both within each molecule and between CD209 and CD209L.", [["neck region", "ANATOMY", 5, 16], ["nucleotide", "CHEMICAL", 31, 41], ["nucleotide", "CHEMICAL", 31, 41], ["neck", "ORGAN", 5, 9], ["CD209", "GENE_OR_GENE_PRODUCT", 106, 111], ["CD209L", "GENE_OR_GENE_PRODUCT", 116, 122], ["CD209", "PROTEIN", 106, 111], ["CD209L", "PROTEIN", 116, 122], ["high nucleotide identity between repeats", "PROBLEM", 26, 66], ["CD209", "TEST", 106, 111], ["neck", "ANATOMY", 5, 9], ["high nucleotide identity", "OBSERVATION", 26, 50]]], ["It has been shown that this region plays a crucial role in the oligomerization and support of the carbohydraterecognition domain; therefore, it influences the pathogen-binding properties of these two receptors (Soilleux et al. 2000 (Soilleux et al. , 2003 Feinberg et al. 2005) .", [["carbohydraterecognition domain", "PROTEIN", 98, 128], ["the carbohydraterecognition domain", "PROBLEM", 94, 128], ["these two receptors", "TREATMENT", 190, 209]]], ["In regard to expression profiles, CD209 is expressed primarily on phagocytic cells, such as dendritic cells and macrophages, whereas CD209L expression is restricted to endothelial cells in liver and lymph nodes (Bashirova et al. 2001; Soilleux et al. 2001 Soilleux et al. , 2002 .", [["phagocytic cells", "ANATOMY", 66, 82], ["dendritic cells", "ANATOMY", 92, 107], ["macrophages", "ANATOMY", 112, 123], ["endothelial cells", "ANATOMY", 168, 185], ["liver", "ANATOMY", 189, 194], ["lymph nodes", "ANATOMY", 199, 210], ["CD209", "GENE_OR_GENE_PRODUCT", 34, 39], ["phagocytic cells", "CELL", 66, 82], ["dendritic cells", "CELL", 92, 107], ["macrophages", "CELL", 112, 123], ["CD209L", "GENE_OR_GENE_PRODUCT", 133, 139], ["endothelial cells", "CELL", 168, 185], ["liver", "ORGAN", 189, 194], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 199, 210], ["CD209", "PROTEIN", 34, 39], ["phagocytic cells", "CELL_TYPE", 66, 82], ["dendritic cells", "CELL_TYPE", 92, 107], ["macrophages", "CELL_TYPE", 112, 123], ["CD209L", "PROTEIN", 133, 139], ["endothelial cells", "CELL_TYPE", 168, 185], ["expression profiles", "TEST", 13, 32], ["phagocytic cells", "PROBLEM", 66, 82], ["dendritic cells", "PROBLEM", 92, 107], ["macrophages", "PROBLEM", 112, 123], ["endothelial cells in liver and lymph nodes", "PROBLEM", 168, 210], ["phagocytic cells", "OBSERVATION", 66, 82], ["dendritic cells", "OBSERVATION", 92, 107], ["endothelial cells", "OBSERVATION", 168, 185], ["liver", "ANATOMY", 189, 194], ["lymph nodes", "OBSERVATION", 199, 210]]], ["As pathogen-recognition receptors, the two lectins have been shown to recognize a vast range of microbes, some of which are of major public health importance (Geijtenbeek et al. 2004) .", [["pathogen-recognition receptors", "GENE_OR_GENE_PRODUCT", 3, 33], ["lectins", "GENE_OR_GENE_PRODUCT", 43, 50], ["pathogen-recognition receptors", "PROTEIN", 3, 33], ["lectins", "PROTEIN", 43, 50]]], ["Indeed, CD209 captures bacteria such as Mycobacterium tuberculosis, Helicobacter pylori, and certain Klebsiela pneumonia strains; viruses such as HIV-1, Ebola virus, cytomegalovirus, hepatitis C virus, Dengue virus, and SARS-coronavirus; and parasites like Leish-mania pifanoi and Schistosoma mansoni (Geijtenbeek et al. 2000a Alvarez et al. 2002; Colmenares et al. 2002; Halary et al. 2002; Appelmelk et al. 2003; Lozach et al. 2003; Tailleux et al. 2003; Tassaneetrithep et al. 2003; Bergman et al. 2004; Marzi et al. 2004) .", [["Mycobacterium tuberculosis", "DISEASE", 40, 66], ["Helicobacter pylori", "DISEASE", 68, 87], ["Klebsiela pneumonia", "DISEASE", 101, 120], ["HIV-1, Ebola virus, cytomegalovirus, hepatitis C virus", "DISEASE", 146, 200], ["Dengue virus", "DISEASE", 202, 214], ["SARS-coronavirus", "DISEASE", 220, 236], ["Leish-mania", "DISEASE", 257, 268], ["Schistosoma mansoni", "DISEASE", 281, 300], ["CD209", "GENE_OR_GENE_PRODUCT", 8, 13], ["Mycobacterium tuberculosis", "ORGANISM", 40, 66], ["Helicobacter pylori", "ORGANISM", 68, 87], ["Klebsiela pneumonia strains", "ORGANISM", 101, 128], ["HIV-1", "ORGANISM", 146, 151], ["Ebola virus", "ORGANISM", 153, 164], ["cytomegalovirus", "ORGANISM", 166, 181], ["hepatitis C virus", "ORGANISM", 183, 200], ["Dengue virus", "ORGANISM", 202, 214], ["SARS-coronavirus", "ORGANISM", 220, 236], ["Leish-mania pifanoi", "ORGANISM", 257, 276], ["Schistosoma mansoni", "ORGANISM", 281, 300], ["CD209", "PROTEIN", 8, 13], ["Mycobacterium tuberculosis", "SPECIES", 40, 66], ["Helicobacter pylori", "SPECIES", 68, 87], ["Klebsiela pneumonia", "SPECIES", 101, 120], ["HIV-1", "SPECIES", 146, 151], ["Ebola virus", "SPECIES", 153, 164], ["hepatitis C virus", "SPECIES", 183, 200], ["Dengue virus", "SPECIES", 202, 214], ["SARS-coronavirus", "SPECIES", 220, 236], ["Leish-mania pifanoi", "SPECIES", 257, 276], ["Schistosoma mansoni", "SPECIES", 281, 300], ["Mycobacterium tuberculosis", "SPECIES", 40, 66], ["Helicobacter pylori", "SPECIES", 68, 87], ["Klebsiela pneumonia", "SPECIES", 101, 120], ["HIV-1", "SPECIES", 146, 151], ["Ebola virus", "SPECIES", 153, 164], ["hepatitis C virus", "SPECIES", 183, 200], ["Dengue virus", "SPECIES", 202, 214], ["SARS-coronavirus", "SPECIES", 220, 236], ["Leish-mania pifanoi", "SPECIES", 257, 276], ["Schistosoma mansoni", "SPECIES", 281, 300], ["CD209 captures bacteria", "PROBLEM", 8, 31], ["Mycobacterium tuberculosis", "PROBLEM", 40, 66], ["Helicobacter pylori", "PROBLEM", 68, 87], ["certain Klebsiela pneumonia strains", "PROBLEM", 93, 128], ["viruses", "PROBLEM", 130, 137], ["HIV", "TEST", 146, 149], ["Ebola virus", "PROBLEM", 153, 164], ["cytomegalovirus", "PROBLEM", 166, 181], ["hepatitis C virus", "PROBLEM", 183, 200], ["Dengue virus", "PROBLEM", 202, 214], ["SARS", "PROBLEM", 220, 224], ["coronavirus", "PROBLEM", 225, 236], ["parasites", "PROBLEM", 242, 251], ["mania pifanoi", "TREATMENT", 263, 276], ["Schistosoma mansoni", "PROBLEM", 281, 300], ["Mycobacterium tuberculosis", "OBSERVATION", 40, 66], ["Helicobacter pylori", "OBSERVATION", 68, 87], ["pneumonia", "OBSERVATION", 111, 120], ["cytomegalovirus", "OBSERVATION", 166, 181], ["Schistosoma mansoni", "OBSERVATION", 281, 300]]], ["With regard to CD209L, studies to date have shown an interaction with a variety of viruses, including HIV, hepatitis C, Ebola, and coronavirus, as well as with the parasite Schistosoma mansoni (Bashirova et al. 2001; Alvarez et al. 2002; Gardner et al. 2003; Jeffers et al. 2004; Van Liempt et al. 2004) .", [["HIV, hepatitis C, Ebola, and coronavirus", "DISEASE", 102, 142], ["Schistosoma mansoni", "DISEASE", 173, 192], ["CD209L", "GENE_OR_GENE_PRODUCT", 15, 21], ["HIV", "ORGANISM", 102, 105], ["hepatitis C", "ORGANISM", 107, 118], ["Ebola", "ORGANISM", 120, 125], ["coronavirus", "ORGANISM", 131, 142], ["Schistosoma mansoni", "ORGANISM", 173, 192], ["CD209L", "PROTEIN", 15, 21], ["HIV", "SPECIES", 102, 105], ["Schistosoma mansoni", "SPECIES", 173, 192], ["HIV", "SPECIES", 102, 105], ["hepatitis C", "SPECIES", 107, 118], ["Schistosoma mansoni", "SPECIES", 173, 192], ["studies", "TEST", 23, 30], ["a variety of viruses", "PROBLEM", 70, 90], ["HIV", "PROBLEM", 102, 105], ["hepatitis C", "PROBLEM", 107, 118], ["Ebola", "PROBLEM", 120, 125], ["coronavirus", "PROBLEM", 131, 142], ["the parasite Schistosoma mansoni", "PROBLEM", 160, 192], ["viruses", "OBSERVATION", 83, 90], ["Schistosoma mansoni", "OBSERVATION", 173, 192]]], ["In this context, the efficiency of the two lectins in pathogen recognition and subsequent processing may have important consequences for the quality of host immune responses and consequent pathogen control and/or clearance.Figure 1An important step forward in the understanding of human adaptation to pathogens and control of infectious diseases includes the description of quality and quantity of genetic variation in genes involved in host recognition of infectious agents.", [["infectious diseases", "DISEASE", 326, 345], ["human", "ORGANISM", 281, 286], ["human", "SPECIES", 281, 286], ["human", "SPECIES", 281, 286], ["the two lectins in pathogen recognition", "PROBLEM", 35, 74], ["consequent pathogen control", "TREATMENT", 178, 205], ["pathogens", "PROBLEM", 301, 310], ["infectious diseases", "PROBLEM", 326, 345], ["infectious agents", "TREATMENT", 457, 474], ["infectious", "OBSERVATION", 326, 336], ["infectious", "OBSERVATION", 457, 467]]], ["Given the direct interaction of CD209 and CD209L with a large variety of pathogens, the CD209/CD209L genomic region provides an excellent model system to illustrate the extent to which pathogens have exerted selective pressures on host immunity genes.", [["CD209", "GENE_OR_GENE_PRODUCT", 32, 37], ["CD209L", "GENE_OR_GENE_PRODUCT", 42, 48], ["CD209", "GENE_OR_GENE_PRODUCT", 88, 93], ["CD209", "PROTEIN", 32, 37], ["CD209L", "PROTEIN", 42, 48], ["CD209/CD209L genomic region", "DNA", 88, 115], ["host immunity genes", "DNA", 231, 250], ["a large variety of pathogens", "PROBLEM", 54, 82], ["the CD209/CD209L genomic region", "TREATMENT", 84, 115], ["large", "OBSERVATION_MODIFIER", 56, 61], ["variety", "OBSERVATION_MODIFIER", 62, 69], ["pathogens", "OBSERVATION", 73, 82], ["selective", "OBSERVATION_MODIFIER", 208, 217], ["pressures", "OBSERVATION_MODIFIER", 218, 227], ["host immunity genes", "OBSERVATION", 231, 250]]], ["An additional feature that makes these genes highly interesting in evolutionary studies is that they are likely to have been influenced by similar genomic forces (recombination, mutation rates, etc.) because of their close physical proximity (\u223c15 kb), high nucleotide (73%) and amino acid (77%) identity, and identical exon-intron organization (Soilleux 2003) 1 ).", [["nucleotide", "CHEMICAL", 257, 267], ["amino acid", "CHEMICAL", 278, 288], ["nucleotide", "CHEMICAL", 257, 267], ["amino acid", "CHEMICAL", 278, 288], ["amino acid", "AMINO_ACID", 278, 288], ["evolutionary studies", "TEST", 67, 87], ["mutation rates", "TEST", 178, 192], ["high nucleotide", "TEST", 252, 267], ["amino acid", "TEST", 278, 288], ["genomic forces", "OBSERVATION", 147, 161]]], ["In addition, it has been proposed that gene duplication of immunity genes is a molecular strategy developed by the host to enlarge its defense potential (Ohno 1970; Trowsdale and Parham 2004) .", [["immunity genes", "DNA", 59, 73], ["gene duplication of immunity genes", "PROBLEM", 39, 73], ["a molecular strategy", "PROBLEM", 77, 97], ["immunity genes", "OBSERVATION", 59, 73]]], ["A number of immune-system gene families have evolved, by gene duplication followed by natural selection, to provide responses to a wider range of pathogens, with welldocumented examples in immunoglobulin and MHC genes (Hughes et al. 1994; Ota et al. 2000) .", [["immunoglobulin", "GENE_OR_GENE_PRODUCT", 189, 203], ["MHC", "GENE_OR_GENE_PRODUCT", 208, 211], ["immune-system gene families", "DNA", 12, 39], ["immunoglobulin and MHC genes", "DNA", 189, 217], ["gene duplication", "PROBLEM", 57, 73], ["pathogens", "PROBLEM", 146, 155]]], ["In this context, duplicated genes in cis, like CD209 and CD209L, may have undergone differential selective pressures to enlarge the defense role of these lectins.", [["CD209", "GENE_OR_GENE_PRODUCT", 47, 52], ["CD209L", "GENE_OR_GENE_PRODUCT", 57, 63], ["lectins", "GENE_OR_GENE_PRODUCT", 154, 161], ["duplicated genes", "DNA", 17, 33], ["CD209", "DNA", 47, 52], ["CD209L", "DNA", 57, 63], ["lectins", "PROTEIN", 154, 161], ["duplicated genes in cis", "PROBLEM", 17, 40], ["differential selective pressures", "TREATMENT", 84, 116], ["pressures", "OBSERVATION_MODIFIER", 107, 116]]], ["To address these complex issues, we performed a sequence-based survey of the entire CD209/CD209L region in a panel of individuals of different ethnic origins.", [["CD209/CD209L region", "ANATOMY", 84, 103], ["CD209", "GENE_OR_GENE_PRODUCT", 84, 89], ["CD209L", "GENE_OR_GENE_PRODUCT", 90, 96], ["CD209", "DNA", 84, 89], ["CD209L region", "DNA", 90, 103], ["a sequence", "TEST", 46, 56], ["different", "OBSERVATION_MODIFIER", 133, 142], ["ethnic origins", "OBSERVATION", 143, 157]]], ["Here, we report evidence showing that these two closely related innate immunity genes have gone through completely different evolutionary processes that are reflected in their current patterns of diversity.", [["innate immunity genes", "DNA", 64, 85]]], ["In addition, our study provides novel insights into how pathogens have shaped the patterns of variability of immunity genes resulting from gene duplication.Population SamplesSequence variation of the CD209/CD209L region was determined in 41 sub-Saharan Africans, 43 Europeans, and 43 East Asians, in a total of 254 chromosomes from the Human Genome Diversity Panel (HGDP)-CEPH panel ).", [["chromosomes", "ANATOMY", 315, 326], ["CD209", "GENE_OR_GENE_PRODUCT", 200, 205], ["CD209L", "GENE_OR_GENE_PRODUCT", 206, 212], ["chromosomes", "CELLULAR_COMPONENT", 315, 326], ["Human", "ORGANISM", 336, 341], ["immunity genes", "DNA", 109, 123], ["CD209", "DNA", 200, 205], ["CD209L region", "DNA", 206, 219], ["Human", "SPECIES", 336, 341], ["our study", "TEST", 13, 22], ["immunity genes", "PROBLEM", 109, 123], ["gene duplication", "PROBLEM", 139, 155], ["the CD209/CD209L region", "TEST", 196, 219], ["HGDP", "TEST", 366, 370], ["CEPH panel", "TEST", 372, 382], ["immunity genes", "OBSERVATION", 109, 123], ["gene duplication", "OBSERVATION", 139, 155]]], ["The variation in the repeat number of the neck region of CD209 and CD209L was defined in the entire HGDP-CEPH panel, comprising 1,064 DNA samples from 52 worldwide populations.", [["neck region", "ANATOMY", 42, 53], ["samples", "ANATOMY", 138, 145], ["neck", "ORGAN", 42, 46], ["CD209", "GENE_OR_GENE_PRODUCT", 57, 62], ["CD209L", "GENE_OR_GENE_PRODUCT", 67, 73], ["DNA", "CELLULAR_COMPONENT", 134, 137], ["CD209", "DNA", 57, 62], ["CD209L", "DNA", 67, 73], ["HGDP", "DNA", 100, 104], ["CD209", "TEST", 57, 62], ["DNA samples", "TEST", 134, 145], ["variation", "OBSERVATION_MODIFIER", 4, 13], ["neck", "ANATOMY", 42, 46], ["region", "ANATOMY_MODIFIER", 47, 53]]], ["In addition, the orthologous regions for both genes were sequenced in four chimpanzees (Pan troglodytes).Molecular AnalysesThe sequenced fragments of the CD209/CD209L genomic region are shown in figure 1.", [["chimpanzees", "ORGANISM", 75, 86], ["Pan troglodytes", "ORGANISM", 88, 103], ["CD209", "GENE_OR_GENE_PRODUCT", 154, 159], ["orthologous regions", "DNA", 17, 36], ["CD209", "DNA", 154, 159], ["CD209L genomic region", "DNA", 160, 181], ["Pan troglodytes", "SPECIES", 88, 103], ["Pan troglodytes", "SPECIES", 88, 103], ["Molecular Analyses", "TEST", 105, 123], ["The sequenced fragments", "PROBLEM", 123, 146], ["the CD209", "TEST", 150, 159], ["fragments", "OBSERVATION_MODIFIER", 137, 146]]], ["The entire CD209 region-including exons, introns, and \u223c1 kb of the 5 UTR corresponding to the promoter region-was sequenced, for a total of 5.5 kb per individual.", [["CD209", "GENE_OR_GENE_PRODUCT", 11, 16], ["CD209 region", "DNA", 11, 23], ["exons", "DNA", 34, 39], ["introns", "DNA", 41, 48], ["5 UTR", "DNA", 67, 72], ["promoter region", "DNA", 94, 109], ["introns", "TEST", 41, 48]]], ["For CD209L, we sequenced a total of \u223c5.4 kb per individual, following the same approach used for CD209, with the exception of the neck region.", [["neck region", "ANATOMY", 130, 141], ["CD209L", "GENE_OR_GENE_PRODUCT", 4, 10], ["CD209", "GENE_OR_GENE_PRODUCT", 97, 102], ["neck", "ORGAN", 130, 134], ["CD209L", "PROTEIN", 4, 10], ["CD209", "PROTEIN", 97, 102], ["CD209", "TREATMENT", 97, 102], ["neck", "ANATOMY", 130, 134], ["region", "ANATOMY_MODIFIER", 135, 141]]], ["That region was genotyped for its number of repeats, since it turned out to be highly polymorphic, which prevented the sequencing process.", [["highly", "OBSERVATION_MODIFIER", 79, 85], ["polymorphic", "OBSERVATION", 86, 97]]], ["Genotyping was performed by a single PCR amplification followed by migration in 2% agarose gels.", [["Genotyping", "TEST", 0, 10], ["a single PCR amplification", "TREATMENT", 28, 54], ["migration in 2% agarose gels", "TREATMENT", 67, 95]]], ["Human primers were used to both amplify and sequence the orthologous regions in chimpanzees.", [["Human", "ORGANISM", 0, 5], ["chimpanzees", "ORGANISM", 80, 91], ["Human primers", "DNA", 0, 13], ["orthologous regions", "DNA", 57, 76], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human primers", "TREATMENT", 0, 13]]], ["However, because of polymorphisms specific to the chimpanzee lineage, we could not obtain the entirety of the sequence.", [["chimpanzee", "ORGANISM", 50, 60], ["chimpanzee lineage", "CELL_TYPE", 50, 68], ["polymorphisms", "PROBLEM", 20, 33]]], ["Thus, 4.9 kb (90% of the total) of the chimpanzee CD209 sequence were obtained, and 5.3 kb (98% of the total) of CD209L.", [["chimpanzee", "ORGANISM", 39, 49], ["CD209", "GENE_OR_GENE_PRODUCT", 50, 55], ["CD209L", "GENE_OR_GENE_PRODUCT", 113, 119], ["chimpanzee CD209 sequence", "DNA", 39, 64], ["CD209L", "DNA", 113, 119], ["chimpanzee", "SPECIES", 39, 49], ["the chimpanzee CD209 sequence", "TEST", 35, 64], ["kb", "TEST", 88, 90], ["CD209L", "TEST", 113, 119]]], ["Detailed information on primer sequences and PCR amplification conditions is available on request.", [["primer sequences", "DNA", 24, 40], ["primer sequences", "TEST", 24, 40], ["PCR amplification conditions", "TEST", 45, 73]]], ["All nucleotide sequences were obtained using the Big Dye terminator kit and the 3100 automated sequencer from Applied Biosystems.", [["nucleotide", "CHEMICAL", 4, 14], ["All nucleotide sequences", "TEST", 0, 24]]], ["Sequence files and chromatograms were inspected using the GENALYS software (Takahashi et al. 2003 ; Centre National de Genotypage).", [["Sequence files", "TEST", 0, 14], ["chromatograms", "TEST", 19, 32]]], ["As a measure of quality control, when new mutations were identified in primer binding regions, new primers were designed and sequence reactions were repeated, to avoid allele-specific amplification.", [["primer binding regions", "DNA", 71, 93], ["allele", "DNA", 168, 174], ["new mutations", "PROBLEM", 38, 51], ["new primers", "TEST", 95, 106], ["sequence reactions", "TEST", 125, 143]]], ["All singletons observed in our data set were systematically reamplified and resequenced.Statistical AnalysesOn the basis of the levels of diversity observed in the CD209/CD209L genomic region, we calculated the average number of pairwise differences (p) and the Watterson's estimator ( ) (Watterson 1975 (Fay and Wu 2000) .", [["CD209", "GENE_OR_GENE_PRODUCT", 164, 169], ["CD209/CD209L genomic region", "DNA", 164, 191], ["All singletons", "PROBLEM", 0, 14], ["diversity", "OBSERVATION", 138, 147], ["average", "OBSERVATION_MODIFIER", 211, 218], ["number", "OBSERVATION_MODIFIER", 219, 225]]], ["P values for the different tests were estimated from coalescent simulations under an infinite-site 4 10 model, with use of a fixed number of segregating sites and the assumption of no recombination, which has been shown to be a conservative assumption (Gilad et al. 2002) .", [["P", "DNA", 0, 1], ["P values", "TEST", 0, 8], ["the different tests", "TEST", 13, 32], ["an infinite-site", "TREATMENT", 82, 98], ["segregating sites", "PROBLEM", 141, 158]]], ["In parallel, we estimated P values for all these tests, using the empirical distribution obtained from sequencing data of 132 genes in a panel of 24 African Americans and 23 European Americans (Akey et al. 2004 ).", [["P", "DNA", 26, 27], ["all these tests", "TEST", 39, 54], ["sequencing data", "TEST", 103, 118]]], ["All these analyses, together with the interspecies McDonald-Kreitman (McDonald and Kreitman 1991) and K A /K S (Kimura 1968 ) tests, were performed using the DnaSP package (Rozas et al. 2003) .", [["All these analyses", "TEST", 0, 18], ["K A /K S", "TEST", 102, 110], ["tests", "TEST", 126, 131], ["the DnaSP package", "TREATMENT", 154, 171]]], ["Genetic distances between populations (F ST ) and heterozygosity values were estimated using the Arlequin package (Schneider et al. 2000) .", [["heterozygosity values", "PROBLEM", 50, 71], ["the Arlequin package", "TREATMENT", 93, 113]]], ["F ST statistical significance was assessed using 10,000 bootstrap replications.", [["bootstrap replications", "TREATMENT", 56, 78]]], ["To bear out a deficit or an excess of heterozygosity in the neck region of CD209 and CD209L, we used BOTTLENECK (Cornuet and Luikart 1996) to compute for each geographic region, the distribution of the heterozygosity expected from the observed number of alleles, given the sample size (n) under the assumption of mutational-drift equilibrium.", [["neck region", "ANATOMY", 60, 71], ["neck", "ORGAN", 60, 64], ["CD209", "GENE_OR_GENE_PRODUCT", 75, 80], ["CD209L", "GENE_OR_GENE_PRODUCT", 85, 91], ["CD209", "PROTEIN", 75, 80], ["CD209L", "PROTEIN", 85, 91], ["a deficit", "PROBLEM", 12, 21], ["heterozygosity in the neck region", "PROBLEM", 38, 71], ["the heterozygosity", "PROBLEM", 198, 216], ["mutational-drift equilibrium", "PROBLEM", 313, 341], ["deficit", "OBSERVATION", 14, 21], ["heterozygosity", "OBSERVATION", 38, 52], ["neck", "ANATOMY", 60, 64], ["region", "ANATOMY_MODIFIER", 65, 71], ["heterozygosity", "OBSERVATION", 202, 216], ["drift equilibrium", "OBSERVATION", 324, 341]]], ["This distribution was obtained through simulation of the coalescent process of n genes under two mutational models, the infinite-site model and the stepwise mutation model.", [["n genes", "DNA", 79, 86]]], ["In addition, to obtain information on the fraction of genetic variance in the neck region that is due to intraand interpopulation differences, we performed an anal-ysis of molecular variance (AMOVA), using the Arlequin package (Schneider et al. 2000) .", [["neck region", "ANATOMY", 78, 89], ["neck", "ORGANISM_SUBDIVISION", 78, 82], ["genetic variance in the neck region", "PROBLEM", 54, 89], ["intraand interpopulation differences", "PROBLEM", 105, 141], ["the Arlequin package", "TREATMENT", 206, 226], ["neck", "ANATOMY", 78, 82], ["anal", "ANATOMY", 159, 163]]], ["The AMOVA results were compared with those of 377 microsatellites analyzed in the same population panel .Statistical AnalysesHaplotype reconstruction was performed by use of the Bayesian statistical method implemented in Phase (v.2.1.1) (Stephens and Donnelly 2003) .", [["microsatellites", "TEST", 50, 65], ["Haplotype reconstruction", "TREATMENT", 125, 149]]], ["After haplotype reconstruction, linkage disequilibrium (LD) between pairs of SNPs was computed using Lewontin's D index (Lewontin 1964) .", [["haplotype reconstruction", "TREATMENT", 6, 30], ["linkage disequilibrium (LD) between pairs of SNPs", "PROBLEM", 32, 81], ["Lewontin's D index", "TREATMENT", 101, 119]]], ["For this analysis, only markers presenting a minimum allele frequency (MAF) of 10% were considered, since rare alleles have been shown to present a higher probability of being in significant LD than do common ones (Reich et al. 2001) .", [["this analysis", "TEST", 4, 17]]], ["Under this model, we assumed that there was, at most, one hotspot of unknown position.", [["unknown position", "OBSERVATION", 69, 85]]], ["To obtain better estimates, we increased 10 times the number of iterations of the final run of the algorithm.", [["the algorithm", "TEST", 95, 108]]], ["All our estimations were obtained by averaging results of five independent runs with use of different seed numbers.", [["All our estimations", "TEST", 0, 19]]], ["Since the model used is Bayesian, we could also estimate, for each population, the posterior probability of a hotspot of intensity 11 ( ) l 1 1 and 110 ( ). l 1 10 We obtained the gene tree and estimated the time of the most recent common ancestor (T MRCA ) for CD209, using the maximum-likelihood coalescent method implemented in GENETREE (Griffiths and Tavare 1994) .", [["CD209", "GENE_OR_GENE_PRODUCT", 262, 267], ["CD209", "PROTEIN", 262, 267], ["CD209", "TREATMENT", 262, 267]]], ["The mutation rate m for each gene was estimated on the basis of the net divergence between humans and chimpanzees and under the assumption both that the species separation occurred 5 million years ago (MYA) and of a generation time of 20 years.", [["humans", "ORGANISM", 91, 97], ["chimpanzees", "ORGANISM", 102, 113], ["humans", "SPECIES", 91, 97], ["humans", "SPECIES", 91, 97], ["The mutation rate m", "TREATMENT", 0, 19], ["the species separation", "PROBLEM", 149, 171]]], ["Using this m and v maximum likelihood (v ML ), we estimated the effective population size parameter ( ).", [["effective", "OBSERVATION_MODIFIER", 64, 73], ["population", "OBSERVATION_MODIFIER", 74, 84], ["size", "OBSERVATION_MODIFIER", 85, 89]]], ["With the assumption of a N e generation time of 20 years and the estimated , the N e coalescence time, scaled in units, was converted into 2N e years.", [["the N e coalescence time", "TREATMENT", 77, 101]]], ["The coalescence process implemented in SIM-COAL2 (Laval and Excoffier 2004 ) allowed us to estimate the probability of the T MRCA for CD209, through simulations, with use of both the number of 4 2 # 10 observed segregating sites and the estimated .", [["CD209", "GENE_OR_GENE_PRODUCT", 134, 139], ["CD209", "PROTEIN", 134, 139], ["The coalescence process", "PROBLEM", 0, 23], ["the T MRCA", "TEST", 119, 129], ["segregating sites", "PROBLEM", 211, 228], ["coalescence", "OBSERVATION_MODIFIER", 4, 15], ["process", "OBSERVATION", 16, 23]]], ["N eResultsWe determined sequence diversity in the CD209 and CD209L genes ( fig. 1 ) as well as length variation of the neck region in 254 chromosomes originating from three major ethnic groups: sub-Saharan Africans, Europeans, and East Asians.", [["neck region", "ANATOMY", 119, 130], ["chromosomes", "ANATOMY", 138, 149], ["CD209", "GENE_OR_GENE_PRODUCT", 50, 55], ["CD209L", "GENE_OR_GENE_PRODUCT", 60, 66], ["chromosomes", "CELLULAR_COMPONENT", 138, 149], ["CD209 and CD209L genes", "DNA", 50, 72], ["sequence diversity", "TEST", 24, 42], ["the CD209", "TEST", 46, 55], ["length variation of the neck region", "PROBLEM", 95, 130], ["length", "OBSERVATION_MODIFIER", 95, 101], ["variation", "OBSERVATION_MODIFIER", 102, 111], ["neck", "ANATOMY", 119, 123], ["region", "ANATOMY_MODIFIER", 124, 130], ["254 chromosomes", "OBSERVATION_MODIFIER", 134, 149], ["sub", "OBSERVATION_MODIFIER", 194, 197]]], ["In addition, the orthologous sequences were obtained in four chimpanzees, to infer the ancestral state at each site, to estimate the divergence between humans and chimpanzees, and to perform a number of interspecies neutrality tests.Patterns of Nucleotide and Haplotype Diversity in the CD209/CD209L RegionFor CD209, we identified a total of 79 SNPs and 2 indels, including 5 nonsynonymous, 5 synonymous, and 71 noncoding variants.", [["chimpanzees", "ORGANISM", 61, 72], ["humans", "ORGANISM", 152, 158], ["chimpanzees", "ORGANISM", 163, 174], ["CD209", "GENE_OR_GENE_PRODUCT", 287, 292], ["orthologous sequences", "DNA", 17, 38], ["CD209", "DNA", 287, 292], ["CD209L", "DNA", 293, 299], ["CD209", "DNA", 310, 315], ["humans", "SPECIES", 152, 158], ["humans", "SPECIES", 152, 158], ["the orthologous sequences", "TEST", 13, 38], ["interspecies neutrality tests", "TEST", 203, 232], ["Nucleotide and Haplotype Diversity", "PROBLEM", 245, 279], ["noncoding variants", "OBSERVATION", 412, 430]]], ["The five nonsynonymous SNPs were all located in the neck region (exon 4): SNPs 1839 (ArgrGln), 1888 (GlurAsp), and 1908 (ArgrGln) achieved a frequency of \u223c15%, and SNP 1970 (Leur Val), a frequency of 6%.", [["neck region", "ANATOMY", 52, 63], ["SNP", "CHEMICAL", 164, 167], ["neck region", "DNA", 52, 63], ["exon 4", "DNA", 65, 71], ["SNPs 1839", "DNA", 74, 83], ["ArgrGln", "DNA", 85, 92], ["GlurAsp", "DNA", 101, 108], ["ArgrGln", "DNA", 121, 128], ["SNP 1970", "DNA", 164, 172], ["The five nonsynonymous SNPs", "TEST", 0, 27], ["SNPs", "TEST", 74, 78], ["SNP", "TEST", 164, 167], ["nonsynonymous SNPs", "OBSERVATION", 9, 27], ["neck", "ANATOMY", 52, 56], ["region", "ANATOMY_MODIFIER", 57, 63]]], ["These mutations were restricted to the African sample.", [["These mutations", "PROBLEM", 0, 15]]], ["SNP 1472 (AlarThr) was observed as a singleton in an East-Asian individual.", [["SNP", "CHEMICAL", 0, 3], ["Thr", "CHEMICAL", 14, 17], ["AlarThr)", "GENE_OR_GENE_PRODUCT", 10, 18], ["SNP 1472", "DNA", 0, 8], ["SNP", "TEST", 0, 3]]], ["For CD209L, we identified 64 SNPs and 2 indels, including 4 nonsynonymous and 62 noncoding variants.", [["CD209L", "GENE_OR_GENE_PRODUCT", 4, 10], ["CD209L", "PROTEIN", 4, 10], ["SNPs", "TEST", 29, 33], ["noncoding variants", "OBSERVATION", 81, 99]]], ["The four nonsynonymous variants were located in different exons: SNP 141 (ThrrAla) in exon 2, SNP 3476 (Aspr Asn) in exon 5, SNP 4268 (ThrrAla) in exon 6, and SNP 5580 (ArgrGln) in exon 7.", [["SNP", "CHEMICAL", 65, 68], ["SNP", "CHEMICAL", 159, 162], ["Asn", "CHEMICAL", 109, 112], ["SNP 141 (ThrrAla) in exon 2", "GENE_OR_GENE_PRODUCT", 65, 92], ["Aspr Asn", "GENE_OR_GENE_PRODUCT", 104, 112], ["exons", "DNA", 58, 63], ["SNP 141", "DNA", 65, 72], ["ThrrAla", "DNA", 74, 81], ["exon 2", "DNA", 86, 92], ["SNP 3476", "DNA", 94, 102], ["Aspr Asn", "DNA", 104, 112], ["exon 5", "DNA", 117, 123], ["SNP 4268", "DNA", 125, 133], ["ThrrAla", "DNA", 135, 142], ["exon 6", "DNA", 147, 153], ["SNP 5580", "DNA", 159, 167], ["ArgrGln", "DNA", 169, 176], ["exon 7", "DNA", 181, 187], ["The four nonsynonymous variants", "PROBLEM", 0, 31], ["SNP", "TEST", 65, 68], ["SNP", "TEST", 94, 97], ["Aspr Asn", "TEST", 104, 112], ["SNP", "TEST", 125, 128], ["SNP", "TREATMENT", 159, 162], ["nonsynonymous variants", "OBSERVATION", 9, 31]]], ["All these mutations were singletons except SNP 3476, which presented high frequencies for its derived allele in all geographic regions: 97.6% in Africans, 57% in Europeans, and 77% in East Asians.", [["SNP", "CHEMICAL", 43, 46], ["SNP 3476", "DNA", 43, 51], ["allele", "DNA", 102, 108], ["SNP", "TEST", 43, 46], ["Africans", "TEST", 145, 153], ["Europeans", "TEST", 162, 171]]], ["All variable sites were in Hardy-Weinberg equilibrium for both CD209 and CD209L, after Bonferroni correction for multiple testing.Patterns of Nucleotide and Haplotype Diversity in the CD209/CD209L RegionThe allelic composition of CD209 and CD209L haplotypes and their frequency distribution in the three major ethnic groups is illustrated in figure 2, along with the haplotype composed of the ancestral allelic state of each SNP inferred from chimpanzee data.", [["SNP", "CHEMICAL", 425, 428], ["CD209", "GENE_OR_GENE_PRODUCT", 63, 68], ["CD209L", "GENE_OR_GENE_PRODUCT", 73, 79], ["CD209", "GENE_OR_GENE_PRODUCT", 184, 189], ["CD209", "GENE_OR_GENE_PRODUCT", 230, 235], ["CD209L", "GENE_OR_GENE_PRODUCT", 240, 246], ["chimpanzee", "ORGANISM", 443, 453], ["CD209", "PROTEIN", 63, 68], ["CD209L", "PROTEIN", 73, 79], ["CD209", "DNA", 184, 189], ["CD209L Region", "DNA", 190, 203], ["CD209", "DNA", 230, 235], ["All variable sites", "PROBLEM", 0, 18], ["Bonferroni correction", "TREATMENT", 87, 108], ["multiple testing", "TEST", 113, 129], ["Nucleotide and Haplotype Diversity", "PROBLEM", 142, 176], ["the CD209", "TEST", 180, 189], ["The allelic composition of CD209", "PROBLEM", 203, 235], ["CD209L haplotypes", "PROBLEM", 240, 257], ["variable", "OBSERVATION_MODIFIER", 4, 12], ["sites", "OBSERVATION_MODIFIER", 13, 18], ["allelic", "OBSERVATION_MODIFIER", 207, 214], ["composition", "OBSERVATION_MODIFIER", 215, 226]]], ["For CD209, we identified 42 different haplotypes, with an overall heterozygosity of 84% (table 2) .", [["CD209", "GENE_OR_GENE_PRODUCT", 4, 9], ["CD209", "PROTEIN", 4, 9], ["42 different haplotypes", "PROBLEM", 25, 48], ["an overall heterozygosity", "TEST", 55, 80]]], ["Three major haplotypes (H2, H29, and H40) accounted for \u223c50% of the African variability, whereas they were at very low frequency (H2 at \u223c5%) or absent (H29 and H40) in Europeans and East Asians ( fig. 2A ).", [["H2", "TEST", 130, 132]]], ["In turn, the two haplotypes (H1 and H3) that accounted for 58% and 83% of the European and East Asian variability, respectively, were observed at very low frequency (H1 at 6%) or even absent (H3) in Africa.", [["H3", "GENE_OR_GENE_PRODUCT", 36, 38], ["H3", "PROTEIN", 36, 38], ["H1", "PROTEIN", 166, 168], ["the two haplotypes (H1 and H3", "TREATMENT", 9, 38], ["very low frequency (H1", "PROBLEM", 146, 168]]], ["However, H3, which had a frequency of 36% and 20% in Europe and East Asia, respectively, is just a one-step mutation (SNP 871) from H2, the most frequent haplotype in the African sample.", [["SNP", "CHEMICAL", 118, 121], ["H3", "GENE_OR_GENE_PRODUCT", 9, 11], ["H3", "PROTEIN", 9, 11], ["H3", "PROBLEM", 9, 11], ["H2", "TREATMENT", 132, 134]]], ["The most in-Figure 2Inferred haplotypes for CD209 (A) and CD209L (B).", [["CD209 (A)", "GENE_OR_GENE_PRODUCT", 44, 53], ["CD209L (B)", "GENE_OR_GENE_PRODUCT", 58, 68], ["CD209", "PROTEIN", 44, 49], ["CD209L", "PROTEIN", 58, 64]]], ["The chimpanzee sequence was used to deduce the ancestral state at each position, except for the CD209L positions 1232, 1236, and 1240.", [["chimpanzee", "ORGANISM", 4, 14], ["chimpanzee sequence", "DNA", 4, 23], ["CD209L positions 1232, 1236, and 1240", "DNA", 96, 133], ["The chimpanzee sequence", "TREATMENT", 0, 23]]], ["For those polymorphisms, the ancestral state was considered to be the most frequent allele.", [["allele", "DNA", 84, 90]]], ["Dark boxes correspond to the derived state at each position.", [["Dark boxes", "PROBLEM", 0, 10]]], ["The numbers on the right of the figure indicate the absolute frequency of each haplotype in the different populations studied.", [["each haplotype", "PROBLEM", 74, 88], ["numbers", "OBSERVATION_MODIFIER", 4, 11], ["right", "ANATOMY_MODIFIER", 19, 24], ["absolute", "OBSERVATION_MODIFIER", 52, 60]]], ["Repeat-number variation in the neck region of each gene is reported in the gray columns with the column heads \"NR.\"", [["neck region", "ANATOMY", 31, 42], ["neck", "ORGAN", 31, 35], ["Repeat", "TEST", 0, 6], ["number", "OBSERVATION_MODIFIER", 7, 13], ["variation", "OBSERVATION_MODIFIER", 14, 23], ["neck", "ANATOMY", 31, 35], ["region", "ANATOMY_MODIFIER", 36, 42]]], ["Indel polymorphisms are referred as to \"1\" for insertion and \"0\" for deletion.Figure 2teresting observation of the CD209 haplotype variability was the presence of a highly divergent haplotype cluster.", [["CD209", "GENE_OR_GENE_PRODUCT", 115, 120], ["CD209", "DNA", 115, 120], ["Indel polymorphisms", "PROBLEM", 0, 19], ["deletion", "PROBLEM", 69, 77], ["the CD209 haplotype variability", "PROBLEM", 111, 142], ["a highly divergent haplotype cluster", "PROBLEM", 163, 199]]], ["Cluster A is Africa specific and is present at a frequency of \u223c15%, whereas cluster B is present in the remaining African and all non-African samples.", [["samples", "ANATOMY", 142, 149], ["cluster B", "GENE_OR_GENE_PRODUCT", 76, 85]]], ["It is worth noting that three (SNPs 1839 (SNPs , 1888 (SNPs , and 1908 of the five nonsynonymous mutations identified for this gene are unique to cluster A. In all cases, these three mutations were segregating together, with the exception of one haplotype, H41, which does not contain the SNP 1839.", [["SNP", "CHEMICAL", 289, 292], ["H41", "DNA", 257, 260], ["SNP 1839", "DNA", 289, 297], ["A.", "SPECIES", 154, 156], ["SNPs", "TEST", 42, 46], ["SNPs", "TEST", 55, 59], ["the five nonsynonymous mutations", "PROBLEM", 74, 106]]], ["Samples from cluster A are geographically wide- 2B) , with an overall heterozygosity of 94% (table 2) .", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["an overall heterozygosity", "TEST", 59, 84], ["overall", "OBSERVATION_MODIFIER", 62, 69], ["heterozygosity", "OBSERVATION", 70, 84]]], ["Only one haplotype (H38) at a frequency of \u223c15% was shared in the three continental regions.Figure 2To assess the degree of population differentiation, if any, we computed Wright's F ST (Wright 1931) , using haplotype frequencies.Figure 2estimates were significant F ST ( ) for all population comparisons, indicating P ! .0001 continental differentiation for both CD209 and CD209L.", [["CD209", "GENE_OR_GENE_PRODUCT", 364, 369], ["CD209L", "GENE_OR_GENE_PRODUCT", 374, 380], ["CD209", "PROTEIN", 364, 369], ["CD209L", "PROTEIN", 374, 380], ["three", "ANATOMY_MODIFIER", 66, 71], ["continental", "ANATOMY_MODIFIER", 72, 83], ["regions", "ANATOMY_MODIFIER", 84, 91], ["population", "OBSERVATION", 124, 134]]], ["However, substantial differences were observed between the two genes: the overall F ST for CD209 among Africans, Europeans, and East-Asians was 0.15, whereas CD209L presented a threefold lower F ST value of 0.05.", [["CD209", "GENE_OR_GENE_PRODUCT", 91, 96], ["substantial", "OBSERVATION_MODIFIER", 9, 20]]], ["For both genes, the larger F ST values were observed between African and East Asian populations, with F ST values of 0.22 for CD209 and 0.07 for CD209L.Levels of Polymorphism and Divergence between Humans and ChimpanzeesThe average nucleotide diversity (p) was strikingly different, both between the two genes and among populations (table 2) .", [["nucleotide", "CHEMICAL", 232, 242], ["nucleotide", "CHEMICAL", 232, 242], ["CD209", "GENE_OR_GENE_PRODUCT", 126, 131], ["CD209L", "GENE_OR_GENE_PRODUCT", 145, 151], ["CD209L", "PROTEIN", 145, 151], ["the larger F ST values", "PROBLEM", 16, 38], ["F ST values", "TEST", 102, 113], ["CD209", "TEST", 126, 131], ["CD209L", "TREATMENT", 145, 151], ["Levels of Polymorphism", "PROBLEM", 152, 174], ["Humans", "TREATMENT", 198, 204], ["Chimpanzees", "TREATMENT", 209, 220], ["Polymorphism", "OBSERVATION", 162, 174], ["diversity", "OBSERVATION_MODIFIER", 243, 252]]], ["Globally, p values were three-to fivefold lower for CD209 ( ) than for CD209LLevels of Polymorphism and Divergence between Humans and Chimpanzees\u03ea4 3-7 # 10 (\u223c16 # 10 \u03ea4 ), except for African populations, for whom the CD209 p value was unusually high ( ) be-\u03ea4 26 # 10 cause of the presence of the highly divergent cluster A. Indeed, when cluster A was excluded from the analysis, the African p value dropped to .", [["CD209", "GENE_OR_GENE_PRODUCT", 52, 57], ["CD209", "GENE_OR_GENE_PRODUCT", 218, 223], ["CD209", "PROTEIN", 52, 57], ["Globally, p values", "TEST", 0, 18], ["CD209", "TEST", 52, 57], ["Polymorphism", "PROBLEM", 87, 99], ["Humans and Chimpanzees\u03ea4", "TREATMENT", 123, 147], ["the CD209 p value", "TEST", 214, 231], ["the analysis", "TEST", 367, 379], ["the African p value", "TEST", 381, 400]]], ["To estimate \u03ea4 8 # 10 the substitution rate of each region and evince possible mutational differences that could explain the strong contrast observed in nucleotide-diversity patterns, we determined the human-chimpanzee divergence for both genes.", [["nucleotide", "CHEMICAL", 153, 163], ["nucleotide", "CHEMICAL", 153, 163], ["human", "ORGANISM", 202, 207], ["chimpanzee", "ORGANISM", 208, 218], ["\u03ea4 8 # 10", "DNA", 12, 21], ["human", "SPECIES", 202, 207], ["human-chimpanzee", "SPECIES", 202, 218], ["the substitution rate of each region", "TREATMENT", 22, 58], ["mutational differences", "PROBLEM", 79, 101]]], ["The average net number of differences between the two species was 77.3 substitutions (or 0.0157 substitutions per nucleotide) for CD209 and 90.6 substitutions (or 0.0171 substitutions per nucleotide) for CD209L.", [["nucleotide", "CHEMICAL", 114, 124], ["nucleotide", "CHEMICAL", 188, 198], ["CD209L", "GENE_OR_GENE_PRODUCT", 204, 210], ["CD209L", "PROTEIN", 204, 210], ["CD209", "TEST", 130, 135], ["CD209L", "TREATMENT", 204, 210], ["average", "OBSERVATION_MODIFIER", 4, 11], ["net", "OBSERVATION_MODIFIER", 12, 15], ["number", "OBSERVATION_MODIFIER", 16, 22]]], ["Since the human-chimpanzee speciation occurred 5 MYA, we obtained similar nucleotide-substitution rates per site per year (CD209, ;Levels of Polymorphism and Divergence between Humans and Chimpanzees\u03ea9 1.57 # 10 CD209L,Levels of Polymorphism and Divergence between Humans and Chimpanzees).Levels of Polymorphism and Divergence between Humans and Chimpanzees\u03ea9 1.70 # 10LDTo assess the patterns of LD in the CD209/CD209L region, haplotypes for the entire genomic region were reconstructed using markers with an MAF of 10%.", [["CD209/CD209L region", "ANATOMY", 407, 426], ["nucleotide", "CHEMICAL", 74, 84], ["nucleotide", "CHEMICAL", 74, 84], ["human", "ORGANISM", 10, 15], ["chimpanzee", "ORGANISM", 16, 26], ["CD209", "GENE_OR_GENE_PRODUCT", 407, 412], ["CD209L", "GENE_OR_GENE_PRODUCT", 413, 419], ["LD", "DNA", 397, 399], ["CD209", "DNA", 407, 412], ["CD209L region", "DNA", 413, 426], ["human", "SPECIES", 10, 15], ["human-chimpanzee", "SPECIES", 10, 26], ["similar nucleotide-substitution rates", "TREATMENT", 66, 103], ["Polymorphism", "TEST", 141, 153], ["Chimpanzees\u03ea9", "TEST", 188, 201], ["Polymorphism", "TREATMENT", 229, 241], ["Divergence between Humans and Chimpanzees", "TREATMENT", 246, 287], ["Levels of Polymorphism", "PROBLEM", 289, 311], ["Chimpanzees\u03ea9", "TEST", 346, 359], ["an MAF", "TEST", 507, 513], ["Polymorphism", "OBSERVATION", 299, 311]]], ["D measures among these markers were estimated for African and non-African populations independently; the graphical representation of LD levels is illustrated in figure 3.", [["D measures", "TREATMENT", 0, 10], ["these markers", "TEST", 17, 30], ["African and non-African populations", "TREATMENT", 50, 85], ["LD levels", "TEST", 133, 142]]], ["Two distinct regions, which correspond to either CD209 or CD209L, showed strong LD and are separated by a boundary that corresponds to the intergenic region.", [["CD209", "GENE_OR_GENE_PRODUCT", 49, 54], ["CD209L", "GENE_OR_GENE_PRODUCT", 58, 64], ["CD209", "DNA", 49, 54], ["CD209L", "DNA", 58, 64], ["intergenic region", "DNA", 139, 156], ["distinct", "OBSERVATION_MODIFIER", 4, 12], ["strong", "OBSERVATION_MODIFIER", 73, 79], ["LD", "OBSERVATION_MODIFIER", 80, 82], ["intergenic", "ANATOMY_MODIFIER", 139, 149], ["region", "ANATOMY_MODIFIER", 150, 156]]], ["For CD209, a block of intragenic LD was observed in both African and non-African populations.", [["CD209", "GENE_OR_GENE_PRODUCT", 4, 9], ["CD209", "PROTEIN", 4, 9], ["intragenic LD", "PROBLEM", 22, 35]]], ["For the African sample, 89% of all pairwise comparisons indicated significant levels of LD, whereas, for non-Africans, all D pairwise comparisons were significant.", [["the African sample", "TEST", 4, 22], ["all pairwise comparisons", "TEST", 31, 55], ["significant levels of LD", "PROBLEM", 66, 90], ["all D pairwise comparisons", "TEST", 119, 145], ["significant", "OBSERVATION_MODIFIER", 66, 77]]], ["The magnitude of intragenic recombination (and/or gene conversion) of CD209L was slightly higher than for CD209.", [["CD209L", "GENE_OR_GENE_PRODUCT", 70, 76], ["CD209", "GENE_OR_GENE_PRODUCT", 106, 111], ["CD209L", "PROTEIN", 70, 76], ["CD209", "PROTEIN", 106, 111], ["intragenic recombination", "TREATMENT", 17, 41], ["CD209L", "TEST", 70, 76], ["intragenic recombination", "OBSERVATION", 17, 41]]], ["Nevertheless, considerable and significant levels of LD were observed between sites: 83% of all LD pairwise comparisons were significant in the African group, and 99% were in the non-African sample.", [["significant levels of LD", "PROBLEM", 31, 55], ["all LD pairwise comparisons", "TEST", 92, 119], ["significant", "OBSERVATION_MODIFIER", 31, 42]]], ["Overall, CD209 exhibited a blocklike structure in both groups, whereas CD209L presented lower-although mostlyFigure 3Pairwise D LD plots in non-African and African populations.", [["CD209", "GENE_OR_GENE_PRODUCT", 9, 14], ["CD209L", "GENE_OR_GENE_PRODUCT", 71, 77], ["CD209", "PROTEIN", 9, 14], ["CD209L", "PROTEIN", 71, 77], ["a blocklike structure in both groups", "PROBLEM", 25, 61], ["blocklike structure", "OBSERVATION", 27, 46], ["both", "ANATOMY_MODIFIER", 50, 54], ["lower", "OBSERVATION_MODIFIER", 88, 93]]], ["Red tags indicate the physical position of each SNP across the genomic region studied.", [["SNP", "CHEMICAL", 48, 51], ["SNP", "CHEMICAL", 48, 51], ["Red tags", "TEST", 0, 8], ["physical position", "OBSERVATION_MODIFIER", 22, 39]]], ["Blue and green lines label the SNPs ( ) used for CD209 and CD209L, respectively, in the LD plot.", [["green lines", "CELL", 9, 20], ["CD209", "GENE_OR_GENE_PRODUCT", 49, 54], ["CD209L", "GENE_OR_GENE_PRODUCT", 59, 65], ["SNPs", "DNA", 31, 35], ["CD209", "PROTEIN", 49, 54], ["CD209L", "PROTEIN", 59, 65], ["Blue", "TREATMENT", 0, 4], ["CD209 and CD209L", "TREATMENT", 49, 65], ["green lines", "OBSERVATION", 9, 20]]], ["For CD209, 47 MAF 1 10% SNPs presented an in the African sample and 5 in the non-African, whereas, for CD209L, 18 SNPs showed an in MAF 1 10% MAF 1 10% Africans and 20 in non-Africans.", [["CD209", "GENE_OR_GENE_PRODUCT", 4, 9], ["CD209L", "GENE_OR_GENE_PRODUCT", 103, 109], ["non-Africans", "CANCER", 171, 183], ["CD209", "DNA", 4, 9], ["CD209", "TEST", 4, 9], ["MAF", "TEST", 14, 17], ["CD209L", "TEST", 103, 109], ["SNPs", "TEST", 114, 118], ["MAF", "TEST", 132, 135], ["MAF", "TEST", 142, 145], ["Africans", "TEST", 152, 160]]], ["The high prevalence of SNPs with for CD209 in Africa is due to the presence of the highly MAF 1 10% divergent cluster A, which presents 35 diagnostic variants with a frequency of 15%. significant-LD levels, in particular among the non-African sample.Figure 3The strong decay in LD observed in the intergenic region ( fig. 3) , which spans only \u223c14 kb, suggests the occurrence of a number of recombination events.", [["CD209", "GENE_OR_GENE_PRODUCT", 37, 42], ["CD209", "PROTEIN", 37, 42], ["MAF 1", "DNA", 90, 95], ["LD", "DNA", 278, 280], ["intergenic region", "DNA", 297, 314], ["SNPs", "TREATMENT", 23, 27], ["LD levels", "TEST", 196, 205], ["recombination events", "PROBLEM", 391, 411], ["high", "OBSERVATION_MODIFIER", 4, 8], ["intergenic", "ANATOMY_MODIFIER", 297, 307], ["region", "ANATOMY_MODIFIER", 308, 314]]], ["To test the hypothesis of a possible recombination hotspot situated within this region, recombination parameters across the entire CD209/CD209L region (\u223c26 kb) were computed for the three populations, by use of the recombination model implemented in Phase (v.2.1.1) ( fig. 4 ).", [["CD209", "GENE_OR_GENE_PRODUCT", 131, 136], ["CD209", "DNA", 131, 136], ["CD209L region", "DNA", 137, 150], ["recombination hotspot", "PROBLEM", 37, 58], ["recombination parameters", "TEST", 88, 112]]], ["This model (Stephens and Donnelly 2003) estimates the position and relative intensity of the hotspot (l) as compared with the background population recombination rate (r) (see the \"Material and Methods\" section).", [["intensity", "OBSERVATION_MODIFIER", 76, 85]]], ["A l value of 1 corresponds to absence of recombinationrate variation, whereas l values 11 indicate the presence of a hotspot.", [["A l value", "TEST", 0, 9], ["recombinationrate variation", "PROBLEM", 41, 68], ["recombinationrate variation", "OBSERVATION", 41, 68]]], ["The model detected the occurrence of a hotspot in the intergenic region, with Africans presenting a l of 18, whereas Europeans and East Asians exhibited l values of 63 and 53, respectively ( fig. 4) .", [["intergenic region", "DNA", 54, 71], ["l values", "TEST", 153, 161], ["intergenic", "ANATOMY_MODIFIER", 54, 64], ["region", "ANATOMY_MODIFIER", 65, 71], ["Africans", "OBSERVATION_MODIFIER", 78, 86]]], ["We estimated the posterior probabilities of a hotspot of any kind, , and of at least 10 times the background re-Pr (l 1 1) combination rate, . was 100% for Pr (l 1 10) Pr (l 1 1) all population groups, and was 64% for Af-Pr (l 1 10) ricans, 97% for Europeans, and 92% for East Asians.", [["combination rate", "TEST", 123, 139], ["Pr", "TEST", 156, 158], ["Pr", "TEST", 168, 170], ["Af", "TEST", 218, 220], ["ricans", "TEST", 233, 239], ["Europeans", "TEST", 249, 258], ["posterior", "ANATOMY_MODIFIER", 17, 26]]], ["Thus, our data clearly indicate a relative increase of the recombination levels between the two genes, which suggests the occurrence of a hotspot of recombination, the magnitude of which varies among the major ethnic groups.", [["a relative increase of the recombination levels", "PROBLEM", 32, 79], ["relative", "OBSERVATION_MODIFIER", 34, 42], ["increase", "OBSERVATION_MODIFIER", 43, 51]]], ["However, our data do not include intergenic SNPs; therefore, the exact location and width of the recombination hotspot within the intergenic region remains unclear, since this observation would be consistent with either an intense narrow hotspot or a weaker but wider hotspot.Neutrality TestsThe identification of a strong decay in LD between CD209 and CD209L facilitated the interpretation of neutrality tests, because the noise introduced by hitchhiking effects between the genes is reduced.", [["CD209", "GENE_OR_GENE_PRODUCT", 343, 348], ["CD209L", "GENE_OR_GENE_PRODUCT", 353, 359], ["intergenic SNPs", "DNA", 33, 48], ["intergenic region", "DNA", 130, 147], ["CD209", "DNA", 343, 348], ["CD209L", "CELL_LINE", 353, 359], ["intergenic SNPs", "PROBLEM", 33, 48], ["an intense narrow hotspot", "PROBLEM", 220, 245], ["a weaker", "PROBLEM", 249, 257], ["Neutrality Tests", "TEST", 276, 292], ["neutrality tests", "TEST", 394, 410], ["the noise", "PROBLEM", 420, 429], ["width", "OBSERVATION_MODIFIER", 84, 89], ["intergenic", "OBSERVATION_MODIFIER", 130, 140], ["consistent with", "UNCERTAINTY", 197, 212], ["intense", "OBSERVATION_MODIFIER", 223, 230], ["narrow", "OBSERVATION", 231, 237], ["weaker", "OBSERVATION_MODIFIER", 251, 257], ["reduced", "OBSERVATION_MODIFIER", 485, 492]]], ["We applied Tajima's D and Fay and Wu's H tests to determine whether these statistics significantly deviated from expectations under neutrality, using both coalescent simulations and the empirical distribution obtained from Akey et al. (2004) .", [["Tajima's D", "TREATMENT", 11, 21], ["Wu's H tests", "TEST", 34, 46], ["both coalescent simulations", "TREATMENT", 150, 177]]], ["Globally, Tajima's D test indicated different tendencies for the two genes (table 2) .", [["Tajima's D test", "TEST", 10, 25], ["different tendencies", "PROBLEM", 36, 56]]], ["CD209 always yielded negative values for Tajima's D but never achieved significance to reject the hypothesis of neutrality, whereas CD209L yielded significantly positive values for non-African populations, with use of bothFigure 4Estimates of the hotspot intensity (l) for Africans, Europeans, and East Asians.", [["CD209", "GENE_OR_GENE_PRODUCT", 0, 5], ["CD209L", "GENE_OR_GENE_PRODUCT", 132, 138], ["CD209", "PROTEIN", 0, 5], ["CD209L", "PROTEIN", 132, 138], ["Tajima's D", "PROBLEM", 41, 51], ["significantly positive values", "PROBLEM", 147, 176], ["non-African populations", "PROBLEM", 181, 204], ["bothFigure", "TREATMENT", 218, 228], ["Africans", "PROBLEM", 273, 281], ["negative", "OBSERVATION", 21, 29]]], ["Estimates of the population recombination rate (r) for each population as well as the posterior probabilities of and are also reported in the key. l 1 1 l 1 10 (table 2) .", [["the population recombination rate", "TEST", 13, 46], ["posterior", "ANATOMY_MODIFIER", 86, 95]]], ["To evaluate the selective pressures at the protein level, we performed two interspecies tests: K A /K S , which gives the ratio of nonsynonymous and synonymous changes between species, and the McDonald-Kreitman test, which tests the null hypothesis that the ratio of the number of fixed differences to polymorphisms is the same for both nonsynonymous and synonymous mutations.", [["K", "CHEMICAL", 95, 96], ["K", "CHEMICAL", 100, 101], ["the selective pressures", "TEST", 12, 35], ["nonsynonymous and synonymous changes between species", "PROBLEM", 131, 183], ["the McDonald-Kreitman test", "TEST", 189, 215], ["fixed differences to polymorphisms", "PROBLEM", 281, 315], ["both nonsynonymous and synonymous mutations", "PROBLEM", 332, 375], ["synonymous changes", "OBSERVATION", 149, 167], ["synonymous mutations", "OBSERVATION", 355, 375]]], ["For the K A /K S test, CD209 and CD209L showed similar values, 0.34 and 0.37, respectively.", [["K S", "GENE_OR_GENE_PRODUCT", 13, 16], ["CD209", "GENE_OR_GENE_PRODUCT", 23, 28], ["CD209L", "GENE_OR_GENE_PRODUCT", 33, 39], ["CD209", "PROTEIN", 23, 28], ["CD209L", "PROTEIN", 33, 39], ["the K A /K S test", "TEST", 4, 21], ["CD209", "TEST", 23, 28], ["CD209L", "TEST", 33, 39]]], ["For the McDonald-Kreitman test, the hypothesis of neutrality was rejected for only CD209, because of a clear lack of nonsynonymous polymorphic sites (table 3) .Neck-Region Length Variation in Worldwide PopulationsThe identical genomic organization of CD209 and CD209L is extended to the neck region, which, in both genes, encodes a track of seven coding repeats of 23 aa each ( fig. 1) (Soilleux et al. 2000) .", [["neck region", "ANATOMY", 287, 298], ["CD209", "GENE_OR_GENE_PRODUCT", 83, 88], ["CD209", "GENE_OR_GENE_PRODUCT", 251, 256], ["CD209L", "GENE_OR_GENE_PRODUCT", 261, 267], ["neck", "ORGAN", 287, 291], ["CD209", "PROTEIN", 83, 88], ["nonsynonymous polymorphic sites", "DNA", 117, 148], ["CD209", "DNA", 251, 256], ["CD209L", "DNA", 261, 267], ["the McDonald-Kreitman test", "TEST", 4, 30], ["nonsynonymous polymorphic sites", "PROBLEM", 117, 148], ["CD209", "TEST", 251, 256], ["Region", "OBSERVATION_MODIFIER", 165, 171], ["Length", "OBSERVATION_MODIFIER", 172, 178], ["Variation", "OBSERVATION_MODIFIER", 179, 188], ["Worldwide", "OBSERVATION_MODIFIER", 192, 201], ["Populations", "OBSERVATION_MODIFIER", 202, 213], ["genomic organization", "OBSERVATION", 227, 247], ["neck", "ANATOMY", 287, 291], ["region", "ANATOMY_MODIFIER", 292, 298]]], ["A previous study has shown that the length of the neck region of CD209L varied between individuals of European descent (Bashirova et al. 2001) .", [["neck region", "ANATOMY", 50, 61], ["neck", "ORGAN", 50, 54], ["CD209L", "GENE_OR_GENE_PRODUCT", 65, 71], ["CD209L", "PROTEIN", 65, 71], ["A previous study", "TEST", 0, 16], ["length", "OBSERVATION_MODIFIER", 36, 42], ["neck", "ANATOMY", 50, 54], ["region", "ANATOMY_MODIFIER", 55, 61]]], ["To investigate the degree of polymorphism of the neck region in both CD209 and CD209L, we genotyped it in the entire HGDP-CEPH panel (1,064 individuals from 52 worldwide populations).", [["neck region", "ANATOMY", 49, 60], ["neck", "ORGAN", 49, 53], ["CD209", "GENE_OR_GENE_PRODUCT", 69, 74], ["CD209L", "GENE_OR_GENE_PRODUCT", 79, 85], ["CD209", "PROTEIN", 69, 74], ["CD209L", "PROTEIN", 79, 85], ["polymorphism of the neck region", "PROBLEM", 29, 60], ["polymorphism", "OBSERVATION", 29, 41], ["neck", "ANATOMY", 49, 53], ["region", "ANATOMY_MODIFIER", 54, 60], ["both", "ANATOMY_MODIFIER", 64, 68]]], ["Striking differences were observed between the two genes (see fig. 5 and table 4 for detailed allele frequencies in each population).", [["Striking differences", "PROBLEM", 0, 20]]], ["For CD209, virtually no variation was observed, and the 7-repeat allele accounted for 99% of the total variability.", [["CD209", "GENE_OR_GENE_PRODUCT", 4, 9], ["CD209", "DNA", 4, 9], ["7-repeat allele", "DNA", 56, 71], ["repeat allele", "TEST", 58, 71], ["the total variability", "TEST", 93, 114]]], ["Despite this limited variation, eight different alleles were observed, with an allele size range of 2-10 repeats, not including a 9-repeat allele.", [["9-repeat allele", "DNA", 130, 145], ["size", "OBSERVATION_MODIFIER", 86, 90]]], ["The geographic region that presented the highest variability was the Middle East, with five of the eight different alleles observed ( fig. 5A and table 4) .", [["geographic", "OBSERVATION_MODIFIER", 4, 14], ["highest", "OBSERVATION_MODIFIER", 41, 48], ["variability", "OBSERVATION_MODIFIER", 49, 60], ["Middle", "ANATOMY_MODIFIER", 69, 75]]], ["For CD209L, a com-pletely different pattern emerged, with strong variation in allelic frequencies of different repeat numbers.", [["CD209L", "GENE_OR_GENE_PRODUCT", 4, 10], ["CD209L", "PROTEIN", 4, 10], ["strong variation in allelic frequencies", "PROBLEM", 58, 97], ["different repeat numbers", "TEST", 101, 125]]], ["Of the seven alleles observed (from 4-10-repeat allele size classes), the three most common overall were the 7-(57.42%), the 5-(23.92%), and the 6-(11.37%) repeat alleles.", [["repeat alleles", "TEST", 156, 170]]], ["European, Asian, and Pacific populations presented a mosaic composition of different allelic classes, whereas 7-and 6-repeat alleles accounted for most (96%) of the African diversity ( fig. 5B ).", [["7-and 6-repeat alleles", "DNA", 110, 132], ["repeat alleles", "TEST", 118, 132]]], ["The strong difference in the neck-region lengths between the two genes was consequently visible in the heterozygosity values: CD209 exhibited an overall heterozygosity of only 2%, whereas CD209L presented a value of 54% (table 5) .", [["neck-region", "ANATOMY", 29, 40], ["CD209", "GENE_OR_GENE_PRODUCT", 126, 131], ["CD209L", "PROTEIN", 188, 194], ["The strong difference in the neck-region lengths", "PROBLEM", 0, 48], ["strong", "OBSERVATION_MODIFIER", 4, 10], ["difference", "OBSERVATION_MODIFIER", 11, 21], ["neck", "ANATOMY", 29, 33], ["region", "ANATOMY_MODIFIER", 34, 40], ["overall", "OBSERVATION_MODIFIER", 145, 152], ["heterozygosity", "OBSERVATION", 153, 167]]], ["Our results showed that the levels of heterozygosity observed at CD209 were considerably lower than expected, regardless of the mutation model considered (i.e., Infinite Site or Stepwise Mutation Models) (table 5).", [["CD209", "GENE_OR_GENE_PRODUCT", 65, 70], ["CD209", "PROTEIN", 65, 70], ["the levels of heterozygosity", "PROBLEM", 24, 52], ["the mutation model", "PROBLEM", 124, 142]]], ["In strong contrast, although not statistically significant for individual populations, CD209L exhibited a pattern of an excess of heterozygosity in all populations.Table 4 Allele Relative Frequencies of Neck-Region Repeat Variation in CD209 and CD209L in Individual PopulationsThe table is available in its entirety in the online edition of The American Journal of Human Genetics.Time of the Most Recent Common Ancestor for CD209The low levels of intragenic recombination observed in CD209 allowed maximum-likelihood coalescent analysis (Griffiths and Tavare 1994) for estimation of the time scale of the origin and evolution of this gene.", [["CD209", "CHEMICAL", 424, 429], ["CD209", "CHEMICAL", 424, 429], ["CD209L", "GENE_OR_GENE_PRODUCT", 87, 93], ["Human", "ORGANISM", 365, 370], ["CD209", "GENE_OR_GENE_PRODUCT", 484, 489], ["CD209L", "PROTEIN", 87, 93], ["CD209", "DNA", 235, 240], ["CD209L", "DNA", 245, 251], ["CD209", "CELL_LINE", 424, 429], ["CD209", "DNA", 484, 489], ["Human", "SPECIES", 365, 370], ["individual populations", "PROBLEM", 63, 85], ["heterozygosity in all populations", "PROBLEM", 130, 163], ["Repeat Variation", "TEST", 215, 231], ["CD209", "TEST", 235, 240], ["intragenic recombination", "PROBLEM", 447, 471], ["excess", "OBSERVATION_MODIFIER", 120, 126], ["heterozygosity", "OBSERVATION", 130, 144], ["all", "OBSERVATION_MODIFIER", 148, 151], ["populations", "OBSERVATION_MODIFIER", 152, 163], ["Neck", "ANATOMY", 203, 207], ["low levels", "OBSERVATION_MODIFIER", 433, 443], ["origin", "ANATOMY_MODIFIER", 605, 611]]], ["Since this method assumes an infinite-site model without recombination, the same analysis for CD209L was not conducted because of the substantial amount of recombinant haplotypes observed.", [["CD209L", "GENE_OR_GENE_PRODUCT", 94, 100], ["CD209L", "PROTEIN", 94, 100], ["the same analysis", "TEST", 72, 89], ["CD209L", "TREATMENT", 94, 100], ["recombinant haplotypes", "PROBLEM", 156, 178], ["substantial", "OBSERVATION_MODIFIER", 134, 145], ["amount", "OBSERVATION_MODIFIER", 146, 152], ["recombinant haplotypes", "OBSERVATION", 156, 178]]], ["For CD209, only 29 of the 254 chromosomes analyzed had to be excluded, as did a single segregating site (SNP 939).", [["chromosomes", "ANATOMY", 30, 41], ["SNP", "CHEMICAL", 105, 108], ["CD209", "GENE_OR_GENE_PRODUCT", 4, 9], ["chromosomes", "CELLULAR_COMPONENT", 30, 41], ["CD209", "DNA", 4, 9], ["segregating site", "DNA", 87, 103], ["SNP 939", "DNA", 105, 112], ["CD209", "TEST", 4, 9], ["a single segregating site", "PROBLEM", 78, 103]]], ["The resulting CD209 gene tree estimate, rooted with the chimpanzee sequence (i.e., the chimpanzee sequence was used to define ancestral/derived status of human mutations), is shown in figure 6 .", [["CD209", "GENE_OR_GENE_PRODUCT", 14, 19], ["chimpanzee", "ORGANISM", 56, 66], ["chimpanzee", "ORGANISM", 87, 97], ["human", "ORGANISM", 154, 159], ["CD209 gene tree", "DNA", 14, 29], ["chimpanzee sequence", "DNA", 56, 75], ["chimpanzee sequence", "DNA", 87, 106], ["human", "SPECIES", 154, 159], ["human", "SPECIES", 154, 159], ["the chimpanzee sequence", "TEST", 52, 75], ["the chimpanzee sequence", "TREATMENT", 83, 106]]], ["The tree is partitioned into two deep branches that correspond to haplotype clusters A and B. African samples were observed in both sides of the deepest node of the tree (i.e., in both clusters A and B), whereas non-African samples are restricted to one branch of the tree (i.e., cluster B).", [["samples", "ANATOMY", 102, 109], ["node", "ANATOMY", 153, 157], ["samples", "ANATOMY", 224, 231], ["deepest node", "MULTI-TISSUE_STRUCTURE", 145, 157], ["haplotype clusters A and B. African samples", "PROBLEM", 66, 109], ["non-African samples", "TEST", 212, 231], ["tree", "ANATOMY_MODIFIER", 4, 8], ["deep", "ANATOMY_MODIFIER", 33, 37], ["branches", "ANATOMY_MODIFIER", 38, 46], ["haplotype clusters", "OBSERVATION", 66, 84], ["deepest", "ANATOMY_MODIFIER", 145, 152], ["node", "OBSERVATION", 153, 157], ["tree", "ANATOMY_MODIFIER", 165, 169], ["branch", "ANATOMY_MODIFIER", 254, 260], ["tree", "ANATOMY_MODIFIER", 268, 272]]], ["The maximum-likelihood estimate of v (v ML ) for CD209 was 8.4.", [["CD209", "TEST", 49, 54]]], ["On the basis of this v ML value and the estimated mutation rate ( per gene \u03ea4 1.54 # 10 per generation), the effective population size ( ) was N e 13,636, a value comparable to most figures reported in the literature (for a review, see Tishkoff and Verrelli [2003] ).", [["this v ML value", "TEST", 16, 31], ["the estimated mutation rate", "TEST", 36, 63], ["a value", "TEST", 155, 162], ["size", "OBSERVATION_MODIFIER", 130, 134]]], ["The T MRCA of the CD209 tree was then estimated at MYA, one of the oldest T MRCA val-2.8 \u202b\u05e2\u202c 0.22 ues estimated so far in the human genome (Excoffier 2002 ).DiscussionThe CD209/CD209L region possesses a number of characteristics that make it a powerful tool for evolutionary inference.", [["CD209 tree", "ANATOMY", 18, 28], ["CD209 tree", "MULTI-TISSUE_STRUCTURE", 18, 28], ["human", "ORGANISM", 126, 131], ["CD209", "GENE_OR_GENE_PRODUCT", 171, 176], ["CD209L", "GENE_OR_GENE_PRODUCT", 177, 183], ["CD209 tree", "DNA", 18, 28], ["human genome", "DNA", 126, 138], ["CD209", "DNA", 171, 176], ["CD209L region", "DNA", 177, 190], ["human", "SPECIES", 126, 131], ["human", "SPECIES", 126, 131], ["The T MRCA", "TEST", 0, 10], ["The CD209/CD209L region", "TREATMENT", 167, 190], ["human genome", "ANATOMY", 126, 138]]], ["Moreover, our results suggest that the CD209/CD209L region is a uniform landscape of genomic forces, since the two lectincoding genes present similar mutation rates, as well as high nucleotide identity and conserved exon-intron organization ( fig. 1 ).Contrasting Patterns of Diversity in the CD209/CD209L RegionOur diversity study revealed completely different patterns for the two genes.", [["nucleotide", "CHEMICAL", 182, 192], ["nucleotide", "CHEMICAL", 182, 192], ["CD209", "GENE_OR_GENE_PRODUCT", 39, 44], ["CD209L", "GENE_OR_GENE_PRODUCT", 45, 51], ["lectincoding", "GENE_OR_GENE_PRODUCT", 115, 127], ["CD209", "GENE_OR_GENE_PRODUCT", 293, 298], ["CD209/CD209L region", "DNA", 39, 58], ["lectincoding genes", "DNA", 115, 133], ["CD209", "DNA", 293, 298], ["CD209L", "DNA", 299, 305], ["the CD209/CD209L region", "PROBLEM", 35, 58], ["high nucleotide identity", "PROBLEM", 177, 201], ["the CD209", "TEST", 289, 298], ["RegionOur diversity study", "TEST", 306, 331], ["uniform", "OBSERVATION_MODIFIER", 64, 71], ["landscape", "OBSERVATION_MODIFIER", 72, 81], ["genomic forces", "OBSERVATION", 85, 99], ["Diversity", "OBSERVATION_MODIFIER", 276, 285], ["completely different", "OBSERVATION_MODIFIER", 341, 361]]], ["First, levels of nucleotide diversity (p) were found to be much lower for CD209 than for CD209L (table 2) .", [["nucleotide", "CHEMICAL", 17, 27], ["nucleotide", "CHEMICAL", 17, 27], ["CD209", "GENE_OR_GENE_PRODUCT", 74, 79], ["CD209L", "GENE_OR_GENE_PRODUCT", 89, 95], ["CD209", "PROTEIN", 74, 79], ["CD209L", "PROTEIN", 89, 95], ["nucleotide diversity", "TEST", 17, 37]]], ["On the basis of 1.42 million SNPs, the International SNP Map Working Group defined as the average value of nucleotide di-\u03ea4 7.5 # 10 versity for the human genome and showed that 95% of all bins presented p values varying from to \u03ea4 2.0 # 10 (Sachidanandam et al. 2001 ).", [["SNP", "CHEMICAL", 53, 56], ["nucleotide", "CHEMICAL", 107, 117], ["human", "ORGANISM", 149, 154], ["human genome", "DNA", 149, 161], ["human", "SPECIES", 149, 154], ["human", "SPECIES", 149, 154], ["the International SNP Map", "TREATMENT", 35, 60], ["nucleotide di", "TEST", 107, 120], ["the human genome", "TEST", 145, 161]]], ["In addition,Contrasting Patterns of Diversity in the CD209/CD209L Region\u03ea4 15.8 # 10 an independent study analyzed nucleotide and haplotype diversity for 313 genes and defined the average p value as (Stephens et al. 2001) .", [["nucleotide", "CHEMICAL", 115, 125], ["nucleotide", "CHEMICAL", 115, 125], ["CD209", "DNA", 53, 58], ["CD209L", "DNA", 59, 65], ["Diversity", "TEST", 36, 45], ["the CD209", "TEST", 49, 58], ["an independent study", "TEST", 85, 105], ["haplotype diversity", "TEST", 130, 149], ["Diversity", "OBSERVATION_MODIFIER", 36, 45]]], ["In this context, the ) are at least twofold higher than average \u03ea4 16-18 # 10 genome estimates and fall into the upper limit of the 95% CI defined by the SNP Consortium (Sachidanandam et al. 2001) .", [["SNP", "CHEMICAL", 154, 157], ["twofold", "OBSERVATION_MODIFIER", 36, 43], ["higher", "OBSERVATION_MODIFIER", 44, 50], ["upper limit", "OBSERVATION_MODIFIER", 113, 124]]], ["This contrast in nucleotide diversity between the two genes can be explained either by a disparity in local mutation rates or by actual differences in selective pressures.", [["nucleotide", "CHEMICAL", 17, 27], ["nucleotide", "CHEMICAL", 17, 27], ["a disparity in local mutation rates", "PROBLEM", 87, 122], ["selective pressures", "TEST", 151, 170], ["selective", "OBSERVATION_MODIFIER", 151, 160], ["pressures", "OBSERVATION_MODIFIER", 161, 170]]], ["However, no major differences in mutation rates ( vs. ) were ob-\u03ea9 \u03ea91.57 # 10 1.70 # 10 served between the two homologues, nor was there substantial variation in GC content, which has been positively correlated with mutation rates and levels of polymorphisms (Sachidanandam et al. 2001; Smith et al. 2002; Waterston et al. 2002; Hellmann et al. 2003) .", [["mutation rates", "TEST", 33, 47], ["ob", "TEST", 61, 63], ["substantial variation in GC content", "PROBLEM", 138, 173], ["mutation rates", "TEST", 217, 231], ["no", "UNCERTAINTY", 9, 11], ["major", "OBSERVATION_MODIFIER", 12, 17], ["substantial", "OBSERVATION_MODIFIER", 138, 149], ["variation", "OBSERVATION_MODIFIER", 150, 159], ["GC content", "OBSERVATION", 163, 173]]], ["Indeed, the GC content for CD209 (53.7%) was slightly higher than that observed for CD209L (50.9%), which reinforces the idea that different selective pressures may indeed have been the driving force behind the distinct patterns of diversity observed.", [["CD209", "GENE_OR_GENE_PRODUCT", 27, 32], ["CD209L", "GENE_OR_GENE_PRODUCT", 84, 90], ["CD209", "PROTEIN", 27, 32], ["CD209L", "PROTEIN", 84, 90], ["the GC content", "TEST", 8, 22], ["CD209", "TEST", 27, 32], ["CD209L", "TEST", 84, 90], ["different selective pressures", "TREATMENT", 131, 160], ["distinct", "OBSERVATION_MODIFIER", 211, 219], ["diversity", "OBSERVATION", 232, 241]]], ["Second, the patterns of repeat variation in the neck region also turned out to be strikingly different between the two genes.", [["neck region", "ANATOMY", 48, 59], ["neck", "ORGAN", 48, 52], ["repeat variation in the neck region", "PROBLEM", 24, 59], ["variation", "OBSERVATION_MODIFIER", 31, 40], ["neck", "ANATOMY", 48, 52], ["region", "ANATOMY_MODIFIER", 53, 59]]], ["CD209 showed levels of heterozygosity of only 2%, whereas CD209L presented an extraordinarily high level of worldwide diversity, with an overall heterozygosity of 54% (table 5 and fig. 5 ).", [["CD209", "GENE_OR_GENE_PRODUCT", 0, 5], ["CD209L", "GENE_OR_GENE_PRODUCT", 58, 64], ["CD209", "PROTEIN", 0, 5], ["CD209L", "PROTEIN", 58, 64], ["levels", "TEST", 13, 19], ["heterozygosity", "TEST", 23, 37], ["an overall heterozygosity", "TEST", 134, 159], ["extraordinarily", "OBSERVATION_MODIFIER", 78, 93], ["high", "OBSERVATION", 94, 98]]], ["Although the neck regions of both genes share 92% of nucleotide identity, nonuniform mutation rates could, again, explain the patterns observed.", [["neck regions", "ANATOMY", 13, 25], ["nucleotide", "CHEMICAL", 53, 63], ["nucleotide", "CHEMICAL", 53, 63], ["neck", "ORGANISM_SUBDIVISION", 13, 17], ["neck regions", "DNA", 13, 25], ["nucleotide identity", "TEST", 53, 72], ["nonuniform mutation rates", "PROBLEM", 74, 99], ["neck", "ANATOMY", 13, 17], ["regions", "ANATOMY_MODIFIER", 18, 25]]], ["However, this does not seem to be the case, since mutation-rate variation should influence the number of alleles observed rather than their frequencies, which are subject either to genetic drift or to natural selection.", [["mutation-rate variation", "PROBLEM", 50, 73]]], ["Indeed, we observed an even higher number of repeat alleles for CD209 (eight alleles) than for CD209L (seven alleles) (table 4 and fig. 5 ).", [["CD209", "GENE_OR_GENE_PRODUCT", 64, 69], ["CD209L", "GENE_OR_GENE_PRODUCT", 95, 101], ["repeat alleles", "DNA", 45, 59], ["CD209", "DNA", 64, 69], ["CD209L", "DNA", 95, 101], ["repeat alleles", "TEST", 45, 59], ["CD209", "TEST", 64, 69]]], ["Overall, differences in genomic forces seem to be insufficient to explain the contrasting patterns observed at both the sequence and neck-region length variation levels; therefore, the action of differential selective pressures acting on these genes becomes the most plausible scenario.CD209: The Signature of a Functional ConstraintFor CD209, not only nucleotide diversity but also F ST intercontinental values (0.15) were in conformity with previous worldwide estimations (Harpending and Rogers 2000; Akey et al. 2002; Cavalli-Sforza and Feldman 2003) .", [["neck", "ANATOMY", 133, 137], ["nucleotide", "CHEMICAL", 353, 363], ["CD209", "GENE_OR_GENE_PRODUCT", 286, 291], ["CD209", "PROTEIN", 286, 291], ["differential selective pressures", "TREATMENT", 195, 227], ["CD209", "TEST", 337, 342], ["nucleotide diversity", "PROBLEM", 353, 373], ["genomic forces", "OBSERVATION", 24, 38], ["neck", "ANATOMY", 133, 137]]], ["For frequency-spectrum-based tests, only Fay and Wu's H test detected an excess of highly frequently derived alleles for the African and East Asian samples, a picture that may be interpreted as the result of a selective sweep.", [["based tests", "TEST", 23, 34], ["Wu's H test", "TEST", 49, 60], ["a selective sweep", "PROBLEM", 208, 225]]], ["However, the significantly negative value observed in Africa is, again, exclusively due to the presence of cluster A, since 22 of the 35 fixed SNPs distinguishing it from cluster B corresponded to the derived allelic status in the latter cluster.", [["cluster B", "GENE_OR_GENE_PRODUCT", 171, 180], ["the 35 fixed SNPs", "TREATMENT", 130, 147]]], ["The extent to which the presence of this cluster is due to either natural selection or population structure will be discussed in detail below.", [["natural selection or population structure", "PROBLEM", 66, 107], ["extent", "OBSERVATION_MODIFIER", 4, 10]]], ["For East Asia, the significance of the H test is also questionable when accounting for the confounding effects of demography.", [["the H test", "TEST", 35, 45]]], ["Indeed, when we plotted our H value against the empirical distribution of 132 H values from non-African populations (Akey et al. 2004) , the East Asian P value became nonsignificant (CD209: The Signature of a Functional Constraint).", [["non-African populations", "TEST", 92, 115], ["the East Asian P value", "TEST", 137, 159]]], ["This observation reinforces the idea that the P p .36 H test is particularly sensitive to past bottlenecks and/ or population subdivision (Przeworski 2002) .", [["P p .36 H", "DNA", 46, 55], ["the P p .36 H test", "TEST", 42, 60]]], ["Thus, regarding the global levels of sequence diversity, the CD209 locus seems to evolve under evolutionary neutrality.", [["CD209", "GENE_OR_GENE_PRODUCT", 61, 66], ["CD209 locus", "DNA", 61, 72], ["the CD209 locus", "PROBLEM", 57, 72], ["evolutionary neutrality", "OBSERVATION", 95, 118]]], ["Nevertheless, when we focused our analyses at the protein level, signs of natural selection were uncovered.", [["natural selection", "PROBLEM", 74, 91], ["natural selection", "OBSERVATION", 74, 91]]], ["Indeed, the McDonald-Kreitman test rejected neutrality for this gene because of a clear excess of polymorphic synonymous sites (i.e., a lack of nonsynonymous variants).", [["Kreitman", "DNA", 21, 29], ["polymorphic synonymous sites", "DNA", 98, 126], ["polymorphic synonymous sites", "PROBLEM", 98, 126], ["polymorphic", "OBSERVATION_MODIFIER", 98, 109], ["synonymous sites", "OBSERVATION", 110, 126], ["nonsynonymous variants", "OBSERVATION", 144, 166]]], ["In addition, when the number of synonymous sites (146) versus nonsynonymous sites (499) was compared with the observed number of synonymous (5) versus nonsynonymous (0) mutations, we detected a significant lack of nonsynonymous mutations (twotailed Fisher exact test, ).", [["nonsynonymous sites", "DNA", 62, 81], ["nonsynonymous sites", "TEST", 62, 81], ["mutations", "PROBLEM", 169, 178], ["nonsynonymous mutations", "PROBLEM", 214, 237], ["synonymous", "OBSERVATION", 129, 139], ["nonsynonymous mutations", "OBSERVATION", 214, 237]]], ["These obser-\u03ea4 P p 6.3 # 10 vations point to a strong selective constraint acting on CD209 that prevents the accumulation of amino acid replacements over time.CD209: The Signature of a Functional ConstraintFurther support for a functional constraint in CD209 comes from the patterns of diversity observed in the neck region.", [["neck region", "ANATOMY", 312, 323], ["CD209", "CHEMICAL", 85, 90], ["amino acid", "CHEMICAL", 125, 135], ["amino acid", "CHEMICAL", 125, 135], ["CD209", "GENE_OR_GENE_PRODUCT", 85, 90], ["amino acid", "AMINO_ACID", 125, 135], ["CD209", "GENE_OR_GENE_PRODUCT", 159, 164], ["CD209", "GENE_OR_GENE_PRODUCT", 253, 258], ["neck", "ORGAN", 312, 316], ["CD209", "PROTEIN", 85, 90], ["CD209", "PROTEIN", 159, 164], ["CD209", "DNA", 253, 258], ["These obser", "TEST", 0, 11], ["p", "TEST", 17, 18], ["CD209", "TREATMENT", 85, 90], ["amino acid replacements", "TREATMENT", 125, 148], ["a Functional ConstraintFurther support", "TREATMENT", 183, 221], ["a functional constraint in CD209", "PROBLEM", 226, 258], ["amino acid replacements", "OBSERVATION", 125, 148], ["diversity", "OBSERVATION", 286, 295], ["neck", "ANATOMY", 312, 316], ["region", "ANATOMY_MODIFIER", 317, 323]]], ["In contrast to CD209L, virtually no variation was observed at CD209 ( fig. 5A) , with the 7-repeat allele accounting for 99% of the total variability.", [["CD209L", "GENE_OR_GENE_PRODUCT", 15, 21], ["CD209", "GENE_OR_GENE_PRODUCT", 62, 67], ["CD209L", "PROTEIN", 15, 21], ["CD209", "PROTEIN", 62, 67], ["7-repeat allele", "DNA", 90, 105], ["the total variability", "TEST", 128, 149]]], ["Moreover, the low levels of heterozygosity observed resulted in a consistent rejection of mutation-drift equilibrium in almost all geographical regions (table 5).", [["the low levels of heterozygosity", "PROBLEM", 10, 42], ["a consistent rejection of mutation", "PROBLEM", 64, 98], ["drift equilibrium", "PROBLEM", 99, 116], ["low levels", "OBSERVATION_MODIFIER", 14, 24], ["rejection", "OBSERVATION", 77, 86], ["mutation", "OBSERVATION", 90, 98], ["drift", "OBSERVATION_MODIFIER", 99, 104], ["equilibrium", "OBSERVATION_MODIFIER", 105, 116]]], ["The probability of finding such a low heterozygosity value, given the overall number of alleles observed, was estimated to be !0.2%, independent of the mutational model considered (table 5) .", [["a low heterozygosity value", "PROBLEM", 32, 58]]], ["Thus, the fact that no alleles other than the 7repeat allele have increased in frequency, together with recent studies addressing the functional consequences of a Populations are grouped as described by Rosenberg et al. (2002) . b AMOVA values are from our CD209L study; 95% CIs are defined from 377 autosomal microsatellites in the same population panel repeat-number variation in this region (Bernhard et al. 2004; Feinberg et al. 2005) , strongly suggests a clear reduced fitness of any allele other than the 7-repeat allele.", [["7repeat allele", "DNA", 46, 60], ["allele", "DNA", 490, 496], ["7-repeat allele", "DNA", 512, 527], ["alleles", "PROBLEM", 23, 30], ["recent studies", "TEST", 104, 118], ["b AMOVA values", "TEST", 229, 243], ["our CD209L study", "TEST", 253, 269], ["autosomal microsatellites", "PROBLEM", 300, 325], ["repeat", "TEST", 355, 361], ["increased", "OBSERVATION_MODIFIER", 66, 75]]], ["Interestingly, it has been recently shown that a protein with two fewer repeats (a 5-repeat allele) results in a partial dissociation of the final tetramer, whereas a protein with !5 repeats exhibits a dramatic reduction in overall stability (Feinberg et al. 2005) , with all these differences having a direct impact on the quality of ligand-binding functions (Bernhard et al. 2004) .", [["5-repeat allele", "DNA", 83, 98], ["!5 repeats", "PROTEIN", 180, 190], ["a dramatic reduction", "PROBLEM", 200, 220], ["dramatic", "OBSERVATION_MODIFIER", 202, 210], ["reduction", "OBSERVATION_MODIFIER", 211, 220], ["overall", "OBSERVATION_MODIFIER", 224, 231], ["stability", "OBSERVATION_MODIFIER", 232, 241]]], ["Taken together, the patterns of diversity observed at CD209 clearly point to a strong functional constraint acting on this gene and further support the proposed crucial role of this lectin in pathogen recognition and in the early steps of immune response (Geijtenbeek et al. 2000b (Geijtenbeek et al. , 2004 .CD209L: Relaxation of the Functional Constraint or Balancing Selection?In clear contrast to its homologue, CD209L presented extremely elevated nucleotide-diversity levels.", [["nucleotide", "CHEMICAL", 452, 462], ["nucleotide", "CHEMICAL", 452, 462], ["CD209", "GENE_OR_GENE_PRODUCT", 54, 59], ["lectin", "GENE_OR_GENE_PRODUCT", 182, 188], ["CD209L", "GENE_OR_GENE_PRODUCT", 416, 422], ["CD209", "PROTEIN", 54, 59], ["lectin", "PROTEIN", 182, 188], ["CD209L", "PROTEIN", 416, 422], ["diversity", "PROBLEM", 32, 41], ["immune response", "PROBLEM", 239, 254], ["extremely elevated nucleotide-diversity levels", "PROBLEM", 433, 479], ["extremely", "OBSERVATION_MODIFIER", 433, 442], ["elevated", "OBSERVATION", 443, 451], ["diversity", "OBSERVATION_MODIFIER", 463, 472]]], ["High levels of diversity can result either from a relaxation of the functional constraint, which allows the stochastic accumulation of new mutations, or from the action of balancing selection, which maintains over time two or more functionally different alleles (and all linked variation) at intermediate frequencies.CD209L: Relaxation of the Functional Constraint or Balancing Selection?Several lines of evidence lend support to the selective hypothesis.", [["new mutations", "PROBLEM", 135, 148], ["balancing selection", "TREATMENT", 172, 191], ["the selective hypothesis", "PROBLEM", 430, 454], ["new", "OBSERVATION_MODIFIER", 135, 138], ["selective", "OBSERVATION_MODIFIER", 434, 443], ["hypothesis", "OBSERVATION", 444, 454]]], ["First, if CD209L nucleotide diversity has been driven by the action of balancing selection, population-genetics relationships would have been accordingly altered.", [["nucleotide", "CHEMICAL", 17, 27], ["nucleotide", "CHEMICAL", 17, 27], ["CD209L", "GENE_OR_GENE_PRODUCT", 10, 16], ["CD209L", "PROTEIN", 10, 16], ["CD209L nucleotide diversity", "PROBLEM", 10, 37], ["balancing selection", "TREATMENT", 71, 90]]], ["In this context, diversity studies in neutral, or assumedly neutral, regions of the genome-such as the Y chromosome (Underhill et al. 2000; Hammer et al. 2001; Jobling and Tyler-Smith 2003) , mtDNA (Wallace et al. 1999; Ingman et al. 2000; Mishmar et al. 2003) , Alu insertions (Watkins et al. 2001) , as well as some autosomal genes (Stephens et al. 2001; Akey et al. 2004 )-showed that African populations are genetically more diverse than are non-Africans, an observation generally interpreted as a support of the \"Out of Africa\" model for the origin of modern humans (Lewin 1987) .", [["Y chromosome", "ANATOMY", 103, 115], ["chromosome", "CELLULAR_COMPONENT", 105, 115], ["mtDNA", "CELLULAR_COMPONENT", 192, 197], ["humans", "ORGANISM", 564, 570], ["Y chromosome", "DNA", 103, 115], ["Alu insertions", "DNA", 263, 277], ["autosomal genes", "DNA", 318, 333], ["humans", "SPECIES", 564, 570], ["humans", "SPECIES", 564, 570], ["diversity studies", "TEST", 17, 34], ["Alu insertions", "TREATMENT", 263, 277], ["African populations", "PROBLEM", 388, 407]]], ["For CD209L, even if we observed 1.5 times more segregating sites in African than in non-African populations, as indicated by the higher value found in Africa, similar values of nucleotide v w diversity were detected in the three groups, with Europeans presenting even higher p values than do Africans.", [["nucleotide", "CHEMICAL", 177, 187], ["CD209L", "GENE_OR_GENE_PRODUCT", 4, 10], ["nucleotide v w", "GENE_OR_GENE_PRODUCT", 177, 191], ["CD209L", "PROTEIN", 4, 10], ["CD209L", "TREATMENT", 4, 10], ["nucleotide v w diversity", "PROBLEM", 177, 201]]], ["This unusual scenario, which is at odds with neutral expectations, has already been described for other regions of the genome, such as the b-globin gene and the 5 cis-regulatory region of CCR5, for which the action of balancing selection has been convincingly proposed (Harding et al. 1997; Bamshad et al. 2002) .", [["genome", "CELLULAR_COMPONENT", 119, 125], ["b-globin", "GENE_OR_GENE_PRODUCT", 139, 147], ["CCR5", "GENE_OR_GENE_PRODUCT", 188, 192], ["b-globin gene", "DNA", 139, 152], ["5 cis-regulatory region", "DNA", 161, 184], ["CCR5", "PROTEIN", 188, 192], ["balancing selection", "TREATMENT", 218, 237], ["genome", "OBSERVATION", 119, 125], ["CCR5", "ANATOMY", 188, 192]]], ["Second, balancing selection tends to increase within-population diversity while decreasing F ST , compared with neutrally evolving loci (Cavalli-Sforza 1966; Harpending and Rogers 2000; Akey et al. 2002; Bamshad and Wooding 2003; Cavalli-Sforza and Feldman 2003) .", [["F ST", "DNA", 91, 95], ["decreasing F ST", "PROBLEM", 80, 95], ["increase", "OBSERVATION_MODIFIER", 37, 45]]], ["Indeed, our data are compatible with these predictions, since the 5% F ST value observed for CD209L is threefold lower than that estimated for CD209 (15%) and is similar to that found, for example, for the bitter-taste receptor gene (5.6%), for which there is compelling evidence of balancing-selection action (Wooding et al. 2004) .", [["CD209L", "GENE_OR_GENE_PRODUCT", 93, 99], ["CD209", "GENE_OR_GENE_PRODUCT", 143, 148], ["bitter-taste receptor", "GENE_OR_GENE_PRODUCT", 206, 227], ["CD209L", "PROTEIN", 93, 99], ["CD209", "PROTEIN", 143, 148], ["bitter-taste receptor gene", "DNA", 206, 232], ["the 5% F ST value", "TEST", 62, 79], ["CD209L", "TEST", 93, 99], ["CD209", "TEST", 143, 148]]], ["Third, results of our Tajima's D analysis were significantly positive for European and East Asian populations, because of the skew of CD209L frequency spectrum toward an excess of intermediate-frequency alleles (table 2), a pattern that further supports the action of balancing selection.", [["CD209L", "GENE_OR_GENE_PRODUCT", 134, 140], ["CD209L", "PROTEIN", 134, 140], ["our Tajima's D analysis", "TEST", 18, 41], ["balancing selection", "TREATMENT", 268, 287]]], ["However, since the null model used to assess significance makes unrealistic assumptions about past population demography (i.e., constant population sizes), the rejection of the standard neutral model cannot be interpreted as unambiguous evidence of selection.", [["the null model", "TEST", 15, 29], ["sizes", "OBSERVATION_MODIFIER", 148, 153], ["rejection", "OBSERVATION", 160, 169]]], ["Indeed, the observation that only non-African populations showed a significant departure from neutrality raises the question of whether these patterns could have resulted instead from the bottleneck that occurred during the Out of Africa exodus.", [["a significant departure from neutrality", "PROBLEM", 65, 104], ["significant", "OBSERVATION_MODIFIER", 67, 78]]], ["Our values remained significant for CD209L, which therefore reinforces the idea that the pattern observed is unlikely to be the sole result of demography.CD209L: Relaxation of the Functional Constraint or Balancing Selection?Last, if the patterns of variation in CD209L represent the molecular signature of balancing selection, at least in non-Africans, then a functional target of such selective regime is needed.", [["CD209L", "GENE_OR_GENE_PRODUCT", 36, 42], ["CD209L", "GENE_OR_GENE_PRODUCT", 263, 269], ["CD209L", "PROTEIN", 36, 42], ["CD209L", "PROTEIN", 263, 269], ["Our values", "TEST", 0, 10], ["CD209L", "PROBLEM", 36, 42], ["such selective regime", "TREATMENT", 382, 403], ["balancing selection", "OBSERVATION", 307, 326]]], ["In this context, the neck region constitutes an excellent candidate, since it plays a major mediating role in the orientation and flexibility of the carbohydrate-recognition domain.", [["neck region", "ANATOMY", 21, 32], ["carbohydrate", "CHEMICAL", 149, 161], ["neck", "ORGAN", 21, 25], ["carbohydrate-recognition domain", "PROTEIN", 149, 180], ["neck", "ANATOMY", 21, 25], ["excellent", "OBSERVATION", 48, 57]]], ["Since this domain is directly involved in pathogen recognition, neck-region length variation has important consequences for the pathogen-binding properties of these lectins (Mitchell et al. 2001; Bernhard et al. 2004; Feinberg et al. 2005) .", [["neck", "ANATOMY", 64, 68], ["neck", "ANATOMY", 64, 68]]], ["In perfect agreement with the results of our sequence-based data set, higher diversity in repeat variation was observed in the neck region among non-African populations (Native Americans excepted).", [["neck region", "ANATOMY", 127, 138], ["neck", "ORGAN", 127, 131], ["our sequence", "TEST", 41, 53], ["repeat variation", "TEST", 90, 106], ["higher", "OBSERVATION_MODIFIER", 70, 76], ["diversity", "OBSERVATION_MODIFIER", 77, 86], ["neck", "ANATOMY", 127, 131]]], ["Out of Africa, at least three alleles account for most population diversity, whereas, in Africa, the 6-and 7-repeat alleles alone account for 96% of the global variability ( fig. 5B ).", [["6-and 7-repeat alleles", "DNA", 101, 123]]], ["Again, the higher diversity observed out of Africa could be due to a higher level of relaxation of the functional constraint of the neck region in non-African compared with African populations, which would lead to a random accumulation of proteins with varying neck-region lengths among non-Africans.", [["neck region", "ANATOMY", 132, 143], ["neck", "ANATOMY", 261, 265], ["neck", "ORGAN", 132, 136], ["the higher diversity", "PROBLEM", 7, 27], ["a random accumulation of proteins", "PROBLEM", 214, 247], ["varying neck-region lengths", "PROBLEM", 253, 280], ["higher", "OBSERVATION_MODIFIER", 11, 17], ["diversity", "OBSERVATION_MODIFIER", 18, 27], ["relaxation", "OBSERVATION", 85, 95], ["functional constraint", "OBSERVATION", 103, 124], ["neck", "ANATOMY", 132, 136], ["region", "ANATOMY_MODIFIER", 137, 143], ["neck", "ANATOMY", 261, 265]]], ["Conversely, these patterns could also be explained by the action of balancing selection in non-Africans and could therefore point to the neck region as the functional target of such selective regime.", [["neck region", "ANATOMY", 137, 148], ["neck", "ORGAN", 137, 141], ["balancing selection", "TREATMENT", 68, 87], ["such selective regime", "TREATMENT", 177, 198], ["neck", "ANATOMY", 137, 141], ["region", "ANATOMY_MODIFIER", 142, 148]]], ["To evaluate the plausibility of these two conflicting scenarios, we compared the variation in the CD209L neck region with that inferred from 377 neutral autosomal microsatellites typed elsewhere for the same population panel .", [["CD209L neck region", "ANATOMY", 98, 116], ["CD209L neck region", "DNA", 98, 116], ["neutral autosomal microsatellites", "PROBLEM", 145, 178], ["the same population panel", "TEST", 199, 224], ["neck", "ANATOMY", 105, 109]]], ["We reasoned that if CD209L diversity has been shaped only by demography (i.e., bottleneck out of Africa), the distribution of genetic variance at different hierarchical levels should be comparable to that inferred through the neutral markers.", [["CD209L", "GENE_OR_GENE_PRODUCT", 20, 26], ["CD209L", "PROTEIN", 20, 26], ["CD209L diversity", "PROBLEM", 20, 36], ["genetic variance", "PROBLEM", 126, 142], ["shaped", "OBSERVATION_MODIFIER", 46, 52]]], ["On the other hand, if selection has driven the CD209L neckregion diversity, population-genetics distances would be influenced accordingly and would therefore differ from neutral expectations.", [["CD209L", "GENE_OR_GENE_PRODUCT", 47, 53], ["CD209L", "DNA", 47, 53]]], ["Indeed, the AMOVA values inferred for CD209L fell systematically outside the 95% CI defined for the microsatellite data set (table 6).", [["CD209L", "GENE_OR_GENE_PRODUCT", 38, 44], ["AMOVA", "DNA", 12, 17], ["CD209L", "PROTEIN", 38, 44], ["the AMOVA values", "TEST", 8, 24], ["the microsatellite data", "TEST", 96, 119]]], ["We observed that populations within Europe, Asia, the Middle East, and Oceania exhibited lower-than-expected diversity among populations within the same region.", [["populations", "OBSERVATION_MODIFIER", 17, 28], ["Middle", "ANATOMY_MODIFIER", 54, 60], ["lower", "OBSERVATION_MODIFIER", 89, 94], ["diversity", "OBSERVATION", 109, 118]]], ["A reduction of genetic distances between populations is expected under balancing selection; therefore, the results from the CD209L neck region favor, once again, the action of this selective regime in most non-African populations, in detriment of the neutral hypothesis.", [["CD209L neck region", "ANATOMY", 124, 142], ["A reduction of genetic distances between populations", "PROBLEM", 0, 52], ["this selective regime", "TREATMENT", 176, 197], ["the neutral hypothesis", "PROBLEM", 247, 269], ["reduction", "OBSERVATION_MODIFIER", 2, 11], ["neutral hypothesis", "OBSERVATION", 251, 269]]], ["One may argue that the differences in the proportions of genetic variance between our data and those of could be due to differences in the pace of mutation between microsatellite loci and our neck repeated region that could be considered a \"coding minisatellite.\"", [["neck", "ANATOMY", 192, 196], ["neck", "ORGANISM_SUBDIVISION", 192, 196], ["microsatellite loci", "DNA", 164, 183], ["coding minisatellite", "DNA", 241, 261], ["our data", "TEST", 82, 90], ["mutation between microsatellite loci and our neck repeated region", "PROBLEM", 147, 212], ["neck", "ANATOMY", 192, 196]]], ["However, under neutrality, differences in mutation rate should have a similar and proportional effect in all population comparisons and should influence all values with a similar tendency (i.e., higher or lower values).", [["mutation rate", "TEST", 42, 55], ["a similar tendency", "PROBLEM", 169, 187]]], ["Indeed, this is not the case: populations within Europe, the Middle East, Central/South Asia, East Asia, and Oceania turned out to be genetically closer than expected, whereas populations within Africa and the Americas exhibited the opposite pattern (table 6) , which makes it highly unlikely that mutation-rate differences influenced our conclusions.CD209L: Relaxation of the Functional Constraint or Balancing Selection?Taken together, the integration of the results from levels of nucleotide and amino acid diversity, neutrality tests, population-genetics distances, and neck-region length variation in CD209 and CD209L clearly points to a situation in which CD209 has been under a strong selective constraint that prevents accumulation of any of amino acid changes over time, whereas CD209L variability has most likely been driven by the action of balancing selection, at least in non-African populations.The Footprints of Ancestral Population DiversityIn apparent dichotomy with the strong selective constraint described for CD209, we observed an unusual excess of diversity of 35 fixed differences separating the two basal branches of the gene tree ( fig. 6 ).", [["neck-region", "ANATOMY", 574, 585], ["nucleotide", "CHEMICAL", 484, 494], ["amino acid", "CHEMICAL", 499, 509], ["amino acid", "CHEMICAL", 750, 760], ["nucleotide", "CHEMICAL", 484, 494], ["amino acid", "CHEMICAL", 499, 509], ["amino acid", "CHEMICAL", 750, 760], ["amino acid", "AMINO_ACID", 499, 509], ["CD209", "GENE_OR_GENE_PRODUCT", 606, 611], ["CD209L", "GENE_OR_GENE_PRODUCT", 616, 622], ["CD209", "GENE_OR_GENE_PRODUCT", 662, 667], ["amino acid", "AMINO_ACID", 750, 760], ["CD209L", "GENE_OR_GENE_PRODUCT", 788, 794], ["CD209", "GENE_OR_GENE_PRODUCT", 1030, 1035], ["CD209", "PROTEIN", 606, 611], ["CD209L", "PROTEIN", 616, 622], ["CD209", "PROTEIN", 662, 667], ["CD209L", "PROTEIN", 788, 794], ["CD209", "PROTEIN", 1030, 1035], ["mutation-rate differences", "PROBLEM", 298, 323], ["nucleotide and amino acid diversity", "TREATMENT", 484, 519], ["neutrality tests", "TEST", 521, 537], ["neck-region length variation", "PROBLEM", 574, 602], ["CD209", "TEST", 606, 611], ["amino acid changes", "PROBLEM", 750, 768], ["balancing selection", "TREATMENT", 852, 871], ["Middle", "ANATOMY_MODIFIER", 61, 67], ["neck", "ANATOMY", 574, 578], ["amino acid", "OBSERVATION", 750, 760], ["most likely", "UNCERTAINTY", 811, 822], ["Footprints", "OBSERVATION_MODIFIER", 913, 923], ["Ancestral", "OBSERVATION_MODIFIER", 927, 936], ["Population Diversity", "OBSERVATION", 937, 957], ["two", "ANATOMY_MODIFIER", 1119, 1122], ["basal", "ANATOMY_MODIFIER", 1123, 1128], ["branches", "ANATOMY_MODIFIER", 1129, 1137], ["gene tree", "OBSERVATION", 1145, 1154]]], ["In addition, we estimated a T MRCA of MYA, a time that 2.8 \u202b\u05e2\u202c 0.22 places the most recent common ancestor of CD209 back in the Pliocene epoch, before the estimated time for the origins of the genus Homo \u223c1.9 MYA (Wood 1996; Wood and Collard 1999) .", [["CD209", "GENE_OR_GENE_PRODUCT", 110, 115], ["Pliocene epoch", "OBSERVATION", 128, 142], ["origins", "ANATOMY_MODIFIER", 178, 185], ["genus Homo", "ANATOMY", 193, 203]]], ["A number of studies have already reported loci that present unusually deep coalescent times (Harris and Hey 1999; Zhao et al. 2000; Webster et al. 2003; Garrigan et al. 2005a Garrigan et al. , 2005b , but our estimation for CD209 remains one of the deepest T MRCA values yet reported (Excoffier 2002) .", [["CD209", "PROTEIN", 224, 229], ["our estimation", "TEST", 205, 219]]], ["The probability of finding such a deep coalescence time under a scenario of a random-mating population was estimated, through a coalescent process (Laval and Excoffier 2004) , to be very low ( ) (see fig. 7 ).", [["a deep coalescence time", "PROBLEM", 32, 55], ["a coalescent process", "PROBLEM", 126, 146], ["deep", "OBSERVATION_MODIFIER", 34, 38], ["coalescence", "OBSERVATION_MODIFIER", 39, 50], ["coalescent", "OBSERVATION_MODIFIER", 128, 138]]], ["In addition to the P p .018 unexpected antiquity of the CD209 locus, we observed a peculiar tree topology made of two highly divergent and frequency-unbalanced lineages, cluster A embracing only 2 internal haplotypes and cluster B comprising the remaining 23 ( fig. 6 ).The Footprints of Ancestral Population DiversityDifferent hypotheses can account for such elongated and divergent haplotype patterns.", [["CD209", "GENE_OR_GENE_PRODUCT", 56, 61], ["P p .018", "DNA", 19, 27], ["CD209 locus", "DNA", 56, 67], ["unbalanced lineages", "PROBLEM", 149, 168], ["Ancestral Population DiversityDifferent hypotheses", "TREATMENT", 288, 338], ["such elongated and divergent haplotype patterns", "PROBLEM", 355, 402], ["Footprints", "OBSERVATION_MODIFIER", 274, 284], ["Ancestral Population", "OBSERVATION", 288, 308]]], ["Indeed, the high levels of nucleotide identity between CD209 and CD209L could have led to gene conversion between the two genes, an event that would explain the outlier position of cluster A in the context of CD209 phylogeny.", [["nucleotide", "CHEMICAL", 27, 37], ["nucleotide", "CHEMICAL", 27, 37], ["CD209", "GENE_OR_GENE_PRODUCT", 55, 60], ["CD209L", "GENE_OR_GENE_PRODUCT", 65, 71], ["CD209", "GENE_OR_GENE_PRODUCT", 209, 214], ["CD209", "DNA", 55, 60], ["CD209L", "DNA", 65, 71], ["CD209 phylogeny", "DNA", 209, 224]]], ["We reasoned that if gene conversion has occurred, we expect that the derived alleles distinguishing clusters A and B in CD209 would correspond to the allelic state observed in their homologous positions in CD209L.", [["B", "GENE_OR_GENE_PRODUCT", 115, 116], ["CD209", "GENE_OR_GENE_PRODUCT", 120, 125], ["CD209L", "GENE_OR_GENE_PRODUCT", 206, 212], ["alleles", "DNA", 77, 84], ["CD209", "DNA", 120, 125], ["CD209L", "DNA", 206, 212], ["gene conversion", "PROBLEM", 20, 35], ["the allelic state", "PROBLEM", 146, 163]]], ["Of all positions, only four fit this criterion.", [["positions", "OBSERVATION_MODIFIER", 7, 16]]], ["In addition, these positions were not physically clustered, which therefore excludes a major gene-conversion event as the explanation of the divergent CD209 phylogeny.The Footprints of Ancestral Population DiversityTwo other circumstances may be responsible for the topology and the time depth of the CD209 gene tree: long-standing balancing selection or ancient population structure, with Africa, in both cases, being the arena of such events (i.e., cluster A is restricted to Africa).", [["CD209", "GENE_OR_GENE_PRODUCT", 151, 156], ["CD209", "GENE_OR_GENE_PRODUCT", 301, 306], ["CD209", "DNA", 151, 156], ["CD209 gene tree", "DNA", 301, 316], ["Ancestral Population Diversity", "TREATMENT", 185, 215], ["long-standing balancing selection", "TREATMENT", 318, 351], ["Africa", "PROBLEM", 390, 396], ["such events", "PROBLEM", 432, 443], ["Footprints", "OBSERVATION_MODIFIER", 171, 181]]], ["First, under this selective regime, one would expect that Tajima's D test would also point in this direction by yielding significantly positive values, which is not the case (table 2) .", [["this selective regime", "TREATMENT", 13, 34], ["Tajima's D test", "TEST", 58, 73], ["significantly positive values", "PROBLEM", 121, 150]]], ["Second, such a long-standing balancing selection in Africa would have entailed a number of recombinant haplotypes between clusters A and B, which, again, is not the case, as illustrated by the high LD levels at CD209 (fig. 3) .", [["B", "GENE_OR_GENE_PRODUCT", 137, 138], ["CD209", "PROTEIN", 211, 216], ["a long-standing balancing selection", "TREATMENT", 13, 48]]], ["Third, a claim of balancing selection at this locus must imply a functional difference between the two balanced alleles.", [["locus", "CELLULAR_COMPONENT", 46, 51], ["alleles", "DNA", 112, 119], ["balancing selection", "TREATMENT", 18, 37]]], ["Indeed, three nonsynonymous mutations, situated in the neck region, separate cluster A and B, and they could correspond to the alleles under selection.", [["neck region", "ANATOMY", 55, 66], ["B", "GENE_OR_GENE_PRODUCT", 91, 92], ["neck region", "DNA", 55, 66], ["alleles", "DNA", 127, 134], ["three nonsynonymous mutations", "PROBLEM", 8, 37], ["nonsynonymous mutations", "OBSERVATION", 14, 37], ["neck", "ANATOMY", 55, 59], ["region", "ANATOMY_MODIFIER", 60, 66], ["separate", "OBSERVATION_MODIFIER", 68, 76], ["cluster", "OBSERVATION_MODIFIER", 77, 84]]], ["But, if the neck region is the target of selection, it is more likely that the balanced alleles would correspond to different numbers of repeats rather than punctual nucleotide variation within each track, as observed for CD209L and suggested by functional studies (Bernhard et al. 2004; Feinberg et al. 2005) .", [["neck region", "ANATOMY", 12, 23], ["nucleotide", "CHEMICAL", 166, 176], ["nucleotide", "CHEMICAL", 166, 176], ["neck", "ORGAN", 12, 16], ["CD209L", "GENE_OR_GENE_PRODUCT", 222, 228], ["CD209L", "PROTEIN", 222, 228], ["the balanced alleles", "PROBLEM", 75, 95], ["punctual nucleotide variation", "PROBLEM", 157, 186], ["neck", "ANATOMY", 12, 16], ["more likely", "UNCERTAINTY", 58, 69]]], ["Since no variation in the number of repeats was detected between both clusters, we predict that there are no major functional differences between the two lineages.", [["no", "UNCERTAINTY", 6, 8], ["variation", "OBSERVATION_MODIFIER", 9, 18], ["no", "UNCERTAINTY", 106, 108]]], ["Taken together, maintenance of ancient lineages by balancing selection does not seem to be responsible for the observed haplotype divergence.", [["ancient lineages", "TREATMENT", 31, 47], ["the observed haplotype divergence", "PROBLEM", 107, 140]]], ["In this view, the patterns observed are best explained by an ancestral population structure on the African continent.", [["an ancestral population structure", "PROBLEM", 58, 91], ["ancestral", "OBSERVATION_MODIFIER", 61, 70], ["population", "OBSERVATION", 71, 81]]], ["Indeed, several studies have already proposed that African populations must have been more strongly subdivided and isolated than non-African ones (Harris and Hey 1999; Labuda et al. 2000; Excoffier 2002; Goldstein and Chikhi 2002; Harding and McVean 2004; Satta and Takahata 2004; Garrigan et al. 2005a) .", [["several studies", "TEST", 8, 23], ["African populations", "PROBLEM", 51, 70]]], ["In particular, a recent study of the Xp21.1 locus presented convincing statistical evidence that supports the hypothesis that our species does not descend from a single, historically panmictic population (Garrigan et al. 2005a ).", [["Xp21.1", "GENE_OR_GENE_PRODUCT", 37, 43], ["Xp21.1 locus", "DNA", 37, 49], ["a recent study", "TEST", 15, 29]]], ["The divergent haplotype pattern observed at the Xp21.1 locus prompted those authors to explain their data under the isolation-and-admixture (IAA) model and/or a metapopulation model (Harding and McVean 2004; Wakeley 2004) .", [["Xp21.1 locus", "DNA", 48, 60], ["The divergent haplotype pattern", "PROBLEM", 0, 31], ["the isolation", "TEST", 112, 125], ["divergent", "OBSERVATION_MODIFIER", 4, 13], ["haplotype pattern", "OBSERVATION", 14, 31]]], ["Indeed, as observed for CD209, under an IAA model, the two basal branches are expected to be longer than those under a Wright-Fisher model, depending on the length of time subpopulations spent in isolation.", [["basal branches", "ANATOMY", 59, 73], ["IAA", "CHEMICAL", 40, 43], ["CD209", "GENE_OR_GENE_PRODUCT", 24, 29], ["basal branches", "MULTI-TISSUE_STRUCTURE", 59, 73], ["CD209", "PROTEIN", 24, 29], ["an IAA model", "TREATMENT", 37, 49], ["basal", "ANATOMY_MODIFIER", 59, 64], ["branches", "ANATOMY_MODIFIER", 65, 73]]], ["The extent to which the IAA model fits the data depends on the number of mutations, referred as to \"congruent sites,\" occurring in the two basal branches of the genealogy.", [["IAA", "CHEMICAL", 24, 27], ["IAA", "CHEMICAL", 24, 27], ["basal", "ANATOMY_MODIFIER", 139, 144], ["branches", "ANATOMY_MODIFIER", 145, 153], ["genealogy", "OBSERVATION", 161, 170]]], ["For Xp21.1, 10 congruent sites over 24 polymorphisms were observed (i.e., \u223c42% of the total number of sites).", [["Xp21.1", "GENE_OR_GENE_PRODUCT", 4, 10], ["Xp21.1", "DNA", 4, 10]]], ["We applied the same approach to CD209 and obtained a very similar percentage of \u223c45%, in good accordance with the IAA model.", [["IAA", "CHEMICAL", 114, 117], ["IAA", "CHEMICAL", 114, 117], ["CD209", "CANCER", 32, 37], ["IAA", "SIMPLE_CHEMICAL", 114, 117], ["CD209", "CELL_LINE", 32, 37]]], ["Our observations, together with a number of autosomal diversity studies, show that modern human diversity appears to have kept genetic traces of admixture among archaic hominid populations.", [["human", "ORGANISM", 90, 95], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 90, 95], ["autosomal diversity studies", "TEST", 44, 71], ["modern human diversity", "PROBLEM", 83, 105], ["archaic hominid", "OBSERVATION", 161, 176]]], ["However, a number of questions remain unanswered, such as the time when these admixture events occurred (i.e., before or after the appearance of anatomically modern humans), the precise quantitative contribution of ancient genetic material to our modern gene pool, and the geographic provenance of these genetic vestiges.ConclusionsThe need of continuous evolution for both the human host and the pathogens is predicted by the Red Queen hypothesis (Van Valen 1973; Bell 1982) , in reference to the remark of the Red Queen to Alice in Through the Looking Glass (Carroll 1872) : \"Now, here, you see, it takes all the running you can do, to keep in the same place.\"", [["humans", "ORGANISM", 165, 171], ["human", "ORGANISM", 378, 383], ["humans", "SPECIES", 165, 171], ["human", "SPECIES", 378, 383], ["human", "SPECIES", 378, 383], ["ancient genetic material", "PROBLEM", 215, 239]]], ["This metaphor provides a conceptual framework for understanding how interactions between the two species lead to constant natural selection for adaptation and counteradaptation.", [["counteradaptation", "TREATMENT", 159, 176]]], ["In this context, one feature exploited by the host immunity genes to increase their defense potential is gene duplication by retention, through conservation of one duplicate, of the currently useful function of the encoded protein, while its twin is liberated to mutate and possibly acquire novel functions (Ohno 1970; Trowsdale and Parham 2004) .", [["host immunity genes", "DNA", 46, 65], ["encoded protein", "PROTEIN", 215, 230], ["gene duplication", "PROBLEM", 105, 121], ["gene duplication", "OBSERVATION", 105, 121], ["retention", "OBSERVATION_MODIFIER", 125, 134]]], ["The lectins CD209 and CD209L represent a prototypic model of a duplicated progeny of ancestral genes that interact with a vast spectrum of pathogens.", [["CD209", "GENE_OR_GENE_PRODUCT", 12, 17], ["CD209L", "GENE_OR_GENE_PRODUCT", 22, 28], ["lectins", "PROTEIN", 4, 11], ["CD209", "PROTEIN", 12, 17], ["CD209L", "PROTEIN", 22, 28], ["ancestral genes", "DNA", 85, 100], ["The lectins CD209", "TEST", 0, 17], ["pathogens", "PROBLEM", 139, 148], ["pathogens", "OBSERVATION", 139, 148]]], ["Our results clearly indicate that these duplicated genes have evolved, and might still evolve, under completely different evolutionary pressures.", [["pressures", "OBSERVATION_MODIFIER", 135, 144]]], ["Whereas one, CD209, shows signals of strong conservation, its paralogue, CD209L, exhibits an excess of sequence diversity compatible with the action of balancing selection.", [["CD209", "GENE_OR_GENE_PRODUCT", 13, 18], ["CD209L", "GENE_OR_GENE_PRODUCT", 73, 79], ["CD209", "PROTEIN", 13, 18], ["CD209L", "PROTEIN", 73, 79], ["an excess of sequence diversity", "PROBLEM", 90, 121], ["balancing selection", "TREATMENT", 152, 171], ["strong conservation", "OBSERVATION", 37, 56]]], ["In addition, the strong contrast observed in length variation of the neck region between the two genes may have important consequences in medical genetics.", [["neck region", "ANATOMY", 69, 80], ["neck", "ORGAN", 69, 73], ["length", "OBSERVATION_MODIFIER", 45, 51], ["neck", "ANATOMY", 69, 73], ["region", "ANATOMY_MODIFIER", 74, 80]]], ["In this context, association studies are now needed that correlate length variation of the neck region and susceptibility to infectious diseases whose etiological agents are known to interact with one (or both) of these lectins.ConclusionsMore generally, our study has revealed that even a short segment of the human genome can help uncover an extraordinarily complex evolutionary history, including different pathogen pressures on host immunity genes, as well as traces of ancient population structure in the African continent.", [["neck region", "ANATOMY", 91, 102], ["infectious diseases", "DISEASE", 125, 144], ["neck", "ORGAN", 91, 95], ["lectins", "GENE_OR_GENE_PRODUCT", 220, 227], ["human", "ORGANISM", 311, 316], ["lectins", "PROTEIN", 220, 227], ["human genome", "DNA", 311, 323], ["host immunity genes", "DNA", 432, 451], ["human", "SPECIES", 311, 316], ["human", "SPECIES", 311, 316], ["association studies", "TEST", 17, 36], ["length variation of the neck region", "PROBLEM", 67, 102], ["infectious diseases", "PROBLEM", 125, 144], ["our study", "TEST", 255, 264], ["a short segment of the human genome", "PROBLEM", 288, 323], ["different pathogen pressures", "PROBLEM", 400, 428], ["neck", "ANATOMY", 91, 95], ["infectious", "OBSERVATION_MODIFIER", 125, 135], ["human genome", "OBSERVATION", 311, 323], ["extraordinarily", "OBSERVATION_MODIFIER", 344, 359], ["pathogen", "OBSERVATION_MODIFIER", 410, 418], ["pressures", "OBSERVATION_MODIFIER", 419, 428], ["ancient", "OBSERVATION_MODIFIER", 474, 481], ["population", "OBSERVATION", 482, 492]]], ["The coming years will certainly bring unprecedented large data sets of sequence diversity, genomewide and populationwide, with each genomic region possibly revealing a different aspect of human history.", [["human", "ORGANISM", 188, 193], ["human", "SPECIES", 188, 193], ["human", "SPECIES", 188, 193]]], ["The integration of all these apparently independent pieces of the same reality will provide us with a much broader and more realistic view of the demographic history of the human species, as well as of human adaptation to the different environmental conditions imposed not only by pathogens but also by other major factors such as climate and nutritional resources.", [["human", "ORGANISM", 173, 178], ["human", "ORGANISM", 202, 207], ["human", "SPECIES", 173, 178], ["human", "SPECIES", 202, 207], ["human", "SPECIES", 173, 178], ["human", "SPECIES", 202, 207], ["the human species", "PROBLEM", 169, 186]]]], "6a473d4601cf6849cff387c5e1c0081f20e933e5": [["ABSTRACTAcute kidney injury (AKI) has been reported to be associated with excess risks of death, kidney disease progression and cardiovascular events although previous studies have important limitations.", [["kidney", "ANATOMY", 14, 20], ["kidney", "ANATOMY", 97, 103], ["cardiovascular", "ANATOMY", 128, 142], ["ABSTRACTAcute kidney injury", "DISEASE", 0, 27], ["AKI", "DISEASE", 29, 32], ["death", "DISEASE", 90, 95], ["kidney disease", "DISEASE", 97, 111], ["kidney", "ORGAN", 14, 20], ["kidney", "ORGAN", 97, 103], ["cardiovascular", "ANATOMICAL_SYSTEM", 128, 142], ["ABSTRACTAcute kidney injury", "PROBLEM", 0, 27], ["AKI", "PROBLEM", 29, 32], ["death", "PROBLEM", 90, 95], ["kidney disease progression", "PROBLEM", 97, 123], ["cardiovascular events", "PROBLEM", 128, 149], ["previous studies", "TEST", 159, 175], ["kidney", "ANATOMY", 14, 20], ["injury", "OBSERVATION", 21, 27], ["AKI", "OBSERVATION", 29, 32], ["kidney", "ANATOMY", 97, 103], ["disease", "OBSERVATION", 104, 111]]], ["To further examine this, we prospectively studied adults from four clinical centers surviving three months and more after hospitalization with or without AKI who were matched on center, pre-admission CKD status, and an integrated priority score based on age, prior cardiovascular disease or diabetes mellitus, preadmission estimated glomerular filtration rate (eGFR) and treatment in the intensive care unit during the index hospitalization between December 2009-February 2015, with follow-up through November 2018.", [["cardiovascular", "ANATOMY", 265, 279], ["glomerular", "ANATOMY", 333, 343], ["AKI", "DISEASE", 154, 157], ["CKD", "DISEASE", 200, 203], ["cardiovascular disease", "DISEASE", 265, 287], ["diabetes mellitus", "DISEASE", 291, 308], ["adults", "ORGANISM", 50, 56], ["glomerular", "TISSUE", 333, 343], ["AKI", "PROBLEM", 154, 157], ["pre-admission CKD status", "PROBLEM", 186, 210], ["prior cardiovascular disease", "PROBLEM", 259, 287], ["diabetes mellitus", "PROBLEM", 291, 308], ["glomerular filtration rate", "TEST", 333, 359], ["treatment", "TREATMENT", 371, 380], ["cardiovascular", "ANATOMY", 265, 279], ["disease", "OBSERVATION", 280, 287]]], ["All participants had assessments of kidney function before (eGFR) and at three months and annually (eGFR and proteinuria) after the index hospitalization.", [["kidney", "ANATOMY", 36, 42], ["proteinuria", "DISEASE", 109, 120], ["kidney", "ORGAN", 36, 42], ["participants", "SPECIES", 4, 16], ["eGFR", "TEST", 60, 64], ["eGFR", "TEST", 100, 104], ["proteinuria", "PROBLEM", 109, 120], ["the index hospitalization", "TREATMENT", 128, 153], ["kidney", "ANATOMY", 36, 42], ["proteinuria", "OBSERVATION", 109, 120]]], ["Associations of AKI with outcomes were examined after accounting for pre-admission and three-month post-discharge factors.", [["AKI", "DISEASE", 16, 19], ["AKI", "PROBLEM", 16, 19], ["AKI", "OBSERVATION", 16, 19]]], ["Among 769 AKI (73% Stage 1, 14% Stage 2, 13% Stage 3) and 769 matched non-AKI adults, AKI was associated with higher adjusted rates of incident CKD (adjusted hazard ratio 3.98, 95% confidence interval 2.51-6.31), CKD progression (2.37,1.", [["AKI", "DISEASE", 10, 13], ["AKI", "DISEASE", 86, 89], ["CKD", "DISEASE", 144, 147], ["CKD", "DISEASE", 213, 216], ["AKI", "TEST", 10, 13], ["Stage", "TEST", 19, 24], ["Stage", "TEST", 32, 37], ["AKI", "PROBLEM", 86, 89], ["incident CKD", "PROBLEM", 135, 147], ["hazard ratio", "TEST", 158, 170], ["interval", "TEST", 192, 200], ["CKD progression", "PROBLEM", 213, 228], ["AKI", "OBSERVATION", 10, 13], ["AKI", "OBSERVATION", 86, 89], ["CKD", "OBSERVATION_MODIFIER", 213, 216], ["progression", "OBSERVATION_MODIFIER", 217, 228]]], ["28-4.39) , heart failure events (1.68, 1.", [["heart", "ANATOMY", 11, 16], ["heart failure", "DISEASE", 11, 24], ["heart", "ORGAN", 11, 16], ["heart failure events", "PROBLEM", 11, 31], ["heart", "ANATOMY", 11, 16], ["failure", "OBSERVATION", 17, 24]]], ["22-2.31 ) and allcause death (1.78, 1.24-2.56).", [["death", "DISEASE", 23, 28]]], ["AKI was not associated with major atherosclerotic cardiovascular events in multivariable analysis (0.95, 0.70-1.28).", [["cardiovascular", "ANATOMY", 50, 64], ["AKI", "DISEASE", 0, 3], ["atherosclerotic cardiovascular events", "DISEASE", 34, 71], ["cardiovascular", "ANATOMICAL_SYSTEM", 50, 64], ["AKI", "PROBLEM", 0, 3], ["major atherosclerotic cardiovascular events", "PROBLEM", 28, 71], ["multivariable analysis", "TEST", 75, 97], ["not associated with", "UNCERTAINTY", 8, 27], ["atherosclerotic", "OBSERVATION_MODIFIER", 34, 49], ["cardiovascular", "ANATOMY", 50, 64]]], ["After accounting for degree of kidney function recovery and proteinuria at three months after discharge, the associations of AKI with heart failure (1.13, 0.80-1.61) and death (1.29, 0.84-1.98) were attenuated and no longer significant.", [["kidney", "ANATOMY", 31, 37], ["heart", "ANATOMY", 134, 139], ["proteinuria", "DISEASE", 60, 71], ["AKI", "DISEASE", 125, 128], ["heart failure", "DISEASE", 134, 147], ["death", "DISEASE", 170, 175], ["kidney", "ORGAN", 31, 37], ["heart", "ORGAN", 134, 139], ["kidney function recovery", "PROBLEM", 31, 55], ["proteinuria", "PROBLEM", 60, 71], ["AKI", "PROBLEM", 125, 128], ["heart failure", "PROBLEM", 134, 147], ["death", "TEST", 170, 175], ["kidney", "ANATOMY", 31, 37], ["function", "OBSERVATION", 38, 46], ["proteinuria", "OBSERVATION", 60, 71], ["AKI", "OBSERVATION", 125, 128], ["heart", "ANATOMY", 134, 139], ["failure", "OBSERVATION", 140, 147], ["no longer", "UNCERTAINTY", 214, 223]]], ["Thus, assessing kidney function recovery and proteinuria status three months after AKI provides important prognostic information for long-term clinical outcomes.INTRODUCTIONAcute kidney injury (AKI) reflects an abrupt decline in kidney function that occurs frequently among hospitalized adults and has been reported to be associated with excess risks of death, kidney disease progression and cardiovascular events.", [["kidney", "ANATOMY", 16, 22], ["kidney", "ANATOMY", 179, 185], ["kidney", "ANATOMY", 229, 235], ["kidney", "ANATOMY", 361, 367], ["cardiovascular", "ANATOMY", 392, 406], ["proteinuria", "DISEASE", 45, 56], ["AKI", "DISEASE", 83, 86], ["kidney injury", "DISEASE", 179, 192], ["AKI", "DISEASE", 194, 197], ["death", "DISEASE", 354, 359], ["kidney disease", "DISEASE", 361, 375], ["kidney", "ORGAN", 16, 22], ["kidney", "ORGAN", 179, 185], ["kidney", "ORGAN", 229, 235], ["kidney", "ORGAN", 361, 367], ["cardiovascular", "ANATOMICAL_SYSTEM", 392, 406], ["assessing kidney function recovery", "TEST", 6, 40], ["proteinuria status", "PROBLEM", 45, 63], ["AKI", "PROBLEM", 83, 86], ["INTRODUCTIONAcute kidney injury", "PROBLEM", 161, 192], ["AKI", "PROBLEM", 194, 197], ["an abrupt decline in kidney function", "PROBLEM", 208, 244], ["death", "PROBLEM", 354, 359], ["kidney disease progression", "PROBLEM", 361, 387], ["cardiovascular events", "PROBLEM", 392, 413], ["kidney", "ANATOMY", 16, 22], ["proteinuria", "OBSERVATION", 45, 56], ["kidney", "ANATOMY", 179, 185], ["injury", "OBSERVATION", 186, 192], ["AKI", "OBSERVATION", 194, 197], ["abrupt", "OBSERVATION_MODIFIER", 211, 217], ["decline", "OBSERVATION", 218, 225], ["kidney", "ANATOMY", 229, 235], ["function", "OBSERVATION", 236, 244], ["kidney", "ANATOMY", 361, 367], ["disease", "OBSERVATION", 368, 375]]], ["[1] [2] [3] [4] [5] [6] [7] [8] The potential importance of AKI has been further highlighted during the coronavirus disease 2019 (COVID-19) pandemic.", [["AKI", "DISEASE", 60, 63], ["coronavirus disease", "DISEASE", 104, 123], ["COVID-19", "CHEMICAL", 130, 138], ["[1] [2] [3] [4] [5] [6] [7] [8]", "SIMPLE_CHEMICAL", 0, 31], ["AKI", "PROBLEM", 60, 63], ["the coronavirus disease", "PROBLEM", 100, 123], ["COVID", "TEST", 130, 135], ["pandemic", "PROBLEM", 140, 148], ["AKI", "OBSERVATION", 60, 63]]], ["9 However, there are important limitations of many existing studies examining clinical complications after AKI.", [["AKI", "DISEASE", 107, 110], ["many existing studies", "TEST", 46, 67], ["clinical complications", "PROBLEM", 78, 100], ["AKI", "PROBLEM", 107, 110]]], ["These include primarily retrospective designs that are susceptible to multiple biases, lack of systematic assessment of kidney function before and after the AKI episode, use of varying definitions of AKI, lack of adjudication of potential cardiovascular events, and inclusion of study populations with limited demographic diversity.", [["kidney", "ANATOMY", 120, 126], ["cardiovascular", "ANATOMY", 239, 253], ["AKI", "DISEASE", 157, 160], ["AKI", "DISEASE", 200, 203], ["kidney", "ORGAN", 120, 126], ["cardiovascular", "ANATOMICAL_SYSTEM", 239, 253], ["systematic assessment", "TEST", 95, 116], ["kidney function", "TEST", 120, 135], ["the AKI episode", "PROBLEM", 153, 168], ["AKI", "PROBLEM", 200, 203], ["potential cardiovascular events", "PROBLEM", 229, 260], ["study populations", "TEST", 279, 296], ["kidney", "ANATOMY", 120, 126], ["AKI", "OBSERVATION", 200, 203]]], ["In addition, hospitalized patients, who may be at increased risk for these events, are not always compared to similar hospitalized patients without AKI.", [["AKI", "DISEASE", 148, 151], ["patients", "ORGANISM", 26, 34], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 131, 139], ["these events", "PROBLEM", 69, 81], ["AKI", "PROBLEM", 148, 151], ["AKI", "OBSERVATION", 148, 151]]], ["Furthermore, the limited number of existing prospective studies have primarily focused on selected populations (e.g., coronary angiography, 10 cardiac surgery, [11] [12] [13] or myocardial infarction 14 ) and have not examined heart failure separately with atherosclerotic cardiovascular events.INTRODUCTIONGiven the global burden of AKI and the need for additional evidence-based clinical guidance, we addressed these issues by prospectively examining the association between AKI with subsequent kidney-related consequences, heart failure, major atherosclerotic cardiovascular events (MACE), and death among matched adults surviving a hospitalization with or without AKI.", [["coronary", "ANATOMY", 118, 126], ["cardiac", "ANATOMY", 143, 150], ["myocardial", "ANATOMY", 178, 188], ["heart", "ANATOMY", 227, 232], ["cardiovascular", "ANATOMY", 273, 287], ["kidney", "ANATOMY", 497, 503], ["heart", "ANATOMY", 526, 531], ["cardiovascular", "ANATOMY", 563, 577], ["myocardial infarction", "DISEASE", 178, 199], ["heart failure", "DISEASE", 227, 240], ["atherosclerotic cardiovascular events", "DISEASE", 257, 294], ["AKI", "DISEASE", 334, 337], ["AKI", "DISEASE", 477, 480], ["heart failure", "DISEASE", 526, 539], ["atherosclerotic cardiovascular events", "DISEASE", 547, 584], ["death", "DISEASE", 597, 602], ["AKI", "DISEASE", 668, 671], ["coronary", "MULTI-TISSUE_STRUCTURE", 118, 126], ["myocardial", "MULTI-TISSUE_STRUCTURE", 178, 188], ["heart", "ORGAN", 227, 232], ["cardiovascular", "ANATOMICAL_SYSTEM", 273, 287], ["kidney", "ORGAN", 497, 503], ["heart", "ORGAN", 526, 531], ["cardiovascular", "ANATOMICAL_SYSTEM", 563, 577], ["existing prospective studies", "TEST", 35, 63], ["coronary angiography", "TEST", 118, 138], ["cardiac surgery", "TREATMENT", 143, 158], ["myocardial infarction", "PROBLEM", 178, 199], ["heart failure", "PROBLEM", 227, 240], ["atherosclerotic cardiovascular events", "PROBLEM", 257, 294], ["AKI", "PROBLEM", 334, 337], ["AKI", "PROBLEM", 477, 480], ["heart failure", "PROBLEM", 526, 539], ["major atherosclerotic cardiovascular events", "PROBLEM", 541, 584], ["AKI", "PROBLEM", 668, 671], ["coronary", "ANATOMY", 118, 126], ["myocardial", "ANATOMY", 178, 188], ["infarction", "OBSERVATION", 189, 199], ["heart", "ANATOMY", 227, 232], ["failure", "OBSERVATION", 233, 240], ["atherosclerotic", "OBSERVATION", 257, 272], ["global", "OBSERVATION_MODIFIER", 317, 323], ["burden", "OBSERVATION_MODIFIER", 324, 330], ["AKI", "OBSERVATION", 334, 337], ["AKI", "OBSERVATION", 477, 480], ["kidney", "ANATOMY", 497, 503], ["heart", "ANATOMY", 526, 531], ["failure", "OBSERVATION", 532, 539], ["major", "OBSERVATION_MODIFIER", 541, 546], ["atherosclerotic", "OBSERVATION_MODIFIER", 547, 562], ["cardiovascular", "ANATOMY", 563, 577]]], ["We hypothesized AKI would be independently associated with higher risks of each of these events in the presence or absence of pre-existing chronic kidney disease (CKD).Baseline characteristics and follow-upWe enrolled and individually matched 769 adults with AKI and 769 adults without AKI, with 39.8% having pre-existing CKD (Figure 1) replacement therapy.", [["kidney", "ANATOMY", 147, 153], ["AKI", "DISEASE", 16, 19], ["chronic kidney disease", "DISEASE", 139, 161], ["CKD", "DISEASE", 163, 166], ["AKI", "DISEASE", 259, 262], ["AKI", "DISEASE", 286, 289], ["CKD", "DISEASE", 322, 325], ["kidney", "ORGAN", 147, 153], ["AKI", "PROBLEM", 16, 19], ["pre-existing chronic kidney disease", "PROBLEM", 126, 161], ["CKD", "PROBLEM", 163, 166], ["AKI", "TEST", 259, 262], ["AKI", "PROBLEM", 286, 289], ["pre-existing CKD", "PROBLEM", 309, 325], ["replacement therapy", "TREATMENT", 337, 356], ["AKI", "OBSERVATION", 16, 19], ["chronic", "OBSERVATION_MODIFIER", 139, 146], ["kidney", "ANATOMY", 147, 153], ["disease", "OBSERVATION", 154, 161], ["CKD", "OBSERVATION", 322, 325]]], ["Furthermore, 48% of AKI episodes were of brief duration, 22% were of medium duration, 12% were of long duration, and 18% were of very long duration.", [["AKI", "DISEASE", 20, 23], ["AKI episodes", "PROBLEM", 20, 32], ["AKI", "OBSERVATION", 20, 23]]], ["Regardless of CKD status, compared with non-AKI participants, those with AKI were modestly younger, had slightly lower pre-admission eGFR, and were more likely to have prior cardiovascular disease, diabetes, receive care in an intensive care unit, be diagnosed with sepsis during the index hospitalization and have higher baseline study visit levels of plasma cystatin C and proteinuria.Baseline characteristics and follow-upIn contrast, there were no significant differences in Hispanic ethnicity, smoking status, or baseline study visit measures of body mass index, systolic or diastolic blood pressure ( Table 1) .Baseline characteristics and follow-upAmong participants without pre-existing CKD, the proportion of women was lower in those with AKI, but there was no significant difference in self-reported race.", [["cardiovascular", "ANATOMY", 174, 188], ["plasma", "ANATOMY", 353, 359], ["body", "ANATOMY", 551, 555], ["blood", "ANATOMY", 590, 595], ["CKD", "DISEASE", 14, 17], ["AKI", "DISEASE", 73, 76], ["cardiovascular disease", "DISEASE", 174, 196], ["diabetes", "DISEASE", 198, 206], ["sepsis", "DISEASE", 266, 272], ["proteinuria", "DISEASE", 375, 386], ["CKD", "DISEASE", 695, 698], ["AKI", "DISEASE", 748, 751], ["plasma", "ORGANISM_SUBSTANCE", 353, 359], ["cystatin C", "GENE_OR_GENE_PRODUCT", 360, 370], ["body", "ORGANISM_SUBDIVISION", 551, 555], ["blood", "ORGANISM_SUBSTANCE", 590, 595], ["women", "ORGANISM", 718, 723], ["plasma cystatin C", "PROTEIN", 353, 370], ["participants", "SPECIES", 48, 60], ["participants", "SPECIES", 661, 673], ["women", "SPECIES", 718, 723], ["CKD status", "PROBLEM", 14, 24], ["AKI", "PROBLEM", 73, 76], ["slightly lower pre-admission eGFR", "PROBLEM", 104, 137], ["prior cardiovascular disease", "PROBLEM", 168, 196], ["diabetes", "PROBLEM", 198, 206], ["sepsis", "PROBLEM", 266, 272], ["plasma cystatin C", "PROBLEM", 353, 370], ["proteinuria", "PROBLEM", 375, 386], ["follow-upIn contrast", "TEST", 416, 436], ["baseline study", "TEST", 518, 532], ["body mass index", "TEST", 551, 566], ["systolic", "TEST", 568, 576], ["diastolic blood pressure", "TEST", 580, 604], ["pre-existing CKD", "PROBLEM", 682, 698], ["AKI", "PROBLEM", 748, 751], ["CKD", "OBSERVATION", 14, 17], ["cardiovascular", "ANATOMY", 174, 188], ["disease", "OBSERVATION", 189, 196], ["sepsis", "OBSERVATION", 266, 272], ["proteinuria", "OBSERVATION", 375, 386], ["no", "UNCERTAINTY", 449, 451], ["significant", "OBSERVATION_MODIFIER", 452, 463], ["differences", "OBSERVATION_MODIFIER", 464, 475], ["CKD", "OBSERVATION", 695, 698], ["AKI", "OBSERVATION", 748, 751], ["no", "UNCERTAINTY", 767, 769], ["significant", "OBSERVATION_MODIFIER", 770, 781]]], ["In participants with pre-existing CKD, there was no significant difference in gender between groups, but those with AKI were less likely to be white ( Table 1) .Baseline characteristics and follow-upMean (SD) follow-up was 4.5 (1.8) years overall, with mean (SD) follow-up of 4.3 (1.8) years in AKI participants and 4.4 (1.8) years and non-AKI participants.", [["CKD", "DISEASE", 34, 37], ["AKI", "DISEASE", 116, 119], ["AKI", "DISEASE", 295, 298], ["participants", "SPECIES", 3, 15], ["participants", "SPECIES", 299, 311], ["participants", "SPECIES", 344, 356], ["pre-existing CKD", "PROBLEM", 21, 37], ["significant difference in gender between groups", "PROBLEM", 52, 99], ["AKI", "PROBLEM", 116, 119], ["CKD", "OBSERVATION", 34, 37], ["no", "UNCERTAINTY", 49, 51], ["significant", "OBSERVATION_MODIFIER", 52, 63], ["difference", "OBSERVATION", 64, 74], ["AKI", "OBSERVATION", 116, 119]]], ["During follow-up, 82 AKI and 82 non-AKI participants withdrew from the study.Kidney outcomesDuring follow-up, CKD incidence was 4.1 per 100 person-years in AKI participants compared with 1.8 per 100 person-years in matched non-AKI adults (P<0.0001) (Figure 2A) .", [["Kidney", "ANATOMY", 77, 83], ["AKI", "DISEASE", 21, 24], ["AKI", "DISEASE", 36, 39], ["CKD", "DISEASE", 110, 113], ["AKI", "DISEASE", 156, 159], ["Kidney", "ORGAN", 77, 83], ["participants", "SPECIES", 40, 52], ["participants", "SPECIES", 160, 172], ["person", "SPECIES", 199, 205], ["AKI", "TEST", 21, 24], ["the study", "TEST", 67, 76], ["CKD incidence", "PROBLEM", 110, 123]]], ["In participants with pre-existing CKD, the rate of those experiencing CKD progression was 2.1 per 100 person-years in AKI participants compared with 0.7 per 100 person-years in matched non-AKI participants (P<0.0001) ( Figure 2B) .Kidney outcomesIn multivariable analysis among matched participants without pre-existing CKD, AKI was associated with a 3.4-fold higher adjusted rate of incident CKD (Model 1, Table 2 ).", [["Kidney", "ANATOMY", 231, 237], ["CKD", "DISEASE", 34, 37], ["CKD", "DISEASE", 70, 73], ["AKI", "DISEASE", 118, 121], ["CKD", "DISEASE", 320, 323], ["AKI", "DISEASE", 325, 328], ["CKD", "DISEASE", 393, 396], ["Kidney", "ORGAN", 231, 237], ["participants", "SPECIES", 3, 15], ["participants", "SPECIES", 122, 134], ["person", "SPECIES", 161, 167], ["participants", "SPECIES", 193, 205], ["participants", "SPECIES", 286, 298], ["pre-existing CKD", "PROBLEM", 21, 37], ["CKD progression", "PROBLEM", 70, 85], ["AKI", "PROBLEM", 118, 121], ["multivariable analysis", "TEST", 249, 271], ["pre-existing CKD", "PROBLEM", 307, 323], ["AKI", "PROBLEM", 325, 328], ["CKD", "PROBLEM", 393, 396], ["CKD", "OBSERVATION", 34, 37], ["CKD", "OBSERVATION", 320, 323], ["AKI", "OBSERVATION", 325, 328]]], ["Further adjustment for additional demographic characteristics, sepsis during the index admission and smoking, diabetes status and body mass index at the baseline visit strengthened the association (adjusted hazard ratio 3.98, 95%CI:2.51 to 6.31) (Model 2, Table 2 ).", [["body", "ANATOMY", 130, 134], ["sepsis", "DISEASE", 63, 69], ["smoking", "CHEMICAL", 101, 108], ["diabetes", "DISEASE", 110, 118], ["body", "ORGANISM_SUBDIVISION", 130, 134], ["sepsis", "PROBLEM", 63, 69], ["diabetes status", "PROBLEM", 110, 125], ["body mass index", "PROBLEM", 130, 145], ["hazard ratio", "TEST", 207, 219], ["CI", "TEST", 229, 231], ["Model", "TEST", 247, 252], ["sepsis", "OBSERVATION", 63, 69]]], ["AKI was associated with a 2.3-fold higher adjusted rate of CKD progression in matched participants (Model 1, Table 2 ), and the association with CKD progression increased after adjustment for additional potential confounders (adjusted hazard ratio 2.37, 95%CI:1.28 to 4.39) (Model 2, Table 2 ).", [["AKI", "DISEASE", 0, 3], ["CKD", "DISEASE", 59, 62], ["CKD", "DISEASE", 145, 148], ["participants", "SPECIES", 86, 98], ["AKI", "PROBLEM", 0, 3], ["a 2.3-fold", "PROBLEM", 24, 34], ["CKD progression", "PROBLEM", 59, 74], ["CKD progression", "PROBLEM", 145, 160], ["hazard ratio", "TEST", 235, 247], ["CI", "TEST", 257, 259], ["CKD", "OBSERVATION", 59, 62], ["CKD", "OBSERVATION", 145, 148]]], ["For both incident and progressive CKD, there was also a significant trend (P<0.001 for linear trend) with more severe and longer AKI in multivariable analyses (Supplemental Appendix 2 and 3).", [["CKD", "DISEASE", 34, 37], ["AKI", "DISEASE", 129, 132], ["progressive CKD", "PROBLEM", 22, 37], ["more severe and longer AKI", "PROBLEM", 106, 132], ["multivariable analyses", "TEST", 136, 158], ["progressive", "OBSERVATION_MODIFIER", 22, 33], ["CKD", "OBSERVATION", 34, 37], ["significant", "OBSERVATION_MODIFIER", 56, 67], ["trend", "OBSERVATION_MODIFIER", 68, 73], ["severe", "OBSERVATION_MODIFIER", 111, 117], ["longer", "OBSERVATION_MODIFIER", 122, 128], ["AKI", "OBSERVATION", 129, 132]]], ["In a sensitivity analysis among AKI and non-AKI participants exactly matched on each matching criteria, results were similar to the main analyses (Supplementary Appendix 4).Heart failure eventsAmong matched participants without prior CKD, the incidence of hospitalization for heart failure was higher in those with vs. without AKI (3.0 vs. 1.1 per 100 person-years, respectively, P<0.001).", [["Heart", "ANATOMY", 173, 178], ["heart", "ANATOMY", 276, 281], ["AKI", "DISEASE", 32, 35], ["Heart failure", "DISEASE", 173, 186], ["CKD", "DISEASE", 234, 237], ["heart failure", "DISEASE", 276, 289], ["AKI", "DISEASE", 327, 330], ["Heart", "ORGAN", 173, 178], ["heart", "ORGAN", 276, 281], ["participants", "SPECIES", 48, 60], ["participants", "SPECIES", 207, 219], ["a sensitivity analysis", "TEST", 3, 25], ["AKI", "PROBLEM", 32, 35], ["Heart failure events", "PROBLEM", 173, 193], ["prior CKD", "PROBLEM", 228, 237], ["heart failure", "PROBLEM", 276, 289], ["AKI", "PROBLEM", 327, 330], ["failure", "OBSERVATION", 179, 186], ["heart", "ANATOMY", 276, 281], ["failure", "OBSERVATION", 282, 289], ["AKI", "OBSERVATION", 327, 330]]], ["The pattern was similar in those with pre-existing CKD, with a higher incidence in those with vs. without AKI (5.9 vs. 3.9 per 100 person-years, respectively, P=0.014) ( Figure 2C ).Heart failure eventsIn multivariable analysis among matched participants, AKI was associated with a nearly twofold higher adjusted rate of heart failure events (Model 1, Table 3 ) that was attenuated after additional adjustment for potential confounders (adjusted hazard ratio 1.68, 95%CI:1.22 to 2.31) (Model 2, Table 3 ).", [["Heart", "ANATOMY", 182, 187], ["heart", "ANATOMY", 321, 326], ["CKD", "DISEASE", 51, 54], ["AKI", "DISEASE", 106, 109], ["Heart failure", "DISEASE", 182, 195], ["AKI", "DISEASE", 256, 259], ["heart failure", "DISEASE", 321, 334], ["Heart", "ORGAN", 182, 187], ["heart", "ORGAN", 321, 326], ["participants", "SPECIES", 242, 254], ["pre-existing CKD", "PROBLEM", 38, 54], ["AKI", "PROBLEM", 106, 109], ["Heart failure events", "PROBLEM", 182, 202], ["AKI", "PROBLEM", 256, 259], ["heart failure events", "PROBLEM", 321, 341], ["hazard ratio", "TEST", 446, 458], ["CI", "TEST", 468, 470], ["similar", "OBSERVATION_MODIFIER", 16, 23], ["CKD", "OBSERVATION", 51, 54], ["higher", "OBSERVATION_MODIFIER", 63, 69], ["AKI", "OBSERVATION", 106, 109], ["failure", "OBSERVATION", 188, 195], ["AKI", "OBSERVATION", 256, 259], ["heart", "ANATOMY", 321, 326], ["failure", "OBSERVATION", 327, 334]]], ["However, further adjustment for eGFR, cystatin C and proteinuria measured at the 3-month post-discharge baseline visit markedly attenuated the association of AKI with subsequent heart failure hospitalization which was no longer significant (Model 3, Table 3 ).", [["heart", "ANATOMY", 178, 183], ["proteinuria", "DISEASE", 53, 64], ["AKI", "DISEASE", 158, 161], ["heart failure", "DISEASE", 178, 191], ["cystatin C", "GENE_OR_GENE_PRODUCT", 38, 48], ["heart", "ORGAN", 178, 183], ["cystatin C", "PROTEIN", 38, 48], ["eGFR", "TEST", 32, 36], ["cystatin C", "PROBLEM", 38, 48], ["proteinuria", "PROBLEM", 53, 64], ["AKI", "PROBLEM", 158, 161], ["subsequent heart failure hospitalization", "PROBLEM", 167, 207], ["proteinuria", "OBSERVATION", 53, 64], ["AKI", "OBSERVATION", 158, 161], ["heart", "ANATOMY", 178, 183], ["failure", "OBSERVATION", 184, 191], ["no longer", "UNCERTAINTY", 218, 227]]], ["The relative strength of association was weaker in those with vs. in those without pre-existing CKD, but the patterns with multivariable adjustment were similar ( Table 3 ).Heart failure eventsIn addition, after accounting for matching variables and potential confounders, there was a significant association of more severe AKI with heart failure hospitalization in those without pre-existing CKD (P=0.022 for linear trend) but not in those with pre-existing CKD (P=0.62 for linear trend).", [["Heart", "ANATOMY", 173, 178], ["heart", "ANATOMY", 333, 338], ["CKD", "DISEASE", 96, 99], ["Heart failure", "DISEASE", 173, 186], ["AKI", "DISEASE", 324, 327], ["heart failure", "DISEASE", 333, 346], ["CKD", "DISEASE", 393, 396], ["CKD", "DISEASE", 459, 462], ["Heart", "ORGAN", 173, 178], ["heart", "ORGAN", 333, 338], ["pre-existing CKD", "PROBLEM", 83, 99], ["Heart failure events", "PROBLEM", 173, 193], ["more severe AKI", "PROBLEM", 312, 327], ["heart failure hospitalization", "PROBLEM", 333, 362], ["pre-existing CKD", "PROBLEM", 380, 396], ["P", "TEST", 398, 399], ["pre-existing CKD", "PROBLEM", 446, 462], ["P", "TEST", 464, 465], ["strength", "OBSERVATION_MODIFIER", 13, 21], ["CKD", "OBSERVATION", 96, 99], ["failure", "OBSERVATION", 179, 186], ["severe", "OBSERVATION_MODIFIER", 317, 323], ["AKI", "OBSERVATION", 324, 327], ["heart", "ANATOMY", 333, 338], ["failure", "OBSERVATION", 339, 346], ["CKD", "OBSERVATION", 459, 462]]], ["The association in those without pre-existing CKD was notably attenuated and no longer significant after further adjustment for baseline visit measures of kidney function and proteinuria (Supplemental Appendix 2).", [["kidney", "ANATOMY", 155, 161], ["CKD", "DISEASE", 46, 49], ["proteinuria", "DISEASE", 175, 186], ["kidney", "ORGAN", 155, 161], ["pre-existing CKD", "PROBLEM", 33, 49], ["kidney function", "TEST", 155, 170], ["proteinuria", "PROBLEM", 175, 186], ["CKD", "OBSERVATION", 46, 49], ["attenuated", "OBSERVATION", 62, 72], ["no longer", "UNCERTAINTY", 77, 86], ["kidney", "ANATOMY", 155, 161], ["proteinuria", "OBSERVATION", 175, 186]]], ["Longer AKI duration was associated with higher adjusted rate of heart failure hospitalization in a fully-adjusted model (Supplemental Appendix 3).", [["heart", "ANATOMY", 64, 69], ["AKI", "DISEASE", 7, 10], ["heart failure", "DISEASE", 64, 77], ["heart", "ORGAN", 64, 69], ["Longer AKI duration", "PROBLEM", 0, 19], ["heart failure hospitalization", "PROBLEM", 64, 93], ["a fully-adjusted model (Supplemental Appendix", "TREATMENT", 97, 142], ["heart", "ANATOMY", 64, 69], ["failure", "OBSERVATION", 70, 77]]], ["In a sensitivity analysis of exactly matched AKI and non-AKI participants, results were similar to the main analysis except that there remained a twofold higher adjusted risk of heart failure events associated with AKI and no pre-existing CKD, even after additionally accounting for three-month post-discharge measures of kidney function and proteinuria (SupplementalMajor atherosclerotic cardiovascular eventsIn those without underlying CKD, the incidence of MACE was 1.5 per 100 person-years in AKI participants compared to 1.6 per 100 person-years in matched non-AKI participants (P=0.66).", [["heart", "ANATOMY", 178, 183], ["kidney", "ANATOMY", 322, 328], ["cardiovascular", "ANATOMY", 389, 403], ["AKI", "DISEASE", 45, 48], ["heart failure", "DISEASE", 178, 191], ["AKI", "DISEASE", 215, 218], ["CKD", "DISEASE", 239, 242], ["proteinuria", "DISEASE", 342, 353], ["atherosclerotic cardiovascular events", "DISEASE", 373, 410], ["CKD", "DISEASE", 438, 441], ["MACE", "DISEASE", 460, 464], ["AKI", "DISEASE", 497, 500], ["heart", "ORGAN", 178, 183], ["kidney", "ORGAN", 322, 328], ["participants", "SPECIES", 61, 73], ["participants", "SPECIES", 501, 513], ["person", "SPECIES", 538, 544], ["participants", "SPECIES", 570, 582], ["a sensitivity analysis", "TEST", 3, 25], ["AKI", "PROBLEM", 45, 48], ["the main analysis", "TEST", 99, 116], ["heart failure events", "PROBLEM", 178, 198], ["AKI", "PROBLEM", 215, 218], ["pre-existing CKD", "PROBLEM", 226, 242], ["kidney function", "PROBLEM", 322, 337], ["proteinuria", "PROBLEM", 342, 353], ["SupplementalMajor atherosclerotic cardiovascular events", "PROBLEM", 355, 410], ["underlying CKD", "PROBLEM", 427, 441], ["MACE", "TEST", 460, 464], ["AKI", "PROBLEM", 497, 500], ["heart", "ANATOMY", 178, 183], ["failure", "OBSERVATION", 184, 191], ["AKI", "OBSERVATION", 215, 218], ["CKD", "OBSERVATION", 239, 242], ["kidney", "ANATOMY", 322, 328], ["proteinuria", "OBSERVATION", 342, 353], ["atherosclerotic", "OBSERVATION_MODIFIER", 373, 388], ["cardiovascular", "ANATOMY", 389, 403], ["without", "UNCERTAINTY", 419, 426], ["CKD", "OBSERVATION", 438, 441]]], ["There was also no significant difference in MACE incidence between those with CKD with AKI vs. without AKI (3.6 vs. 3.1 per 100 person-years, respectively, P=0.64) ( Figure 2D ).", [["CKD", "DISEASE", 78, 81], ["AKI", "DISEASE", 87, 90], ["AKI", "DISEASE", 103, 106], ["CKD", "PROBLEM", 78, 81], ["AKI", "PROBLEM", 87, 90], ["AKI", "PROBLEM", 103, 106], ["no", "UNCERTAINTY", 15, 17], ["significant", "OBSERVATION_MODIFIER", 18, 29], ["difference", "OBSERVATION_MODIFIER", 30, 40], ["AKI", "OBSERVATION", 87, 90], ["AKI", "OBSERVATION", 103, 106]]], ["There was also no significant association between AKI severity and MACE (Supplemental Appendix 2).", [["AKI", "DISEASE", 50, 53], ["AKI severity", "PROBLEM", 50, 62], ["MACE (Supplemental Appendix", "TREATMENT", 67, 94], ["no", "UNCERTAINTY", 15, 17], ["significant", "OBSERVATION_MODIFIER", 18, 29], ["AKI", "OBSERVATION", 50, 53]]], ["Results were similar to the main analysis in a sensitivity analysis among the subset of AKI and non-AKI participants that were exactly matched on all matching criteria (Supplemental Appendix 4).MortalityAll-cause mortality was higher in those with vs. without AKI and in the presence or absence of pre-existing CKD ( Figure 2E ).", [["AKI", "DISEASE", 88, 91], ["AKI", "DISEASE", 260, 263], ["CKD", "DISEASE", 311, 314], ["participants", "SPECIES", 104, 116], ["the main analysis", "TEST", 24, 41], ["a sensitivity analysis", "TEST", 45, 67], ["AKI", "PROBLEM", 88, 91], ["mortality", "PROBLEM", 213, 222], ["AKI", "PROBLEM", 260, 263], ["pre-existing CKD", "PROBLEM", 298, 314], ["AKI", "OBSERVATION", 88, 91], ["higher", "OBSERVATION_MODIFIER", 227, 233], ["AKI", "OBSERVATION", 260, 263], ["CKD", "OBSERVATION", 311, 314]]], ["After accounting for matching and additional confounders, AKI was associated with a 78% higher rate of death (Model 2, Table 3 ) that was markedly attenuated and no longer significant after further accounting for degree of renal recovery and proteinuria status at three months post-discharge (Model 3, Table 3 ).", [["renal", "ANATOMY", 223, 228], ["AKI", "DISEASE", 58, 61], ["death", "DISEASE", 103, 108], ["proteinuria", "DISEASE", 242, 253], ["renal", "ORGAN", 223, 228], ["AKI", "PROBLEM", 58, 61], ["markedly attenuated", "PROBLEM", 138, 157], ["renal recovery", "PROBLEM", 223, 237], ["proteinuria status", "PROBLEM", 242, 260], ["AKI", "OBSERVATION", 58, 61], ["no longer", "UNCERTAINTY", 162, 171], ["renal", "ANATOMY", 223, 228], ["recovery", "OBSERVATION", 229, 237], ["proteinuria", "OBSERVATION", 242, 253]]], ["Results were similar in fully-adjusted models regardless of the presence of pre-existing CKD ( Table 3) .MortalityThere was a significant trend of more severe AKI with excess mortality that was attenuated and no longer significant after adjustment for three-month post-discharge kidney function and proteinuria, while longer AKI duration was independently associated with higher mortality (Supplemental Appendix 2 and 3).", [["kidney", "ANATOMY", 279, 285], ["CKD", "DISEASE", 89, 92], ["AKI", "DISEASE", 159, 162], ["proteinuria", "DISEASE", 299, 310], ["AKI", "DISEASE", 325, 328], ["kidney", "ORGAN", 279, 285], ["pre-existing CKD", "PROBLEM", 76, 92], ["more severe AKI", "PROBLEM", 147, 162], ["excess mortality", "PROBLEM", 168, 184], ["proteinuria", "PROBLEM", 299, 310], ["longer AKI duration", "PROBLEM", 318, 337], ["CKD", "OBSERVATION", 89, 92], ["significant", "OBSERVATION_MODIFIER", 126, 137], ["trend", "OBSERVATION_MODIFIER", 138, 143], ["severe", "OBSERVATION_MODIFIER", 152, 158], ["AKI", "OBSERVATION", 159, 162], ["no longer", "UNCERTAINTY", 209, 218], ["kidney", "ANATOMY", 279, 285], ["proteinuria", "OBSERVATION", 299, 310]]], ["In sensitivity analyses in the subset of AKI and non-AKI participants that were exactly matched on all matching criteria, results were similar to the main analyses, except that AKI was independently associated with a nearly twofold higher rate of death in those with pre-existing CKD even after additional adjustment for three-month postdischarge kidney function and proteinuria (Supplemental Appendix 4).DISCUSSIONIn a prospective cohort of matched hospital survivors, AKI was independently associated with higher subsequent risks of both incident CKD and progressive CKD.", [["kidney", "ANATOMY", 347, 353], ["AKI", "DISEASE", 41, 44], ["AKI", "DISEASE", 177, 180], ["death", "DISEASE", 247, 252], ["CKD", "DISEASE", 280, 283], ["proteinuria", "DISEASE", 367, 378], ["AKI", "DISEASE", 470, 473], ["CKD", "DISEASE", 549, 552], ["CKD", "DISEASE", 569, 572], ["kidney", "ORGAN", 347, 353], ["participants", "SPECIES", 57, 69], ["sensitivity analyses", "TEST", 3, 23], ["AKI", "PROBLEM", 41, 44], ["AKI", "PROBLEM", 177, 180], ["pre-existing CKD", "PROBLEM", 267, 283], ["proteinuria", "PROBLEM", 367, 378], ["AKI", "PROBLEM", 470, 473], ["CKD", "PROBLEM", 549, 552], ["progressive CKD", "PROBLEM", 557, 572], ["AKI", "OBSERVATION", 41, 44], ["AKI", "OBSERVATION", 177, 180], ["CKD", "OBSERVATION", 280, 283], ["kidney", "ANATOMY", 347, 353], ["proteinuria", "OBSERVATION", 367, 378], ["progressive", "OBSERVATION_MODIFIER", 557, 568], ["CKD", "OBSERVATION", 569, 572]]], ["In the overall matched cohort, AKI was also associated with excess risks of heart failure hospitalization and all-cause death-regardless of the presence or absence of pre-existing CKD-but these associations were substantially attenuated and no longer statistically significant after accounting for residual kidney function and proteinuria measured three months after discharge.", [["heart", "ANATOMY", 76, 81], ["kidney", "ANATOMY", 307, 313], ["AKI", "DISEASE", 31, 34], ["heart failure", "DISEASE", 76, 89], ["death", "DISEASE", 120, 125], ["CKD", "DISEASE", 180, 183], ["proteinuria", "DISEASE", 327, 338], ["heart", "ORGAN", 76, 81], ["kidney", "ORGAN", 307, 313], ["AKI", "PROBLEM", 31, 34], ["heart failure hospitalization", "PROBLEM", 76, 105], ["death", "PROBLEM", 120, 125], ["pre-existing CKD", "PROBLEM", 167, 183], ["residual kidney function", "PROBLEM", 298, 322], ["proteinuria", "PROBLEM", 327, 338], ["AKI", "OBSERVATION", 31, 34], ["heart", "ANATOMY", 76, 81], ["failure", "OBSERVATION", 82, 89], ["CKD", "OBSERVATION", 180, 183], ["no longer", "UNCERTAINTY", 241, 250], ["kidney", "ANATOMY", 307, 313], ["proteinuria", "OBSERVATION", 327, 338]]], ["In fully-adjusted models stratified by pre-existing CKD status, we also found that AKI remained significantly associated with an excess risk of heart failure events in patients without pre-existing CKD, while there was a significantly higher risk of all-cause death in those with pre-existing CKD.", [["heart", "ANATOMY", 144, 149], ["CKD", "DISEASE", 52, 55], ["AKI", "DISEASE", 83, 86], ["heart failure", "DISEASE", 144, 157], ["CKD", "DISEASE", 198, 201], ["death", "DISEASE", 260, 265], ["CKD", "DISEASE", 293, 296], ["heart", "ORGAN", 144, 149], ["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 168, 176], ["pre-existing CKD status", "PROBLEM", 39, 62], ["AKI", "PROBLEM", 83, 86], ["heart failure events", "PROBLEM", 144, 164], ["pre-existing CKD", "PROBLEM", 185, 201], ["death", "PROBLEM", 260, 265], ["pre-existing CKD", "PROBLEM", 280, 296], ["CKD", "OBSERVATION", 52, 55], ["AKI", "OBSERVATION", 83, 86], ["heart", "ANATOMY", 144, 149], ["failure", "OBSERVATION", 150, 157], ["CKD", "OBSERVATION", 198, 201], ["CKD", "OBSERVATION", 293, 296]]], ["However, AKI was not significantly associated with MACE, overall or in those with or without pre-existing CKD.DISCUSSIONThe ASSESS-AKI Study is unique as it represents the largest prospective cohort study of a broad population of carefully-matched adults who survived at least three months after hospital discharge to examine the association of AKI with kidney and cardiovascular events over a long follow-up period.", [["kidney", "ANATOMY", 354, 360], ["cardiovascular", "ANATOMY", 365, 379], ["AKI", "DISEASE", 9, 12], ["CKD", "DISEASE", 106, 109], ["AKI", "DISEASE", 131, 134], ["AKI", "DISEASE", 345, 348], ["kidney and cardiovascular events", "DISEASE", 354, 386], ["adults", "ORGANISM", 248, 254], ["kidney", "ORGAN", 354, 360], ["cardiovascular", "ANATOMICAL_SYSTEM", 365, 379], ["AKI", "PROBLEM", 9, 12], ["MACE", "PROBLEM", 51, 55], ["pre-existing CKD", "PROBLEM", 93, 109], ["AKI", "PROBLEM", 345, 348], ["kidney and cardiovascular events", "PROBLEM", 354, 386], ["AKI", "OBSERVATION", 9, 12], ["CKD", "OBSERVATION", 106, 109], ["AKI", "OBSERVATION", 345, 348], ["kidney", "ANATOMY", 354, 360], ["cardiovascular", "ANATOMY", 365, 379]]], ["This population is highly relevant clinically as an increasingly common scenario that physicians encounter in the outpatient setting of post-hospitalization AKI survivors.DISCUSSIONTwo additional key features of ASSESS-AKI compared with previous studies are the prespecified availability of a pre-index hospitalization serum creatinine (7 to 365 days before admission) and completion of a three-month post-discharge study visit as entry criteria.", [["serum", "ANATOMY", 319, 324], ["AKI", "DISEASE", 157, 160], ["AKI", "DISEASE", 219, 222], ["creatinine", "CHEMICAL", 325, 335], ["creatinine", "CHEMICAL", 325, 335], ["serum", "ORGANISM_SUBSTANCE", 319, 324], ["AKI survivors", "TREATMENT", 157, 170], ["AKI", "PROBLEM", 219, 222], ["previous studies", "TEST", 237, 253], ["serum creatinine", "TEST", 319, 335]]], ["The true pre-index hospitalization \"baseline\" serum creatinine concentration allowed us to diagnose AKI and its severity with greater precision using currently recommended criteria.", [["serum", "ANATOMY", 46, 51], ["creatinine", "CHEMICAL", 52, 62], ["AKI", "DISEASE", 100, 103], ["creatinine", "CHEMICAL", 52, 62], ["serum", "ORGANISM_SUBSTANCE", 46, 51], ["creatinine", "SIMPLE_CHEMICAL", 52, 62], ["serum creatinine concentration", "TEST", 46, 76], ["AKI", "PROBLEM", 100, 103]]], ["15 The systematic measurement of eGFR, plasma cystatin C and proteinuria at three months post-discharge was also critical, as we demonstrated that the overall associations of AKI with excess risks of heart failure and death were notably attenuated after accounting for residual kidney function and damage.", [["plasma", "ANATOMY", 39, 45], ["heart", "ANATOMY", 200, 205], ["kidney", "ANATOMY", 278, 284], ["proteinuria", "DISEASE", 61, 72], ["AKI", "DISEASE", 175, 178], ["heart failure", "DISEASE", 200, 213], ["death", "DISEASE", 218, 223], ["plasma", "ORGANISM_SUBSTANCE", 39, 45], ["cystatin C", "GENE_OR_GENE_PRODUCT", 46, 56], ["heart", "ORGAN", 200, 205], ["kidney", "ORGAN", 278, 284], ["plasma cystatin C", "PROTEIN", 39, 56], ["The systematic measurement", "TEST", 3, 29], ["eGFR", "TEST", 33, 37], ["plasma cystatin C", "PROBLEM", 39, 56], ["proteinuria", "PROBLEM", 61, 72], ["AKI", "PROBLEM", 175, 178], ["heart failure", "PROBLEM", 200, 213], ["death", "PROBLEM", 218, 223], ["residual kidney function", "PROBLEM", 269, 293], ["damage", "PROBLEM", 298, 304], ["proteinuria", "OBSERVATION", 61, 72], ["AKI", "OBSERVATION", 175, 178], ["heart", "ANATOMY", 200, 205], ["failure", "OBSERVATION", 206, 213], ["kidney", "ANATOMY", 278, 284], ["function", "OBSERVATION", 285, 293]]], ["This finding has significant clinical practice implications since evaluation of kidney function and proteinuria three months after discharge, which can be readily obtained through primary care, would yield important long-term prognostic information.", [["kidney", "ANATOMY", 80, 86], ["proteinuria", "DISEASE", 100, 111], ["kidney", "ORGAN", 80, 86], ["evaluation of kidney function", "TEST", 66, 95], ["proteinuria", "PROBLEM", 100, 111], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["kidney", "ANATOMY", 80, 86], ["proteinuria", "OBSERVATION", 100, 111]]], ["Our study had several additional strengths beyond the prospective design and structured protocol among a matched cohort that helps overcome many biases that can affect retrospective studies.", [["Our study", "TEST", 0, 9], ["structured protocol", "TREATMENT", 77, 96], ["a matched cohort", "TREATMENT", 103, 119], ["retrospective studies", "TEST", 168, 189]]], ["We had systematic, long-term follow-up measurements of post-discharge kidney function and identification and validation of heart failure events and MACE using standardized criteria.", [["kidney", "ANATOMY", 70, 76], ["heart", "ANATOMY", 123, 128], ["heart failure", "DISEASE", 123, 136], ["kidney", "ORGAN", 70, 76], ["heart", "ORGAN", 123, 128], ["discharge kidney function", "TEST", 60, 85], ["identification", "TEST", 90, 104], ["heart failure events", "PROBLEM", 123, 143], ["standardized criteria", "TEST", 159, 180], ["kidney", "ANATOMY", 70, 76], ["heart", "ANATOMY", 123, 128], ["failure", "OBSERVATION", 129, 136]]], ["Our cohort also included a geographically diverse set of patients recruited from ICU and non-ICU hospitalized settings.DISCUSSIONOur study also has several limitations.", [["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["non-ICU hospitalized settings", "TREATMENT", 89, 118], ["DISCUSSIONOur study", "TEST", 119, 138]]], ["Information was not available on the presence and severity of proteinuria before the index hospitalization.", [["proteinuria", "DISEASE", 62, 73], ["proteinuria", "PROBLEM", 62, 73], ["proteinuria", "OBSERVATION", 62, 73]]], ["Data were also unavailable on preadmission eGFR slope, as well as aetiology of the AKI episode, although we note there is no generally acceptable approach to adjudicate accurately the true aetiology of AKI.", [["AKI", "DISEASE", 83, 86], ["AKI", "DISEASE", 202, 205], ["preadmission eGFR slope", "TEST", 30, 53], ["the AKI episode", "PROBLEM", 79, 94], ["AKI", "PROBLEM", 202, 205], ["AKI", "OBSERVATION", 83, 86], ["AKI", "OBSERVATION", 202, 205]]], ["16 Information on pre-admission blood pressure was also unavailable.", [["blood", "ANATOMY", 32, 37], ["blood", "ORGANISM_SUBSTANCE", 32, 37], ["pre-admission blood pressure", "TEST", 18, 46]]], ["Given our cohort was based in NorthDISCUSSIONAmerican clinical centers and enriched with patients undergoing cardiac surgery or treated in an intensive care unit, our results may not fully generalize to all hospitalized patients, practice settings or geographic areas.", [["cardiac", "ANATOMY", 109, 116], ["patients", "ORGANISM", 89, 97], ["cardiac", "ORGAN", 109, 116], ["patients", "ORGANISM", 220, 228], ["patients", "SPECIES", 89, 97], ["patients", "SPECIES", 220, 228], ["cardiac surgery", "TREATMENT", 109, 124], ["practice settings", "TREATMENT", 230, 247], ["cardiac", "ANATOMY", 109, 116], ["surgery", "OBSERVATION", 117, 124]]], ["As an observational study, we cannot prove causal relationships between an episode of AKI and subsequent clinical outcomes, as we cannot rule out residual or unmeasured confounding.DISCUSSIONThe population of survivors of AKI is growing in parallel with the number of patients experiencing sepsis or cardiovascular diseases, including heart failure.", [["cardiovascular", "ANATOMY", 300, 314], ["heart", "ANATOMY", 335, 340], ["AKI", "DISEASE", 86, 89], ["AKI", "DISEASE", 222, 225], ["sepsis", "DISEASE", 290, 296], ["cardiovascular diseases", "DISEASE", 300, 323], ["heart failure", "DISEASE", 335, 348], ["patients", "ORGANISM", 268, 276], ["heart", "ORGAN", 335, 340], ["patients", "SPECIES", 268, 276], ["an observational study", "TEST", 3, 25], ["AKI", "PROBLEM", 86, 89], ["residual or unmeasured confounding", "PROBLEM", 146, 180], ["AKI", "PROBLEM", 222, 225], ["sepsis", "PROBLEM", 290, 296], ["cardiovascular diseases", "PROBLEM", 300, 323], ["heart failure", "PROBLEM", 335, 348], ["AKI", "OBSERVATION", 86, 89], ["AKI", "OBSERVATION", 222, 225], ["growing", "OBSERVATION_MODIFIER", 229, 236], ["sepsis", "OBSERVATION", 290, 296], ["cardiovascular", "ANATOMY", 300, 314], ["diseases", "OBSERVATION", 315, 323], ["heart", "ANATOMY", 335, 340], ["failure", "OBSERVATION", 341, 348]]], ["17, 18 Our findings that suggest AKI, even its mildest form, may contribute to long-term adverse outcomes have important implications.", [["AKI", "DISEASE", 33, 36], ["AKI", "PROBLEM", 33, 36], ["long-term adverse outcomes", "PROBLEM", 79, 105], ["suggest", "UNCERTAINTY", 25, 32], ["AKI", "OBSERVATION", 33, 36]]], ["[19] [20] [21] While previous studies have examined the association of AKI on kidney and cardiac complications in hospitalized patients, many suffer from several limitations.DISCUSSIONNearly all studies were retrospective in design with their accompanying biases, and several relied only on administrative codes to assign AKI status rather than objective pre-admission and in-hospital serum creatinine results.", [["kidney", "ANATOMY", 78, 84], ["cardiac", "ANATOMY", 89, 96], ["serum", "ANATOMY", 385, 390], ["AKI", "DISEASE", 71, 74], ["cardiac complications", "DISEASE", 89, 110], ["AKI", "DISEASE", 322, 325], ["creatinine", "CHEMICAL", 391, 401], ["creatinine", "CHEMICAL", 391, 401], ["kidney", "ORGAN", 78, 84], ["cardiac", "ORGAN", 89, 96], ["patients", "ORGANISM", 127, 135], ["serum", "ORGANISM_SUBSTANCE", 385, 390], ["patients", "SPECIES", 127, 135], ["previous studies", "TEST", 21, 37], ["AKI on kidney", "PROBLEM", 71, 84], ["cardiac complications", "PROBLEM", 89, 110], ["all studies", "TEST", 191, 202], ["AKI status", "PROBLEM", 322, 332], ["in-hospital serum creatinine", "TEST", 373, 401], ["AKI", "OBSERVATION", 71, 74], ["kidney", "ANATOMY", 78, 84], ["cardiac", "ANATOMY", 89, 96], ["complications", "OBSERVATION", 97, 110]]], ["Our study materially expands on a recent prospective study of 968 adults undergoing cardiac surgery which found that AKI was associated with a higher adjusted rate of the composite outcome of death or hospitalization for acute coronary syndrome, heart failure or receipt of coronary revascularization.", [["cardiac", "ANATOMY", 84, 91], ["coronary", "ANATOMY", 227, 235], ["heart", "ANATOMY", 246, 251], ["coronary", "ANATOMY", 274, 282], ["AKI", "DISEASE", 117, 120], ["death", "DISEASE", 192, 197], ["acute coronary syndrome", "DISEASE", 221, 244], ["heart failure", "DISEASE", 246, 259], ["adults", "ORGANISM", 66, 72], ["cardiac", "ORGAN", 84, 91], ["heart", "ORGAN", 246, 251], ["coronary", "MULTI-TISSUE_STRUCTURE", 274, 282], ["Our study", "TEST", 0, 9], ["a recent prospective study", "TEST", 32, 58], ["cardiac surgery", "TREATMENT", 84, 99], ["AKI", "PROBLEM", 117, 120], ["acute coronary syndrome", "PROBLEM", 221, 244], ["heart failure", "PROBLEM", 246, 259], ["coronary revascularization", "TREATMENT", 274, 300], ["cardiac", "ANATOMY", 84, 91], ["surgery", "OBSERVATION", 92, 99], ["AKI", "OBSERVATION", 117, 120], ["coronary", "ANATOMY", 227, 235], ["syndrome", "OBSERVATION", 236, 244], ["heart", "ANATOMY", 246, 251], ["failure", "OBSERVATION", 252, 259], ["coronary", "ANATOMY", 274, 282], ["revascularization", "OBSERVATION", 283, 300]]], ["22 Mechanisms by which AKI drives development and progression of CKD, as well as excess heart failure complications, are not fully elucidated.", [["heart", "ANATOMY", 88, 93], ["AKI", "DISEASE", 23, 26], ["CKD", "DISEASE", 65, 68], ["heart failure", "DISEASE", 88, 101], ["heart", "ORGAN", 88, 93], ["CKD", "PROBLEM", 65, 68], ["excess heart failure complications", "PROBLEM", 81, 115], ["AKI", "OBSERVATION", 23, 26], ["progression", "OBSERVATION_MODIFIER", 50, 61], ["CKD", "OBSERVATION", 65, 68], ["heart", "ANATOMY", 88, 93], ["failure", "OBSERVATION", 94, 101]]], ["23 AKI is associated with increased levels of inflammatory cytokines, 24 endothelial dysfunction, 25 dysregulation in mineral metabolism, 26, 27 and myocardial damage.", [["endothelial", "ANATOMY", 73, 84], ["myocardial", "ANATOMY", 149, 159], ["AKI", "DISEASE", 3, 6], ["endothelial dysfunction", "DISEASE", 73, 96], ["myocardial damage", "DISEASE", 149, 166], ["endothelial", "CELL", 73, 84], ["mineral", "TISSUE", 118, 125], ["myocardial", "MULTI-TISSUE_STRUCTURE", 149, 159], ["inflammatory cytokines", "PROTEIN", 46, 68], ["AKI", "PROBLEM", 3, 6], ["inflammatory cytokines", "PROBLEM", 46, 68], ["24 endothelial dysfunction", "PROBLEM", 70, 96], ["25 dysregulation in mineral metabolism", "PROBLEM", 98, 136], ["myocardial damage", "PROBLEM", 149, 166], ["AKI", "OBSERVATION", 3, 6], ["increased", "OBSERVATION_MODIFIER", 26, 35], ["inflammatory cytokines", "OBSERVATION", 46, 68], ["endothelial dysfunction", "OBSERVATION", 73, 96], ["mineral metabolism", "OBSERVATION", 118, 136], ["myocardial", "ANATOMY", 149, 159], ["damage", "OBSERVATION", 160, 166]]], ["28 Yet, shared risk factors between AKI, CKD, and cardiovascular disease (e.g., age, diabetes, hypertension) and lack of mechanistic studies have raised some skepticism about a causal relationship between AKI and future adverse outcomes.", [["cardiovascular", "ANATOMY", 50, 64], ["AKI", "DISEASE", 36, 39], ["CKD", "DISEASE", 41, 44], ["cardiovascular disease", "DISEASE", 50, 72], ["diabetes", "DISEASE", 85, 93], ["hypertension", "DISEASE", 95, 107], ["AKI", "DISEASE", 205, 208], ["AKI", "PROBLEM", 36, 39], ["CKD", "PROBLEM", 41, 44], ["cardiovascular disease", "PROBLEM", 50, 72], ["diabetes", "PROBLEM", 85, 93], ["hypertension", "PROBLEM", 95, 107], ["mechanistic studies", "TEST", 121, 140], ["AKI", "PROBLEM", 205, 208], ["future adverse outcomes", "PROBLEM", 213, 236], ["AKI", "OBSERVATION", 36, 39], ["CKD", "OBSERVATION", 41, 44], ["cardiovascular", "ANATOMY", 50, 64], ["disease", "OBSERVATION", 65, 72], ["hypertension", "OBSERVATION", 95, 107]]], ["23 One potential explanation is that the kidney plays a critical role in sodium handling and subsequent volume status and blood pressure control.", [["kidney", "ANATOMY", 41, 47], ["blood", "ANATOMY", 122, 127], ["sodium", "CHEMICAL", 73, 79], ["sodium", "CHEMICAL", 73, 79], ["kidney", "ORGAN", 41, 47], ["sodium", "SIMPLE_CHEMICAL", 73, 79], ["blood", "ORGANISM_SUBSTANCE", 122, 127], ["sodium handling", "TREATMENT", 73, 88], ["subsequent volume status", "TREATMENT", 93, 117], ["blood pressure control", "TREATMENT", 122, 144], ["kidney", "ANATOMY", 41, 47]]], ["Tubular injury sustained during AKI, especially in severe forms, could lead to impaired natriuresis that can predispose to subclinical vascular congestion during high sodium intake.", [["Tubular", "ANATOMY", 0, 7], ["vascular", "ANATOMY", 135, 143], ["Tubular injury", "DISEASE", 0, 14], ["AKI", "DISEASE", 32, 35], ["sodium", "CHEMICAL", 167, 173], ["sodium", "CHEMICAL", 167, 173], ["Tubular", "MULTI-TISSUE_STRUCTURE", 0, 7], ["vascular", "MULTI-TISSUE_STRUCTURE", 135, 143], ["sodium", "SIMPLE_CHEMICAL", 167, 173], ["Tubular injury", "PROBLEM", 0, 14], ["AKI", "PROBLEM", 32, 35], ["impaired natriuresis", "PROBLEM", 79, 99], ["subclinical vascular congestion", "PROBLEM", 123, 154], ["high sodium intake", "PROBLEM", 162, 180], ["injury", "OBSERVATION", 8, 14], ["AKI", "OBSERVATION", 32, 35], ["natriuresis", "OBSERVATION", 88, 99], ["subclinical", "OBSERVATION_MODIFIER", 123, 134], ["vascular", "ANATOMY", 135, 143], ["congestion", "OBSERVATION", 144, 154]]], ["23, [29] [30] [31] This would, in turn, result in subtle tubular dysfunction whose effects on vulnerable kidneys may accumulate over time leading to a vicious cycle of recurrent AKI episodes, heart failure and progressive CKD.DISCUSSIONIn summary, we found that AKI independently associated with higher rates of incident and progressive CKD, as well as subsequent heart failure events and death among survivors of a recent hospitalization.", [["tubular", "ANATOMY", 57, 64], ["kidneys", "ANATOMY", 105, 112], ["heart", "ANATOMY", 192, 197], ["heart", "ANATOMY", 364, 369], ["AKI", "DISEASE", 178, 181], ["heart failure", "DISEASE", 192, 205], ["AKI", "DISEASE", 262, 265], ["CKD", "DISEASE", 337, 340], ["heart failure", "DISEASE", 364, 377], ["death", "DISEASE", 389, 394], ["tubular", "TISSUE", 57, 64], ["kidneys", "ORGAN", 105, 112], ["heart", "ORGAN", 192, 197], ["heart", "ORGAN", 364, 369], ["subtle tubular dysfunction", "PROBLEM", 50, 76], ["vulnerable kidneys", "PROBLEM", 94, 112], ["recurrent AKI episodes", "PROBLEM", 168, 190], ["heart failure", "PROBLEM", 192, 205], ["AKI", "PROBLEM", 262, 265], ["progressive CKD", "PROBLEM", 325, 340], ["subsequent heart failure events", "PROBLEM", 353, 384], ["death", "PROBLEM", 389, 394], ["tubular", "ANATOMY_MODIFIER", 57, 64], ["dysfunction", "OBSERVATION", 65, 76], ["kidneys", "ANATOMY", 105, 112], ["recurrent", "OBSERVATION_MODIFIER", 168, 177], ["AKI", "OBSERVATION", 178, 181], ["heart", "ANATOMY", 192, 197], ["failure", "OBSERVATION", 198, 205], ["progressive", "OBSERVATION_MODIFIER", 210, 221], ["AKI", "OBSERVATION", 262, 265], ["progressive", "OBSERVATION_MODIFIER", 325, 336], ["CKD", "OBSERVATION", 337, 340], ["heart", "ANATOMY", 364, 369], ["failure", "OBSERVATION", 370, 377]]], ["However, after additionally accounting for degree of renal recovery and proteinuria status three months after discharge, the associations of AKI with heart failure and death were not significant.", [["renal", "ANATOMY", 53, 58], ["heart", "ANATOMY", 150, 155], ["proteinuria", "DISEASE", 72, 83], ["AKI", "DISEASE", 141, 144], ["heart failure", "DISEASE", 150, 163], ["death", "DISEASE", 168, 173], ["renal", "ORGAN", 53, 58], ["heart", "ORGAN", 150, 155], ["renal recovery", "PROBLEM", 53, 67], ["proteinuria status", "PROBLEM", 72, 90], ["AKI", "PROBLEM", 141, 144], ["heart failure", "PROBLEM", 150, 163], ["death", "PROBLEM", 168, 173], ["renal", "ANATOMY", 53, 58], ["recovery", "OBSERVATION", 59, 67], ["proteinuria", "OBSERVATION", 72, 83], ["AKI", "OBSERVATION", 141, 144], ["heart", "ANATOMY", 150, 155], ["failure", "OBSERVATION", 156, 163]]], ["More severe and longer AKI duration may also be associated with worse clinical outcomes.", [["AKI", "DISEASE", 23, 26], ["More severe and longer AKI duration", "PROBLEM", 0, 35], ["severe", "OBSERVATION_MODIFIER", 5, 11], ["longer AKI", "OBSERVATION_MODIFIER", 16, 26], ["may also be associated with", "UNCERTAINTY", 36, 63]]], ["Our study provides new data to support systematically evaluating level of kidney function recovery and proteinuria three months after an episode of AKI to provide relevant prognostic information that may help guide clinical decision-making.", [["kidney", "ANATOMY", 74, 80], ["proteinuria", "DISEASE", 103, 114], ["AKI", "DISEASE", 148, 151], ["kidney", "ORGAN", 74, 80], ["Our study", "TEST", 0, 9], ["proteinuria", "PROBLEM", 103, 114], ["AKI", "PROBLEM", 148, 151], ["kidney", "ANATOMY", 74, 80], ["proteinuria", "OBSERVATION", 103, 114], ["AKI", "OBSERVATION", 148, 151]]], ["Furthermore, definitive randomized trial evidence is needed to determine if strategies to prevent AKI or interventions early in the course of AKI can reduce the risks of future adverse renal and cardiovascular outcomes.", [["renal", "ANATOMY", 185, 190], ["cardiovascular", "ANATOMY", 195, 209], ["AKI", "DISEASE", 98, 101], ["AKI", "DISEASE", 142, 145], ["renal", "MULTI-TISSUE_STRUCTURE", 185, 190], ["cardiovascular", "ANATOMICAL_SYSTEM", 195, 209], ["AKI", "PROBLEM", 98, 101], ["interventions", "TREATMENT", 105, 118], ["AKI", "PROBLEM", 142, 145], ["future adverse renal and cardiovascular outcomes", "PROBLEM", 170, 218], ["cardiovascular", "ANATOMY", 195, 209]]], ["23Study PopulationThe ASSESS-AKI Study, sponsored by the National Institute of Diabetes, Digestive and Kidney Diseases of the U.S. National Institutes of Health, is a prospective, matched cohort study of hospitalized persons who did or did not experience an episode of AKI and survived to complete an in-person baseline study visit three months after discharge.", [["Kidney", "ANATOMY", 103, 109], ["AKI", "DISEASE", 29, 32], ["Diabetes", "DISEASE", 79, 87], ["Digestive and Kidney Diseases", "DISEASE", 89, 118], ["AKI", "DISEASE", 269, 272], ["Kidney", "ORGAN", 103, 109], ["persons", "ORGANISM", 217, 224], ["persons", "SPECIES", 217, 224], ["AKI Study", "TEST", 29, 38], ["Diabetes", "PROBLEM", 79, 87], ["Digestive and Kidney Diseases", "PROBLEM", 89, 118], ["AKI", "PROBLEM", 269, 272], ["Diabetes", "OBSERVATION", 79, 87], ["Kidney", "ANATOMY", 103, 109], ["Diseases", "OBSERVATION", 110, 118], ["AKI", "OBSERVATION", 269, 272]]], ["32 Briefly, the main inclusion criteria included age 18-89 years and having a baseline outpatient, non-emergency department serum creatinine value within 365 days before enrollment.", [["serum", "ANATOMY", 124, 129], ["creatinine", "CHEMICAL", 130, 140], ["creatinine", "CHEMICAL", 130, 140], ["serum", "ORGANISM_SUBSTANCE", 124, 129], ["creatinine", "SIMPLE_CHEMICAL", 130, 140], ["serum creatinine value", "TEST", 124, 146], ["main", "OBSERVATION_MODIFIER", 16, 20]]], ["Major exclusion criteria included inability to provide consent; acute glomerulonephritis; hepatorenal syndrome; multiple myeloma, metastatic or actively treated malignancy; significant urinary tract obstruction; severe heart failure; death, receiving chronic dialysis, kidney or other transplant before the three-month post-discharge baseline visit; pregnant or breastfeeding; enrolled in an interventional study at the baseline study visit; or predicted survival of 12 months of less by a study physician.Study PopulationThe study was carried out in a clinical research facility.", [["myeloma", "ANATOMY", 121, 128], ["malignancy", "ANATOMY", 161, 171], ["urinary tract", "ANATOMY", 185, 198], ["heart", "ANATOMY", 219, 224], ["kidney", "ANATOMY", 269, 275], ["glomerulonephritis", "DISEASE", 70, 88], ["hepatorenal syndrome", "DISEASE", 90, 110], ["multiple myeloma", "DISEASE", 112, 128], ["malignancy", "DISEASE", 161, 171], ["urinary tract obstruction", "DISEASE", 185, 210], ["heart failure", "DISEASE", 219, 232], ["death", "DISEASE", 234, 239], ["myeloma", "CANCER", 121, 128], ["urinary tract", "ORGANISM_SUBDIVISION", 185, 198], ["heart", "ORGAN", 219, 224], ["kidney", "ORGAN", 269, 275], ["acute glomerulonephritis", "PROBLEM", 64, 88], ["hepatorenal syndrome", "PROBLEM", 90, 110], ["multiple myeloma", "PROBLEM", 112, 128], ["metastatic or actively treated malignancy", "PROBLEM", 130, 171], ["significant urinary tract obstruction", "PROBLEM", 173, 210], ["severe heart failure", "PROBLEM", 212, 232], ["death", "PROBLEM", 234, 239], ["chronic dialysis", "TREATMENT", 251, 267], ["kidney", "TREATMENT", 269, 275], ["other transplant", "TREATMENT", 279, 295], ["an interventional study", "TEST", 389, 412], ["The study", "TEST", 522, 531], ["acute", "OBSERVATION_MODIFIER", 64, 69], ["glomerulonephritis", "OBSERVATION", 70, 88], ["hepatorenal syndrome", "OBSERVATION", 90, 110], ["multiple", "OBSERVATION_MODIFIER", 112, 120], ["myeloma", "OBSERVATION", 121, 128], ["metastatic", "OBSERVATION_MODIFIER", 130, 140], ["treated", "OBSERVATION_MODIFIER", 153, 160], ["malignancy", "OBSERVATION", 161, 171], ["significant", "OBSERVATION_MODIFIER", 173, 184], ["urinary tract", "ANATOMY", 185, 198], ["obstruction", "OBSERVATION", 199, 210], ["severe", "OBSERVATION_MODIFIER", 212, 218], ["heart", "ANATOMY", 219, 224], ["failure", "OBSERVATION", 225, 232], ["chronic", "OBSERVATION_MODIFIER", 251, 258], ["dialysis", "OBSERVATION", 259, 267], ["kidney", "ANATOMY", 269, 275], ["transplant", "OBSERVATION", 285, 295]]], ["All the study participants were volunteers.", [["participants", "ORGANISM", 14, 26], ["volunteers", "ORGANISM", 32, 42], ["participants", "SPECIES", 14, 26]]], ["Neither the study participants nor the public were involved in the development of research questions, study design and measures, or assessment of the time required to participate in the research.", [["participants", "SPECIES", 18, 30], ["the study", "TEST", 8, 17], ["assessment", "TEST", 132, 142]]], ["The study was approved by institutional review boards of the participating institutions, and written informed consent was obtained from participants.", [["participants", "SPECIES", 136, 148], ["The study", "TEST", 0, 9]]], ["Results of the study will be shared with study participants.Study VisitsAt the three-month post-discharge baseline visit, we obtained information on sociodemographic characteristics; nephrotoxic exposures and complications occurring during the index hospitalization; cardiovascular, renal and other medical history; tobacco use; and prescription and over-the-counter medication use.", [["cardiovascular", "ANATOMY", 267, 281], ["renal", "ANATOMY", 283, 288], ["nephrotoxic", "DISEASE", 183, 194], ["renal", "ORGAN", 283, 288], ["tobacco", "ORGANISM", 316, 323], ["participants", "SPECIES", 47, 59], ["the study", "TEST", 11, 20], ["nephrotoxic exposures", "PROBLEM", 183, 204], ["complications", "PROBLEM", 209, 222], ["renal", "ANATOMY", 283, 288]]], ["32 In addition, height, weight, blood pressure and heart rate were measured using standardized methods.", [["blood", "ANATOMY", 32, 37], ["heart", "ANATOMY", 51, 56], ["blood", "ORGANISM_SUBSTANCE", 32, 37], ["heart", "ORGAN", 51, 56], ["height", "TEST", 16, 22], ["weight", "TEST", 24, 30], ["blood pressure", "TEST", 32, 46], ["heart rate", "TEST", 51, 61], ["standardized methods", "TREATMENT", 82, 102], ["heart", "ANATOMY", 51, 56]]], ["32 Blood samples for DNA, sera and plasma were collected; a urine dipstick proteinuria test performed; and 12-lead electrocardiogram was obtained using standardized methods.Study VisitsA follow-up visit was conducted 12 months after the index hospitalization and annually thereafter (with determination of eGFR), with interim phone contacts at 6-month intervals.", [["Blood samples", "ANATOMY", 3, 16], ["sera", "ANATOMY", 26, 30], ["plasma", "ANATOMY", 35, 41], ["urine", "ANATOMY", 60, 65], ["proteinuria", "DISEASE", 75, 86], ["Blood samples", "ORGANISM_SUBSTANCE", 3, 16], ["DNA", "CELLULAR_COMPONENT", 21, 24], ["sera", "ORGANISM_SUBSTANCE", 26, 30], ["plasma", "ORGANISM_SUBSTANCE", 35, 41], ["urine", "ORGANISM_SUBSTANCE", 60, 65], ["Blood samples", "TEST", 3, 16], ["DNA", "TEST", 21, 24], ["sera", "TEST", 26, 30], ["plasma", "TEST", 35, 41], ["a urine dipstick proteinuria test", "TEST", 58, 91], ["lead electrocardiogram", "TEST", 110, 132], ["standardized methods", "TREATMENT", 152, 172]]], ["32 Medical history, including interim hospitalizations, and medication use were updated at each contact.Follow-up and Outcome AscertainmentFollow-up occurred through November 2018, with censoring due to withdrawal or end of study follow-up.", [["withdrawal", "PROBLEM", 203, 213]]], ["Kidney and cardiovascular events were a priori considered primary outcomes.Follow-up and Outcome AscertainmentKidney events included incident CKD and CKD progression.", [["Kidney", "ANATOMY", 0, 6], ["cardiovascular", "ANATOMY", 11, 25], ["CKD", "DISEASE", 142, 145], ["CKD", "DISEASE", 150, 153], ["Kidney", "ORGAN", 0, 6], ["cardiovascular", "ANATOMICAL_SYSTEM", 11, 25], ["Kidney and cardiovascular events", "PROBLEM", 0, 32], ["CKD", "PROBLEM", 142, 145], ["CKD progression", "PROBLEM", 150, 165], ["cardiovascular", "ANATOMY", 11, 25], ["CKD", "OBSERVATION", 142, 145], ["CKD", "OBSERVATION", 150, 153], ["progression", "OBSERVATION_MODIFIER", 154, 165]]], ["Incident CKD among participants without pre-existing CKD at the index hospitalization was defined as the combination of \u226525% reduction in eGFR (compared with pre-index admission eGFR) and achieving CKD Stage 3 or worse.", [["CKD", "DISEASE", 9, 12], ["CKD", "DISEASE", 53, 56], ["CKD", "DISEASE", 198, 201], ["participants", "SPECIES", 19, 31], ["Incident CKD", "PROBLEM", 0, 12], ["pre-existing CKD", "PROBLEM", 40, 56], ["\u226525% reduction in eGFR", "PROBLEM", 120, 142], ["eGFR", "TEST", 178, 182], ["CKD Stage 3", "PROBLEM", 198, 209], ["CKD", "OBSERVATION", 9, 12], ["CKD", "OBSERVATION", 53, 56], ["CKD", "OBSERVATION", 198, 201], ["worse", "OBSERVATION_MODIFIER", 213, 218]]], ["36 In participants with pre-existing CKD at the index hospitalization (defined as pre-admission eGFR <60 ml/min/1.73 m 2 ), CKD progression was defined as \u226550% reduction in eGFR compared with baseline, reaching CKD Stage 5 or receiving renal replacement therapy (chronic dialysis or kidney transplant).", [["renal", "ANATOMY", 236, 241], ["kidney", "ANATOMY", 283, 289], ["CKD", "DISEASE", 37, 40], ["CKD", "DISEASE", 124, 127], ["CKD", "DISEASE", 211, 214], ["renal", "ORGAN", 236, 241], ["kidney", "ORGAN", 283, 289], ["participants", "SPECIES", 6, 18], ["pre-existing CKD", "PROBLEM", 24, 40], ["eGFR", "TEST", 96, 100], ["CKD progression", "PROBLEM", 124, 139], ["eGFR", "TEST", 173, 177], ["CKD Stage 5", "PROBLEM", 211, 222], ["renal replacement therapy", "TREATMENT", 236, 261], ["chronic dialysis", "TREATMENT", 263, 279], ["kidney transplant", "TREATMENT", 283, 300], ["CKD", "OBSERVATION", 37, 40], ["CKD", "OBSERVATION", 124, 127], ["renal", "ANATOMY", 236, 241], ["replacement", "OBSERVATION", 242, 253], ["kidney", "ANATOMY", 283, 289], ["transplant", "OBSERVATION", 290, 300]]], ["36 We ascertained potential heart failure events and MACE based on participant self-report, and by periodic searches of electronic medical records.", [["heart", "ANATOMY", 28, 33], ["heart failure", "DISEASE", 28, 41], ["heart", "ORGAN", 28, 33], ["potential heart failure events", "PROBLEM", 18, 48], ["heart", "ANATOMY", 28, 33], ["failure", "OBSERVATION", 34, 41]]], ["For all hospitalizations, we initially obtained information on International Classification of Diseases, Ninth or Tenth Edition diagnostic codes for heart failure and MACE, including myocardial infarction, ischemic stroke and peripheral artery disease (codes available on request).", [["heart", "ANATOMY", 149, 154], ["myocardial", "ANATOMY", 183, 193], ["peripheral artery", "ANATOMY", 226, 243], ["heart failure", "DISEASE", 149, 162], ["MACE", "DISEASE", 167, 171], ["myocardial infarction", "DISEASE", 183, 204], ["ischemic stroke", "DISEASE", 206, 221], ["peripheral artery disease", "DISEASE", 226, 251], ["heart", "ORGAN", 149, 154], ["myocardial", "MULTI-TISSUE_STRUCTURE", 183, 193], ["peripheral artery", "MULTI-TISSUE_STRUCTURE", 226, 243], ["heart failure", "PROBLEM", 149, 162], ["MACE", "TREATMENT", 167, 171], ["myocardial infarction", "PROBLEM", 183, 204], ["ischemic stroke", "PROBLEM", 206, 221], ["peripheral artery disease", "PROBLEM", 226, 251], ["heart", "ANATOMY", 149, 154], ["failure", "OBSERVATION", 155, 162], ["myocardial", "ANATOMY", 183, 193], ["infarction", "OBSERVATION", 194, 204], ["ischemic", "OBSERVATION_MODIFIER", 206, 214], ["stroke", "OBSERVATION", 215, 221], ["peripheral artery", "ANATOMY", 226, 243], ["disease", "OBSERVATION", 244, 251]]], ["32 For hospitalizations without a qualifying code, the discharge summary was reviewed by a study investigator to ensure no heart failure events or MACE were missed.", [["heart", "ANATOMY", 123, 128], ["heart failure", "DISEASE", 123, 136], ["heart", "ORGAN", 123, 128], ["a study investigator", "TEST", 89, 109], ["heart failure events", "PROBLEM", 123, 143], ["MACE", "PROBLEM", 147, 151], ["no", "UNCERTAINTY", 120, 122], ["heart", "ANATOMY", 123, 128], ["failure", "OBSERVATION", 129, 136]]], ["The event adjudication committee, comprised of trained physicians from each clinical center, centrally and locally adjudicated potential cardiovascular events based on a review of medical records using Framingham Heart Study clinical criteria 37 for heart failure and standardized criteria 38, 39 for MACE.Follow-up and Outcome AscertainmentVital status was captured through protocol-driven phone-based surveillance complemented by proxy reporting by participants' contacts, information from sites' electronic medical record systems, and death certificate data, as available at each participating center.CovariatesDemographic characteristics included age, gender and self-reported race (white, black, other) and Hispanic ethnicity.", [["cardiovascular", "ANATOMY", 137, 151], ["heart", "ANATOMY", 250, 255], ["heart failure", "DISEASE", 250, 263], ["death", "DISEASE", 538, 543], ["cardiovascular", "ANATOMICAL_SYSTEM", 137, 151], ["heart", "ORGAN", 250, 255], ["participants", "SPECIES", 451, 463], ["cardiovascular events", "PROBLEM", 137, 158], ["Framingham Heart Study", "TEST", 202, 224], ["clinical criteria", "TEST", 225, 242], ["heart failure", "PROBLEM", 250, 263], ["standardized criteria", "TEST", 268, 289], ["Heart", "ANATOMY", 213, 218], ["heart", "ANATOMY", 250, 255], ["failure", "OBSERVATION", 256, 263]]], ["We recorded self-reported tobacco use and prior cardiovascular disease (i.e., heart failure, myocardial infarction, stroke or peripheral artery disease).CovariatesHypertension was based on self-report combined with receipt of antihypertensive agents, or having a study visit systolic blood pressure >140 mmHg and/or diastolic blood pressure >90 mmHg.", [["cardiovascular", "ANATOMY", 48, 62], ["heart", "ANATOMY", 78, 83], ["myocardial", "ANATOMY", 93, 103], ["peripheral artery", "ANATOMY", 126, 143], ["blood", "ANATOMY", 284, 289], ["blood", "ANATOMY", 326, 331], ["cardiovascular disease", "DISEASE", 48, 70], ["heart failure", "DISEASE", 78, 91], ["myocardial infarction", "DISEASE", 93, 114], ["stroke", "DISEASE", 116, 122], ["peripheral artery disease", "DISEASE", 126, 151], ["Hypertension", "DISEASE", 163, 175], ["tobacco", "ORGANISM", 26, 33], ["heart", "ORGAN", 78, 83], ["myocardial", "MULTI-TISSUE_STRUCTURE", 93, 103], ["peripheral artery", "MULTI-TISSUE_STRUCTURE", 126, 143], ["blood", "ORGANISM_SUBSTANCE", 284, 289], ["blood", "ORGANISM_SUBSTANCE", 326, 331], ["tobacco", "SPECIES", 26, 33], ["prior cardiovascular disease", "PROBLEM", 42, 70], ["heart failure", "PROBLEM", 78, 91], ["myocardial infarction", "PROBLEM", 93, 114], ["stroke", "PROBLEM", 116, 122], ["peripheral artery disease)", "PROBLEM", 126, 152], ["CovariatesHypertension", "PROBLEM", 153, 175], ["antihypertensive agents", "TREATMENT", 226, 249], ["a study", "TEST", 261, 268], ["systolic blood pressure", "TEST", 275, 298], ["diastolic blood pressure", "TEST", 316, 340], ["cardiovascular", "ANATOMY", 48, 62], ["disease", "OBSERVATION", 63, 70], ["heart", "ANATOMY", 78, 83], ["failure", "OBSERVATION", 84, 91], ["myocardial", "ANATOMY", 93, 103], ["infarction", "OBSERVATION", 104, 114], ["peripheral artery", "ANATOMY", 126, 143], ["disease", "OBSERVATION", 144, 151], ["Hypertension", "OBSERVATION", 163, 175]]], ["Diabetes mellitus was based on self-report, receipt of antidiabetic agents or glycosylated hemoglobin \u22656.5%.", [["Diabetes mellitus", "DISEASE", 0, 17], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 91, 101], ["hemoglobin", "PROTEIN", 91, 101], ["Diabetes mellitus", "PROBLEM", 0, 17], ["antidiabetic agents", "TREATMENT", 55, 74], ["glycosylated hemoglobin", "TEST", 78, 101]]], ["At the baseline visit occurring at 90 days post-discharge, we measured serum creatinine using an IDMS-traceable enzymatic assay (Roche Diagnostics, Indianapolis, IN), plasma cystatin C standardized against the international calibrator standard ERMDA471/IFCC (Gentian, Moss, Norway), and a random spot urine protein-to-creatinine ratio using a turbidimetric method (Roche, Indianapolis, IN).Statistical approachAnalyses were conducted using SAS software, version 9.4 (Cary, NC).", [["serum", "ANATOMY", 71, 76], ["plasma", "ANATOMY", 167, 173], ["urine", "ANATOMY", 301, 306], ["creatinine", "CHEMICAL", 77, 87], ["creatinine", "CHEMICAL", 318, 328], ["creatinine", "CHEMICAL", 77, 87], ["creatinine", "CHEMICAL", 318, 328], ["serum", "ORGANISM_SUBSTANCE", 71, 76], ["creatinine", "SIMPLE_CHEMICAL", 77, 87], ["plasma", "ORGANISM_SUBSTANCE", 167, 173], ["cystatin C", "GENE_OR_GENE_PRODUCT", 174, 184], ["urine", "ORGANISM_SUBSTANCE", 301, 306], ["creatinine", "SIMPLE_CHEMICAL", 318, 328], ["plasma cystatin C", "PROTEIN", 167, 184], ["serum creatinine", "TEST", 71, 87], ["an IDMS", "TEST", 94, 101], ["plasma cystatin C", "TREATMENT", 167, 184], ["a random spot urine protein", "TEST", 287, 314], ["creatinine ratio", "TEST", 318, 334], ["a turbidimetric method", "TEST", 341, 363], ["SAS software", "TEST", 440, 452], ["version", "TEST", 454, 461]]], ["Characteristics were compared between matched AKI and non-AKI participants using paired t tests or Wilcoxon signed-rank tests for continuous variables and McNemar's tests for categorical variables.", [["AKI", "DISEASE", 46, 49], ["participants", "SPECIES", 62, 74], ["paired t tests", "TEST", 81, 95], ["rank tests", "TEST", 115, 125], ["continuous variables", "TEST", 130, 150], ["McNemar's tests", "TEST", 155, 170], ["categorical variables", "TEST", 175, 196]]], ["Rates of each outcome (per 100 person-years) with associated 95% confidence limits were calculated for AKI and non-AKI participants, and cumulative incidence curves compared using a log-rank test.Statistical approachFor each outcome, after confirming no violation of the proportional hazards assumption by examining log-log-survival curves, we performed nested Fine-Gray subdistribution hazard analyses 40 accounting for individual matching and competing risk of death, with additional incremental adjustment for variables not included in the matching criteria that have been previously reported or hypothesized to be risk factors for kidney and cardiovascular events, or differing between AKI and non-AKI participants at the baseline study visit.", [["kidney", "ANATOMY", 635, 641], ["cardiovascular", "ANATOMY", 646, 660], ["AKI", "DISEASE", 103, 106], ["death", "DISEASE", 463, 468], ["kidney and cardiovascular events", "DISEASE", 635, 667], ["AKI", "DISEASE", 690, 693], ["kidney", "ORGAN", 635, 641], ["cardiovascular", "ANATOMICAL_SYSTEM", 646, 660], ["participants", "SPECIES", 119, 131], ["participants", "SPECIES", 706, 718], ["AKI", "PROBLEM", 103, 106], ["cumulative incidence curves", "PROBLEM", 137, 164], ["a log-rank test", "TEST", 180, 195], ["death", "PROBLEM", 463, 468], ["kidney and cardiovascular events", "PROBLEM", 635, 667], ["AKI", "PROBLEM", 690, 693], ["kidney", "ANATOMY", 635, 641], ["cardiovascular", "ANATOMY", 646, 660]]], ["Based on an a priori hypothesis, pre-specified overall and stratified analyses were performed to evaluate for a potential interaction between an episode of AKI and pre-existing CKD status.", [["AKI", "DISEASE", 156, 159], ["CKD", "DISEASE", 177, 180], ["stratified analyses", "TEST", 59, 78], ["AKI", "PROBLEM", 156, 159], ["pre-existing CKD status", "PROBLEM", 164, 187], ["AKI", "OBSERVATION", 156, 159], ["CKD", "OBSERVATION", 177, 180]]], ["32 For cardiovascular and death outcomes, the final model additionally adjusted for three-month postdischarge measures of kidney function and proteinuria based on a priori hypotheses that levels of residual kidney function and damage may explain, at least in part, any observed excess risks for these clinical outcomes after an episode of AKI.", [["cardiovascular", "ANATOMY", 7, 21], ["kidney", "ANATOMY", 122, 128], ["kidney", "ANATOMY", 207, 213], ["cardiovascular and death", "DISEASE", 7, 31], ["proteinuria", "DISEASE", 142, 153], ["AKI", "DISEASE", 339, 342], ["cardiovascular", "ANATOMICAL_SYSTEM", 7, 21], ["kidney", "ORGAN", 122, 128], ["kidney", "ORGAN", 207, 213], ["kidney function", "TEST", 122, 137], ["proteinuria", "PROBLEM", 142, 153], ["a priori hypotheses", "TEST", 163, 182], ["residual kidney function", "PROBLEM", 198, 222], ["damage", "PROBLEM", 227, 233], ["AKI", "PROBLEM", 339, 342], ["kidney", "ANATOMY", 122, 128], ["proteinuria", "OBSERVATION", 142, 153], ["kidney", "ANATOMY", 207, 213], ["AKI", "OBSERVATION", 339, 342]]], ["Models were performed overall and stratified by pre-existing CKD status, as appropriate.", [["CKD", "DISEASE", 61, 64], ["pre-existing CKD status", "PROBLEM", 48, 71], ["CKD", "OBSERVATION", 61, 64]]], ["Because outcomes were time-to-event with rightcensoring due to death, study withdrawal or end of study follow-up, we did not impose any procedure to account for potential missingness in the outcomes.Statistical approachWe separately examined the association of severity of the index AKI episode with outcomes of interest by modeling KDIGO stage of AKI (1, 2 or 3) as a linear term.", [["death", "DISEASE", 63, 68], ["AKI", "DISEASE", 283, 286], ["AKI", "DISEASE", 348, 351], ["death", "PROBLEM", 63, 68], ["study withdrawal", "PROBLEM", 70, 86], ["study", "TEST", 97, 102], ["any procedure", "TREATMENT", 132, 145], ["potential missingness in the outcomes", "PROBLEM", 161, 198], ["the index AKI episode", "PROBLEM", 273, 294], ["AKI", "PROBLEM", 348, 351], ["index AKI", "OBSERVATION", 277, 286], ["AKI", "OBSERVATION", 348, 351]]], ["We used a similar approach to separately examine the association of AKI episode duration (non-AKI, AKI", [["AKI", "DISEASE", 68, 71], ["AKI", "DISEASE", 94, 97], ["AKI", "DISEASE", 99, 102], ["a similar approach", "TREATMENT", 8, 26], ["AKI episode duration", "PROBLEM", 68, 88], ["AKI", "PROBLEM", 94, 97], ["AKI", "PROBLEM", 99, 102], ["AKI", "OBSERVATION", 68, 71], ["AKI", "OBSERVATION", 94, 97], ["AKI", "OBSERVATION", 99, 102]]]], "6b63e8e461aa4e021df619f15a2dfb5ae6cc99dc": [["Background COVID-19 (coronavirus disease) is greatly influencing our society.", [["coronavirus disease", "DISEASE", 21, 40], ["COVID-19", "GENE_OR_GENE_PRODUCT", 11, 19], ["coronavirus", "ORGANISM", 21, 32], ["Background COVID", "TEST", 0, 16], ["coronavirus disease)", "PROBLEM", 21, 41], ["coronavirus disease", "OBSERVATION", 21, 40]]]], "0fa6e26b053037098f47252e99c4910f1626a376": [["IntroductionSevere bronchopulmonary dysplasia (sBPD) affects approximately 20% of extremely low-birthweight infants [1] .", [["bronchopulmonary dysplasia", "ANATOMY", 19, 45], ["bronchopulmonary dysplasia", "DISEASE", 19, 45], ["sBPD", "DISEASE", 47, 51], ["bronchopulmonary dysplasia", "PATHOLOGICAL_FORMATION", 19, 45], ["infants", "ORGANISM", 108, 115], ["infants", "SPECIES", 108, 115], ["bronchopulmonary dysplasia", "PROBLEM", 19, 45], ["bronchopulmonary", "ANATOMY", 19, 35], ["dysplasia", "OBSERVATION", 36, 45]]], ["Pulmonary arterial hypertension (PH) can occur in 15-25% of infants with sBPD, and is associated with an increased risk of mortality [2] [3] [4] .", [["Pulmonary arterial", "ANATOMY", 0, 18], ["Pulmonary arterial hypertension", "DISEASE", 0, 31], ["PH", "DISEASE", 33, 35], ["sBPD", "DISEASE", 73, 77], ["Pulmonary arterial", "MULTI-TISSUE_STRUCTURE", 0, 18], ["infants", "ORGANISM", 60, 67], ["infants", "SPECIES", 60, 67], ["Pulmonary arterial hypertension", "PROBLEM", 0, 31], ["sBPD", "PROBLEM", 73, 77], ["an increased risk of mortality", "PROBLEM", 102, 132], ["arterial", "ANATOMY", 10, 18], ["hypertension", "OBSERVATION", 19, 31], ["increased", "OBSERVATION_MODIFIER", 105, 114]]], ["Recognizing this concern, the American Heart Association recommends screening echocardiography to monitor for PH in infants with BPD [5] .", [["PH", "DISEASE", 110, 112], ["BPD", "DISEASE", 129, 132], ["infants", "ORGANISM", 116, 123], ["infants", "SPECIES", 116, 123], ["screening echocardiography", "TEST", 68, 94], ["PH", "PROBLEM", 110, 112], ["BPD", "PROBLEM", 129, 132]]], ["However, echocardiographic parameters are limited by subjective, varied, or missing measures, as well as modest correlation with pulmonary arterial pressure measured via cardiac catheterization [6] [7] [8] [9] .", [["pulmonary arterial", "ANATOMY", 129, 147], ["cardiac", "ANATOMY", 170, 177], ["pulmonary arterial", "MULTI-TISSUE_STRUCTURE", 129, 147], ["echocardiographic parameters", "TEST", 9, 37], ["pulmonary arterial pressure", "TEST", 129, 156], ["cardiac catheterization", "TEST", 170, 193], ["pulmonary arterial", "ANATOMY", 129, 147], ["cardiac", "ANATOMY", 170, 177], ["catheterization", "OBSERVATION", 178, 193]]], ["Further, screening for PH often varies from center to center.", [["PH", "DISEASE", 23, 25], ["screening", "TEST", 9, 18], ["PH", "TEST", 23, 25]]], ["Understanding whether standard clinically used echocardiographic parameters of PH are associated with mortality would help to inform clinical practices with respect to screening infants with sBPD for PH.IntroductionOur objective was to determine whether interventricular septal position and right ventricular systolic pressure on echocardiography performed between 34 and 44 weeks' post-menstrual age (PMA) were associated with in-hospital mortality in infants with sBPD.", [["interventricular septal", "ANATOMY", 254, 277], ["right ventricular", "ANATOMY", 291, 308], ["PH", "DISEASE", 79, 81], ["sBPD", "DISEASE", 191, 195], ["PH", "DISEASE", 200, 202], ["sBPD", "DISEASE", 466, 470], ["infants", "ORGANISM", 178, 185], ["interventricular septal", "MULTI-TISSUE_STRUCTURE", 254, 277], ["right ventricular", "MULTI-TISSUE_STRUCTURE", 291, 308], ["systolic", "MULTI-TISSUE_STRUCTURE", 309, 317], ["infants", "ORGANISM", 453, 460], ["infants", "SPECIES", 178, 185], ["infants", "SPECIES", 453, 460], ["echocardiographic parameters", "TEST", 47, 75], ["sBPD", "TREATMENT", 191, 195], ["PH", "PROBLEM", 200, 202], ["right ventricular systolic pressure", "TEST", 291, 326], ["echocardiography", "TEST", 330, 346], ["sBPD", "PROBLEM", 466, 470], ["interventricular septal", "ANATOMY", 254, 277], ["right ventricular", "ANATOMY", 291, 308], ["systolic pressure", "OBSERVATION", 309, 326]]], ["We hypothesized that these measures could be used to predict inpatient mortality in a real-world clinical cohort.MethodsWe performed a secondary analysis of data from the Children's Hospitals Neonatal Database (CHND), which includes prospectively collected data on all infants admitted to participating Level IV neonatal intensive care units (NICUs) in the United States and Canada.", [["infants", "ORGANISM", 269, 276], ["Children", "SPECIES", 171, 179], ["infants", "SPECIES", 269, 276]]], ["Infant clinical data were collected by trained chart abstractors at each site, with periodic assessments of inter-rater agreement scores [10] .", [["periodic assessments", "TEST", 84, 104]]], ["De-identified data analyses were approved by the Institutional Review Board of Stanley Manne Research Institute affiliated with the Ann and Robert H. Lurie Children's Hospital of Chicago.", [["Children", "SPECIES", 156, 164], ["De-identified data analyses", "TEST", 0, 27]]], ["All participating centers obtained regulatory oversight to participate in the CHND registry.MethodsWe included infants born <32 weeks' gestation who were admitted to a participating NICU between 2010 and 2015, who had sBPD, and who had at least one echocardiogram between 34 and 44 weeks' PMA. sBPD was defined as receiving positive pressure ventilation, >2 L/min flow by nasal cannula, or fractional inspired oxygen (FiO2) > 0.3 at or after 36 weeks' PMA [2, 10, 11] .", [["nasal", "ANATOMY", 372, 377], ["oxygen", "CHEMICAL", 410, 416], ["PMA", "CHEMICAL", 289, 292], ["oxygen", "CHEMICAL", 410, 416], ["FiO2", "CHEMICAL", 418, 422], ["PMA", "CHEMICAL", 452, 455], ["infants", "ORGANISM", 111, 118], ["oxygen", "SIMPLE_CHEMICAL", 410, 416], ["PMA", "SIMPLE_CHEMICAL", 452, 455], ["infants", "SPECIES", 111, 118], ["one echocardiogram", "TEST", 245, 263], ["positive pressure ventilation", "TREATMENT", 324, 353], ["nasal cannula", "TREATMENT", 372, 385], ["fractional inspired oxygen (FiO2", "TREATMENT", 390, 422], ["pressure ventilation", "OBSERVATION", 333, 353], ["nasal cannula", "ANATOMY", 372, 385]]], ["Infants were excluded if they died prior to 36 weeks' PMA, were transferred out of the participating hospital before discharge, or if they had major congenital anomalies.", [["congenital anomalies", "DISEASE", 149, 169], ["PMA", "CHEMICAL", 54, 57], ["Infants", "ORGANISM", 0, 7], ["Infants", "SPECIES", 0, 7], ["major congenital anomalies", "PROBLEM", 143, 169], ["anomalies", "OBSERVATION", 160, 169]]], ["Infants with an isolated atrial septal defect, ventricular septal defect, or patent ductus arteriosus were retained in the study.MethodsThe primary outcome was mortality between 36 weeks' PMA and discharge from a CHND hospital.", [["atrial septal", "ANATOMY", 25, 38], ["ventricular septal", "ANATOMY", 47, 65], ["patent ductus arteriosus", "ANATOMY", 77, 101], ["atrial septal defect", "DISEASE", 25, 45], ["ventricular septal defect", "DISEASE", 47, 72], ["patent ductus arteriosus", "DISEASE", 77, 101], ["CHND", "DISEASE", 213, 217], ["PMA", "CHEMICAL", 188, 191], ["atrial septal", "MULTI-TISSUE_STRUCTURE", 25, 38], ["ventricular septal", "MULTI-TISSUE_STRUCTURE", 47, 65], ["ductus arteriosus", "MULTI-TISSUE_STRUCTURE", 84, 101], ["Infants", "SPECIES", 0, 7], ["an isolated atrial septal defect", "PROBLEM", 13, 45], ["ventricular septal defect", "PROBLEM", 47, 72], ["patent ductus arteriosus", "PROBLEM", 77, 101], ["the study", "TEST", 119, 128], ["isolated", "OBSERVATION_MODIFIER", 16, 24], ["atrial septal", "ANATOMY", 25, 38], ["defect", "OBSERVATION", 39, 45], ["ventricular septal", "ANATOMY", 47, 65], ["defect", "OBSERVATION", 66, 72], ["patent", "OBSERVATION", 77, 83], ["ductus arteriosus", "OBSERVATION", 84, 101]]], ["Primary exposures of interest were echocardiographic measures of interventricular septal position (SP) and right ventricular systolic pressure (RVSP) recorded between 34 and 44 weeks' PMA.", [["interventricular septal", "ANATOMY", 65, 88], ["right ventricular", "ANATOMY", 107, 124], ["PMA", "CHEMICAL", 184, 187], ["interventricular septal", "MULTI-TISSUE_STRUCTURE", 65, 88], ["ventricular", "MULTI-TISSUE_STRUCTURE", 113, 124], ["PMA", "SIMPLE_CHEMICAL", 184, 187], ["echocardiographic measures", "TEST", 35, 61], ["right ventricular systolic pressure", "TEST", 107, 142], ["RVSP", "TEST", 144, 148], ["interventricular septal", "ANATOMY", 65, 88], ["right ventricular", "ANATOMY", 107, 124], ["systolic pressure", "OBSERVATION", 125, 142]]], ["SP was defined as abnormal if there was documentation of septal position being flattened or bowed to the left.", [["septal", "ANATOMY", 57, 63], ["SP", "PROTEIN", 0, 2], ["septal position", "OBSERVATION", 57, 72], ["flattened", "OBSERVATION_MODIFIER", 79, 88], ["bowed", "OBSERVATION_MODIFIER", 92, 97], ["left", "ANATOMY_MODIFIER", 105, 109]]], ["RVSP was categorized as abnormal if the result was >40 mmHg; this cut-off was determined a priori corresponding to values >40 mmHg being more than half of the systemic blood pressure [7, 12, 13] .", [["blood", "ANATOMY", 168, 173], ["blood", "ORGANISM_SUBSTANCE", 168, 173], ["RVSP", "TEST", 0, 4], ["the systemic blood pressure", "TEST", 155, 182]]], ["For infants with multiple echocardiograms, we examined all reports occurring between 34 and 44 weeks PMA; we categorized the infant as having an abnormal echocardiographic parameter if any available studies had an abnormal parameter.", [["PMA", "CHEMICAL", 101, 104], ["infants", "ORGANISM", 4, 11], ["infant", "ORGANISM", 125, 131], ["infants", "SPECIES", 4, 11], ["multiple echocardiograms", "TEST", 17, 41], ["an abnormal echocardiographic parameter", "PROBLEM", 142, 181], ["any available studies", "TEST", 185, 206]]], ["If no available echocardiography reports documented RVSP or SP, we categorized the data as missing and retained that infant in the dataset.", [["available echocardiography", "TEST", 6, 32], ["RVSP", "PROBLEM", 52, 56], ["SP", "PROBLEM", 60, 62], ["RVSP", "OBSERVATION", 52, 56]]], ["Direction of flow across the patent ductus arteriosus (PDA) and the interatrial septum were not considered as exposures for this study because the PDA was closed and interatrial septal flow was minimal in nearly all subjects between 34 and 44 weeks' PMA.", [["patent ductus arteriosus", "ANATOMY", 29, 53], ["interatrial septum", "ANATOMY", 68, 86], ["interatrial septal", "ANATOMY", 166, 184], ["PMA", "CHEMICAL", 250, 253], ["ductus arteriosus", "MULTI-TISSUE_STRUCTURE", 36, 53], ["interatrial septum", "MULTI-TISSUE_STRUCTURE", 68, 86], ["septal", "MULTI-TISSUE_STRUCTURE", 178, 184], ["PMA", "SIMPLE_CHEMICAL", 250, 253], ["this study", "TEST", 124, 134], ["the PDA", "TEST", 143, 150], ["interatrial septal flow", "PROBLEM", 166, 189], ["flow", "OBSERVATION", 13, 17], ["patent", "OBSERVATION", 29, 35], ["ductus arteriosus", "ANATOMY", 36, 53], ["interatrial septum", "ANATOMY", 68, 86], ["not considered", "UNCERTAINTY", 92, 106], ["PDA", "OBSERVATION", 147, 150], ["interatrial", "ANATOMY", 166, 177], ["septal flow", "OBSERVATION", 178, 189], ["minimal", "OBSERVATION_MODIFIER", 194, 201]]], ["Instead, PDA ligation and interatrial communication were included as potential covariates.MethodsWe included other clinical covariates available in the CHND that we hypothesized might confound the relationship between echocardiographic parameters and mortality.", [["interatrial", "ANATOMY", 26, 37], ["PDA ligation", "TREATMENT", 9, 21], ["interatrial communication", "TREATMENT", 26, 51], ["echocardiographic parameters", "TEST", 218, 246], ["PDA", "OBSERVATION_MODIFIER", 9, 12], ["ligation", "OBSERVATION", 13, 21], ["interatrial", "ANATOMY", 26, 37]]], ["Maternal characteristics included were race, diabetes, hypertension, chorioamnionitis, multiple gestation, and receipt of antenatal steroids.", [["diabetes", "DISEASE", 45, 53], ["hypertension", "DISEASE", 55, 67], ["chorioamnionitis", "DISEASE", 69, 85], ["steroids", "CHEMICAL", 132, 140], ["steroids", "CHEMICAL", 132, 140], ["diabetes", "PROBLEM", 45, 53], ["hypertension", "PROBLEM", 55, 67], ["chorioamnionitis", "PROBLEM", 69, 85], ["multiple gestation", "PROBLEM", 87, 105], ["antenatal steroids", "TREATMENT", 122, 140], ["hypertension", "OBSERVATION", 55, 67], ["chorioamnionitis", "OBSERVATION", 69, 85], ["multiple", "OBSERVATION_MODIFIER", 87, 95], ["gestation", "OBSERVATION", 96, 105]]], ["Neonatal characteristics included gestational age, birthweight, small for gestational age (defined as sex-specific \u2264 10th percentile of birthweight for gestational age) [14] , duration of mechanical ventilation in the CHND nursery, receipt of mechanical ventilation at 36 weeks' PMA, receipt of systemic corticosteroids, bloodstream infections, atrial septal communications, or PDA ligation.", [["bloodstream", "ANATOMY", 321, 332], ["atrial septal", "ANATOMY", 345, 358], ["CHND", "DISEASE", 218, 222], ["bloodstream infections", "DISEASE", 321, 343], ["atrial septal communications", "DISEASE", 345, 373], ["PMA", "CHEMICAL", 279, 282], ["atrial septal", "MULTI-TISSUE_STRUCTURE", 345, 358], ["birthweight", "TEST", 51, 62], ["mechanical ventilation", "TREATMENT", 188, 210], ["mechanical ventilation", "TREATMENT", 243, 265], ["systemic corticosteroids", "TREATMENT", 295, 319], ["bloodstream infections", "PROBLEM", 321, 343], ["atrial septal communications", "TREATMENT", 345, 373], ["PDA ligation", "TREATMENT", 378, 390], ["small", "OBSERVATION_MODIFIER", 64, 69], ["mechanical ventilation", "OBSERVATION", 188, 210], ["mechanical ventilation", "OBSERVATION", 243, 265], ["atrial septal", "ANATOMY", 345, 358], ["PDA ligation", "OBSERVATION", 378, 390]]], ["A respiratory severity score was also calculated as a product of the mean airway pressure and the fractional oxygen requirement (MAP \u00d7 FiO 2 ) at 36 weeks' PMA and compared between groups (see Table 1 ).", [["respiratory", "ANATOMY", 2, 13], ["airway", "ANATOMY", 74, 80], ["oxygen", "CHEMICAL", 109, 115], ["oxygen", "CHEMICAL", 109, 115], ["PMA", "CHEMICAL", 156, 159], ["airway", "MULTI-TISSUE_STRUCTURE", 74, 80], ["oxygen", "SIMPLE_CHEMICAL", 109, 115], ["A respiratory severity score", "PROBLEM", 0, 28], ["the mean airway pressure", "TEST", 65, 89], ["the fractional oxygen requirement", "PROBLEM", 94, 127], ["MAP", "TEST", 129, 132], ["FiO", "TEST", 135, 138], ["airway pressure", "OBSERVATION", 74, 89], ["fractional", "OBSERVATION_MODIFIER", 98, 108], ["oxygen requirement", "OBSERVATION", 109, 127]]], ["Bloodstream infections were defined as any confirmed bacterial or fungal organisms recovered from a blood culture during the hospital admission.", [["Bloodstream", "ANATOMY", 0, 11], ["blood", "ANATOMY", 100, 105], ["Bloodstream infections", "DISEASE", 0, 22], ["blood", "ORGANISM_SUBSTANCE", 100, 105], ["Bloodstream infections", "PROBLEM", 0, 22], ["bacterial or fungal organisms", "PROBLEM", 53, 82], ["a blood culture", "TEST", 98, 113], ["infections", "OBSERVATION", 12, 22], ["fungal organisms", "OBSERVATION", 66, 82]]], ["Necrotizing enterocolitis was defined as any of the following conditions: (1) Surgical NEC; (2) NEC at post-mortem examination or (3) if both clinical symptoms (bilious aspirate or emesis, abdominal distention, and occult/gross blood in stool) and radiographic findings (pneumotosis intestinalis, hepatobiliary gas or pneumoperitonem) were present.", [["bilious aspirate", "ANATOMY", 161, 177], ["abdominal", "ANATOMY", 189, 198], ["blood", "ANATOMY", 228, 233], ["stool", "ANATOMY", 237, 242], ["hepatobiliary", "ANATOMY", 297, 310], ["Necrotizing enterocolitis", "DISEASE", 0, 25], ["NEC", "DISEASE", 87, 90], ["NEC", "DISEASE", 96, 99], ["emesis", "DISEASE", 181, 187], ["abdominal distention", "DISEASE", 189, 209], ["pneumotosis intestinalis", "DISEASE", 271, 295], ["NEC", "PATHOLOGICAL_FORMATION", 96, 99], ["abdominal", "ORGANISM_SUBDIVISION", 189, 198], ["blood", "ORGANISM_SUBSTANCE", 228, 233], ["stool", "ORGANISM_SUBSTANCE", 237, 242], ["hepatobiliary", "ORGAN", 297, 310], ["Necrotizing enterocolitis", "PROBLEM", 0, 25], ["Surgical NEC", "PROBLEM", 78, 90], ["NEC", "PROBLEM", 96, 99], ["post-mortem examination", "TEST", 103, 126], ["both clinical symptoms", "PROBLEM", 137, 159], ["bilious aspirate", "PROBLEM", 161, 177], ["emesis", "PROBLEM", 181, 187], ["abdominal distention", "PROBLEM", 189, 209], ["occult/gross blood in stool", "PROBLEM", 215, 242], ["radiographic findings", "TEST", 248, 269], ["pneumotosis intestinalis", "PROBLEM", 271, 295], ["hepatobiliary gas", "PROBLEM", 297, 314], ["pneumoperitonem", "PROBLEM", 318, 333], ["enterocolitis", "OBSERVATION", 12, 25], ["abdominal", "ANATOMY", 189, 198], ["pneumotosis", "OBSERVATION", 271, 282], ["hepatobiliary", "ANATOMY", 297, 310]]], ["These findings correspond to a NEC Stage IIb or higher.", [["NEC", "DISEASE", 31, 34], ["NEC Stage IIb", "CANCER", 31, 44], ["a NEC Stage IIb", "PROBLEM", 29, 44], ["NEC", "OBSERVATION_MODIFIER", 31, 34], ["Stage IIb", "OBSERVATION_MODIFIER", 35, 44], ["higher", "OBSERVATION_MODIFIER", 48, 54]]], ["Airway comorbidities were defined as laryngeal, tracheal, or bronchial malacia, laryngeal or tracheal stenosis, or vocal cord paralysis or paresis.Statistical analysisWe first assessed the proportion of echocardiographic parameters that were normal, abnormal and missing in the study cohort.", [["Airway", "ANATOMY", 0, 6], ["laryngeal", "ANATOMY", 37, 46], ["tracheal", "ANATOMY", 48, 56], ["bronchial", "ANATOMY", 61, 70], ["laryngeal", "ANATOMY", 80, 89], ["tracheal", "ANATOMY", 93, 101], ["vocal cord", "ANATOMY", 115, 125], ["laryngeal or tracheal stenosis", "DISEASE", 80, 110], ["vocal cord paralysis", "DISEASE", 115, 135], ["paresis", "DISEASE", 139, 146], ["Airway", "MULTI-TISSUE_STRUCTURE", 0, 6], ["laryngeal", "ORGAN", 37, 46], ["tracheal", "MULTI-TISSUE_STRUCTURE", 48, 56], ["laryngeal", "MULTI-TISSUE_STRUCTURE", 80, 89], ["tracheal", "MULTI-TISSUE_STRUCTURE", 93, 101], ["cord", "ORGAN", 121, 125], ["Airway comorbidities", "PROBLEM", 0, 20], ["laryngeal, tracheal, or bronchial malacia", "PROBLEM", 37, 78], ["laryngeal or tracheal stenosis", "PROBLEM", 80, 110], ["vocal cord paralysis", "PROBLEM", 115, 135], ["paresis", "PROBLEM", 139, 146], ["echocardiographic parameters", "TEST", 203, 231], ["comorbidities", "OBSERVATION", 7, 20], ["laryngeal", "ANATOMY", 37, 46], ["tracheal", "ANATOMY", 48, 56], ["bronchial", "ANATOMY", 61, 70], ["malacia", "OBSERVATION", 71, 78], ["laryngeal", "ANATOMY", 80, 89], ["tracheal", "ANATOMY", 93, 101], ["stenosis", "OBSERVATION", 102, 110], ["vocal cord", "ANATOMY", 115, 125], ["paralysis", "OBSERVATION", 126, 135], ["paresis", "OBSERVATION", 139, 146], ["normal", "OBSERVATION", 242, 248]]], ["We compared the clinical characteristics by SP and RVSP groups of normal, abnormal and missing, using chi-squared or Fisher's exact tests for differences in proportion and Kruskal\u2212Wallis nonparametric tests for differences of medians.", [["SP and RVSP groups", "TEST", 44, 62], ["Fisher's exact tests", "TEST", 117, 137], ["Wallis nonparametric tests", "TEST", 180, 206], ["normal", "OBSERVATION", 66, 72], ["abnormal", "OBSERVATION_MODIFIER", 74, 82]]], ["For the unadjusted association between echocardiographic parameters and mortality, we calculated the sensitivity, specificity, positive and negative predictive value, and relative risk.", [["echocardiographic parameters", "TEST", 39, 67], ["the sensitivity", "TEST", 97, 112], ["specificity", "TEST", 114, 125]]], ["Because we assumed the echocardiographic exposure variables to be collinear, we ran two separate models, one with septal position alone as the exposure, and one with RVSP alone as the exposure.", [["the echocardiographic exposure variables", "PROBLEM", 19, 59]]], ["For each model, abnormal and missing echocardiographic parameters were each tested against a referent group of infants with normal echocardiographic parameters.", [["infants", "ORGANISM", 111, 118], ["infants", "SPECIES", 111, 118], ["abnormal and missing echocardiographic parameters", "PROBLEM", 16, 65]]], ["SAS v 9.2 (SAS Institute, Cary, North Carolina) was used for analyses.ResultsThe database included 12,221 infants born <32 weeks' gestation who were alive at 36 weeks' PMA and who did not have congenital anomalies.", [["congenital anomalies", "DISEASE", 193, 213], ["PMA", "CHEMICAL", 168, 171], ["infants", "ORGANISM", 106, 113], ["infants", "SPECIES", 106, 113], ["SAS v", "TEST", 0, 5], ["congenital anomalies", "PROBLEM", 193, 213], ["congenital", "OBSERVATION_MODIFIER", 193, 203], ["anomalies", "OBSERVATION", 204, 213]]], ["Of those, 2806 infants had sBPD and 1412 (50%) infants with sBPD had one or more echocardiograms between 34 and 44 weeks' PMA.", [["sBPD", "DISEASE", 60, 64], ["PMA", "CHEMICAL", 122, 125], ["infants", "ORGANISM", 15, 22], ["infants", "ORGANISM", 47, 54], ["PMA", "SIMPLE_CHEMICAL", 122, 125], ["infants", "SPECIES", 15, 22], ["infants", "SPECIES", 47, 54], ["sBPD", "TEST", 27, 31], ["echocardiograms", "TEST", 81, 96]]], ["We excluded 255 infants who were transferred to another hospital before discharge.", [["infants", "ORGANISM", 16, 23], ["infants", "SPECIES", 16, 23]]], ["Septal position (SP) was categorized as normal in 616 (53%) infants, abnormal in 227 (20%) infants, and missing in 314 (27%) of infants.", [["Septal", "ANATOMY", 0, 6], ["infants", "ORGANISM", 60, 67], ["infants", "ORGANISM", 91, 98], ["infants", "ORGANISM", 128, 135], ["infants", "SPECIES", 60, 67], ["infants", "SPECIES", 91, 98], ["infants", "SPECIES", 128, 135], ["Septal position (SP)", "TEST", 0, 20], ["position", "OBSERVATION_MODIFIER", 7, 15], ["normal", "OBSERVATION", 40, 46]]], ["Table 1 (top) compares characteristics of infants by SP.", [["infants", "ORGANISM", 42, 49], ["SP", "PROTEIN", 53, 55], ["infants", "SPECIES", 42, 49]]], ["SP groups differed with respect to gestational age and birthweight, age at referral to CHND NICU, birthweight < 10th percentile for gestational age, maternal race, duration of mechanical ventilation, respiratory severity score at 36 weeks' PMA, receipt of systemic corticosteroids, bloodstream infections, and atrial septal defects.", [["respiratory", "ANATOMY", 200, 211], ["bloodstream", "ANATOMY", 282, 293], ["atrial septal", "ANATOMY", 310, 323], ["CHND", "DISEASE", 87, 91], ["bloodstream infections", "DISEASE", 282, 304], ["atrial septal defects", "DISEASE", 310, 331], ["atrial septal", "MULTI-TISSUE_STRUCTURE", 310, 323], ["birthweight", "TEST", 98, 109], ["mechanical ventilation", "TREATMENT", 176, 198], ["respiratory severity score", "PROBLEM", 200, 226], ["systemic corticosteroids", "TREATMENT", 256, 280], ["bloodstream infections", "PROBLEM", 282, 304], ["atrial septal defects", "PROBLEM", 310, 331], ["mechanical ventilation", "OBSERVATION", 176, 198], ["systemic corticosteroids", "OBSERVATION", 256, 280], ["bloodstream infections", "OBSERVATION", 282, 304], ["atrial septal", "ANATOMY", 310, 323], ["defects", "OBSERVATION", 324, 331]]], ["The proportion of infants receiving PDA ligation was similar between groups but the PMA at PDA ligation was later in infants with abnormal SP.", [["PMA", "CHEMICAL", 84, 87], ["PMA", "CHEMICAL", 84, 87], ["infants", "ORGANISM", 18, 25], ["PMA", "SIMPLE_CHEMICAL", 84, 87], ["infants", "ORGANISM", 117, 124], ["SP", "PROTEIN", 139, 141], ["infants", "SPECIES", 18, 25], ["infants", "SPECIES", 117, 124], ["PDA ligation", "TREATMENT", 36, 48], ["the PMA at PDA ligation", "TREATMENT", 80, 103], ["abnormal SP", "PROBLEM", 130, 141], ["ligation", "OBSERVATION", 40, 48]]], ["Infants with missing SP had clinical characteristics that were similar to those of infants with normal position.", [["Infants", "ORGANISM", 0, 7], ["infants", "ORGANISM", 83, 90], ["Infants", "SPECIES", 0, 7], ["infants", "SPECIES", 83, 90], ["missing SP", "PROBLEM", 13, 23], ["normal", "OBSERVATION", 96, 102], ["position", "OBSERVATION_MODIFIER", 103, 111]]], ["RVSP was categorized as normal in 230 (20%) infants, abnormal in 84 (7%), and missing in 843 (73%).", [["infants", "ORGANISM", 44, 51], ["infants", "SPECIES", 44, 51], ["RVSP", "TEST", 0, 4], ["normal", "OBSERVATION", 24, 30]]], ["Table 1 (bottom) compares characteristics of infants by RVSP.", [["infants", "ORGANISM", 45, 52], ["infants", "SPECIES", 45, 52]]], ["RVSP categories differed in categories of birthweight, sex, maternal race, singleton birth and atrial septal defects.", [["atrial septal", "ANATOMY", 95, 108], ["atrial septal defects", "DISEASE", 95, 116], ["atrial septal", "MULTI-TISSUE_STRUCTURE", 95, 108], ["RVSP categories", "PROBLEM", 0, 15], ["singleton birth", "PROBLEM", 75, 90], ["atrial septal defects", "PROBLEM", 95, 116], ["atrial septal", "ANATOMY", 95, 108], ["defects", "OBSERVATION", 109, 116]]], ["Rates of PDA ligation were similar between groups but the median PMA at ligation was later in infants with abnormal RVSP.", [["PMA", "CHEMICAL", 65, 68], ["PMA", "CHEMICAL", 65, 68], ["PMA", "SIMPLE_CHEMICAL", 65, 68], ["infants", "ORGANISM", 94, 101], ["infants", "SPECIES", 94, 101], ["PDA ligation", "TREATMENT", 9, 21], ["the median PMA at ligation", "TREATMENT", 54, 80], ["abnormal RVSP", "PROBLEM", 107, 120], ["PDA", "OBSERVATION_MODIFIER", 9, 12], ["ligation", "OBSERVATION", 13, 21], ["RVSP", "OBSERVATION", 116, 120]]], ["Infants with missing RVSP had the largest birthweight, the lowest receipt of postnatal systemic steroids, and the lowest proportion of atrial septal defects.ResultsAbnormal SP and RVSP were each associated with higher odds of mortality ( Table 2 , top).", [["atrial septal", "ANATOMY", 135, 148], ["steroids", "CHEMICAL", 96, 104], ["atrial septal defects", "DISEASE", 135, 156], ["steroids", "CHEMICAL", 96, 104], ["Infants", "ORGANISM", 0, 7], ["atrial septal", "MULTI-TISSUE_STRUCTURE", 135, 148], ["SP", "PROTEIN", 173, 175], ["Infants", "SPECIES", 0, 7], ["missing RVSP", "PROBLEM", 13, 25], ["postnatal systemic steroids", "TREATMENT", 77, 104], ["atrial septal defects", "PROBLEM", 135, 156], ["RVSP", "TEST", 180, 184], ["RVSP", "OBSERVATION", 21, 25], ["largest", "OBSERVATION_MODIFIER", 34, 41], ["systemic steroids", "OBSERVATION", 87, 104], ["atrial septal", "ANATOMY", 135, 148], ["defects", "OBSERVATION", 149, 156], ["RVSP", "OBSERVATION", 180, 184]]], ["In unadjusted analysis, abnormal SP was associated with 2.6-fold increase in mortality, and after adjustment for significant covariates, SP was associated with 1.9-times the odds of mortality, when compared with infants with normal SP (p = 0.01).", [["SP", "PROTEIN", 33, 35], ["infants", "SPECIES", 212, 219], ["unadjusted analysis", "TEST", 3, 22], ["abnormal SP", "PROBLEM", 24, 35], ["2.6-fold increase in mortality", "PROBLEM", 56, 86], ["significant covariates", "PROBLEM", 113, 135], ["abnormal", "OBSERVATION_MODIFIER", 24, 32], ["increase", "OBSERVATION_MODIFIER", 65, 73]]], ["However, infants with missing SP did not have significantly different odds of mortality from those with normal SP.", [["infants", "ORGANISM", 9, 16], ["SP", "PROTEIN", 111, 113], ["infants", "SPECIES", 9, 16]]], ["Receiving ventilation at 36 weeks' PMA, having a bloodstream infection, receiving postnatal steroids, and being admitted at a later PMA were also significant risk factors for mortality in both unadjusted and adjusted SP models.", [["bloodstream", "ANATOMY", 49, 60], ["bloodstream infection", "DISEASE", 49, 70], ["steroids", "CHEMICAL", 92, 100], ["PMA", "CHEMICAL", 35, 38], ["steroids", "CHEMICAL", 92, 100], ["PMA", "CHEMICAL", 132, 135], ["PMA", "SIMPLE_CHEMICAL", 132, 135], ["ventilation", "TREATMENT", 10, 21], ["a bloodstream infection", "PROBLEM", 47, 70], ["postnatal steroids", "TREATMENT", 82, 100], ["bloodstream", "ANATOMY", 49, 60], ["infection", "OBSERVATION", 61, 70]]], ["Similarly, in both unadjusted models and adjusted models, abnormal RVSP was associated with a 2.2-fold increase in mortality (p = 0.02), whereas infants with missing RVSP data had mortality rates that were similar to infants with normal RVSP values ( Table 2 , bottom).", [["infants", "ORGANISM", 145, 152], ["infants", "ORGANISM", 217, 224], ["infants", "SPECIES", 145, 152], ["infants", "SPECIES", 217, 224], ["abnormal RVSP", "PROBLEM", 58, 71], ["a 2.2-fold increase in mortality", "PROBLEM", 92, 124], ["missing RVSP data", "PROBLEM", 158, 175], ["mortality rates", "PROBLEM", 180, 195], ["abnormal", "OBSERVATION_MODIFIER", 58, 66], ["RVSP", "OBSERVATION", 67, 71], ["increase", "OBSERVATION_MODIFIER", 103, 111], ["RVSP", "OBSERVATION", 237, 241]]], ["Ventilation at 36 wks' PMA, bloodstream infection, postnatal steroid use, and admission PMA remained significantly associated with mortality in adjusted RVSP models.", [["bloodstream", "ANATOMY", 28, 39], ["bloodstream infection", "DISEASE", 28, 49], ["steroid", "CHEMICAL", 61, 68], ["PMA", "CHEMICAL", 23, 26], ["steroid", "CHEMICAL", 61, 68], ["PMA", "CHEMICAL", 88, 91], ["PMA", "SIMPLE_CHEMICAL", 23, 26], ["bloodstream", "IMMATERIAL_ANATOMICAL_ENTITY", 28, 39], ["steroid", "SIMPLE_CHEMICAL", 61, 68], ["PMA", "SIMPLE_CHEMICAL", 88, 91], ["Ventilation", "TREATMENT", 0, 11], ["bloodstream infection", "PROBLEM", 28, 49], ["postnatal steroid use", "TREATMENT", 51, 72], ["bloodstream", "ANATOMY", 28, 39], ["infection", "OBSERVATION", 40, 49]]], ["Whereas atrial septal defects marginally increased the odds of mortality in SP models, the presence of an interatrial communication significantly increased mortality by 1.9-fold in RVSP models.ResultsOverall, infants with abnormal septal position had a mortality rate that was 19% compared with 8% of infants with normal SP, and 8% for infants with normal/missing data (abnormal SP n = 43/227 vs. normal SP n = 50/616 or normal/missing SP n = 72/930).", [["atrial septal", "ANATOMY", 8, 21], ["interatrial", "ANATOMY", 106, 117], ["septal", "ANATOMY", 231, 237], ["atrial septal defects", "DISEASE", 8, 29], ["atrial septal", "MULTI-TISSUE_STRUCTURE", 8, 21], ["interatrial", "MULTI-TISSUE_STRUCTURE", 106, 117], ["infants", "ORGANISM", 209, 216], ["infants", "ORGANISM", 301, 308], ["infants", "ORGANISM", 336, 343], ["infants", "SPECIES", 209, 216], ["infants", "SPECIES", 301, 308], ["infants", "SPECIES", 336, 343], ["atrial septal defects", "PROBLEM", 8, 29], ["an interatrial communication significantly increased mortality", "PROBLEM", 103, 165], ["abnormal septal position", "PROBLEM", 222, 246], ["a mortality rate", "TEST", 251, 267], ["abnormal SP n", "PROBLEM", 370, 383], ["atrial", "ANATOMY", 8, 14], ["septal", "ANATOMY_MODIFIER", 15, 21], ["defects", "OBSERVATION", 22, 29], ["marginally", "OBSERVATION_MODIFIER", 30, 40], ["increased", "OBSERVATION_MODIFIER", 41, 50], ["interatrial", "ANATOMY", 106, 117], ["significantly", "OBSERVATION_MODIFIER", 132, 145], ["increased", "OBSERVATION_MODIFIER", 146, 155], ["mortality", "OBSERVATION_MODIFIER", 156, 165], ["RVSP", "ANATOMY", 181, 185], ["abnormal", "OBSERVATION_MODIFIER", 222, 230], ["septal position", "OBSERVATION", 231, 246]]], ["Mortality for infants with abnormal RVSP was 20% (n = 17/84) compared with 10% for infants with normal data (n = 24/230) and 9% for infant with normal/missing data (n = 98/1073).ResultsTest characteristics of the abnormal echocardiographic parameters are shown in Table 3 .", [["infants", "ORGANISM", 14, 21], ["infants", "ORGANISM", 83, 90], ["infants", "SPECIES", 14, 21], ["infants", "SPECIES", 83, 90], ["abnormal RVSP", "PROBLEM", 27, 40], ["the abnormal echocardiographic parameters", "PROBLEM", 209, 250]]], ["When comparing infants with abnormal SP or RVSP to those with normal parameters, these parameters were highly specific (82% and 94%, respectively) but poorly sensitive (37% and 15%) markers of mortality.", [["infants", "ORGANISM", 15, 22], ["abnormal SP", "PROTEIN", 28, 39], ["infants", "SPECIES", 15, 22], ["abnormal SP", "PROBLEM", 28, 39], ["these parameters", "TEST", 81, 97]]], ["This pattern was nearly identical when comparing abnormal SP or RVSP to infants either a normal or missing parameter.DiscussionIn this multicenter clinical cohort of infants with sBPD, we found that septal position and RVSP > 40 mmHg were significantly associated with in-hospital mortality after adjusting for significant clinical characteristics.", [["septal", "ANATOMY", 199, 205], ["sBPD", "DISEASE", 179, 183], ["infants", "ORGANISM", 72, 79], ["infants", "ORGANISM", 166, 173], ["septal", "MULTI-TISSUE_STRUCTURE", 199, 205], ["SP", "PROTEIN", 58, 60], ["infants", "SPECIES", 72, 79], ["infants", "SPECIES", 166, 173], ["abnormal SP", "PROBLEM", 49, 60], ["RVSP", "TEST", 219, 223], ["normal", "OBSERVATION", 89, 95], ["septal", "OBSERVATION", 199, 205]]], ["We also found that infants with missing documentation of RVSP and/or septal position had clinical and mortality outcomes similar to those with documented normal echocardiographic parameters.DiscussionPulmonary hypertension is a significant contributor to morbidity and mortality in premature infants with BPD [2, [15] [16] [17] [18] .", [["septal", "ANATOMY", 69, 75], ["hypertension", "DISEASE", 210, 222], ["BPD", "DISEASE", 305, 308], ["infants", "ORGANISM", 19, 26], ["infants", "ORGANISM", 292, 299], ["[15] [16] [17] [18]", "SIMPLE_CHEMICAL", 313, 332], ["infants", "SPECIES", 19, 26], ["infants", "SPECIES", 292, 299], ["RVSP", "TEST", 57, 61], ["DiscussionPulmonary hypertension", "PROBLEM", 190, 222], ["morbidity", "PROBLEM", 255, 264], ["mortality in premature infants", "PROBLEM", 269, 299], ["BPD", "PROBLEM", 305, 308], ["septal", "ANATOMY_MODIFIER", 69, 75], ["hypertension", "OBSERVATION", 210, 222]]], ["In 2015, the American Heart Association recommended echocardiographic screening of infants with Mortality rates for infants with abnormal SP were 19% compared with 8% for infants with normal or normal/missing data.", [["infants", "ORGANISM", 83, 90], ["infants", "ORGANISM", 116, 123], ["infants", "ORGANISM", 171, 178], ["infants", "SPECIES", 83, 90], ["infants", "SPECIES", 116, 123], ["infants", "SPECIES", 171, 178], ["echocardiographic screening", "TEST", 52, 79], ["Mortality rates", "TEST", 96, 111], ["abnormal SP", "PROBLEM", 129, 140], ["Heart", "ANATOMY", 22, 27]]], ["Mortality rates for infants with abnormal RVSP were 20% compared with 9-10% for infants with normal or normal/missing data.", [["infants", "ORGANISM", 20, 27], ["infants", "ORGANISM", 80, 87], ["infants", "SPECIES", 20, 27], ["infants", "SPECIES", 80, 87], ["Mortality rates", "TEST", 0, 15], ["abnormal RVSP", "PROBLEM", 33, 46]]], ["Test characteristics of sensitivity, specificity, positive-predictive value (PPV) and negative predictive value (NPV) are shown Multivariable models were constructed to evaluate the effect of septal position alone, and right ventricular systolic pressure (RVSP) alone on mortality.", [["septal", "ANATOMY", 192, 198], ["right ventricular", "ANATOMY", 219, 236], ["ventricular", "MULTI-TISSUE_STRUCTURE", 225, 236], ["sensitivity", "TEST", 24, 35], ["specificity", "TEST", 37, 48], ["PPV", "TEST", 77, 80], ["NPV", "TEST", 113, 116], ["Multivariable models", "TEST", 128, 148], ["septal position alone", "TREATMENT", 192, 213], ["right ventricular systolic pressure", "TEST", 219, 254], ["septal position", "OBSERVATION", 192, 207], ["right ventricular", "ANATOMY", 219, 236], ["systolic pressure", "OBSERVATION", 237, 254]]], ["Significant clinical covariates, including gestational age, the need for ventilation at 36 weeks' postmenstrual age, the presence of an atrial septal defect, the diagnosis of a bloodstream infection, the receipt of postnatal steroids and the postmenstrual age in weeks at the time of admission, were controlled in each model.", [["atrial septal", "ANATOMY", 136, 149], ["bloodstream", "ANATOMY", 177, 188], ["atrial septal defect", "DISEASE", 136, 156], ["bloodstream infection", "DISEASE", 177, 198], ["steroids", "CHEMICAL", 225, 233], ["steroids", "CHEMICAL", 225, 233], ["atrial septal", "MULTI-TISSUE_STRUCTURE", 136, 149], ["Significant clinical covariates", "PROBLEM", 0, 31], ["ventilation", "TREATMENT", 73, 84], ["an atrial septal defect", "PROBLEM", 133, 156], ["a bloodstream infection", "PROBLEM", 175, 198], ["postnatal steroids", "TREATMENT", 215, 233], ["atrial septal", "ANATOMY", 136, 149], ["defect", "OBSERVATION", 150, 156], ["bloodstream", "OBSERVATION_MODIFIER", 177, 188], ["infection", "OBSERVATION", 189, 198]]], ["Odds ratios and 95% confidence intervals were calculated using logistic regression *p < 0.05 in multivariable models moderate or severe BPD beginning at 36 weeks PMA with serial echocardiography thereafter [5] .", [["BPD", "DISEASE", 136, 139], ["PMA", "CHEMICAL", 162, 165], ["Odds ratios", "TEST", 0, 11], ["logistic regression *p", "TEST", 63, 85], ["severe BPD", "PROBLEM", 129, 139], ["serial echocardiography", "TEST", 171, 194], ["moderate", "OBSERVATION_MODIFIER", 117, 125], ["severe", "OBSERVATION_MODIFIER", 129, 135], ["BPD", "OBSERVATION", 136, 139]]], ["Compared to cardiac catheterization, echocardiographic screening for PH has been limited in its ability to detect and grade the severity of pulmonary hypertension [7] .", [["cardiac", "ANATOMY", 12, 19], ["pulmonary", "ANATOMY", 140, 149], ["PH", "DISEASE", 69, 71], ["pulmonary hypertension", "DISEASE", 140, 162], ["cardiac", "ORGAN", 12, 19], ["pulmonary", "ORGAN", 140, 149], ["cardiac catheterization", "TEST", 12, 35], ["echocardiographic screening", "TEST", 37, 64], ["PH", "TEST", 69, 71], ["pulmonary hypertension", "PROBLEM", 140, 162], ["catheterization", "OBSERVATION", 20, 35], ["pulmonary", "ANATOMY", 140, 149], ["hypertension", "OBSERVATION", 150, 162]]], ["We found that infants with documented abnormal RVSP or septal position had approximately double the odds of mortality, compared to infants with normal echocardiographic parameters.", [["septal", "ANATOMY", 55, 61], ["infants", "ORGANISM", 14, 21], ["infants", "ORGANISM", 131, 138], ["infants", "SPECIES", 14, 21], ["infants", "SPECIES", 131, 138], ["documented abnormal RVSP", "PROBLEM", 27, 51], ["abnormal", "OBSERVATION_MODIFIER", 38, 46], ["RVSP", "OBSERVATION", 47, 51], ["septal", "ANATOMY_MODIFIER", 55, 61], ["position", "OBSERVATION_MODIFIER", 62, 70]]], ["This association persisted even after adjusting for other significant predictors of mortality including gestational age, receipt of mechanical ventilation at 36 weeks' PMA, atrial septal defect, bloodstream infection, postnatal corticosteroid use, and PMA at admission to the participating center.", [["atrial septal", "ANATOMY", 173, 186], ["bloodstream", "ANATOMY", 195, 206], ["atrial septal defect", "DISEASE", 173, 193], ["bloodstream infection", "DISEASE", 195, 216], ["PMA", "CHEMICAL", 252, 255], ["PMA", "CHEMICAL", 252, 255], ["atrial septal", "MULTI-TISSUE_STRUCTURE", 173, 186], ["PMA", "SIMPLE_CHEMICAL", 252, 255], ["mechanical ventilation", "TREATMENT", 132, 154], ["atrial septal defect", "PROBLEM", 173, 193], ["bloodstream infection", "PROBLEM", 195, 216], ["postnatal corticosteroid use", "TREATMENT", 218, 246], ["mechanical ventilation", "OBSERVATION", 132, 154], ["atrial septal", "ANATOMY", 173, 186], ["defect", "OBSERVATION", 187, 193], ["bloodstream infection", "OBSERVATION", 195, 216]]], ["These results demonstrate that even among sick neonates with severe BPD, abnormal SP and RVSP are independent predictors of mortality.", [["BPD", "DISEASE", 68, 71], ["severe BPD", "PROBLEM", 61, 71], ["abnormal SP", "PROBLEM", 73, 84], ["severe", "OBSERVATION_MODIFIER", 61, 67], ["BPD", "OBSERVATION", 68, 71]]], ["In that context, our results demonstrating the potential impact of real-world echocardiographic data provide further support for adherence to the new guidelines.DiscussionWhen we compared infants with missing echocardiographic data to infants with normal parameters for septal position, we found that infants with missing data had an odds of mortality that was similar to infants with normal echocardiographic parameters.", [["septal", "ANATOMY", 270, 276], ["infants", "ORGANISM", 188, 195], ["infants", "ORGANISM", 235, 242], ["infants", "ORGANISM", 301, 308], ["infants", "ORGANISM", 372, 379], ["infants", "SPECIES", 188, 195], ["infants", "SPECIES", 235, 242], ["infants", "SPECIES", 301, 308], ["infants", "SPECIES", 372, 379], ["further support", "TREATMENT", 109, 124], ["missing echocardiographic data", "TEST", 201, 231]]], ["Mourani et al. found that the sensitivity and positive-predictive value of echocardiographic parameters for the detection of PH is enhanced when tricuspid regurgitant jet velocity can be measured as a proxy for pulmonary artery pressure [7] .", [["tricuspid regurgitant", "ANATOMY", 145, 166], ["pulmonary artery", "ANATOMY", 211, 227], ["PH", "DISEASE", 125, 127], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 211, 227], ["the sensitivity", "TEST", 26, 41], ["echocardiographic parameters", "TEST", 75, 103], ["tricuspid regurgitant jet velocity", "TEST", 145, 179], ["pulmonary artery pressure", "TEST", 211, 236], ["jet velocity", "OBSERVATION", 167, 179], ["pulmonary artery", "ANATOMY", 211, 227]]], ["Unfortunately, several studies have noted the challenge of obtaining tricuspid regurgitant jet velocity measurements, even when echocardiography is being performed in accordance with prespecified research protocols and on older pediatric patients [19, 20] .", [["tricuspid", "ANATOMY", 69, 78], ["patients", "ORGANISM", 238, 246], ["patients", "SPECIES", 238, 246], ["several studies", "TEST", 15, 30], ["tricuspid regurgitant jet velocity measurements", "TEST", 69, 116], ["echocardiography", "TEST", 128, 144], ["regurgitant jet", "OBSERVATION", 79, 94]]], ["Indeed, in our cohort, tricuspid regurgitant jet velocity and resultant right ventricular systolic pressure was recorded in only 27% of echocardiographic reports, highlighting the practical limitations of obtaining this important variable at the bedside.", [["tricuspid regurgitant", "ANATOMY", 23, 44], ["right ventricular", "ANATOMY", 72, 89], ["right ventricular", "MULTI-TISSUE_STRUCTURE", 72, 89], ["systolic", "MULTI-TISSUE_STRUCTURE", 90, 98], ["tricuspid regurgitant jet velocity", "TEST", 23, 57], ["resultant right ventricular systolic pressure", "TEST", 62, 107], ["echocardiographic reports", "TEST", 136, 161], ["tricuspid regurgitant", "ANATOMY", 23, 44], ["jet velocity", "OBSERVATION", 45, 57], ["right ventricular", "ANATOMY", 72, 89], ["systolic pressure", "OBSERVATION", 90, 107]]], ["Septal position was more commonly documented in our cohort, with 73% of echocardiographic reports having documentation of septal position.", [["septal", "ANATOMY", 122, 128], ["septal", "MULTI-TISSUE_STRUCTURE", 122, 128], ["position", "OBSERVATION_MODIFIER", 7, 15], ["septal position", "OBSERVATION", 122, 137]]], ["Assignment of septal position may be subject to considerable subjectivity and interobserver variability [21] .", [["septal", "ANATOMY", 14, 20], ["septal", "MULTI-TISSUE_STRUCTURE", 14, 20], ["interobserver variability", "TEST", 78, 103], ["septal position", "OBSERVATION", 14, 29]]], ["More quantitative measures of septal position, such as eccentricity index, are now being investigated in infants with BPD and hold promise as a means of standardizing the echocardiographic approach [19, 22] .", [["septal", "ANATOMY", 30, 36], ["BPD", "DISEASE", 118, 121], ["septal", "MULTI-TISSUE_STRUCTURE", 30, 36], ["infants", "ORGANISM", 105, 112], ["infants", "SPECIES", 105, 112], ["eccentricity index", "PROBLEM", 55, 73], ["BPD", "PROBLEM", 118, 121], ["septal position", "OBSERVATION", 30, 45], ["eccentricity index", "OBSERVATION", 55, 73]]], ["Nonetheless, our finding that infants with missing echocardiographic data had mortality rates similar to infants with documented normal echocardiographic parameters suggests that the inherent difficulties of obtaining standard echocardiographic measurements should not prevent efforts at screening.", [["infants", "ORGANISM", 30, 37], ["infants", "ORGANISM", 105, 112], ["infants", "SPECIES", 30, 37], ["infants", "SPECIES", 105, 112], ["missing echocardiographic data", "TEST", 43, 73], ["mortality rates", "PROBLEM", 78, 93], ["standard echocardiographic measurements", "TEST", 218, 257], ["screening", "TEST", 288, 297]]], ["Further, echocardiography correctly identified infants who were likely to survive, as shown by the high specificity and negative predictive values of both septal flattening and RVSP in our study.", [["septal", "ANATOMY", 155, 161], ["infants", "ORGANISM", 47, 54], ["septal", "MULTI-TISSUE_STRUCTURE", 155, 161], ["infants", "SPECIES", 47, 54], ["echocardiography", "TEST", 9, 25], ["our study", "TEST", 185, 194], ["septal", "ANATOMY_MODIFIER", 155, 161], ["flattening", "OBSERVATION", 162, 172], ["RVSP", "OBSERVATION", 177, 181]]], ["As such, septal position and RVSP measures on echocardiography between 34 and 44 weeks' PMA can be helpful in delineating risk status for in-hospital mortality in infants with sBPD.DiscussionSurprisingly, only half of our initial cohort of infants with severe BPD had screening echocardiography between 34 and 44 weeks' PMA.", [["septal", "ANATOMY", 9, 15], ["sBPD", "DISEASE", 176, 180], ["BPD", "DISEASE", 260, 263], ["PMA", "CHEMICAL", 88, 91], ["PMA", "CHEMICAL", 320, 323], ["septal", "MULTI-TISSUE_STRUCTURE", 9, 15], ["PMA", "SIMPLE_CHEMICAL", 88, 91], ["infants", "ORGANISM", 163, 170], ["infants", "ORGANISM", 240, 247], ["infants", "SPECIES", 163, 170], ["infants", "SPECIES", 240, 247], ["septal position", "TREATMENT", 9, 24], ["RVSP measures", "TEST", 29, 42], ["echocardiography", "TEST", 46, 62], ["sBPD", "PROBLEM", 176, 180], ["severe BPD", "PROBLEM", 253, 263], ["screening echocardiography", "TEST", 268, 294], ["septal position", "OBSERVATION", 9, 24], ["RVSP", "OBSERVATION", 29, 33]]], ["This survey found that 83% of physicians would obtain an echocardiogram at 36 weeks' corrected gestational age for infants with moderate or severe BPD, but only 46% of respondents had a formal screening program in place at their institution that facilitated the implementation of these guidelines [23] .", [["BPD", "DISEASE", 147, 150], ["infants", "ORGANISM", 115, 122], ["infants", "SPECIES", 115, 122], ["an echocardiogram", "TEST", 54, 71], ["moderate or severe BPD", "PROBLEM", 128, 150], ["a formal screening program", "TEST", 184, 210], ["severe", "OBSERVATION_MODIFIER", 140, 146], ["BPD", "OBSERVATION", 147, 150]]], ["Our study cohort occurred prior to the publication of the recent American Heart Association screening guidelines; future work, including our observations in this study, should serve to increase the rate of screening for PH in infants with BPD.", [["PH", "DISEASE", 220, 222], ["BPD", "DISEASE", 239, 242], ["infants", "ORGANISM", 226, 233], ["infants", "SPECIES", 226, 233], ["Our study", "TEST", 0, 9], ["this study", "TEST", 157, 167], ["screening", "TEST", 206, 215], ["BPD", "PROBLEM", 239, 242]]], ["Quality initiatives to standardize the approach to PH screening in infants with BPD across sites are now being developed.", [["PH", "DISEASE", 51, 53], ["BPD", "DISEASE", 80, 83], ["infants", "ORGANISM", 67, 74], ["infants", "SPECIES", 67, 74], ["PH screening", "TEST", 51, 63], ["BPD across sites", "PROBLEM", 80, 96]]], ["Even as screening efforts advance, we acknowledge that data are limited on whether early detection and pharmacologic treatment of pulmonary hypertension in infants with severe BPD improves survival.", [["pulmonary", "ANATOMY", 130, 139], ["pulmonary hypertension", "DISEASE", 130, 152], ["BPD", "DISEASE", 176, 179], ["pulmonary", "ORGAN", 130, 139], ["infants", "ORGANISM", 156, 163], ["infants", "SPECIES", 156, 163], ["pharmacologic treatment", "TREATMENT", 103, 126], ["pulmonary hypertension", "PROBLEM", 130, 152], ["severe BPD", "PROBLEM", 169, 179], ["pulmonary", "ANATOMY", 130, 139], ["hypertension", "OBSERVATION", 140, 152]]], ["Retrospective evaluations of this association may be plagued with concerns about confounding by indication, and the feasibility and cost of randomized controlled trials can be prohibitive.", [["Retrospective evaluations", "TEST", 0, 25], ["randomized controlled trials", "TREATMENT", 140, 168]]], ["Additionally, the natural course of milder forms of pulmonary hypertension is to resolve without pharmacologic therapy [24, 25] .", [["pulmonary", "ANATOMY", 52, 61], ["pulmonary hypertension", "DISEASE", 52, 74], ["pulmonary", "ORGAN", 52, 61], ["pulmonary hypertension", "PROBLEM", 52, 74], ["pharmacologic therapy", "TREATMENT", 97, 118], ["natural", "OBSERVATION_MODIFIER", 18, 25], ["course", "OBSERVATION_MODIFIER", 26, 32], ["milder", "OBSERVATION_MODIFIER", 36, 42], ["pulmonary", "ANATOMY", 52, 61], ["hypertension", "OBSERVATION", 62, 74]]], ["However, identifying the patients at risk for poor outcomes is essential in the neonatal period to allow appropriate risk categorization and followup after hospital discharge.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["poor outcomes", "PROBLEM", 46, 59]]], ["Overall, one in four infants with severe BPD may develop pulmonary hypertension, but 41 \u221262% will be diagnosed after hospital discharge and will experience morbidity and mortality in the first year of life as a result of their diagnosis [1, 2, 24, 26] .", [["pulmonary", "ANATOMY", 57, 66], ["BPD", "DISEASE", 41, 44], ["pulmonary hypertension", "DISEASE", 57, 79], ["infants", "ORGANISM", 21, 28], ["pulmonary", "ORGAN", 57, 66], ["infants", "SPECIES", 21, 28], ["severe BPD", "PROBLEM", 34, 44], ["pulmonary hypertension", "PROBLEM", 57, 79], ["morbidity", "PROBLEM", 156, 165], ["severe", "OBSERVATION_MODIFIER", 34, 40], ["BPD", "OBSERVATION", 41, 44], ["pulmonary", "ANATOMY", 57, 66], ["hypertension", "OBSERVATION", 67, 79]]], ["As such, even while the efficacy of pharmacologic therapy for pulmonary hypertension is being evaluated, echocardiographic screening for infants with severe BPD may allow proven interventions such as aggressive management of respiratory acidosis, prevention of intermittent hypoxia, targeting of optimal nutrition and feeding modes, and engagement of multidisciplinary care to be employed early and aggressively in order to improve outcomes for high-risk infants [1, [27] [28] [29] [30] [31] .DiscussionOur study has important limitations.", [["pulmonary", "ANATOMY", 62, 71], ["respiratory", "ANATOMY", 225, 236], ["pulmonary hypertension", "DISEASE", 62, 84], ["BPD", "DISEASE", 157, 160], ["respiratory acidosis", "DISEASE", 225, 245], ["hypoxia", "DISEASE", 274, 281], ["pulmonary", "ORGAN", 62, 71], ["infants", "ORGANISM", 137, 144], ["infants", "ORGANISM", 455, 462], ["[27] [28] [29] [30] [31]", "SIMPLE_CHEMICAL", 467, 491], ["infants", "SPECIES", 137, 144], ["infants", "SPECIES", 455, 462], ["pharmacologic therapy", "TREATMENT", 36, 57], ["pulmonary hypertension", "PROBLEM", 62, 84], ["echocardiographic screening", "TEST", 105, 132], ["severe BPD", "PROBLEM", 150, 160], ["interventions", "TREATMENT", 178, 191], ["aggressive management", "TREATMENT", 200, 221], ["respiratory acidosis", "PROBLEM", 225, 245], ["intermittent hypoxia", "PROBLEM", 261, 281], ["optimal nutrition and feeding modes", "TREATMENT", 296, 331], ["multidisciplinary care", "TREATMENT", 351, 373], ["DiscussionOur study", "TEST", 493, 512], ["pulmonary", "ANATOMY", 62, 71], ["hypertension", "OBSERVATION", 72, 84], ["respiratory acidosis", "OBSERVATION", 225, 245], ["intermittent", "OBSERVATION_MODIFIER", 261, 273], ["hypoxia", "OBSERVATION", 274, 281]]], ["Our cohort was derived from a referral-based, quaternary care population and may not be generalizable to other cohorts.", [["quaternary care population", "TREATMENT", 46, 72]]], ["We further recognize that the infants in our cohort had severe BPD, and although controlling for the need for mechanical ventilation at 36 weeks' post-menstrual age may have adjusted for the sickest patients, it is possible that associations between echocardiographic parameters and mortality may differ in infants with less severe lung disease.", [["lung", "ANATOMY", 332, 336], ["BPD", "DISEASE", 63, 66], ["lung disease", "DISEASE", 332, 344], ["infants", "ORGANISM", 30, 37], ["patients", "ORGANISM", 199, 207], ["infants", "ORGANISM", 307, 314], ["lung", "ORGAN", 332, 336], ["infants", "SPECIES", 30, 37], ["patients", "SPECIES", 199, 207], ["infants", "SPECIES", 307, 314], ["severe BPD", "PROBLEM", 56, 66], ["mechanical ventilation", "TREATMENT", 110, 132], ["echocardiographic parameters", "TEST", 250, 278], ["less severe lung disease", "PROBLEM", 320, 344], ["severe", "OBSERVATION_MODIFIER", 56, 62], ["BPD", "OBSERVATION", 63, 66], ["severe", "OBSERVATION_MODIFIER", 325, 331], ["lung", "ANATOMY", 332, 336], ["disease", "OBSERVATION", 337, 344]]], ["The echocardiograms in our study were performed at clinical discretion, which may lead to some ascertainment and selection bias in our sample.DiscussionIn conclusion, we have shown that abnormalities in echocardiographic parameters, such as septal flattening and RVSP, are associated with nearly a two-fold increase in the odds of mortality prior to hospital discharge in infants with severe BPD.", [["septal", "ANATOMY", 241, 247], ["BPD", "DISEASE", 392, 395], ["septal", "MULTI-TISSUE_STRUCTURE", 241, 247], ["infants", "ORGANISM", 372, 379], ["infants", "SPECIES", 372, 379], ["The echocardiograms", "TEST", 0, 19], ["our study", "TEST", 23, 32], ["our sample", "TEST", 131, 141], ["echocardiographic parameters", "TEST", 203, 231], ["septal flattening and RVSP", "PROBLEM", 241, 267], ["severe BPD", "PROBLEM", 385, 395], ["septal", "ANATOMY_MODIFIER", 241, 247], ["flattening", "OBSERVATION", 248, 258], ["RVSP", "OBSERVATION", 263, 267], ["increase", "OBSERVATION_MODIFIER", 307, 315], ["severe", "OBSERVATION_MODIFIER", 385, 391], ["BPD", "OBSERVATION", 392, 395]]], ["Further, infants with normal parameters are more likely to survive their initial hospitalization than those with abnormal values in our cohort.", [["infants", "ORGANISM", 9, 16], ["infants", "SPECIES", 9, 16], ["abnormal values", "PROBLEM", 113, 128]]], ["These findings support the recommendation to implement pulmonary hypertension screening for infants with severe BPD despite the known limitations of echocardiography in a neonatal population.", [["pulmonary", "ANATOMY", 55, 64], ["pulmonary hypertension", "DISEASE", 55, 77], ["BPD", "DISEASE", 112, 115], ["pulmonary", "ORGAN", 55, 64], ["infants", "ORGANISM", 92, 99], ["infants", "SPECIES", 92, 99], ["pulmonary hypertension screening", "TEST", 55, 87], ["severe BPD", "PROBLEM", 105, 115], ["echocardiography", "TEST", 149, 165], ["a neonatal population", "TREATMENT", 169, 190], ["pulmonary", "ANATOMY", 55, 64], ["hypertension", "OBSERVATION", 65, 77]]], ["Future quality improvement initiatives that define the timing and standardize the optimal approach to echocardiography in this high-risk population are warranted.Code availabilityThe computer code used to generate statistical analyses may be made available upon request to the Children's Hospitals Neonatal Consortium.Compliance with ethical standardsConflict of interest The authors declare that they have no conflict of interest.Compliance with ethical standardsPublisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [["Children", "SPECIES", 277, 285], ["echocardiography", "TEST", 102, 118], ["this high-risk population", "TREATMENT", 122, 147], ["ethical standards", "TREATMENT", 334, 351], ["ethical standards", "TREATMENT", 447, 464]]]], "PMC7189617": [["Critical Illness, Species Evolution, and Individual DevelopmentThe reasons behind the evolutionary success of mammals and other multicellular organisms is their extraordinary capacity to adapt to changing environmental conditions and survive by maintaining their homeostasis (1).", [["Critical Illness", "PROBLEM", 0, 16], ["other multicellular organisms", "PROBLEM", 122, 151], ["Illness", "OBSERVATION", 9, 16], ["Species Evolution", "OBSERVATION", 18, 35]]], ["Homeostasis refers to the relative stability in the activity of the physiological systems of the organism that are essential to support life (2).", [["stability", "OBSERVATION_MODIFIER", 35, 44]]], ["The process of maintaining stability within a harmless range via homeostatic physiologic corrections to both predictable and unpredictable adverse forces or stressors is termed \u201ceustasis\u201d (2).", [["homeostatic physiologic corrections", "TREATMENT", 65, 100], ["unpredictable adverse forces", "PROBLEM", 125, 153], ["stability", "OBSERVATION_MODIFIER", 27, 36]]], ["In the course of human evolution, homeostatic corrections have emerged to increase the host's ability to cope with adverse or even catastrophic events (3).", [["human", "ORGANISM", 17, 22], ["human", "SPECIES", 17, 22], ["human", "SPECIES", 17, 22], ["even catastrophic events", "PROBLEM", 126, 150]]], ["These responses are shaped by trade-offs, sometimes with benefits and disadvantages in different periods of the life cycle (4).", [["shaped", "OBSERVATION_MODIFIER", 20, 26]]], ["Following the Cambrian explosion, about 450 million years ago, when multicellular organisms\u2014originally formed in water environments\u2014colonized the land physiological homeostatic changes emerged to allow survival.", [["multicellular organisms\u2014originally formed in water environments", "PROBLEM", 68, 131]]], ["These corrective changes were essential to mammalian species evolution and emerged to solve a frequent conflict between environmental changes and preservation of the individual allowing survival and, hence, reproduction.", [["These corrective changes", "PROBLEM", 0, 24], ["mammalian species evolution", "PROBLEM", 43, 70], ["a frequent conflict between environmental changes", "PROBLEM", 92, 141], ["corrective", "OBSERVATION", 6, 16]]], ["These alterations permitted progression to future generations i.e., survival of the species through the active process of natural selection (5).", [["the species", "PROBLEM", 80, 91], ["active", "OBSERVATION_MODIFIER", 104, 110]]], ["These corrections involved profound neural, metabolic and immune changes mediated by a few major physiological systems (e.g., the central nervous, autonomic, cardiorespiratory, endocrine, and immune systems), and acting through integrated crosstalk pathways, that was associated with appropriate responses throughout the organism (5).", [["neural", "ANATOMY", 36, 42], ["central nervous", "ANATOMY", 130, 145], ["endocrine", "ANATOMY", 177, 186], ["nervous", "ANATOMICAL_SYSTEM", 138, 145], ["endocrine", "ANATOMICAL_SYSTEM", 177, 186], ["profound neural, metabolic and immune changes", "PROBLEM", 27, 72], ["the central nervous, autonomic, cardiorespiratory, endocrine, and immune systems", "PROBLEM", 126, 206], ["profound", "OBSERVATION_MODIFIER", 27, 35], ["neural", "OBSERVATION", 36, 42], ["central nervous", "ANATOMY", 130, 145]]], ["Such changes have been relatively conserved across many vertebrates, including mammalian species (6, 7).", [["many", "OBSERVATION_MODIFIER", 51, 55], ["vertebrates", "OBSERVATION_MODIFIER", 56, 67], ["mammalian species", "OBSERVATION", 79, 96]]], ["They have evolved to allow coping with lack of energy, dehydration, hemorrhage, infections, toxic substances, or relatively short-lived inflammatory responses, such as those of wound healing or exposure to foreign substances (7).Critical Illness, Species Evolution, and Individual DevelopmentWhen the organism is exposed to stressors that exceed the harmless stability range, individual survival is maintained at the expense of this organism's health and longevity.", [["wound", "ANATOMY", 177, 182], ["dehydration", "DISEASE", 55, 66], ["hemorrhage", "DISEASE", 68, 78], ["infections", "DISEASE", 80, 90], ["wound", "PATHOLOGICAL_FORMATION", 177, 182], ["dehydration", "PROBLEM", 55, 66], ["hemorrhage", "PROBLEM", 68, 78], ["infections", "PROBLEM", 80, 90], ["toxic substances", "PROBLEM", 92, 108], ["relatively short-lived inflammatory responses", "PROBLEM", 113, 158], ["wound healing", "PROBLEM", 177, 190], ["Critical Illness", "PROBLEM", 229, 245], ["hemorrhage", "OBSERVATION", 68, 78], ["infections", "OBSERVATION", 80, 90], ["wound", "ANATOMY", 177, 182], ["healing", "OBSERVATION", 183, 190], ["Illness", "OBSERVATION", 238, 245], ["Species Evolution", "OBSERVATION", 247, 264]]], ["This condition is different from healthy homeostasis or eustasis and is called \u201callo-stasis\u201d or different (allo)-stasis or even more accurately \u201ccaco (bad) \u2013stasis.", [["eustasis", "DISEASE", 56, 64], ["eustasis", "PROBLEM", 56, 64], ["stasis", "PROBLEM", 113, 119], ["\u2013stasis", "PROBLEM", 156, 163], ["different", "OBSERVATION_MODIFIER", 18, 27], ["stasis", "OBSERVATION", 113, 119]]], ["The cumulative cost of cacostasis for the organism, has been called allostatic or cacostatic burden.", [["cacostasis", "PROBLEM", 23, 33], ["the organism", "PROBLEM", 38, 50], ["cacostatic burden", "PROBLEM", 82, 99], ["cumulative", "OBSERVATION_MODIFIER", 4, 14], ["cost", "OBSERVATION", 15, 19]]], ["Excessive or prolonged cacostatic burden results in severe acute and/or chronic cacostatic pathology (2, 8).", [["Excessive or prolonged cacostatic burden", "PROBLEM", 0, 40], ["severe acute and/or chronic cacostatic pathology", "PROBLEM", 52, 100], ["prolonged", "OBSERVATION_MODIFIER", 13, 22], ["cacostatic", "OBSERVATION_MODIFIER", 23, 33], ["severe", "OBSERVATION_MODIFIER", 52, 58], ["acute", "OBSERVATION_MODIFIER", 59, 64], ["chronic", "OBSERVATION_MODIFIER", 72, 79], ["cacostatic", "OBSERVATION_MODIFIER", 80, 90], ["pathology", "OBSERVATION", 91, 100]]], ["The intensive care unit (ICU) stress state represents a new and very different ecosystem from those within which humans evolved in the past.", [["humans", "ORGANISM", 113, 119], ["humans", "SPECIES", 113, 119], ["humans", "SPECIES", 113, 119], ["a new and very different ecosystem", "PROBLEM", 54, 88], ["new", "OBSERVATION_MODIFIER", 56, 59]]], ["Actually, critical illness epitomizes an acute and/or chronic cacostatic burden that goes beyond an evolutionarily conserved physiological adaptive response, and if left untreated it could rapidly exhaust homeostatic compensation and lead to death of an organism (lethal cacostasis).", [["death", "DISEASE", 242, 247], ["cacostasis", "DISEASE", 271, 281], ["critical illness epitomizes", "PROBLEM", 10, 37], ["chronic cacostatic burden", "PROBLEM", 54, 79], ["homeostatic compensation", "PROBLEM", 205, 229], ["death", "PROBLEM", 242, 247], ["an organism (lethal cacostasis", "PROBLEM", 251, 281], ["acute", "OBSERVATION_MODIFIER", 41, 46], ["chronic", "OBSERVATION_MODIFIER", 54, 61], ["cacostatic", "OBSERVATION_MODIFIER", 62, 72], ["burden", "OBSERVATION", 73, 79]]], ["In critically ill patients, the need for vital organ support (maintenance of arterial blood pressure, mechanical ventilation, and other support measures, which were not available until the middle of the last century), reflects near exhaustion or exhaustion of (i) neuroendocrine homeostatic compensation, also known as \u201ccritical illness-related corticosteroid insufficiency\u201d (CIRCI) (8); (ii) cell bio-energetic and other functions; and (iii) reserves of vital micronutrients (vitamins and minerals).", [["organ", "ANATOMY", 47, 52], ["arterial", "ANATOMY", 77, 85], ["blood", "ANATOMY", 86, 91], ["neuroendocrine", "ANATOMY", 264, 278], ["cell", "ANATOMY", 393, 397], ["critically ill", "DISEASE", 3, 17], ["illness", "DISEASE", 329, 336], ["corticosteroid insufficiency", "DISEASE", 345, 373], ["vitamins and minerals", "CHEMICAL", 477, 498], ["vitamins", "CHEMICAL", 477, 485], ["patients", "ORGANISM", 18, 26], ["organ", "ORGAN", 47, 52], ["arterial blood", "MULTI-TISSUE_STRUCTURE", 77, 91], ["neuroendocrine", "CELL", 264, 278], ["cell", "CELL", 393, 397], ["vitamins", "SIMPLE_CHEMICAL", 477, 485], ["minerals", "SIMPLE_CHEMICAL", 490, 498], ["patients", "SPECIES", 18, 26], ["vital organ support", "TREATMENT", 41, 60], ["arterial blood pressure", "TREATMENT", 77, 100], ["mechanical ventilation", "TREATMENT", 102, 124], ["other support measures", "TREATMENT", 130, 152], ["exhaustion of (i) neuroendocrine homeostatic compensation", "PROBLEM", 246, 303], ["critical illness", "PROBLEM", 320, 336], ["corticosteroid insufficiency", "PROBLEM", 345, 373], ["(ii) cell bio-energetic and other functions", "PROBLEM", 388, 431], ["vital micronutrients (vitamins and minerals", "TREATMENT", 455, 498], ["mechanical ventilation", "OBSERVATION", 102, 124], ["homeostatic compensation", "OBSERVATION", 279, 303], ["corticosteroid insufficiency", "OBSERVATION", 345, 373]]], ["Even when it allows survival of the patient, homeostatic failure, ranging in acuity and severity, has a major impact on morbidity and mortality during and after hospitalization.", [["homeostatic failure", "DISEASE", 45, 64], ["patient", "ORGANISM", 36, 43], ["patient", "SPECIES", 36, 43], ["homeostatic failure", "PROBLEM", 45, 64], ["ranging in acuity and severity", "PROBLEM", 66, 96], ["failure", "OBSERVATION", 57, 64], ["morbidity", "OBSERVATION", 120, 129]]], ["CIRCI-associated dysregulated systemic inflammation and mitochondrial dysfunction are central to the increased morbidity and mortality of acute and/or chronic critical illness and the subject of this review.Innate Immunity and Nuclear Factor-\u03baBIn multicellular organisms, the innate immune system with its recognition and signaling mechanisms is the most ancient form of host defense to infectious and non-infectious threats during evolution (9).", [["mitochondrial", "ANATOMY", 56, 69], ["CIRCI", "CHEMICAL", 0, 5], ["systemic inflammation", "DISEASE", 30, 51], ["mitochondrial dysfunction", "DISEASE", 56, 81], ["mitochondrial", "CELLULAR_COMPONENT", 56, 69], ["Nuclear Factor-\u03ba", "GENE_OR_GENE_PRODUCT", 227, 243], ["CIRCI", "TEST", 0, 5], ["dysregulated systemic inflammation", "PROBLEM", 17, 51], ["mitochondrial dysfunction", "PROBLEM", 56, 81], ["the increased morbidity", "PROBLEM", 97, 120], ["chronic critical illness", "PROBLEM", 151, 175], ["Nuclear Factor", "TEST", 227, 241], ["BIn multicellular organisms", "PROBLEM", 243, 270], ["signaling mechanisms", "PROBLEM", 322, 342], ["dysregulated", "OBSERVATION_MODIFIER", 17, 29], ["systemic", "OBSERVATION_MODIFIER", 30, 38], ["inflammation", "OBSERVATION", 39, 51], ["mitochondrial dysfunction", "OBSERVATION", 56, 81], ["increased", "OBSERVATION_MODIFIER", 101, 110], ["morbidity", "OBSERVATION", 111, 120], ["acute", "OBSERVATION_MODIFIER", 138, 143], ["chronic", "OBSERVATION_MODIFIER", 151, 158], ["critical", "OBSERVATION_MODIFIER", 159, 167], ["illness", "OBSERVATION", 168, 175], ["most ancient", "OBSERVATION_MODIFIER", 350, 362], ["infectious", "OBSERVATION_MODIFIER", 387, 397], ["non-infectious", "OBSERVATION", 402, 416]]], ["The nuclear factor-\u03baB (NF-\u03baB) system, a \u201crapidly-acting\u201d primary transcription factor regulated cellular response, is a central activator of innate immunity.", [["cellular", "ANATOMY", 96, 104], ["nuclear factor-\u03baB", "GENE_OR_GENE_PRODUCT", 4, 21], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 23, 28], ["cellular", "CELL", 96, 104], ["nuclear factor-\u03baB (NF-\u03baB", "PROTEIN", 4, 28], ["transcription factor", "PROTEIN", 65, 85], ["The nuclear factor", "TEST", 0, 18], ["\u03baB", "TEST", 19, 21], ["cellular response", "OBSERVATION", 96, 113]]], ["It appears that the NF-\u03baB was incorporated into this ancient signaling pathway more than 420 million years ago, and has been shown to play independent roles in vertebrate and insect lineages (9, 10).", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 20, 25], ["NF-\u03baB", "PROTEIN", 20, 25], ["vertebrate and insect lineages", "CELL_TYPE", 160, 190]]], ["In most cell types, the inactive form of NF-\u03baB, a heterodimeric protein composed of the DNA-binding proteins p65 and p50, is retained in the cytosol by association with inhibitory factors, such as I\u03baB proteins; when activated, the latter are rapidly phosphorylated and degraded via the proteasomal pathway, liberating NF-\u03baB and allowing it to translocate into the nucleus (11).", [["cell", "ANATOMY", 8, 12], ["cytosol", "ANATOMY", 141, 148], ["proteasomal", "ANATOMY", 286, 297], ["nucleus", "ANATOMY", 364, 371], ["cell", "CELL", 8, 12], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 41, 46], ["DNA", "CELLULAR_COMPONENT", 88, 91], ["p65", "GENE_OR_GENE_PRODUCT", 109, 112], ["p50", "GENE_OR_GENE_PRODUCT", 117, 120], ["cytosol", "CELLULAR_COMPONENT", 141, 148], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 197, 200], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 318, 323], ["nucleus", "CELLULAR_COMPONENT", 364, 371], ["NF-\u03baB", "PROTEIN", 41, 46], ["heterodimeric protein", "PROTEIN", 50, 71], ["DNA-binding proteins", "PROTEIN", 88, 108], ["p65", "PROTEIN", 109, 112], ["p50", "PROTEIN", 117, 120], ["inhibitory factors", "PROTEIN", 169, 187], ["I\u03baB proteins", "PROTEIN", 197, 209], ["NF-\u03baB", "PROTEIN", 318, 323], ["NF", "TEST", 41, 43], ["a heterodimeric protein", "TEST", 48, 71], ["the DNA-binding proteins p65", "TEST", 84, 112], ["p50", "TEST", 117, 120], ["inhibitory factors", "PROBLEM", 169, 187], ["I\u03baB proteins", "PROBLEM", 197, 209], ["rapidly phosphorylated", "PROBLEM", 242, 264], ["most cell types", "OBSERVATION", 3, 18], ["nucleus", "ANATOMY", 364, 371]]], ["In tumor necrosis factor-\u03b1 (TNF-\u03b1)-stimulated HeLa cells, a genome-wide study identified 12,552 genome binding sites of p65 (12).", [["HeLa cells", "ANATOMY", 46, 56], ["tumor", "DISEASE", 3, 8], ["necrosis", "DISEASE", 9, 17], ["tumor necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 3, 26], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 28, 33], ["HeLa cells", "CELL", 46, 56], ["p65 (12)", "GENE_OR_GENE_PRODUCT", 120, 128], ["tumor necrosis factor-\u03b1 (TNF-\u03b1)-stimulated HeLa cells", "CELL_LINE", 3, 56], ["12,552 genome binding sites", "DNA", 89, 116], ["p65 (12)", "PROTEIN", 120, 128], ["tumor necrosis factor", "TEST", 3, 24], ["TNF", "TEST", 28, 31], ["stimulated HeLa cells", "PROBLEM", 35, 56], ["a genome-wide study", "TEST", 58, 77], ["tumor", "OBSERVATION_MODIFIER", 3, 8], ["necrosis", "OBSERVATION", 9, 17]]], ["Among the 1,667 distinct NF-\u03baB target genes identified, NF-\u03baB controlled the expression of 249 target genes, including inflammatory cytokines, chemokines, inflammatory enzymes, adhesion molecules, and immune system receptors, which are known to orchestrate the integrated inflammatory and immune responses.", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 25, 30], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 56, 61], ["NF-\u03baB target genes", "DNA", 25, 43], ["NF-\u03baB", "PROTEIN", 56, 61], ["249 target genes", "DNA", 91, 107], ["inflammatory cytokines", "PROTEIN", 119, 141], ["chemokines", "PROTEIN", 143, 153], ["inflammatory enzymes", "PROTEIN", 155, 175], ["adhesion molecules", "PROTEIN", 177, 195], ["immune system receptors", "PROTEIN", 201, 224], ["NF", "TEST", 25, 27], ["NF", "TEST", 56, 58], ["inflammatory cytokines", "PROBLEM", 119, 141], ["inflammatory enzymes", "PROBLEM", 155, 175], ["adhesion molecules", "PROBLEM", 177, 195], ["immune system receptors", "PROBLEM", 201, 224], ["inflammatory", "OBSERVATION_MODIFIER", 119, 131], ["inflammatory", "OBSERVATION_MODIFIER", 272, 284]]], ["Interestingly, an additional 626 identified NF-\u03baB target genes were involved in metabolic processes (13).Innate Immunity and Nuclear Factor-\u03baBIn critical illness, NF-\u03baB-driven systemic inflammation, also known as a \u201ccytokine storm\u201d (14), activates a multi-system response that includes at least three major domains: (i) the stress system composed by the hypothalamic-pituitary-adrenal (HPA) axis and the locus caeruleus-norepinephrine/sympathetic nervous system activated to provide sufficient energy and hemodynamic stability to overcome the initial phase of critical illness (15); (ii) the acute-phase reaction (APR), which has several adaptive functions, including increasing the production of procoagulant factors in preparation for possible tissue damage (16); and (iii) the tissue defense response (TDR) of the target organs [Figure 1; (11, 17)].", [["sympathetic nervous system", "ANATOMY", 435, 461], ["tissue", "ANATOMY", 746, 752], ["tissue", "ANATOMY", 780, 786], ["organs", "ANATOMY", 824, 830], ["illness", "DISEASE", 154, 161], ["systemic inflammation", "DISEASE", 176, 197], ["norepinephrine", "CHEMICAL", 420, 434], ["tissue damage", "DISEASE", 746, 759], ["norepinephrine", "CHEMICAL", 420, 434], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 44, 49], ["Nuclear Factor-\u03ba", "GENE_OR_GENE_PRODUCT", 125, 141], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 163, 168], ["hypothalamic-pituitary-adrenal", "GENE_OR_GENE_PRODUCT", 354, 384], ["sympathetic nervous system", "ANATOMICAL_SYSTEM", 435, 461], ["procoagulant factors", "GENE_OR_GENE_PRODUCT", 697, 717], ["tissue", "TISSUE", 746, 752], ["tissue", "TISSUE", 780, 786], ["organs", "ORGAN", 824, 830], ["NF-\u03baB target genes", "DNA", 44, 62], ["NF-\u03baB", "PROTEIN", 163, 168], ["cytokine", "PROTEIN", 216, 224], ["procoagulant factors", "PROTEIN", 697, 717], ["NF", "TEST", 44, 46], ["Nuclear Factor", "TEST", 125, 139], ["BIn critical illness", "PROBLEM", 141, 161], ["NF", "TEST", 163, 165], ["systemic inflammation", "PROBLEM", 176, 197], ["a multi-system response", "PROBLEM", 248, 271], ["the stress system", "PROBLEM", 320, 337], ["adrenal (HPA) axis", "PROBLEM", 377, 395], ["the locus caeruleus", "PROBLEM", 400, 419], ["norepinephrine/sympathetic nervous system", "TREATMENT", 420, 461], ["critical illness", "PROBLEM", 560, 576], ["the acute-phase reaction", "PROBLEM", 588, 612], ["procoagulant factors", "TREATMENT", 697, 717], ["tissue damage", "PROBLEM", 746, 759], ["metabolic processes", "OBSERVATION", 80, 99], ["systemic", "ANATOMY", 176, 184], ["inflammation", "OBSERVATION", 185, 197], ["pituitary", "ANATOMY", 367, 376], ["adrenal", "ANATOMY", 377, 384], ["sympathetic nervous", "ANATOMY", 435, 454], ["acute", "OBSERVATION_MODIFIER", 592, 597]]], ["The main effectors of systemic inflammation are the inflammatory cytokines, the acute-phase reactants, and the peripheral effectors of the sensory afferent nervous system.", [["sensory afferent nervous system", "ANATOMY", 139, 170], ["inflammation", "DISEASE", 31, 43], ["sensory", "ANATOMICAL_SYSTEM", 139, 146], ["afferent nervous system", "ANATOMICAL_SYSTEM", 147, 170], ["inflammatory cytokines", "PROTEIN", 52, 74], ["systemic inflammation", "PROBLEM", 22, 43], ["the inflammatory cytokines", "PROBLEM", 48, 74], ["the acute-phase reactants", "PROBLEM", 76, 101], ["main", "OBSERVATION_MODIFIER", 4, 8], ["systemic", "OBSERVATION_MODIFIER", 22, 30], ["inflammation", "OBSERVATION", 31, 43], ["inflammatory", "OBSERVATION_MODIFIER", 52, 64], ["acute", "OBSERVATION_MODIFIER", 80, 85], ["-phase", "OBSERVATION_MODIFIER", 85, 91], ["reactants", "OBSERVATION_MODIFIER", 92, 101], ["peripheral", "ANATOMY_MODIFIER", 111, 121], ["effectors", "OBSERVATION", 122, 131], ["sensory", "ANATOMY_MODIFIER", 139, 146], ["afferent", "ANATOMY_MODIFIER", 147, 155], ["nervous system", "ANATOMY", 156, 170]]], ["The inflammatory cytokines include TNF-\u03b1, interleukin-1\u03b2 (IL-1\u03b2), IL-6, chemokines, and other mediators of inflammation.", [["inflammation", "DISEASE", 107, 119], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 35, 40], ["interleukin-1\u03b2", "GENE_OR_GENE_PRODUCT", 42, 56], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 58, 63], ["IL-6", "GENE_OR_GENE_PRODUCT", 66, 70], ["inflammatory cytokines", "PROTEIN", 4, 26], ["TNF", "PROTEIN", 35, 38], ["interleukin-1\u03b2 (IL-1\u03b2", "PROTEIN", 42, 63], ["IL-6", "PROTEIN", 66, 70], ["chemokines", "PROTEIN", 72, 82], ["The inflammatory cytokines", "TEST", 0, 26], ["TNF", "TEST", 35, 38], ["interleukin", "TEST", 42, 53], ["IL", "TEST", 58, 60], ["IL", "TEST", 66, 68], ["chemokines", "PROBLEM", 72, 82], ["inflammation", "PROBLEM", 107, 119], ["inflammatory", "OBSERVATION_MODIFIER", 4, 16], ["inflammation", "OBSERVATION", 107, 119]]], ["The acute-phase reactants are mostly of hepatic origin and include the C-reactive protein (CRP), fibrinogen, and plasminogen activator inhibitor-1.", [["hepatic", "ANATOMY", 40, 47], ["hepatic", "ORGAN", 40, 47], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 71, 89], ["CRP", "GENE_OR_GENE_PRODUCT", 91, 94], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 97, 107], ["plasminogen activator inhibitor-1", "GENE_OR_GENE_PRODUCT", 113, 146], ["C-reactive protein", "PROTEIN", 71, 89], ["CRP", "PROTEIN", 91, 94], ["fibrinogen", "PROTEIN", 97, 107], ["plasminogen activator inhibitor-1", "PROTEIN", 113, 146], ["The acute-phase reactants", "PROBLEM", 0, 25], ["the C-reactive protein", "TEST", 67, 89], ["CRP", "TEST", 91, 94], ["fibrinogen", "TEST", 97, 107], ["plasminogen activator inhibitor", "TREATMENT", 113, 144], ["acute", "OBSERVATION_MODIFIER", 4, 9], ["-phase", "OBSERVATION_MODIFIER", 9, 15], ["reactants", "OBSERVATION", 16, 25], ["hepatic", "ANATOMY", 40, 47], ["origin", "ANATOMY_MODIFIER", 48, 54]]], ["During the acute-phase reaction, myelopoiesis is favored at the expense of both lymphopoiesis and hematopoiesis, explaining in part the persistent lymphopenia and anemia of critical illness (18).", [["lymphopenia", "DISEASE", 147, 158], ["anemia", "DISEASE", 163, 169], ["critical illness", "DISEASE", 173, 189], ["the acute-phase reaction", "PROBLEM", 7, 31], ["myelopoiesis", "PROBLEM", 33, 45], ["both lymphopoiesis", "PROBLEM", 75, 93], ["hematopoiesis", "PROBLEM", 98, 111], ["the persistent lymphopenia", "PROBLEM", 132, 158], ["anemia of critical illness", "PROBLEM", 163, 189], ["acute", "OBSERVATION_MODIFIER", 11, 16], ["myelopoiesis", "OBSERVATION", 33, 45], ["both", "OBSERVATION_MODIFIER", 75, 79], ["lymphopoiesis", "OBSERVATION", 80, 93], ["hematopoiesis", "OBSERVATION", 98, 111], ["persistent", "OBSERVATION_MODIFIER", 136, 146], ["lymphopenia", "OBSERVATION", 147, 158], ["anemia", "OBSERVATION", 163, 169]]], ["Substance P is an example of an effector of the sensory afferent nervous system, while hypothalamic corticotropin releasing hormone (CRH), vasopressin, cortisol, the catecholamines (norepinephrine and epinephrine), and peripheral neuronal CRH represent effectors of the stress system [reviewed in (19)].Innate Immunity and Nuclear Factor-\u03baBThe tissue defense response is an integrated network of three simultaneously NF-\u03baB-activated pathways that account for much of the histological, physiological, and laboratory changes observed in vital organs during critical illness (11).", [["sensory afferent nervous system", "ANATOMY", 48, 79], ["neuronal", "ANATOMY", 230, 238], ["tissue", "ANATOMY", 344, 350], ["organs", "ANATOMY", 541, 547], ["vasopressin", "CHEMICAL", 139, 150], ["cortisol", "CHEMICAL", 152, 160], ["catecholamines", "CHEMICAL", 166, 180], ["norepinephrine", "CHEMICAL", 182, 196], ["epinephrine", "CHEMICAL", 201, 212], ["cortisol", "CHEMICAL", 152, 160], ["catecholamines", "CHEMICAL", 166, 180], ["norepinephrine", "CHEMICAL", 182, 196], ["epinephrine", "CHEMICAL", 201, 212], ["Substance P", "GENE_OR_GENE_PRODUCT", 0, 11], ["sensory", "ANATOMICAL_SYSTEM", 48, 55], ["afferent nervous system", "ANATOMICAL_SYSTEM", 56, 79], ["hypothalamic", "GENE_OR_GENE_PRODUCT", 87, 99], ["corticotropin releasing hormone", "GENE_OR_GENE_PRODUCT", 100, 131], ["CRH", "GENE_OR_GENE_PRODUCT", 133, 136], ["vasopressin", "GENE_OR_GENE_PRODUCT", 139, 150], ["cortisol", "GENE_OR_GENE_PRODUCT", 152, 160], ["catecholamines", "SIMPLE_CHEMICAL", 166, 180], ["norepinephrine", "SIMPLE_CHEMICAL", 182, 196], ["epinephrine", "SIMPLE_CHEMICAL", 201, 212], ["neuronal", "CELL", 230, 238], ["CRH", "GENE_OR_GENE_PRODUCT", 239, 242], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 417, 422], ["organs", "ORGAN", 541, 547], ["NF-\u03baB", "PROTEIN", 417, 422], ["hypothalamic corticotropin releasing hormone", "TREATMENT", 87, 131], ["vasopressin", "TREATMENT", 139, 150], ["cortisol", "TREATMENT", 152, 160], ["the catecholamines", "TREATMENT", 162, 180], ["norepinephrine", "TREATMENT", 182, 196], ["epinephrine", "TREATMENT", 201, 212], ["peripheral neuronal CRH", "TREATMENT", 219, 242], ["Nuclear Factor", "TEST", 323, 337], ["laboratory changes", "PROBLEM", 504, 522], ["sensory afferent", "OBSERVATION", 48, 64], ["nervous system", "ANATOMY", 65, 79]]], ["These three pathways are those of tissue inflammation, hemostasis, and tissue damage repair: (i) tissue inflammation includes changes in the endothelium, such as loss of the glycocalyx, adhesion/diapedesis of activated neutrophils, endothelial injury, increased porosity with interstitial exudative edema, and loss of vascular tone, and changes in the epithelium, such as loss of integrity and cell apoptosis; (ii) the hemostasis pathway includes platelet activation and aggregation, intravascular clotting with decreased microvascular patency, extra-vascular fibrin deposition, and, lastly, inhibition of fibrinolysis, and (iii) tissue damage repair includes regenerating native parenchymal cells, fibroproliferation and deposition of extracellular matrix, resolution of granulation tissue, and clearance of apoptotic cells and debris (11).Innate Immunity and Nuclear Factor-\u03baBThe roles of macrophages and mitochondria in homeostatic corrections is the subject of intense research.", [["tissue", "ANATOMY", 34, 40], ["tissue", "ANATOMY", 71, 77], ["tissue", "ANATOMY", 97, 103], ["endothelium", "ANATOMY", 141, 152], ["glycocalyx", "ANATOMY", 174, 184], ["neutrophils", "ANATOMY", 219, 230], ["endothelial", "ANATOMY", 232, 243], ["interstitial", "ANATOMY", 276, 288], ["vascular", "ANATOMY", 318, 326], ["epithelium", "ANATOMY", 352, 362], ["cell", "ANATOMY", 394, 398], ["platelet", "ANATOMY", 447, 455], ["intravascular", "ANATOMY", 484, 497], ["microvascular", "ANATOMY", 522, 535], ["extra-vascular fibrin", "ANATOMY", 545, 566], ["tissue", "ANATOMY", 630, 636], ["parenchymal cells", "ANATOMY", 680, 697], ["extracellular matrix", "ANATOMY", 736, 756], ["granulation tissue", "ANATOMY", 772, 790], ["cells", "ANATOMY", 819, 824], ["macrophages", "ANATOMY", 891, 902], ["mitochondria", "ANATOMY", 907, 919], ["inflammation", "DISEASE", 41, 53], ["inflammation", "DISEASE", 104, 116], ["edema", "DISEASE", 299, 304], ["tissue", "TISSUE", 34, 40], ["tissue", "TISSUE", 71, 77], ["tissue", "TISSUE", 97, 103], ["endothelium", "TISSUE", 141, 152], ["glycocalyx", "CELLULAR_COMPONENT", 174, 184], ["neutrophils", "CELL", 219, 230], ["endothelial", "TISSUE", 232, 243], ["vascular", "MULTI-TISSUE_STRUCTURE", 318, 326], ["epithelium", "TISSUE", 352, 362], ["cell", "CELL", 394, 398], ["platelet", "CELL", 447, 455], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 484, 497], ["microvascular", "TISSUE", 522, 535], ["fibrin", "GENE_OR_GENE_PRODUCT", 560, 566], ["tissue", "TISSUE", 630, 636], ["parenchymal cells", "CELL", 680, 697], ["extracellular matrix", "CELLULAR_COMPONENT", 736, 756], ["granulation tissue", "TISSUE", 772, 790], ["cells", "CELL", 819, 824], ["Nuclear Factor-\u03baBThe", "GENE_OR_GENE_PRODUCT", 861, 881], ["macrophages", "CELL", 891, 902], ["mitochondria", "CELLULAR_COMPONENT", 907, 919], ["activated neutrophils", "CELL_TYPE", 209, 230], ["native parenchymal cells", "CELL_TYPE", 673, 697], ["apoptotic cells", "CELL_TYPE", 809, 824], ["macrophages", "CELL_TYPE", 891, 902], ["tissue inflammation", "PROBLEM", 34, 53], ["hemostasis", "TREATMENT", 55, 65], ["tissue damage repair", "TREATMENT", 71, 91], ["tissue inflammation", "PROBLEM", 97, 116], ["changes in the endothelium", "PROBLEM", 126, 152], ["loss of the glycocalyx", "PROBLEM", 162, 184], ["activated neutrophils", "PROBLEM", 209, 230], ["endothelial injury", "PROBLEM", 232, 250], ["increased porosity", "PROBLEM", 252, 270], ["interstitial exudative edema", "PROBLEM", 276, 304], ["loss of vascular tone", "PROBLEM", 310, 331], ["changes in the epithelium", "PROBLEM", 337, 362], ["loss of integrity", "PROBLEM", 372, 389], ["cell apoptosis", "PROBLEM", 394, 408], ["the hemostasis pathway", "PROBLEM", 415, 437], ["platelet activation", "PROBLEM", 447, 466], ["aggregation", "PROBLEM", 471, 482], ["intravascular clotting", "PROBLEM", 484, 506], ["decreased microvascular patency", "PROBLEM", 512, 543], ["extra-vascular fibrin deposition", "PROBLEM", 545, 577], ["fibrinolysis", "PROBLEM", 606, 618], ["(iii) tissue damage repair", "TREATMENT", 624, 650], ["regenerating native parenchymal cells", "PROBLEM", 660, 697], ["fibroproliferation", "PROBLEM", 699, 717], ["deposition of extracellular matrix", "PROBLEM", 722, 756], ["granulation tissue", "PROBLEM", 772, 790], ["apoptotic cells", "PROBLEM", 809, 824], ["debris", "PROBLEM", 829, 835], ["Nuclear Factor", "TEST", 861, 875], ["macrophages", "PROBLEM", 891, 902], ["tissue", "OBSERVATION_MODIFIER", 34, 40], ["inflammation", "OBSERVATION", 41, 53], ["hemostasis", "OBSERVATION", 55, 65], ["tissue", "OBSERVATION_MODIFIER", 71, 77], ["damage", "OBSERVATION_MODIFIER", 78, 84], ["repair", "OBSERVATION", 85, 91], ["inflammation", "OBSERVATION", 104, 116], ["endothelium", "ANATOMY", 141, 152], ["loss", "OBSERVATION_MODIFIER", 162, 166], ["glycocalyx", "ANATOMY_MODIFIER", 174, 184], ["adhesion", "OBSERVATION_MODIFIER", 186, 194], ["diapedesis", "OBSERVATION_MODIFIER", 195, 205], ["activated neutrophils", "OBSERVATION", 209, 230], ["endothelial", "ANATOMY", 232, 243], ["injury", "OBSERVATION", 244, 250], ["increased", "OBSERVATION_MODIFIER", 252, 261], ["porosity", "OBSERVATION_MODIFIER", 262, 270], ["interstitial", "ANATOMY_MODIFIER", 276, 288], ["exudative", "OBSERVATION_MODIFIER", 289, 298], ["edema", "OBSERVATION", 299, 304], ["loss", "OBSERVATION_MODIFIER", 310, 314], ["vascular tone", "ANATOMY", 318, 331], ["epithelium", "ANATOMY_MODIFIER", 352, 362], ["loss", "OBSERVATION_MODIFIER", 372, 376], ["integrity", "OBSERVATION_MODIFIER", 380, 389], ["cell apoptosis", "OBSERVATION", 394, 408], ["platelet activation", "OBSERVATION", 447, 466], ["intravascular clotting", "OBSERVATION", 484, 506], ["decreased", "OBSERVATION_MODIFIER", 512, 521], ["microvascular", "OBSERVATION_MODIFIER", 522, 535], ["patency", "OBSERVATION_MODIFIER", 536, 543], ["extra-vascular", "OBSERVATION_MODIFIER", 545, 559], ["fibrin deposition", "OBSERVATION", 560, 577], ["fibrinolysis", "OBSERVATION", 606, 618], ["damage repair", "OBSERVATION", 637, 650], ["regenerating", "OBSERVATION_MODIFIER", 660, 672], ["native", "OBSERVATION_MODIFIER", 673, 679], ["parenchymal cells", "OBSERVATION", 680, 697], ["deposition", "OBSERVATION_MODIFIER", 722, 732], ["extracellular matrix", "OBSERVATION", 736, 756], ["resolution", "OBSERVATION_MODIFIER", 758, 768], ["granulation tissue", "OBSERVATION", 772, 790], ["apoptotic cells", "OBSERVATION", 809, 824], ["debris", "OBSERVATION_MODIFIER", 829, 835], ["macrophages", "OBSERVATION", 891, 902], ["homeostatic corrections", "OBSERVATION", 923, 946]]], ["Mononuclear phagocytic cells (MPCs), including macrophages and dendritic cells, are widely distributed throughout the tissues of the organism, where they perform essential homeostatic, surveillance, and regenerative tasks.", [["Mononuclear phagocytic cells", "ANATOMY", 0, 28], ["MPCs", "ANATOMY", 30, 34], ["macrophages", "ANATOMY", 47, 58], ["dendritic cells", "ANATOMY", 63, 78], ["tissues", "ANATOMY", 118, 125], ["Mononuclear phagocytic cells", "CELL", 0, 28], ["MPCs", "CELL", 30, 34], ["macrophages", "CELL", 47, 58], ["dendritic cells", "CELL", 63, 78], ["tissues", "TISSUE", 118, 125], ["Mononuclear phagocytic cells", "CELL_TYPE", 0, 28], ["MPCs", "CELL_TYPE", 30, 34], ["macrophages", "CELL_TYPE", 47, 58], ["dendritic cells", "CELL_TYPE", 63, 78], ["Mononuclear phagocytic cells", "TEST", 0, 28], ["MPCs", "TEST", 30, 34], ["macrophages", "PROBLEM", 47, 58], ["dendritic cells", "PROBLEM", 63, 78], ["phagocytic cells", "OBSERVATION", 12, 28], ["macrophages", "ANATOMY", 47, 58], ["dendritic cells", "OBSERVATION", 63, 78], ["widely", "OBSERVATION_MODIFIER", 84, 90], ["homeostatic", "OBSERVATION_MODIFIER", 172, 183]]], ["As the neuro-endocrine-immune response progresses, macrophages change phenotype and play an essential role in both innate and adaptive immune responses, in the resolution of inflammation and in the tissue repair and regeneration (discussed further in section Glucocorticoid Receptor-Alpha and Homeostatic Corrections) (20).", [["macrophages", "ANATOMY", 51, 62], ["tissue", "ANATOMY", 198, 204], ["inflammation", "DISEASE", 174, 186], ["macrophages", "CELL", 51, 62], ["tissue", "TISSUE", 198, 204], ["Glucocorticoid Receptor-Alpha", "GENE_OR_GENE_PRODUCT", 259, 288], ["macrophages", "CELL_TYPE", 51, 62], ["Glucocorticoid Receptor", "PROTEIN", 259, 282], ["the neuro-endocrine", "TEST", 3, 22], ["macrophages change phenotype", "PROBLEM", 51, 79], ["inflammation", "PROBLEM", 174, 186], ["the tissue repair", "TREATMENT", 194, 211], ["regeneration", "PROBLEM", 216, 228], ["further in section Glucocorticoid Receptor", "TREATMENT", 240, 282], ["macrophages", "OBSERVATION", 51, 62], ["inflammation", "OBSERVATION", 174, 186], ["tissue", "ANATOMY", 198, 204], ["repair", "OBSERVATION", 205, 211]]], ["Mitochondria are targets of GR and critical modulators of homeostatic corrections owing to their critical role in energy production, synthesis of stress-associated steroid hormones, and their capacity to generate signals that promote cellular adaptation (see section Cellular Energetics\u2014Mitochondrial Function) (21).Innate Immunity and Nuclear Factor-\u03baBSystemic homeostatic corrections are driven by elevated levels of circulating inflammatory cytokines, and based on disease progression, can be broadly divided into either adaptive/resolving (regulated systemic inflammation) vs. maladaptive/unresolving (dysregulated systemic inflammation) (11, 14).", [["Mitochondria", "ANATOMY", 0, 12], ["cellular", "ANATOMY", 234, 242], ["Mitochondrial", "ANATOMY", 287, 300], ["steroid", "CHEMICAL", 164, 171], ["inflammation", "DISEASE", 563, 575], ["inflammation", "DISEASE", 628, 640], ["steroid", "CHEMICAL", 164, 171], ["Mitochondria", "CELLULAR_COMPONENT", 0, 12], ["GR", "GENE_OR_GENE_PRODUCT", 28, 30], ["cellular", "CELL", 234, 242], ["Nuclear Factor-\u03ba", "GENE_OR_GENE_PRODUCT", 336, 352], ["GR", "PROTEIN", 28, 30], ["inflammatory cytokines", "PROTEIN", 431, 453], ["Mitochondria", "PROBLEM", 0, 12], ["stress-associated steroid hormones", "PROBLEM", 146, 180], ["their capacity", "PROBLEM", 186, 200], ["Nuclear Factor", "TEST", 336, 350], ["BSystemic homeostatic corrections", "PROBLEM", 352, 385], ["elevated levels of circulating inflammatory cytokines", "PROBLEM", 400, 453], ["disease progression", "PROBLEM", 468, 487], ["regulated systemic inflammation", "PROBLEM", 544, 575], ["maladaptive/unresolving (dysregulated systemic inflammation", "PROBLEM", 581, 640], ["steroid hormones", "OBSERVATION", 164, 180], ["inflammatory cytokines", "OBSERVATION", 431, 453], ["systemic", "OBSERVATION_MODIFIER", 554, 562], ["inflammation", "OBSERVATION", 563, 575], ["dysregulated", "OBSERVATION_MODIFIER", 606, 618], ["systemic", "OBSERVATION_MODIFIER", 619, 627], ["inflammation", "OBSERVATION", 628, 640]]], ["Evidence from the literature on severe sepsis (22\u201330), acute respiratory distress syndrome (ARDS) (31\u201335), and trauma (14, 36) provides strong support that the degree of NF-\u03baB-driven elevation in inflammatory biomarkers at ICU entry and during ICU stay correlates with disease severity and hospital mortality (33, 37\u201339).", [["respiratory", "ANATOMY", 61, 72], ["sepsis", "DISEASE", 39, 45], ["acute respiratory distress syndrome", "DISEASE", 55, 90], ["ARDS", "DISEASE", 92, 96], ["trauma", "DISEASE", 111, 117], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 170, 175], ["NF-\u03baB", "PROTEIN", 170, 175], ["severe sepsis", "PROBLEM", 32, 45], ["acute respiratory distress syndrome", "PROBLEM", 55, 90], ["ARDS", "PROBLEM", 92, 96], ["trauma", "PROBLEM", 111, 117], ["NF", "PROBLEM", 170, 172], ["elevation in inflammatory biomarkers", "PROBLEM", 183, 219], ["disease severity", "PROBLEM", 269, 285], ["severe", "OBSERVATION_MODIFIER", 32, 38], ["sepsis", "OBSERVATION", 39, 45], ["acute", "OBSERVATION_MODIFIER", 55, 60], ["respiratory distress syndrome", "OBSERVATION", 61, 90], ["inflammatory", "OBSERVATION_MODIFIER", 196, 208]]], ["In addition to elevated inflammatory markers, critically ill patients have profound activation of the coagulation system (elevated D-dimer levels, prolonged prothrombin time and activated partial thromboplastin time, and reduced levels of the anticoagulant proteins, protein C and antithrombin) and evidence of endothelial cell activation with disturbed vascular integrity that correlates with disease severity and outcome (see section Endothelium) (40\u201342).", [["endothelial cell", "ANATOMY", 311, 327], ["vascular", "ANATOMY", 354, 362], ["critically ill", "DISEASE", 46, 60], ["patients", "ORGANISM", 61, 69], ["D-dimer", "GENE_OR_GENE_PRODUCT", 131, 138], ["prothrombin", "GENE_OR_GENE_PRODUCT", 157, 168], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 196, 210], ["protein C", "GENE_OR_GENE_PRODUCT", 267, 276], ["antithrombin", "GENE_OR_GENE_PRODUCT", 281, 293], ["endothelial cell", "CELL", 311, 327], ["vascular", "MULTI-TISSUE_STRUCTURE", 354, 362], ["inflammatory markers", "PROTEIN", 24, 44], ["D-dimer", "PROTEIN", 131, 138], ["anticoagulant proteins", "PROTEIN", 243, 265], ["protein C", "PROTEIN", 267, 276], ["antithrombin", "PROTEIN", 281, 293], ["patients", "SPECIES", 61, 69], ["elevated inflammatory markers", "PROBLEM", 15, 44], ["profound activation of the coagulation system", "PROBLEM", 75, 120], ["elevated D-dimer levels", "PROBLEM", 122, 145], ["prolonged prothrombin time", "PROBLEM", 147, 173], ["activated partial thromboplastin time", "TREATMENT", 178, 215], ["the anticoagulant proteins", "TREATMENT", 239, 265], ["protein C", "TREATMENT", 267, 276], ["antithrombin", "TEST", 281, 293], ["endothelial cell activation", "PROBLEM", 311, 338], ["disturbed vascular integrity", "PROBLEM", 344, 372], ["disease severity", "PROBLEM", 394, 410], ["elevated", "OBSERVATION_MODIFIER", 15, 23], ["inflammatory markers", "OBSERVATION", 24, 44], ["evidence of", "UNCERTAINTY", 299, 310], ["endothelial cell activation", "OBSERVATION", 311, 338], ["vascular", "ANATOMY", 354, 362]]], ["Evidence that hemostasis and inflammation evolved from a single-triggered mechanism can be traced back more than 450 million years ago, based on studies with the horse-shoe crab (Limulus polyphemus) (43).Innate Immunity and Nuclear Factor-\u03baBIn hospital survivors, failure to achieve homeostatic correction has a significant negative long-term impact, with experimental work suggesting that it might potentiate the peripheral and brain pro-inflammatory cytokine response to a subsequent inflammatory challenge (44).", [["brain", "ANATOMY", 429, 434], ["inflammation", "DISEASE", 29, 41], ["horse-shoe crab", "ORGANISM", 162, 177], ["Limulus polyphemus", "ORGANISM", 179, 197], ["Nuclear Factor-\u03ba", "GENE_OR_GENE_PRODUCT", 224, 240], ["peripheral", "TISSUE", 414, 424], ["brain", "ORGAN", 429, 434], ["cytokine", "PROTEIN", 452, 460], ["horse", "SPECIES", 162, 167], ["Limulus polyphemus", "SPECIES", 179, 197], ["horse-shoe crab", "SPECIES", 162, 177], ["Limulus polyphemus", "SPECIES", 179, 197], ["hemostasis", "PROBLEM", 14, 24], ["inflammation", "PROBLEM", 29, 41], ["a single-triggered mechanism", "PROBLEM", 55, 83], ["studies", "TEST", 145, 152], ["the horse", "TEST", 158, 167], ["Limulus polyphemus", "TEST", 179, 197], ["Nuclear Factor", "TEST", 224, 238], ["failure", "PROBLEM", 264, 271], ["the peripheral and brain pro-inflammatory cytokine response", "PROBLEM", 410, 469], ["a subsequent inflammatory challenge", "PROBLEM", 473, 508], ["hemostasis", "OBSERVATION", 14, 24], ["inflammation", "OBSERVATION", 29, 41], ["significant", "OBSERVATION_MODIFIER", 312, 323], ["negative long-term impact", "OBSERVATION_MODIFIER", 324, 349], ["peripheral", "ANATOMY_MODIFIER", 414, 424], ["brain", "ANATOMY", 429, 434], ["pro-inflammatory cytokine", "OBSERVATION", 435, 460], ["inflammatory", "OBSERVATION_MODIFIER", 486, 498]]], ["Independently of age and comorbidities, patients with elevated circulating biomarkers of inflammation and hemostasis at hospital discharge have persistent elevation over time with increased risk for cardiovascular events, re-hospitalizations, and 1-year mortality (41, 45, 46).", [["cardiovascular", "ANATOMY", 199, 213], ["inflammation", "DISEASE", 89, 101], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["elevated circulating biomarkers of inflammation", "PROBLEM", 54, 101], ["hemostasis", "TREATMENT", 106, 116], ["persistent elevation", "PROBLEM", 144, 164], ["cardiovascular events", "PROBLEM", 199, 220], ["inflammation", "OBSERVATION", 89, 101], ["persistent", "OBSERVATION_MODIFIER", 144, 154], ["elevation", "OBSERVATION", 155, 164], ["cardiovascular", "ANATOMY", 199, 213]]], ["\u201cPersistent Inflammation, Immunosuppression, and Catabolism Syndrome\u201d (PICS) has been postulated as the underlying pathophysiology of chronic critical illness (CCI) (18, 47).", [["Inflammation", "DISEASE", 12, 24], ["Immunosuppression", "DISEASE", 26, 43], ["PICS", "DISEASE", 71, 75], ["chronic critical illness", "DISEASE", 134, 158], ["CCI", "DISEASE", 160, 163], ["Persistent Inflammation", "PROBLEM", 1, 24], ["Immunosuppression", "TREATMENT", 26, 43], ["Catabolism Syndrome", "PROBLEM", 49, 68], ["chronic critical illness", "PROBLEM", 134, 158], ["Persistent", "OBSERVATION_MODIFIER", 1, 11], ["Inflammation", "OBSERVATION", 12, 24], ["Immunosuppression", "OBSERVATION", 26, 43], ["Catabolism Syndrome", "OBSERVATION", 49, 68], ["chronic", "OBSERVATION_MODIFIER", 134, 141], ["critical", "OBSERVATION_MODIFIER", 142, 150], ["illness", "OBSERVATION", 151, 158]]], ["About 50% of sepsis patients have a debilitating condition characterized by a self-perpetuating cycle of persistent low-grade systemic inflammation mimicking chronic stress (elevated cortisol) (44, 48, 49), glucocorticoid resistance, altered hemostasis (50, 51), mitochondrial dysfunction (52, 53), and accelerated inflamm-aging (9, 54), with increased risk for chronic inflammatory systemic diseases (7, 55).", [["mitochondrial", "ANATOMY", 263, 276], ["inflamm", "ANATOMY", 315, 322], ["sepsis", "DISEASE", 13, 19], ["inflammation", "DISEASE", 135, 147], ["cortisol", "CHEMICAL", 183, 191], ["mitochondrial dysfunction", "DISEASE", 263, 288], ["systemic diseases", "DISEASE", 383, 400], ["cortisol", "CHEMICAL", 183, 191], ["patients", "ORGANISM", 20, 28], ["mitochondrial", "CELLULAR_COMPONENT", 263, 276], ["patients", "SPECIES", 20, 28], ["sepsis", "PROBLEM", 13, 19], ["a debilitating condition", "PROBLEM", 34, 58], ["persistent low-grade systemic inflammation", "PROBLEM", 105, 147], ["chronic stress (elevated cortisol)", "PROBLEM", 158, 192], ["glucocorticoid resistance", "TEST", 207, 232], ["altered hemostasis", "PROBLEM", 234, 252], ["mitochondrial dysfunction", "PROBLEM", 263, 288], ["accelerated inflamm-aging", "PROBLEM", 303, 328], ["chronic inflammatory systemic diseases", "PROBLEM", 362, 400], ["sepsis", "OBSERVATION", 13, 19], ["persistent", "OBSERVATION_MODIFIER", 105, 115], ["low-grade", "OBSERVATION_MODIFIER", 116, 125], ["systemic", "OBSERVATION_MODIFIER", 126, 134], ["inflammation", "OBSERVATION", 135, 147], ["chronic", "OBSERVATION_MODIFIER", 158, 165], ["glucocorticoid resistance", "OBSERVATION", 207, 232], ["altered", "OBSERVATION_MODIFIER", 234, 241], ["hemostasis", "OBSERVATION", 242, 252], ["mitochondrial dysfunction", "OBSERVATION", 263, 288], ["increased", "OBSERVATION_MODIFIER", 343, 352], ["risk for", "UNCERTAINTY", 353, 361], ["chronic", "OBSERVATION_MODIFIER", 362, 369], ["inflammatory", "OBSERVATION_MODIFIER", 370, 382], ["systemic diseases", "OBSERVATION", 383, 400]]], ["The evolutionary trade-off between acutely beneficial and chronically harmful homeostatic corrections was the subject of a recent review (7).Innate Immunity and Nuclear Factor-\u03baBRecently, a critical role was identified for the FKBP5 gene, which encodes the FK506 binding protein 51, a co-chaperone of the GR along heat shock proteins (hsp), including hsp90.", [["FK506", "CHEMICAL", 257, 262], ["FK506", "CHEMICAL", 257, 262], ["Nuclear Factor-\u03ba", "GENE_OR_GENE_PRODUCT", 161, 177], ["FKBP5", "GENE_OR_GENE_PRODUCT", 227, 232], ["FK506 binding protein 51", "GENE_OR_GENE_PRODUCT", 257, 281], ["GR", "GENE_OR_GENE_PRODUCT", 305, 307], ["heat shock proteins", "GENE_OR_GENE_PRODUCT", 314, 333], ["hsp", "GENE_OR_GENE_PRODUCT", 335, 338], ["hsp90", "GENE_OR_GENE_PRODUCT", 351, 356], ["Nuclear Factor-\u03baBRecently", "PROTEIN", 161, 186], ["FKBP5 gene", "DNA", 227, 237], ["FK506 binding protein 51", "PROTEIN", 257, 281], ["GR", "PROTEIN", 305, 307], ["heat shock proteins", "PROTEIN", 314, 333], ["hsp", "PROTEIN", 335, 338], ["hsp90", "PROTEIN", 351, 356], ["Nuclear Factor", "TEST", 161, 175], ["the FK506 binding protein", "TEST", 253, 278], ["the GR along heat shock proteins", "TREATMENT", 301, 333], ["hsp90", "TEST", 351, 356]]], ["The expression of FK506 is stimulated by glucocorticoids and has an inhibitory effect on GR signaling, preventing the nuclear translocation of GR.", [["nuclear", "ANATOMY", 118, 125], ["FK506", "CHEMICAL", 18, 23], ["glucocorticoids", "CHEMICAL", 41, 56], ["FK506", "CHEMICAL", 18, 23], ["FK506", "SIMPLE_CHEMICAL", 18, 23], ["glucocorticoids", "SIMPLE_CHEMICAL", 41, 56], ["GR", "GENE_OR_GENE_PRODUCT", 89, 91], ["nuclear", "CELLULAR_COMPONENT", 118, 125], ["GR", "GENE_OR_GENE_PRODUCT", 143, 145], ["GR", "PROTEIN", 89, 91], ["GR", "PROTEIN", 143, 145], ["FK506", "TREATMENT", 18, 23], ["glucocorticoids", "TREATMENT", 41, 56], ["GR signaling", "PROBLEM", 89, 101]]], ["If short-lived, this negative feedback mechanism to reduce GC signaling may be important to restore HPA axis homeostasis.", [["GC", "CELL", 59, 61], ["HPA axis", "GENE_OR_GENE_PRODUCT", 100, 108], ["GC signaling", "PROBLEM", 59, 71]]], ["However, aging and certain stress-related phenotypes are associated with epigenetic up-regulation of FKBP5 via decreases in DNA methylation at selected enhancer-related FKBP5 sites, promoting NF-\u03baB\u2013related peripheral inflammation and chemotaxis, and heightened cardiovascular risk (56).", [["cardiovascular", "ANATOMY", 261, 275], ["peripheral inflammation", "DISEASE", 206, 229], ["FKBP5", "GENE_OR_GENE_PRODUCT", 101, 106], ["DNA", "CELLULAR_COMPONENT", 124, 127], ["FKBP5", "GENE_OR_GENE_PRODUCT", 169, 174], ["NF-\u03ba", "GENE_OR_GENE_PRODUCT", 192, 196], ["FKBP5", "PROTEIN", 101, 106], ["FKBP5 sites", "DNA", 169, 180], ["certain stress", "PROBLEM", 19, 33], ["related phenotypes", "PROBLEM", 34, 52], ["FKBP5", "PROBLEM", 101, 106], ["DNA methylation", "TREATMENT", 124, 139], ["FKBP5 sites", "PROBLEM", 169, 180], ["B\u2013related peripheral inflammation", "PROBLEM", 196, 229], ["chemotaxis", "PROBLEM", 234, 244], ["heightened cardiovascular risk", "PROBLEM", 250, 280], ["decreases", "OBSERVATION_MODIFIER", 111, 120], ["peripheral", "ANATOMY_MODIFIER", 206, 216], ["inflammation", "OBSERVATION", 217, 229], ["chemotaxis", "OBSERVATION_MODIFIER", 234, 244]]], ["Importantly, translational research indicates that the type of response (regulated or dysregulated) is established early in critical illness (14, 31, 57), and the previously espoused hypotheses of the second-hit model (14, 22), or the two-phase model (compensatory anti-inflammatory response syndrome) are now both considered obsolete (29, 58, 59).Innate Immunity and Nuclear Factor-\u03baBBased on this pathophysiological construct, we will focus on emerging evidence indicating the central role played by the activated glucocorticoid receptor-alpha (GR\u03b1), the master regulator of NF-\u03baB and homeostatic corrections, in the development and resolution of critical illness.", [["compensatory anti-inflammatory response syndrome", "DISEASE", 252, 300], ["Nuclear Factor-\u03ba", "GENE_OR_GENE_PRODUCT", 368, 384], ["glucocorticoid receptor-alpha", "GENE_OR_GENE_PRODUCT", 516, 545], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 547, 550], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 577, 582], ["Nuclear Factor-\u03baBBased", "PROTEIN", 368, 390], ["glucocorticoid receptor", "PROTEIN", 516, 539], ["alpha", "PROTEIN", 540, 545], ["GR\u03b1", "PROTEIN", 547, 550], ["NF-\u03baB", "PROTEIN", 577, 582], ["compensatory anti-inflammatory response syndrome", "PROBLEM", 252, 300], ["Nuclear Factor", "TEST", 368, 382], ["homeostatic corrections", "TREATMENT", 587, 610], ["critical illness", "PROBLEM", 649, 665], ["anti-inflammatory response syndrome", "OBSERVATION", 265, 300]]], ["This role is conditioned by its interdependence with functioning mitochondria and by presence of adequate micronutrient reserves.", [["mitochondria", "ANATOMY", 65, 77], ["mitochondria", "CELLULAR_COMPONENT", 65, 77], ["micronutrient reserves", "OBSERVATION", 106, 128]]], ["Additionally, we present evidence on how CIRCI, mitochondrial dysfunction/damage, and hypovitaminosis negatively interact to accelerate an anti-homeostatic process of natural selection.Glucocorticoid Receptor-AlphaThe stress system is a complex, sophisticated, and carefully regulated adaptation mechanism that has been shaped by natural selection because it offers a selective advantage (4).", [["mitochondrial", "ANATOMY", 48, 61], ["mitochondrial dysfunction", "DISEASE", 48, 73], ["hypovitaminosis", "DISEASE", 86, 101], ["mitochondrial", "CELLULAR_COMPONENT", 48, 61], ["Glucocorticoid Receptor-Alpha", "GENE_OR_GENE_PRODUCT", 185, 214], ["Glucocorticoid Receptor-Alpha", "PROTEIN", 185, 214], ["mitochondrial dysfunction", "PROBLEM", 48, 73], ["damage", "PROBLEM", 74, 80], ["hypovitaminosis", "PROBLEM", 86, 101], ["Glucocorticoid Receptor", "TREATMENT", 185, 208], ["natural selection", "OBSERVATION", 167, 184], ["Alpha", "OBSERVATION_MODIFIER", 209, 214], ["stress system", "OBSERVATION", 218, 231]]], ["All vertebrates express the proopiomelanocortin protein (POMC) that gives rise to adrenocorticotropic hormone (ACTH) which then stimulates the secretion of glucocorticoids.", [["proopiomelanocortin protein", "GENE_OR_GENE_PRODUCT", 28, 55], ["POMC", "GENE_OR_GENE_PRODUCT", 57, 61], ["adrenocorticotropic hormone", "GENE_OR_GENE_PRODUCT", 82, 109], ["ACTH", "GENE_OR_GENE_PRODUCT", 111, 115], ["glucocorticoids", "SIMPLE_CHEMICAL", 156, 171], ["proopiomelanocortin protein", "PROTEIN", 28, 55], ["POMC", "PROTEIN", 57, 61], ["adrenocorticotropic hormone", "TEST", 82, 109]]], ["ACTH has long been closely associated with other signaling molecules, such as CRH, vasopressin, biogenic amines (epinephrine and norepinephrine), steroids such as cortisol and aldosterone, cytokines, such as IL-1\u03b2, and nitric oxide.", [["vasopressin", "CHEMICAL", 83, 94], ["amines", "CHEMICAL", 105, 111], ["epinephrine", "CHEMICAL", 113, 124], ["norepinephrine", "CHEMICAL", 129, 143], ["steroids", "CHEMICAL", 146, 154], ["cortisol", "CHEMICAL", 163, 171], ["aldosterone", "CHEMICAL", 176, 187], ["nitric oxide", "CHEMICAL", 219, 231], ["vasopressin", "CHEMICAL", 83, 94], ["amines", "CHEMICAL", 105, 111], ["epinephrine", "CHEMICAL", 113, 124], ["norepinephrine", "CHEMICAL", 129, 143], ["steroids", "CHEMICAL", 146, 154], ["cortisol", "CHEMICAL", 163, 171], ["aldosterone", "CHEMICAL", 176, 187], ["nitric oxide", "CHEMICAL", 219, 231], ["ACTH", "GENE_OR_GENE_PRODUCT", 0, 4], ["CRH", "GENE_OR_GENE_PRODUCT", 78, 81], ["vasopressin", "GENE_OR_GENE_PRODUCT", 83, 94], ["biogenic amines", "SIMPLE_CHEMICAL", 96, 111], ["epinephrine", "SIMPLE_CHEMICAL", 113, 124], ["norepinephrine", "SIMPLE_CHEMICAL", 129, 143], ["steroids", "SIMPLE_CHEMICAL", 146, 154], ["cortisol", "GENE_OR_GENE_PRODUCT", 163, 171], ["aldosterone", "SIMPLE_CHEMICAL", 176, 187], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 208, 213], ["nitric oxide", "SIMPLE_CHEMICAL", 219, 231], ["signaling molecules", "PROTEIN", 49, 68], ["cytokines", "PROTEIN", 189, 198], ["IL-1\u03b2", "PROTEIN", 208, 213], ["other signaling molecules", "PROBLEM", 43, 68], ["CRH", "TEST", 78, 81], ["vasopressin", "TREATMENT", 83, 94], ["biogenic amines", "TREATMENT", 96, 111], ["epinephrine", "TREATMENT", 113, 124], ["norepinephrine", "TREATMENT", 129, 143], ["steroids", "TREATMENT", 146, 154], ["cortisol", "TREATMENT", 163, 171], ["aldosterone", "TREATMENT", 176, 187], ["cytokines", "TREATMENT", 189, 198], ["IL", "TREATMENT", 208, 210], ["nitric oxide", "TREATMENT", 219, 231]]], ["All of these substances are crucial to adaptation to stressors.", [["substances", "OBSERVATION", 13, 23]]], ["It is remarkable that the gene DNA sequences for these molecules have not only been conserved over hundreds of millions of years but also continue to serve closely related adaptive functions (4).", [["DNA", "CELLULAR_COMPONENT", 31, 34], ["gene DNA sequences", "DNA", 26, 44], ["the gene DNA sequences", "TEST", 22, 44]]], ["This is apparently a result of strong selective forces against mutations that change their sequences and functionality of their products.Glucocorticoid Receptor-AlphaCortisol, the end-product of HPA axis activation, is synthesized from cholesterol in the mitochondria and endoplasmic reticulum of the zona fasciculata of the adrenal cortex.", [["mitochondria", "ANATOMY", 255, 267], ["endoplasmic reticulum", "ANATOMY", 272, 293], ["zona fasciculata", "ANATOMY", 301, 317], ["adrenal cortex", "ANATOMY", 325, 339], ["AlphaCortisol", "CHEMICAL", 161, 174], ["cholesterol", "CHEMICAL", 236, 247], ["cholesterol", "CHEMICAL", 236, 247], ["Glucocorticoid Receptor-AlphaCortisol", "GENE_OR_GENE_PRODUCT", 137, 174], ["HPA axis", "GENE_OR_GENE_PRODUCT", 195, 203], ["cholesterol", "SIMPLE_CHEMICAL", 236, 247], ["mitochondria", "CELLULAR_COMPONENT", 255, 267], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 272, 293], ["zona fasciculata", "CELLULAR_COMPONENT", 301, 317], ["adrenal cortex", "MULTI-TISSUE_STRUCTURE", 325, 339], ["Glucocorticoid Receptor", "PROTEIN", 137, 160], ["strong selective forces against mutations", "PROBLEM", 31, 72], ["Glucocorticoid Receptor", "TREATMENT", 137, 160], ["AlphaCortisol", "TREATMENT", 161, 174], ["HPA axis activation", "PROBLEM", 195, 214], ["mitochondria", "ANATOMY", 255, 267], ["endoplasmic reticulum", "OBSERVATION", 272, 293], ["zona", "ANATOMY_MODIFIER", 301, 305], ["fasciculata", "ANATOMY_MODIFIER", 306, 317], ["adrenal", "ANATOMY", 325, 332], ["cortex", "ANATOMY_MODIFIER", 333, 339]]], ["Its synthesis depends entirely on scavenger receptor class B type-I (SR-BI)-mediated cholesteryl ester selective uptake from circulating high-density (HDLs) and low-density (LDLs) lipoproteins (60).", [["cholesteryl ester", "CHEMICAL", 85, 102], ["cholesteryl ester", "CHEMICAL", 85, 102], ["class B type-I", "GENE_OR_GENE_PRODUCT", 53, 67], ["SR-BI", "SIMPLE_CHEMICAL", 69, 74], ["cholesteryl ester", "SIMPLE_CHEMICAL", 85, 102], ["HDLs", "SIMPLE_CHEMICAL", 151, 155], ["LDLs", "SIMPLE_CHEMICAL", 174, 178], ["low-density (LDLs) lipoproteins", "PROTEIN", 161, 192], ["mediated cholesteryl ester selective uptake", "PROBLEM", 76, 119], ["lipoproteins", "TEST", 180, 192], ["high-density", "OBSERVATION_MODIFIER", 137, 149], ["low-density", "OBSERVATION_MODIFIER", 161, 172]]], ["In critically ill patients, low serum HDL levels correlate negatively with circulating TNF-\u03b1 and IL-6 levels (61, 62), and positively with mortality (61, 63).", [["serum", "ANATOMY", 32, 37], ["critically ill", "DISEASE", 3, 17], ["patients", "ORGANISM", 18, 26], ["serum", "ORGANISM_SUBSTANCE", 32, 37], ["HDL", "GENE_OR_GENE_PRODUCT", 38, 41], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 87, 92], ["IL-6", "GENE_OR_GENE_PRODUCT", 97, 101], ["TNF", "PROTEIN", 87, 90], ["patients", "SPECIES", 18, 26], ["low serum HDL levels", "PROBLEM", 28, 48], ["circulating TNF", "TEST", 75, 90], ["IL", "TEST", 97, 99], ["mortality", "TEST", 139, 148]]], ["The combined effects of reduced HDL and SR-BI during systemic inflammation may lead to significant reductions in glucocorticoid production (64).", [["inflammation", "DISEASE", 62, 74], ["HDL", "SIMPLE_CHEMICAL", 32, 35], ["SR-BI", "GENE_OR_GENE_PRODUCT", 40, 45], ["glucocorticoid", "SIMPLE_CHEMICAL", 113, 127], ["reduced HDL", "PROBLEM", 24, 35], ["systemic inflammation", "PROBLEM", 53, 74], ["significant reductions in glucocorticoid production", "PROBLEM", 87, 138], ["inflammation", "OBSERVATION", 62, 74], ["significant", "OBSERVATION_MODIFIER", 87, 98], ["reductions", "OBSERVATION_MODIFIER", 99, 109], ["glucocorticoid production", "OBSERVATION", 113, 138]]], ["Low HDL (65) and low total cholesterol (66) correlate with inadequate response to ACTH stimulation.", [["cholesterol", "CHEMICAL", 27, 38], ["cholesterol", "CHEMICAL", 27, 38], ["HDL", "GENE_OR_GENE_PRODUCT", 4, 7], ["cholesterol", "SIMPLE_CHEMICAL", 27, 38], ["ACTH", "GENE_OR_GENE_PRODUCT", 82, 86], ["Low HDL", "TEST", 0, 7], ["low total cholesterol", "TEST", 17, 38], ["ACTH stimulation", "TEST", 82, 98]]], ["In septic shock, prolonged glucocorticoid administration is associated with significant increase in total cholesterol levels within 3 days of treatment (66).Glucocorticoid Receptor-AlphaGlucocorticoids are the primary adaptive response mediators, whose signaling system interacts with other cell signaling systems, all essential for maintaining the homeostasis of many of the body's complex functions, including neural, cardiorespiratory, endocrine, metabolic, bioenergetic, and immune responses (67).", [["cell", "ANATOMY", 291, 295], ["body", "ANATOMY", 376, 380], ["neural", "ANATOMY", 412, 418], ["endocrine", "ANATOMY", 439, 448], ["septic shock", "DISEASE", 3, 15], ["cholesterol", "CHEMICAL", 106, 117], ["cholesterol", "CHEMICAL", 106, 117], ["glucocorticoid", "SIMPLE_CHEMICAL", 27, 41], ["cholesterol", "SIMPLE_CHEMICAL", 106, 117], ["Glucocorticoid Receptor-AlphaGlucocorticoids", "GENE_OR_GENE_PRODUCT", 157, 201], ["cell", "CELL", 291, 295], ["body", "ORGANISM_SUBDIVISION", 376, 380], ["endocrine", "ANATOMICAL_SYSTEM", 439, 448], ["Glucocorticoid Receptor", "PROTEIN", 157, 180], ["septic shock", "PROBLEM", 3, 15], ["prolonged glucocorticoid administration", "TREATMENT", 17, 56], ["significant increase in total cholesterol levels", "PROBLEM", 76, 124], ["treatment", "TREATMENT", 142, 151], ["Glucocorticoid Receptor", "TREATMENT", 157, 180], ["AlphaGlucocorticoids", "TREATMENT", 181, 201], ["other cell signaling systems", "PROBLEM", 285, 313], ["septic shock", "OBSERVATION", 3, 15], ["prolonged glucocorticoid administration", "OBSERVATION", 17, 56], ["significant", "OBSERVATION_MODIFIER", 76, 87], ["increase", "OBSERVATION_MODIFIER", 88, 96], ["total cholesterol", "OBSERVATION", 100, 117]]], ["Within tissues, glucocorticoids are regulated at the pre-receptor level by the isozymes of 11\u03b2- hydroxysteroid dehydrogenase (11\u03b2-HSD), which are located in the endoplasmic reticulum (ER).", [["tissues", "ANATOMY", 7, 14], ["endoplasmic reticulum", "ANATOMY", 161, 182], ["ER", "ANATOMY", 184, 186], ["11\u03b2- hydroxysteroid", "CHEMICAL", 91, 110], ["tissues", "TISSUE", 7, 14], ["glucocorticoids", "SIMPLE_CHEMICAL", 16, 31], ["11\u03b2- hydroxysteroid dehydrogenase", "GENE_OR_GENE_PRODUCT", 91, 124], ["11\u03b2-HSD", "GENE_OR_GENE_PRODUCT", 126, 133], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 161, 182], ["ER", "GENE_OR_GENE_PRODUCT", 184, 186], ["isozymes", "PROTEIN", 79, 87], ["11\u03b2- hydroxysteroid dehydrogenase", "PROTEIN", 91, 124], ["\u03b2", "PROTEIN", 128, 129], ["HSD", "PROTEIN", 130, 133], ["ER", "PROTEIN", 184, 186], ["glucocorticoids", "TREATMENT", 16, 31], ["the isozymes", "TEST", 75, 87], ["hydroxysteroid dehydrogenase", "PROBLEM", 96, 124], ["glucocorticoids", "ANATOMY", 16, 31], ["endoplasmic reticulum", "ANATOMY", 161, 182]]], ["Glucocorticoids (GCs) bind to the ligand-binding domain of GR\u03b1 to produce a biological response.", [["GCs", "SIMPLE_CHEMICAL", 17, 20], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 59, 62], ["ligand-binding domain", "PROTEIN", 34, 55], ["GR\u03b1", "PROTEIN", 59, 62], ["Glucocorticoids (GCs)", "TREATMENT", 0, 21], ["the ligand", "TEST", 30, 40]]], ["Because of their lipophilic nature, GCs can readily diffuse across cellular membranes to bind to their intracellular receptor and produce a biological/pharmacological response [Figure 2; (15, 68, 69)].", [["cellular membranes", "ANATOMY", 67, 85], ["intracellular", "ANATOMY", 103, 116], ["GCs", "SIMPLE_CHEMICAL", 36, 39], ["cellular membranes", "CELLULAR_COMPONENT", 67, 85], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 103, 116], ["intracellular receptor", "PROTEIN", 103, 125], ["readily diffuse across cellular membranes", "PROBLEM", 44, 85], ["a biological/pharmacological response", "PROBLEM", 138, 175], ["lipophilic nature", "OBSERVATION_MODIFIER", 17, 34], ["diffuse", "OBSERVATION_MODIFIER", 52, 59], ["cellular membranes", "OBSERVATION", 67, 85]]], ["The glucocorticoid receptor is a member of the nuclear receptor (NRs) (70) superfamily that emerged in the vertebrate lineage ~420\u2013440 million years ago (similarly to NF-\u03baB) from sequential duplications of two ancestral genes, those of the estrogen and the glucocorticoid receptors; the latter ultimately evolved into the glucocorticoid and the mineralocorticoid receptors (67, 71).", [["nuclear", "ANATOMY", 47, 54], ["estrogen", "CHEMICAL", 240, 248], ["estrogen", "CHEMICAL", 240, 248], ["glucocorticoid receptor", "GENE_OR_GENE_PRODUCT", 4, 27], ["nuclear receptor (NRs) (70)", "GENE_OR_GENE_PRODUCT", 47, 74], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 167, 172], ["estrogen", "SIMPLE_CHEMICAL", 240, 248], ["glucocorticoid receptors", "GENE_OR_GENE_PRODUCT", 257, 281], ["mineralocorticoid receptors", "GENE_OR_GENE_PRODUCT", 345, 372], ["glucocorticoid receptor", "PROTEIN", 4, 27], ["nuclear receptor (NRs) (70) superfamily", "PROTEIN", 47, 86], ["NF", "PROTEIN", 167, 169], ["\u03baB", "PROTEIN", 170, 172], ["glucocorticoid receptors", "PROTEIN", 257, 281], ["mineralocorticoid receptors", "PROTEIN", 345, 372], ["The glucocorticoid receptor", "TREATMENT", 0, 27], ["sequential duplications of two ancestral genes", "PROBLEM", 179, 225], ["the estrogen", "TREATMENT", 236, 248], ["the glucocorticoid receptors", "TREATMENT", 253, 281], ["glucocorticoid receptor", "OBSERVATION", 4, 27], ["ancestral genes", "OBSERVATION", 210, 225], ["glucocorticoid", "ANATOMY", 322, 336], ["mineralocorticoid receptors", "ANATOMY", 345, 372]]], ["Underlying its essential role in formation and regulation of multicellular life, the GR is required to establish the necessary cellular context for maintaining normal uterine biology and fertility through the regulation of uterine-specific actions (72) while GRs are vital for the structural and functional maturation of fetal organs (73, 74), affecting almost 4,000 genes (75).", [["cellular", "ANATOMY", 127, 135], ["uterine", "ANATOMY", 167, 174], ["uterine", "ANATOMY", 223, 230], ["fetal organs", "ANATOMY", 321, 333], ["GR", "GENE_OR_GENE_PRODUCT", 85, 87], ["cellular", "CELL", 127, 135], ["uterine", "MULTI-TISSUE_STRUCTURE", 167, 174], ["uterine", "ORGAN", 223, 230], ["GRs", "GENE_OR_GENE_PRODUCT", 259, 262], ["fetal organs", "MULTI-TISSUE_STRUCTURE", 321, 333], ["GR", "PROTEIN", 85, 87], ["GRs", "PROTEIN", 259, 262], ["multicellular life", "TREATMENT", 61, 79], ["essential", "OBSERVATION_MODIFIER", 15, 24], ["uterine", "ANATOMY", 167, 174], ["uterine", "ANATOMY", 223, 230], ["fetal organs", "ANATOMY", 321, 333]]], ["In late gestation of mammals, fetal glucocorticoid levels rise dramatically, an essential step for maturation in preparation for life after birth.", [["fetal", "ANATOMY", 30, 35], ["fetal", "ANATOMICAL_SYSTEM", 30, 35], ["glucocorticoid", "GENE_OR_GENE_PRODUCT", 36, 50], ["fetal glucocorticoid levels", "TEST", 30, 57], ["glucocorticoid levels", "OBSERVATION", 36, 57]]], ["Also, an association was found between greater maternal affection and warmth in early life and increased expression of glucocorticoid receptor genes in the offspring resulting in long-term health benefits (76).Glucocorticoid Receptor-AlphaGRs are present in the cytoplasm (68) and cell membrane (non-genomic effects) (77) in almost all cells of the body and in high concentrations (in neutrophils ~5,000; in macrophages ~10,000) (78).", [["cytoplasm", "ANATOMY", 262, 271], ["cell membrane", "ANATOMY", 281, 294], ["cells", "ANATOMY", 336, 341], ["body", "ANATOMY", 349, 353], ["neutrophils", "ANATOMY", 385, 396], ["macrophages", "ANATOMY", 408, 419], ["glucocorticoid receptor", "GENE_OR_GENE_PRODUCT", 119, 142], ["Glucocorticoid Receptor-AlphaGRs", "GENE_OR_GENE_PRODUCT", 210, 242], ["cytoplasm", "ORGANISM_SUBSTANCE", 262, 271], ["cell membrane", "CELLULAR_COMPONENT", 281, 294], ["cells", "CELL", 336, 341], ["body", "ORGANISM_SUBDIVISION", 349, 353], ["neutrophils", "CELL", 385, 396], ["macrophages", "CELL", 408, 419], ["glucocorticoid receptor genes", "DNA", 119, 148], ["Glucocorticoid Receptor", "PROTEIN", 210, 233], ["AlphaGRs", "PROTEIN", 234, 242], ["neutrophils", "CELL_TYPE", 385, 396], ["macrophages", "CELL_TYPE", 408, 419], ["greater maternal affection", "PROBLEM", 39, 65], ["warmth", "PROBLEM", 70, 76], ["glucocorticoid receptor genes", "TREATMENT", 119, 148], ["Glucocorticoid Receptor", "TEST", 210, 233], ["AlphaGRs", "TREATMENT", 234, 242], ["cell membrane", "TEST", 281, 294], ["high concentrations", "PROBLEM", 361, 380], ["neutrophils", "TEST", 385, 396], ["macrophages", "TEST", 408, 419], ["affection", "OBSERVATION", 56, 65], ["warmth", "OBSERVATION", 70, 76], ["body", "ANATOMY", 349, 353], ["high concentrations", "OBSERVATION_MODIFIER", 361, 380]]], ["However, GR levels within the cell are not static, but are tightly controlled by numerous factors and at multiple levels.", [["cell", "ANATOMY", 30, 34], ["GR", "GENE_OR_GENE_PRODUCT", 9, 11], ["cell", "CELL", 30, 34], ["GR", "PROTEIN", 9, 11], ["GR levels", "TEST", 9, 18], ["cell", "OBSERVATION_MODIFIER", 30, 34], ["not", "UNCERTAINTY", 39, 42], ["static", "OBSERVATION_MODIFIER", 43, 49], ["tightly", "OBSERVATION_MODIFIER", 59, 66], ["numerous", "OBSERVATION_MODIFIER", 81, 89], ["factors", "OBSERVATION", 90, 97]]], ["Notably, 16 variants of the human GR (hGR) have been identified to date with the potential of at least 256 combinations of homo- and hetero-dimers (68).", [["human", "ORGANISM", 28, 33], ["GR", "GENE_OR_GENE_PRODUCT", 34, 36], ["hGR", "GENE_OR_GENE_PRODUCT", 38, 41], ["human GR", "PROTEIN", 28, 36], ["hGR", "PROTEIN", 38, 41], ["homo- and hetero-dimers", "PROTEIN", 123, 146], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 28, 33]]], ["Recent research indicates that the expression of different GR transcriptional and translational isoforms might be a significant factor determining how GCs influence the biological function and activity of specific cells and tissues (75).", [["GCs", "ANATOMY", 151, 154], ["cells", "ANATOMY", 214, 219], ["tissues", "ANATOMY", 224, 231], ["GR", "GENE_OR_GENE_PRODUCT", 59, 61], ["GCs", "CELL", 151, 154], ["cells", "CELL", 214, 219], ["tissues", "TISSUE", 224, 231], ["GR transcriptional and translational isoforms", "PROTEIN", 59, 104]]], ["In contrast to GR\u03b1, the alternatively transcribed GR\u03b2, which resides primarily in the cell nucleus, does not bind glucocorticoid, but can form homodimers with itself or heterodimers with a GR\u03b1 subtype, functioning as an antagonist of GR\u03b1.", [["cell nucleus", "ANATOMY", 86, 98], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 15, 18], ["GR\u03b2", "GENE_OR_GENE_PRODUCT", 50, 53], ["cell nucleus", "CELLULAR_COMPONENT", 86, 98], ["glucocorticoid", "SIMPLE_CHEMICAL", 114, 128], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 189, 192], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 234, 237], ["GR\u03b1", "PROTEIN", 15, 18], ["GR\u03b2", "PROTEIN", 50, 53], ["homodimers", "PROTEIN", 143, 153], ["heterodimers", "PROTEIN", 169, 181], ["GR\u03b1 subtype", "PROTEIN", 189, 200], ["GR\u03b1", "PROTEIN", 234, 237], ["heterodimers", "TREATMENT", 169, 181], ["a GR\u03b1 subtype", "PROBLEM", 187, 200], ["an antagonist of GR\u03b1", "TREATMENT", 217, 237], ["cell nucleus", "ANATOMY", 86, 98], ["not", "UNCERTAINTY", 105, 108], ["bind glucocorticoid", "OBSERVATION", 109, 128]]], ["GR\u03b2 homodimers can interact with glucocorticoid response elements (GRE) in the DNA, however their binding does not activate transcription (69).", [["GR\u03b2", "GENE_OR_GENE_PRODUCT", 0, 3], ["DNA", "CELLULAR_COMPONENT", 79, 82], ["GR\u03b2 homodimers", "PROTEIN", 0, 14], ["glucocorticoid response elements", "DNA", 33, 65], ["GRE", "DNA", 67, 70], ["glucocorticoid response elements", "TREATMENT", 33, 65]]], ["Generally, GR\u03b2 is expressed at very low levels compared to GR\u03b1; however, its expression is increased in inflammatory diseases, including critical illness, and this might be associated with decreased sensitivity to GCs and CIRCI (79).Glucocorticoid Receptor-AlphaActivation of GR\u03b1 is not only an essential component of the general adaptation to stress, but also contributes to the maintenance of homeostasis in stress-free conditions (15).", [["inflammatory diseases", "DISEASE", 104, 125], ["critical illness", "DISEASE", 137, 153], ["GR\u03b2", "GENE_OR_GENE_PRODUCT", 11, 14], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 59, 62], ["Glucocorticoid Receptor", "GENE_OR_GENE_PRODUCT", 233, 256], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 276, 279], ["GR\u03b2", "PROTEIN", 11, 14], ["GR\u03b1", "PROTEIN", 59, 62], ["Glucocorticoid Receptor", "PROTEIN", 233, 256], ["GR\u03b1", "PROTEIN", 276, 279], ["very low levels", "PROBLEM", 31, 46], ["inflammatory diseases", "PROBLEM", 104, 125], ["critical illness", "PROBLEM", 137, 153], ["decreased sensitivity", "PROBLEM", 189, 210], ["GCs", "TEST", 214, 217], ["CIRCI", "TEST", 222, 227], ["Glucocorticoid Receptor", "TREATMENT", 233, 256], ["AlphaActivation of GR", "TREATMENT", 257, 278], ["increased", "OBSERVATION_MODIFIER", 91, 100], ["inflammatory", "OBSERVATION_MODIFIER", 104, 116]]], ["The biological response to the GC-GR\u03b1 complex is affected by cell type, tissue type, and species-specific variations in the repertoire of partnering proteins, ligand concentrations, and other contextual variables (80, 81).", [["cell", "ANATOMY", 61, 65], ["tissue", "ANATOMY", 72, 78], ["GC-GR\u03b1", "GENE_OR_GENE_PRODUCT", 31, 37], ["cell type", "CELL", 61, 70], ["tissue", "TISSUE", 72, 78], ["GC-GR\u03b1 complex", "PROTEIN", 31, 45], ["partnering proteins", "PROTEIN", 138, 157], ["the GC", "TEST", 27, 33], ["ligand concentrations", "TEST", 159, 180], ["cell type", "OBSERVATION", 61, 70]]], ["In stimulated HeLa and neuronal PC12 cells, genome-wide studies identified 8,306 and 2,252 GR genomic binding sites upon treatment with GC, respectively (12, 81).", [["HeLa", "ANATOMY", 14, 18], ["neuronal PC12 cells", "ANATOMY", 23, 42], ["HeLa", "CELL", 14, 18], ["neuronal PC12 cells", "CELL", 23, 42], ["GR", "GENE_OR_GENE_PRODUCT", 91, 93], ["HeLa", "CELL_LINE", 14, 18], ["neuronal PC12 cells", "CELL_LINE", 23, 42], ["8,306 and 2,252 GR genomic binding sites", "DNA", 75, 115], ["neuronal PC12 cells", "TEST", 23, 42], ["wide studies", "TEST", 51, 63], ["GR genomic binding sites", "PROBLEM", 91, 115], ["GC", "TEST", 136, 138], ["PC12 cells", "OBSERVATION", 32, 42]]], ["Of interest, the availability of these binding sites for interacting with the GC-GR complex depends on the chromatin landscape, which is tissue- and cell type-specific, explaining to some extent, why the GR has a certain effect on one tissue and a totally different effect on another (67).", [["chromatin", "ANATOMY", 107, 116], ["tissue", "ANATOMY", 137, 143], ["cell", "ANATOMY", 149, 153], ["tissue", "ANATOMY", 235, 241], ["GC-GR", "GENE_OR_GENE_PRODUCT", 78, 83], ["chromatin", "CELLULAR_COMPONENT", 107, 116], ["tissue", "TISSUE", 137, 143], ["cell", "CELL", 149, 153], ["GR", "GENE_OR_GENE_PRODUCT", 204, 206], ["tissue", "TISSUE", 235, 241], ["GC-GR complex", "PROTEIN", 78, 91], ["GR", "PROTEIN", 204, 206], ["these binding sites", "PROBLEM", 33, 52], ["the GC", "TEST", 74, 80], ["chromatin landscape", "OBSERVATION", 107, 126]]], ["Thus, even though the signaling system is the same, the landscape of the landing site is not.", [["landing site", "DNA", 73, 85], ["landing site", "OBSERVATION", 73, 85]]], ["Thus, different cells recognize these signals differently, resulting in a highly context-dependent action by glucocorticoids (67).Glucocorticoid Receptor-AlphaAfter GC binding takes place in the cytoplasm, the activated GC-GR\u03b1 complex can either (i) bind to several pro-inflammatory transcription factors, or (ii) act as a transcription factor, after translocation into the nucleus and mitochondria (69, 82).", [["cells", "ANATOMY", 16, 21], ["cytoplasm", "ANATOMY", 195, 204], ["nucleus", "ANATOMY", 374, 381], ["mitochondria", "ANATOMY", 386, 398], ["glucocorticoids", "CHEMICAL", 109, 124], ["cells", "CELL", 16, 21], ["glucocorticoids", "SIMPLE_CHEMICAL", 109, 124], ["Glucocorticoid Receptor", "GENE_OR_GENE_PRODUCT", 130, 153], ["cytoplasm", "ORGANISM_SUBSTANCE", 195, 204], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 223, 226], ["nucleus", "CELLULAR_COMPONENT", 374, 381], ["mitochondria", "CELLULAR_COMPONENT", 386, 398], ["Glucocorticoid Receptor", "PROTEIN", 130, 153], ["GR\u03b1 complex", "PROTEIN", 223, 234], ["pro-inflammatory transcription factors", "PROTEIN", 266, 304], ["transcription factor", "PROTEIN", 323, 343], ["Glucocorticoid Receptor", "TREATMENT", 130, 153], ["AlphaAfter GC binding", "TREATMENT", 154, 175], ["several pro-inflammatory transcription factors", "PROBLEM", 258, 304], ["nucleus", "ANATOMY", 374, 381], ["mitochondria", "ANATOMY", 386, 398]]], ["Glucocorticoids regulation of mitochondrial transcription via activation of mtGRE was the subject of a recent review (53).", [["mitochondrial", "ANATOMY", 30, 43], ["mitochondrial", "CELLULAR_COMPONENT", 30, 43], ["mtGRE", "GENE_OR_GENE_PRODUCT", 76, 81], ["mtGRE", "PROTEIN", 76, 81], ["Glucocorticoids regulation", "TREATMENT", 0, 26], ["mitochondrial transcription", "TREATMENT", 30, 57]]], ["In pathway (i), the activated GC-GR\u03b1 complex interacts directly with activated transcription factors NF-\u03baB and AP-1, leading to the transcriptional repression of major downstream proinflammatory factors.", [["GC-GR\u03b1", "GENE_OR_GENE_PRODUCT", 30, 36], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 101, 106], ["AP-1", "GENE_OR_GENE_PRODUCT", 111, 115], ["GR\u03b1 complex", "PROTEIN", 33, 44], ["transcription factors", "PROTEIN", 79, 100], ["NF-\u03baB", "PROTEIN", 101, 106], ["AP-1", "PROTEIN", 111, 115], ["major downstream proinflammatory factors", "PROTEIN", 162, 202], ["NF", "TEST", 101, 103], ["AP", "TEST", 111, 113], ["major downstream proinflammatory factors", "PROBLEM", 162, 202], ["proinflammatory factors", "OBSERVATION", 179, 202]]], ["In pathway (ii), GC-GR\u03b1 binds to positive (transactivation) or negative (transrepression) specific DNA regions, the glucocorticoid-response elements (GREs) on the nuclear and mitochondrial DNA (83), to directly regulate transcription of target genes.", [["nuclear", "ANATOMY", 163, 170], ["mitochondrial", "ANATOMY", 175, 188], ["GC-GR\u03b1", "GENE_OR_GENE_PRODUCT", 17, 23], ["DNA", "CELLULAR_COMPONENT", 99, 102], ["glucocorticoid-response elements", "GENE_OR_GENE_PRODUCT", 116, 148], ["nuclear", "CELLULAR_COMPONENT", 163, 170], ["mitochondrial", "CELLULAR_COMPONENT", 175, 188], ["DNA", "CELLULAR_COMPONENT", 189, 192], ["GR\u03b1", "PROTEIN", 20, 23], ["DNA regions", "DNA", 99, 110], ["glucocorticoid-response elements", "DNA", 116, 148], ["GREs", "DNA", 150, 154], ["nuclear and mitochondrial DNA", "DNA", 163, 192], ["target genes", "DNA", 237, 249], ["GC", "TEST", 17, 19], ["GR\u03b1 binds", "TEST", 20, 29], ["transactivation", "TEST", 43, 58], ["specific DNA regions", "PROBLEM", 90, 110], ["mitochondrial DNA", "TEST", 175, 192], ["response elements", "OBSERVATION", 131, 148]]], ["Finally, GC activation of membrane-bound GR rapidly induces the activity of several kinases, such as the mitogen-activated protein kinase (MAPK) or the phosphatidylinositol 3-kinase (PI3K) pathways [Figure 2; (69)].", [["membrane", "ANATOMY", 26, 34], ["phosphatidylinositol", "CHEMICAL", 152, 172], ["membrane", "CELLULAR_COMPONENT", 26, 34], ["GR", "GENE_OR_GENE_PRODUCT", 41, 43], ["mitogen-activated protein kinase", "GENE_OR_GENE_PRODUCT", 105, 137], ["MAPK", "GENE_OR_GENE_PRODUCT", 139, 143], ["phosphatidylinositol 3-kinase", "GENE_OR_GENE_PRODUCT", 152, 181], ["PI3K", "GENE_OR_GENE_PRODUCT", 183, 187], ["(69)", "SIMPLE_CHEMICAL", 209, 213], ["GR", "PROTEIN", 41, 43], ["kinases", "PROTEIN", 84, 91], ["mitogen-activated protein kinase", "PROTEIN", 105, 137], ["MAPK", "PROTEIN", 139, 143], ["phosphatidylinositol 3-kinase", "PROTEIN", 152, 181], ["PI3K", "PROTEIN", 183, 187], ["the mitogen", "TEST", 101, 112], ["MAPK", "TEST", 139, 143], ["the phosphatidylinositol", "TEST", 148, 172]]], ["The non-genomic effects of GCs clearly differ from their well-known genomic effects, with the former responding within several minutes independently of protein synthesis.", [["GCs", "CELL", 27, 30], ["GCs", "PROBLEM", 27, 30], ["protein synthesis", "TREATMENT", 152, 169], ["genomic effects", "OBSERVATION", 68, 83]]], ["Genomic studies have shown that the GC-GR\u03b1 complex regulates more than 3,000 genes in unstimulated peripheral blood mononuclear cells (PBMC) from healthy donors (84), in human pulmonary type II cells (85), and several organs, including the heart (86), liver (87, 88), and uterus (72) of unstimulated mice, underscoring its essential role as a master modulator in sustaining life and restoring health.", [["peripheral blood mononuclear cells", "ANATOMY", 99, 133], ["PBMC", "ANATOMY", 135, 139], ["pulmonary type II cells", "ANATOMY", 176, 199], ["organs", "ANATOMY", 218, 224], ["heart", "ANATOMY", 240, 245], ["liver", "ANATOMY", 252, 257], ["uterus", "ANATOMY", 272, 278], ["GC-GR\u03b1", "GENE_OR_GENE_PRODUCT", 36, 42], ["peripheral blood mononuclear cells", "CELL", 99, 133], ["PBMC", "CELL", 135, 139], ["donors", "ORGANISM", 154, 160], ["human", "ORGANISM", 170, 175], ["pulmonary type II cells", "CELL", 176, 199], ["organs", "ORGAN", 218, 224], ["heart", "ORGAN", 240, 245], ["liver", "ORGAN", 252, 257], ["uterus", "ORGAN", 272, 278], ["mice", "ORGANISM", 300, 304], ["GC-GR\u03b1 complex", "PROTEIN", 36, 50], ["unstimulated peripheral blood mononuclear cells", "CELL_TYPE", 86, 133], ["PBMC", "CELL_TYPE", 135, 139], ["human pulmonary type II cells", "CELL_TYPE", 170, 199], ["human", "SPECIES", 170, 175], ["mice", "SPECIES", 300, 304], ["human", "SPECIES", 170, 175], ["mice", "SPECIES", 300, 304], ["Genomic studies", "TEST", 0, 15], ["the GC", "TEST", 32, 38], ["unstimulated peripheral blood mononuclear cells", "PROBLEM", 86, 133], ["PBMC", "TEST", 135, 139], ["healthy donors", "TEST", 146, 160], ["liver", "TEST", 252, 257], ["peripheral", "ANATOMY_MODIFIER", 99, 109], ["blood", "ANATOMY", 110, 115], ["mononuclear cells", "OBSERVATION", 116, 133], ["pulmonary", "ANATOMY", 176, 185], ["heart", "ANATOMY", 240, 245], ["liver", "ANATOMY", 252, 257], ["uterus", "ANATOMY", 272, 278]]], ["The discordance between the number of regulated genes and the GR sites (12, 81) suggests that multiple sites are involved in the regulation of a single gene and/or that binding of a transcription factor is not sufficient to drive gene expression (12).Glucocorticoid Receptor-AlphaControl of mRNA turnover is critical in regulating the levels of inflammatory- and immune-mediated gene expression.", [["GR", "GENE_OR_GENE_PRODUCT", 62, 64], ["Glucocorticoid Receptor", "GENE_OR_GENE_PRODUCT", 251, 274], ["regulated genes", "DNA", 38, 53], ["GR sites", "DNA", 62, 70], ["transcription factor", "PROTEIN", 182, 202], ["Glucocorticoid Receptor", "PROTEIN", 251, 274], ["multiple sites", "PROBLEM", 94, 108], ["a transcription factor", "PROBLEM", 180, 202], ["Glucocorticoid Receptor", "TREATMENT", 251, 274], ["AlphaControl of mRNA turnover", "TREATMENT", 275, 304], ["inflammatory", "PROBLEM", 345, 357], ["discordance", "OBSERVATION", 4, 15], ["genes", "OBSERVATION_MODIFIER", 48, 53], ["multiple", "OBSERVATION_MODIFIER", 94, 102], ["sites", "OBSERVATION", 103, 108], ["inflammatory", "OBSERVATION_MODIFIER", 345, 357]]], ["Recent studies indicate that the GR can mediate GC actions beyond transcriptional gene control; it may actually directly participate, via association with mRNA, in GC-mediated control of cytoplasmic post-transcriptional mechanisms of gene expression (89).", [["cytoplasmic", "ANATOMY", 187, 198], ["GR", "GENE_OR_GENE_PRODUCT", 33, 35], ["cytoplasmic", "ORGANISM_SUBSTANCE", 187, 198], ["GR", "PROTEIN", 33, 35], ["mRNA", "RNA", 155, 159], ["Recent studies", "TEST", 0, 14], ["the GR", "PROBLEM", 29, 35], ["transcriptional gene control", "TREATMENT", 66, 94]]], ["In an experimental model (SPRET/Ei mice), increased GR levels and activity were associated with strongly reduced expression levels of cytokines and chemokines in response to LPS-induced lethal inflammation (90).Glucocorticoid Receptor-Alpha and Homeostatic CorrectionsIn 1984, Munck et al. reviewed the actions of cortisol and proposed that \u201cstress-induced increases in glucocorticoids levels protect, not against the source of stress itself, but rather against the body's normal reactions to stress, preventing those reactions from overshooting and threatening homeostasis (91).\u201d", [["body", "ANATOMY", 466, 470], ["LPS", "CHEMICAL", 174, 177], ["inflammation", "DISEASE", 193, 205], ["cortisol", "CHEMICAL", 314, 322], ["glucocorticoids", "CHEMICAL", 370, 385], ["cortisol", "CHEMICAL", 314, 322], ["SPRET/Ei mice", "ORGANISM", 26, 39], ["GR", "GENE_OR_GENE_PRODUCT", 52, 54], ["LPS", "SIMPLE_CHEMICAL", 174, 177], ["Glucocorticoid Receptor-Alpha", "GENE_OR_GENE_PRODUCT", 211, 240], ["cortisol", "SIMPLE_CHEMICAL", 314, 322], ["glucocorticoids", "SIMPLE_CHEMICAL", 370, 385], ["body", "ORGANISM_SUBDIVISION", 466, 470], ["GR", "PROTEIN", 52, 54], ["cytokines", "PROTEIN", 134, 143], ["chemokines", "PROTEIN", 148, 158], ["mice", "SPECIES", 35, 39], ["increased GR levels", "PROBLEM", 42, 61], ["cytokines and chemokines", "TREATMENT", 134, 158], ["LPS", "TEST", 174, 177], ["lethal inflammation", "PROBLEM", 186, 205], ["Glucocorticoid Receptor", "TREATMENT", 211, 234], ["cortisol", "TREATMENT", 314, 322], ["glucocorticoids levels", "TREATMENT", 370, 392], ["stress itself", "PROBLEM", 428, 441], ["stress", "PROBLEM", 493, 499], ["those reactions", "PROBLEM", 512, 527], ["overshooting and threatening homeostasis", "PROBLEM", 533, 573]]], ["This work and the results of the above genomic studies have led to a reevaluation of glucocorticoids' role in homeostatic corrections.", [["the above genomic studies", "TEST", 29, 54], ["glucocorticoids'", "TREATMENT", 85, 101]]], ["Busillo and Cidlowski (92) recently reviewed the master regulatory role played the activated GC-GR\u03b1 complex in the three major phases of homeostatic correction involved in disease development and resolution (Figure 3).", [["GC-GR\u03b1", "GENE_OR_GENE_PRODUCT", 93, 99], ["activated GC-GR\u03b1 complex", "PROTEIN", 83, 107], ["homeostatic correction", "TREATMENT", 137, 159], ["homeostatic correction", "OBSERVATION", 137, 159]]], ["While distinctions are made between the different states, variable degrees of overlap are likely.", [["variable degrees of overlap", "PROBLEM", 58, 85], ["variable degrees", "OBSERVATION_MODIFIER", 58, 74], ["are likely", "UNCERTAINTY", 86, 96]]], ["First, in the pro-inflammatory phase, GC-GR\u03b1 prime the innate immune system to remove or neutralize pathogens by: (i) inducing the expression of Toll-like receptor 2, NOD-like receptor pyrin containing 3 (NLRP3) inflammasome, and purinergic receptor P2Y2R; (ii) repressing adaptive immunity (energy conservation); and (iii) cooperating with pro-inflammatory transcription factors NF-\u03baB and activator protein 1 (AP-1) in promoting leukocyte redistribution.", [["leukocyte", "ANATOMY", 430, 439], ["GC-GR\u03b1", "GENE_OR_GENE_PRODUCT", 38, 44], ["Toll-like receptor 2", "GENE_OR_GENE_PRODUCT", 145, 165], ["NOD-like receptor pyrin containing 3", "GENE_OR_GENE_PRODUCT", 167, 203], ["NLRP3", "GENE_OR_GENE_PRODUCT", 205, 210], ["P2Y2R", "GENE_OR_GENE_PRODUCT", 250, 255], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 380, 385], ["activator protein 1", "GENE_OR_GENE_PRODUCT", 390, 409], ["AP-1", "GENE_OR_GENE_PRODUCT", 411, 415], ["leukocyte", "CELL", 430, 439], ["GR\u03b1", "PROTEIN", 41, 44], ["Toll-like receptor 2", "PROTEIN", 145, 165], ["NOD-like receptor pyrin containing 3 (NLRP3) inflammasome", "PROTEIN", 167, 224], ["purinergic receptor P2Y2R", "PROTEIN", 230, 255], ["pro-inflammatory transcription factors", "PROTEIN", 341, 379], ["NF-\u03baB", "PROTEIN", 380, 385], ["activator protein 1", "PROTEIN", 390, 409], ["AP-1", "PROTEIN", 411, 415], ["the pro-inflammatory phase", "TEST", 10, 36], ["GC", "TEST", 38, 40], ["Toll-like receptor", "TREATMENT", 145, 163], ["NOD-like receptor pyrin containing", "TREATMENT", 167, 201], ["purinergic receptor P2Y2R", "TREATMENT", 230, 255], ["adaptive immunity (energy conservation", "TREATMENT", 273, 311], ["pro-inflammatory transcription factors", "TEST", 341, 379], ["NF", "TEST", 380, 382], ["activator protein", "TEST", 390, 407], ["promoting leukocyte redistribution", "PROBLEM", 420, 454], ["leukocyte redistribution", "OBSERVATION", 430, 454]]], ["The GC induction of NLRP3 sensitizes the cells to extracellular ATP and significantly enhances the ATP-mediated release of proinflammatory molecules, including mature IL-1\u03b2, TNF-\u03b1, and IL-6 (93).", [["cells", "ANATOMY", 41, 46], ["extracellular", "ANATOMY", 50, 63], ["ATP", "CHEMICAL", 64, 67], ["ATP", "CHEMICAL", 99, 102], ["ATP", "CHEMICAL", 64, 67], ["ATP", "CHEMICAL", 99, 102], ["NLRP3", "GENE_OR_GENE_PRODUCT", 20, 25], ["cells", "CELL", 41, 46], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 50, 63], ["ATP", "SIMPLE_CHEMICAL", 64, 67], ["ATP", "SIMPLE_CHEMICAL", 99, 102], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 167, 172], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 174, 179], ["IL-6", "GENE_OR_GENE_PRODUCT", 185, 189], ["NLRP3", "PROTEIN", 20, 25], ["proinflammatory molecules", "PROTEIN", 123, 148], ["mature IL-1\u03b2", "PROTEIN", 160, 172], ["TNF", "PROTEIN", 174, 177], ["The GC induction of NLRP3", "TREATMENT", 0, 25], ["extracellular ATP", "TEST", 50, 67], ["the ATP", "TEST", 95, 102], ["proinflammatory molecules", "PROBLEM", 123, 148], ["mature IL", "TEST", 160, 169], ["TNF", "TEST", 174, 177], ["IL", "TEST", 185, 187], ["proinflammatory molecules", "OBSERVATION", 123, 148]]], ["In addition, inflammatory cytokines, particularly IL-6, nitric oxide, and GCs trigger and modulate the systemic and hepatic acute phase protein response (94).", [["hepatic", "ANATOMY", 116, 123], ["nitric oxide", "CHEMICAL", 56, 68], ["nitric oxide", "CHEMICAL", 56, 68], ["IL-6", "GENE_OR_GENE_PRODUCT", 50, 54], ["nitric oxide", "SIMPLE_CHEMICAL", 56, 68], ["GCs", "SIMPLE_CHEMICAL", 74, 77], ["inflammatory cytokines", "PROTEIN", 13, 35], ["IL-6", "PROTEIN", 50, 54], ["inflammatory cytokines", "PROBLEM", 13, 35], ["IL", "TEST", 50, 52], ["nitric oxide", "TREATMENT", 56, 68], ["GCs trigger", "TEST", 74, 85], ["hepatic acute phase protein response", "TEST", 116, 152], ["inflammatory cytokines", "OBSERVATION", 13, 35], ["hepatic", "ANATOMY", 116, 123], ["acute", "OBSERVATION_MODIFIER", 124, 129]]], ["In stimulated HeLa cells, a genome-wide study identified 1,932 gene collectively regulated by the activation of NF-\u03baB and GR\u03b1, with 43% of regulated genes responding only when both ligands are added, indicating that GR\u03b1 and NF-\u03baB crosstalk alters signaling pathways that are regulated by each factor separately (12).Glucocorticoid Receptor-Alpha and Homeostatic CorrectionsDuring systemic inflammation, peripherally generated TNF-\u03b1, IL-1\u03b2, IL-6, and other inflammatory cytokines activate the HPA axis at multiple levels to produce GC (95\u201398).", [["HeLa cells", "ANATOMY", 14, 24], ["inflammation", "DISEASE", 389, 401], ["HeLa cells", "CELL", 14, 24], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 112, 117], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 122, 125], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 216, 219], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 224, 229], ["Glucocorticoid Receptor-Alpha", "GENE_OR_GENE_PRODUCT", 316, 345], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 426, 431], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 433, 438], ["IL-6", "GENE_OR_GENE_PRODUCT", 440, 444], ["HeLa cells", "CELL_LINE", 14, 24], ["1,932 gene", "DNA", 57, 67], ["NF-\u03baB", "PROTEIN", 112, 117], ["GR\u03b1", "PROTEIN", 122, 125], ["GR\u03b1", "PROTEIN", 216, 219], ["\u03baB", "PROTEIN", 227, 229], ["Glucocorticoid Receptor", "PROTEIN", 316, 339], ["TNF", "PROTEIN", 426, 429], ["IL-6", "PROTEIN", 440, 444], ["inflammatory cytokines", "PROTEIN", 456, 478], ["a genome-wide study", "TEST", 26, 45], ["NF", "TEST", 112, 114], ["Glucocorticoid Receptor", "TREATMENT", 316, 339], ["systemic inflammation", "PROBLEM", 380, 401], ["TNF", "TEST", 426, 429], ["IL", "TEST", 433, 435], ["IL", "TEST", 440, 442], ["other inflammatory cytokines", "TEST", 450, 478], ["GC", "TEST", 531, 533], ["HeLa cells", "OBSERVATION", 14, 24], ["inflammatory", "OBSERVATION", 456, 468]]], ["In addition, inflammatory cytokines increase the expression and enzymatic activity of 11\u03b2 hydroxysteroid dehydrogenase type 1 (11\u03b2HSD1), which converts the inactive cortisone to the active cortisol in different cell types, as for example occurs after addition of TNF-\u03b1 or IL-1\u03b2 on endothelial (99) or lung epithelial cells (100).", [["cell", "ANATOMY", 211, 215], ["endothelial", "ANATOMY", 281, 292], ["lung epithelial cells", "ANATOMY", 301, 322], ["cortisone", "CHEMICAL", 165, 174], ["cortisol", "CHEMICAL", 189, 197], ["11\u03b2 hydroxysteroid", "CHEMICAL", 86, 104], ["cortisone", "CHEMICAL", 165, 174], ["cortisol", "CHEMICAL", 189, 197], ["11\u03b2 hydroxysteroid dehydrogenase type 1", "GENE_OR_GENE_PRODUCT", 86, 125], ["11\u03b2HSD1", "GENE_OR_GENE_PRODUCT", 127, 134], ["cortisone", "SIMPLE_CHEMICAL", 165, 174], ["cortisol", "SIMPLE_CHEMICAL", 189, 197], ["cell", "CELL", 211, 215], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 263, 268], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 272, 277], ["endothelial", "CELL", 281, 292], ["lung epithelial cells", "CELL", 301, 322], ["inflammatory cytokines", "PROTEIN", 13, 35], ["11\u03b2 hydroxysteroid dehydrogenase type 1", "PROTEIN", 86, 125], ["TNF", "PROTEIN", 263, 266], ["IL-1\u03b2", "PROTEIN", 272, 277], ["lung epithelial cells", "CELL_TYPE", 301, 322], ["inflammatory cytokines", "PROBLEM", 13, 35], ["enzymatic activity", "TEST", 64, 82], ["hydroxysteroid dehydrogenase type 1", "PROBLEM", 90, 125], ["the inactive cortisone", "PROBLEM", 152, 174], ["TNF", "TEST", 263, 266], ["IL", "TEST", 272, 274], ["endothelial", "TEST", 281, 292], ["lung epithelial cells", "TEST", 301, 322], ["inflammatory", "OBSERVATION_MODIFIER", 13, 25], ["cytokines", "OBSERVATION", 26, 35], ["different cell types", "OBSERVATION", 201, 221], ["lung", "ANATOMY", 301, 305], ["epithelial cells", "OBSERVATION", 306, 322]]], ["Thus, cytokines seem to amplify GC bioavailability (101).", [["cytokines", "PROTEIN", 6, 15], ["GC bioavailability", "TEST", 32, 50]]], ["Microarray studies have shown that TNF-\u03b1 and GC synergistically co-regulate 210 genes involved in inflammation (100).", [["inflammation", "DISEASE", 98, 110], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 35, 40], ["GC", "SIMPLE_CHEMICAL", 45, 47], ["TNF", "PROTEIN", 35, 38], ["210 genes", "DNA", 76, 85], ["Microarray studies", "TEST", 0, 18], ["TNF", "TEST", 35, 38], ["GC synergistically", "TEST", 45, 63], ["inflammation", "PROBLEM", 98, 110], ["inflammation", "OBSERVATION", 98, 110]]], ["In this context, the synergy between GCs and pro-inflammatory cytokines is a useful mechanism for rapidly re-enforcing initial pro-inflammatory responses.", [["GCs", "CELL", 37, 40], ["pro-inflammatory cytokines", "PROTEIN", 45, 71], ["the synergy between GCs and pro-inflammatory cytokines", "PROBLEM", 17, 71]]], ["Importantly, GC-GR\u03b1 is necessary to prevent excessive phagocytic cell activation and improve intracellular bacterial killing (102).Glucocorticoid Receptor-Alpha and Homeostatic CorrectionsIn the second phase, when regulated systemic inflammation prevails, GC-GR\u03b1 exerts classic anti-inflammatory action by (i) inhibiting NF\u2013\u03baB, AP-1 and other signaling pathways involved in inflammation, and (ii) increasing transcription of anti-inflammatory genes and the NF\u2013\u03baB inhibitory protein I\u03baB (68, 103).", [["phagocytic cell", "ANATOMY", 54, 69], ["intracellular", "ANATOMY", 93, 106], ["inflammation", "DISEASE", 233, 245], ["inflammation", "DISEASE", 374, 386], ["GC-GR\u03b1", "GENE_OR_GENE_PRODUCT", 13, 19], ["phagocytic cell", "CELL", 54, 69], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 93, 106], ["Glucocorticoid Receptor-Alpha", "GENE_OR_GENE_PRODUCT", 131, 160], ["GC-GR\u03b1", "GENE_OR_GENE_PRODUCT", 256, 262], ["NF\u2013\u03baB", "GENE_OR_GENE_PRODUCT", 321, 326], ["AP-1", "GENE_OR_GENE_PRODUCT", 328, 332], ["NF\u2013\u03baB", "GENE_OR_GENE_PRODUCT", 457, 462], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 482, 485], ["GR\u03b1", "PROTEIN", 16, 19], ["Glucocorticoid Receptor-Alpha", "PROTEIN", 131, 160], ["GR\u03b1", "PROTEIN", 259, 262], ["NF\u2013\u03baB", "PROTEIN", 321, 326], ["AP-1", "PROTEIN", 328, 332], ["anti-inflammatory genes", "DNA", 425, 448], ["NF\u2013\u03baB inhibitory protein", "PROTEIN", 457, 481], ["I\u03baB", "PROTEIN", 482, 485], ["excessive phagocytic cell activation", "PROBLEM", 44, 80], ["intracellular bacterial killing", "PROBLEM", 93, 124], ["Glucocorticoid Receptor", "TREATMENT", 131, 154], ["Alpha", "TREATMENT", 155, 160], ["systemic inflammation", "PROBLEM", 224, 245], ["GC", "TEST", 256, 258], ["AP", "TEST", 328, 330], ["other signaling pathways", "PROBLEM", 337, 361], ["inflammation", "PROBLEM", 374, 386], ["anti-inflammatory genes", "TREATMENT", 425, 448], ["the NF\u2013\u03baB inhibitory protein I\u03baB", "TEST", 453, 485], ["phagocytic cell activation", "OBSERVATION", 54, 80], ["bacterial killing", "OBSERVATION", 107, 124], ["systemic", "ANATOMY", 224, 232], ["inflammation", "OBSERVATION", 233, 245], ["inflammation", "OBSERVATION", 374, 386], ["anti-inflammatory genes", "OBSERVATION", 425, 448]]], ["GC-GR\u03b1 anti-inflammatory action has been extensively investigated, and we direct the reader to excellent reviews on the (11, 68, 101, 104\u2013106).", [["GC-GR\u03b1", "GENE_OR_GENE_PRODUCT", 0, 6], ["GR", "PROTEIN", 3, 5], ["GC", "TEST", 0, 2]]], ["In upcoming sections, we will review selected mechanisms involved in GC-GR\u03b1 failure to downregulate systemic inflammation and achieve disease resolution.Glucocorticoid Receptor-Alpha and Homeostatic CorrectionsThe third phase involving disease resolution, i.e., restoration of tissue anatomy/structure and function, is an active and elegantly orchestrated process associated with multiple biochemical pathways, including switching production from pro-inflammatory to pro-resolving mediators (92).", [["sections", "ANATOMY", 12, 20], ["tissue", "ANATOMY", 277, 283], ["inflammation", "DISEASE", 109, 121], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 72, 75], ["Glucocorticoid Receptor-Alpha", "GENE_OR_GENE_PRODUCT", 153, 182], ["tissue", "TISSUE", 277, 283], ["GR", "PROTEIN", 72, 74], ["Glucocorticoid Receptor", "PROTEIN", 153, 176], ["pro-resolving mediators", "PROTEIN", 467, 490], ["GC", "TEST", 69, 71], ["GR\u03b1 failure", "PROBLEM", 72, 83], ["systemic inflammation", "PROBLEM", 100, 121], ["disease resolution", "PROBLEM", 134, 152], ["Glucocorticoid Receptor", "TREATMENT", 153, 176], ["disease resolution", "PROBLEM", 236, 254], ["an active and elegantly orchestrated process", "PROBLEM", 319, 363], ["multiple biochemical pathways", "PROBLEM", 380, 409], ["systemic", "OBSERVATION_MODIFIER", 100, 108], ["inflammation", "OBSERVATION", 109, 121], ["Alpha", "ANATOMY", 177, 182], ["active", "OBSERVATION_MODIFIER", 322, 328]]], ["As downregulation of systemic and tissue inflammation continues, the activated GC-GR\u03b1 engages in a host of pro-resolution mechanisms changing, among others, the phenotype of both granulocytes and macrophages.", [["tissue", "ANATOMY", 34, 40], ["granulocytes", "ANATOMY", 179, 191], ["macrophages", "ANATOMY", 196, 207], ["inflammation", "DISEASE", 41, 53], ["tissue", "TISSUE", 34, 40], ["GC-GR\u03b1", "GENE_OR_GENE_PRODUCT", 79, 85], ["granulocytes", "CELL", 179, 191], ["macrophages", "CELL", 196, 207], ["GR\u03b1", "PROTEIN", 82, 85], ["granulocytes", "CELL_TYPE", 179, 191], ["macrophages", "CELL_TYPE", 196, 207], ["systemic and tissue inflammation", "PROBLEM", 21, 53], ["systemic", "OBSERVATION_MODIFIER", 21, 29], ["tissue", "ANATOMY", 34, 40], ["inflammation", "OBSERVATION", 41, 53], ["macrophages", "ANATOMY", 196, 207]]], ["In these immune cells, via genomic mechanisms, GC-GR\u03b1 increases the expression of AnnexinA1 (AnxA1), AnxA1 receptor (ALXR), and glucocorticoid-induced leucine zipper (GILZ), while via non-genomic mechanisms it increases the secretion of AnxA1 (107\u2013109).", [["immune cells", "ANATOMY", 9, 21], ["leucine", "CHEMICAL", 151, 158], ["immune cells", "CELL", 9, 21], ["GC-GR\u03b1", "GENE_OR_GENE_PRODUCT", 47, 53], ["AnnexinA1", "GENE_OR_GENE_PRODUCT", 82, 91], ["AnxA1", "GENE_OR_GENE_PRODUCT", 93, 98], ["AnxA1 receptor", "GENE_OR_GENE_PRODUCT", 101, 115], ["ALXR", "GENE_OR_GENE_PRODUCT", 117, 121], ["glucocorticoid-induced leucine zipper", "GENE_OR_GENE_PRODUCT", 128, 165], ["GILZ", "GENE_OR_GENE_PRODUCT", 167, 171], ["AnxA1", "GENE_OR_GENE_PRODUCT", 237, 242], ["immune cells", "CELL_TYPE", 9, 21], ["GR\u03b1", "PROTEIN", 50, 53], ["AnnexinA1", "PROTEIN", 82, 91], ["AnxA1", "PROTEIN", 93, 98], ["AnxA1 receptor", "PROTEIN", 101, 115], ["ALXR", "PROTEIN", 117, 121], ["glucocorticoid-induced leucine zipper", "PROTEIN", 128, 165], ["GILZ", "PROTEIN", 167, 171], ["AnxA1", "PROTEIN", 237, 242], ["genomic mechanisms", "TEST", 27, 45], ["GC", "TEST", 47, 49], ["AnnexinA1 (AnxA1)", "TREATMENT", 82, 99], ["AnxA1 receptor (ALXR)", "TREATMENT", 101, 122], ["glucocorticoid-induced leucine zipper", "TREATMENT", 128, 165], ["AnxA1", "TEST", 237, 242], ["immune cells", "OBSERVATION", 9, 21], ["glucocorticoid", "ANATOMY", 128, 142]]], ["The coordinated action of GILZ and AnxA1 is essential to regulating resolution (109).", [["GILZ", "GENE_OR_GENE_PRODUCT", 26, 30], ["AnxA1", "GENE_OR_GENE_PRODUCT", 35, 40], ["GILZ", "PROTEIN", 26, 30], ["AnxA1", "PROTEIN", 35, 40], ["GILZ and AnxA1", "TREATMENT", 26, 40]]], ["Granulocytes undergo constitutive apoptosis, disabling their potentially injurious secretion responses, i.e., NF\u2013\u03baB activation and transcription of inflammatory cytokines, and decreasing trans-endothelial migration leading to their rapid recognition and internalization by macrophages (efferocytosis) (109\u2013112).Glucocorticoid Receptor-Alpha and Homeostatic CorrectionsApoptotic cells also serve as resolution cues for macrophages, which, after phagocytosis of apoptotic granulocytes, change their phenotype toward a more resolving/restorative one.", [["Granulocytes", "ANATOMY", 0, 12], ["endothelial", "ANATOMY", 193, 204], ["macrophages", "ANATOMY", 273, 284], ["cells", "ANATOMY", 378, 383], ["macrophages", "ANATOMY", 418, 429], ["granulocytes", "ANATOMY", 470, 482], ["Granulocytes", "CELL", 0, 12], ["NF\u2013\u03baB", "GENE_OR_GENE_PRODUCT", 110, 115], ["endothelial", "CELL", 193, 204], ["macrophages", "CELL", 273, 284], ["Glucocorticoid Receptor-Alpha", "GENE_OR_GENE_PRODUCT", 311, 340], ["Apoptotic cells", "CELL", 368, 383], ["macrophages", "CELL", 418, 429], ["granulocytes", "CELL", 470, 482], ["Granulocytes", "CELL_TYPE", 0, 12], ["NF\u2013\u03baB", "PROTEIN", 110, 115], ["inflammatory cytokines", "PROTEIN", 148, 170], ["macrophages", "CELL_TYPE", 273, 284], ["Glucocorticoid Receptor-Alpha", "PROTEIN", 311, 340], ["macrophages", "CELL_TYPE", 418, 429], ["apoptotic granulocytes", "CELL_TYPE", 460, 482], ["Granulocytes", "TEST", 0, 12], ["constitutive apoptosis", "PROBLEM", 21, 43], ["injurious secretion responses", "PROBLEM", 73, 102], ["inflammatory cytokines", "PROBLEM", 148, 170], ["decreasing trans-endothelial migration", "PROBLEM", 176, 214], ["their rapid recognition", "PROBLEM", 226, 249], ["Glucocorticoid Receptor", "TREATMENT", 311, 334], ["Alpha", "TREATMENT", 335, 340], ["Homeostatic CorrectionsApoptotic cells", "TREATMENT", 345, 383], ["macrophages", "PROBLEM", 418, 429], ["apoptotic granulocytes", "PROBLEM", 460, 482], ["constitutive apoptosis", "OBSERVATION", 21, 43], ["inflammatory", "OBSERVATION_MODIFIER", 148, 160], ["endothelial migration", "OBSERVATION", 193, 214], ["macrophages", "OBSERVATION", 273, 284], ["apoptotic granulocytes", "OBSERVATION", 460, 482]]], ["The changes in phenotype from M1 (classically) to M2 (alternatively) leads to an orchestrated series of actions leading to successful resolution of inflammation.", [["inflammation", "DISEASE", 148, 160], ["M2", "GENE_OR_GENE_PRODUCT", 50, 52], ["inflammation", "PATHOLOGICAL_FORMATION", 148, 160], ["M1", "PROTEIN", 30, 32], ["M2", "PROTEIN", 50, 52], ["The changes in phenotype", "PROBLEM", 0, 24], ["inflammation", "PROBLEM", 148, 160], ["inflammation", "OBSERVATION", 148, 160]]], ["Interestingly, GCs promote phagocytosis (112, 113) and reduce the apoptotic granulocyte ingestion requirements for generation of M2 (114).", [["GCs", "ANATOMY", 15, 18], ["granulocyte", "ANATOMY", 76, 87], ["GCs", "CELL", 15, 18], ["granulocyte", "CELL", 76, 87], ["GCs", "TEST", 15, 18], ["phagocytosis", "TEST", 27, 39], ["the apoptotic granulocyte ingestion requirements", "PROBLEM", 62, 110], ["phagocytosis", "OBSERVATION_MODIFIER", 27, 39], ["apoptotic granulocyte ingestion", "OBSERVATION", 66, 97]]], ["GC-mediated change to M2 phenotype is associated with (i) immune silencing, where the release of inflammatory mediators and inducible nitric oxide synthase (iNOS) are suppressed (114); (ii) an increased release of the anti-inflammatory mediators IL-10 and TGF\u03b2 and several pro-resolving lipid mediators (114); (iii) protection from apoptosis; (iv) non-phlogistic degradation; (v) production of angiogenic growth factors; (vi) increased macrophage chemokinesis (by upregulation of genes involved in cell mobility) and lymphatic clearance; and (vii) induction of acquired immunity (110, 111, 113\u2013117).", [["macrophage", "ANATOMY", 436, 446], ["cell", "ANATOMY", 498, 502], ["lymphatic", "ANATOMY", 517, 526], ["nitric oxide", "CHEMICAL", 134, 146], ["nitric oxide", "CHEMICAL", 134, 146], ["M2", "GENE_OR_GENE_PRODUCT", 22, 24], ["inducible nitric oxide synthase", "GENE_OR_GENE_PRODUCT", 124, 155], ["iNOS", "GENE_OR_GENE_PRODUCT", 157, 161], ["IL-10", "GENE_OR_GENE_PRODUCT", 246, 251], ["TGF\u03b2", "GENE_OR_GENE_PRODUCT", 256, 260], ["macrophage", "CELL", 436, 446], ["cell", "CELL", 498, 502], ["lymphatic", "ORGAN", 517, 526], ["inflammatory mediators", "PROTEIN", 97, 119], ["nitric oxide synthase", "PROTEIN", 134, 155], ["iNOS", "PROTEIN", 157, 161], ["anti-inflammatory mediators", "PROTEIN", 218, 245], ["IL-10", "PROTEIN", 246, 251], ["TGF\u03b2", "PROTEIN", 256, 260], ["angiogenic growth factors", "PROTEIN", 394, 419], ["GC", "TEST", 0, 2], ["immune silencing", "PROBLEM", 58, 74], ["inflammatory mediators", "TREATMENT", 97, 119], ["inducible nitric oxide synthase", "TREATMENT", 124, 155], ["the anti-inflammatory mediators IL", "TREATMENT", 214, 248], ["several pro-resolving lipid mediators", "TREATMENT", 265, 302], ["apoptosis", "PROBLEM", 332, 341], ["non-phlogistic degradation", "PROBLEM", 348, 374], ["angiogenic growth factors", "PROBLEM", 394, 419], ["increased macrophage chemokinesis", "PROBLEM", 426, 459], ["lymphatic clearance", "TEST", 517, 536], ["inflammatory", "OBSERVATION", 97, 109], ["macrophage chemokinesis", "OBSERVATION", 436, 459], ["lymphatic", "ANATOMY", 517, 526]]], ["GC-mediated Annexin 1-derived peptide (Ac2\u2212\u221226) acting through the ALXR receptor has a pivotal role in the clearance of apoptotic cells (118).", [["cells", "ANATOMY", 130, 135], ["Ac2\u2212\u221226", "CHEMICAL", 39, 46], ["Annexin 1", "GENE_OR_GENE_PRODUCT", 12, 21], ["Ac2\u2212\u221226", "GENE_OR_GENE_PRODUCT", 39, 46], ["ALXR receptor", "GENE_OR_GENE_PRODUCT", 67, 80], ["cells", "CELL", 130, 135], ["ALXR receptor", "PROTEIN", 67, 80], ["apoptotic cells", "CELL_TYPE", 120, 135], ["GC", "TEST", 0, 2], ["mediated Annexin", "TREATMENT", 3, 19], ["Ac2", "TEST", 39, 42], ["apoptotic cells", "OBSERVATION", 120, 135]]], ["In models of self-resolving inflammation, various phenotypes of macrophages may coexist.", [["macrophages", "ANATOMY", 64, 75], ["inflammation", "DISEASE", 28, 40], ["macrophages", "CELL", 64, 75], ["macrophages", "CELL_TYPE", 64, 75], ["self-resolving inflammation", "PROBLEM", 13, 40], ["various phenotypes of macrophages", "PROBLEM", 42, 75], ["self-resolving", "OBSERVATION_MODIFIER", 13, 27], ["inflammation", "OBSERVATION", 28, 40], ["macrophages", "OBSERVATION", 64, 75]]], ["In the later phase of resolution, M2 macrophages switch to the resolution-promoting macrophage (Mres) phenotype, which display reduced phagocytosis, while producing antifibrotic and antioxidant proteins that limit tissue damage and fibrosis (resolution of granulation tissue) (119).", [["M2 macrophages", "ANATOMY", 34, 48], ["macrophage", "ANATOMY", 84, 94], ["Mres", "ANATOMY", 96, 100], ["tissue", "ANATOMY", 214, 220], ["granulation tissue", "ANATOMY", 256, 274], ["tissue damage", "DISEASE", 214, 227], ["fibrosis", "DISEASE", 232, 240], ["M2 macrophages", "CELL", 34, 48], ["macrophage", "CELL", 84, 94], ["Mres", "GENE_OR_GENE_PRODUCT", 96, 100], ["tissue", "TISSUE", 214, 220], ["granulation tissue", "TISSUE", 256, 274], ["M2 macrophages", "CELL_TYPE", 34, 48], ["antioxidant proteins", "PROTEIN", 182, 202], ["M2 macrophages", "TREATMENT", 34, 48], ["reduced phagocytosis", "PROBLEM", 127, 147], ["antifibrotic and antioxidant proteins", "PROBLEM", 165, 202], ["tissue damage", "PROBLEM", 214, 227], ["fibrosis", "PROBLEM", 232, 240], ["granulation tissue", "PROBLEM", 256, 274], ["macrophage", "OBSERVATION_MODIFIER", 84, 94], ["reduced phagocytosis", "OBSERVATION", 127, 147], ["antifibrotic", "OBSERVATION_MODIFIER", 165, 177], ["limit tissue", "OBSERVATION_MODIFIER", 208, 220], ["damage", "OBSERVATION", 221, 227], ["fibrosis", "OBSERVATION", 232, 240], ["granulation tissue", "OBSERVATION", 256, 274]]], ["In human monocytes, GCs induce the expression of 133 genes with upregulation of anti-oxidation, migration, phagocytosis, and anti-inflammation with consequent downregulation of adhesion, apoptosis, and oxidation (113).", [["monocytes", "ANATOMY", 9, 18], ["GCs", "ANATOMY", 20, 23], ["human", "ORGANISM", 3, 8], ["monocytes", "CELL", 9, 18], ["GCs", "CELL", 20, 23], ["human monocytes", "CELL_TYPE", 3, 18], ["133 genes", "DNA", 49, 58], ["human", "SPECIES", 3, 8], ["human", "SPECIES", 3, 8], ["human monocytes", "TEST", 3, 18], ["GCs", "TEST", 20, 23], ["upregulation of anti-oxidation", "TREATMENT", 64, 94], ["migration", "TREATMENT", 96, 105], ["phagocytosis", "PROBLEM", 107, 119], ["anti-inflammation", "TREATMENT", 125, 142], ["adhesion", "PROBLEM", 177, 185], ["apoptosis", "PROBLEM", 187, 196], ["human monocytes", "OBSERVATION", 3, 18], ["anti-oxidation", "OBSERVATION_MODIFIER", 80, 94], ["downregulation", "OBSERVATION_MODIFIER", 159, 173], ["adhesion", "OBSERVATION_MODIFIER", 177, 185], ["apoptosis", "OBSERVATION_MODIFIER", 187, 196]]], ["In agreement with microarray data, spontaneous, as well as PMA-induced production of reactive oxygen species, was significantly reduced in GC-treated cells, and GCs promoted survival of an anti-inflammatory monocytic phenotype in inflammatory reactions (113).Glucocorticoid Receptor Alpha in Critical IllnessSince GR\u03b1 ultimately controls GC-mediated activity, any condition that affects its concentration, binding affinity, transport to the nucleus, interactions with GREs (nuclear and mitochondrial), cofactor activity (see section Hypovitaminoses), or interaction of other relevant transcription factors (NF-\u03baB, AP-1) and co-regulators, can eventually affect the response of cells to glucocorticoids (101, 120).", [["cells", "ANATOMY", 150, 155], ["GCs", "ANATOMY", 161, 164], ["monocytic", "ANATOMY", 207, 216], ["nucleus", "ANATOMY", 441, 448], ["nuclear", "ANATOMY", 474, 481], ["mitochondrial", "ANATOMY", 486, 499], ["cells", "ANATOMY", 677, 682], ["PMA", "CHEMICAL", 59, 62], ["oxygen", "CHEMICAL", 94, 100], ["glucocorticoids", "CHEMICAL", 686, 701], ["PMA", "CHEMICAL", 59, 62], ["oxygen", "CHEMICAL", 94, 100], ["PMA", "SIMPLE_CHEMICAL", 59, 62], ["reactive oxygen species", "SIMPLE_CHEMICAL", 85, 108], ["GC", "CELL", 139, 141], ["cells", "CELL", 150, 155], ["GCs", "CELL", 161, 164], ["monocytic", "CELL", 207, 216], ["Glucocorticoid Receptor Alpha", "GENE_OR_GENE_PRODUCT", 259, 288], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 314, 317], ["GC", "CELL", 338, 340], ["nucleus", "CELLULAR_COMPONENT", 441, 448], ["GREs", "GENE_OR_GENE_PRODUCT", 468, 472], ["nuclear", "CELLULAR_COMPONENT", 474, 481], ["mitochondrial", "CELLULAR_COMPONENT", 486, 499], ["Hypovitaminoses", "GENE_OR_GENE_PRODUCT", 533, 548], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 607, 612], ["AP-1", "GENE_OR_GENE_PRODUCT", 614, 618], ["cells", "CELL", 677, 682], ["glucocorticoids", "SIMPLE_CHEMICAL", 686, 701], ["GC-treated cells", "CELL_LINE", 139, 155], ["Glucocorticoid Receptor Alpha", "PROTEIN", 259, 288], ["GR\u03b1", "PROTEIN", 314, 317], ["GREs", "PROTEIN", 468, 472], ["transcription factors", "PROTEIN", 584, 605], ["NF-\u03baB", "PROTEIN", 607, 612], ["AP", "PROTEIN", 614, 616], ["co-regulators", "PROTEIN", 624, 637], ["microarray data", "TEST", 18, 33], ["PMA", "PROBLEM", 59, 62], ["reactive oxygen species", "PROBLEM", 85, 108], ["GC-treated cells", "TREATMENT", 139, 155], ["GCs", "TEST", 161, 164], ["an anti-inflammatory monocytic phenotype", "PROBLEM", 186, 226], ["inflammatory reactions", "PROBLEM", 230, 252], ["Glucocorticoid Receptor", "TREATMENT", 259, 282], ["Critical Illness", "PROBLEM", 292, 308], ["any condition", "PROBLEM", 360, 373], ["binding affinity", "PROBLEM", 406, 422], ["cofactor activity", "PROBLEM", 502, 519], ["NF", "TEST", 607, 609], ["glucocorticoids", "TEST", 686, 701], ["reactive", "OBSERVATION_MODIFIER", 85, 93], ["oxygen species", "OBSERVATION", 94, 108], ["anti-inflammatory monocytic phenotype", "OBSERVATION", 189, 226], ["inflammatory", "OBSERVATION_MODIFIER", 230, 242], ["nucleus", "ANATOMY", 441, 448]]], ["The many different ways GR\u03b1 function can be negatively influenced by the pro-inflammatory environment of critical illness was the subject of recent reviews (101, 121).Glucocorticoid Receptor Alpha in Critical IllnessCritical illness-related corticosteroid insufficiency is a term used to define the central role played by the HPA-axis and the activated GR\u03b1 complex in the pathogenesis of dysregulated systemic inflammation in critical illness (17).", [["critical illness", "DISEASE", 105, 121], ["IllnessCritical illness", "DISEASE", 209, 232], ["corticosteroid insufficiency", "DISEASE", 241, 269], ["systemic inflammation", "DISEASE", 401, 422], ["critical illness", "DISEASE", 426, 442], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 24, 27], ["Glucocorticoid Receptor Alpha", "GENE_OR_GENE_PRODUCT", 167, 196], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 353, 356], ["GR\u03b1", "PROTEIN", 24, 27], ["Glucocorticoid Receptor Alpha", "PROTEIN", 167, 196], ["GR\u03b1 complex", "PROTEIN", 353, 364], ["Glucocorticoid Receptor Alpha", "TREATMENT", 167, 196], ["Critical IllnessCritical illness", "PROBLEM", 200, 232], ["corticosteroid insufficiency", "PROBLEM", 241, 269], ["the activated GR\u03b1 complex", "PROBLEM", 339, 364], ["dysregulated systemic inflammation", "PROBLEM", 388, 422], ["corticosteroid insufficiency", "OBSERVATION", 241, 269], ["dysregulated", "OBSERVATION_MODIFIER", 388, 400], ["systemic", "OBSERVATION_MODIFIER", 401, 409], ["inflammation", "OBSERVATION", 410, 422]]], ["Three major pathophysiologic events account for the neuroendocrine decompensation observed in CIRCI: (i) multi-level dysregulation of the HPA-axis correlating with circulating inflammatory cytokine levels; (ii) altered cortisol metabolism [reviewed in (122)], and (iii) secondary generalized circulating and tissue specific reduction in GR\u03b1 number/function with observed multifactorial tissue resistance to endogenous glucocorticoids (17).", [["neuroendocrine", "ANATOMY", 52, 66], ["tissue", "ANATOMY", 308, 314], ["tissue", "ANATOMY", 386, 392], ["neuroendocrine decompensation", "DISEASE", 52, 81], ["CIRCI", "DISEASE", 94, 99], ["cortisol", "CHEMICAL", 219, 227], ["glucocorticoids", "CHEMICAL", 418, 433], ["cortisol", "CHEMICAL", 219, 227], ["neuroendocrine", "CELL", 52, 66], ["cortisol", "SIMPLE_CHEMICAL", 219, 227], ["tissue", "TISSUE", 308, 314], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 337, 340], ["tissue", "TISSUE", 386, 392], ["inflammatory cytokine", "PROTEIN", 176, 197], ["GR\u03b1", "PROTEIN", 337, 340], ["Three major pathophysiologic events", "PROBLEM", 0, 35], ["the neuroendocrine decompensation", "PROBLEM", 48, 81], ["multi-level dysregulation of the HPA", "PROBLEM", 105, 141], ["circulating inflammatory cytokine levels", "TEST", 164, 204], ["altered cortisol metabolism", "PROBLEM", 211, 238], ["secondary generalized circulating and tissue specific reduction", "PROBLEM", 270, 333], ["multifactorial tissue resistance to endogenous glucocorticoids", "PROBLEM", 371, 433], ["neuroendocrine decompensation", "OBSERVATION", 52, 81], ["dysregulation", "OBSERVATION", 117, 130], ["generalized", "OBSERVATION_MODIFIER", 280, 291], ["circulating", "OBSERVATION", 292, 303], ["reduction", "OBSERVATION_MODIFIER", 324, 333], ["multifactorial tissue resistance", "OBSERVATION", 371, 403], ["endogenous glucocorticoids", "OBSERVATION", 407, 433]]], ["The role of mitochondrial oxidative stress in reducing GR\u03b1 number/function is reviewed later (see section Oxidative Stress and CIRCI).Glucocorticoid Receptor Alpha in Critical IllnessExperimental and clinical studies have demonstrated that critical illness is associated with a significant reduction in GR\u03b1 density and transcription and an increase in GR\u03b2-mediated dominant negative activity on GR\u03b1-induced transcription.", [["mitochondrial", "ANATOMY", 12, 25], ["illness", "DISEASE", 249, 256], ["mitochondrial", "CELLULAR_COMPONENT", 12, 25], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 55, 58], ["Glucocorticoid Receptor Alpha", "GENE_OR_GENE_PRODUCT", 134, 163], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 303, 306], ["GR\u03b2", "GENE_OR_GENE_PRODUCT", 352, 355], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 395, 398], ["GR\u03b1", "PROTEIN", 55, 58], ["Glucocorticoid Receptor Alpha", "PROTEIN", 134, 163], ["GR\u03b1", "PROTEIN", 303, 306], ["GR\u03b2", "PROTEIN", 352, 355], ["GR\u03b1", "PROTEIN", 395, 398], ["mitochondrial oxidative stress", "PROBLEM", 12, 42], ["Glucocorticoid Receptor", "TREATMENT", 134, 157], ["clinical studies", "TEST", 200, 216], ["critical illness", "PROBLEM", 240, 256], ["a significant reduction in GR\u03b1 density", "PROBLEM", 276, 314], ["GR\u03b2", "TEST", 352, 355], ["mitochondrial", "OBSERVATION", 12, 25], ["oxidative stress", "OBSERVATION", 26, 42], ["illness", "OBSERVATION", 249, 256], ["significant", "OBSERVATION_MODIFIER", 278, 289], ["reduction", "OBSERVATION_MODIFIER", 290, 299], ["GR\u03b1 density", "OBSERVATION", 303, 314], ["increase", "OBSERVATION_MODIFIER", 340, 348], ["dominant", "OBSERVATION_MODIFIER", 365, 373], ["negative activity", "OBSERVATION", 374, 391]]], ["In a human cell line, activation of NF-\u03baB by TNF-\u03b1 had a direct dose- and time-dependent effect on GR levels with a disproportionate increase in GR\u03b2 over GR\u03b1 (123).", [["cell line", "ANATOMY", 11, 20], ["human", "ORGANISM", 5, 10], ["cell line", "CELL", 11, 20], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 36, 41], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 45, 50], ["GR", "GENE_OR_GENE_PRODUCT", 99, 101], ["GR\u03b2", "GENE_OR_GENE_PRODUCT", 145, 148], ["GR\u03b1 (123)", "GENE_OR_GENE_PRODUCT", 154, 163], ["human cell line", "CELL_LINE", 5, 20], ["NF-\u03baB", "PROTEIN", 36, 41], ["TNF", "PROTEIN", 45, 48], ["GR", "PROTEIN", 99, 101], ["GR\u03b2", "PROTEIN", 145, 148], ["GR\u03b1", "PROTEIN", 154, 157], ["human", "SPECIES", 5, 10], ["human", "SPECIES", 5, 10], ["a human cell line", "TREATMENT", 3, 20], ["NF", "TEST", 36, 38], ["TNF", "TEST", 45, 48], ["GR levels", "TEST", 99, 108], ["a disproportionate increase", "PROBLEM", 114, 141], ["cell line", "OBSERVATION", 11, 20], ["disproportionate", "OBSERVATION_MODIFIER", 116, 132], ["increase", "OBSERVATION_MODIFIER", 133, 141]]], ["Experimental sepsis is associated with decreased GR\u03b1 transcription in circulating cells (124), heart (125), lymph node-spleen (124), liver (125\u2013127), kidney (127), lung tissue (125\u2013129), and skeletal muscle (125).", [["cells", "ANATOMY", 82, 87], ["heart", "ANATOMY", 95, 100], ["lymph node", "ANATOMY", 108, 118], ["spleen", "ANATOMY", 119, 125], ["liver", "ANATOMY", 133, 138], ["kidney", "ANATOMY", 150, 156], ["lung tissue", "ANATOMY", 164, 175], ["skeletal muscle", "ANATOMY", 191, 206], ["sepsis", "DISEASE", 13, 19], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 49, 52], ["circulating cells", "CELL", 70, 87], ["heart", "ORGAN", 95, 100], ["lymph node", "MULTI-TISSUE_STRUCTURE", 108, 118], ["-spleen", "MULTI-TISSUE_STRUCTURE", 118, 125], ["liver", "ORGAN", 133, 138], ["kidney", "ORGAN", 150, 156], ["lung tissue", "TISSUE", 164, 175], ["skeletal muscle", "TISSUE", 191, 206], ["GR\u03b1", "PROTEIN", 49, 52], ["circulating cells", "CELL_TYPE", 70, 87], ["Experimental sepsis", "PROBLEM", 0, 19], ["decreased GR\u03b1 transcription in circulating cells", "PROBLEM", 39, 87], ["heart", "TEST", 95, 100], ["lymph node", "TEST", 108, 118], ["lung tissue", "TEST", 164, 175], ["sepsis", "OBSERVATION", 13, 19], ["decreased", "OBSERVATION_MODIFIER", 39, 48], ["circulating cells", "OBSERVATION", 70, 87], ["heart", "ANATOMY", 95, 100], ["lymph node", "OBSERVATION", 108, 118], ["spleen", "ANATOMY", 119, 125], ["liver", "ANATOMY", 133, 138], ["kidney", "ANATOMY", 150, 156], ["lung", "ANATOMY", 164, 168], ["tissue", "ANATOMY_MODIFIER", 169, 175], ["skeletal muscle", "ANATOMY", 191, 206]]], ["Moreover, the endothelial GR\u03b1 is required for protection against sepsis (see section Endothelium) (130).", [["endothelial", "ANATOMY", 14, 25], ["sepsis", "DISEASE", 65, 71], ["endothelial", "CELL", 14, 25], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 26, 29], ["endothelial GR\u03b1", "PROTEIN", 14, 29], ["sepsis", "PROBLEM", 65, 71]]], ["Importantly, the reduction of GR\u03b1 expression is rapid and persists for at least 5 days (125) while it is associated with increased GR\u03b2 expression in the heart and lung but not liver (125), and increased NF-\u03baB activation (127).", [["heart", "ANATOMY", 153, 158], ["lung", "ANATOMY", 163, 167], ["liver", "ANATOMY", 176, 181], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 30, 33], ["GR\u03b2", "GENE_OR_GENE_PRODUCT", 131, 134], ["heart", "ORGAN", 153, 158], ["lung", "ORGAN", 163, 167], ["liver", "ORGAN", 176, 181], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 203, 208], ["GR\u03b1", "PROTEIN", 30, 33], ["GR\u03b2", "PROTEIN", 131, 134], ["NF-\u03baB", "PROTEIN", 203, 208], ["increased GR\u03b2 expression in the heart and lung", "PROBLEM", 121, 167], ["increased NF", "PROBLEM", 193, 205], ["reduction", "OBSERVATION_MODIFIER", 17, 26], ["rapid", "OBSERVATION_MODIFIER", 48, 53], ["increased", "OBSERVATION_MODIFIER", 121, 130], ["GR\u03b2 expression", "OBSERVATION", 131, 145], ["heart", "ANATOMY", 153, 158], ["lung", "ANATOMY", 163, 167], ["not", "UNCERTAINTY", 172, 175], ["liver", "ANATOMY", 176, 181], ["increased", "OBSERVATION_MODIFIER", 193, 202]]], ["Similarly, in experimental ARDS, lung tissue shows a significant reduction in GR\u03b1 expression (128, 131, 132) and an increase in GR\u03b2 expression (131), leading to decreased GR\u03b1 nuclear translocation (131).", [["lung tissue", "ANATOMY", 33, 44], ["nuclear", "ANATOMY", 175, 182], ["ARDS", "DISEASE", 27, 31], ["lung tissue", "TISSUE", 33, 44], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 78, 81], ["GR\u03b2", "GENE_OR_GENE_PRODUCT", 128, 131], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 171, 174], ["GR\u03b1", "PROTEIN", 78, 81], ["GR\u03b2", "PROTEIN", 128, 131], ["GR\u03b1", "PROTEIN", 171, 174], ["experimental ARDS", "PROBLEM", 14, 31], ["lung tissue", "PROBLEM", 33, 44], ["a significant reduction in GR\u03b1 expression", "PROBLEM", 51, 92], ["an increase in GR\u03b2 expression", "PROBLEM", 113, 142], ["decreased GR\u03b1 nuclear translocation", "PROBLEM", 161, 196], ["experimental", "OBSERVATION_MODIFIER", 14, 26], ["ARDS", "OBSERVATION", 27, 31], ["lung", "ANATOMY", 33, 37], ["tissue", "ANATOMY_MODIFIER", 38, 44], ["significant", "OBSERVATION_MODIFIER", 53, 64], ["reduction", "OBSERVATION_MODIFIER", 65, 74], ["GR\u03b1 expression", "OBSERVATION", 78, 92], ["increase", "OBSERVATION_MODIFIER", 116, 124], ["GR\u03b2", "OBSERVATION_MODIFIER", 128, 131], ["expression", "OBSERVATION_MODIFIER", 132, 142], ["decreased", "OBSERVATION_MODIFIER", 161, 170], ["nuclear translocation", "OBSERVATION", 175, 196]]], ["In transgenic mice, expression of GR\u03b1 above wild-type levels leads to increased resistance to LPS-induced endotoxic shock (133).Glucocorticoid Receptor Alpha in Critical IllnessClinical studies, including autopsies, in patients with severe sepsis and septic shock have reported a significant reduction in GR\u03b1 expression in circulating cells (79, 134\u2013137); heart (125), liver and skeletal muscle (125, 138), and a significant increase in GR\u03b2 expression in the heart and liver (125).", [["cells", "ANATOMY", 335, 340], ["heart", "ANATOMY", 356, 361], ["liver", "ANATOMY", 369, 374], ["skeletal muscle", "ANATOMY", 379, 394], ["heart", "ANATOMY", 459, 464], ["liver", "ANATOMY", 469, 474], ["LPS", "CHEMICAL", 94, 97], ["endotoxic shock", "DISEASE", 106, 121], ["sepsis", "DISEASE", 240, 246], ["septic shock", "DISEASE", 251, 263], ["mice", "ORGANISM", 14, 18], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 34, 37], ["LPS", "SIMPLE_CHEMICAL", 94, 97], ["Glucocorticoid Receptor Alpha", "GENE_OR_GENE_PRODUCT", 128, 157], ["patients", "ORGANISM", 219, 227], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 305, 308], ["cells", "CELL", 335, 340], ["heart", "ORGAN", 356, 361], ["liver", "ORGAN", 369, 374], ["skeletal muscle", "ORGAN", 379, 394], ["GR\u03b2", "GENE_OR_GENE_PRODUCT", 437, 440], ["heart", "ORGAN", 459, 464], ["liver", "ORGAN", 469, 474], ["GR\u03b1", "PROTEIN", 34, 37], ["Glucocorticoid Receptor Alpha", "PROTEIN", 128, 157], ["GR\u03b1", "PROTEIN", 305, 308], ["circulating cells", "CELL_TYPE", 323, 340], ["GR\u03b2", "PROTEIN", 437, 440], ["mice", "SPECIES", 14, 18], ["patients", "SPECIES", 219, 227], ["mice", "SPECIES", 14, 18], ["type levels", "PROBLEM", 49, 60], ["increased resistance to LPS", "PROBLEM", 70, 97], ["endotoxic shock", "PROBLEM", 106, 121], ["Glucocorticoid", "TREATMENT", 128, 142], ["Clinical studies", "TEST", 177, 193], ["autopsies", "TEST", 205, 214], ["severe sepsis", "PROBLEM", 233, 246], ["septic shock", "PROBLEM", 251, 263], ["a significant reduction in GR\u03b1 expression in circulating cells", "PROBLEM", 278, 340], ["heart", "TEST", 356, 361], ["a significant increase in GR\u03b2 expression in the heart and liver", "PROBLEM", 411, 474], ["endotoxic shock", "OBSERVATION", 106, 121], ["severe", "OBSERVATION_MODIFIER", 233, 239], ["sepsis", "OBSERVATION", 240, 246], ["septic shock", "OBSERVATION", 251, 263], ["significant", "OBSERVATION_MODIFIER", 280, 291], ["reduction", "OBSERVATION_MODIFIER", 292, 301], ["GR\u03b1 expression", "OBSERVATION", 305, 319], ["circulating cells", "OBSERVATION", 323, 340], ["heart", "ANATOMY", 356, 361], ["liver", "ANATOMY", 369, 374], ["skeletal muscle", "ANATOMY", 379, 394], ["significant", "OBSERVATION_MODIFIER", 413, 424], ["increase", "OBSERVATION_MODIFIER", 425, 433], ["GR\u03b2 expression", "OBSERVATION", 437, 451], ["heart", "ANATOMY", 459, 464], ["liver", "ANATOMY", 469, 474]]], ["GR\u03b1 mRNA in neutrophils correlates negatively with plasma IL-6 levels and shows gradual recovery overtime in survivors (135).", [["neutrophils", "ANATOMY", 12, 23], ["plasma", "ANATOMY", 51, 57], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 0, 3], ["neutrophils", "CELL", 12, 23], ["plasma", "ORGANISM_SUBSTANCE", 51, 57], ["IL-6", "GENE_OR_GENE_PRODUCT", 58, 62], ["GR\u03b1 mRNA", "RNA", 0, 8], ["neutrophils", "CELL_TYPE", 12, 23], ["IL", "PROTEIN", 58, 60], ["GR\u03b1 mRNA in neutrophils", "TEST", 0, 23], ["plasma IL", "TEST", 51, 60], ["gradual", "OBSERVATION_MODIFIER", 80, 87]]], ["In another study, neutrophil GR\u03b1 mRNA levels decreased 4-fold by day 4 in the ICU and remained low for 2 weeks (79).", [["neutrophil", "ANATOMY", 18, 28], ["neutrophil", "CELL", 18, 28], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 29, 32], ["neutrophil GR\u03b1 mRNA", "RNA", 18, 37], ["another study", "TEST", 3, 16], ["neutrophil GR", "TEST", 18, 31], ["mRNA levels", "TEST", 33, 44]]], ["In ex vivo experiments with PBMCs exposed to longitudinal plasma samples from patients with ARDS results suggested that insufficient GC-GR\u03b1-mediated activity at disease onset and over time was a central mechanism for the upregulation of NF-\u03baB activity (Figure 4).", [["PBMCs", "ANATOMY", 28, 33], ["plasma samples", "ANATOMY", 58, 72], ["ARDS", "DISEASE", 92, 96], ["PBMCs", "CELL", 28, 33], ["plasma samples", "ORGANISM_SUBSTANCE", 58, 72], ["patients", "ORGANISM", 78, 86], ["GC-GR\u03b1", "GENE_OR_GENE_PRODUCT", 133, 139], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 237, 242], ["PBMCs", "CELL_TYPE", 28, 33], ["GR\u03b1", "PROTEIN", 136, 139], ["NF-\u03baB", "PROTEIN", 237, 242], ["patients", "SPECIES", 78, 86], ["PBMCs", "PROBLEM", 28, 33], ["longitudinal plasma samples", "TEST", 45, 72], ["ARDS", "PROBLEM", 92, 96], ["GC", "TEST", 133, 135], ["mediated activity at disease onset", "PROBLEM", 140, 174], ["the upregulation of NF", "TREATMENT", 217, 239]]], ["Over time, patients with regulated systemic inflammation have a progressive increase in all measured GC-GR\u03b1-mediated activities, including GR\u03b1 number, binding to NF-\u03baB and to nuclear GRE, as well as increased transcription of I\u03baB\u03b1 and IL-10, and a corresponding reduction in NF-\u03baB nuclear binding, and transcription of TNF-\u03b1 and IL-1\u03b2.", [["nuclear", "ANATOMY", 175, 182], ["nuclear", "ANATOMY", 281, 288], ["inflammation", "DISEASE", 44, 56], ["patients", "ORGANISM", 11, 19], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 104, 107], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 139, 142], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 162, 167], ["nuclear", "CELLULAR_COMPONENT", 175, 182], ["I\u03baB\u03b1", "GENE_OR_GENE_PRODUCT", 226, 230], ["IL-10", "GENE_OR_GENE_PRODUCT", 235, 240], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 275, 280], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 319, 324], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 329, 334], ["GR\u03b1", "PROTEIN", 104, 107], ["GR\u03b1", "PROTEIN", 139, 142], ["NF-\u03baB", "PROTEIN", 162, 167], ["nuclear GRE", "DNA", 175, 186], ["I\u03baB\u03b1", "PROTEIN", 226, 230], ["IL-10", "PROTEIN", 235, 240], ["NF-\u03baB", "PROTEIN", 275, 280], ["TNF-\u03b1 and IL-1\u03b2", "PROTEIN", 319, 334], ["patients", "SPECIES", 11, 19], ["regulated systemic inflammation", "PROBLEM", 25, 56], ["a progressive increase", "PROBLEM", 62, 84], ["GC", "TEST", 101, 103], ["nuclear GRE", "TEST", 175, 186], ["a corresponding reduction in NF", "PROBLEM", 246, 277], ["TNF", "TEST", 319, 322], ["systemic", "ANATOMY", 35, 43], ["inflammation", "OBSERVATION", 44, 56], ["progressive", "OBSERVATION_MODIFIER", 64, 75], ["increase", "OBSERVATION_MODIFIER", 76, 84]]], ["In contrast, patients with dysregulated systemic inflammation had only a modest longitudinal increase in GC-GR\u03b1-mediated activities and a progressive increase in NF-\u03baB nuclear binding that was most striking in non-survivors (33).", [["nuclear", "ANATOMY", 168, 175], ["systemic inflammation", "DISEASE", 40, 61], ["patients", "ORGANISM", 13, 21], ["GC-GR\u03b1", "GENE_OR_GENE_PRODUCT", 105, 111], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 162, 167], ["GR\u03b1", "PROTEIN", 108, 111], ["NF-\u03baB", "PROTEIN", 162, 167], ["patients", "SPECIES", 13, 21], ["dysregulated systemic inflammation", "PROBLEM", 27, 61], ["a modest longitudinal increase", "PROBLEM", 71, 101], ["GC", "TEST", 105, 107], ["a progressive increase in NF", "PROBLEM", 136, 164], ["B nuclear binding", "PROBLEM", 166, 183], ["systemic", "ANATOMY", 40, 48], ["inflammation", "OBSERVATION", 49, 61], ["modest", "OBSERVATION_MODIFIER", 73, 79], ["longitudinal", "OBSERVATION_MODIFIER", 80, 92], ["increase", "OBSERVATION_MODIFIER", 93, 101], ["progressive", "OBSERVATION_MODIFIER", 138, 149], ["increase", "OBSERVATION_MODIFIER", 150, 158]]], ["By day 3 of ARDS, no overlap was observed between groups for NF-\u03baB and GC-GR\u03b1 nuclear binding.", [["nuclear", "ANATOMY", 78, 85], ["ARDS", "DISEASE", 12, 16], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 61, 66], ["GC-GR\u03b1", "GENE_OR_GENE_PRODUCT", 71, 77], ["NF-\u03baB", "PROTEIN", 61, 66], ["GR\u03b1", "PROTEIN", 74, 77], ["ARDS", "PROBLEM", 12, 16], ["NF", "TEST", 61, 63], ["GC", "TEST", 71, 73], ["ARDS", "OBSERVATION", 12, 16]]], ["In lung tissue obtained by open lung biopsy, histological severity correlated with increased nuclear uptake of NF-\u03baB and a lower ratio of GR\u03b1: NF-kB uptake (33).", [["lung tissue", "ANATOMY", 3, 14], ["lung", "ANATOMY", 32, 36], ["nuclear", "ANATOMY", 93, 100], ["lung tissue", "TISSUE", 3, 14], ["lung biopsy", "MULTI-TISSUE_STRUCTURE", 32, 43], ["nuclear", "CELLULAR_COMPONENT", 93, 100], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 111, 116], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 138, 141], ["NF-kB", "GENE_OR_GENE_PRODUCT", 143, 148], ["NF-\u03baB", "PROTEIN", 111, 116], ["GR\u03b1", "PROTEIN", 138, 141], ["open lung biopsy", "TEST", 27, 43], ["histological severity", "TEST", 45, 66], ["increased nuclear uptake of NF", "PROBLEM", 83, 113], ["kB uptake", "TEST", 146, 155], ["lung", "ANATOMY", 3, 7], ["tissue", "OBSERVATION", 8, 14], ["lung", "ANATOMY", 32, 36], ["biopsy", "OBSERVATION", 37, 43]]], ["A decrease in GR\u03b1 expression in critical illness is maladaptive granted that proinflammatory pathways are not properly restrained (124).Glucocorticoid Receptor Alpha in Critical IllnessRandomized studies (103, 129, 132) demonstrated in both circulating and tissue cells, that quantitatively adequate and prolonged glucocorticoid supplementation increased GR\u03b1 number and function, reversing critical illness-associated cellular glucocorticoid resistance.", [["tissue cells", "ANATOMY", 257, 269], ["cellular", "ANATOMY", 418, 426], ["illness", "DISEASE", 399, 406], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 14, 17], ["Glucocorticoid Receptor Alpha", "GENE_OR_GENE_PRODUCT", 136, 165], ["tissue cells", "CELL", 257, 269], ["glucocorticoid", "SIMPLE_CHEMICAL", 314, 328], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 355, 358], ["cellular", "CELL", 418, 426], ["GR\u03b1", "PROTEIN", 14, 17], ["Glucocorticoid Receptor Alpha", "PROTEIN", 136, 165], ["tissue cells", "CELL_TYPE", 257, 269], ["GR\u03b1", "PROTEIN", 355, 358], ["A decrease in GR\u03b1 expression", "PROBLEM", 0, 28], ["Glucocorticoid", "TEST", 136, 150], ["Randomized studies", "TEST", 185, 203], ["prolonged glucocorticoid supplementation", "TREATMENT", 304, 344], ["critical illness", "PROBLEM", 390, 406], ["cellular glucocorticoid resistance", "PROBLEM", 418, 452], ["decrease", "OBSERVATION_MODIFIER", 2, 10], ["GR\u03b1", "OBSERVATION_MODIFIER", 14, 17], ["both", "ANATOMY_MODIFIER", 236, 240], ["circulating", "ANATOMY", 241, 252], ["tissue cells", "OBSERVATION", 257, 269], ["illness", "OBSERVATION", 399, 406], ["cellular glucocorticoid resistance", "OBSERVATION", 418, 452]]], ["In experimental ARDS, low-dose glucocorticoid treatment restored GR\u03b1 number and function leading to resolution of pulmonary inflammation (129, 132).", [["pulmonary", "ANATOMY", 114, 123], ["ARDS", "DISEASE", 16, 20], ["pulmonary inflammation", "DISEASE", 114, 136], ["glucocorticoid", "SIMPLE_CHEMICAL", 31, 45], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 65, 68], ["pulmonary", "ORGAN", 114, 123], ["GR\u03b1", "PROTEIN", 65, 68], ["experimental ARDS", "PROBLEM", 3, 20], ["low-dose glucocorticoid treatment", "TREATMENT", 22, 55], ["pulmonary inflammation", "PROBLEM", 114, 136], ["ARDS", "OBSERVATION", 16, 20], ["low-dose glucocorticoid", "OBSERVATION_MODIFIER", 22, 45], ["resolution", "OBSERVATION_MODIFIER", 100, 110], ["pulmonary", "ANATOMY", 114, 123], ["inflammation", "OBSERVATION", 124, 136]]], ["Similarly, in an ex vivo ARDS study, prolonged methylprednisolone treatment was associated with upregulation in all measurements of GR\u03b1 activity leading to reduction in NF-\u03baB DNA-binding and transcription of inflammatory cytokines [Figure 4; (103)].", [["ARDS", "DISEASE", 25, 29], ["methylprednisolone", "CHEMICAL", 47, 65], ["methylprednisolone", "CHEMICAL", 47, 65], ["methylprednisolone", "SIMPLE_CHEMICAL", 47, 65], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 132, 135], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 169, 174], ["DNA", "CELLULAR_COMPONENT", 175, 178], ["GR\u03b1", "PROTEIN", 132, 135], ["NF-\u03baB", "PROTEIN", 169, 174], ["inflammatory cytokines", "PROTEIN", 208, 230], ["an ex vivo ARDS study", "TEST", 14, 35], ["prolonged methylprednisolone treatment", "TREATMENT", 37, 75], ["GR\u03b1 activity", "PROBLEM", 132, 144], ["NF", "TEST", 169, 171], ["B DNA", "PROBLEM", 173, 178], ["inflammatory cytokines", "PROBLEM", 208, 230], ["ARDS", "OBSERVATION", 25, 29], ["reduction", "OBSERVATION_MODIFIER", 156, 165], ["inflammatory", "OBSERVATION_MODIFIER", 208, 220]]], ["Glucocorticoid treatment changes the longitudinal direction of systemic inflammation from dysregulated (NF-\u03baB-driven, maladaptive response) to regulated (GR\u03b1-driven, adaptive response) with significant improvement in indices of alveolar-capillary membrane permeability and markers of inflammation, hemostasis, and tissue repair (11).EndotheliumThe vascular endothelium constitutes the innermost lining of the body's circulatory system and the largest tissue in the body (close to 100,000 miles long) containing ~2.5 \u00d7 1012 endothelial cells that are typically flat and susceptible to injury, with a thin basement membrane enriched in type IV collagen and laminin (140).", [["alveolar", "ANATOMY", 228, 236], ["capillary membrane", "ANATOMY", 237, 255], ["tissue", "ANATOMY", 314, 320], ["Endothelium", "ANATOMY", 333, 344], ["vascular endothelium", "ANATOMY", 348, 368], ["innermost lining", "ANATOMY", 385, 401], ["body", "ANATOMY", 409, 413], ["circulatory system", "ANATOMY", 416, 434], ["tissue", "ANATOMY", 451, 457], ["body", "ANATOMY", 465, 469], ["endothelial cells", "ANATOMY", 523, 540], ["basement membrane", "ANATOMY", 604, 621], ["inflammation", "DISEASE", 72, 84], ["inflammation", "DISEASE", 284, 296], ["Glucocorticoid", "SIMPLE_CHEMICAL", 0, 14], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 104, 109], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 154, 157], ["alveolar-capillary membrane", "TISSUE", 228, 255], ["tissue", "TISSUE", 314, 320], ["Endothelium", "TISSUE", 333, 344], ["vascular endothelium", "TISSUE", 348, 368], ["lining", "IMMATERIAL_ANATOMICAL_ENTITY", 395, 401], ["body", "IMMATERIAL_ANATOMICAL_ENTITY", 409, 413], ["circulatory system", "ANATOMICAL_SYSTEM", 416, 434], ["tissue", "TISSUE", 451, 457], ["body", "ORGANISM_SUBDIVISION", 465, 469], ["endothelial cells", "CELL", 523, 540], ["basement membrane", "CELLULAR_COMPONENT", 604, 621], ["type IV collagen", "GENE_OR_GENE_PRODUCT", 634, 650], ["laminin (140)", "GENE_OR_GENE_PRODUCT", 655, 668], ["NF-\u03baB", "PROTEIN", 104, 109], ["GR\u03b1", "PROTEIN", 154, 157], ["endothelial cells", "CELL_TYPE", 523, 540], ["type IV collagen", "PROTEIN", 634, 650], ["laminin", "PROTEIN", 655, 662], ["Glucocorticoid treatment", "TREATMENT", 0, 24], ["systemic inflammation", "PROBLEM", 63, 84], ["dysregulated (NF", "PROBLEM", 90, 106], ["alveolar-capillary membrane permeability", "PROBLEM", 228, 268], ["inflammation", "PROBLEM", 284, 296], ["hemostasis", "TREATMENT", 298, 308], ["tissue repair", "TREATMENT", 314, 327], ["injury", "PROBLEM", 584, 590], ["a thin basement membrane", "PROBLEM", 597, 621], ["type IV collagen and laminin", "TREATMENT", 634, 662], ["systemic", "OBSERVATION_MODIFIER", 63, 71], ["inflammation", "OBSERVATION", 72, 84], ["significant", "OBSERVATION_MODIFIER", 190, 201], ["improvement", "OBSERVATION_MODIFIER", 202, 213], ["alveolar", "ANATOMY_MODIFIER", 228, 236], ["capillary membrane permeability", "OBSERVATION", 237, 268], ["inflammation", "OBSERVATION", 284, 296], ["tissue repair", "OBSERVATION", 314, 327], ["vascular endothelium", "ANATOMY", 348, 368], ["innermost", "ANATOMY_MODIFIER", 385, 394], ["lining", "ANATOMY_MODIFIER", 395, 401], ["body", "ANATOMY_MODIFIER", 409, 413], ["circulatory system", "ANATOMY", 416, 434], ["largest", "OBSERVATION_MODIFIER", 443, 450], ["tissue", "OBSERVATION", 451, 457], ["body", "ANATOMY_MODIFIER", 465, 469], ["endothelial cells", "OBSERVATION", 523, 540], ["flat", "OBSERVATION_MODIFIER", 560, 564], ["injury", "OBSERVATION", 584, 590], ["thin basement membrane", "OBSERVATION_MODIFIER", 599, 621], ["enriched", "OBSERVATION_MODIFIER", 622, 630], ["type IV collagen", "OBSERVATION_MODIFIER", 634, 650]]], ["The endothelial lining is in continuous contact with circulating cells and soluble proteins, and the capillaries, represent the primary barrier between elements in the blood and the parenchymal cells.", [["endothelial lining", "ANATOMY", 4, 22], ["cells", "ANATOMY", 65, 70], ["capillaries", "ANATOMY", 101, 112], ["blood", "ANATOMY", 168, 173], ["parenchymal cells", "ANATOMY", 182, 199], ["endothelial lining", "TISSUE", 4, 22], ["cells", "CELL", 65, 70], ["capillaries", "TISSUE", 101, 112], ["blood", "ORGANISM_SUBSTANCE", 168, 173], ["parenchymal cells", "CELL", 182, 199], ["circulating cells", "CELL_TYPE", 53, 70], ["soluble proteins", "PROTEIN", 75, 91], ["parenchymal cells", "CELL_TYPE", 182, 199], ["soluble proteins", "TEST", 75, 91], ["endothelial", "ANATOMY", 4, 15], ["lining", "ANATOMY_MODIFIER", 16, 22], ["circulating cells", "OBSERVATION", 53, 70], ["soluble proteins", "OBSERVATION", 75, 91], ["capillaries", "ANATOMY", 101, 112], ["primary", "OBSERVATION_MODIFIER", 128, 135], ["blood", "ANATOMY", 168, 173], ["parenchymal cells", "ANATOMY", 182, 199]]], ["The space between two contiguous endothelial cells, known as the endothelial cleft (ETC), acts as an important site of regulation of endothelial (paracellular) permeability (141).", [["endothelial cells", "ANATOMY", 33, 50], ["endothelial cleft", "ANATOMY", 65, 82], ["endothelial", "ANATOMY", 133, 144], ["paracellular", "ANATOMY", 146, 158], ["endothelial cells", "CELL", 33, 50], ["endothelial cleft", "TISSUE", 65, 82], ["ETC", "CELLULAR_COMPONENT", 84, 87], ["endothelial", "CELL", 133, 144], ["paracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 146, 158], ["endothelial cells", "CELL_TYPE", 33, 50], ["The space between two contiguous endothelial cells", "PROBLEM", 0, 50], ["the endothelial cleft", "PROBLEM", 61, 82], ["space", "ANATOMY_MODIFIER", 4, 9], ["endothelial cells", "OBSERVATION", 33, 50], ["endothelial", "ANATOMY", 65, 76], ["cleft", "OBSERVATION", 77, 82], ["endothelial", "ANATOMY", 133, 144]]], ["Importantly, the vascular endothelium (micro- and macro-circulation) is clothed with a protective barrier, the glycocalyx, which is critical to maintain endothelial homeostasis.", [["vascular endothelium", "ANATOMY", 17, 37], ["glycocalyx", "ANATOMY", 111, 121], ["endothelial", "ANATOMY", 153, 164], ["vascular endothelium", "TISSUE", 17, 37], ["glycocalyx", "CELLULAR_COMPONENT", 111, 121], ["endothelial", "CELL", 153, 164], ["a protective barrier", "TREATMENT", 85, 105], ["the glycocalyx", "TREATMENT", 107, 121], ["vascular endothelium", "ANATOMY", 17, 37], ["endothelial homeostasis", "OBSERVATION", 153, 176]]], ["The endothelial glycocalyx is a negatively charged, organized mesh of membranous glycoproteins and plasma proteins that include superoxide dismutase, antithrombin III, and cell adhesion molecules, all involved in maintaining the oncotic gradient across the endothelial barrier (141).", [["endothelial glycocalyx", "ANATOMY", 4, 26], ["membranous glycoproteins", "ANATOMY", 70, 94], ["plasma", "ANATOMY", 99, 105], ["cell", "ANATOMY", 172, 176], ["oncotic", "ANATOMY", 229, 236], ["endothelial barrier", "ANATOMY", 257, 276], ["superoxide", "CHEMICAL", 128, 138], ["superoxide", "CHEMICAL", 128, 138], ["endothelial glycocalyx", "CELLULAR_COMPONENT", 4, 26], ["plasma", "ORGANISM_SUBSTANCE", 99, 105], ["superoxide dismutase", "GENE_OR_GENE_PRODUCT", 128, 148], ["antithrombin III", "GENE_OR_GENE_PRODUCT", 150, 166], ["cell", "CELL", 172, 176], ["endothelial barrier", "TISSUE", 257, 276], ["membranous glycoproteins", "PROTEIN", 70, 94], ["plasma proteins", "PROTEIN", 99, 114], ["superoxide dismutase", "PROTEIN", 128, 148], ["antithrombin III", "PROTEIN", 150, 166], ["cell adhesion molecules", "PROTEIN", 172, 195], ["a negatively charged", "PROBLEM", 30, 50], ["membranous glycoproteins", "PROBLEM", 70, 94], ["plasma proteins", "TREATMENT", 99, 114], ["superoxide dismutase", "TREATMENT", 128, 148], ["antithrombin III", "TREATMENT", 150, 166], ["cell adhesion molecules", "TREATMENT", 172, 195], ["the oncotic gradient", "TREATMENT", 225, 245], ["endothelial", "ANATOMY", 4, 15], ["glycocalyx", "ANATOMY_MODIFIER", 16, 26], ["negatively charged", "OBSERVATION_MODIFIER", 32, 50], ["mesh", "OBSERVATION", 62, 66], ["membranous glycoproteins", "OBSERVATION", 70, 94], ["cell adhesion molecules", "OBSERVATION", 172, 195], ["oncotic gradient", "OBSERVATION", 229, 245], ["endothelial", "ANATOMY", 257, 268]]], ["The intact glycocalyx protects endothelial cells from oxidative stress and prevents the interaction between circulating leukocytes and endothelial adhesion molecules (141).", [["glycocalyx", "ANATOMY", 11, 21], ["endothelial cells", "ANATOMY", 31, 48], ["leukocytes", "ANATOMY", 120, 130], ["glycocalyx", "CELL", 11, 21], ["endothelial cells", "CELL", 31, 48], ["leukocytes", "CELL", 120, 130], ["endothelial adhesion molecules", "GENE_OR_GENE_PRODUCT", 135, 165], ["endothelial cells", "CELL_TYPE", 31, 48], ["circulating leukocytes", "CELL_TYPE", 108, 130], ["endothelial adhesion molecules", "PROTEIN", 135, 165], ["oxidative stress", "PROBLEM", 54, 70], ["circulating leukocytes", "TEST", 108, 130], ["endothelial adhesion molecules", "TEST", 135, 165], ["intact", "OBSERVATION", 4, 10], ["glycocalyx", "ANATOMY_MODIFIER", 11, 21], ["protects endothelial cells", "OBSERVATION", 22, 48], ["oxidative stress", "OBSERVATION", 54, 70], ["endothelial", "ANATOMY", 135, 146]]], ["Conformational changes in glycocalyx structure lead to short bursts in the release of endothelial nitric oxide (eNO) (141), inhibiting vascular smooth muscle contraction, platelet aggregation, and leukocyte adhesion, all three processes essential for patency of microcirculation.", [["glycocalyx", "ANATOMY", 26, 36], ["vascular smooth muscle", "ANATOMY", 135, 157], ["platelet", "ANATOMY", 171, 179], ["leukocyte", "ANATOMY", 197, 206], ["nitric oxide", "CHEMICAL", 98, 110], ["eNO", "CHEMICAL", 112, 115], ["platelet aggregation", "DISEASE", 171, 191], ["nitric oxide", "CHEMICAL", 98, 110], ["eNO", "CHEMICAL", 112, 115], ["glycocalyx", "CELLULAR_COMPONENT", 26, 36], ["endothelial nitric oxide", "SIMPLE_CHEMICAL", 86, 110], ["eNO) (141)", "GENE_OR_GENE_PRODUCT", 112, 122], ["vascular smooth muscle", "TISSUE", 135, 157], ["platelet", "CELL", 171, 179], ["leukocyte", "CELL", 197, 206], ["Conformational changes in glycocalyx structure", "PROBLEM", 0, 46], ["short bursts", "PROBLEM", 55, 67], ["endothelial nitric oxide", "TREATMENT", 86, 110], ["inhibiting vascular smooth muscle contraction", "PROBLEM", 124, 169], ["platelet aggregation", "PROBLEM", 171, 191], ["leukocyte adhesion", "PROBLEM", 197, 215], ["patency of microcirculation", "PROBLEM", 251, 278], ["glycocalyx structure", "OBSERVATION", 26, 46], ["short bursts", "OBSERVATION_MODIFIER", 55, 67], ["vascular", "ANATOMY", 135, 143], ["smooth muscle contraction", "OBSERVATION", 144, 169], ["platelet aggregation", "OBSERVATION", 171, 191], ["leukocyte adhesion", "OBSERVATION", 197, 215], ["patency", "OBSERVATION_MODIFIER", 251, 258], ["microcirculation", "OBSERVATION_MODIFIER", 262, 278]]], ["The blood-brain barrier (BBB), composed of highly specialized endothelial cells with tight junctions that seal paracellular spaces to restrict permeability, serves as a highly restrictive interface between the systemic circulatory system and the brain (142).EndotheliumDamage to the glycocalyx precedes vascular pathology.", [["blood-brain barrier", "ANATOMY", 4, 23], ["BBB", "ANATOMY", 25, 28], ["endothelial cells", "ANATOMY", 62, 79], ["tight junctions", "ANATOMY", 85, 100], ["paracellular", "ANATOMY", 111, 123], ["systemic circulatory system", "ANATOMY", 210, 237], ["brain", "ANATOMY", 246, 251], ["glycocalyx", "ANATOMY", 283, 293], ["vascular", "ANATOMY", 303, 311], ["blood-", "MULTI-TISSUE_STRUCTURE", 4, 10], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 10, 23], ["BBB", "MULTI-TISSUE_STRUCTURE", 25, 28], ["endothelial cells", "CELL", 62, 79], ["tight junctions", "CELLULAR_COMPONENT", 85, 100], ["paracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 111, 123], ["brain", "ORGAN", 246, 251], ["EndotheliumDamage", "SIMPLE_CHEMICAL", 258, 275], ["glycocalyx", "CELLULAR_COMPONENT", 283, 293], ["vascular", "MULTI-TISSUE_STRUCTURE", 303, 311], ["endothelial cells", "CELL_TYPE", 62, 79], ["The blood", "TEST", 0, 9], ["highly specialized endothelial cells", "PROBLEM", 43, 79], ["EndotheliumDamage", "TREATMENT", 258, 275], ["blood", "ANATOMY", 4, 9], ["brain", "ANATOMY", 10, 15], ["highly", "OBSERVATION_MODIFIER", 43, 49], ["specialized endothelial cells", "OBSERVATION", 50, 79], ["tight junctions", "OBSERVATION", 85, 100], ["seal", "OBSERVATION_MODIFIER", 106, 110], ["paracellular spaces", "OBSERVATION", 111, 130], ["restrict permeability", "OBSERVATION", 134, 155], ["highly", "OBSERVATION_MODIFIER", 169, 175], ["restrictive", "OBSERVATION", 176, 187], ["systemic", "ANATOMY_MODIFIER", 210, 218], ["circulatory system", "ANATOMY", 219, 237], ["brain", "ANATOMY", 246, 251], ["glycocalyx", "ANATOMY_MODIFIER", 283, 293], ["vascular", "ANATOMY", 303, 311], ["pathology", "OBSERVATION", 312, 321]]], ["Endothelial activation with ubiquitous shedding of the glycocalyx is a major component of critical illnesses and a key pathogenic mechanism in multiple organ dysfunction.", [["Endothelial", "ANATOMY", 0, 11], ["glycocalyx", "ANATOMY", 55, 65], ["organ", "ANATOMY", 152, 157], ["organ dysfunction", "DISEASE", 152, 169], ["Endothelial", "CELL", 0, 11], ["glycocalyx", "CELLULAR_COMPONENT", 55, 65], ["organ", "ORGAN", 152, 157], ["Endothelial activation", "PROBLEM", 0, 22], ["critical illnesses", "PROBLEM", 90, 108], ["a key pathogenic mechanism", "PROBLEM", 113, 139], ["multiple organ dysfunction", "PROBLEM", 143, 169], ["ubiquitous", "OBSERVATION_MODIFIER", 28, 38], ["shedding", "OBSERVATION", 39, 47], ["glycocalyx", "ANATOMY", 55, 65], ["critical", "OBSERVATION_MODIFIER", 90, 98], ["illnesses", "OBSERVATION", 99, 108], ["multiple", "OBSERVATION_MODIFIER", 143, 151], ["organ", "ANATOMY", 152, 157], ["dysfunction", "OBSERVATION", 158, 169]]], ["The pathways by which sepsis induces injury to the endothelium were recently reviewed (143).", [["endothelium", "ANATOMY", 51, 62], ["sepsis", "DISEASE", 22, 28], ["endothelium", "TISSUE", 51, 62], ["sepsis", "PROBLEM", 22, 28], ["injury", "PROBLEM", 37, 43], ["sepsis", "OBSERVATION", 22, 28], ["injury", "OBSERVATION", 37, 43], ["endothelium", "ANATOMY", 51, 62]]], ["The \u201cvasculo-centric view\u201d of critical illness derives from the observation that, despite the remarkable heterogeneity of diseases, the pathobiology of multiple organ dysfunction shares near-stereotypical features that are mostly related to widespread endothelial dysfunction (144).", [["organ", "ANATOMY", 161, 166], ["endothelial", "ANATOMY", 252, 263], ["critical illness", "DISEASE", 30, 46], ["organ dysfunction", "DISEASE", 161, 178], ["endothelial dysfunction", "DISEASE", 252, 275], ["organ", "ORGAN", 161, 166], ["endothelial", "TISSUE", 252, 263], ["the remarkable heterogeneity of diseases", "PROBLEM", 90, 130], ["multiple organ dysfunction", "PROBLEM", 152, 178], ["widespread endothelial dysfunction", "PROBLEM", 241, 275], ["diseases", "OBSERVATION", 122, 130], ["multiple", "OBSERVATION_MODIFIER", 152, 160], ["organ dysfunction", "OBSERVATION", 161, 178], ["mostly related to", "UNCERTAINTY", 223, 240], ["widespread", "OBSERVATION_MODIFIER", 241, 251], ["endothelial dysfunction", "OBSERVATION", 252, 275]]], ["Endothelial dysfunction manifests with a diffuse increase in paracellular permeability, expression of luminal cell adhesion molecules, recruitment of activate leukocytes, altered vasomotor tone, and microvascular thrombosis with decreased capillary density (145).", [["Endothelial", "ANATOMY", 0, 11], ["paracellular", "ANATOMY", 61, 73], ["luminal cell", "ANATOMY", 102, 114], ["leukocytes", "ANATOMY", 159, 169], ["vasomotor", "ANATOMY", 179, 188], ["microvascular", "ANATOMY", 199, 212], ["capillary", "ANATOMY", 239, 248], ["Endothelial dysfunction", "DISEASE", 0, 23], ["luminal", "CHEMICAL", 102, 109], ["thrombosis", "DISEASE", 213, 223], ["Endothelial", "CELL", 0, 11], ["paracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 61, 73], ["luminal cell adhesion molecules", "GENE_OR_GENE_PRODUCT", 102, 133], ["leukocytes", "CELL", 159, 169], ["microvascular", "TISSUE", 199, 212], ["capillary", "TISSUE", 239, 248], ["luminal cell adhesion molecules", "PROTEIN", 102, 133], ["leukocytes", "CELL_TYPE", 159, 169], ["Endothelial dysfunction", "PROBLEM", 0, 23], ["a diffuse increase in paracellular permeability", "PROBLEM", 39, 86], ["luminal cell adhesion molecules", "PROBLEM", 102, 133], ["activate leukocytes", "PROBLEM", 150, 169], ["altered vasomotor tone", "PROBLEM", 171, 193], ["microvascular thrombosis", "PROBLEM", 199, 223], ["decreased capillary density", "PROBLEM", 229, 256], ["dysfunction", "OBSERVATION", 12, 23], ["diffuse", "OBSERVATION_MODIFIER", 41, 48], ["increase", "OBSERVATION_MODIFIER", 49, 57], ["paracellular permeability", "OBSERVATION", 61, 86], ["luminal", "ANATOMY_MODIFIER", 102, 109], ["cell adhesion molecules", "OBSERVATION", 110, 133], ["activate leukocytes", "OBSERVATION", 150, 169], ["altered", "OBSERVATION_MODIFIER", 171, 178], ["vasomotor tone", "OBSERVATION", 179, 193], ["microvascular", "ANATOMY", 199, 212], ["thrombosis", "OBSERVATION", 213, 223], ["decreased", "OBSERVATION_MODIFIER", 229, 238], ["capillary density", "OBSERVATION", 239, 256]]], ["Increasing evidence points to endothelial dysfunction with impairment of the BBB as a critical component of the pathobiology of delirium during critical illness (146).EndotheliumOxidative stress (see section Mitochondrial Cacostatic Load, Oxidative Stress, and Mitochondrial Damage) impairs endothelial function by interfering with eNO synthesis (147) and by participating in the degradation of the glycocalyx (141).", [["endothelial", "ANATOMY", 30, 41], ["BBB", "ANATOMY", 77, 80], ["Mitochondrial", "ANATOMY", 208, 221], ["Mitochondrial", "ANATOMY", 261, 274], ["endothelial", "ANATOMY", 291, 302], ["glycocalyx", "ANATOMY", 399, 409], ["endothelial dysfunction", "DISEASE", 30, 53], ["delirium", "DISEASE", 128, 136], ["critical illness", "DISEASE", 144, 160], ["eNO", "CHEMICAL", 332, 335], ["endothelial", "TISSUE", 30, 41], ["BBB", "MULTI-TISSUE_STRUCTURE", 77, 80], ["Mitochondrial", "CELLULAR_COMPONENT", 261, 274], ["endothelial", "TISSUE", 291, 302], ["eNO", "GENE_OR_GENE_PRODUCT", 332, 335], ["glycocalyx", "CELLULAR_COMPONENT", 399, 409], ["eNO", "PROTEIN", 332, 335], ["endothelial dysfunction", "PROBLEM", 30, 53], ["impairment of the BBB", "PROBLEM", 59, 80], ["delirium", "PROBLEM", 128, 136], ["EndotheliumOxidative stress", "PROBLEM", 167, 194], ["Mitochondrial Cacostatic Load", "TREATMENT", 208, 237], ["Oxidative Stress", "PROBLEM", 239, 255], ["Mitochondrial Damage", "PROBLEM", 261, 281], ["eNO synthesis", "TEST", 332, 345], ["endothelial dysfunction", "OBSERVATION", 30, 53]]], ["After shedding of the glycocalyx, adhesion molecules are released in the blood and can be found in the circulation (35).", [["glycocalyx", "ANATOMY", 22, 32], ["blood", "ANATOMY", 73, 78], ["glycocalyx", "CELLULAR_COMPONENT", 22, 32], ["blood", "ORGANISM_SUBSTANCE", 73, 78], ["adhesion molecules", "PROTEIN", 34, 52], ["adhesion molecules", "PROBLEM", 34, 52], ["glycocalyx", "ANATOMY_MODIFIER", 22, 32], ["adhesion molecules", "OBSERVATION", 34, 52], ["blood", "ANATOMY", 73, 78], ["circulation", "ANATOMY", 103, 114]]], ["Microvascular alterations, such as decreased functional capillary density and increased perfusion heterogeneity, are frequently observed in patients with sepsis and contribute to the defect in oxygen extraction by the peripheral organs and tissues of the organism (148).EndotheliumEndothelial activation may also affect the HPA-axis.", [["Microvascular", "ANATOMY", 0, 13], ["capillary", "ANATOMY", 56, 65], ["peripheral organs", "ANATOMY", 218, 235], ["tissues", "ANATOMY", 240, 247], ["sepsis", "DISEASE", 154, 160], ["oxygen", "CHEMICAL", 193, 199], ["oxygen", "CHEMICAL", 193, 199], ["Microvascular", "TISSUE", 0, 13], ["capillary", "TISSUE", 56, 65], ["patients", "ORGANISM", 140, 148], ["oxygen", "SIMPLE_CHEMICAL", 193, 199], ["peripheral organs", "TISSUE", 218, 235], ["tissues", "TISSUE", 240, 247], ["patients", "SPECIES", 140, 148], ["Microvascular alterations", "PROBLEM", 0, 25], ["decreased functional capillary density", "PROBLEM", 35, 73], ["increased perfusion heterogeneity", "PROBLEM", 78, 111], ["sepsis", "PROBLEM", 154, 160], ["the defect", "PROBLEM", 179, 189], ["oxygen extraction", "TREATMENT", 193, 210], ["EndotheliumEndothelial activation", "PROBLEM", 270, 303], ["alterations", "OBSERVATION", 14, 25], ["decreased", "OBSERVATION_MODIFIER", 35, 44], ["functional", "OBSERVATION_MODIFIER", 45, 55], ["capillary density", "OBSERVATION", 56, 73], ["increased", "OBSERVATION_MODIFIER", 78, 87], ["perfusion heterogeneity", "OBSERVATION", 88, 111], ["sepsis", "OBSERVATION", 154, 160], ["defect", "OBSERVATION", 183, 189], ["oxygen extraction", "OBSERVATION", 193, 210], ["peripheral", "ANATOMY_MODIFIER", 218, 228], ["organs", "ANATOMY", 229, 235], ["may also affect", "UNCERTAINTY", 304, 319]]], ["The adrenal gland is a highly vascularized organ, with every steroidogenic cell in close vicinity with at least one sinusoid, and a clear positive relation between adrenal blood flow and steroidogenesis has been demonstrated (149).", [["adrenal gland", "ANATOMY", 4, 17], ["organ", "ANATOMY", 43, 48], ["steroidogenic cell", "ANATOMY", 61, 79], ["sinusoid", "ANATOMY", 116, 124], ["adrenal blood", "ANATOMY", 164, 177], ["adrenal gland", "ORGAN", 4, 17], ["organ", "ORGAN", 43, 48], ["steroidogenic cell", "CELL", 61, 79], ["adrenal blood", "MULTI-TISSUE_STRUCTURE", 164, 177], ["steroidogenic cell", "CELL_TYPE", 61, 79], ["every steroidogenic cell", "PROBLEM", 55, 79], ["adrenal blood flow", "TEST", 164, 182], ["adrenal gland", "ANATOMY", 4, 17], ["highly", "OBSERVATION_MODIFIER", 23, 29], ["vascularized", "OBSERVATION", 30, 42], ["steroidogenic cell", "OBSERVATION", 61, 79], ["at least", "OBSERVATION_MODIFIER", 103, 111], ["clear", "OBSERVATION_MODIFIER", 132, 137], ["positive", "OBSERVATION", 138, 146], ["adrenal", "ANATOMY", 164, 171], ["blood flow", "OBSERVATION", 172, 182]]], ["In critical illness, disruption of endothelial homeostasis within the adrenal gland can contribute to the HPA-axis dysfunction (150).", [["endothelial", "ANATOMY", 35, 46], ["adrenal gland", "ANATOMY", 70, 83], ["endothelial", "CELL", 35, 46], ["adrenal gland", "ORGAN", 70, 83], ["endothelial homeostasis within the adrenal gland", "PROBLEM", 35, 83], ["the HPA-axis dysfunction", "PROBLEM", 102, 126], ["critical", "OBSERVATION_MODIFIER", 3, 11], ["illness", "OBSERVATION", 12, 19], ["endothelial homeostasis", "OBSERVATION", 35, 58], ["adrenal gland", "ANATOMY", 70, 83], ["axis", "ANATOMY", 110, 114], ["dysfunction", "OBSERVATION", 115, 126]]], ["Hypovitaminosis may also contribute to endothelial dysfunction (see section Hypovitaminoses).EndotheliumIn studies of circulating inflammatory cytokines, there is substantial evidence that in critically ill patients, an increase in circulating markers of endothelial integrity (angiopoietin-1; Angpt-1) (145), dysfunction [angiopoietin-2 (Angpt-2), von Willebrand factor (VVF) (150), soluble intercellular adhesion molecule-1 (sICAM-1), (35) vascular endothelial growth factor (VEGF)] (145, 151), and cell damage associated with circulating endothelial cells (152, 153) correlate with disease severity and mortality.", [["endothelial", "ANATOMY", 39, 50], ["endothelial", "ANATOMY", 255, 266], ["cell", "ANATOMY", 501, 505], ["endothelial cells", "ANATOMY", 541, 558], ["Hypovitaminosis", "CHEMICAL", 0, 15], ["endothelial dysfunction", "DISEASE", 39, 62], ["critically ill", "DISEASE", 192, 206], ["endothelial", "TISSUE", 39, 50], ["patients", "ORGANISM", 207, 215], ["endothelial", "TISSUE", 255, 266], ["angiopoietin-1", "GENE_OR_GENE_PRODUCT", 278, 292], ["Angpt-1", "GENE_OR_GENE_PRODUCT", 294, 301], ["angiopoietin-2", "GENE_OR_GENE_PRODUCT", 323, 337], ["Angpt-2", "GENE_OR_GENE_PRODUCT", 339, 346], ["von Willebrand factor", "GENE_OR_GENE_PRODUCT", 349, 370], ["VVF) (150)", "GENE_OR_GENE_PRODUCT", 372, 382], ["soluble intercellular adhesion molecule-1", "GENE_OR_GENE_PRODUCT", 384, 425], ["sICAM-1", "GENE_OR_GENE_PRODUCT", 427, 434], ["(35) vascular endothelial growth factor", "GENE_OR_GENE_PRODUCT", 437, 476], ["VEGF", "GENE_OR_GENE_PRODUCT", 478, 482], ["cell", "CELL", 501, 505], ["endothelial cells", "CELL", 541, 558], ["inflammatory cytokines", "PROTEIN", 130, 152], ["angiopoietin-1", "PROTEIN", 278, 292], ["Angpt", "PROTEIN", 294, 299], ["angiopoietin-2", "PROTEIN", 323, 337], ["Angpt", "PROTEIN", 339, 344], ["VVF", "PROTEIN", 372, 375], ["soluble intercellular adhesion molecule-1 (sICAM-1", "PROTEIN", 384, 434], ["vascular endothelial growth factor", "PROTEIN", 442, 476], ["VEGF", "PROTEIN", 478, 482], ["circulating endothelial cells", "CELL_TYPE", 529, 558], ["patients", "SPECIES", 207, 215], ["Hypovitaminosis", "PROBLEM", 0, 15], ["endothelial dysfunction", "PROBLEM", 39, 62], ["EndotheliumIn studies", "TEST", 93, 114], ["circulating inflammatory cytokines", "PROBLEM", 118, 152], ["endothelial integrity", "TEST", 255, 276], ["angiopoietin", "TEST", 278, 290], ["Angpt", "TEST", 294, 299], ["dysfunction", "PROBLEM", 310, 321], ["angiopoietin", "TEST", 323, 335], ["Angpt", "TEST", 339, 344], ["von Willebrand factor (VVF", "TREATMENT", 349, 375], ["soluble intercellular adhesion molecule", "TREATMENT", 384, 423], ["vascular endothelial growth factor", "TEST", 442, 476], ["cell damage", "PROBLEM", 501, 512], ["circulating endothelial cells", "PROBLEM", 529, 558], ["disease severity and mortality", "PROBLEM", 585, 615], ["may also contribute to", "UNCERTAINTY", 16, 38], ["endothelial dysfunction", "OBSERVATION", 39, 62], ["inflammatory cytokines", "OBSERVATION", 130, 152], ["substantial", "OBSERVATION_MODIFIER", 163, 174], ["increase", "OBSERVATION_MODIFIER", 220, 228], ["circulating markers", "OBSERVATION", 232, 251], ["endothelial", "ANATOMY", 255, 266], ["vascular endothelial", "ANATOMY", 442, 462], ["cell damage", "OBSERVATION", 501, 512], ["circulating endothelial cells", "OBSERVATION", 529, 558]]], ["Fittingly, a large study acquiring sublingual measurements of microcirculation in early sepsis, found that mortality strongly correlated with the severity of alterations in the proportion of perfused small vessels, i.e., the functional capillary density (154).EndotheliumThe endothelial GR\u03b1 is a critical regulator of vascular homeostatic corrections and essential for decreasing the rolling on and adhesion of activated neutrophils to the endothelium (155).", [["sublingual", "ANATOMY", 35, 45], ["small vessels", "ANATOMY", 200, 213], ["capillary", "ANATOMY", 236, 245], ["Endothelium", "ANATOMY", 260, 271], ["endothelial", "ANATOMY", 275, 286], ["vascular", "ANATOMY", 318, 326], ["neutrophils", "ANATOMY", 421, 432], ["endothelium", "ANATOMY", 440, 451], ["sepsis", "DISEASE", 88, 94], ["sublingual", "MULTI-TISSUE_STRUCTURE", 35, 45], ["small vessels", "MULTI-TISSUE_STRUCTURE", 200, 213], ["capillary", "TISSUE", 236, 245], ["Endothelium", "CELL", 260, 271], ["endothelial GR\u03b1", "GENE_OR_GENE_PRODUCT", 275, 290], ["vascular", "MULTI-TISSUE_STRUCTURE", 318, 326], ["neutrophils", "CELL", 421, 432], ["endothelium", "TISSUE", 440, 451], ["endothelial GR\u03b1", "PROTEIN", 275, 290], ["activated neutrophils", "CELL_TYPE", 411, 432], ["a large study", "TEST", 11, 24], ["sublingual measurements", "TEST", 35, 58], ["early sepsis", "PROBLEM", 82, 94], ["the functional capillary density", "TEST", 221, 253], ["large", "OBSERVATION_MODIFIER", 13, 18], ["early", "OBSERVATION_MODIFIER", 82, 87], ["sepsis", "OBSERVATION", 88, 94], ["alterations", "OBSERVATION", 158, 169], ["perfused", "OBSERVATION", 191, 199], ["small vessels", "OBSERVATION", 200, 213], ["functional", "OBSERVATION_MODIFIER", 225, 235], ["capillary density", "OBSERVATION", 236, 253], ["endothelial", "ANATOMY", 275, 286], ["vascular", "ANATOMY", 318, 326], ["rolling", "OBSERVATION_MODIFIER", 384, 391], ["endothelium", "ANATOMY", 440, 451]]], ["In experimental sepsis, elimination of the endothelial GR\u03b1 resulted in prolonged activation of endothelial NF-\u03baB, with increased expression of iNOS and inflammatory cytokines, both accounting for hemodynamic collapse and mortality (130).", [["endothelial", "ANATOMY", 43, 54], ["sepsis", "DISEASE", 16, 22], ["endothelial", "CELL", 43, 54], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 55, 58], ["endothelial", "CELL", 95, 106], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 107, 112], ["iNOS", "GENE_OR_GENE_PRODUCT", 143, 147], ["endothelial GR\u03b1", "PROTEIN", 43, 58], ["endothelial NF-\u03baB", "PROTEIN", 95, 112], ["iNOS", "PROTEIN", 143, 147], ["inflammatory cytokines", "PROTEIN", 152, 174], ["experimental sepsis", "PROBLEM", 3, 22], ["prolonged activation of endothelial NF", "PROBLEM", 71, 109], ["iNOS and inflammatory cytokines", "PROBLEM", 143, 174], ["hemodynamic collapse", "PROBLEM", 196, 216], ["sepsis", "OBSERVATION", 16, 22], ["endothelial", "ANATOMY", 43, 54], ["endothelial", "ANATOMY", 95, 106], ["iNOS", "OBSERVATION", 143, 147], ["inflammatory cytokines", "OBSERVATION", 152, 174], ["collapse", "OBSERVATION", 208, 216]]], ["Importantly, the presence of the endothelial GR itself was necessary for GC-mediated suppression of NF-\u03baB and for achieving survival (130).", [["endothelial", "ANATOMY", 33, 44], ["endothelial GR", "GENE_OR_GENE_PRODUCT", 33, 47], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 100, 105], ["endothelial GR", "PROTEIN", 33, 47], ["NF-\u03baB", "PROTEIN", 100, 105], ["GC-mediated suppression of NF", "TREATMENT", 73, 102], ["endothelial", "ANATOMY", 33, 44]]], ["GR\u03b1 also regulates the tightness of the BBB, inducing expression of the tight junction proteins occludin and claudin-5, and the adherens junction protein vascular endothelium cadherin (VE-Cadherin) (156).EndotheliumGC-GR\u03b1 is also strongly involved in vascular development (81).", [["BBB", "ANATOMY", 40, 43], ["tight junction", "ANATOMY", 72, 86], ["adherens junction", "ANATOMY", 128, 145], ["vascular", "ANATOMY", 251, 259], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 0, 3], ["BBB", "MULTI-TISSUE_STRUCTURE", 40, 43], ["occludin", "GENE_OR_GENE_PRODUCT", 96, 104], ["claudin-5", "GENE_OR_GENE_PRODUCT", 109, 118], ["adherens junction", "CELLULAR_COMPONENT", 128, 145], ["vascular endothelium cadherin", "GENE_OR_GENE_PRODUCT", 154, 183], ["VE-Cadherin", "GENE_OR_GENE_PRODUCT", 185, 196], ["EndotheliumGC-GR\u03b1", "GENE_OR_GENE_PRODUCT", 204, 221], ["vascular", "MULTI-TISSUE_STRUCTURE", 251, 259], ["GR\u03b1", "PROTEIN", 0, 3], ["tight junction proteins", "PROTEIN", 72, 95], ["occludin", "PROTEIN", 96, 104], ["claudin-5", "PROTEIN", 109, 118], ["adherens junction protein", "PROTEIN", 128, 153], ["vascular endothelium cadherin", "PROTEIN", 154, 183], ["VE", "PROTEIN", 185, 187], ["Cadherin", "PROTEIN", 188, 196], ["EndotheliumGC", "PROTEIN", 204, 217], ["GR\u03b1", "PROTEIN", 218, 221], ["the tightness of the BBB", "PROBLEM", 19, 43], ["claudin", "TEST", 109, 116], ["the adherens junction protein vascular endothelium cadherin", "TREATMENT", 124, 183], ["EndotheliumGC", "TEST", 204, 217], ["tightness", "OBSERVATION", 23, 32], ["BBB", "ANATOMY", 40, 43], ["tight junction", "ANATOMY", 72, 86], ["junction", "ANATOMY_MODIFIER", 137, 145], ["vascular endothelium", "ANATOMY", 154, 174], ["vascular", "ANATOMY", 251, 259]]], ["Experimental studies have shown GR-dependent upregulation of multiple mediators involved in endothelial cell homeostasis, such as sphingosine kinase 1 (SphK1) (157), angiopoietin-1 (Angpt-1) (158), serum glucocorticoid kinase-1 (SGK-1) (159, 160), GILZ (161), and eNOS (162\u2013164).", [["endothelial cell", "ANATOMY", 92, 108], ["sphingosine", "CHEMICAL", 130, 141], ["sphingosine", "CHEMICAL", 130, 141], ["GR", "GENE_OR_GENE_PRODUCT", 32, 34], ["endothelial cell", "CELL", 92, 108], ["sphingosine kinase 1", "GENE_OR_GENE_PRODUCT", 130, 150], ["SphK1", "GENE_OR_GENE_PRODUCT", 152, 157], ["angiopoietin-1", "GENE_OR_GENE_PRODUCT", 166, 180], ["Angpt-1", "GENE_OR_GENE_PRODUCT", 182, 189], ["serum glucocorticoid kinase-1", "GENE_OR_GENE_PRODUCT", 198, 227], ["SGK-1", "GENE_OR_GENE_PRODUCT", 229, 234], ["GILZ", "GENE_OR_GENE_PRODUCT", 248, 252], ["eNOS", "GENE_OR_GENE_PRODUCT", 264, 268], ["GR", "PROTEIN", 32, 34], ["sphingosine kinase 1", "PROTEIN", 130, 150], ["SphK1", "PROTEIN", 152, 157], ["angiopoietin-1", "PROTEIN", 166, 180], ["Angpt", "PROTEIN", 182, 187], ["serum glucocorticoid kinase-1 (SGK-1", "PROTEIN", 198, 234], ["GILZ", "PROTEIN", 248, 252], ["eNOS", "PROTEIN", 264, 268], ["Experimental studies", "TEST", 0, 20], ["GR-dependent upregulation of multiple mediators", "PROBLEM", 32, 79], ["endothelial cell homeostasis", "PROBLEM", 92, 120], ["sphingosine kinase", "TEST", 130, 148], ["SphK1", "TEST", 152, 157], ["angiopoietin", "TEST", 166, 178], ["Angpt", "TEST", 182, 187], ["serum glucocorticoid kinase", "TEST", 198, 225], ["SGK", "TEST", 229, 232], ["GILZ", "TEST", 248, 252], ["eNOS", "TEST", 264, 268], ["dependent upregulation", "OBSERVATION_MODIFIER", 35, 57], ["multiple", "OBSERVATION_MODIFIER", 61, 69], ["endothelial cell homeostasis", "OBSERVATION", 92, 120]]], ["In experimental ARDS, upregulation of SphK1, an important regulator of endothelial barrier integrity, was shown to improve alveolo-capillary membrane (ACM) permeability (157).", [["endothelial barrier", "ANATOMY", 71, 90], ["alveolo-capillary membrane", "ANATOMY", 123, 149], ["ACM", "ANATOMY", 151, 154], ["ARDS", "DISEASE", 16, 20], ["SphK1", "GENE_OR_GENE_PRODUCT", 38, 43], ["endothelial barrier", "TISSUE", 71, 90], ["alveolo-capillary membrane", "TISSUE", 123, 149], ["SphK1", "PROTEIN", 38, 43], ["experimental ARDS", "PROBLEM", 3, 20], ["upregulation of SphK1", "PROBLEM", 22, 43], ["endothelial barrier integrity", "TREATMENT", 71, 100], ["ARDS", "OBSERVATION", 16, 20], ["SphK1", "OBSERVATION_MODIFIER", 38, 43], ["capillary membrane", "ANATOMY", 131, 149]]], ["In human brain microvascular endothelial cells (HBMECs), GC treatment was associated with transcriptional activation of Angpt-1 and suppression of VEGF (158).", [["brain microvascular endothelial cells", "ANATOMY", 9, 46], ["HBMECs", "ANATOMY", 48, 54], ["human", "ORGANISM", 3, 8], ["brain microvascular endothelial cells", "CELL", 9, 46], ["HBMECs", "CELL", 48, 54], ["GC", "CELL", 57, 59], ["Angpt-1", "GENE_OR_GENE_PRODUCT", 120, 127], ["VEGF (158)", "GENE_OR_GENE_PRODUCT", 147, 157], ["human brain microvascular endothelial cells", "CELL_TYPE", 3, 46], ["HBMECs", "CELL_TYPE", 48, 54], ["Angpt", "PROTEIN", 120, 125], ["VEGF", "PROTEIN", 147, 151], ["human", "SPECIES", 3, 8], ["human", "SPECIES", 3, 8], ["GC treatment", "TREATMENT", 57, 69], ["Angpt", "TEST", 120, 125], ["VEGF", "TEST", 147, 151], ["human", "ANATOMY_MODIFIER", 3, 8], ["brain microvascular", "ANATOMY", 9, 28], ["endothelial cells", "OBSERVATION", 29, 46]]], ["In umbilical vein endothelial cells (HUVECs), upregulation of SGK-1 reduced oxidative stress and improved cell survival and senescence (159); meanwhile, GR-induced GILZ expression (see section Glucocorticoid Receptor-Alpha and Homeostatic Corrections) correlated negatively with vascular inflammation (161).", [["umbilical vein endothelial cells", "ANATOMY", 3, 35], ["HUVECs", "ANATOMY", 37, 43], ["cell", "ANATOMY", 106, 110], ["vascular", "ANATOMY", 279, 287], ["inflammation", "DISEASE", 288, 300], ["umbilical vein endothelial cells", "CELL", 3, 35], ["HUVECs", "CELL", 37, 43], ["SGK-1", "GENE_OR_GENE_PRODUCT", 62, 67], ["cell", "CELL", 106, 110], ["GR", "GENE_OR_GENE_PRODUCT", 153, 155], ["GILZ", "GENE_OR_GENE_PRODUCT", 164, 168], ["Glucocorticoid Receptor-Alpha", "GENE_OR_GENE_PRODUCT", 193, 222], ["vascular", "MULTI-TISSUE_STRUCTURE", 279, 287], ["umbilical vein endothelial cells", "CELL_TYPE", 3, 35], ["HUVECs", "CELL_LINE", 37, 43], ["SGK-1", "PROTEIN", 62, 67], ["GR", "PROTEIN", 153, 155], ["GILZ", "PROTEIN", 164, 168], ["Glucocorticoid Receptor", "PROTEIN", 193, 216], ["Alpha", "PROTEIN", 217, 222], ["HUVECs", "TEST", 37, 43], ["SGK", "TEST", 62, 65], ["reduced oxidative stress", "PROBLEM", 68, 92], ["senescence", "TEST", 124, 134], ["GR-induced GILZ expression", "TREATMENT", 153, 179], ["vascular inflammation", "PROBLEM", 279, 300], ["umbilical vein", "ANATOMY", 3, 17], ["endothelial cells", "OBSERVATION", 18, 35], ["improved cell survival", "OBSERVATION", 97, 119], ["vascular", "ANATOMY", 279, 287], ["inflammation", "OBSERVATION", 288, 300]]], ["In neuro-vascular tissue, physiological doses of hydrocortisone rapidly activated eNOS via non-genomic mechanisms (163, 164).EndotheliumGR\u03b1 is also a critical regulator of myocardial function.", [["neuro-vascular tissue", "ANATOMY", 3, 24], ["myocardial", "ANATOMY", 172, 182], ["hydrocortisone", "CHEMICAL", 49, 63], ["hydrocortisone", "CHEMICAL", 49, 63], ["neuro-vascular tissue", "TISSUE", 3, 24], ["hydrocortisone", "SIMPLE_CHEMICAL", 49, 63], ["eNOS", "GENE_OR_GENE_PRODUCT", 82, 86], ["EndotheliumGR\u03b1", "GENE_OR_GENE_PRODUCT", 125, 139], ["myocardial", "MULTI-TISSUE_STRUCTURE", 172, 182], ["eNOS", "PROTEIN", 82, 86], ["EndotheliumGR\u03b1", "PROTEIN", 125, 139], ["hydrocortisone", "TREATMENT", 49, 63], ["neuro-vascular tissue", "ANATOMY", 3, 24], ["myocardial", "ANATOMY", 172, 182]]], ["In experimental work, the GR\u2014via Kruppel-like Factor 13\u2014was found to play a direct role in the regulation of cardiomyocyte function and protection from hypoxia and DNA damage (86).", [["cardiomyocyte", "ANATOMY", 109, 122], ["hypoxia", "DISEASE", 152, 159], ["Kruppel-like Factor 13", "GENE_OR_GENE_PRODUCT", 33, 55], ["cardiomyocyte", "CELL", 109, 122], ["DNA", "CELLULAR_COMPONENT", 164, 167], ["GR\u2014via Kruppel-like Factor 13", "PROTEIN", 26, 55], ["hypoxia", "PROBLEM", 152, 159], ["DNA damage", "PROBLEM", 164, 174], ["cardiomyocyte", "ANATOMY", 109, 122], ["hypoxia", "OBSERVATION", 152, 159]]], ["GR inhibits cells death triggered by ischemia reperfusion, mechanical stress, or TNF\u03b1 [reviewed in (86)].EndotheliumThe endothelial response to GCs in inflammatory diseases was extensively reviewed covering topics such as inhibition of pro-inflammatory transcription factors, restoration of endothelial barrier integrity, and induction of protective molecules (140).", [["cells", "ANATOMY", 12, 17], ["Endothelium", "ANATOMY", 105, 116], ["endothelial", "ANATOMY", 120, 131], ["GCs", "ANATOMY", 144, 147], ["endothelial barrier", "ANATOMY", 291, 310], ["death", "DISEASE", 18, 23], ["ischemia", "DISEASE", 37, 45], ["inflammatory diseases", "DISEASE", 151, 172], ["GR", "GENE_OR_GENE_PRODUCT", 0, 2], ["cells", "CELL", 12, 17], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 81, 85], ["Endothelium", "CELL", 105, 116], ["endothelial", "CELL", 120, 131], ["endothelial barrier", "TISSUE", 291, 310], ["GR", "PROTEIN", 0, 2], ["TNF", "PROTEIN", 81, 84], ["pro-inflammatory transcription factors", "PROTEIN", 236, 274], ["protective molecules", "PROTEIN", 339, 359], ["GR inhibits cells death", "PROBLEM", 0, 23], ["ischemia reperfusion", "TREATMENT", 37, 57], ["mechanical stress", "PROBLEM", 59, 76], ["TNF", "PROBLEM", 81, 84], ["inflammatory diseases", "PROBLEM", 151, 172], ["pro-inflammatory transcription factors", "TREATMENT", 236, 274], ["endothelial barrier integrity", "TREATMENT", 291, 320], ["induction of protective molecules", "TREATMENT", 326, 359], ["inhibits cells death", "OBSERVATION", 3, 23], ["ischemia reperfusion", "OBSERVATION", 37, 57], ["mechanical stress", "OBSERVATION", 59, 76], ["endothelial", "ANATOMY", 120, 131], ["inflammatory", "OBSERVATION_MODIFIER", 151, 163], ["endothelial", "ANATOMY", 291, 302]]], ["In experimental sepsis, low-dose glucocorticoid (hydrocortisone or dexamethasone) preserved the endothelial glycocalyx, sustained the vascular barrier and reduced interstitial edema (165, 166), and had beneficial effects on mesenteric blood flow and helped with resolution of organ injury (167).", [["endothelial glycocalyx", "ANATOMY", 96, 118], ["vascular barrier", "ANATOMY", 134, 150], ["interstitial edema", "ANATOMY", 163, 181], ["mesenteric blood", "ANATOMY", 224, 240], ["organ", "ANATOMY", 276, 281], ["sepsis", "DISEASE", 16, 22], ["hydrocortisone", "CHEMICAL", 49, 63], ["dexamethasone", "CHEMICAL", 67, 80], ["interstitial edema", "DISEASE", 163, 181], ["organ injury", "DISEASE", 276, 288], ["hydrocortisone", "CHEMICAL", 49, 63], ["dexamethasone", "CHEMICAL", 67, 80], ["glucocorticoid", "SIMPLE_CHEMICAL", 33, 47], ["hydrocortisone", "SIMPLE_CHEMICAL", 49, 63], ["dexamethasone", "SIMPLE_CHEMICAL", 67, 80], ["endothelial glycocalyx", "TISSUE", 96, 118], ["vascular barrier", "TISSUE", 134, 150], ["interstitial edema", "PATHOLOGICAL_FORMATION", 163, 181], ["mesenteric", "MULTI-TISSUE_STRUCTURE", 224, 234], ["blood", "ORGANISM_SUBSTANCE", 235, 240], ["organ", "ORGAN", 276, 281], ["experimental sepsis", "PROBLEM", 3, 22], ["low-dose glucocorticoid (hydrocortisone", "TREATMENT", 24, 63], ["dexamethasone", "TREATMENT", 67, 80], ["the endothelial glycocalyx", "PROBLEM", 92, 118], ["the vascular barrier", "PROBLEM", 130, 150], ["reduced interstitial edema", "PROBLEM", 155, 181], ["mesenteric blood flow", "TEST", 224, 245], ["organ injury", "PROBLEM", 276, 288], ["sepsis", "OBSERVATION", 16, 22], ["low", "OBSERVATION_MODIFIER", 24, 27], ["endothelial glycocalyx", "ANATOMY", 96, 118], ["vascular", "ANATOMY", 134, 142], ["reduced", "OBSERVATION_MODIFIER", 155, 162], ["interstitial", "ANATOMY_MODIFIER", 163, 175], ["edema", "OBSERVATION", 176, 181], ["mesenteric", "ANATOMY", 224, 234], ["organ", "ANATOMY", 276, 281], ["injury", "OBSERVATION", 282, 288]]], ["GCs play an important role in the control of vascular smooth muscle tone by their permissive effects in potentiating vasoconstrictive responses to catecholamines and other hormones, such as arginine-vasopressin, through glucocorticoid receptors (168).", [["GCs", "ANATOMY", 0, 3], ["vascular smooth muscle", "ANATOMY", 45, 67], ["catecholamines", "CHEMICAL", 147, 161], ["arginine-vasopressin", "CHEMICAL", 190, 210], ["catecholamines", "CHEMICAL", 147, 161], ["arginine", "CHEMICAL", 190, 198], ["GCs", "CELL", 0, 3], ["vascular smooth muscle", "TISSUE", 45, 67], ["catecholamines", "SIMPLE_CHEMICAL", 147, 161], ["arginine-vasopressin", "GENE_OR_GENE_PRODUCT", 190, 210], ["glucocorticoid receptors", "GENE_OR_GENE_PRODUCT", 220, 244], ["glucocorticoid receptors", "PROTEIN", 220, 244], ["catecholamines", "TREATMENT", 147, 161], ["arginine", "TREATMENT", 190, 198], ["vasopressin", "TREATMENT", 199, 210], ["glucocorticoid receptors", "TREATMENT", 220, 244], ["vascular", "ANATOMY", 45, 53], ["smooth muscle", "ANATOMY", 54, 67]]], ["Finally, they inhibit the expression of inducible nitric oxide synthase and other vasodilatory agents in vascular endothelial cells (169).", [["vascular endothelial cells", "ANATOMY", 105, 131], ["nitric oxide", "CHEMICAL", 50, 62], ["nitric oxide", "CHEMICAL", 50, 62], ["inducible nitric oxide synthase", "GENE_OR_GENE_PRODUCT", 40, 71], ["vascular endothelial cells", "CELL", 105, 131], ["nitric oxide synthase", "PROTEIN", 50, 71], ["vascular endothelial cells", "CELL_TYPE", 105, 131], ["inducible nitric oxide synthase", "TREATMENT", 40, 71], ["other vasodilatory agents", "TREATMENT", 76, 101], ["vascular endothelial cells", "TEST", 105, 131], ["vascular endothelial", "ANATOMY", 105, 125]]], ["Additional experimental studies have shown that GR stimulates transcription of the zonula occludens (ZO)-1 tight junction protein, leading to reduced BBB paracellular permeability (142), while it activates eNOS increasing cerebral blood flow (163).EndotheliumIn patients with septic shock (170, 171) or ARDS (172, 173), prolonged glucocorticoid (hydrocortisone or methylprednisolone) treatment resulted in the following: (i) increased plasma activated protein C levels (173); (ii) reduction in markers of endothelial injury such as sICAM-1 (35); (iii) rapid and consistent improvement in capillary perfusion, independently of the cortisol response to ACTH (170); and (iv) improvement in alveolar-capillary (172) and renal (171) endothelial permeability.", [["BBB paracellular", "ANATOMY", 150, 166], ["cerebral blood", "ANATOMY", 222, 236], ["plasma", "ANATOMY", 435, 441], ["endothelial", "ANATOMY", 505, 516], ["capillary", "ANATOMY", 588, 597], ["alveolar-capillary", "ANATOMY", 687, 705], ["renal", "ANATOMY", 716, 721], ["endothelial", "ANATOMY", 728, 739], ["septic shock", "DISEASE", 276, 288], ["ARDS", "DISEASE", 303, 307], ["hydrocortisone", "CHEMICAL", 346, 360], ["methylprednisolone", "CHEMICAL", 364, 382], ["cortisol", "CHEMICAL", 630, 638], ["hydrocortisone", "CHEMICAL", 346, 360], ["methylprednisolone", "CHEMICAL", 364, 382], ["cortisol", "CHEMICAL", 630, 638], ["GR", "GENE_OR_GENE_PRODUCT", 48, 50], ["zonula occludens (ZO)-1", "GENE_OR_GENE_PRODUCT", 83, 106], ["BBB paracellular", "TISSUE", 150, 166], ["eNOS", "GENE_OR_GENE_PRODUCT", 206, 210], ["cerebral blood", "MULTI-TISSUE_STRUCTURE", 222, 236], ["patients", "ORGANISM", 262, 270], ["glucocorticoid", "SIMPLE_CHEMICAL", 330, 344], ["hydrocortisone", "SIMPLE_CHEMICAL", 346, 360], ["methylprednisolone", "SIMPLE_CHEMICAL", 364, 382], ["plasma", "ORGANISM_SUBSTANCE", 435, 441], ["protein C", "GENE_OR_GENE_PRODUCT", 452, 461], ["endothelial", "TISSUE", 505, 516], ["sICAM-1", "GENE_OR_GENE_PRODUCT", 532, 539], ["capillary", "TISSUE", 588, 597], ["cortisol", "SIMPLE_CHEMICAL", 630, 638], ["ACTH", "SIMPLE_CHEMICAL", 651, 655], ["alveolar-capillary", "TISSUE", 687, 705], ["endothelial", "TISSUE", 728, 739], ["GR", "PROTEIN", 48, 50], ["zonula occludens (ZO)-1 tight junction protein", "PROTEIN", 83, 129], ["eNOS", "PROTEIN", 206, 210], ["plasma activated protein C", "PROTEIN", 435, 461], ["sICAM", "PROTEIN", 532, 537], ["patients", "SPECIES", 262, 270], ["Additional experimental studies", "TEST", 0, 31], ["reduced BBB paracellular permeability", "PROBLEM", 142, 179], ["cerebral blood flow", "TEST", 222, 241], ["septic shock", "PROBLEM", 276, 288], ["ARDS", "PROBLEM", 303, 307], ["prolonged glucocorticoid (hydrocortisone", "TREATMENT", 320, 360], ["methylprednisolone) treatment", "TREATMENT", 364, 393], ["increased plasma activated protein C levels", "PROBLEM", 425, 468], ["endothelial injury", "PROBLEM", 505, 523], ["sICAM", "TEST", 532, 537], ["capillary perfusion", "TEST", 588, 607], ["the cortisol response", "TEST", 626, 647], ["ACTH", "TEST", 651, 655], ["alveolar-capillary", "TEST", 687, 705], ["endothelial permeability", "TEST", 728, 752], ["reduced", "OBSERVATION_MODIFIER", 142, 149], ["BBB", "ANATOMY_MODIFIER", 150, 153], ["paracellular permeability", "OBSERVATION", 154, 179], ["increasing", "OBSERVATION_MODIFIER", 211, 221], ["cerebral blood", "ANATOMY", 222, 236], ["flow", "OBSERVATION_MODIFIER", 237, 241], ["septic shock", "OBSERVATION", 276, 288], ["ARDS", "OBSERVATION", 303, 307], ["endothelial", "ANATOMY", 505, 516], ["injury", "OBSERVATION", 517, 523], ["improvement", "OBSERVATION_MODIFIER", 573, 584], ["capillary perfusion", "OBSERVATION", 588, 607], ["alveolar", "ANATOMY_MODIFIER", 687, 695], ["capillary", "ANATOMY_MODIFIER", 696, 705], ["renal", "ANATOMY", 716, 721], ["endothelial permeability", "OBSERVATION", 728, 752]]], ["In addition, septic shock is associated with vascular dysfunction through NF-\u03baB-mediated downregulation of the endothelial mineralocorticoid receptor (MR) and \u03b11-adrenoceptor, which can be restored with mineralocorticoid (fludrocortisone) treatment (174).Cellular Energetics\u2014 Mitochondrial FunctionA transforming event in the history of life was the evolution of photosynthetic bacteria, with biochemical pathways that allowed them to capture energy from sunlight and store it in simple sugars, a process known as photosynthesis that generates oxygen as a waste product.", [["vascular", "ANATOMY", 45, 53], ["endothelial", "ANATOMY", 111, 122], ["Cellular", "ANATOMY", 255, 263], ["Mitochondrial", "ANATOMY", 276, 289], ["septic shock", "DISEASE", 13, 25], ["vascular dysfunction", "DISEASE", 45, 65], ["fludrocortisone", "CHEMICAL", 222, 237], ["oxygen", "CHEMICAL", 544, 550], ["fludrocortisone", "CHEMICAL", 222, 237], ["sugars", "CHEMICAL", 487, 493], ["oxygen", "CHEMICAL", 544, 550], ["vascular", "MULTI-TISSUE_STRUCTURE", 45, 53], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 74, 79], ["endothelial mineralocorticoid receptor", "GENE_OR_GENE_PRODUCT", 111, 149], ["\u03b11-adrenoceptor", "GENE_OR_GENE_PRODUCT", 159, 174], ["mineralocorticoid", "SIMPLE_CHEMICAL", 203, 220], ["fludrocortisone", "SIMPLE_CHEMICAL", 222, 237], ["Mitochondrial", "CELLULAR_COMPONENT", 276, 289], ["oxygen", "SIMPLE_CHEMICAL", 544, 550], ["NF-\u03baB", "PROTEIN", 74, 79], ["endothelial mineralocorticoid receptor", "PROTEIN", 111, 149], ["MR", "PROTEIN", 151, 153], ["\u03b11", "PROTEIN", 159, 161], ["septic shock", "PROBLEM", 13, 25], ["vascular dysfunction", "PROBLEM", 45, 65], ["NF", "TEST", 74, 76], ["the endothelial mineralocorticoid receptor", "TREATMENT", 107, 149], ["MR", "TEST", 151, 153], ["\u03b11-adrenoceptor", "TREATMENT", 159, 174], ["mineralocorticoid (fludrocortisone) treatment", "TREATMENT", 203, 248], ["Cellular Energetics", "PROBLEM", 255, 274], ["Mitochondrial FunctionA transforming event", "PROBLEM", 276, 318], ["photosynthetic bacteria", "PROBLEM", 363, 386], ["biochemical pathways", "PROBLEM", 393, 413], ["simple sugars", "PROBLEM", 480, 493], ["oxygen", "TREATMENT", 544, 550], ["a waste product", "TREATMENT", 554, 569], ["septic shock", "OBSERVATION", 13, 25], ["associated with", "UNCERTAINTY", 29, 44], ["vascular", "ANATOMY", 45, 53], ["dysfunction", "OBSERVATION", 54, 65], ["endothelial", "ANATOMY", 111, 122], ["Mitochondrial FunctionA", "OBSERVATION", 276, 299], ["photosynthetic bacteria", "OBSERVATION", 363, 386]]], ["As a result, over the course of about one billion years, the earth's atmospheric oxygen increased from almost zero to nearly modern levels (175).", [["oxygen", "CHEMICAL", 81, 87], ["oxygen", "CHEMICAL", 81, 87], ["oxygen", "SIMPLE_CHEMICAL", 81, 87], ["the earth's atmospheric oxygen", "TEST", 57, 87]]], ["The development of an ozone layer in the upper atmosphere to absorb damaging UV radiation from the sun, a derived outcome of increased atmospheric oxygen, permitted organisms to live on land for the first time (175).", [["ozone", "CHEMICAL", 22, 27], ["UV", "CHEMICAL", 77, 79], ["oxygen", "CHEMICAL", 147, 153], ["ozone", "CHEMICAL", 22, 27], ["oxygen", "CHEMICAL", 147, 153], ["oxygen", "SIMPLE_CHEMICAL", 147, 153], ["an ozone layer", "PROBLEM", 19, 33], ["absorb damaging UV radiation", "TREATMENT", 61, 89], ["increased atmospheric oxygen", "TREATMENT", 125, 153], ["ozone", "OBSERVATION_MODIFIER", 22, 27], ["layer", "OBSERVATION_MODIFIER", 28, 33], ["upper", "ANATOMY_MODIFIER", 41, 46], ["absorb", "OBSERVATION_MODIFIER", 61, 67], ["damaging", "OBSERVATION_MODIFIER", 68, 76], ["UV radiation", "OBSERVATION", 77, 89], ["increased", "OBSERVATION_MODIFIER", 125, 134], ["atmospheric oxygen", "OBSERVATION", 135, 153]]], ["Some groups of organisms adapted to increased oxygen levels; the most notable adaptation was the evolution of the biochemical pathways of cellular respiration, which use oxygen to extract the energy stored in organic molecules much more efficiently.Cellular Energetics\u2014 Mitochondrial FunctionAbout 2 billion years ago, complex life surfaced with two major endosymbiotic (eukaryotic cells ingesting a prokaryote bacterium that resulted in a symbiotic relationship between the engulfing and engulfed cells) events igniting the evolutionary progression to animals and plants (176, 177).", [["cellular", "ANATOMY", 138, 146], ["Cellular", "ANATOMY", 249, 257], ["Mitochondrial", "ANATOMY", 270, 283], ["cells", "ANATOMY", 382, 387], ["cells", "ANATOMY", 498, 503], ["oxygen", "CHEMICAL", 46, 52], ["oxygen", "CHEMICAL", 170, 176], ["oxygen", "CHEMICAL", 46, 52], ["oxygen", "CHEMICAL", 170, 176], ["oxygen", "SIMPLE_CHEMICAL", 46, 52], ["cellular", "CELL", 138, 146], ["oxygen", "SIMPLE_CHEMICAL", 170, 176], ["cells", "CELL", 382, 387], ["cells", "CELL", 498, 503], ["eukaryotic cells", "CELL_TYPE", 371, 387], ["engulfing and engulfed cells", "CELL_TYPE", 475, 503], ["Some groups of organisms", "PROBLEM", 0, 24], ["increased oxygen levels", "PROBLEM", 36, 59], ["oxygen", "TREATMENT", 170, 176], ["two major endosymbiotic (eukaryotic cells", "PROBLEM", 346, 387], ["a prokaryote bacterium", "PROBLEM", 398, 420], ["organisms", "OBSERVATION", 15, 24], ["increased", "OBSERVATION_MODIFIER", 36, 45], ["oxygen levels", "OBSERVATION", 46, 59], ["cellular respiration", "OBSERVATION", 138, 158], ["eukaryotic cells", "OBSERVATION", 371, 387], ["engulfed cells", "OBSERVATION", 489, 503], ["progression", "OBSERVATION_MODIFIER", 538, 549]]], ["First, the ancestral eukaryotic cell engulfed an aerobic prokaryote bacterium (i.e., capable of using oxygen to produce energy) that eventually evolved into mitochondria (specialized for cellular respiration) populating the cell cytoplasm (modern heterotrophic eukaryote) to afford a selective advantage for survival (178).", [["cell", "ANATOMY", 32, 36], ["mitochondria", "ANATOMY", 157, 169], ["cellular", "ANATOMY", 187, 195], ["cell cytoplasm", "ANATOMY", 224, 238], ["oxygen", "CHEMICAL", 102, 108], ["oxygen", "CHEMICAL", 102, 108], ["cell", "CELL", 32, 36], ["oxygen", "SIMPLE_CHEMICAL", 102, 108], ["mitochondria", "CELLULAR_COMPONENT", 157, 169], ["cellular", "CELL", 187, 195], ["cell", "CELLULAR_COMPONENT", 224, 228], ["cytoplasm", "ORGANISM_SUBSTANCE", 229, 238], ["an aerobic prokaryote bacterium", "PROBLEM", 46, 77], ["oxygen", "TREATMENT", 102, 108], ["cellular respiration", "TREATMENT", 187, 207], ["the cell cytoplasm", "PROBLEM", 220, 238], ["modern heterotrophic eukaryote", "TREATMENT", 240, 270], ["eukaryotic cell engulfed", "OBSERVATION", 21, 45], ["aerobic prokaryote bacterium", "OBSERVATION", 49, 77], ["cell cytoplasm", "OBSERVATION", 224, 238]]], ["In the second endosymbiotic event, the early eukaryotic cell engulfed a photosynthetic prokaryote bacterium that evolved into the chloroplast (modern photosynthetic eukaryote).Cellular Energetics\u2014 Mitochondrial FunctionCentral to the integrated actions of immune and neuroendocrine responses (3, 17, 179) is cellular energetics, involving the mobilization of energy resources from GC-GR\u03b1-mediated breakdown of glucose (via glycolysis), fatty acids and amino acids for mitochondrial energy production (180).", [["cell", "ANATOMY", 56, 60], ["chloroplast", "ANATOMY", 130, 141], ["Cellular", "ANATOMY", 176, 184], ["Mitochondrial", "ANATOMY", 197, 210], ["neuroendocrine", "ANATOMY", 267, 281], ["cellular", "ANATOMY", 308, 316], ["mitochondrial", "ANATOMY", 468, 481], ["glucose", "CHEMICAL", 410, 417], ["fatty acids", "CHEMICAL", 436, 447], ["amino acids", "CHEMICAL", 452, 463], ["glucose", "CHEMICAL", 410, 417], ["fatty acids", "CHEMICAL", 436, 447], ["amino acids", "CHEMICAL", 452, 463], ["cell", "CELL", 56, 60], ["chloroplast", "CELLULAR_COMPONENT", 130, 141], ["Mitochondrial", "CELLULAR_COMPONENT", 197, 210], ["neuroendocrine", "CELL", 267, 281], ["cellular", "CELL", 308, 316], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 384, 387], ["glucose", "SIMPLE_CHEMICAL", 410, 417], ["fatty acids", "SIMPLE_CHEMICAL", 436, 447], ["amino acids", "AMINO_ACID", 452, 463], ["mitochondrial", "CELLULAR_COMPONENT", 468, 481], ["early eukaryotic cell", "CELL_TYPE", 39, 60], ["GR\u03b1", "PROTEIN", 384, 387], ["a photosynthetic prokaryote bacterium", "PROBLEM", 70, 107], ["modern photosynthetic eukaryote", "TREATMENT", 143, 174], ["cellular energetics", "PROBLEM", 308, 327], ["GC", "TEST", 381, 383], ["glucose (via glycolysis)", "TREATMENT", 410, 434], ["fatty acids", "TEST", 436, 447], ["amino acids", "TEST", 452, 463], ["mitochondrial energy production", "PROBLEM", 468, 499], ["early", "OBSERVATION_MODIFIER", 39, 44], ["eukaryotic cell engulfed", "OBSERVATION", 45, 69], ["photosynthetic prokaryote bacterium", "OBSERVATION", 72, 107]]], ["In fact, GCs were originally named by Hans Selye based on their ability to increase blood glucose concentration.", [["blood", "ANATOMY", 84, 89], ["glucose", "CHEMICAL", 90, 97], ["glucose", "CHEMICAL", 90, 97], ["GCs", "CELL", 9, 12], ["blood", "ORGANISM_SUBSTANCE", 84, 89], ["glucose", "SIMPLE_CHEMICAL", 90, 97], ["GCs", "TEST", 9, 12], ["blood glucose concentration", "TEST", 84, 111]]], ["Activation of the HPA axis mobilizes these energetic substrates into the circulation within minutes, underscoring the widespread role of GC-GR\u03b1 in the regulation of systemic metabolism (181).Cellular Energetics\u2014 Mitochondrial FunctionMammalian cells, apart from erythrocytes, contain within their cytoplasm hundreds to thousands of mitochondria, the number determined by the energy demand of each cell type.", [["Cellular", "ANATOMY", 191, 199], ["Mitochondrial FunctionMammalian cells", "ANATOMY", 212, 249], ["erythrocytes", "ANATOMY", 262, 274], ["cytoplasm", "ANATOMY", 297, 306], ["mitochondria", "ANATOMY", 332, 344], ["cell", "ANATOMY", 397, 401], ["HPA", "GENE_OR_GENE_PRODUCT", 18, 21], ["GC-GR\u03b1", "GENE_OR_GENE_PRODUCT", 137, 143], ["Mitochondrial FunctionMammalian cells", "CELL", 212, 249], ["erythrocytes", "CELL", 262, 274], ["cytoplasm", "ORGANISM_SUBSTANCE", 297, 306], ["mitochondria", "CELLULAR_COMPONENT", 332, 344], ["cell type", "CELL", 397, 406], ["GR\u03b1", "PROTEIN", 140, 143], ["Mitochondrial FunctionMammalian cells", "CELL_TYPE", 212, 249], ["erythrocytes", "CELL_TYPE", 262, 274], ["Cellular Energetics", "TEST", 191, 210], ["Mitochondrial FunctionMammalian cells", "PROBLEM", 212, 249], ["erythrocytes", "PROBLEM", 262, 274], ["widespread", "OBSERVATION_MODIFIER", 118, 128], ["systemic metabolism", "ANATOMY", 165, 184], ["Mitochondrial FunctionMammalian cells", "OBSERVATION", 212, 249], ["each cell type", "OBSERVATION", 392, 406]]], ["Mitochondria are autonomous and highly dynamic double-membrane organelles that function as the powerhouses of the cell and utilize ~98% of total body oxygen consumption.", [["Mitochondria", "ANATOMY", 0, 12], ["double-membrane organelles", "ANATOMY", 47, 73], ["cell", "ANATOMY", 114, 118], ["body", "ANATOMY", 145, 149], ["oxygen", "CHEMICAL", 150, 156], ["oxygen", "CHEMICAL", 150, 156], ["Mitochondria", "CELLULAR_COMPONENT", 0, 12], ["membrane organelles", "CELLULAR_COMPONENT", 54, 73], ["cell", "CELL", 114, 118], ["body", "ORGANISM_SUBDIVISION", 145, 149], ["oxygen", "SIMPLE_CHEMICAL", 150, 156], ["Mitochondria", "CELL_TYPE", 0, 12], ["total body oxygen consumption", "TREATMENT", 139, 168], ["autonomous", "OBSERVATION", 17, 27], ["oxygen consumption", "OBSERVATION", 150, 168]]], ["Oxidative phosphorylation (OXPHOS) is the metabolic pathway in the inner membrane of the mitochondria which use enzymes to oxidize ingested calories to produce adenosine triphosphate (ATP) required for normal cell functioning.", [["inner membrane", "ANATOMY", 67, 81], ["mitochondria", "ANATOMY", 89, 101], ["cell", "ANATOMY", 209, 213], ["adenosine triphosphate", "CHEMICAL", 160, 182], ["ATP", "CHEMICAL", 184, 187], ["adenosine triphosphate", "CHEMICAL", 160, 182], ["ATP", "CHEMICAL", 184, 187], ["OXPHOS", "GENE_OR_GENE_PRODUCT", 27, 33], ["inner membrane", "CELLULAR_COMPONENT", 67, 81], ["mitochondria", "CELLULAR_COMPONENT", 89, 101], ["calories", "SIMPLE_CHEMICAL", 140, 148], ["adenosine triphosphate", "SIMPLE_CHEMICAL", 160, 182], ["ATP", "SIMPLE_CHEMICAL", 184, 187], ["cell", "CELL", 209, 213], ["OXPHOS", "PROTEIN", 27, 33], ["Oxidative phosphorylation (OXPHOS)", "TREATMENT", 0, 34], ["enzymes to oxidize ingested calories", "TREATMENT", 112, 148], ["adenosine triphosphate (ATP", "TREATMENT", 160, 187], ["cell functioning", "OBSERVATION", 209, 225]]], ["Ultimately, this conversion provides energy for most cellular processes within the body intracellular reactions (gene transcription and translation, epigenetic modifications), hormonal changes in the endocrine system, structural changes in tissue, and behavioral and cognitive responses] (181), and in theory, determines the limits of an organism adaptive capacity (21).Cellular Energetics\u2014 Mitochondrial FunctionBy virtue of their origins as aerobic bacteria, mitochondria have their DNA, RNA, and protein synthesis systems.", [["cellular", "ANATOMY", 53, 61], ["body intracellular", "ANATOMY", 83, 101], ["endocrine system", "ANATOMY", 200, 216], ["tissue", "ANATOMY", 240, 246], ["Cellular", "ANATOMY", 370, 378], ["Mitochondrial", "ANATOMY", 391, 404], ["mitochondria", "ANATOMY", 461, 473], ["cellular", "CELL", 53, 61], ["body", "CELLULAR_COMPONENT", 83, 87], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 88, 101], ["tissue", "TISSUE", 240, 246], ["Mitochondrial", "CELLULAR_COMPONENT", 391, 404], ["mitochondria", "CELLULAR_COMPONENT", 461, 473], ["DNA", "CELLULAR_COMPONENT", 485, 488], ["most cellular processes", "PROBLEM", 48, 71], ["the body intracellular reactions", "PROBLEM", 79, 111], ["gene transcription", "TREATMENT", 113, 131], ["epigenetic modifications", "TREATMENT", 149, 173], ["hormonal changes in the endocrine system", "PROBLEM", 176, 216], ["structural changes in tissue", "PROBLEM", 218, 246], ["Cellular Energetics", "TEST", 370, 389], ["aerobic bacteria", "PROBLEM", 443, 459], ["their DNA", "TEST", 479, 488], ["RNA", "TEST", 490, 493], ["Mitochondrial FunctionBy", "OBSERVATION", 391, 415]]], ["The mitochondrial DNA (mtDNA) in our proto-eukaryotic ancestors was significantly larger in genetic complement, but transfer of mtDNA encoded genes to the nucleus has occurred over the 1.5\u20132 billion years since the origin of the eukaryotic cell, and today the mammalian mtDNA (inherited from the mother) encodes 13 polypeptides, two rRNAs (12S and 16S) and 22 tRNAs that are essential for OXPHOS and proper cell function (178).", [["mitochondrial", "ANATOMY", 4, 17], ["nucleus", "ANATOMY", 155, 162], ["cell", "ANATOMY", 240, 244], ["cell", "ANATOMY", 407, 411], ["mitochondrial DNA", "CELLULAR_COMPONENT", 4, 21], ["mtDNA", "CELLULAR_COMPONENT", 23, 28], ["mtDNA", "CELLULAR_COMPONENT", 128, 133], ["nucleus", "CELLULAR_COMPONENT", 155, 162], ["cell", "CELL", 240, 244], ["mtDNA", "CELLULAR_COMPONENT", 270, 275], ["12S", "CELLULAR_COMPONENT", 340, 343], ["OXPHOS", "GENE_OR_GENE_PRODUCT", 389, 395], ["cell", "CELL", 407, 411], ["mitochondrial DNA", "DNA", 4, 21], ["mtDNA encoded genes", "DNA", 128, 147], ["eukaryotic cell", "CELL_TYPE", 229, 244], ["mammalian mtDNA", "DNA", 260, 275], ["13 polypeptides", "RNA", 312, 327], ["rRNAs", "RNA", 333, 338], ["12S", "DNA", 340, 343], ["16S", "DNA", 348, 351], ["OXPHOS", "PROTEIN", 389, 395], ["The mitochondrial DNA (mtDNA", "PROBLEM", 0, 28], ["two rRNAs", "TEST", 329, 338], ["22 tRNAs", "TREATMENT", 357, 365], ["OXPHOS", "TEST", 389, 395], ["proper cell function", "TEST", 400, 420], ["mitochondrial DNA", "OBSERVATION", 4, 21], ["significantly", "OBSERVATION_MODIFIER", 68, 81], ["larger", "OBSERVATION_MODIFIER", 82, 88], ["nucleus", "ANATOMY", 155, 162], ["eukaryotic cell", "OBSERVATION", 229, 244], ["proper cell function", "OBSERVATION", 400, 420]]], ["Since the mtDNA encodes for only a handful of proteins, mitochondria depend on the cell nucleus and other cellular compartments for most of their proteins and lipids (182).", [["mitochondria", "ANATOMY", 56, 68], ["cell nucleus", "ANATOMY", 83, 95], ["cellular compartments", "ANATOMY", 106, 127], ["mtDNA", "CELLULAR_COMPONENT", 10, 15], ["mitochondria", "CELLULAR_COMPONENT", 56, 68], ["cell nucleus", "CELLULAR_COMPONENT", 83, 95], ["cellular compartments", "CELLULAR_COMPONENT", 106, 127], ["lipids", "SIMPLE_CHEMICAL", 159, 165], ["mtDNA", "DNA", 10, 15], ["lipids", "TEST", 159, 165], ["cell nucleus", "OBSERVATION", 83, 95]]], ["In addition to being the major source of intracellular ATP, mitochondria are deeply involved in signaling pathways, elicited by perturbations in homeostasis, which promote cell adaptation (183, 184).Cellular Energetics\u2014 Mitochondrial FunctionMitochondria constantly generate reactive oxygen species (ROS) as a by-product of substrate oxidation and oxidative phosphorylation, a physiological process that is normally kept in check by a diversified set of antioxidant defenses (184).", [["intracellular", "ANATOMY", 41, 54], ["mitochondria", "ANATOMY", 60, 72], ["cell", "ANATOMY", 172, 176], ["Cellular", "ANATOMY", 199, 207], ["Mitochondrial", "ANATOMY", 220, 233], ["ATP", "CHEMICAL", 55, 58], ["oxygen", "CHEMICAL", 284, 290], ["ROS", "CHEMICAL", 300, 303], ["ATP", "CHEMICAL", 55, 58], ["oxygen", "CHEMICAL", 284, 290], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 41, 54], ["ATP", "SIMPLE_CHEMICAL", 55, 58], ["mitochondria", "CELLULAR_COMPONENT", 60, 72], ["cell", "CELL", 172, 176], ["Mitochondrial", "CELLULAR_COMPONENT", 220, 233], ["reactive oxygen species", "SIMPLE_CHEMICAL", 275, 298], ["ROS", "SIMPLE_CHEMICAL", 300, 303], ["intracellular ATP", "PROBLEM", 41, 58], ["perturbations in homeostasis", "PROBLEM", 128, 156], ["Cellular Energetics", "TEST", 199, 218], ["Mitochondrial FunctionMitochondria", "TEST", 220, 254], ["reactive oxygen species", "PROBLEM", 275, 298], ["substrate oxidation", "TREATMENT", 324, 343], ["oxidative phosphorylation", "PROBLEM", 348, 373], ["a physiological process", "PROBLEM", 375, 398], ["intracellular ATP", "OBSERVATION", 41, 58], ["Mitochondrial FunctionMitochondria", "OBSERVATION", 220, 254], ["reactive", "OBSERVATION_MODIFIER", 275, 283], ["oxygen species", "OBSERVATION", 284, 298], ["oxidative phosphorylation", "OBSERVATION", 348, 373]]], ["The introduction of oxygen to earth's early biosphere stimulated remarkable evolutionary adaptations, and in this context, ROS should be viewed as an essential consequence and driver of evolution and survival over time (185).", [["oxygen", "CHEMICAL", 20, 26], ["ROS", "CHEMICAL", 123, 126], ["oxygen", "CHEMICAL", 20, 26], ["oxygen", "SIMPLE_CHEMICAL", 20, 26], ["ROS", "SIMPLE_CHEMICAL", 123, 126], ["oxygen", "TREATMENT", 20, 26]]], ["Reactive oxygen species are required in numerous physiological cell functions, such as cellular signaling systems linked to the transcriptional machinery, maintenance of vascular tone, oxygen sensing, and host defense against pathogens (186).", [["cell", "ANATOMY", 63, 67], ["cellular", "ANATOMY", 87, 95], ["vascular", "ANATOMY", 170, 178], ["oxygen", "CHEMICAL", 9, 15], ["oxygen", "CHEMICAL", 185, 191], ["oxygen", "CHEMICAL", 9, 15], ["oxygen", "CHEMICAL", 185, 191], ["Reactive oxygen species", "SIMPLE_CHEMICAL", 0, 23], ["cell", "CELL", 63, 67], ["cellular", "CELL", 87, 95], ["vascular", "MULTI-TISSUE_STRUCTURE", 170, 178], ["oxygen", "SIMPLE_CHEMICAL", 185, 191], ["Reactive oxygen species", "PROBLEM", 0, 23], ["oxygen sensing", "TREATMENT", 185, 199], ["pathogens", "PROBLEM", 226, 235], ["oxygen species", "OBSERVATION", 9, 23], ["physiological cell functions", "OBSERVATION", 49, 77], ["vascular tone", "ANATOMY", 170, 183]]], ["One of the mitochondrial oxidases, the NADPH oxidase of polymorphonuclear leukocytes (primarily neutrophils), is pivotal to the body's defense against pathogenic microorganisms (187).Cellular Energetics\u2014 Mitochondrial FunctionMitochondria are involved in a multitude of cellular processes, well-beyond their long-established role as the cell's powerhouse.", [["mitochondrial", "ANATOMY", 11, 24], ["polymorphonuclear leukocytes", "ANATOMY", 56, 84], ["neutrophils", "ANATOMY", 96, 107], ["body", "ANATOMY", 128, 132], ["Cellular", "ANATOMY", 183, 191], ["Mitochondrial", "ANATOMY", 204, 217], ["cellular", "ANATOMY", 270, 278], ["cell", "ANATOMY", 337, 341], ["NADPH", "CHEMICAL", 39, 44], ["NADPH", "CHEMICAL", 39, 44], ["mitochondrial", "CELLULAR_COMPONENT", 11, 24], ["NADPH oxidase", "GENE_OR_GENE_PRODUCT", 39, 52], ["polymorphonuclear leukocytes", "CELL", 56, 84], ["neutrophils", "CELL", 96, 107], ["body", "ORGANISM_SUBDIVISION", 128, 132], ["Mitochondrial", "CELLULAR_COMPONENT", 204, 217], ["cellular", "CELL", 270, 278], ["cell", "CELL", 337, 341], ["mitochondrial oxidases", "PROTEIN", 11, 33], ["NADPH oxidase", "PROTEIN", 39, 52], ["polymorphonuclear leukocytes", "CELL_TYPE", 56, 84], ["neutrophils", "CELL_TYPE", 96, 107], ["the mitochondrial oxidases", "TEST", 7, 33], ["the NADPH oxidase", "TEST", 35, 52], ["polymorphonuclear leukocytes", "PROBLEM", 56, 84], ["neutrophils", "TEST", 96, 107], ["pathogenic microorganisms", "PROBLEM", 151, 176], ["mitochondrial oxidases", "OBSERVATION", 11, 33], ["NADPH oxidase", "OBSERVATION", 39, 52], ["polymorphonuclear leukocytes", "OBSERVATION", 56, 84], ["Mitochondrial FunctionMitochondria", "OBSERVATION", 204, 238]]], ["These include processes such as intracellular calcium homeostasis (buffering of cytosolic calcium), regulation of mitochondrial metabolism, cell migration, production of biomolecules such as amino acids, lipids, hemes, purines, and steroid hormones (see section Mitochondria and HPA-Axis Cross-Talk), and activation of cell death pathways (188).", [["intracellular", "ANATOMY", 32, 45], ["cytosolic", "ANATOMY", 80, 89], ["mitochondrial", "ANATOMY", 114, 127], ["cell", "ANATOMY", 140, 144], ["Mitochondria", "ANATOMY", 262, 274], ["cell", "ANATOMY", 319, 323], ["calcium", "CHEMICAL", 46, 53], ["calcium", "CHEMICAL", 90, 97], ["amino acids", "CHEMICAL", 191, 202], ["purines", "CHEMICAL", 219, 226], ["steroid", "CHEMICAL", 232, 239], ["calcium", "CHEMICAL", 46, 53], ["calcium", "CHEMICAL", 90, 97], ["amino acids", "CHEMICAL", 191, 202], ["hemes", "CHEMICAL", 212, 217], ["purines", "CHEMICAL", 219, 226], ["steroid", "CHEMICAL", 232, 239], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 32, 45], ["calcium", "SIMPLE_CHEMICAL", 46, 53], ["calcium", "SIMPLE_CHEMICAL", 90, 97], ["mitochondrial", "CELLULAR_COMPONENT", 114, 127], ["cell", "CELL", 140, 144], ["amino acids", "AMINO_ACID", 191, 202], ["lipids", "SIMPLE_CHEMICAL", 204, 210], ["hemes", "SIMPLE_CHEMICAL", 212, 217], ["purines", "SIMPLE_CHEMICAL", 219, 226], ["steroid", "SIMPLE_CHEMICAL", 232, 239], ["Mitochondria", "CELLULAR_COMPONENT", 262, 274], ["HPA-Axis", "GENE_OR_GENE_PRODUCT", 279, 287], ["cell", "CELL", 319, 323], ["intracellular calcium homeostasis", "PROBLEM", 32, 65], ["cytosolic calcium", "TEST", 80, 97], ["mitochondrial metabolism", "PROBLEM", 114, 138], ["cell migration", "PROBLEM", 140, 154], ["production of biomolecules", "PROBLEM", 156, 182], ["amino acids", "TEST", 191, 202], ["lipids", "TEST", 204, 210], ["purines", "TEST", 219, 226], ["steroid hormones", "PROBLEM", 232, 248], ["HPA", "TEST", 279, 282], ["mitochondrial metabolism", "OBSERVATION", 114, 138], ["cell migration", "OBSERVATION", 140, 154]]], ["Mitochondria trigger cell death pathways by two mechanisms, first via necrosis when ATP levels fall below a certain threshold, and second via apoptosis through the release of mitochondrial cytochrome c into the cytoplasm (189).", [["Mitochondria", "ANATOMY", 0, 12], ["cell", "ANATOMY", 21, 25], ["mitochondrial", "ANATOMY", 175, 188], ["cytoplasm", "ANATOMY", 211, 220], ["death", "DISEASE", 26, 31], ["necrosis", "DISEASE", 70, 78], ["ATP", "CHEMICAL", 84, 87], ["ATP", "CHEMICAL", 84, 87], ["Mitochondria", "CELL", 0, 12], ["cell", "CELL", 21, 25], ["ATP", "SIMPLE_CHEMICAL", 84, 87], ["mitochondrial", "CELLULAR_COMPONENT", 175, 188], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 189, 201], ["cytoplasm", "ORGANISM_SUBSTANCE", 211, 220], ["mitochondrial cytochrome c", "PROTEIN", 175, 201], ["Mitochondria trigger cell death pathways", "PROBLEM", 0, 40], ["necrosis", "PROBLEM", 70, 78], ["ATP levels", "TEST", 84, 94], ["mitochondrial cytochrome", "TREATMENT", 175, 199], ["cell death", "OBSERVATION", 21, 31], ["necrosis", "OBSERVATION", 70, 78], ["mitochondrial cytochrome", "OBSERVATION", 175, 199]]], ["Mitochondrial integrity is, therefore, essential for the function and survival of cells, and several recent publications have highlighted the critical role played by these organelles in sustaining homeostatic corrections (82, 180\u2013182, 190\u2013192).Mitochondrial Cacostatic Load, Oxidative Stress, and Mitochondrial DamageIn critical illness, tissue oxygen consumption and total energy expenditure are increased, with intracellular metabolism boosted by up to 200% compared to the healthy state (193).", [["Mitochondrial", "ANATOMY", 0, 13], ["cells", "ANATOMY", 82, 87], ["organelles", "ANATOMY", 172, 182], ["Mitochondrial", "ANATOMY", 244, 257], ["Mitochondrial", "ANATOMY", 297, 310], ["tissue", "ANATOMY", 338, 344], ["intracellular", "ANATOMY", 413, 426], ["oxygen", "CHEMICAL", 345, 351], ["oxygen", "CHEMICAL", 345, 351], ["Mitochondrial", "CELLULAR_COMPONENT", 0, 13], ["cells", "CELL", 82, 87], ["organelles", "CELLULAR_COMPONENT", 172, 182], ["Mitochondrial", "CELLULAR_COMPONENT", 244, 257], ["Mitochondrial", "CELLULAR_COMPONENT", 297, 310], ["tissue", "TISSUE", 338, 344], ["oxygen", "SIMPLE_CHEMICAL", 345, 351], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 413, 426], ["survival of cells", "PROBLEM", 70, 87], ["Mitochondrial Cacostatic Load", "PROBLEM", 244, 273], ["Oxidative Stress", "PROBLEM", 275, 291], ["Mitochondrial DamageIn critical illness", "PROBLEM", 297, 336], ["tissue oxygen consumption", "TREATMENT", 338, 363], ["total energy expenditure", "PROBLEM", 368, 392], ["intracellular metabolism", "PROBLEM", 413, 437], ["integrity", "OBSERVATION", 14, 23], ["Cacostatic Load", "OBSERVATION", 258, 273], ["Oxidative Stress", "OBSERVATION", 275, 291], ["oxygen consumption", "OBSERVATION", 345, 363], ["increased", "OBSERVATION_MODIFIER", 397, 406]]], ["Cells that represent the innate immune system, like neutrophils, and macrophages, are mainly responsible for the oxidative burst that takes place early in critical illness (194) along with the generation of ROS and nitrogen oxygen species (RNS) that are important for host defenses.", [["Cells", "ANATOMY", 0, 5], ["immune system", "ANATOMY", 32, 45], ["neutrophils", "ANATOMY", 52, 63], ["macrophages", "ANATOMY", 69, 80], ["ROS", "CHEMICAL", 207, 210], ["nitrogen oxygen", "CHEMICAL", 215, 230], ["nitrogen", "CHEMICAL", 215, 223], ["oxygen", "CHEMICAL", 224, 230], ["Cells", "CELL", 0, 5], ["neutrophils", "CELL", 52, 63], ["macrophages", "CELL", 69, 80], ["ROS", "SIMPLE_CHEMICAL", 207, 210], ["nitrogen oxygen species", "SIMPLE_CHEMICAL", 215, 238], ["RNS", "SIMPLE_CHEMICAL", 240, 243], ["neutrophils", "CELL_TYPE", 52, 63], ["macrophages", "CELL_TYPE", 69, 80], ["neutrophils", "TEST", 52, 63], ["macrophages", "PROBLEM", 69, 80], ["the oxidative burst", "PROBLEM", 109, 128], ["nitrogen oxygen species", "TREATMENT", 215, 238], ["neutrophils", "OBSERVATION", 52, 63], ["macrophages", "OBSERVATION", 69, 80], ["oxidative burst", "OBSERVATION", 113, 128]]], ["In neutrophils of critically ill patients, oxidative activity correlates positively with the degree of intranuclear NF-\u03baB expression (195).", [["neutrophils", "ANATOMY", 3, 14], ["critically ill", "DISEASE", 18, 32], ["neutrophils", "CELL", 3, 14], ["patients", "ORGANISM", 33, 41], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 116, 121], ["neutrophils", "CELL_TYPE", 3, 14], ["intranuclear NF-\u03baB", "PROTEIN", 103, 121], ["patients", "SPECIES", 33, 41], ["oxidative activity", "TEST", 43, 61], ["intranuclear NF", "PROBLEM", 103, 118], ["critically ill", "OBSERVATION_MODIFIER", 18, 32], ["intranuclear NF", "OBSERVATION", 103, 118]]], ["According to the \u201cmitohormesis theory,\u201d when present in moderate amounts, ROS and RNS function as intracellular signaling molecules that may improve systemic defense mechanisms by inducing an adaptive response (196).", [["intracellular", "ANATOMY", 98, 111], ["ROS", "CHEMICAL", 74, 77], ["ROS", "SIMPLE_CHEMICAL", 74, 77], ["RNS", "SIMPLE_CHEMICAL", 82, 85], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 98, 111], ["intracellular signaling molecules", "PROTEIN", 98, 131], ["intracellular signaling molecules", "PROBLEM", 98, 131], ["systemic defense mechanisms", "PROBLEM", 149, 176]]], ["However, when intracellular ROS and RNS concentrations overwhelm antioxidant defenses, cell homeostasis becomes compromised (196).", [["intracellular", "ANATOMY", 14, 27], ["cell", "ANATOMY", 87, 91], ["ROS", "CHEMICAL", 28, 31], ["RNS", "CHEMICAL", 36, 39], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 14, 27], ["ROS", "SIMPLE_CHEMICAL", 28, 31], ["RNS", "SIMPLE_CHEMICAL", 36, 39], ["cell", "CELL", 87, 91], ["intracellular ROS", "TEST", 14, 31], ["antioxidant defenses", "PROBLEM", 65, 85], ["cell homeostasis", "PROBLEM", 87, 103]]], ["For example, peroxidation of the mitochondrial lipid cardiolipin in the inner mitochondrial membrane leads to dissociation of cytochrome c, reduced production of ATP, and increased generation of ROS (197).Mitochondrial Cacostatic Load, Oxidative Stress, and Mitochondrial DamageIncreased energy and metabolic demands associated with NF-\u03baB-driven dysregulated systemic inflammation, leads to overproduction of ROS and RNS, resulting in significant damage of lipids, proteins, and nucleic acids, both within the mitochondria and in other compartments of the cell [Figure 5; (197)].", [["mitochondrial", "ANATOMY", 33, 46], ["inner mitochondrial membrane", "ANATOMY", 72, 100], ["Mitochondrial", "ANATOMY", 205, 218], ["Mitochondrial", "ANATOMY", 258, 271], ["mitochondria", "ANATOMY", 510, 522], ["compartments", "ANATOMY", 536, 548], ["cell", "ANATOMY", 556, 560], ["cardiolipin", "CHEMICAL", 53, 64], ["ATP", "CHEMICAL", 162, 165], ["ROS", "CHEMICAL", 195, 198], ["inflammation", "DISEASE", 368, 380], ["ROS", "CHEMICAL", 409, 412], ["nucleic acids", "CHEMICAL", 479, 492], ["cardiolipin", "CHEMICAL", 53, 64], ["ATP", "CHEMICAL", 162, 165], ["mitochondrial", "CELLULAR_COMPONENT", 33, 46], ["cardiolipin", "SIMPLE_CHEMICAL", 53, 64], ["inner mitochondrial membrane", "CELLULAR_COMPONENT", 72, 100], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 126, 138], ["ATP", "SIMPLE_CHEMICAL", 162, 165], ["ROS", "SIMPLE_CHEMICAL", 195, 198], ["Mitochondrial", "CELLULAR_COMPONENT", 205, 218], ["Mitochondrial", "CELLULAR_COMPONENT", 258, 271], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 333, 338], ["ROS", "SIMPLE_CHEMICAL", 409, 412], ["RNS", "SIMPLE_CHEMICAL", 417, 420], ["lipids", "SIMPLE_CHEMICAL", 457, 463], ["nucleic acids", "SIMPLE_CHEMICAL", 479, 492], ["mitochondria", "CELLULAR_COMPONENT", 510, 522], ["cell", "CELL", 556, 560], ["cytochrome c", "PROTEIN", 126, 138], ["NF-\u03baB", "PROTEIN", 333, 338], ["the mitochondrial lipid cardiolipin", "TEST", 29, 64], ["cytochrome c", "PROBLEM", 126, 138], ["reduced production of ATP", "PROBLEM", 140, 165], ["increased generation of ROS", "PROBLEM", 171, 198], ["Mitochondrial Cacostatic Load", "PROBLEM", 205, 234], ["Oxidative Stress", "PROBLEM", 236, 252], ["Mitochondrial DamageIncreased energy", "PROBLEM", 258, 294], ["metabolic demands", "PROBLEM", 299, 316], ["NF", "TEST", 333, 335], ["dysregulated systemic inflammation", "PROBLEM", 346, 380], ["overproduction of ROS", "PROBLEM", 391, 412], ["significant damage of lipids", "PROBLEM", 435, 463], ["nucleic acids", "PROBLEM", 479, 492], ["peroxidation", "OBSERVATION_MODIFIER", 13, 25], ["mitochondrial", "OBSERVATION", 33, 46], ["lipid cardiolipin", "OBSERVATION", 47, 64], ["inner", "ANATOMY_MODIFIER", 72, 77], ["mitochondrial membrane", "OBSERVATION", 78, 100], ["reduced", "OBSERVATION_MODIFIER", 140, 147], ["production", "OBSERVATION_MODIFIER", 148, 158], ["increased", "OBSERVATION_MODIFIER", 171, 180], ["Cacostatic Load", "OBSERVATION", 219, 234], ["Oxidative Stress", "OBSERVATION", 236, 252], ["metabolic demands", "OBSERVATION", 299, 316], ["systemic", "OBSERVATION_MODIFIER", 359, 367], ["inflammation", "OBSERVATION", 368, 380], ["significant", "OBSERVATION_MODIFIER", 435, 446], ["damage", "OBSERVATION", 447, 453], ["nucleic acids", "OBSERVATION", 479, 492], ["cell", "ANATOMY", 556, 560]]], ["Oxidative stress is a predictor of mortality in septic shock patients (198).", [["septic shock", "DISEASE", 48, 60], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["Oxidative stress", "PROBLEM", 0, 16], ["septic shock", "PROBLEM", 48, 60], ["septic shock", "OBSERVATION", 48, 60]]], ["Glutathione is one of the most important redox buffers of the cells, as it can be found in all cell compartments and acts as a cofactor of several enzymes, helps in DNA repair, scavenges ROS (e.g., hydroxyl radicals, hydrogen peroxide, and lipid peroxides), and generates other antioxidants, such as ascorbic acid (see section Hypovitaminoses) and tocopherols (194).", [["cells", "ANATOMY", 62, 67], ["cell compartments", "ANATOMY", 95, 112], ["Glutathione", "CHEMICAL", 0, 11], ["ROS", "CHEMICAL", 187, 190], ["hydroxyl", "CHEMICAL", 198, 206], ["hydrogen peroxide", "CHEMICAL", 217, 234], ["ascorbic acid", "CHEMICAL", 300, 313], ["tocopherols", "CHEMICAL", 348, 359], ["Glutathione", "CHEMICAL", 0, 11], ["hydroxyl", "CHEMICAL", 198, 206], ["hydrogen peroxide", "CHEMICAL", 217, 234], ["peroxides", "CHEMICAL", 246, 255], ["ascorbic acid", "CHEMICAL", 300, 313], ["Hypovitaminoses", "CHEMICAL", 327, 342], ["tocopherols", "CHEMICAL", 348, 359], ["Glutathione", "SIMPLE_CHEMICAL", 0, 11], ["cells", "CELL", 62, 67], ["cell", "CELL", 95, 99], ["DNA", "CELLULAR_COMPONENT", 165, 168], ["ROS", "SIMPLE_CHEMICAL", 187, 190], ["hydroxyl radicals", "SIMPLE_CHEMICAL", 198, 215], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 217, 234], ["lipid peroxides", "SIMPLE_CHEMICAL", 240, 255], ["ascorbic acid", "SIMPLE_CHEMICAL", 300, 313], ["Hypovitaminoses", "SIMPLE_CHEMICAL", 327, 342], ["tocopherols", "SIMPLE_CHEMICAL", 348, 359], ["enzymes", "PROTEIN", 147, 154], ["Glutathione", "TREATMENT", 0, 11], ["several enzymes", "TEST", 139, 154], ["DNA repair", "TREATMENT", 165, 175], ["scavenges ROS", "TREATMENT", 177, 190], ["hydroxyl radicals", "TREATMENT", 198, 215], ["hydrogen peroxide", "TREATMENT", 217, 234], ["lipid peroxides", "TREATMENT", 240, 255], ["other antioxidants", "TREATMENT", 272, 290], ["ascorbic acid", "TREATMENT", 300, 313], ["tocopherols", "TREATMENT", 348, 359], ["one of the most", "OBSERVATION_MODIFIER", 15, 30], ["DNA repair", "OBSERVATION", 165, 175]]], ["Vitamins D and C upregulate glutathione synthesis and prevent depletion (see section Hypovitaminoses) (199, 200).Mitochondrial Cacostatic Load, Oxidative Stress, and Mitochondrial DamageThe multi-level organization of mitochondrial molecular composition, structures, functions, and signaling roles within the cell was recently reviewed (201).", [["Mitochondrial", "ANATOMY", 113, 126], ["Mitochondrial", "ANATOMY", 166, 179], ["mitochondrial", "ANATOMY", 218, 231], ["cell", "ANATOMY", 309, 313], ["Vitamins D", "CHEMICAL", 0, 10], ["glutathione", "CHEMICAL", 28, 39], ["Vitamins D and C", "CHEMICAL", 0, 16], ["glutathione", "CHEMICAL", 28, 39], ["Vitamins D", "SIMPLE_CHEMICAL", 0, 10], ["C", "SIMPLE_CHEMICAL", 15, 16], ["glutathione", "SIMPLE_CHEMICAL", 28, 39], ["Mitochondrial", "CELLULAR_COMPONENT", 113, 126], ["Mitochondrial", "CELLULAR_COMPONENT", 166, 179], ["mitochondrial", "CELLULAR_COMPONENT", 218, 231], ["cell", "CELL", 309, 313], ["Vitamins D", "TREATMENT", 0, 10], ["C upregulate glutathione synthesis", "TREATMENT", 15, 49], ["depletion", "PROBLEM", 62, 71], ["Mitochondrial Cacostatic Load", "PROBLEM", 113, 142], ["Oxidative Stress", "PROBLEM", 144, 160], ["Mitochondrial Damage", "PROBLEM", 166, 186], ["mitochondrial molecular composition", "PROBLEM", 218, 253], ["Cacostatic Load", "OBSERVATION", 127, 142], ["Oxidative Stress", "OBSERVATION", 144, 160], ["Mitochondrial Damage", "OBSERVATION", 166, 186], ["mitochondrial molecular composition", "OBSERVATION", 218, 253]]], ["In laboratory models of sepsis, mitochondrial respiration is often increased in the early phase of illness, but consistently falls with protracted inflammation [reviewed in (202)].", [["mitochondrial", "ANATOMY", 32, 45], ["sepsis", "DISEASE", 24, 30], ["illness", "DISEASE", 99, 106], ["inflammation", "DISEASE", 147, 159], ["mitochondrial", "CELLULAR_COMPONENT", 32, 45], ["sepsis", "PROBLEM", 24, 30], ["mitochondrial respiration", "PROBLEM", 32, 57], ["illness", "PROBLEM", 99, 106], ["protracted inflammation", "PROBLEM", 136, 159], ["sepsis", "OBSERVATION", 24, 30], ["mitochondrial respiration", "OBSERVATION", 32, 57], ["increased", "OBSERVATION_MODIFIER", 67, 76], ["early phase", "OBSERVATION_MODIFIER", 84, 95]]], ["Many clinical studies implicate mitochondrial dysfunction and bioenergetic failure as an important pathophysiological mechanism underlying dysregulated systemic inflammation-associated multiorgan dysfunction.", [["mitochondrial", "ANATOMY", 32, 45], ["multiorgan", "ANATOMY", 185, 195], ["mitochondrial dysfunction", "DISEASE", 32, 57], ["inflammation", "DISEASE", 161, 173], ["multiorgan dysfunction", "DISEASE", 185, 207], ["mitochondrial", "CELLULAR_COMPONENT", 32, 45], ["multiorgan", "ORGAN", 185, 195], ["Many clinical studies", "TEST", 0, 21], ["mitochondrial dysfunction", "PROBLEM", 32, 57], ["bioenergetic failure", "PROBLEM", 62, 82], ["dysregulated systemic inflammation", "PROBLEM", 139, 173], ["multiorgan dysfunction", "PROBLEM", 185, 207], ["mitochondrial dysfunction", "OBSERVATION", 32, 57], ["bioenergetic failure", "OBSERVATION", 62, 82], ["dysregulated", "OBSERVATION_MODIFIER", 139, 151], ["systemic", "OBSERVATION_MODIFIER", 152, 160], ["inflammation", "OBSERVATION", 161, 173], ["multiorgan dysfunction", "OBSERVATION", 185, 207]]], ["In a study of skeletal muscle biopsies obtained in septic patients, an association was first reported between nitric oxide overproduction, antioxidant depletion, mitochondrial dysfunction, and decreased ATP concentrations, with progression of multiorgan failure and mortality (203).", [["skeletal muscle biopsies", "ANATOMY", 14, 38], ["mitochondrial", "ANATOMY", 162, 175], ["multiorgan", "ANATOMY", 243, 253], ["septic", "DISEASE", 51, 57], ["nitric oxide", "CHEMICAL", 110, 122], ["mitochondrial dysfunction", "DISEASE", 162, 187], ["ATP", "CHEMICAL", 203, 206], ["multiorgan failure", "DISEASE", 243, 261], ["nitric oxide", "CHEMICAL", 110, 122], ["ATP", "CHEMICAL", 203, 206], ["skeletal muscle biopsies", "TISSUE", 14, 38], ["patients", "ORGANISM", 58, 66], ["nitric oxide", "SIMPLE_CHEMICAL", 110, 122], ["antioxidant", "SIMPLE_CHEMICAL", 139, 150], ["mitochondrial", "CELLULAR_COMPONENT", 162, 175], ["ATP", "SIMPLE_CHEMICAL", 203, 206], ["multiorgan", "ORGAN", 243, 253], ["patients", "SPECIES", 58, 66], ["a study", "TEST", 3, 10], ["skeletal muscle biopsies", "TEST", 14, 38], ["nitric oxide overproduction", "TREATMENT", 110, 137], ["antioxidant depletion", "TREATMENT", 139, 160], ["mitochondrial dysfunction", "PROBLEM", 162, 187], ["decreased ATP concentrations", "PROBLEM", 193, 221], ["multiorgan failure", "PROBLEM", 243, 261], ["skeletal muscle", "ANATOMY", 14, 29], ["septic", "OBSERVATION_MODIFIER", 51, 57], ["antioxidant depletion", "OBSERVATION", 139, 160], ["mitochondrial dysfunction", "OBSERVATION", 162, 187], ["decreased", "OBSERVATION_MODIFIER", 193, 202], ["ATP concentrations", "OBSERVATION", 203, 221], ["multiorgan failure", "OBSERVATION", 243, 261]]], ["Human septic cardiomyopathy is accompanied by widespread down-regulation of cardiac mitochondrial genes and decrease in the expression of genes that govern cardiac myocyte contractility, analogous to the transcriptional reprogramming that occurs in myocardial hibernation (204).", [["cardiac mitochondrial", "ANATOMY", 76, 97], ["cardiac myocyte", "ANATOMY", 156, 171], ["myocardial", "ANATOMY", 249, 259], ["septic cardiomyopathy", "DISEASE", 6, 27], ["Human", "ORGANISM", 0, 5], ["cardiac mitochondrial", "CELLULAR_COMPONENT", 76, 97], ["cardiac myocyte", "CELL", 156, 171], ["myocardial", "MULTI-TISSUE_STRUCTURE", 249, 259], ["cardiac mitochondrial genes", "DNA", 76, 103], ["Human", "SPECIES", 0, 5], ["Human septic cardiomyopathy", "PROBLEM", 0, 27], ["cardiac mitochondrial genes", "PROBLEM", 76, 103], ["the transcriptional reprogramming", "PROBLEM", 200, 233], ["septic cardiomyopathy", "OBSERVATION", 6, 27], ["widespread", "OBSERVATION_MODIFIER", 46, 56], ["down", "OBSERVATION", 57, 61], ["cardiac", "ANATOMY", 76, 83], ["mitochondrial genes", "OBSERVATION", 84, 103], ["decrease", "OBSERVATION_MODIFIER", 108, 116], ["myocyte contractility", "OBSERVATION", 164, 185], ["myocardial", "ANATOMY", 249, 259], ["hibernation", "OBSERVATION", 260, 271]]], ["Early sepsis is associated with a reduction in PBMC mitochondrial copy number, and a rise in markers of mitochondrial damage, in a linear relation to proinflammatory cytokine expression (205).", [["mitochondrial", "ANATOMY", 52, 65], ["mitochondrial", "ANATOMY", 104, 117], ["sepsis", "DISEASE", 6, 12], ["mitochondrial damage", "DISEASE", 104, 124], ["PBMC", "CELL", 47, 51], ["mitochondrial", "CELLULAR_COMPONENT", 52, 65], ["mitochondrial", "CELLULAR_COMPONENT", 104, 117], ["PBMC", "CELL_TYPE", 47, 51], ["proinflammatory cytokine", "PROTEIN", 150, 174], ["Early sepsis", "PROBLEM", 0, 12], ["a reduction in PBMC mitochondrial copy number", "PROBLEM", 32, 77], ["mitochondrial damage", "PROBLEM", 104, 124], ["proinflammatory cytokine expression", "PROBLEM", 150, 185], ["sepsis", "OBSERVATION", 6, 12], ["associated with", "UNCERTAINTY", 16, 31], ["reduction", "OBSERVATION_MODIFIER", 34, 43], ["PBMC mitochondrial", "OBSERVATION", 47, 65], ["rise", "OBSERVATION_MODIFIER", 85, 89], ["mitochondrial damage", "OBSERVATION", 104, 124], ["proinflammatory cytokine expression", "OBSERVATION", 150, 185]]], ["The PBMCs of patients with severe vs. less severe pneumonia have increased ROS density, increased DNA damage, and decreased superoxide dismutase (SOD) concentrations (206).", [["PBMCs", "ANATOMY", 4, 9], ["pneumonia", "DISEASE", 50, 59], ["ROS", "CHEMICAL", 75, 78], ["superoxide", "CHEMICAL", 124, 134], ["superoxide", "CHEMICAL", 124, 134], ["PBMCs", "CELL", 4, 9], ["patients", "ORGANISM", 13, 21], ["ROS", "SIMPLE_CHEMICAL", 75, 78], ["DNA", "CELLULAR_COMPONENT", 98, 101], ["superoxide dismutase", "GENE_OR_GENE_PRODUCT", 124, 144], ["SOD", "SIMPLE_CHEMICAL", 146, 149], ["PBMCs", "CELL_TYPE", 4, 9], ["superoxide dismutase", "PROTEIN", 124, 144], ["SOD", "PROTEIN", 146, 149], ["patients", "SPECIES", 13, 21], ["severe vs", "PROBLEM", 27, 36], ["less severe pneumonia", "PROBLEM", 38, 59], ["increased ROS density", "PROBLEM", 65, 86], ["increased DNA damage", "PROBLEM", 88, 108], ["decreased superoxide dismutase (SOD) concentrations", "PROBLEM", 114, 165], ["severe", "OBSERVATION_MODIFIER", 27, 33], ["severe", "OBSERVATION_MODIFIER", 43, 49], ["pneumonia", "OBSERVATION", 50, 59], ["increased", "OBSERVATION_MODIFIER", 65, 74], ["ROS", "OBSERVATION_MODIFIER", 75, 78], ["density", "OBSERVATION_MODIFIER", 79, 86], ["increased", "OBSERVATION_MODIFIER", 88, 97], ["DNA", "OBSERVATION_MODIFIER", 98, 101], ["damage", "OBSERVATION_MODIFIER", 102, 108], ["decreased", "OBSERVATION_MODIFIER", 114, 123], ["superoxide dismutase", "OBSERVATION", 124, 144]]], ["Loss of mitochondrial function may lead to compensatory secondary metabolism, glycolysis, to produce ATP as well as lactate (207).", [["mitochondrial", "ANATOMY", 8, 21], ["ATP", "CHEMICAL", 101, 104], ["lactate", "CHEMICAL", 116, 123], ["ATP", "CHEMICAL", 101, 104], ["lactate", "CHEMICAL", 116, 123], ["mitochondrial", "CELLULAR_COMPONENT", 8, 21], ["ATP", "SIMPLE_CHEMICAL", 101, 104], ["lactate", "SIMPLE_CHEMICAL", 116, 123], ["Loss of mitochondrial function", "PROBLEM", 0, 30], ["compensatory secondary metabolism", "PROBLEM", 43, 76], ["ATP", "PROBLEM", 101, 104], ["lactate", "TEST", 116, 123], ["mitochondrial function", "OBSERVATION", 8, 30], ["secondary metabolism", "OBSERVATION", 56, 76]]], ["A epithelial cell line study demonstrated that this glycolytic switch is promoted by the activation of the redox sensitive phosphoinositide 3-kinase (PI3K) pathway and subsequent inactivation of glycogen synthase kinase-3\u03b2 (GSK-3\u03b2) resulting in increased production of inflammatory cytokines and reduced sensitivity to glucocorticoids (207).Mitochondrial Cacostatic Load, Oxidative Stress, and Mitochondrial DamageDecades of laboratory and clinical studies have revealed that dysregulated systemic inflammation, including sepsis, is associated with significant macromolecular damage to mitochondria, particularly in the cells of highly metabolically active tissues, such as the liver, heart, kidneys, brain, and skeletal muscles (191, 208).", [["epithelial cell line", "ANATOMY", 2, 22], ["Mitochondrial", "ANATOMY", 341, 354], ["Mitochondrial", "ANATOMY", 394, 407], ["mitochondria", "ANATOMY", 586, 598], ["cells", "ANATOMY", 620, 625], ["tissues", "ANATOMY", 657, 664], ["liver", "ANATOMY", 678, 683], ["heart", "ANATOMY", 685, 690], ["kidneys", "ANATOMY", 692, 699], ["brain", "ANATOMY", 701, 706], ["skeletal muscles", "ANATOMY", 712, 728], ["glycogen", "CHEMICAL", 195, 203], ["glucocorticoids", "CHEMICAL", 319, 334], ["systemic inflammation", "DISEASE", 489, 510], ["sepsis", "DISEASE", 522, 528], ["epithelial cell line", "CELL", 2, 22], ["phosphoinositide 3-kinase", "GENE_OR_GENE_PRODUCT", 123, 148], ["PI3K", "GENE_OR_GENE_PRODUCT", 150, 154], ["glycogen synthase kinase-3\u03b2", "GENE_OR_GENE_PRODUCT", 195, 222], ["GSK-3\u03b2", "GENE_OR_GENE_PRODUCT", 224, 230], ["glucocorticoids", "SIMPLE_CHEMICAL", 319, 334], ["Mitochondrial", "CELLULAR_COMPONENT", 341, 354], ["Mitochondrial", "CELLULAR_COMPONENT", 394, 407], ["mitochondria", "CELLULAR_COMPONENT", 586, 598], ["cells", "CELL", 620, 625], ["tissues", "TISSUE", 657, 664], ["liver", "ORGAN", 678, 683], ["heart", "ORGAN", 685, 690], ["kidneys", "ORGAN", 692, 699], ["brain", "ORGAN", 701, 706], ["skeletal muscles", "ORGAN", 712, 728], ["epithelial cell line", "CELL_LINE", 2, 22], ["phosphoinositide 3-kinase", "PROTEIN", 123, 148], ["PI3K", "PROTEIN", 150, 154], ["glycogen synthase kinase-3\u03b2 (GSK-3\u03b2", "PROTEIN", 195, 230], ["inflammatory cytokines", "PROTEIN", 269, 291], ["A epithelial cell line study", "TEST", 0, 28], ["the redox sensitive phosphoinositide", "TEST", 103, 139], ["glycogen synthase kinase", "TEST", 195, 219], ["GSK", "TEST", 224, 227], ["inflammatory cytokines", "PROBLEM", 269, 291], ["reduced sensitivity to glucocorticoids", "PROBLEM", 296, 334], ["Mitochondrial Cacostatic Load", "PROBLEM", 341, 370], ["Oxidative Stress", "PROBLEM", 372, 388], ["clinical studies", "TEST", 440, 456], ["dysregulated systemic inflammation", "PROBLEM", 476, 510], ["sepsis", "PROBLEM", 522, 528], ["significant macromolecular damage to mitochondria", "PROBLEM", 549, 598], ["the liver, heart, kidneys, brain, and skeletal muscles", "PROBLEM", 674, 728], ["epithelial cell line", "OBSERVATION", 2, 22], ["increased", "OBSERVATION_MODIFIER", 245, 254], ["production", "OBSERVATION_MODIFIER", 255, 265], ["inflammatory cytokines", "OBSERVATION", 269, 291], ["Cacostatic Load", "OBSERVATION", 355, 370], ["Oxidative Stress", "OBSERVATION", 372, 388], ["dysregulated", "OBSERVATION_MODIFIER", 476, 488], ["systemic", "OBSERVATION_MODIFIER", 489, 497], ["inflammation", "OBSERVATION", 498, 510], ["sepsis", "OBSERVATION", 522, 528], ["significant", "OBSERVATION_MODIFIER", 549, 560], ["macromolecular damage", "OBSERVATION", 561, 582], ["highly", "OBSERVATION_MODIFIER", 629, 635], ["metabolically", "OBSERVATION_MODIFIER", 636, 649], ["active tissues", "OBSERVATION", 650, 664], ["liver", "ANATOMY", 678, 683], ["heart", "ANATOMY", 685, 690], ["kidneys", "ANATOMY", 692, 699], ["brain", "ANATOMY", 701, 706], ["skeletal muscles", "ANATOMY", 712, 728]]], ["In contrast to nuclear DNA, which is non-immunogenic, mitochondrial DNA resembles bacterial DNA (see section Cellular Energetics\u2014Mitochondrial Function) and acts as a damage-associated molecular pathogen (DAMP) to activate immune responses through Toll-like receptor 9-mediated activation of NF-\u03baB (209) and the NLRP3 inflammasome (210).", [["nuclear", "ANATOMY", 15, 22], ["mitochondrial", "ANATOMY", 54, 67], ["Mitochondrial", "ANATOMY", 129, 142], ["nuclear", "CELLULAR_COMPONENT", 15, 22], ["DNA", "CELLULAR_COMPONENT", 23, 26], ["mitochondrial", "CELLULAR_COMPONENT", 54, 67], ["DNA", "CELLULAR_COMPONENT", 68, 71], ["DNA", "CELLULAR_COMPONENT", 92, 95], ["Mitochondrial", "CELLULAR_COMPONENT", 129, 142], ["damage-associated molecular pathogen", "GENE_OR_GENE_PRODUCT", 167, 203], ["DAMP", "GENE_OR_GENE_PRODUCT", 205, 209], ["Toll-like receptor 9", "GENE_OR_GENE_PRODUCT", 248, 268], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 292, 297], ["NLRP3", "GENE_OR_GENE_PRODUCT", 312, 317], ["nuclear DNA", "DNA", 15, 26], ["mitochondrial DNA", "DNA", 54, 71], ["bacterial DNA", "DNA", 82, 95], ["Toll-like receptor 9", "PROTEIN", 248, 268], ["NF-\u03baB", "PROTEIN", 292, 297], ["NLRP3", "PROTEIN", 312, 317], ["non-immunogenic", "PROBLEM", 37, 52], ["mitochondrial DNA", "PROBLEM", 54, 71], ["bacterial DNA", "PROBLEM", 82, 95], ["a damage", "PROBLEM", 165, 173], ["molecular pathogen (DAMP", "PROBLEM", 185, 209], ["the NLRP3 inflammasome", "TREATMENT", 308, 330], ["nuclear DNA", "OBSERVATION_MODIFIER", 15, 26], ["bacterial DNA", "OBSERVATION", 82, 95]]], ["Also, in comparison to nuclear DNA, mtDNA is 50-fold more sensitive to oxidative stress (191), as its close proximity to the electron transport chain and the absence of chromatin proteins makes it an easy target for oxidative damage (197).Mitochondrial Cacostatic Load, Oxidative Stress, and Mitochondrial DamageAs a consequence of increased ROS generation, mtDNA can undergo several qualitative and/or quantitative alterations.", [["nuclear", "ANATOMY", 23, 30], ["chromatin", "ANATOMY", 169, 178], ["Mitochondrial", "ANATOMY", 239, 252], ["Mitochondrial", "ANATOMY", 292, 305], ["ROS", "CHEMICAL", 342, 345], ["nuclear", "CELLULAR_COMPONENT", 23, 30], ["DNA", "CELLULAR_COMPONENT", 31, 34], ["mtDNA", "CELLULAR_COMPONENT", 36, 41], ["chromatin", "CELLULAR_COMPONENT", 169, 178], ["Mitochondrial", "CELLULAR_COMPONENT", 239, 252], ["Mitochondrial", "CELLULAR_COMPONENT", 292, 305], ["ROS", "SIMPLE_CHEMICAL", 342, 345], ["mtDNA", "CELLULAR_COMPONENT", 358, 363], ["nuclear DNA", "DNA", 23, 34], ["electron transport chain", "PROTEIN", 125, 149], ["chromatin proteins", "PROTEIN", 169, 187], ["nuclear DNA", "TEST", 23, 34], ["mtDNA", "TEST", 36, 41], ["chromatin proteins", "PROBLEM", 169, 187], ["oxidative damage", "PROBLEM", 216, 232], ["Mitochondrial Cacostatic Load", "PROBLEM", 239, 268], ["Oxidative Stress", "PROBLEM", 270, 286], ["Mitochondrial DamageAs", "PROBLEM", 292, 314], ["increased ROS generation", "PROBLEM", 332, 356], ["quantitative alterations", "PROBLEM", 403, 427], ["Cacostatic Load", "OBSERVATION", 253, 268], ["Oxidative Stress", "OBSERVATION", 270, 286], ["Mitochondrial DamageAs", "OBSERVATION", 292, 314]]], ["Recent studies have found that critically ill patients have decreased cellular mtDNA levels and increased circulating cell-free mtDNA levels (205, 210, 211).", [["cellular", "ANATOMY", 70, 78], ["cell", "ANATOMY", 118, 122], ["critically ill", "DISEASE", 31, 45], ["patients", "ORGANISM", 46, 54], ["cellular", "CELL", 70, 78], ["cell", "CELL", 118, 122], ["mtDNA", "CELLULAR_COMPONENT", 128, 133], ["patients", "SPECIES", 46, 54], ["Recent studies", "TEST", 0, 14], ["critically ill", "PROBLEM", 31, 45], ["decreased cellular mtDNA levels", "PROBLEM", 60, 91], ["increased circulating cell-free mtDNA levels", "PROBLEM", 96, 140], ["decreased", "OBSERVATION_MODIFIER", 60, 69], ["cellular mtDNA levels", "OBSERVATION", 70, 91], ["increased", "OBSERVATION_MODIFIER", 96, 105], ["circulating cell", "OBSERVATION", 106, 122], ["free mtDNA", "OBSERVATION", 123, 133]]], ["In septic patients, mtDNA depletion in circulating cells (mainly neutrophils) correlates with severity of illness (APACHE II scores) (212), while high TNF-\u03b1 expression in neutrophil lysates correlates with increased plasma mtDNA levels (205).", [["cells", "ANATOMY", 51, 56], ["neutrophils", "ANATOMY", 65, 76], ["neutrophil lysates", "ANATOMY", 171, 189], ["plasma", "ANATOMY", 216, 222], ["septic", "DISEASE", 3, 9], ["illness", "DISEASE", 106, 113], ["patients", "ORGANISM", 10, 18], ["mtDNA", "CELLULAR_COMPONENT", 20, 25], ["cells", "CELL", 51, 56], ["neutrophils", "CELL", 65, 76], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 151, 156], ["neutrophil", "CELL", 171, 181], ["plasma", "ORGANISM_SUBSTANCE", 216, 222], ["mtDNA", "CELLULAR_COMPONENT", 223, 228], ["circulating cells", "CELL_TYPE", 39, 56], ["neutrophils", "CELL_TYPE", 65, 76], ["TNF", "PROTEIN", 151, 154], ["patients", "SPECIES", 10, 18], ["mtDNA depletion in circulating cells", "PROBLEM", 20, 56], ["illness", "PROBLEM", 106, 113], ["APACHE II scores", "TEST", 115, 131], ["high TNF", "PROBLEM", 146, 154], ["neutrophil lysates", "TEST", 171, 189], ["increased plasma mtDNA levels", "PROBLEM", 206, 235], ["septic", "OBSERVATION_MODIFIER", 3, 9], ["mtDNA depletion", "OBSERVATION", 20, 35], ["circulating cells", "OBSERVATION", 39, 56]]], ["The exact mechanism of mtDNA delivery into the cytoplasm and then into the systemic circulation is currently unknown (189).", [["cytoplasm", "ANATOMY", 47, 56], ["mtDNA", "CELLULAR_COMPONENT", 23, 28], ["cytoplasm", "ORGANISM_SUBSTANCE", 47, 56], ["mtDNA delivery", "TREATMENT", 23, 37], ["systemic circulation", "ANATOMY", 75, 95]]], ["In ICU patients with sepsis and ARDS, elevated plasma mtDNA levels (>3,200 copies/\u03bcl) are associated with dysregulation of phospholipid metabolism (211), and increased mortality (210).Mitochondrial Cacostatic Load, Oxidative Stress, and Mitochondrial DamageThe cycle of mtDNA damage with loss of function of electron transport enzymes (ATP depletion) and increased ROS generation, a state in which the antioxidant systems are overwhelmed may eventually lead to cell death, a phenomenon known as the \u201ctoxic oxidative stress\u201d (213).", [["plasma", "ANATOMY", 47, 53], ["Mitochondrial", "ANATOMY", 184, 197], ["Mitochondrial", "ANATOMY", 237, 250], ["cell", "ANATOMY", 461, 465], ["sepsis", "DISEASE", 21, 27], ["ARDS", "DISEASE", 32, 36], ["ATP", "CHEMICAL", 336, 339], ["ROS", "CHEMICAL", 365, 368], ["death", "DISEASE", 466, 471], ["ATP", "CHEMICAL", 336, 339], ["patients", "ORGANISM", 7, 15], ["plasma", "ORGANISM_SUBSTANCE", 47, 53], ["mtDNA", "CELLULAR_COMPONENT", 54, 59], ["phospholipid", "SIMPLE_CHEMICAL", 123, 135], ["Mitochondrial", "CELLULAR_COMPONENT", 184, 197], ["Mitochondrial", "CELLULAR_COMPONENT", 237, 250], ["mtDNA", "CELLULAR_COMPONENT", 270, 275], ["electron transport enzymes", "GENE_OR_GENE_PRODUCT", 308, 334], ["ATP", "SIMPLE_CHEMICAL", 336, 339], ["ROS", "SIMPLE_CHEMICAL", 365, 368], ["cell", "CELL", 461, 465], ["electron transport enzymes", "PROTEIN", 308, 334], ["patients", "SPECIES", 7, 15], ["sepsis", "PROBLEM", 21, 27], ["ARDS", "PROBLEM", 32, 36], ["elevated plasma mtDNA levels", "PROBLEM", 38, 66], ["dysregulation of phospholipid metabolism", "PROBLEM", 106, 146], ["increased mortality", "PROBLEM", 158, 177], ["Mitochondrial Cacostatic Load", "PROBLEM", 184, 213], ["Oxidative Stress", "PROBLEM", 215, 231], ["Mitochondrial Damage", "PROBLEM", 237, 257], ["mtDNA damage", "PROBLEM", 270, 282], ["electron transport enzymes", "TEST", 308, 334], ["ATP depletion", "PROBLEM", 336, 349], ["increased ROS generation", "PROBLEM", 355, 379], ["cell death", "PROBLEM", 461, 471], ["a phenomenon", "PROBLEM", 473, 485], ["sepsis", "OBSERVATION", 21, 27], ["ARDS", "OBSERVATION", 32, 36], ["phospholipid metabolism", "OBSERVATION", 123, 146], ["increased", "OBSERVATION_MODIFIER", 158, 167], ["mortality", "OBSERVATION_MODIFIER", 168, 177], ["Cacostatic Load", "OBSERVATION", 198, 213], ["Oxidative Stress", "OBSERVATION", 215, 231], ["Mitochondrial Damage", "OBSERVATION", 237, 257], ["mtDNA damage", "OBSERVATION", 270, 282], ["ATP depletion", "OBSERVATION", 336, 349], ["increased", "OBSERVATION_MODIFIER", 355, 364], ["ROS generation", "OBSERVATION", 365, 379]]], ["In critical illness, impaired cell energy metabolism and mitochondrial damage augment systemic inflammation directly via NF-\u03baB activation and indirectly by multi-level impairment of the HPA axis and GR homeostatic functions (see section Oxidative Stress and CIRCI).", [["cell", "ANATOMY", 30, 34], ["mitochondrial", "ANATOMY", 57, 70], ["mitochondrial damage", "DISEASE", 57, 77], ["inflammation", "DISEASE", 95, 107], ["cell", "CELL", 30, 34], ["mitochondrial", "CELLULAR_COMPONENT", 57, 70], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 121, 126], ["GR", "GENE_OR_GENE_PRODUCT", 199, 201], ["NF-\u03baB", "PROTEIN", 121, 126], ["GR", "PROTEIN", 199, 201], ["impaired cell energy metabolism", "PROBLEM", 21, 52], ["mitochondrial damage augment systemic inflammation", "PROBLEM", 57, 107], ["multi-level impairment of the HPA axis", "PROBLEM", 156, 194], ["GR homeostatic functions", "PROBLEM", 199, 223], ["impaired cell energy metabolism", "OBSERVATION", 21, 52], ["mitochondrial damage", "OBSERVATION", 57, 77], ["systemic", "OBSERVATION_MODIFIER", 86, 94], ["inflammation", "OBSERVATION", 95, 107]]], ["Effective homeostatic corrections in the adaptive response during the resolution of critical illness are associated with increased mitochondrial biogenesis, restoration of oxidative metabolism, and mitochondrial content (205).", [["mitochondrial", "ANATOMY", 131, 144], ["mitochondrial", "ANATOMY", 198, 211], ["mitochondrial", "CELLULAR_COMPONENT", 131, 144], ["mitochondrial", "CELLULAR_COMPONENT", 198, 211], ["Effective homeostatic corrections", "TREATMENT", 0, 33], ["critical illness", "PROBLEM", 84, 100], ["increased mitochondrial biogenesis", "PROBLEM", 121, 155], ["oxidative metabolism", "PROBLEM", 172, 192], ["mitochondrial biogenesis", "OBSERVATION", 131, 155], ["oxidative metabolism", "OBSERVATION", 172, 192], ["mitochondrial content", "OBSERVATION", 198, 219]]], ["In many studies, restoration of mitochondrial homeostatic functions was observed in association with improved organ recovery and survival [reviewed in (205)].", [["mitochondrial", "ANATOMY", 32, 45], ["organ", "ANATOMY", 110, 115], ["mitochondrial", "CELLULAR_COMPONENT", 32, 45], ["organ", "ORGAN", 110, 115], ["many studies", "TEST", 3, 15], ["mitochondrial homeostatic functions", "PROBLEM", 32, 67], ["mitochondrial homeostatic functions", "OBSERVATION", 32, 67]]], ["The association between mitochondrial dysfunction, circulating cell-free mtDNA, muscle wasting, sterile inflammation, and inflamm-aging was recently reviewed (189).Mitochondrial Cacostatic Load, Oxidative Stress, and Mitochondrial DamageMicronutrient deficiencies may also impair mitochondrial function.", [["mitochondrial", "ANATOMY", 24, 37], ["cell", "ANATOMY", 63, 67], ["muscle", "ANATOMY", 80, 86], ["Mitochondrial", "ANATOMY", 164, 177], ["Mitochondrial", "ANATOMY", 217, 230], ["mitochondrial", "ANATOMY", 280, 293], ["mitochondrial dysfunction", "DISEASE", 24, 49], ["muscle wasting", "DISEASE", 80, 94], ["inflammation", "DISEASE", 104, 116], ["mitochondrial", "CELLULAR_COMPONENT", 24, 37], ["cell", "CELL", 63, 67], ["mtDNA", "CELLULAR_COMPONENT", 73, 78], ["muscle", "ORGAN", 80, 86], ["Mitochondrial", "CELLULAR_COMPONENT", 164, 177], ["Mitochondrial", "CELLULAR_COMPONENT", 217, 230], ["mitochondrial", "CELLULAR_COMPONENT", 280, 293], ["mitochondrial dysfunction", "PROBLEM", 24, 49], ["circulating cell-free mtDNA", "PROBLEM", 51, 78], ["muscle wasting", "PROBLEM", 80, 94], ["sterile inflammation", "PROBLEM", 96, 116], ["Mitochondrial Cacostatic Load", "PROBLEM", 164, 193], ["Oxidative Stress", "PROBLEM", 195, 211], ["Mitochondrial DamageMicronutrient deficiencies", "PROBLEM", 217, 263], ["mitochondrial dysfunction", "OBSERVATION", 24, 49], ["circulating cell", "OBSERVATION", 51, 67], ["free mtDNA", "OBSERVATION", 68, 78], ["muscle", "ANATOMY", 80, 86], ["wasting", "OBSERVATION", 87, 94], ["sterile", "OBSERVATION_MODIFIER", 96, 103], ["inflammation", "OBSERVATION", 104, 116], ["Cacostatic Load", "OBSERVATION", 178, 193], ["Oxidative Stress", "OBSERVATION", 195, 211], ["Mitochondrial DamageMicronutrient deficiencies", "OBSERVATION", 217, 263], ["mitochondrial function", "OBSERVATION", 280, 302]]], ["In septic patients, the marked early reduction in selenium levels may affect selenium-dependent anti-oxidants glutathione peroxidase and thioredoxin (214).", [["septic", "DISEASE", 3, 9], ["selenium", "CHEMICAL", 50, 58], ["selenium", "CHEMICAL", 77, 85], ["glutathione", "CHEMICAL", 110, 121], ["selenium", "CHEMICAL", 50, 58], ["selenium", "CHEMICAL", 77, 85], ["glutathione", "CHEMICAL", 110, 121], ["patients", "ORGANISM", 10, 18], ["selenium", "SIMPLE_CHEMICAL", 50, 58], ["selenium", "SIMPLE_CHEMICAL", 77, 85], ["glutathione peroxidase", "GENE_OR_GENE_PRODUCT", 110, 132], ["thioredoxin", "GENE_OR_GENE_PRODUCT", 137, 148], ["glutathione peroxidase", "PROTEIN", 110, 132], ["thioredoxin", "PROTEIN", 137, 148], ["patients", "SPECIES", 10, 18], ["the marked early reduction in selenium levels", "PROBLEM", 20, 65], ["selenium-dependent anti-oxidants glutathione peroxidase", "TREATMENT", 77, 132], ["thioredoxin", "TREATMENT", 137, 148], ["septic", "OBSERVATION_MODIFIER", 3, 9], ["marked", "OBSERVATION_MODIFIER", 24, 30], ["early", "OBSERVATION_MODIFIER", 31, 36], ["reduction", "OBSERVATION_MODIFIER", 37, 46], ["selenium levels", "OBSERVATION", 50, 65]]], ["The role of hypovitaminoses on mitochondrial function is reviewed in section Hypovitaminoses.Mitochondria And HPA-Axis Cross-TalkAbundant mitochondria are one of the most prominent ultrastructural features of the adrenocortical cells (208) in which intracellular steroidogenic cholesterol is ultimately converted to cortisol in a tightly controlled manner (82).", [["mitochondrial", "ANATOMY", 31, 44], ["Mitochondria", "ANATOMY", 93, 105], ["mitochondria", "ANATOMY", 138, 150], ["adrenocortical cells", "ANATOMY", 213, 233], ["intracellular", "ANATOMY", 249, 262], ["hypovitaminoses", "CHEMICAL", 12, 27], ["cholesterol", "CHEMICAL", 277, 288], ["cortisol", "CHEMICAL", 316, 324], ["hypovitaminoses", "CHEMICAL", 12, 27], ["cholesterol", "CHEMICAL", 277, 288], ["cortisol", "CHEMICAL", 316, 324], ["hypovitaminoses", "SIMPLE_CHEMICAL", 12, 27], ["mitochondrial", "CELLULAR_COMPONENT", 31, 44], ["Mitochondria", "CELLULAR_COMPONENT", 93, 105], ["HPA-Axis", "GENE_OR_GENE_PRODUCT", 110, 118], ["mitochondria", "CELLULAR_COMPONENT", 138, 150], ["adrenocortical cells", "CELL", 213, 233], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 249, 262], ["cholesterol", "SIMPLE_CHEMICAL", 277, 288], ["cortisol", "SIMPLE_CHEMICAL", 316, 324], ["adrenocortical cells", "CELL_TYPE", 213, 233], ["mitochondrial function", "TEST", 31, 53], ["Mitochondria", "TEST", 93, 105], ["HPA", "TEST", 110, 113], ["Axis Cross-TalkAbundant mitochondria", "PROBLEM", 114, 150], ["intracellular steroidogenic cholesterol", "TEST", 249, 288], ["cortisol", "TEST", 316, 324], ["most prominent", "OBSERVATION_MODIFIER", 166, 180], ["adrenocortical cells", "OBSERVATION", 213, 233], ["steroidogenic cholesterol", "OBSERVATION", 263, 288]]], ["The central role of mitochondria in essential physiological processes has rendered these organelles a receiver and integrator hub of multiple regulatory signals (215).", [["mitochondria", "ANATOMY", 20, 32], ["organelles", "ANATOMY", 89, 99], ["mitochondria", "CELLULAR_COMPONENT", 20, 32], ["organelles", "CELLULAR_COMPONENT", 89, 99], ["central", "ANATOMY_MODIFIER", 4, 11], ["multiple", "OBSERVATION_MODIFIER", 133, 141]]], ["Mitochondria participate in the stress response, in part, by sensing levels of glucocorticoids (183).", [["Mitochondria", "ANATOMY", 0, 12], ["glucocorticoids", "CHEMICAL", 79, 94], ["Mitochondria", "CELLULAR_COMPONENT", 0, 12], ["glucocorticoids", "SIMPLE_CHEMICAL", 79, 94], ["Mitochondria", "PROBLEM", 0, 12], ["the stress response", "PROBLEM", 28, 47], ["glucocorticoids", "TEST", 79, 94]]], ["It is now accepted that mitochondria are under GC control because GRs are present in mitochondria, and GREs reside in the mitochondrial genome (82, 192).", [["mitochondria", "ANATOMY", 24, 36], ["mitochondria", "ANATOMY", 85, 97], ["mitochondrial genome", "ANATOMY", 122, 142], ["mitochondria", "CELLULAR_COMPONENT", 24, 36], ["GRs", "GENE_OR_GENE_PRODUCT", 66, 69], ["mitochondria", "CELLULAR_COMPONENT", 85, 97], ["GREs", "GENE_OR_GENE_PRODUCT", 103, 107], ["mitochondrial", "CELLULAR_COMPONENT", 122, 135], ["GRs", "PROTEIN", 66, 69], ["GREs", "PROTEIN", 103, 107], ["mitochondrial genome", "DNA", 122, 142], ["GC control", "TREATMENT", 47, 57], ["mitochondrial genome", "OBSERVATION", 122, 142]]], ["A number of studies in several tissues have observed a cytoplasmic-to-mitochondrion GR translocation or vice versa in response to GC, indicating that mitochondrial GR is dynamically regulated upon exposure to GCs (69).", [["tissues", "ANATOMY", 31, 38], ["cytoplasmic", "ANATOMY", 55, 66], ["mitochondrion", "ANATOMY", 70, 83], ["mitochondrial", "ANATOMY", 150, 163], ["tissues", "TISSUE", 31, 38], ["cytoplasmic", "ORGANISM_SUBSTANCE", 55, 66], ["mitochondrion", "CELLULAR_COMPONENT", 70, 83], ["GR", "GENE_OR_GENE_PRODUCT", 84, 86], ["mitochondrial", "CELLULAR_COMPONENT", 150, 163], ["GR", "GENE_OR_GENE_PRODUCT", 164, 166], ["GR", "PROTEIN", 84, 86], ["mitochondrial GR", "PROTEIN", 150, 166], ["GC", "TEST", 130, 132], ["mitochondrial GR", "PROBLEM", 150, 166], ["GCs", "TEST", 209, 212]]], ["Lee and collaborators have classified five pathways in the functional modulation of the mitochondria by GC-GR (82).", [["mitochondria", "ANATOMY", 88, 100], ["mitochondria", "CELLULAR_COMPONENT", 88, 100], ["GC-GR", "GENE_OR_GENE_PRODUCT", 104, 109], ["GR", "PROTEIN", 107, 109]]], ["In addition to direct mitochondrial GR-mtGRE interactions, mitochondrial gene expression is regulated indirectly by nuclear GR-nuGRE interactions that result in increased transcription of the following: (i) genes encoding OXPHOS and other mitochondrial regulatory functions, (ii) transcription factors for control of nuDNA-encoded mitochondrial proteins, and (iii) several antioxidant mechanisms including uncoupling protein-2 (UCP2) (69, 82, 113, 192, 216, 217).", [["mitochondrial", "ANATOMY", 22, 35], ["mitochondrial", "ANATOMY", 59, 72], ["nuclear", "ANATOMY", 116, 123], ["mitochondrial", "ANATOMY", 239, 252], ["mitochondrial", "ANATOMY", 331, 344], ["mitochondrial", "CELLULAR_COMPONENT", 22, 35], ["GR", "GENE_OR_GENE_PRODUCT", 36, 38], ["mtGRE", "GENE_OR_GENE_PRODUCT", 39, 44], ["mitochondrial", "CELLULAR_COMPONENT", 59, 72], ["nuclear", "CELLULAR_COMPONENT", 116, 123], ["GR", "GENE_OR_GENE_PRODUCT", 124, 126], ["nuGRE", "GENE_OR_GENE_PRODUCT", 127, 132], ["OXPHOS", "GENE_OR_GENE_PRODUCT", 222, 228], ["mitochondrial", "CELLULAR_COMPONENT", 239, 252], ["nuDNA", "GENE_OR_GENE_PRODUCT", 317, 322], ["mitochondrial", "CELLULAR_COMPONENT", 331, 344], ["uncoupling protein-2", "GENE_OR_GENE_PRODUCT", 406, 426], ["UCP2", "GENE_OR_GENE_PRODUCT", 428, 432], ["GR", "PROTEIN", 36, 38], ["mtGRE", "PROTEIN", 39, 44], ["GR", "PROTEIN", 124, 126], ["nuGRE", "PROTEIN", 127, 132], ["OXPHOS", "PROTEIN", 222, 228], ["transcription factors", "PROTEIN", 280, 301], ["nuDNA", "PROTEIN", 317, 322], ["mitochondrial proteins", "PROTEIN", 331, 353], ["uncoupling protein-2", "PROTEIN", 406, 426], ["UCP2", "PROTEIN", 428, 432], ["direct mitochondrial GR-mtGRE interactions", "TREATMENT", 15, 57], ["mitochondrial gene expression", "PROBLEM", 59, 88], ["encoding OXPHOS", "PROBLEM", 213, 228], ["other mitochondrial regulatory functions", "PROBLEM", 233, 273], ["nuDNA", "PROBLEM", 317, 322], ["encoded mitochondrial proteins", "PROBLEM", 323, 353], ["uncoupling protein-2 (UCP2", "TEST", 406, 432]]], ["Of interest, mitochondrial thioredoxin, an antioxidant and anti-apoptotic factor essential for cell viability and vascular homeostasis (218), interacts directly with both the ligand and the DNA-binding domains of GR, keeping the receptor in a reduced, transcriptionally active form (219, 220).Mitochondria And HPA-Axis Cross-TalkStudies have shown that fine-tuning of the response to cellular demands is coordinately regulated by the nucleus and mitochondria, making mitochondrial-nuclear interaction vital to optimal mitochondrial function (82), with GC-GR-mediated increased mtDNA gene expression augmenting the total number of mitochondria per cell, and, thus, total cellular energy production capacity (216).", [["mitochondrial", "ANATOMY", 13, 26], ["cell", "ANATOMY", 95, 99], ["vascular", "ANATOMY", 114, 122], ["Mitochondria", "ANATOMY", 293, 305], ["cellular", "ANATOMY", 384, 392], ["nucleus", "ANATOMY", 434, 441], ["mitochondria", "ANATOMY", 446, 458], ["mitochondrial", "ANATOMY", 467, 480], ["nuclear", "ANATOMY", 481, 488], ["mitochondrial", "ANATOMY", 518, 531], ["mitochondria", "ANATOMY", 630, 642], ["cell", "ANATOMY", 647, 651], ["cellular", "ANATOMY", 670, 678], ["mitochondrial", "CELLULAR_COMPONENT", 13, 26], ["thioredoxin", "GENE_OR_GENE_PRODUCT", 27, 38], ["cell", "CELL", 95, 99], ["vascular", "MULTI-TISSUE_STRUCTURE", 114, 122], ["DNA", "CELLULAR_COMPONENT", 190, 193], ["GR", "GENE_OR_GENE_PRODUCT", 213, 215], ["Mitochondria", "CELLULAR_COMPONENT", 293, 305], ["HPA-Axis", "GENE_OR_GENE_PRODUCT", 310, 318], ["cellular", "CELL", 384, 392], ["nucleus", "CELLULAR_COMPONENT", 434, 441], ["mitochondria", "CELLULAR_COMPONENT", 446, 458], ["mitochondrial", "CELLULAR_COMPONENT", 467, 480], ["nuclear", "CELLULAR_COMPONENT", 481, 488], ["mitochondrial", "CELLULAR_COMPONENT", 518, 531], ["GC-GR", "GENE_OR_GENE_PRODUCT", 552, 557], ["mtDNA", "CELLULAR_COMPONENT", 577, 582], ["mitochondria", "CELLULAR_COMPONENT", 630, 642], ["cell", "CELL", 647, 651], ["cellular", "CELL", 670, 678], ["mitochondrial thioredoxin", "PROTEIN", 13, 38], ["anti-apoptotic factor", "PROTEIN", 59, 80], ["DNA-binding domains", "PROTEIN", 190, 209], ["GR", "PROTEIN", 213, 215], ["GR", "PROTEIN", 555, 557], ["mtDNA gene", "DNA", 577, 587], ["mitochondrial thioredoxin", "TREATMENT", 13, 38], ["an antioxidant", "TREATMENT", 40, 54], ["anti-apoptotic factor", "TREATMENT", 59, 80], ["cell viability", "PROBLEM", 95, 109], ["Mitochondria", "TEST", 293, 305], ["HPA", "TEST", 310, 313], ["GC", "TEST", 552, 554], ["increased mtDNA gene expression", "PROBLEM", 567, 598], ["cell viability", "OBSERVATION", 95, 109], ["vascular", "ANATOMY", 114, 122], ["cellular demands", "OBSERVATION", 384, 400], ["nucleus", "ANATOMY_MODIFIER", 434, 441], ["increased mtDNA", "OBSERVATION", 567, 582], ["gene expression", "OBSERVATION", 583, 598], ["total", "OBSERVATION_MODIFIER", 614, 619], ["mitochondria per cell", "OBSERVATION", 630, 651]]], ["Altogether, there is substantial evidence that cross-talk between neuroendocrine control of the stress response and cellular antioxidant systems is essential for mammalian homeostatic regulation (220).", [["neuroendocrine", "ANATOMY", 66, 80], ["cellular", "ANATOMY", 116, 124], ["cellular", "CELL", 116, 124], ["the stress response", "PROBLEM", 92, 111], ["cellular antioxidant systems", "TEST", 116, 144], ["substantial", "OBSERVATION_MODIFIER", 21, 32], ["stress response", "OBSERVATION", 96, 111]]], ["Consistent with the cacostatic load model (21), administration of physiological doses of GCs acutely increases mitochondrial membrane potential, calcium buffering capacity, anti-oxidant capacity, and resistance to apoptotic signaling (8), whereas chronic exposure to high doses of GCs suppresses anti-oxidant capacity, decreases mitochondrial membrane potential, and sensitizes cells to apoptosis (21, 187, 190).Oxidative Stress And CIRCIOxidative stress is accompanied by multi-level impairment of the HPA axis and GR homeostatic functions (Figure 5).", [["mitochondrial membrane", "ANATOMY", 111, 133], ["mitochondrial membrane", "ANATOMY", 329, 351], ["cells", "ANATOMY", 378, 383], ["GCs", "CHEMICAL", 89, 92], ["calcium", "CHEMICAL", 145, 152], ["GCs", "CHEMICAL", 281, 284], ["calcium", "CHEMICAL", 145, 152], ["GCs", "SIMPLE_CHEMICAL", 89, 92], ["mitochondrial membrane", "CELLULAR_COMPONENT", 111, 133], ["calcium", "SIMPLE_CHEMICAL", 145, 152], ["GCs", "SIMPLE_CHEMICAL", 281, 284], ["mitochondrial membrane", "CELLULAR_COMPONENT", 329, 351], ["cells", "CELL", 378, 383], ["GR", "GENE_OR_GENE_PRODUCT", 516, 518], ["GR", "PROTEIN", 516, 518], ["the cacostatic load model", "TREATMENT", 16, 41], ["GCs acutely increases mitochondrial membrane potential", "PROBLEM", 89, 143], ["calcium buffering capacity", "PROBLEM", 145, 171], ["anti-oxidant capacity", "TEST", 173, 194], ["apoptotic signaling", "TEST", 214, 233], ["GCs suppresses anti-oxidant capacity", "PROBLEM", 281, 317], ["mitochondrial membrane potential", "PROBLEM", 329, 361], ["sensitizes cells", "PROBLEM", 367, 383], ["apoptosis", "TEST", 387, 396], ["Oxidative Stress", "PROBLEM", 412, 428], ["CIRCIOxidative stress", "PROBLEM", 433, 454], ["multi-level impairment of the HPA axis", "PROBLEM", 473, 511], ["high doses", "OBSERVATION_MODIFIER", 267, 277], ["impairment", "OBSERVATION", 485, 495], ["HPA axis", "ANATOMY", 503, 511]]], ["In non-survivors of septic shock, marked overexpression of iNOS in hypothalamic parvocellular neurons (PVN) was associated with decreased expression of pituitary ACTH, suggesting that the pro-apoptotic action of iNOS in the PVN may partially account for reduced activity of the HPA axis in sustained septic shock (221, 222).", [["hypothalamic parvocellular neurons", "ANATOMY", 67, 101], ["pituitary", "ANATOMY", 152, 161], ["septic shock", "DISEASE", 20, 32], ["septic shock", "DISEASE", 300, 312], ["iNOS", "GENE_OR_GENE_PRODUCT", 59, 63], ["hypothalamic parvocellular neurons", "CELL", 67, 101], ["PVN", "MULTI-TISSUE_STRUCTURE", 103, 106], ["pituitary ACTH", "GENE_OR_GENE_PRODUCT", 152, 166], ["iNOS", "GENE_OR_GENE_PRODUCT", 212, 216], ["PVN", "SIMPLE_CHEMICAL", 224, 227], ["iNOS", "PROTEIN", 59, 63], ["iNOS", "PROTEIN", 212, 216], ["septic shock", "PROBLEM", 20, 32], ["iNOS in hypothalamic parvocellular neurons", "PROBLEM", 59, 101], ["decreased expression of pituitary ACTH", "PROBLEM", 128, 166], ["iNOS in the PVN", "PROBLEM", 212, 227], ["reduced activity of the HPA axis", "PROBLEM", 254, 286], ["sustained septic shock", "PROBLEM", 290, 312], ["septic shock", "OBSERVATION", 20, 32], ["marked", "OBSERVATION_MODIFIER", 34, 40], ["overexpression", "OBSERVATION_MODIFIER", 41, 55], ["iNOS", "OBSERVATION_MODIFIER", 59, 63], ["hypothalamic", "OBSERVATION", 67, 79], ["parvocellular neurons", "OBSERVATION", 80, 101], ["pituitary ACTH", "OBSERVATION", 152, 166], ["iNOS", "OBSERVATION", 212, 216], ["PVN", "ANATOMY", 224, 227], ["may partially account for", "UNCERTAINTY", 228, 253], ["sustained", "OBSERVATION_MODIFIER", 290, 299], ["septic shock", "OBSERVATION", 300, 312]]], ["In experimental sepsis, adrenal cellular extracts demonstrate a pronounced increase in mRNA for iNOS and inflammatory cytokines that correlate positively with the degree of neutrophil infiltration, adrenal cell apoptosis, and mortality (213).Oxidative Stress And CIRCIChanges within the adrenal gland microenvironment may also affect the HPA axis response in critical illness (149), with mitochondrial damage leading to a decreased responsiveness to ACTH (208).", [["adrenal cellular extracts", "ANATOMY", 24, 49], ["neutrophil", "ANATOMY", 173, 183], ["adrenal cell", "ANATOMY", 198, 210], ["adrenal gland", "ANATOMY", 287, 300], ["mitochondrial", "ANATOMY", 388, 401], ["sepsis", "DISEASE", 16, 22], ["mitochondrial damage", "DISEASE", 388, 408], ["adrenal cellular extracts", "ORGANISM_SUBSTANCE", 24, 49], ["iNOS", "GENE_OR_GENE_PRODUCT", 96, 100], ["neutrophil", "CELL", 173, 183], ["adrenal cell", "CELL", 198, 210], ["adrenal gland", "MULTI-TISSUE_STRUCTURE", 287, 300], ["mitochondrial", "CELLULAR_COMPONENT", 388, 401], ["ACTH", "GENE_OR_GENE_PRODUCT", 450, 454], ["mRNA", "RNA", 87, 91], ["iNOS", "PROTEIN", 96, 100], ["inflammatory cytokines", "PROTEIN", 105, 127], ["experimental sepsis", "PROBLEM", 3, 22], ["adrenal cellular extracts", "PROBLEM", 24, 49], ["iNOS", "PROBLEM", 96, 100], ["inflammatory cytokines", "PROBLEM", 105, 127], ["neutrophil infiltration", "PROBLEM", 173, 196], ["adrenal cell apoptosis", "PROBLEM", 198, 220], ["Oxidative Stress", "PROBLEM", 242, 258], ["CIRCIChanges", "TREATMENT", 263, 275], ["mitochondrial damage", "PROBLEM", 388, 408], ["a decreased responsiveness", "PROBLEM", 420, 446], ["ACTH", "TEST", 450, 454], ["sepsis", "OBSERVATION", 16, 22], ["adrenal", "ANATOMY", 24, 31], ["cellular extracts", "OBSERVATION", 32, 49], ["pronounced", "OBSERVATION_MODIFIER", 64, 74], ["increase", "OBSERVATION_MODIFIER", 75, 83], ["inflammatory", "OBSERVATION_MODIFIER", 105, 117], ["neutrophil infiltration", "OBSERVATION", 173, 196], ["adrenal cell apoptosis", "OBSERVATION", 198, 220], ["adrenal gland", "ANATOMY", 287, 300], ["damage", "OBSERVATION", 402, 408], ["decreased", "OBSERVATION_MODIFIER", 422, 431]]], ["Importantly, iNOS expression in adrenal cells diverges at 48 h, with a significant increase observed in non-survivors vs. a reduction in survivors (223).", [["adrenal cells", "ANATOMY", 32, 45], ["iNOS", "GENE_OR_GENE_PRODUCT", 13, 17], ["adrenal cells", "CELL", 32, 45], ["iNOS", "PROTEIN", 13, 17], ["adrenal cells", "CELL_TYPE", 32, 45], ["iNOS expression in adrenal cells diverges", "PROBLEM", 13, 54], ["a reduction in survivors", "TREATMENT", 122, 146], ["adrenal cells", "OBSERVATION", 32, 45], ["significant", "OBSERVATION_MODIFIER", 71, 82], ["increase", "OBSERVATION_MODIFIER", 83, 91], ["reduction", "OBSERVATION_MODIFIER", 124, 133]]], ["In experimental endotoxemia, NF-\u03baB-mediated iNOS release is associated with mitochondrial oxidative stress in adrenocortical cells with inhibition of steroidogenesis and response to ACTH (208).Oxidative Stress And CIRCIOxidative stress has a direct deleterious impact on GRs number and function.", [["mitochondrial", "ANATOMY", 76, 89], ["adrenocortical cells", "ANATOMY", 110, 130], ["endotoxemia", "DISEASE", 16, 27], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 29, 34], ["iNOS", "GENE_OR_GENE_PRODUCT", 44, 48], ["mitochondrial", "CELLULAR_COMPONENT", 76, 89], ["adrenocortical cells", "CELL", 110, 130], ["ACTH", "GENE_OR_GENE_PRODUCT", 182, 186], ["NF-\u03baB", "PROTEIN", 29, 34], ["iNOS", "PROTEIN", 44, 48], ["adrenocortical cells", "CELL_TYPE", 110, 130], ["experimental endotoxemia", "PROBLEM", 3, 27], ["NF", "TEST", 29, 31], ["B-mediated iNOS release", "TREATMENT", 33, 56], ["mitochondrial oxidative stress in adrenocortical cells", "PROBLEM", 76, 130], ["inhibition of steroidogenesis", "TREATMENT", 136, 165], ["ACTH", "TEST", 182, 186], ["Oxidative Stress", "PROBLEM", 193, 209], ["endotoxemia", "OBSERVATION", 16, 27], ["oxidative stress", "OBSERVATION", 90, 106], ["adrenocortical cells", "OBSERVATION", 110, 130]]], ["Experimental studies involving tissue cultures (220, 224\u2013226) and murine models (227, 228) have demonstrated that oxidative stress is associated with decreased: (i) GR number (228), (ii) GC binding to GR (220, 224\u2013227), (iii) GC-GR nuclear translocation (226, 229), (iv) binding to DNA (224), and (v) inducible gene transcription (220, 225).", [["tissue cultures", "ANATOMY", 31, 46], ["nuclear", "ANATOMY", 232, 239], ["tissue cultures", "CELL", 31, 46], ["murine", "ORGANISM", 66, 72], ["GR", "GENE_OR_GENE_PRODUCT", 165, 167], ["GR", "GENE_OR_GENE_PRODUCT", 201, 203], ["GC-GR", "GENE_OR_GENE_PRODUCT", 226, 231], ["DNA", "CELLULAR_COMPONENT", 282, 285], ["GR", "PROTEIN", 165, 167], ["GR", "PROTEIN", 201, 203], ["GR", "PROTEIN", 229, 231], ["murine", "SPECIES", 66, 72], ["Experimental studies", "TEST", 0, 20], ["tissue cultures", "TEST", 31, 46], ["murine models", "TEST", 66, 79], ["oxidative stress", "PROBLEM", 114, 130], ["GR number", "TEST", 165, 174], ["GC binding", "TEST", 187, 197], ["GR", "TEST", 201, 203], ["GC", "TEST", 226, 228], ["DNA", "TEST", 282, 285], ["(v) inducible gene transcription", "PROBLEM", 297, 329], ["oxidative stress", "OBSERVATION", 114, 130]]], ["Nitrosylation, the covalent incorporation of a nitric oxide \u201cnitrosyl\u201d moiety into the critical cysteine(s) residue(s) of the GR is associated with loss of the steroid binding capacity (230).Oxidative Stress And CIRCIIn human monocytes, genes involved in oxidative functions were significantly overrepresented among GC down-regulated genes, while genes with antioxidant functions were upregulated (113).", [["monocytes", "ANATOMY", 226, 235], ["nitric oxide", "CHEMICAL", 47, 59], ["steroid", "CHEMICAL", 160, 167], ["nitric oxide", "CHEMICAL", 47, 59], ["nitrosyl", "CHEMICAL", 61, 69], ["cysteine", "CHEMICAL", 96, 104], ["steroid", "CHEMICAL", 160, 167], ["nitric oxide", "SIMPLE_CHEMICAL", 47, 59], ["nitrosyl\u201d moiety", "SIMPLE_CHEMICAL", 61, 77], ["cysteine", "AMINO_ACID", 96, 104], ["GR", "GENE_OR_GENE_PRODUCT", 126, 128], ["steroid", "SIMPLE_CHEMICAL", 160, 167], ["human", "ORGANISM", 220, 225], ["monocytes", "CELL", 226, 235], ["GR", "PROTEIN", 126, 128], ["CIRCIIn human monocytes", "CELL_LINE", 212, 235], ["GC down-regulated genes", "DNA", 316, 339], ["human", "SPECIES", 220, 225], ["human", "SPECIES", 220, 225], ["Nitrosylation", "TREATMENT", 0, 13], ["the covalent incorporation", "TREATMENT", 15, 41], ["a nitric oxide \u201cnitrosyl\u201d moiety", "TREATMENT", 45, 77], ["the GR", "PROBLEM", 122, 128], ["loss of the steroid binding capacity", "PROBLEM", 148, 184], ["Oxidative Stress", "PROBLEM", 191, 207], ["CIRCIIn human monocytes", "TREATMENT", 212, 235], ["oxidative functions", "TEST", 255, 274], ["GC down", "TEST", 316, 323], ["GR", "ANATOMY", 126, 128]]], ["A few studies have evaluated the impact of GC treatment on oxidative stress.", [["A few studies", "TEST", 0, 13], ["GC treatment", "TREATMENT", 43, 55], ["oxidative stress", "TREATMENT", 59, 75]]], ["In human monocytes, spontaneous, as well as phorbol myristyl acetate (PMA)-induced production of reactive oxygen species, is significantly reduced in GC-treated cells in comparison to controls (113).", [["monocytes", "ANATOMY", 9, 18], ["cells", "ANATOMY", 161, 166], ["phorbol myristyl acetate", "CHEMICAL", 44, 68], ["PMA", "CHEMICAL", 70, 73], ["oxygen", "CHEMICAL", 106, 112], ["phorbol myristyl acetate", "CHEMICAL", 44, 68], ["PMA", "CHEMICAL", 70, 73], ["oxygen", "CHEMICAL", 106, 112], ["human", "ORGANISM", 3, 8], ["monocytes", "CELL", 9, 18], ["phorbol myristyl acetate", "SIMPLE_CHEMICAL", 44, 68], ["PMA", "SIMPLE_CHEMICAL", 70, 73], ["reactive oxygen species", "SIMPLE_CHEMICAL", 97, 120], ["GC", "CELL", 150, 152], ["cells", "CELL", 161, 166], ["human monocytes", "CELL_TYPE", 3, 18], ["GC-treated cells", "CELL_LINE", 150, 166], ["human", "SPECIES", 3, 8], ["human", "SPECIES", 3, 8], ["human monocytes", "TEST", 3, 18], ["phorbol myristyl acetate", "TREATMENT", 44, 68], ["reactive oxygen species", "PROBLEM", 97, 120], ["human monocytes", "ANATOMY", 3, 18], ["reactive", "OBSERVATION_MODIFIER", 97, 105], ["oxygen species", "OBSERVATION", 106, 120], ["significantly", "OBSERVATION_MODIFIER", 125, 138], ["reduced", "OBSERVATION_MODIFIER", 139, 146]]], ["In murine macrophages, glucocorticoid treatment is associated with rapid (non-genomic) inhibition of superoxide anion production (231).", [["macrophages", "ANATOMY", 10, 21], ["superoxide", "CHEMICAL", 101, 111], ["superoxide", "CHEMICAL", 101, 111], ["murine", "ORGANISM", 3, 9], ["macrophages", "CELL", 10, 21], ["glucocorticoid", "SIMPLE_CHEMICAL", 23, 37], ["superoxide anion", "SIMPLE_CHEMICAL", 101, 117], ["murine macrophages", "CELL_TYPE", 3, 21], ["murine", "SPECIES", 3, 9], ["glucocorticoid treatment", "TREATMENT", 23, 47], ["rapid (non-genomic) inhibition of superoxide anion production", "PROBLEM", 67, 128], ["macrophages", "OBSERVATION", 10, 21], ["glucocorticoid treatment", "OBSERVATION", 23, 47]]], ["In murine sepsis, GC treatment attenuated renal dysfunction by reducing mitochondrial injury with preservation of cytochrome c oxidase and suppression of pro-apoptotic protein levels (232).", [["renal", "ANATOMY", 42, 47], ["mitochondrial", "ANATOMY", 72, 85], ["sepsis", "DISEASE", 10, 16], ["GC", "CHEMICAL", 18, 20], ["renal dysfunction", "DISEASE", 42, 59], ["mitochondrial injury", "DISEASE", 72, 92], ["murine", "ORGANISM", 3, 9], ["renal", "ORGAN", 42, 47], ["mitochondrial", "CELLULAR_COMPONENT", 72, 85], ["cytochrome c oxidase", "GENE_OR_GENE_PRODUCT", 114, 134], ["cytochrome c oxidase", "PROTEIN", 114, 134], ["pro-apoptotic protein", "PROTEIN", 154, 175], ["murine", "SPECIES", 3, 9], ["murine sepsis", "PROBLEM", 3, 16], ["GC treatment", "TREATMENT", 18, 30], ["renal dysfunction", "PROBLEM", 42, 59], ["reducing mitochondrial injury", "PROBLEM", 63, 92], ["cytochrome c oxidase", "TREATMENT", 114, 134], ["pro-apoptotic protein levels", "TEST", 154, 182], ["sepsis", "OBSERVATION", 10, 16], ["renal", "ANATOMY", 42, 47], ["dysfunction", "OBSERVATION", 48, 59], ["mitochondrial injury", "OBSERVATION", 72, 92]]], ["In clinical (233, 234) and experimental (162, 235) randomized trials, participants with severe sepsis receiving GC treatment had, in comparison to controls, a significant reduction in (i) circulating nitric oxide levels (162, 233, 235), and (ii) spontaneous release of hydrogen peroxide (H2O2) by neutrophils (234).Thiamine ::: HypovitaminosesThiamine is a water-soluble vitamin, which is passively absorbed in the small intestine.", [["neutrophils", "ANATOMY", 297, 308], ["small intestine", "ANATOMY", 415, 430], ["sepsis", "DISEASE", 95, 101], ["nitric oxide", "CHEMICAL", 200, 212], ["hydrogen peroxide", "CHEMICAL", 269, 286], ["H2O2", "CHEMICAL", 288, 292], ["Thiamine", "CHEMICAL", 315, 323], ["Hypovitaminoses", "CHEMICAL", 328, 343], ["Thiamine", "CHEMICAL", 343, 351], ["vitamin", "CHEMICAL", 371, 378], ["nitric oxide", "CHEMICAL", 200, 212], ["hydrogen peroxide", "CHEMICAL", 269, 286], ["H2O2", "CHEMICAL", 288, 292], ["Thiamine", "CHEMICAL", 315, 323], ["Thiamine", "CHEMICAL", 343, 351], ["vitamin", "CHEMICAL", 371, 378], ["nitric oxide", "SIMPLE_CHEMICAL", 200, 212], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 269, 286], ["H2O2", "SIMPLE_CHEMICAL", 288, 292], ["neutrophils", "CELL", 297, 308], ["Thiamine", "SIMPLE_CHEMICAL", 315, 323], ["Hypovitaminoses", "SIMPLE_CHEMICAL", 328, 343], ["Thiamine", "SIMPLE_CHEMICAL", 343, 351], ["vitamin", "SIMPLE_CHEMICAL", 371, 378], ["small intestine", "ORGAN", 415, 430], ["neutrophils", "CELL_TYPE", 297, 308], ["participants", "SPECIES", 70, 82], ["severe sepsis", "PROBLEM", 88, 101], ["GC treatment", "TREATMENT", 112, 124], ["a significant reduction", "TREATMENT", 157, 180], ["circulating nitric oxide levels", "TEST", 188, 219], ["hydrogen peroxide", "TREATMENT", 269, 286], ["neutrophils", "TEST", 297, 308], ["Hypovitaminoses", "TREATMENT", 328, 343], ["Thiamine", "TREATMENT", 343, 351], ["a water-soluble vitamin", "TREATMENT", 355, 378], ["severe", "OBSERVATION_MODIFIER", 88, 94], ["sepsis", "OBSERVATION", 95, 101], ["significant", "OBSERVATION_MODIFIER", 159, 170], ["reduction", "OBSERVATION_MODIFIER", 171, 180], ["small intestine", "ANATOMY", 415, 430]]], ["After ingestion, free thiamine is converted to the active form thiamine pyrophosphate (TPP), commonly known as vitamin B1, by thiamine pyrophosphokinase.", [["thiamine", "CHEMICAL", 22, 30], ["thiamine pyrophosphate", "CHEMICAL", 63, 85], ["TPP", "CHEMICAL", 87, 90], ["vitamin B1", "CHEMICAL", 111, 121], ["thiamine", "CHEMICAL", 126, 134], ["thiamine", "CHEMICAL", 22, 30], ["thiamine pyrophosphate", "CHEMICAL", 63, 85], ["TPP", "CHEMICAL", 87, 90], ["vitamin B1", "CHEMICAL", 111, 121], ["thiamine", "CHEMICAL", 126, 134], ["thiamine", "SIMPLE_CHEMICAL", 22, 30], ["thiamine pyrophosphate", "SIMPLE_CHEMICAL", 63, 85], ["TPP", "SIMPLE_CHEMICAL", 87, 90], ["vitamin B1", "SIMPLE_CHEMICAL", 111, 121], ["thiamine pyrophosphokinase", "SIMPLE_CHEMICAL", 126, 152], ["thiamine pyrophosphokinase", "PROTEIN", 126, 152], ["free thiamine", "TREATMENT", 17, 30], ["thiamine pyrophosphate (TPP", "TREATMENT", 63, 90], ["vitamin B1", "TREATMENT", 111, 121], ["thiamine pyrophosphokinase", "TREATMENT", 126, 152]]], ["The majority of TPP in the body is found in erythrocytes and accounts for ~80% of the body's total storage (238).", [["body", "ANATOMY", 27, 31], ["erythrocytes", "ANATOMY", 44, 56], ["body", "ANATOMY", 86, 90], ["TPP", "CHEMICAL", 16, 19], ["TPP", "CHEMICAL", 16, 19], ["TPP", "GENE_OR_GENE_PRODUCT", 16, 19], ["body", "ORGANISM_SUBDIVISION", 27, 31], ["erythrocytes", "CELL", 44, 56], ["body", "ORGANISM_SUBDIVISION", 86, 90], ["TPP", "PROTEIN", 16, 19], ["erythrocytes", "CELL_TYPE", 44, 56], ["TPP in the body", "PROBLEM", 16, 31], ["erythrocytes", "PROBLEM", 44, 56], ["the body's total storage", "TEST", 82, 106], ["TPP", "OBSERVATION", 16, 19], ["body", "ANATOMY", 27, 31], ["erythrocytes", "OBSERVATION", 44, 56]]], ["Thiamine pyrophosphate is a key co-factor for pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, transketolase, and branched-chain keto-acid dehydrogenase (238).", [["Thiamine pyrophosphate", "CHEMICAL", 0, 22], ["pyruvate", "CHEMICAL", 46, 54], ["alpha-ketoglutarate", "CHEMICAL", 70, 89], ["Thiamine pyrophosphate", "CHEMICAL", 0, 22], ["pyruvate", "CHEMICAL", 46, 54], ["alpha-ketoglutarate", "CHEMICAL", 70, 89], ["branched-chain keto-acid", "CHEMICAL", 124, 148], ["Thiamine pyrophosphate", "SIMPLE_CHEMICAL", 0, 22], ["pyruvate dehydrogenase", "GENE_OR_GENE_PRODUCT", 46, 68], ["alpha-ketoglutarate dehydrogenase", "GENE_OR_GENE_PRODUCT", 70, 103], ["transketolase", "GENE_OR_GENE_PRODUCT", 105, 118], ["branched-chain keto-acid dehydrogenase", "GENE_OR_GENE_PRODUCT", 124, 162], ["pyruvate dehydrogenase", "PROTEIN", 46, 68], ["alpha-ketoglutarate dehydrogenase", "PROTEIN", 70, 103], ["transketolase", "PROTEIN", 105, 118], ["branched-chain keto-acid dehydrogenase", "PROTEIN", 124, 162], ["Thiamine pyrophosphate", "TREATMENT", 0, 22], ["pyruvate dehydrogenase", "TEST", 46, 68], ["alpha-ketoglutarate dehydrogenase", "TEST", 70, 103], ["transketolase", "TEST", 105, 118], ["branched-chain keto-acid dehydrogenase", "TEST", 124, 162]]], ["Pyruvate dehydrogenase is the gatekeeper for entry into the Krebs Cycle, without which pyruvate would be converted to lactate as opposed to acetyl-coenzyme A. Alpha-ketoglutarate dehydrogenase is required for completion of the Krebs Cycle once it has begun.", [["Pyruvate", "CHEMICAL", 0, 8], ["pyruvate", "CHEMICAL", 87, 95], ["lactate", "CHEMICAL", 118, 125], ["acetyl", "CHEMICAL", 140, 146], ["Alpha-ketoglutarate", "CHEMICAL", 159, 178], ["Pyruvate", "CHEMICAL", 0, 8], ["pyruvate", "CHEMICAL", 87, 95], ["lactate", "CHEMICAL", 118, 125], ["acetyl", "CHEMICAL", 140, 146], ["Alpha-ketoglutarate", "CHEMICAL", 159, 178], ["Pyruvate dehydrogenase", "GENE_OR_GENE_PRODUCT", 0, 22], ["pyruvate", "SIMPLE_CHEMICAL", 87, 95], ["lactate", "SIMPLE_CHEMICAL", 118, 125], ["acetyl-coenzyme", "SIMPLE_CHEMICAL", 140, 155], ["Alpha-ketoglutarate dehydrogenase", "GENE_OR_GENE_PRODUCT", 159, 192], ["Pyruvate dehydrogenase", "PROTEIN", 0, 22], ["acetyl-coenzyme A. Alpha-ketoglutarate dehydrogenase", "PROTEIN", 140, 192], ["Pyruvate dehydrogenase", "TEST", 0, 22], ["the Krebs Cycle", "TEST", 56, 71], ["lactate", "TEST", 118, 125], ["acetyl", "TREATMENT", 140, 146], ["Alpha-ketoglutarate dehydrogenase", "TREATMENT", 159, 192], ["the Krebs Cycle", "TREATMENT", 223, 238]]], ["Transketolase is a key enzyme for the pentose phosphate pathway and for the production of NADPH with glutathione cycling, an important anti-oxidant pathway (239).", [["Transketolase", "CHEMICAL", 0, 13], ["pentose phosphate", "CHEMICAL", 38, 55], ["NADPH", "CHEMICAL", 90, 95], ["glutathione", "CHEMICAL", 101, 112], ["pentose phosphate", "CHEMICAL", 38, 55], ["NADPH", "CHEMICAL", 90, 95], ["glutathione", "CHEMICAL", 101, 112], ["Transketolase", "GENE_OR_GENE_PRODUCT", 0, 13], ["pentose", "SIMPLE_CHEMICAL", 38, 45], ["NADPH", "SIMPLE_CHEMICAL", 90, 95], ["glutathione", "SIMPLE_CHEMICAL", 101, 112], ["Transketolase", "PROTEIN", 0, 13], ["the pentose phosphate pathway", "TREATMENT", 34, 63], ["glutathione cycling", "TREATMENT", 101, 120]]], ["There are also other proposed non-cofactor roles of thiamine within the immune system, gene regulation, oxidative stress response, cholinergic activity, chloride channel function, and neurotransmission (238).Thiamine ::: HypovitaminosesThe human adult can store around 30 mg of thiamine in muscle tissue, liver and kidneys, however, these stores can become depleted in as little as 18 days after the cessation of thiamine intake (238).", [["immune system", "ANATOMY", 72, 85], ["muscle tissue", "ANATOMY", 290, 303], ["liver", "ANATOMY", 305, 310], ["kidneys", "ANATOMY", 315, 322], ["thiamine", "CHEMICAL", 52, 60], ["chloride", "CHEMICAL", 153, 161], ["Thiamine", "CHEMICAL", 208, 216], ["Hypovitaminoses", "CHEMICAL", 221, 236], ["thiamine", "CHEMICAL", 278, 286], ["thiamine", "CHEMICAL", 413, 421], ["thiamine", "CHEMICAL", 52, 60], ["chloride", "CHEMICAL", 153, 161], ["Thiamine", "CHEMICAL", 208, 216], ["thiamine", "CHEMICAL", 278, 286], ["thiamine", "CHEMICAL", 413, 421], ["thiamine", "SIMPLE_CHEMICAL", 52, 60], ["chloride", "SIMPLE_CHEMICAL", 153, 161], ["Thiamine", "SIMPLE_CHEMICAL", 208, 216], ["Hypovitaminoses", "SIMPLE_CHEMICAL", 221, 236], ["human", "ORGANISM", 240, 245], ["thiamine", "SIMPLE_CHEMICAL", 278, 286], ["muscle tissue", "TISSUE", 290, 303], ["liver", "ORGAN", 305, 310], ["kidneys", "ORGAN", 315, 322], ["thiamine", "SIMPLE_CHEMICAL", 413, 421], ["human", "SPECIES", 240, 245], ["human", "SPECIES", 240, 245], ["thiamine", "TREATMENT", 52, 60], ["oxidative stress response", "PROBLEM", 104, 129], ["chloride channel function", "TEST", 153, 178], ["Thiamine", "TREATMENT", 208, 216], ["Hypovitaminoses", "TREATMENT", 221, 236], ["thiamine", "TREATMENT", 278, 286], ["thiamine intake", "TREATMENT", 413, 428], ["oxidative stress response", "OBSERVATION", 104, 129], ["cholinergic activity", "OBSERVATION", 131, 151], ["muscle tissue", "ANATOMY", 290, 303], ["liver", "ANATOMY", 305, 310], ["kidneys", "ANATOMY", 315, 322], ["depleted", "OBSERVATION", 357, 365]]], ["A thiamine deficiency syndrome, beriberi, bears a number of similarities to sepsis, including peripheral vasodilation, cardiac dysfunction, and elevated lactate levels (237).", [["cardiac", "ANATOMY", 119, 126], ["thiamine", "CHEMICAL", 2, 10], ["beriberi", "DISEASE", 32, 40], ["sepsis", "DISEASE", 76, 82], ["peripheral vasodilation", "DISEASE", 94, 117], ["cardiac dysfunction", "DISEASE", 119, 138], ["lactate", "CHEMICAL", 153, 160], ["thiamine", "CHEMICAL", 2, 10], ["lactate", "CHEMICAL", 153, 160], ["thiamine", "SIMPLE_CHEMICAL", 2, 10], ["peripheral", "TISSUE", 94, 104], ["cardiac", "ORGAN", 119, 126], ["lactate", "SIMPLE_CHEMICAL", 153, 160], ["A thiamine deficiency syndrome", "PROBLEM", 0, 30], ["beriberi", "PROBLEM", 32, 40], ["sepsis", "PROBLEM", 76, 82], ["peripheral vasodilation", "PROBLEM", 94, 117], ["cardiac dysfunction", "PROBLEM", 119, 138], ["elevated lactate levels", "PROBLEM", 144, 167], ["thiamine deficiency syndrome", "OBSERVATION", 2, 30], ["sepsis", "OBSERVATION", 76, 82], ["peripheral", "ANATOMY_MODIFIER", 94, 104], ["vasodilation", "OBSERVATION", 105, 117], ["cardiac", "ANATOMY", 119, 126], ["dysfunction", "OBSERVATION", 127, 138], ["elevated", "OBSERVATION_MODIFIER", 144, 152]]], ["In critical illness, the prevalence of thiamine deficiency is 10\u201320% upon admission (198, 240) and can increase up to 71% during ICU stay, suggesting rapid depletion of this vitamin (198).", [["critical illness", "DISEASE", 3, 19], ["thiamine", "CHEMICAL", 39, 47], ["vitamin", "CHEMICAL", 174, 181], ["thiamine", "CHEMICAL", 39, 47], ["vitamin (198)", "CHEMICAL", 174, 187], ["thiamine", "SIMPLE_CHEMICAL", 39, 47], ["vitamin", "SIMPLE_CHEMICAL", 174, 181], ["thiamine deficiency", "PROBLEM", 39, 58], ["this vitamin", "TREATMENT", 169, 181], ["thiamine deficiency", "OBSERVATION", 39, 58], ["rapid", "OBSERVATION_MODIFIER", 150, 155], ["depletion", "OBSERVATION", 156, 165]]], ["Based on limited data, no association was detected between thiamine levels, markers of oxidative stress (198) and mortality (198, 241).", [["thiamine", "CHEMICAL", 59, 67], ["thiamine", "CHEMICAL", 59, 67], ["thiamine", "SIMPLE_CHEMICAL", 59, 67], ["thiamine levels", "TEST", 59, 74], ["oxidative stress", "TEST", 87, 103]]], ["In one study, a significant negative correlation was reported between thiamine and lactic acid levels in patients with sepsis without liver dysfunction (240).", [["liver", "ANATOMY", 134, 139], ["thiamine", "CHEMICAL", 70, 78], ["lactic acid", "CHEMICAL", 83, 94], ["sepsis", "DISEASE", 119, 125], ["liver dysfunction", "DISEASE", 134, 151], ["thiamine", "CHEMICAL", 70, 78], ["lactic acid", "CHEMICAL", 83, 94], ["thiamine", "SIMPLE_CHEMICAL", 70, 78], ["lactic acid", "SIMPLE_CHEMICAL", 83, 94], ["patients", "ORGANISM", 105, 113], ["liver", "ORGAN", 134, 139], ["patients", "SPECIES", 105, 113], ["one study", "TEST", 3, 12], ["thiamine", "TEST", 70, 78], ["lactic acid levels", "TEST", 83, 101], ["sepsis", "PROBLEM", 119, 125], ["liver dysfunction", "PROBLEM", 134, 151], ["sepsis", "OBSERVATION", 119, 125], ["liver", "ANATOMY", 134, 139], ["dysfunction", "OBSERVATION", 140, 151]]], ["In a pilot randomized controlled trial (RCT) of patients with septic shock (n = 88), the administration of thiamine (200 mg twice a day for 7 days) reduced lactate levels and improved mortality over time in a pre-defined subgroup of patients with thiamine deficiency (35% of cohort) (239).", [["septic shock", "DISEASE", 62, 74], ["thiamine", "CHEMICAL", 107, 115], ["lactate", "CHEMICAL", 156, 163], ["thiamine", "CHEMICAL", 247, 255], ["thiamine", "CHEMICAL", 107, 115], ["lactate", "CHEMICAL", 156, 163], ["thiamine", "CHEMICAL", 247, 255], ["patients", "ORGANISM", 48, 56], ["thiamine", "SIMPLE_CHEMICAL", 107, 115], ["lactate", "SIMPLE_CHEMICAL", 156, 163], ["patients", "ORGANISM", 233, 241], ["thiamine", "SIMPLE_CHEMICAL", 247, 255], ["patients", "SPECIES", 48, 56], ["patients", "SPECIES", 233, 241], ["a pilot randomized controlled trial (RCT", "TREATMENT", 3, 43], ["septic shock", "PROBLEM", 62, 74], ["thiamine", "TREATMENT", 107, 115], ["reduced lactate levels", "PROBLEM", 148, 170], ["thiamine deficiency", "PROBLEM", 247, 266], ["septic shock", "OBSERVATION", 62, 74]]], ["In a retrospective, single-center, matched cohort study, administration of thiamine within 24 h of septic shock (n = 123) was associated with improved likelihood of lactate clearance and a reduction in 28-day mortality (242).", [["thiamine", "CHEMICAL", 75, 83], ["septic shock", "DISEASE", 99, 111], ["lactate", "CHEMICAL", 165, 172], ["thiamine", "CHEMICAL", 75, 83], ["lactate", "CHEMICAL", 165, 172], ["thiamine", "SIMPLE_CHEMICAL", 75, 83], ["lactate", "SIMPLE_CHEMICAL", 165, 172], ["matched cohort study", "TEST", 35, 55], ["thiamine", "TREATMENT", 75, 83], ["septic shock", "PROBLEM", 99, 111], ["lactate clearance", "PROBLEM", 165, 182], ["septic shock", "OBSERVATION", 99, 111]]], ["Despite some promising results, there is insufficient evidence to support or reject thiamine supplementation as a monotherapy in critically ill patients (238).Vitamin D ::: HypovitaminosesVitamin D is an ancient molecule that functions as both a nutrient and a hormone with metabolic and immunomodulatory properties; it regulates over 1,000 genes of the human genome (243, 244).", [["thiamine", "CHEMICAL", 84, 92], ["critically ill", "DISEASE", 129, 143], ["Vitamin D", "CHEMICAL", 159, 168], ["Hypovitaminoses", "CHEMICAL", 173, 188], ["Vitamin D", "CHEMICAL", 188, 197], ["thiamine", "CHEMICAL", 84, 92], ["Vitamin D", "CHEMICAL", 159, 168], ["Hypovitaminoses", "CHEMICAL", 173, 188], ["Vitamin D", "CHEMICAL", 188, 197], ["thiamine", "SIMPLE_CHEMICAL", 84, 92], ["patients", "ORGANISM", 144, 152], ["Vitamin D", "SIMPLE_CHEMICAL", 159, 168], ["Hypovitaminoses", "SIMPLE_CHEMICAL", 173, 188], ["Vitamin D", "SIMPLE_CHEMICAL", 188, 197], ["human", "ORGANISM", 354, 359], ["human genome", "DNA", 354, 366], ["patients", "SPECIES", 144, 152], ["human", "SPECIES", 354, 359], ["human", "SPECIES", 354, 359], ["thiamine supplementation", "TREATMENT", 84, 108], ["a monotherapy", "TREATMENT", 112, 125], ["Hypovitaminoses", "TREATMENT", 173, 188], ["Vitamin D", "TREATMENT", 188, 197], ["metabolic and immunomodulatory properties", "TREATMENT", 274, 315], ["human genome", "ANATOMY", 354, 366]]], ["The vitamin D receptor (VDR) is a member of the nuclear receptor gene family and is expressed in virtually all nucleated cells.", [["nuclear", "ANATOMY", 48, 55], ["cells", "ANATOMY", 121, 126], ["vitamin D", "CHEMICAL", 4, 13], ["vitamin D", "CHEMICAL", 4, 13], ["vitamin D receptor", "GENE_OR_GENE_PRODUCT", 4, 22], ["VDR", "GENE_OR_GENE_PRODUCT", 24, 27], ["cells", "CELL", 121, 126], ["vitamin D receptor", "PROTEIN", 4, 22], ["VDR", "PROTEIN", 24, 27], ["nuclear receptor gene family", "DNA", 48, 76], ["nucleated cells", "CELL_TYPE", 111, 126], ["The vitamin D receptor (VDR)", "TREATMENT", 0, 28], ["nucleated cells", "OBSERVATION", 111, 126]]], ["Decreased serum levels of vitamin D have been associated with several autoimmune inflammatory diseases.", [["serum", "ANATOMY", 10, 15], ["vitamin D", "CHEMICAL", 26, 35], ["autoimmune inflammatory diseases", "DISEASE", 70, 102], ["vitamin D", "CHEMICAL", 26, 35], ["serum", "ORGANISM_SUBSTANCE", 10, 15], ["vitamin D", "SIMPLE_CHEMICAL", 26, 35], ["Decreased serum levels", "PROBLEM", 0, 22], ["vitamin D", "PROBLEM", 26, 35], ["several autoimmune inflammatory diseases", "PROBLEM", 62, 102], ["associated with", "UNCERTAINTY", 46, 61], ["several", "OBSERVATION_MODIFIER", 62, 69], ["autoimmune", "OBSERVATION_MODIFIER", 70, 80], ["inflammatory diseases", "OBSERVATION", 81, 102]]], ["Genome-and transcriptome-wide studies indicate that vitamin D signaling modulates many inflammatory responses on several levels (245), including interference with NF-\u03baB, via upregulation of I\u03baB expression (246).", [["vitamin D", "CHEMICAL", 52, 61], ["vitamin D", "CHEMICAL", 52, 61], ["vitamin D", "SIMPLE_CHEMICAL", 52, 61], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 163, 168], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 190, 193], ["NF-\u03baB", "PROTEIN", 163, 168], ["I\u03baB", "PROTEIN", 190, 193], ["wide studies", "TEST", 25, 37], ["vitamin D signaling modulates", "PROBLEM", 52, 81], ["many inflammatory responses", "PROBLEM", 82, 109], ["NF", "TEST", 163, 165], ["inflammatory", "OBSERVATION_MODIFIER", 87, 99]]], ["In addition, the ability of vitamin D to inhibit metabolic stress and energy expenditure in a cell microenvironment suggests that this pleiotropic hormone has a broad task as a pro-survival agent (244).Vitamin D ::: HypovitaminosesA growing body of scientific and medical literature supports the important anti-inflammatory functions of vitamin D in health and disease, including the enhancement of GC-mediated anti-inflammatory actions (247).", [["cell", "ANATOMY", 94, 98], ["body", "ANATOMY", 241, 245], ["vitamin D", "CHEMICAL", 28, 37], ["Vitamin D", "CHEMICAL", 202, 211], ["HypovitaminosesA", "CHEMICAL", 216, 232], ["vitamin D", "CHEMICAL", 337, 346], ["vitamin D", "CHEMICAL", 28, 37], ["Vitamin D", "CHEMICAL", 202, 211], ["HypovitaminosesA", "CHEMICAL", 216, 232], ["vitamin D", "CHEMICAL", 337, 346], ["vitamin D", "SIMPLE_CHEMICAL", 28, 37], ["cell", "CELL", 94, 98], ["Vitamin D", "SIMPLE_CHEMICAL", 202, 211], ["HypovitaminosesA", "SIMPLE_CHEMICAL", 216, 232], ["body", "ORGANISM_SUBDIVISION", 241, 245], ["vitamin D", "SIMPLE_CHEMICAL", 337, 346], ["GC", "SIMPLE_CHEMICAL", 399, 401], ["vitamin D", "TREATMENT", 28, 37], ["metabolic stress", "PROBLEM", 49, 65], ["this pleiotropic hormone", "PROBLEM", 130, 154], ["a pro-survival agent", "TREATMENT", 175, 195], ["HypovitaminosesA", "TREATMENT", 216, 232], ["vitamin D", "TREATMENT", 337, 346], ["disease", "PROBLEM", 361, 368], ["GC-mediated anti-inflammatory actions", "TREATMENT", 399, 436]]], ["The anti-inflammatory effect of vitamin D was consistently observed in studies of cell lines and human PBMCs, and was the subject of a comprehensive review (248).", [["cell lines", "ANATOMY", 82, 92], ["PBMCs", "ANATOMY", 103, 108], ["vitamin D", "CHEMICAL", 32, 41], ["vitamin D", "CHEMICAL", 32, 41], ["vitamin D", "SIMPLE_CHEMICAL", 32, 41], ["cell lines", "CELL", 82, 92], ["human", "ORGANISM", 97, 102], ["PBMCs", "CELL", 103, 108], ["cell lines", "CELL_LINE", 82, 92], ["human PBMCs", "CELL_TYPE", 97, 108], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 97, 102], ["vitamin D", "TREATMENT", 32, 41], ["cell lines", "TREATMENT", 82, 92], ["human PBMCs", "TEST", 97, 108], ["anti-inflammatory", "OBSERVATION_MODIFIER", 4, 21], ["cell lines", "OBSERVATION", 82, 92]]], ["PBMCs activated with TLR ligands after incubation with 1,25(OH)D3 showed decreased release of TNF-\u03b1 and IL-1\u03b2 and increased anti-bacterial activity (249).", [["PBMCs", "ANATOMY", 0, 5], ["1,25(OH)D3", "CHEMICAL", 55, 65], ["1,25(OH)D3", "CHEMICAL", 55, 65], ["PBMCs", "CELL", 0, 5], ["TLR", "GENE_OR_GENE_PRODUCT", 21, 24], ["1,25(OH)D3", "SIMPLE_CHEMICAL", 55, 65], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 94, 99], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 104, 109], ["PBMCs", "CELL_TYPE", 0, 5], ["TLR", "PROTEIN", 21, 24], ["TNF", "PROTEIN", 94, 97], ["IL-1\u03b2", "PROTEIN", 104, 109], ["TLR ligands", "TREATMENT", 21, 32], ["incubation", "TEST", 39, 49], ["TNF", "TEST", 94, 97], ["IL", "TREATMENT", 104, 106], ["increased anti-bacterial activity", "TREATMENT", 114, 147], ["anti-bacterial activity", "OBSERVATION", 124, 147]]], ["In PBMCs, physiologic levels of vitamin D reduce inflammatory activities, by upregulating GC-mediated mitogen activated protein kinase (MAPK; see section Glucocorticoid Receptor-Alpha) phosphatase-1 (MKP-1) (250) to down-regulate p38 MAPK-mediated inflammatory gene expression (including TNF-\u03b1, IL-1\u03b2, IL-6, and IL-8) (251).", [["PBMCs", "ANATOMY", 3, 8], ["vitamin D", "CHEMICAL", 32, 41], ["vitamin D", "CHEMICAL", 32, 41], ["PBMCs", "CELL", 3, 8], ["vitamin D", "SIMPLE_CHEMICAL", 32, 41], ["GC-mediated mitogen activated protein kinase", "GENE_OR_GENE_PRODUCT", 90, 134], ["MAPK", "GENE_OR_GENE_PRODUCT", 136, 140], ["Glucocorticoid Receptor-Alpha) phosphatase-1", "GENE_OR_GENE_PRODUCT", 154, 198], ["MKP-1", "GENE_OR_GENE_PRODUCT", 200, 205], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 230, 238], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 288, 293], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 295, 300], ["IL-6", "GENE_OR_GENE_PRODUCT", 302, 306], ["IL-8", "GENE_OR_GENE_PRODUCT", 312, 316], ["PBMCs", "CELL_TYPE", 3, 8], ["mitogen activated protein kinase (MAPK; see section Glucocorticoid Receptor-Alpha) phosphatase-1 (MKP-1", "PROTEIN", 102, 205], ["p38 MAPK", "PROTEIN", 230, 238], ["TNF", "PROTEIN", 288, 291], ["PBMCs", "TEST", 3, 8], ["physiologic levels", "TEST", 10, 28], ["vitamin D", "TREATMENT", 32, 41], ["inflammatory activities", "PROBLEM", 49, 72], ["upregulating GC", "TEST", 77, 92], ["protein kinase", "TEST", 120, 134], ["MAPK", "TEST", 136, 140], ["Glucocorticoid Receptor", "TEST", 154, 177], ["Alpha) phosphatase", "TEST", 178, 196], ["MKP", "TEST", 200, 203], ["MAPK", "TEST", 234, 238], ["inflammatory gene expression", "PROBLEM", 248, 276], ["TNF", "TEST", 288, 291], ["IL", "TEST", 295, 297], ["IL", "TEST", 302, 304], ["inflammatory", "OBSERVATION_MODIFIER", 248, 260]]], ["In LPS-activated PBMCs (247) and PBMCs from patients with asthma (252), vitamin D enhanced dexamethasone-induced expression of MKP-1 (247), and this synergism was dependent on vitamin D-induced GM-CSF release (247).", [["PBMCs", "ANATOMY", 17, 22], ["PBMCs", "ANATOMY", 33, 38], ["LPS", "CHEMICAL", 3, 6], ["asthma", "DISEASE", 58, 64], ["vitamin D", "CHEMICAL", 72, 81], ["dexamethasone", "CHEMICAL", 91, 104], ["vitamin D", "CHEMICAL", 176, 185], ["GM", "CHEMICAL", 194, 196], ["vitamin D", "CHEMICAL", 72, 81], ["dexamethasone", "CHEMICAL", 91, 104], ["vitamin D", "CHEMICAL", 176, 185], ["LPS", "SIMPLE_CHEMICAL", 3, 6], ["PBMCs", "CELL", 17, 22], ["PBMCs", "CELL", 33, 38], ["patients", "ORGANISM", 44, 52], ["vitamin D", "SIMPLE_CHEMICAL", 72, 81], ["dexamethasone", "SIMPLE_CHEMICAL", 91, 104], ["MKP-1", "GENE_OR_GENE_PRODUCT", 127, 132], ["vitamin D", "SIMPLE_CHEMICAL", 176, 185], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 194, 200], ["PBMCs", "CELL_TYPE", 17, 22], ["PBMCs", "CELL_TYPE", 33, 38], ["MKP", "PROTEIN", 127, 130], ["CSF", "PROTEIN", 197, 200], ["patients", "SPECIES", 44, 52], ["LPS", "TEST", 3, 6], ["activated PBMCs", "TEST", 7, 22], ["PBMCs", "TEST", 33, 38], ["asthma", "PROBLEM", 58, 64], ["vitamin D enhanced dexamethasone", "TREATMENT", 72, 104], ["MKP", "TEST", 127, 130], ["this synergism", "PROBLEM", 144, 158], ["vitamin D", "TREATMENT", 176, 185], ["CSF release", "TEST", 197, 208]]], ["One study suggested that the interaction between vitamin D, glucocorticoids and their cognate receptors is related to the duration of exposure to vitamin D (253).Vitamin D ::: HypovitaminosesBeside this indirect modulation of signaling cascades, vitamin D and its receptor complex VDR/RXR can interact directly with the GC receptor and other transcription factors (245).", [["vitamin D", "CHEMICAL", 49, 58], ["glucocorticoids", "CHEMICAL", 60, 75], ["vitamin D", "CHEMICAL", 146, 155], ["Vitamin D", "CHEMICAL", 162, 171], ["Hypovitaminoses", "CHEMICAL", 176, 191], ["vitamin D", "CHEMICAL", 246, 255], ["vitamin D", "CHEMICAL", 49, 58], ["vitamin D (253)", "CHEMICAL", 146, 161], ["Vitamin D", "CHEMICAL", 162, 171], ["Hypovitaminoses", "CHEMICAL", 176, 191], ["vitamin D", "CHEMICAL", 246, 255], ["vitamin D", "SIMPLE_CHEMICAL", 49, 58], ["glucocorticoids", "SIMPLE_CHEMICAL", 60, 75], ["vitamin D", "SIMPLE_CHEMICAL", 146, 155], ["Vitamin D", "SIMPLE_CHEMICAL", 162, 171], ["Hypovitaminoses", "SIMPLE_CHEMICAL", 176, 191], ["vitamin D", "SIMPLE_CHEMICAL", 246, 255], ["VDR", "GENE_OR_GENE_PRODUCT", 281, 284], ["RXR", "GENE_OR_GENE_PRODUCT", 285, 288], ["GC receptor", "GENE_OR_GENE_PRODUCT", 320, 331], ["cognate receptors", "PROTEIN", 86, 103], ["VDR", "PROTEIN", 281, 284], ["RXR", "PROTEIN", 285, 288], ["GC receptor", "PROTEIN", 320, 331], ["transcription factors", "PROTEIN", 342, 363], ["One study", "TEST", 0, 9], ["vitamin D, glucocorticoids", "TREATMENT", 49, 75], ["their cognate receptors", "TREATMENT", 80, 103], ["vitamin D", "TREATMENT", 146, 155], ["Hypovitaminoses", "TREATMENT", 176, 191], ["signaling cascades", "TREATMENT", 226, 244], ["vitamin D", "TREATMENT", 246, 255], ["its receptor complex VDR/RXR", "TREATMENT", 260, 288], ["the GC receptor", "TREATMENT", 316, 331]]], ["Of interest, Vitamin D has a high affinity binding for the GR (254), and was recently shown to increase, in a dose- dependent manner, GR concentration in T cells (255).", [["T cells", "ANATOMY", 154, 161], ["Vitamin D", "CHEMICAL", 13, 22], ["Vitamin D", "CHEMICAL", 13, 22], ["Vitamin D", "SIMPLE_CHEMICAL", 13, 22], ["GR", "GENE_OR_GENE_PRODUCT", 59, 61], ["GR", "GENE_OR_GENE_PRODUCT", 134, 136], ["T cells", "CELL", 154, 161], ["GR", "PROTEIN", 59, 61], ["GR", "PROTEIN", 134, 136], ["T cells", "CELL_TYPE", 154, 161], ["Vitamin D", "TREATMENT", 13, 22], ["a high affinity binding", "PROBLEM", 27, 50]]], ["Based on its pleiotropic functions, vitamin D is considered a \u201cmaster tuner\u201d in shifting homeostatic balance from a pro-inflammatory to a pro-resolving status (244).", [["vitamin D", "CHEMICAL", 36, 45], ["vitamin D", "CHEMICAL", 36, 45], ["vitamin D", "SIMPLE_CHEMICAL", 36, 45], ["vitamin D", "TREATMENT", 36, 45], ["homeostatic balance", "OBSERVATION", 89, 108]]], ["Several studies demonstrated a dose-dependent response of vitamin D with respect to reducing inflammation, with 1 nM and 10 nM concentrations causing the greatest effects (248).", [["vitamin D", "CHEMICAL", 58, 67], ["inflammation", "DISEASE", 93, 105], ["vitamin D", "CHEMICAL", 58, 67], ["vitamin D", "SIMPLE_CHEMICAL", 58, 67], ["Several studies", "TEST", 0, 15], ["vitamin D", "TREATMENT", 58, 67], ["reducing inflammation", "PROBLEM", 84, 105], ["10 nM concentrations", "TREATMENT", 121, 141], ["inflammation", "OBSERVATION", 93, 105], ["greatest", "OBSERVATION_MODIFIER", 154, 162]]], ["One study showed that serum 25(OH)D levels as high as 120 nmol/l may be necessary for optimal immune function (256).", [["serum", "ANATOMY", 22, 27], ["25(OH)D", "CHEMICAL", 28, 35], ["25(OH)D", "CHEMICAL", 28, 35], ["serum", "ORGANISM_SUBSTANCE", 22, 27], ["25(OH)D", "SIMPLE_CHEMICAL", 28, 35], ["One study", "TEST", 0, 9], ["serum", "TEST", 22, 27], ["OH)D levels", "TEST", 31, 42]]], ["A small study in healthy patients with hypovitaminosis D reported that significant anti-inflammatory benefits of vitamin D supplementation were only seen by achieving serum 25(OH)D levels greater than 100 nmol/l (256).Vitamin D ::: HypovitaminosesThe mitochondria also appear to be a direct target of the vitamin D endocrine system, and the two most important enzymes responsible for activation or inactivation of 25(OH)D, namely CYP27B1 (1\u03b1-hydroxylase) and CYP24A1 (24-hydroxylase), are located in the mitochondria (257).", [["serum", "ANATOMY", 167, 172], ["mitochondria", "ANATOMY", 251, 263], ["mitochondria", "ANATOMY", 504, 516], ["hypovitaminosis D", "DISEASE", 39, 56], ["vitamin D", "CHEMICAL", 113, 122], ["25(OH)D", "CHEMICAL", 173, 180], ["Vitamin D", "CHEMICAL", 218, 227], ["Hypovitaminoses", "CHEMICAL", 232, 247], ["vitamin D", "CHEMICAL", 305, 314], ["hypovitaminosis D", "CHEMICAL", 39, 56], ["vitamin D", "CHEMICAL", 113, 122], ["25(OH)D", "CHEMICAL", 173, 180], ["Vitamin D", "CHEMICAL", 218, 227], ["Hypovitaminoses", "CHEMICAL", 232, 247], ["vitamin D", "CHEMICAL", 305, 314], ["25(OH)D", "CHEMICAL", 414, 421], ["patients", "ORGANISM", 25, 33], ["vitamin D", "SIMPLE_CHEMICAL", 113, 122], ["serum", "ORGANISM_SUBSTANCE", 167, 172], ["25(OH)D", "SIMPLE_CHEMICAL", 173, 180], ["Vitamin D", "SIMPLE_CHEMICAL", 218, 227], ["mitochondria", "CELLULAR_COMPONENT", 251, 263], ["vitamin D", "GENE_OR_GENE_PRODUCT", 305, 314], ["25(OH)D", "SIMPLE_CHEMICAL", 414, 421], ["CYP27B1", "GENE_OR_GENE_PRODUCT", 430, 437], ["1\u03b1-hydroxylase", "GENE_OR_GENE_PRODUCT", 439, 453], ["CYP24A1 (24-hydroxylase", "GENE_OR_GENE_PRODUCT", 459, 482], ["mitochondria", "CELLULAR_COMPONENT", 504, 516], ["CYP27B1", "PROTEIN", 430, 437], ["1\u03b1-hydroxylase", "PROTEIN", 439, 453], ["CYP24A1 (24-hydroxylase", "PROTEIN", 459, 482], ["patients", "SPECIES", 25, 33], ["A small study", "TEST", 0, 13], ["hypovitaminosis D", "PROBLEM", 39, 56], ["vitamin D supplementation", "TREATMENT", 113, 138], ["serum 25(OH)D levels", "TEST", 167, 187], ["Hypovitaminoses", "TREATMENT", 232, 247], ["CYP27B1", "TEST", 430, 437], ["CYP24A1", "TEST", 459, 466], ["small", "OBSERVATION_MODIFIER", 2, 7], ["significant", "OBSERVATION_MODIFIER", 71, 82], ["anti-inflammatory", "OBSERVATION_MODIFIER", 83, 100], ["mitochondria", "ANATOMY", 504, 516]]], ["In U937 monocytes, 1,25 (OH)2 vitamin D upregulates glutamate cysteine ligase (GCLC) and glutathione reductase (GR), resulting in an increase of cellular glutathione formation, and decreased ROS and IL-8 secretion (258).", [["U937 monocytes", "ANATOMY", 3, 17], ["cellular", "ANATOMY", 145, 153], ["1,25 (OH)2", "CHEMICAL", 19, 29], ["vitamin D", "CHEMICAL", 30, 39], ["glutamate", "CHEMICAL", 52, 61], ["glutathione", "CHEMICAL", 89, 100], ["glutathione", "CHEMICAL", 154, 165], ["ROS", "CHEMICAL", 191, 194], ["1,25 (OH)2 vitamin D", "CHEMICAL", 19, 39], ["glutamate", "CHEMICAL", 52, 61], ["cysteine", "CHEMICAL", 62, 70], ["glutathione", "CHEMICAL", 89, 100], ["glutathione", "CHEMICAL", 154, 165], ["U937 monocytes", "CELL", 3, 17], ["1,25 (OH)2 vitamin D", "SIMPLE_CHEMICAL", 19, 39], ["glutamate cysteine ligase", "GENE_OR_GENE_PRODUCT", 52, 77], ["GCLC", "GENE_OR_GENE_PRODUCT", 79, 83], ["glutathione reductase", "GENE_OR_GENE_PRODUCT", 89, 110], ["GR", "GENE_OR_GENE_PRODUCT", 112, 114], ["cellular", "CELL", 145, 153], ["glutathione", "SIMPLE_CHEMICAL", 154, 165], ["ROS", "SIMPLE_CHEMICAL", 191, 194], ["IL-8", "GENE_OR_GENE_PRODUCT", 199, 203], ["U937 monocytes", "CELL_LINE", 3, 17], ["glutamate cysteine ligase", "PROTEIN", 52, 77], ["GCLC", "PROTEIN", 79, 83], ["glutathione reductase", "PROTEIN", 89, 110], ["GR", "PROTEIN", 112, 114], ["monocytes", "TEST", 8, 17], ["OH", "TEST", 25, 27], ["vitamin D upregulates glutamate cysteine ligase (GCLC)", "TREATMENT", 30, 84], ["glutathione reductase", "TEST", 89, 110], ["cellular glutathione formation", "PROBLEM", 145, 175], ["decreased ROS", "PROBLEM", 181, 194], ["IL", "TEST", 199, 201], ["U937 monocytes", "OBSERVATION", 3, 17], ["increase", "OBSERVATION_MODIFIER", 133, 141], ["cellular glutathione formation", "OBSERVATION", 145, 175], ["decreased", "OBSERVATION_MODIFIER", 181, 190], ["ROS", "OBSERVATION_MODIFIER", 191, 194]]], ["Two recent studies have evaluated the impact of vitamin D on skeletal muscle mitochondrial function.", [["skeletal muscle mitochondrial", "ANATOMY", 61, 90], ["vitamin D", "CHEMICAL", 48, 57], ["vitamin D", "CHEMICAL", 48, 57], ["vitamin D", "SIMPLE_CHEMICAL", 48, 57], ["skeletal muscle mitochondrial", "TISSUE", 61, 90], ["Two recent studies", "TEST", 0, 18], ["vitamin D", "TREATMENT", 48, 57], ["skeletal muscle", "ANATOMY", 61, 76], ["mitochondrial function", "OBSERVATION", 77, 99]]], ["Primary human skeletal muscle cells treated with 1,25(OH)D3 vs. vehicle demonstrated marked effects on mitochondrial number, morphology, physiology, and expression of key mitochondrial proteins, resulting in increased ATP production (259).", [["skeletal muscle cells", "ANATOMY", 14, 35], ["mitochondrial", "ANATOMY", 103, 116], ["mitochondrial", "ANATOMY", 171, 184], ["1,25(OH)D3", "CHEMICAL", 49, 59], ["ATP", "CHEMICAL", 218, 221], ["1,25(OH)D3", "CHEMICAL", 49, 59], ["ATP", "CHEMICAL", 218, 221], ["human", "ORGANISM", 8, 13], ["skeletal muscle cells", "CELL", 14, 35], ["1,25(OH)D3", "SIMPLE_CHEMICAL", 49, 59], ["mitochondrial", "CELLULAR_COMPONENT", 103, 116], ["mitochondrial", "CELLULAR_COMPONENT", 171, 184], ["ATP", "SIMPLE_CHEMICAL", 218, 221], ["human skeletal muscle cells", "CELL_TYPE", 8, 35], ["mitochondrial proteins", "PROTEIN", 171, 193], ["human", "SPECIES", 8, 13], ["human", "SPECIES", 8, 13], ["Primary human skeletal muscle cells", "TREATMENT", 0, 35], ["1,25(OH)D3", "TREATMENT", 49, 59], ["vehicle", "TREATMENT", 64, 71], ["marked effects on mitochondrial number", "PROBLEM", 85, 123], ["key mitochondrial proteins", "PROBLEM", 167, 193], ["increased ATP production", "PROBLEM", 208, 232], ["skeletal muscle", "ANATOMY", 14, 29], ["cells", "ANATOMY", 30, 35], ["marked", "OBSERVATION_MODIFIER", 85, 91], ["mitochondrial proteins", "OBSERVATION", 171, 193], ["increased", "OBSERVATION_MODIFIER", 208, 217], ["ATP production", "OBSERVATION", 218, 232]]], ["In vitamin D-deficient symptomatic patients, Vitamin D supplementation was found, using phosphorus-31 magnetic resonance spectroscopy, to augment muscle mitochondrial maximal oxidative phosphorylation after exercise and improved symptoms of fatigue (260).", [["muscle mitochondrial", "ANATOMY", 146, 166], ["vitamin D", "CHEMICAL", 3, 12], ["Vitamin D", "CHEMICAL", 45, 54], ["phosphorus", "CHEMICAL", 88, 98], ["fatigue", "DISEASE", 241, 248], ["vitamin D", "CHEMICAL", 3, 12], ["Vitamin D", "CHEMICAL", 45, 54], ["phosphorus", "CHEMICAL", 88, 98], ["vitamin D", "SIMPLE_CHEMICAL", 3, 12], ["patients", "ORGANISM", 35, 43], ["Vitamin D", "SIMPLE_CHEMICAL", 45, 54], ["phosphorus", "SIMPLE_CHEMICAL", 88, 98], ["muscle mitochondrial", "TISSUE", 146, 166], ["patients", "SPECIES", 35, 43], ["vitamin D-deficient symptomatic patients", "TREATMENT", 3, 43], ["Vitamin D supplementation", "TREATMENT", 45, 70], ["phosphorus", "TEST", 88, 98], ["magnetic resonance spectroscopy", "TEST", 102, 133], ["muscle mitochondrial maximal oxidative phosphorylation", "TREATMENT", 146, 200], ["improved symptoms of fatigue", "PROBLEM", 220, 248], ["muscle", "ANATOMY", 146, 152]]], ["Treatment of skeletal muscle with vitamin D is associated with a change in expression of ~83 nuclear mRNAs encoding proteins known to localize in mitochondria (259).Vitamin D ::: HypovitaminosesHypovitaminosis D is common in critical illness, despite parallel elevations of PTH (249) with one small study reporting a progressive drop in vitamin D levels in the first week of illness (261), while a low 25(OH)D3 status was significantly associated with all-cause and sepsis mortality (236).", [["skeletal muscle", "ANATOMY", 13, 28], ["nuclear", "ANATOMY", 93, 100], ["mitochondria", "ANATOMY", 146, 158], ["skeletal muscle", "DISEASE", 13, 28], ["vitamin D", "CHEMICAL", 34, 43], ["Vitamin D", "CHEMICAL", 165, 174], ["PTH", "CHEMICAL", 274, 277], ["vitamin D", "CHEMICAL", 337, 346], ["illness", "DISEASE", 375, 382], ["sepsis", "DISEASE", 466, 472], ["vitamin D", "CHEMICAL", 34, 43], ["Vitamin D", "CHEMICAL", 165, 174], ["Hypovitaminosis D", "CHEMICAL", 194, 211], ["vitamin D", "CHEMICAL", 337, 346], ["25(OH)D3", "CHEMICAL", 402, 410], ["skeletal muscle", "TISSUE", 13, 28], ["vitamin D", "SIMPLE_CHEMICAL", 34, 43], ["mitochondria", "CELLULAR_COMPONENT", 146, 158], ["Vitamin D", "SIMPLE_CHEMICAL", 165, 174], ["PTH", "SIMPLE_CHEMICAL", 274, 277], ["vitamin D", "SIMPLE_CHEMICAL", 337, 346], ["25(OH)D3", "SIMPLE_CHEMICAL", 402, 410], ["~83 nuclear mRNAs", "RNA", 89, 106], ["vitamin D", "TREATMENT", 34, 43], ["a change in expression", "PROBLEM", 63, 85], ["HypovitaminosesHypovitaminosis D", "PROBLEM", 179, 211], ["critical illness", "PROBLEM", 225, 241], ["parallel elevations of PTH", "PROBLEM", 251, 277], ["one small study", "TEST", 289, 304], ["a progressive drop in vitamin D levels", "PROBLEM", 315, 353], ["a low 25(OH)D3 status", "PROBLEM", 396, 417], ["sepsis mortality", "PROBLEM", 466, 482], ["skeletal muscle", "ANATOMY", 13, 28], ["progressive", "OBSERVATION_MODIFIER", 317, 328], ["drop", "OBSERVATION", 329, 333], ["vitamin D", "OBSERVATION_MODIFIER", 337, 346], ["sepsis", "OBSERVATION", 466, 472]]], ["In early critical illness, vitamin D status is associated with a differential metabolic profile.", [["vitamin D", "CHEMICAL", 27, 36], ["vitamin D", "CHEMICAL", 27, 36], ["vitamin D", "SIMPLE_CHEMICAL", 27, 36], ["vitamin D status", "PROBLEM", 27, 43], ["early", "OBSERVATION_MODIFIER", 3, 8], ["critical", "OBSERVATION_MODIFIER", 9, 17], ["illness", "OBSERVATION", 18, 25], ["metabolic profile", "OBSERVATION", 78, 95]]], ["Glutathione and glutamate metabolism, which play principal roles in redox regulation and immunomodulation, respectively, were significantly upregulated by vitamin D (199).", [["Glutathione", "CHEMICAL", 0, 11], ["glutamate", "CHEMICAL", 16, 25], ["vitamin D", "CHEMICAL", 155, 164], ["Glutathione", "CHEMICAL", 0, 11], ["glutamate", "CHEMICAL", 16, 25], ["vitamin D (199)", "CHEMICAL", 155, 170], ["Glutathione", "SIMPLE_CHEMICAL", 0, 11], ["glutamate", "SIMPLE_CHEMICAL", 16, 25], ["vitamin D", "SIMPLE_CHEMICAL", 155, 164], ["Glutathione", "TREATMENT", 0, 11], ["glutamate metabolism", "PROBLEM", 16, 36], ["glutamate metabolism", "OBSERVATION", 16, 36]]], ["However, evidence of a mortality benefit of vitamin D as monotherapy still remains uncertain (262, 263).", [["vitamin D", "CHEMICAL", 44, 53], ["vitamin D", "CHEMICAL", 44, 53], ["vitamin D", "SIMPLE_CHEMICAL", 44, 53], ["vitamin D", "TREATMENT", 44, 53], ["monotherapy", "TREATMENT", 57, 68]]], ["A recent large RCT investigated a single dose of 540,000 international units of vitamin D3 in critically ill patients with 1,25(OH)D3 levels <20 ng/ml (264).", [["vitamin D3", "CHEMICAL", 80, 90], ["critically ill", "DISEASE", 94, 108], ["1,25", "CHEMICAL", 123, 127], ["vitamin D3", "CHEMICAL", 80, 90], ["1,25(OH)D3", "CHEMICAL", 123, 133], ["vitamin D3", "SIMPLE_CHEMICAL", 80, 90], ["patients", "ORGANISM", 109, 117], ["1,25(OH)D3", "SIMPLE_CHEMICAL", 123, 133], ["patients", "SPECIES", 109, 117], ["A recent large RCT", "PROBLEM", 0, 18], ["vitamin D3", "TREATMENT", 80, 90], ["D3 levels", "TEST", 131, 140], ["large", "OBSERVATION_MODIFIER", 9, 14], ["RCT", "OBSERVATION", 15, 18]]], ["By day 3, the treated group achieved a level of 25-hydroxyvitamin D of 46.9 \u00b1 23.2 ng/ml; measurements of systemic inflammation were not reported.", [["25-hydroxyvitamin D", "CHEMICAL", 48, 67], ["inflammation", "DISEASE", 115, 127], ["25-hydroxyvitamin D", "CHEMICAL", 48, 67], ["25-hydroxyvitamin D", "SIMPLE_CHEMICAL", 48, 67], ["a level", "TEST", 37, 44], ["hydroxyvitamin D", "TEST", 51, 67], ["systemic inflammation", "PROBLEM", 106, 127], ["systemic", "ANATOMY", 106, 114], ["inflammation", "OBSERVATION", 115, 127]]], ["Treatment was not associated with improvement in mortality or secondary variables (264).Vitamin C ::: HypovitaminosesAscorbic acid (vitamin C) is a potent water-soluble antioxidant and an enzymatic cofactor that plays a key role in neuro-endocrine and immune homeostatic corrections (265).", [["neuro-endocrine", "ANATOMY", 232, 247], ["Vitamin C", "CHEMICAL", 88, 97], ["HypovitaminosesAscorbic acid", "CHEMICAL", 102, 130], ["vitamin C", "CHEMICAL", 132, 141], ["Vitamin C", "CHEMICAL", 88, 97], ["HypovitaminosesAscorbic acid", "CHEMICAL", 102, 130], ["vitamin C", "CHEMICAL", 132, 141], ["Vitamin C", "SIMPLE_CHEMICAL", 88, 97], ["HypovitaminosesAscorbic acid", "SIMPLE_CHEMICAL", 102, 130], ["vitamin C", "SIMPLE_CHEMICAL", 132, 141], ["neuro-endocrine", "CANCER", 232, 247], ["enzymatic cofactor", "PROTEIN", 188, 206], ["Treatment", "TREATMENT", 0, 9], ["HypovitaminosesAscorbic acid (vitamin C)", "TREATMENT", 102, 142], ["a potent water-soluble antioxidant", "TREATMENT", 146, 180], ["an enzymatic cofactor", "TREATMENT", 185, 206]]], ["Most vertebrates can synthesize ascorbic acid from glucose-6-phospate in the liver, with synthesis increasing during stress.", [["liver", "ANATOMY", 77, 82], ["ascorbic acid", "CHEMICAL", 32, 45], ["glucose-6-phospate", "CHEMICAL", 51, 69], ["ascorbic acid", "CHEMICAL", 32, 45], ["glucose-6-phospate", "CHEMICAL", 51, 69], ["ascorbic acid", "SIMPLE_CHEMICAL", 32, 45], ["glucose-6-phospate", "SIMPLE_CHEMICAL", 51, 69], ["liver", "ORGAN", 77, 82], ["ascorbic acid", "TEST", 32, 45], ["glucose", "TEST", 51, 58], ["synthesis", "PROBLEM", 89, 98], ["ascorbic acid", "OBSERVATION", 32, 45], ["liver", "ANATOMY", 77, 82], ["increasing", "OBSERVATION_MODIFIER", 99, 109]]], ["In humans and other primates, however, ascorbic acid cannot be synthesized and has to be obtained through the diet.", [["ascorbic acid", "CHEMICAL", 39, 52], ["ascorbic acid", "CHEMICAL", 39, 52], ["humans", "ORGANISM", 3, 9], ["ascorbic acid", "SIMPLE_CHEMICAL", 39, 52], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["ascorbic acid", "TREATMENT", 39, 52]]], ["This is the result of a random mutation in the enzyme that catalyzes the final step of ascorbic acid biosynthesis in the common ancestor of the teleost fish some 200 million years ago (266, 267).", [["ascorbic acid", "CHEMICAL", 87, 100], ["ascorbic acid", "CHEMICAL", 87, 100], ["ascorbic acid", "SIMPLE_CHEMICAL", 87, 100], ["a random mutation in the enzyme", "PROBLEM", 22, 53], ["ascorbic acid biosynthesis", "TREATMENT", 87, 113]]], ["To date, there is no satisfactory evolutionary explanation for this apparent random loss of ascorbic acid synthetic ability.", [["ascorbic acid", "CHEMICAL", 92, 105], ["ascorbic acid", "CHEMICAL", 92, 105], ["ascorbic acid", "SIMPLE_CHEMICAL", 92, 105], ["this apparent random loss of ascorbic acid synthetic ability", "PROBLEM", 63, 123], ["no", "UNCERTAINTY", 18, 20], ["ascorbic acid", "OBSERVATION", 92, 105]]], ["Individuals from species which have lost the ability to make their own ascorbic acid were not selected against, as long as their diet contained sufficient quantities of vitamin C (266).Vitamin C ::: HypovitaminosesAscorbic acid is actively transported into all cells of the body (except erythrocytes) by the sodium vitamin C transporter-2 (mSVCT2).", [["cells", "ANATOMY", 261, 266], ["body", "ANATOMY", 274, 278], ["erythrocytes", "ANATOMY", 287, 299], ["ascorbic acid", "CHEMICAL", 71, 84], ["vitamin C", "CHEMICAL", 169, 178], ["Vitamin C", "CHEMICAL", 185, 194], ["Hypovitaminoses", "CHEMICAL", 199, 214], ["Ascorbic acid", "CHEMICAL", 214, 227], ["sodium", "CHEMICAL", 308, 314], ["vitamin C", "CHEMICAL", 315, 324], ["ascorbic acid", "CHEMICAL", 71, 84], ["vitamin C", "CHEMICAL", 169, 178], ["Vitamin C", "CHEMICAL", 185, 194], ["Hypovitaminoses", "CHEMICAL", 199, 214], ["Ascorbic acid", "CHEMICAL", 214, 227], ["sodium vitamin C", "CHEMICAL", 308, 324], ["ascorbic acid", "SIMPLE_CHEMICAL", 71, 84], ["vitamin C", "SIMPLE_CHEMICAL", 169, 178], ["Vitamin C", "SIMPLE_CHEMICAL", 185, 194], ["HypovitaminosesAscorbic acid", "SIMPLE_CHEMICAL", 199, 227], ["cells", "CELL", 261, 266], ["body", "ORGANISM_SUBDIVISION", 274, 278], ["erythrocytes", "CELL", 287, 299], ["sodium vitamin C transporter-2", "GENE_OR_GENE_PRODUCT", 308, 338], ["mSVCT2", "GENE_OR_GENE_PRODUCT", 340, 346], ["erythrocytes", "CELL_TYPE", 287, 299], ["sodium vitamin C transporter", "PROTEIN", 308, 336], ["mSVCT2", "PROTEIN", 340, 346], ["ascorbic acid", "TEST", 71, 84], ["vitamin C", "TREATMENT", 169, 178], ["Hypovitaminoses", "TREATMENT", 199, 214], ["Ascorbic acid", "PROBLEM", 214, 227], ["erythrocytes", "TEST", 287, 299], ["the sodium vitamin C transporter", "TREATMENT", 304, 336], ["body", "ANATOMY", 274, 278]]], ["Ascorbic acid is differentially accumulated by most tissues and body fluids.", [["tissues", "ANATOMY", 52, 59], ["body fluids", "ANATOMY", 64, 75], ["Ascorbic acid", "CHEMICAL", 0, 13], ["Ascorbic acid", "CHEMICAL", 0, 13], ["Ascorbic acid", "SIMPLE_CHEMICAL", 0, 13], ["tissues", "TISSUE", 52, 59], ["body fluids", "TISSUE", 64, 75], ["Ascorbic acid", "TREATMENT", 0, 13], ["most tissues", "OBSERVATION_MODIFIER", 47, 59]]], ["Studies using radiolabeled ascorbic acid predict that body stores in healthy humans are about 1,500 mg; scurvy is thought to occur when this level falls below 300 mg, with plasma ascorbic acid concentrations <11.3 \u03bcM (268).", [["body", "ANATOMY", 54, 58], ["plasma", "ANATOMY", 172, 178], ["ascorbic acid", "CHEMICAL", 27, 40], ["scurvy", "DISEASE", 104, 110], ["ascorbic acid", "CHEMICAL", 179, 192], ["ascorbic acid", "CHEMICAL", 27, 40], ["ascorbic acid", "CHEMICAL", 179, 192], ["ascorbic acid", "SIMPLE_CHEMICAL", 27, 40], ["body", "ORGANISM_SUBDIVISION", 54, 58], ["humans", "ORGANISM", 77, 83], ["plasma", "ORGANISM_SUBSTANCE", 172, 178], ["ascorbic acid", "SIMPLE_CHEMICAL", 179, 192], ["humans", "SPECIES", 77, 83], ["humans", "SPECIES", 77, 83], ["Studies", "TEST", 0, 7], ["radiolabeled ascorbic acid predict", "TREATMENT", 14, 48], ["scurvy", "PROBLEM", 104, 110], ["plasma ascorbic acid concentrations", "TEST", 172, 207]]], ["Importantly, the highest concentrations (\u03bcM) of ascorbic acid are found in critical organs involved in homeostatic corrections, such as the pituitary gland (2,300\u20132,800), the adrenals (1,700\u20132,300), the brain norepinephrine-synthesizing nuclei (800\u2013900), and liver (600\u2013900) (268).", [["organs", "ANATOMY", 84, 90], ["pituitary gland", "ANATOMY", 140, 155], ["adrenals", "ANATOMY", 175, 183], ["brain", "ANATOMY", 203, 208], ["nuclei", "ANATOMY", 237, 243], ["liver", "ANATOMY", 259, 264], ["ascorbic acid", "CHEMICAL", 48, 61], ["norepinephrine", "CHEMICAL", 209, 223], ["ascorbic acid", "CHEMICAL", 48, 61], ["norepinephrine", "CHEMICAL", 209, 223], ["ascorbic acid", "SIMPLE_CHEMICAL", 48, 61], ["organs", "ORGAN", 84, 90], ["pituitary gland", "ORGAN", 140, 155], ["adrenals", "ORGAN", 175, 183], ["brain", "ORGAN", 203, 208], ["norepinephrine", "SIMPLE_CHEMICAL", 209, 223], ["nuclei", "CELLULAR_COMPONENT", 237, 243], ["liver", "ORGAN", 259, 264], ["ascorbic acid", "TREATMENT", 48, 61], ["homeostatic corrections", "OBSERVATION", 103, 126], ["pituitary gland", "ANATOMY", 140, 155], ["adrenals", "ANATOMY", 175, 183], ["brain", "ANATOMY", 203, 208], ["liver", "ANATOMY", 259, 264]]], ["This vitamin-sequestering may represent an evolutionary protective or \u201csafety\u201d function.Vitamin C ::: HypovitaminosesAscorbic acid is a key cellular antioxidant.", [["cellular", "ANATOMY", 140, 148], ["vitamin", "CHEMICAL", 5, 12], ["Vitamin C", "CHEMICAL", 88, 97], ["Hypovitaminoses", "CHEMICAL", 102, 117], ["Ascorbic acid", "CHEMICAL", 117, 130], ["vitamin", "CHEMICAL", 5, 12], ["Vitamin C", "CHEMICAL", 88, 97], ["Hypovitaminoses", "CHEMICAL", 102, 117], ["Ascorbic acid", "CHEMICAL", 117, 130], ["vitamin", "SIMPLE_CHEMICAL", 5, 12], ["Vitamin C", "SIMPLE_CHEMICAL", 88, 97], ["HypovitaminosesAscorbic acid", "SIMPLE_CHEMICAL", 102, 130], ["cellular", "CELL", 140, 148], ["This vitamin-sequestering", "TREATMENT", 0, 25], ["Hypovitaminoses", "TREATMENT", 102, 117], ["Ascorbic acid", "TREATMENT", 117, 130], ["may represent", "UNCERTAINTY", 26, 39]]], ["As such, ascorbic acid is an electron donor that directly scavenges for free radicals, and inhibits the generation of new free radicals through its suppressive effects on the NADPH oxidase (NOX) pathway (237).", [["ascorbic acid", "CHEMICAL", 9, 22], ["NADPH", "CHEMICAL", 175, 180], ["ascorbic acid", "CHEMICAL", 9, 22], ["NADPH", "CHEMICAL", 175, 180], ["ascorbic acid", "SIMPLE_CHEMICAL", 9, 22], ["NADPH oxidase", "GENE_OR_GENE_PRODUCT", 175, 188], ["NOX", "GENE_OR_GENE_PRODUCT", 190, 193], ["NADPH oxidase", "PROTEIN", 175, 188], ["NOX", "PROTEIN", 190, 193], ["ascorbic acid", "TREATMENT", 9, 22], ["an electron donor", "TREATMENT", 26, 43], ["free radicals", "PROBLEM", 72, 85], ["new free radicals", "TREATMENT", 118, 135], ["the NADPH oxidase", "TREATMENT", 171, 188], ["new", "OBSERVATION_MODIFIER", 118, 121], ["free radicals", "OBSERVATION", 122, 135]]], ["Ascorbic acid also prevents the depletion of other circulatory antioxidants, such as lipid-soluble vitamin E and glutathione, although this is not the case in reverse (200).", [["Ascorbic acid", "CHEMICAL", 0, 13], ["vitamin E", "CHEMICAL", 99, 108], ["glutathione", "CHEMICAL", 113, 124], ["Ascorbic acid", "CHEMICAL", 0, 13], ["vitamin E", "CHEMICAL", 99, 108], ["glutathione", "CHEMICAL", 113, 124], ["Ascorbic acid", "SIMPLE_CHEMICAL", 0, 13], ["lipid", "SIMPLE_CHEMICAL", 85, 90], ["vitamin E", "SIMPLE_CHEMICAL", 99, 108], ["glutathione", "SIMPLE_CHEMICAL", 113, 124], ["Ascorbic acid", "TREATMENT", 0, 13], ["other circulatory antioxidants", "TREATMENT", 45, 75], ["lipid-soluble vitamin E", "TREATMENT", 85, 108], ["glutathione", "TREATMENT", 113, 124], ["circulatory antioxidants", "OBSERVATION", 51, 75]]], ["The anti-oxidant effects of ascorbic acid result in reduced endothelial permeability, improved microvascular and macrovascular function, attenuated cellular apoptosis in pathological states, and improved GR function (237).Vitamin C ::: HypovitaminosesAscorbic acid is maintained at high levels in mature circulating leukocytes (\u03bcM amounts in lymphocytes ~3,800; monocytes ~3,100, and neutrophils ~1,400) (268), suggesting an important role in many aspects of the immune response.", [["endothelial", "ANATOMY", 60, 71], ["microvascular", "ANATOMY", 95, 108], ["macrovascular", "ANATOMY", 113, 126], ["cellular", "ANATOMY", 148, 156], ["leukocytes", "ANATOMY", 316, 326], ["lymphocytes", "ANATOMY", 342, 353], ["monocytes", "ANATOMY", 362, 371], ["neutrophils", "ANATOMY", 384, 395], ["ascorbic acid", "CHEMICAL", 28, 41], ["Vitamin C", "CHEMICAL", 222, 231], ["Hypovitaminoses", "CHEMICAL", 236, 251], ["Ascorbic acid", "CHEMICAL", 251, 264], ["ascorbic acid", "CHEMICAL", 28, 41], ["Vitamin C", "CHEMICAL", 222, 231], ["Hypovitaminoses", "CHEMICAL", 236, 251], ["Ascorbic acid", "CHEMICAL", 251, 264], ["ascorbic acid", "SIMPLE_CHEMICAL", 28, 41], ["endothelial", "TISSUE", 60, 71], ["microvascular", "TISSUE", 95, 108], ["macrovascular", "MULTI-TISSUE_STRUCTURE", 113, 126], ["cellular", "CELL", 148, 156], ["GR", "GENE_OR_GENE_PRODUCT", 204, 206], ["Vitamin C", "SIMPLE_CHEMICAL", 222, 231], ["HypovitaminosesAscorbic acid", "SIMPLE_CHEMICAL", 236, 264], ["leukocytes", "CELL", 316, 326], ["lymphocytes", "CELL", 342, 353], ["monocytes", "CELL", 362, 371], ["neutrophils", "CELL", 384, 395], ["GR", "PROTEIN", 204, 206], ["mature circulating leukocytes", "CELL_TYPE", 297, 326], ["lymphocytes", "CELL_TYPE", 342, 353], ["monocytes", "CELL_TYPE", 362, 371], ["neutrophils", "CELL_TYPE", 384, 395], ["ascorbic acid", "TEST", 28, 41], ["reduced endothelial permeability", "PROBLEM", 52, 84], ["attenuated cellular apoptosis in pathological states", "PROBLEM", 137, 189], ["Hypovitaminoses", "TEST", 236, 251], ["Ascorbic acid", "TEST", 251, 264], ["lymphocytes", "TEST", 342, 353], ["monocytes", "TEST", 362, 371], ["neutrophils", "TEST", 384, 395], ["ascorbic acid", "OBSERVATION", 28, 41], ["reduced", "OBSERVATION_MODIFIER", 52, 59], ["endothelial permeability", "OBSERVATION", 60, 84], ["improved", "OBSERVATION_MODIFIER", 86, 94], ["microvascular", "OBSERVATION_MODIFIER", 95, 108], ["macrovascular function", "OBSERVATION", 113, 135], ["attenuated", "OBSERVATION_MODIFIER", 137, 147], ["cellular", "OBSERVATION_MODIFIER", 148, 156], ["apoptosis", "OBSERVATION_MODIFIER", 157, 166], ["improved", "OBSERVATION_MODIFIER", 195, 203], ["mature", "OBSERVATION_MODIFIER", 297, 303], ["circulating leukocytes", "OBSERVATION", 304, 326], ["lymphocytes", "ANATOMY", 342, 353]]], ["In leukocytes, ascorbic acid content responds to variations in plasma ascorbate availability (269).", [["leukocytes", "ANATOMY", 3, 13], ["plasma", "ANATOMY", 63, 69], ["ascorbic acid", "CHEMICAL", 15, 28], ["ascorbate", "CHEMICAL", 70, 79], ["ascorbic acid", "CHEMICAL", 15, 28], ["ascorbate", "CHEMICAL", 70, 79], ["leukocytes", "CELL", 3, 13], ["ascorbic acid", "SIMPLE_CHEMICAL", 15, 28], ["plasma", "ORGANISM_SUBSTANCE", 63, 69], ["ascorbate", "SIMPLE_CHEMICAL", 70, 79], ["leukocytes", "CELL_TYPE", 3, 13], ["leukocytes", "TEST", 3, 13], ["ascorbic acid content", "PROBLEM", 15, 36], ["plasma ascorbate availability", "TEST", 63, 92], ["leukocytes", "ANATOMY", 3, 13], ["ascorbic acid content", "OBSERVATION", 15, 36]]], ["Following activation, immune cells undergo dramatic metabolic reprogramming with increased aerobic glycolytic activity and fatty acid oxidation (Warburg effect) under the regulation of hypoxia-inducible factors (HIFs) (270).", [["immune cells", "ANATOMY", 22, 34], ["fatty acid", "CHEMICAL", 123, 133], ["fatty acid", "CHEMICAL", 123, 133], ["immune cells", "CELL", 22, 34], ["fatty acid", "SIMPLE_CHEMICAL", 123, 133], ["hypoxia-inducible factors", "GENE_OR_GENE_PRODUCT", 185, 210], ["HIFs", "GENE_OR_GENE_PRODUCT", 212, 216], ["immune cells", "CELL_TYPE", 22, 34], ["hypoxia-inducible factors", "PROTEIN", 185, 210], ["HIFs", "PROTEIN", 212, 216], ["immune cells", "PROBLEM", 22, 34], ["dramatic metabolic reprogramming", "PROBLEM", 43, 75], ["increased aerobic glycolytic activity", "PROBLEM", 81, 118], ["fatty acid oxidation", "PROBLEM", 123, 143], ["Warburg effect", "PROBLEM", 145, 159], ["hypoxia", "PROBLEM", 185, 192], ["inducible factors", "PROBLEM", 193, 210], ["dramatic", "OBSERVATION_MODIFIER", 43, 51], ["metabolic reprogramming", "OBSERVATION", 52, 75], ["glycolytic activity", "OBSERVATION", 99, 118]]], ["The result of this change is to rapidly provide ATP and metabolic intermediates for the biosynthesis of immune and inflammatory mediators.", [["ATP", "CHEMICAL", 48, 51], ["ATP", "CHEMICAL", 48, 51], ["ATP", "SIMPLE_CHEMICAL", 48, 51], ["inflammatory mediators", "PROTEIN", 115, 137], ["ATP", "TREATMENT", 48, 51], ["immune and inflammatory mediators", "TREATMENT", 104, 137]]], ["Importantly, the hydroxylase enzymes that regulate the actions of the HIFs require ascorbate for optimal activity (269).", [["ascorbate", "CHEMICAL", 83, 92], ["ascorbate", "CHEMICAL", 83, 92], ["hydroxylase enzymes", "GENE_OR_GENE_PRODUCT", 17, 36], ["HIFs", "GENE_OR_GENE_PRODUCT", 70, 74], ["ascorbate", "SIMPLE_CHEMICAL", 83, 92], ["hydroxylase enzymes", "PROTEIN", 17, 36], ["HIFs", "PROTEIN", 70, 74], ["the hydroxylase enzymes", "TEST", 13, 36], ["ascorbate", "TREATMENT", 83, 92]]], ["The immune-enhancing properties of ascorbic acid regulation of HIFs include increased neutrophil and macrophage bacterial killing and phagocytic capacity (269, 271).", [["neutrophil", "ANATOMY", 86, 96], ["macrophage", "ANATOMY", 101, 111], ["ascorbic acid", "CHEMICAL", 35, 48], ["ascorbic acid", "CHEMICAL", 35, 48], ["ascorbic acid", "SIMPLE_CHEMICAL", 35, 48], ["HIFs", "GENE_OR_GENE_PRODUCT", 63, 67], ["neutrophil", "CELL", 86, 96], ["macrophage", "CELL", 101, 111], ["HIFs", "PROTEIN", 63, 67], ["neutrophil", "CELL_TYPE", 86, 96], ["ascorbic acid regulation", "TEST", 35, 59], ["increased neutrophil", "PROBLEM", 76, 96], ["macrophage bacterial killing", "PROBLEM", 101, 129], ["phagocytic capacity", "TEST", 134, 153], ["enhancing", "OBSERVATION_MODIFIER", 11, 20], ["ascorbic acid", "OBSERVATION", 35, 48], ["increased", "OBSERVATION_MODIFIER", 76, 85], ["neutrophil", "OBSERVATION", 86, 96], ["macrophage bacterial killing", "OBSERVATION", 101, 129], ["phagocytic capacity", "OBSERVATION", 134, 153]]], ["In addition, ascorbic acid plays an important role in protecting host cells from the excessive oxidative stress caused by infections (265).Vitamin C ::: HypovitaminosesAscorbic acid plays a crucial role in HPA axis function (Figure 6).", [["cells", "ANATOMY", 70, 75], ["ascorbic acid", "CHEMICAL", 13, 26], ["infections", "DISEASE", 122, 132], ["Vitamin C", "CHEMICAL", 139, 148], ["Hypovitaminoses", "CHEMICAL", 153, 168], ["Ascorbic acid", "CHEMICAL", 168, 181], ["ascorbic acid", "CHEMICAL", 13, 26], ["Vitamin C", "CHEMICAL", 139, 148], ["Hypovitaminoses", "CHEMICAL", 153, 168], ["Ascorbic acid", "CHEMICAL", 168, 181], ["ascorbic acid", "SIMPLE_CHEMICAL", 13, 26], ["host cells", "CELL", 65, 75], ["Vitamin C", "SIMPLE_CHEMICAL", 139, 148], ["Hypovitaminoses", "SIMPLE_CHEMICAL", 153, 168], ["Ascorbic acid", "SIMPLE_CHEMICAL", 168, 181], ["host cells", "CELL_TYPE", 65, 75], ["ascorbic acid", "TREATMENT", 13, 26], ["the excessive oxidative stress", "PROBLEM", 81, 111], ["Hypovitaminoses", "TREATMENT", 153, 168], ["Ascorbic acid", "TREATMENT", 168, 181], ["excessive", "OBSERVATION_MODIFIER", 85, 94], ["oxidative stress", "OBSERVATION", 95, 111]]], ["In adrenocortical cells ascorbic acid is sequestered in two pools, one of which can be depleted by ACTH.", [["adrenocortical cells", "ANATOMY", 3, 23], ["ascorbic acid", "CHEMICAL", 24, 37], ["ascorbic acid", "CHEMICAL", 24, 37], ["adrenocortical cells", "CELL", 3, 23], ["ascorbic acid", "SIMPLE_CHEMICAL", 24, 37], ["ACTH", "GENE_OR_GENE_PRODUCT", 99, 103], ["adrenocortical cells", "CELL_TYPE", 3, 23], ["adrenocortical cells ascorbic acid", "TEST", 3, 37], ["adrenocortical cells", "OBSERVATION", 3, 23], ["ascorbic acid", "OBSERVATION", 24, 37], ["pools", "OBSERVATION_MODIFIER", 60, 65], ["depleted", "OBSERVATION", 87, 95]]], ["In response to inflammatory cytokine-mediated ACTH release from the anterior pituitary gland, the adrenal gland rapidly secretes ascorbic acid in amounts that are sufficient to increase, by several fold, plasma ascorbic acid concentrations in the adrenal vein, without increasing systemic levels (268).", [["anterior pituitary gland", "ANATOMY", 68, 92], ["adrenal gland", "ANATOMY", 98, 111], ["plasma", "ANATOMY", 204, 210], ["adrenal vein", "ANATOMY", 247, 259], ["ascorbic acid", "CHEMICAL", 129, 142], ["ascorbic acid", "CHEMICAL", 211, 224], ["ascorbic acid", "CHEMICAL", 129, 142], ["ascorbic acid", "CHEMICAL", 211, 224], ["ACTH", "GENE_OR_GENE_PRODUCT", 46, 50], ["anterior pituitary gland", "ORGAN", 68, 92], ["adrenal gland", "ORGAN", 98, 111], ["ascorbic acid", "SIMPLE_CHEMICAL", 129, 142], ["plasma", "ORGANISM_SUBSTANCE", 204, 210], ["ascorbic acid", "SIMPLE_CHEMICAL", 211, 224], ["adrenal vein", "MULTI-TISSUE_STRUCTURE", 247, 259], ["inflammatory cytokine", "PROTEIN", 15, 36], ["inflammatory cytokine", "TEST", 15, 36], ["ascorbic acid in amounts", "PROBLEM", 129, 153], ["plasma ascorbic acid concentrations in the adrenal vein", "PROBLEM", 204, 259], ["increasing systemic levels", "PROBLEM", 269, 295], ["inflammatory", "OBSERVATION_MODIFIER", 15, 27], ["anterior", "ANATOMY_MODIFIER", 68, 76], ["pituitary gland", "ANATOMY", 77, 92], ["adrenal gland", "ANATOMY", 98, 111], ["ascorbic acid", "OBSERVATION", 129, 142], ["increase", "OBSERVATION_MODIFIER", 177, 185], ["ascorbic acid concentrations", "OBSERVATION", 211, 239], ["adrenal vein", "ANATOMY", 247, 259], ["without", "UNCERTAINTY", 261, 268], ["increasing", "OBSERVATION_MODIFIER", 269, 279], ["systemic", "OBSERVATION_MODIFIER", 280, 288], ["levels", "OBSERVATION_MODIFIER", 289, 295]]], ["More than 80 years ago Hans Selye, the pioneer of stress research, reported that the adrenal glands not only contain some of the highest concentrations of ascorbic acid in the human body, but they also employ this vitamin to synthesize cortisol in the adrenal cells (272).", [["adrenal glands", "ANATOMY", 85, 99], ["body", "ANATOMY", 182, 186], ["adrenal cells", "ANATOMY", 252, 265], ["ascorbic acid", "CHEMICAL", 155, 168], ["vitamin", "CHEMICAL", 214, 221], ["cortisol", "CHEMICAL", 236, 244], ["ascorbic acid", "CHEMICAL", 155, 168], ["vitamin", "CHEMICAL", 214, 221], ["cortisol", "CHEMICAL", 236, 244], ["adrenal glands", "ORGAN", 85, 99], ["ascorbic acid", "SIMPLE_CHEMICAL", 155, 168], ["human", "ORGANISM", 176, 181], ["body", "ORGANISM_SUBDIVISION", 182, 186], ["vitamin", "SIMPLE_CHEMICAL", 214, 221], ["cortisol", "GENE_OR_GENE_PRODUCT", 236, 244], ["adrenal cells", "CELL", 252, 265], ["adrenal cells", "CELL_TYPE", 252, 265], ["human", "SPECIES", 176, 181], ["human", "SPECIES", 176, 181], ["ascorbic acid in the human body", "PROBLEM", 155, 186], ["this vitamin to synthesize cortisol", "TEST", 209, 244], ["adrenal glands", "ANATOMY", 85, 99], ["ascorbic acid", "OBSERVATION", 155, 168], ["human body", "ANATOMY", 176, 186], ["adrenal cells", "ANATOMY", 252, 265]]], ["Today, in vitro and in vivo studies have shown that ascorbic acid is an essential cofactor required in both adrenal mitochondrial steroidogenesis and catecholamine biosynthesis (272).", [["adrenal mitochondrial", "ANATOMY", 108, 129], ["ascorbic acid", "CHEMICAL", 52, 65], ["catecholamine", "CHEMICAL", 150, 163], ["ascorbic acid", "CHEMICAL", 52, 65], ["catecholamine", "CHEMICAL", 150, 163], ["ascorbic acid", "SIMPLE_CHEMICAL", 52, 65], ["adrenal mitochondrial", "MULTI-TISSUE_STRUCTURE", 108, 129], ["catecholamine", "SIMPLE_CHEMICAL", 150, 163], ["vivo studies", "TEST", 23, 35], ["ascorbic acid", "PROBLEM", 52, 65], ["an essential cofactor", "PROBLEM", 69, 90], ["both adrenal mitochondrial steroidogenesis", "TREATMENT", 103, 145], ["catecholamine biosynthesis", "TREATMENT", 150, 176], ["cofactor", "OBSERVATION", 82, 90], ["adrenal", "ANATOMY", 108, 115], ["mitochondrial steroidogenesis", "OBSERVATION", 116, 145]]], ["The level of ascorbate in the adrenals might affect their capacity to convert cholesterol into pregnenolone, the precursor from which nearly all steroid hormones, including cortisol, are made (273).", [["adrenals", "ANATOMY", 30, 38], ["ascorbate", "CHEMICAL", 13, 22], ["cholesterol", "CHEMICAL", 78, 89], ["pregnenolone", "CHEMICAL", 95, 107], ["steroid", "CHEMICAL", 145, 152], ["cortisol", "CHEMICAL", 173, 181], ["ascorbate", "CHEMICAL", 13, 22], ["cholesterol", "CHEMICAL", 78, 89], ["pregnenolone", "CHEMICAL", 95, 107], ["steroid", "CHEMICAL", 145, 152], ["cortisol", "CHEMICAL", 173, 181], ["ascorbate", "SIMPLE_CHEMICAL", 13, 22], ["adrenals", "ORGAN", 30, 38], ["cholesterol", "SIMPLE_CHEMICAL", 78, 89], ["pregnenolone", "SIMPLE_CHEMICAL", 95, 107], ["cortisol", "GENE_OR_GENE_PRODUCT", 173, 181], ["cholesterol into pregnenolone", "TREATMENT", 78, 107], ["cortisol", "TEST", 173, 181], ["adrenals", "ANATOMY", 30, 38]]], ["Additionally, ascorbic acid, as an antioxidant, has a positive impact on GR functions (see section Oxidative Stress and CIRCI).Vitamin C ::: HypovitaminosesOxidative conditions modulate negatively ligand-dependent and independent nuclear import of the GR, affecting GC-GR\u03b1 DNA binding, and inducible gene expression (225, 229), while a phosphodiester compound of ascorbic acid reverses oxidation of the GR, thereby, restoring the cellular glucocorticoid-responsiveness in oxidant conditions (225).", [["nuclear", "ANATOMY", 230, 237], ["cellular", "ANATOMY", 430, 438], ["ascorbic acid", "CHEMICAL", 14, 27], ["Vitamin C", "CHEMICAL", 127, 136], ["ascorbic acid", "CHEMICAL", 363, 376], ["ascorbic acid", "CHEMICAL", 14, 27], ["Vitamin C", "CHEMICAL", 127, 136], ["phosphodiester", "CHEMICAL", 336, 350], ["ascorbic acid", "CHEMICAL", 363, 376], ["ascorbic acid", "SIMPLE_CHEMICAL", 14, 27], ["GR", "GENE_OR_GENE_PRODUCT", 73, 75], ["Vitamin C", "SIMPLE_CHEMICAL", 127, 136], ["HypovitaminosesOxidative", "SIMPLE_CHEMICAL", 141, 165], ["nuclear", "CELLULAR_COMPONENT", 230, 237], ["GR", "GENE_OR_GENE_PRODUCT", 252, 254], ["GC-GR\u03b1", "GENE_OR_GENE_PRODUCT", 266, 272], ["DNA", "CELLULAR_COMPONENT", 273, 276], ["ascorbic acid", "SIMPLE_CHEMICAL", 363, 376], ["GR", "GENE_OR_GENE_PRODUCT", 403, 405], ["cellular", "CELL", 430, 438], ["GR", "PROTEIN", 73, 75], ["GR", "PROTEIN", 252, 254], ["GR\u03b1", "PROTEIN", 269, 272], ["GR", "PROTEIN", 403, 405], ["ascorbic acid", "TREATMENT", 14, 27], ["a positive impact on GR functions", "PROBLEM", 52, 85], ["HypovitaminosesOxidative conditions", "TREATMENT", 141, 176], ["GC", "TEST", 266, 268], ["DNA binding", "PROBLEM", 273, 284], ["inducible gene expression", "PROBLEM", 290, 315], ["ascorbic acid", "TREATMENT", 363, 376], ["ascorbic acid", "OBSERVATION", 363, 376], ["cellular glucocorticoid", "OBSERVATION", 430, 453]]], ["Finally, the cellular uptake of ascorbic acid, mediated by mSVCT2, is downregulated during inflammatory conditions.", [["cellular", "ANATOMY", 13, 21], ["ascorbic acid", "CHEMICAL", 32, 45], ["ascorbic acid", "CHEMICAL", 32, 45], ["cellular", "CELL", 13, 21], ["ascorbic acid", "SIMPLE_CHEMICAL", 32, 45], ["mSVCT2", "GENE_OR_GENE_PRODUCT", 59, 65], ["mSVCT2", "PROTEIN", 59, 65], ["ascorbic acid", "TEST", 32, 45], ["inflammatory conditions", "PROBLEM", 91, 114], ["cellular", "OBSERVATION_MODIFIER", 13, 21], ["uptake", "OBSERVATION_MODIFIER", 22, 28], ["ascorbic acid", "OBSERVATION", 32, 45], ["downregulated", "OBSERVATION_MODIFIER", 70, 83], ["inflammatory", "OBSERVATION_MODIFIER", 91, 103]]], ["In a time and concentration-dependent manner, GCs increase the expression of mSVCT2, facilitating the uptake of vitamin C into cells (274), providing the rationale for combination treatment using GCs and ascorbic acid (275).", [["cells", "ANATOMY", 127, 132], ["vitamin C", "CHEMICAL", 112, 121], ["ascorbic acid", "CHEMICAL", 204, 217], ["vitamin C", "CHEMICAL", 112, 121], ["ascorbic acid", "CHEMICAL", 204, 217], ["GCs", "CELL", 46, 49], ["mSVCT2", "GENE_OR_GENE_PRODUCT", 77, 83], ["vitamin C", "SIMPLE_CHEMICAL", 112, 121], ["cells", "CELL", 127, 132], ["GCs", "SIMPLE_CHEMICAL", 196, 199], ["ascorbic acid", "SIMPLE_CHEMICAL", 204, 217], ["mSVCT2", "PROTEIN", 77, 83], ["GCs", "TEST", 46, 49], ["vitamin C into cells", "TREATMENT", 112, 132], ["combination treatment", "TREATMENT", 168, 189], ["GCs", "TEST", 196, 199], ["ascorbic acid", "TEST", 204, 217]]], ["Interestingly, there is a strong inverse correlation between the ability of an animal to endogenously produce vitamin C and the induction of a cortisol response when stressed (276).Vitamin C ::: HypovitaminosesIn human cell lines and primary endothelial cells (ECV304 and HUVEC), ascorbic acid inhibits TNF\u03b1 and IL-1\u03b2-induced activation of NF-\u03baB, in a dose-dependent manner, by inhibiting phosphorylation and degradation of I\u03baB\u03b1 (277, 278), independently of its antioxidant properties (277).", [["cell lines", "ANATOMY", 219, 229], ["primary endothelial cells", "ANATOMY", 234, 259], ["ECV304", "ANATOMY", 261, 267], ["HUVEC", "ANATOMY", 272, 277], ["vitamin C", "CHEMICAL", 110, 119], ["cortisol", "CHEMICAL", 143, 151], ["Vitamin C", "CHEMICAL", 181, 190], ["Hypovitaminoses", "CHEMICAL", 195, 210], ["ascorbic acid", "CHEMICAL", 280, 293], ["vitamin C", "CHEMICAL", 110, 119], ["cortisol", "CHEMICAL", 143, 151], ["Vitamin C", "CHEMICAL", 181, 190], ["ascorbic acid", "CHEMICAL", 280, 293], ["vitamin C", "SIMPLE_CHEMICAL", 110, 119], ["cortisol", "SIMPLE_CHEMICAL", 143, 151], ["Vitamin C", "SIMPLE_CHEMICAL", 181, 190], ["Hypovitaminoses", "SIMPLE_CHEMICAL", 195, 210], ["human", "ORGANISM", 213, 218], ["cell lines", "CELL", 219, 229], ["primary endothelial cells", "CELL", 234, 259], ["ECV304", "CELL", 261, 267], ["HUVEC", "CELL", 272, 277], ["ascorbic acid", "SIMPLE_CHEMICAL", 280, 293], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 303, 307], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 312, 317], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 340, 345], ["I\u03baB\u03b1", "GENE_OR_GENE_PRODUCT", 424, 428], ["human cell lines", "CELL_LINE", 213, 229], ["primary endothelial cells", "CELL_TYPE", 234, 259], ["ECV304", "CELL_LINE", 261, 267], ["HUVEC", "CELL_LINE", 272, 277], ["TNF\u03b1", "PROTEIN", 303, 307], ["NF-\u03baB", "PROTEIN", 340, 345], ["I\u03baB\u03b1", "PROTEIN", 424, 428], ["human", "SPECIES", 213, 218], ["human", "SPECIES", 213, 218], ["vitamin C", "TREATMENT", 110, 119], ["a cortisol response", "TEST", 141, 160], ["Hypovitaminoses", "TREATMENT", 195, 210], ["human cell lines", "TREATMENT", 213, 229], ["primary endothelial cells", "TEST", 234, 259], ["ECV304", "TEST", 261, 267], ["HUVEC", "TEST", 272, 277], ["ascorbic acid", "TEST", 280, 293], ["TNF", "TEST", 303, 306], ["IL", "TEST", 312, 314], ["NF", "TEST", 340, 342], ["human cell lines", "OBSERVATION", 213, 229], ["primary endothelial cells", "OBSERVATION", 234, 259]]], ["Preclinical studies show that high-dose vitamin C can prevent or restore microcirculatory flow impairment, reinstate vascular responsiveness to vasoconstrictors, and preserve the endothelial barrier (200).", [["microcirculatory", "ANATOMY", 73, 89], ["vascular", "ANATOMY", 117, 125], ["endothelial barrier", "ANATOMY", 179, 198], ["vitamin C", "CHEMICAL", 40, 49], ["vitamin C", "CHEMICAL", 40, 49], ["vitamin C", "SIMPLE_CHEMICAL", 40, 49], ["vascular", "MULTI-TISSUE_STRUCTURE", 117, 125], ["endothelial barrier", "TISSUE", 179, 198], ["Preclinical studies", "TEST", 0, 19], ["high-dose vitamin C", "TREATMENT", 30, 49], ["restore microcirculatory flow impairment", "PROBLEM", 65, 105], ["vasoconstrictors", "TREATMENT", 144, 160], ["the endothelial barrier", "TREATMENT", 175, 198], ["microcirculatory flow", "OBSERVATION", 73, 94], ["endothelial", "ANATOMY", 179, 190]]], ["Both ascorbic acid (279) and the GR (see section Endothelium) (130) are essential for endothelial cell homeostasis, and the combination of glucocorticoids with ascorbic acid is superior to either one on its own in protecting vascular endothelium that is critical to allow recovery (280).Vitamin C ::: HypovitaminosesMany studies have demonstrated that vitamin C levels are rapidly depleted in critically ill patients, with about 40% of the septic patients having reduced serum levels, similar to those seen at scurvy diagnosis (<11.3 u/mol/l) (281, 282).", [["endothelial cell", "ANATOMY", 86, 102], ["vascular endothelium", "ANATOMY", 225, 245], ["serum", "ANATOMY", 471, 476], ["ascorbic acid", "CHEMICAL", 5, 18], ["ascorbic acid", "CHEMICAL", 160, 173], ["Vitamin C", "CHEMICAL", 287, 296], ["vitamin C", "CHEMICAL", 352, 361], ["critically ill", "DISEASE", 393, 407], ["septic", "DISEASE", 440, 446], ["scurvy", "DISEASE", 510, 516], ["ascorbic acid", "CHEMICAL", 5, 18], ["ascorbic acid", "CHEMICAL", 160, 173], ["Vitamin C", "CHEMICAL", 287, 296], ["Hypovitaminoses", "CHEMICAL", 301, 316], ["vitamin C", "CHEMICAL", 352, 361], ["ascorbic acid", "SIMPLE_CHEMICAL", 5, 18], ["GR", "GENE_OR_GENE_PRODUCT", 33, 35], ["endothelial cell", "CELL", 86, 102], ["glucocorticoids", "SIMPLE_CHEMICAL", 139, 154], ["ascorbic acid", "SIMPLE_CHEMICAL", 160, 173], ["vascular endothelium", "TISSUE", 225, 245], ["Vitamin C", "SIMPLE_CHEMICAL", 287, 296], ["Hypovitaminoses", "SIMPLE_CHEMICAL", 301, 316], ["vitamin C", "SIMPLE_CHEMICAL", 352, 361], ["patients", "ORGANISM", 408, 416], ["patients", "ORGANISM", 447, 455], ["serum", "ORGANISM_SUBSTANCE", 471, 476], ["GR", "PROTEIN", 33, 35], ["patients", "SPECIES", 408, 416], ["patients", "SPECIES", 447, 455], ["Both ascorbic acid", "TEST", 0, 18], ["the GR", "TEST", 29, 35], ["endothelial cell homeostasis", "PROBLEM", 86, 114], ["glucocorticoids", "TREATMENT", 139, 154], ["ascorbic acid", "TREATMENT", 160, 173], ["Hypovitaminoses", "TEST", 301, 316], ["Many studies", "TEST", 316, 328], ["vitamin C levels", "TEST", 352, 368], ["the septic patients", "PROBLEM", 436, 455], ["reduced serum levels", "PROBLEM", 463, 483], ["scurvy diagnosis", "TEST", 510, 526], ["ascorbic acid", "OBSERVATION", 5, 18], ["essential for", "UNCERTAINTY", 72, 85], ["endothelial cell homeostasis", "OBSERVATION", 86, 114], ["glucocorticoids", "OBSERVATION", 139, 154], ["vascular endothelium", "ANATOMY", 225, 245], ["critically ill", "OBSERVATION_MODIFIER", 393, 407], ["septic", "OBSERVATION", 440, 446]]], ["As intracellular ascorbate concentrations in mononuclear leukocytes and in granulocytes are, respectively, 80 and 25 times higher than in plasma, a high production and turnover of these cells may also contribute to its depletion (200).", [["intracellular", "ANATOMY", 3, 16], ["mononuclear leukocytes", "ANATOMY", 45, 67], ["granulocytes", "ANATOMY", 75, 87], ["plasma", "ANATOMY", 138, 144], ["cells", "ANATOMY", 186, 191], ["ascorbate", "CHEMICAL", 17, 26], ["ascorbate", "CHEMICAL", 17, 26], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 3, 16], ["ascorbate", "SIMPLE_CHEMICAL", 17, 26], ["mononuclear leukocytes", "CELL", 45, 67], ["granulocytes", "CELL", 75, 87], ["plasma", "ORGANISM_SUBSTANCE", 138, 144], ["cells", "CELL", 186, 191], ["mononuclear leukocytes", "CELL_TYPE", 45, 67], ["granulocytes", "CELL_TYPE", 75, 87], ["intracellular ascorbate concentrations", "TEST", 3, 41], ["mononuclear leukocytes", "TEST", 45, 67], ["granulocytes", "TEST", 75, 87], ["a high production and turnover of these cells", "PROBLEM", 146, 191], ["its depletion", "PROBLEM", 215, 228], ["ascorbate concentrations", "OBSERVATION", 17, 41], ["mononuclear leukocytes", "OBSERVATION", 45, 67], ["granulocytes", "ANATOMY", 75, 87]]], ["Low plasma concentrations of vitamin C are associated with more severe organ failure and increased risk of mortality (282).", [["plasma", "ANATOMY", 4, 10], ["organ", "ANATOMY", 71, 76], ["vitamin C", "CHEMICAL", 29, 38], ["organ failure", "DISEASE", 71, 84], ["vitamin C", "CHEMICAL", 29, 38], ["plasma", "ORGANISM_SUBSTANCE", 4, 10], ["vitamin C", "SIMPLE_CHEMICAL", 29, 38], ["organ", "ORGAN", 71, 76], ["Low plasma concentrations", "PROBLEM", 0, 25], ["vitamin C", "PROBLEM", 29, 38], ["more severe organ failure", "PROBLEM", 59, 84], ["severe", "OBSERVATION_MODIFIER", 64, 70], ["organ", "ANATOMY", 71, 76], ["failure", "OBSERVATION", 77, 84], ["increased", "OBSERVATION_MODIFIER", 89, 98]]], ["Similar to thiamine, ascorbic acid deficiency syndrome (scurvy) bears a number of similarities to sepsis, including coagulation abnormalities, and breakdown of the endothelial wall (282).Vitamin C ::: HypovitaminosesIn a phase I safety trial, intravenous ascorbic acid infusion was safe, well-tolerated, and associated with improvement in multiple organ dysfunction and decreased biomarkers of inflammation and endothelial injury (281).", [["endothelial wall", "ANATOMY", 164, 180], ["intravenous", "ANATOMY", 243, 254], ["organ", "ANATOMY", 348, 353], ["endothelial", "ANATOMY", 411, 422], ["thiamine", "CHEMICAL", 11, 19], ["ascorbic acid", "CHEMICAL", 21, 34], ["deficiency syndrome", "DISEASE", 35, 54], ["scurvy", "DISEASE", 56, 62], ["sepsis", "DISEASE", 98, 104], ["coagulation abnormalities", "DISEASE", 116, 141], ["Vitamin C", "CHEMICAL", 187, 196], ["Hypovitaminoses", "CHEMICAL", 201, 216], ["ascorbic acid", "CHEMICAL", 255, 268], ["organ dysfunction", "DISEASE", 348, 365], ["inflammation", "DISEASE", 394, 406], ["endothelial injury", "DISEASE", 411, 429], ["thiamine", "CHEMICAL", 11, 19], ["ascorbic acid", "CHEMICAL", 21, 34], ["Vitamin C", "CHEMICAL", 187, 196], ["ascorbic acid", "CHEMICAL", 255, 268], ["thiamine", "SIMPLE_CHEMICAL", 11, 19], ["ascorbic acid", "SIMPLE_CHEMICAL", 21, 34], ["endothelial wall", "TISSUE", 164, 180], ["Vitamin C", "SIMPLE_CHEMICAL", 187, 196], ["Hypovitaminoses", "SIMPLE_CHEMICAL", 201, 216], ["intravenous ascorbic acid", "SIMPLE_CHEMICAL", 243, 268], ["organ", "ORGAN", 348, 353], ["endothelial", "TISSUE", 411, 422], ["thiamine", "TREATMENT", 11, 19], ["ascorbic acid deficiency syndrome", "PROBLEM", 21, 54], ["scurvy)", "PROBLEM", 56, 63], ["sepsis", "PROBLEM", 98, 104], ["coagulation abnormalities", "PROBLEM", 116, 141], ["breakdown of the endothelial wall", "PROBLEM", 147, 180], ["Hypovitaminoses", "TREATMENT", 201, 216], ["intravenous ascorbic acid infusion", "TREATMENT", 243, 277], ["multiple organ dysfunction", "PROBLEM", 339, 365], ["decreased biomarkers of inflammation", "PROBLEM", 370, 406], ["endothelial injury", "PROBLEM", 411, 429], ["ascorbic acid deficiency", "OBSERVATION", 21, 45], ["sepsis", "OBSERVATION", 98, 104], ["coagulation abnormalities", "OBSERVATION", 116, 141], ["breakdown", "OBSERVATION_MODIFIER", 147, 156], ["endothelial", "ANATOMY", 164, 175], ["wall", "ANATOMY_MODIFIER", 176, 180], ["multiple", "OBSERVATION_MODIFIER", 339, 347], ["organ", "ANATOMY", 348, 353], ["dysfunction", "OBSERVATION", 354, 365], ["decreased", "OBSERVATION_MODIFIER", 370, 379], ["inflammation", "OBSERVATION", 394, 406], ["endothelial injury", "OBSERVATION", 411, 429]]], ["Additionally, a small RCT investigating high dose ascorbic acid administration in patients with septic shock reported a reduction in 28-day mortality (283), while a larger trial in patients with sepsis-associated ARDS reported a significant reduction in 28-day all-cause mortality (secondary outcome) (284).", [["ascorbic acid", "CHEMICAL", 50, 63], ["septic shock", "DISEASE", 96, 108], ["sepsis", "DISEASE", 195, 201], ["ARDS", "DISEASE", 213, 217], ["ascorbic acid", "CHEMICAL", 50, 63], ["ascorbic acid", "SIMPLE_CHEMICAL", 50, 63], ["patients", "ORGANISM", 82, 90], ["patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 82, 90], ["patients", "SPECIES", 181, 189], ["a small RCT", "PROBLEM", 14, 25], ["high dose ascorbic acid administration", "TREATMENT", 40, 78], ["septic shock", "PROBLEM", 96, 108], ["a reduction", "TREATMENT", 118, 129], ["sepsis", "PROBLEM", 195, 201], ["ARDS", "PROBLEM", 213, 217], ["a significant reduction", "PROBLEM", 227, 250], ["small", "OBSERVATION_MODIFIER", 16, 21], ["high dose", "OBSERVATION_MODIFIER", 40, 49], ["ascorbic acid", "OBSERVATION", 50, 63], ["septic shock", "OBSERVATION", 96, 108], ["reduction", "OBSERVATION_MODIFIER", 120, 129], ["sepsis", "OBSERVATION", 195, 201], ["ARDS", "OBSERVATION", 213, 217], ["significant", "OBSERVATION_MODIFIER", 229, 240], ["reduction", "OBSERVATION_MODIFIER", 241, 250]]], ["The rationale for glucocorticoid treatment in association with high dose ascorbic acid was the subject of recent reviews (237, 267).", [["ascorbic acid", "CHEMICAL", 73, 86], ["ascorbic acid", "CHEMICAL", 73, 86], ["glucocorticoid", "SIMPLE_CHEMICAL", 18, 32], ["ascorbic acid", "SIMPLE_CHEMICAL", 73, 86], ["glucocorticoid treatment", "TREATMENT", 18, 42], ["high dose ascorbic acid", "TREATMENT", 63, 86]]], ["The promising findings of a recent retrospective study in patients with severe sepsis and septic shock has spurred considerable interest in the subject (275).", [["sepsis", "DISEASE", 79, 85], ["septic shock", "DISEASE", 90, 102], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["a recent retrospective study", "TEST", 26, 54], ["severe sepsis", "PROBLEM", 72, 85], ["septic shock", "PROBLEM", 90, 102], ["severe", "OBSERVATION_MODIFIER", 72, 78], ["sepsis", "OBSERVATION", 79, 85], ["septic shock", "OBSERVATION", 90, 102], ["considerable", "OBSERVATION_MODIFIER", 115, 127], ["interest", "OBSERVATION_MODIFIER", 128, 136]]], ["Randomized data to confirm or refute the observational evidence for the drug combination are needed, and several clinical trials are ongoing or planned in the near future (237).Conclusions and Implications for Glucocorticoid TreatmentIn critical illness, homeostatic corrections, the culmination of millions of years of evolution, are modulated by the activated GC-GR\u03b1 and associated with an enormous bioenergetic and metabolic cost.", [["Glucocorticoid", "SIMPLE_CHEMICAL", 210, 224], ["GC-GR\u03b1", "GENE_OR_GENE_PRODUCT", 362, 368], ["GR\u03b1", "PROTEIN", 365, 368], ["Randomized data", "TEST", 0, 15], ["the drug combination", "TREATMENT", 68, 88], ["Glucocorticoid Treatment", "TREATMENT", 210, 234], ["an enormous bioenergetic and metabolic cost", "PROBLEM", 389, 432], ["critical", "OBSERVATION_MODIFIER", 237, 245], ["illness", "OBSERVATION", 246, 253], ["enormous", "OBSERVATION_MODIFIER", 392, 400], ["bioenergetic", "OBSERVATION", 401, 413], ["metabolic cost", "OBSERVATION", 418, 432]]], ["We have reviewed how CIRCI, mitochondrial dysfunction/damage, and hypovitaminosis collectively interact to accelerate an anti-homeostatic active process of natural selection.", [["mitochondrial", "ANATOMY", 28, 41], ["mitochondrial dysfunction", "DISEASE", 28, 53], ["hypovitaminosis", "DISEASE", 66, 81], ["mitochondrial", "CELLULAR_COMPONENT", 28, 41], ["mitochondrial dysfunction", "PROBLEM", 28, 53], ["damage", "PROBLEM", 54, 60], ["hypovitaminosis", "PROBLEM", 66, 81], ["an anti-homeostatic active process", "PROBLEM", 118, 152], ["active", "OBSERVATION_MODIFIER", 138, 144], ["natural selection", "OBSERVATION", 156, 173]]], ["Importantly, the allostatic overload imposed by homeostatic corrections impacts negatively on both acute and long-term morbidity and mortality, while the bioenergetic and metabolic reserves to support homeostatic corrections are time limited.", [["allostatic overload", "DISEASE", 17, 36], ["the allostatic overload", "PROBLEM", 13, 36], ["homeostatic corrections", "TREATMENT", 201, 224], ["allostatic overload", "OBSERVATION", 17, 36], ["homeostatic corrections", "OBSERVATION", 48, 71], ["acute", "OBSERVATION_MODIFIER", 99, 104], ["long-term morbidity", "OBSERVATION_MODIFIER", 109, 128], ["metabolic reserves", "OBSERVATION", 171, 189]]], ["For these reasons it is prudent to implement early interventions designed to achieve the following: (i) reinforce innate immunity, (ii) inhibit further systemic tissue damage, (iii) limit the metabolic and bioenergetic cacostatic overload imposed during vital organ support, (iv) accelerate disease resolution, and (v) prevent persistent-chronic low-grade systemic inflammation (285).", [["tissue", "ANATOMY", 161, 167], ["organ", "ANATOMY", 260, 265], ["tissue damage", "DISEASE", 161, 174], ["inflammation", "DISEASE", 365, 377], ["tissue", "TISSUE", 161, 167], ["organ", "ORGAN", 260, 265], ["early interventions", "TREATMENT", 45, 64], ["further systemic tissue damage", "PROBLEM", 144, 174], ["the metabolic and bioenergetic cacostatic overload", "PROBLEM", 188, 238], ["vital organ support", "TREATMENT", 254, 273], ["accelerate disease resolution", "PROBLEM", 280, 309], ["persistent-chronic low-grade systemic inflammation", "PROBLEM", 327, 377], ["systemic tissue", "ANATOMY", 152, 167], ["damage", "OBSERVATION", 168, 174], ["cacostatic overload", "OBSERVATION", 219, 238], ["persistent", "OBSERVATION_MODIFIER", 327, 337], ["chronic", "OBSERVATION_MODIFIER", 338, 345], ["low-grade", "OBSERVATION_MODIFIER", 346, 355], ["systemic", "OBSERVATION_MODIFIER", 356, 364], ["inflammation", "OBSERVATION", 365, 377]]], ["This approach is supported by experimental (286) and clinical studies in patients with septic shock or ARDS (287\u2013290).Conclusions and Implications for Glucocorticoid TreatmentThe actions of the activated GR\u03b1 cannot be categorized as merely anti-inflammatory, as it is now clear that insufficient intracellular GR\u03b1 regulatory action and not relative adrenal insufficiency is the primary driver of CIRCI (17).", [["intracellular", "ANATOMY", 296, 309], ["adrenal", "ANATOMY", 349, 356], ["septic shock", "DISEASE", 87, 99], ["ARDS", "DISEASE", 103, 107], ["adrenal insufficiency", "DISEASE", 349, 370], ["patients", "ORGANISM", 73, 81], ["Glucocorticoid", "SIMPLE_CHEMICAL", 151, 165], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 204, 207], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 296, 309], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 310, 313], ["adrenal", "ORGAN", 349, 356], ["GR\u03b1", "PROTEIN", 204, 207], ["GR", "PROTEIN", 310, 312], ["patients", "SPECIES", 73, 81], ["clinical studies", "TEST", 53, 69], ["septic shock", "PROBLEM", 87, 99], ["ARDS", "PROBLEM", 103, 107], ["Glucocorticoid Treatment", "TREATMENT", 151, 175], ["the activated GR\u03b1", "TREATMENT", 190, 207], ["relative adrenal insufficiency", "PROBLEM", 340, 370], ["septic shock", "OBSERVATION", 87, 99], ["ARDS", "OBSERVATION", 103, 107], ["adrenal", "ANATOMY", 349, 356], ["insufficiency", "OBSERVATION", 357, 370]]], ["Therefore, glucocorticoid treatment should not be viewed exclusively as anti-inflammatory or as a hormone replacement for relative adrenal insufficiency.", [["adrenal", "ANATOMY", 131, 138], ["adrenal insufficiency", "DISEASE", 131, 152], ["glucocorticoid", "SIMPLE_CHEMICAL", 11, 25], ["adrenal", "ORGAN", 131, 138], ["glucocorticoid treatment", "TREATMENT", 11, 35], ["a hormone replacement", "TREATMENT", 96, 117], ["relative adrenal insufficiency", "PROBLEM", 122, 152], ["adrenal", "ANATOMY", 131, 138], ["insufficiency", "OBSERVATION", 139, 152]]], ["It also is equally relevant that one should recall that full biological resolution lags weeks behind clinical resolution of an acute illness, making the clinical criteria that we frequently employ to guide duration of treatment, an inadequate reference point (291).", [["an acute illness", "PROBLEM", 124, 140], ["treatment", "TREATMENT", 218, 227], ["acute", "OBSERVATION_MODIFIER", 127, 132], ["illness", "OBSERVATION", 133, 140]]], ["For these reasons, glucocorticoid treatment, and other co-interventions should be directed at supporting the activated GR\u03b1 regulatory function throughout all phases of homeostatic corrections, and not limited to the acute phase of organ support.Conclusions and Implications for Glucocorticoid TreatmentRandomized studies provide evidence that prolonged glucocorticoid administration is associated with increased GR\u03b1 number and function and decreased oxidative stress (see sections Glucocorticoid Receptor Alpha in Critical Illness and Mitochondria and HPA-Axis Cross-Talk).", [["organ", "ANATOMY", 231, 236], ["Mitochondria", "ANATOMY", 535, 547], ["glucocorticoid", "SIMPLE_CHEMICAL", 19, 33], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 119, 122], ["organ", "ORGAN", 231, 236], ["glucocorticoid", "SIMPLE_CHEMICAL", 353, 367], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 412, 415], ["Glucocorticoid Receptor Alpha", "GENE_OR_GENE_PRODUCT", 481, 510], ["Mitochondria", "CELL", 535, 547], ["GR\u03b1", "PROTEIN", 119, 122], ["GR\u03b1", "PROTEIN", 412, 415], ["Glucocorticoid Receptor Alpha", "PROTEIN", 481, 510], ["glucocorticoid treatment", "TREATMENT", 19, 43], ["other co-interventions", "TREATMENT", 49, 71], ["organ support", "TREATMENT", 231, 244], ["Glucocorticoid Treatment", "TREATMENT", 278, 302], ["Randomized studies", "TEST", 302, 320], ["prolonged glucocorticoid administration", "TREATMENT", 343, 382], ["increased GR\u03b1 number and function", "PROBLEM", 402, 435], ["decreased oxidative stress", "PROBLEM", 440, 466], ["Critical Illness", "PROBLEM", 514, 530], ["Mitochondria", "TEST", 535, 547], ["HPA", "TEST", 552, 555], ["decreased", "OBSERVATION_MODIFIER", 440, 449], ["oxidative stress", "OBSERVATION", 450, 466]]], ["Additionally, the activated GR\u03b1 interdependence with functional mitochondria and three vitamin reserves provides a rationale for co-interventions that include rapid replacement of vitamins B1, C, and D. Recent evidence generated from a retrospective before-after clinical study in patients with severe sepsis has generated momentum for increased research in this field (275), with ongoing confirmatory randomized trials in progress (282).Conclusions and Implications for Glucocorticoid TreatmentAdditional co-intervention with critical hormones and mediators involved in homeostatic corrections are also necessary, such as fludrocortisone (174, 292, 293) or vasopressin (294\u2013296) in patients with septic shock.", [["mitochondria", "ANATOMY", 64, 76], ["vitamin", "CHEMICAL", 87, 94], ["sepsis", "DISEASE", 302, 308], ["fludrocortisone", "CHEMICAL", 623, 638], ["174, 292, 293", "CHEMICAL", 640, 653], ["vasopressin", "CHEMICAL", 658, 669], ["septic shock", "DISEASE", 697, 709], ["vitamin", "CHEMICAL", 87, 94], ["vitamins B1, C", "CHEMICAL", 180, 194], ["fludrocortisone", "CHEMICAL", 623, 638], ["vasopressin", "CHEMICAL", 658, 669], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 28, 31], ["mitochondria", "CELLULAR_COMPONENT", 64, 76], ["vitamin", "SIMPLE_CHEMICAL", 87, 94], ["vitamins B1", "SIMPLE_CHEMICAL", 180, 191], ["C", "SIMPLE_CHEMICAL", 193, 194], ["patients", "ORGANISM", 281, 289], ["fludrocortisone", "SIMPLE_CHEMICAL", 623, 638], ["vasopressin", "SIMPLE_CHEMICAL", 658, 669], ["patients", "ORGANISM", 683, 691], ["GR\u03b1", "PROTEIN", 28, 31], ["patients", "SPECIES", 281, 289], ["patients", "SPECIES", 683, 691], ["functional mitochondria", "TREATMENT", 53, 76], ["three vitamin reserves", "TREATMENT", 81, 103], ["co-interventions", "TREATMENT", 129, 145], ["rapid replacement of vitamins B1", "TREATMENT", 159, 191], ["clinical study", "TEST", 263, 277], ["severe sepsis", "PROBLEM", 295, 308], ["Glucocorticoid TreatmentAdditional co-intervention", "TREATMENT", 471, 521], ["fludrocortisone", "TREATMENT", 623, 638], ["vasopressin", "TREATMENT", 658, 669], ["septic shock", "PROBLEM", 697, 709], ["severe", "OBSERVATION_MODIFIER", 295, 301], ["sepsis", "OBSERVATION", 302, 308], ["septic shock", "OBSERVATION", 697, 709]]], ["Fludrocortisone is a mineralocorticoid and glucocorticoid receptor agonist that binds to cytoplasmic receptors, activates their translocation into the nucleus and subsequently initiates the transcription of mineralocorticoid- and glucocorticoid-responsive genes (297).", [["cytoplasmic", "ANATOMY", 89, 100], ["nucleus", "ANATOMY", 151, 158], ["Fludrocortisone", "CHEMICAL", 0, 15], ["Fludrocortisone", "CHEMICAL", 0, 15], ["Fludrocortisone", "SIMPLE_CHEMICAL", 0, 15], ["mineralocorticoid", "SIMPLE_CHEMICAL", 21, 38], ["glucocorticoid receptor", "GENE_OR_GENE_PRODUCT", 43, 66], ["cytoplasmic", "ORGANISM_SUBSTANCE", 89, 100], ["nucleus", "CELLULAR_COMPONENT", 151, 158], ["mineralocorticoid", "GENE_OR_GENE_PRODUCT", 207, 224], ["cytoplasmic receptors", "PROTEIN", 89, 110], ["glucocorticoid-responsive genes", "DNA", 230, 261], ["Fludrocortisone", "TREATMENT", 0, 15], ["a mineralocorticoid and glucocorticoid receptor agonist", "TREATMENT", 19, 74], ["cytoplasmic receptors", "TREATMENT", 89, 110], ["mineralocorticoid", "TEST", 207, 224], ["nucleus", "ANATOMY", 151, 158]]], ["The inclusion or exclusion of fludrocortisone, as a co-intervention with hydrocortisone, may partly explain the differences reported in outcomes of some RCTs (see explanation for Figure 7 below) (292, 298).", [["fludrocortisone", "CHEMICAL", 30, 45], ["hydrocortisone", "CHEMICAL", 73, 87], ["fludrocortisone", "CHEMICAL", 30, 45], ["hydrocortisone", "CHEMICAL", 73, 87], ["fludrocortisone", "SIMPLE_CHEMICAL", 30, 45], ["hydrocortisone", "SIMPLE_CHEMICAL", 73, 87], ["fludrocortisone", "TREATMENT", 30, 45], ["a co-intervention with hydrocortisone", "TREATMENT", 50, 87], ["some RCTs", "TEST", 148, 157]]], ["Other potential co-interventions directed at increasing glucocorticoid receptor expression, such as statins (299), melatonin (300), beta-blockers (301), calcium channel blockers (301), or directed at improving mitochondrial function (194, 302, 303) have not been investigated in association with glucocorticoid treatment in acute illness or alone in chronic critical illness.Conclusions and Implications for Glucocorticoid TreatmentPresent understanding of the activated GC-GR\u03b1's role in immunomodulation and disease resolution should be taken into account when re-evaluating how to administer glucocorticoid treatment and in monitoring treatment responses.", [["mitochondrial", "ANATOMY", 210, 223], ["statins", "CHEMICAL", 100, 107], ["melatonin", "CHEMICAL", 115, 124], ["calcium", "CHEMICAL", 153, 160], ["acute illness", "DISEASE", 324, 337], ["chronic critical illness", "DISEASE", 350, 374], ["statins", "CHEMICAL", 100, 107], ["melatonin", "CHEMICAL", 115, 124], ["calcium", "CHEMICAL", 153, 160], ["glucocorticoid receptor", "GENE_OR_GENE_PRODUCT", 56, 79], ["statins", "SIMPLE_CHEMICAL", 100, 107], ["melatonin", "SIMPLE_CHEMICAL", 115, 124], ["beta-blockers", "SIMPLE_CHEMICAL", 132, 145], ["calcium channel blockers", "SIMPLE_CHEMICAL", 153, 177], ["mitochondrial", "CELLULAR_COMPONENT", 210, 223], ["glucocorticoid", "SIMPLE_CHEMICAL", 296, 310], ["Glucocorticoid", "SIMPLE_CHEMICAL", 408, 422], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 474, 477], ["glucocorticoid receptor", "PROTEIN", 56, 79], ["GR\u03b1", "PROTEIN", 474, 477], ["Other potential co-interventions", "TREATMENT", 0, 32], ["increasing glucocorticoid receptor expression", "TREATMENT", 45, 90], ["statins", "TREATMENT", 100, 107], ["melatonin", "TREATMENT", 115, 124], ["beta-blockers", "TREATMENT", 132, 145], ["calcium channel blockers", "TREATMENT", 153, 177], ["glucocorticoid treatment", "TREATMENT", 296, 320], ["acute illness", "PROBLEM", 324, 337], ["chronic critical illness", "PROBLEM", 350, 374], ["Glucocorticoid Treatment", "TREATMENT", 408, 432], ["immunomodulation", "TREATMENT", 488, 504], ["disease resolution", "PROBLEM", 509, 527], ["glucocorticoid treatment", "TREATMENT", 594, 618], ["chronic", "OBSERVATION_MODIFIER", 350, 357], ["critical", "OBSERVATION_MODIFIER", 358, 366], ["illness", "OBSERVATION", 367, 374]]], ["There are many variables to consider, including the type of GC to be used, timing, dosage, mode of delivery, co-interventions, duration, and tapering.", [["GC", "TREATMENT", 60, 62], ["delivery", "TREATMENT", 99, 107], ["co-interventions", "TREATMENT", 109, 125]]], ["Over the last 40 years, multiple randomized trials investigating GC treatment in critical illness have clearly shown that the design of a treatment protocol has a profound impact on treatment response and outcome (304, 305).", [["multiple randomized trials", "TREATMENT", 24, 50], ["GC treatment", "TREATMENT", 65, 77], ["a treatment protocol", "TREATMENT", 136, 156]]], ["The CONSORT (306) and GRADE (307) systems, while useful in evaluating the quality of a randomized trial, unfortunately lack a position on two fundamental elements of a trial design, namely the disease pathophysiology and the pharmacological principles applicable to the investigated drug.", [["a randomized trial", "TREATMENT", 85, 103], ["a trial design", "TREATMENT", 166, 180], ["the disease pathophysiology", "PROBLEM", 189, 216], ["the pharmacological principles", "TREATMENT", 221, 251]]], ["Unfortunately, lack of these specific reference points has generated misinterpretation of the literature, fueling a non-sensical controversy that clearly is not serving the patient (308).Conclusions and Implications for Glucocorticoid TreatmentBased on this updated pathophysiological understanding, we offer a few observations and make recommendations for future research.", [["patient", "ORGANISM", 173, 180], ["patient", "SPECIES", 173, 180], ["Glucocorticoid TreatmentBased", "TREATMENT", 220, 249]]], ["Early initiation of treatment, before homeostatic corrections reach exhaustion, is critical and should be directed at approaching maximal saturation of the glucocorticoid receptor (~100 mg of methylprednisolone equivalent) (309).", [["methylprednisolone", "CHEMICAL", 192, 210], ["methylprednisolone", "CHEMICAL", 192, 210], ["glucocorticoid receptor", "GENE_OR_GENE_PRODUCT", 156, 179], ["methylprednisolone", "SIMPLE_CHEMICAL", 192, 210], ["glucocorticoid receptor", "PROTEIN", 156, 179], ["treatment", "TREATMENT", 20, 29], ["the glucocorticoid receptor", "TREATMENT", 152, 179], ["methylprednisolone equivalent", "TREATMENT", 192, 221]]], ["An adequate initial loading bolus is necessary to achieve prompt elevation in plasma levels and to assure higher GR\u03b1 saturation in the cytoplasm and on the cell membrane for genomic and non-genomic actions, respectively.", [["plasma", "ANATOMY", 78, 84], ["cytoplasm", "ANATOMY", 135, 144], ["cell membrane", "ANATOMY", 156, 169], ["plasma", "ORGANISM_SUBSTANCE", 78, 84], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 113, 116], ["cytoplasm", "ORGANISM_SUBSTANCE", 135, 144], ["cell membrane", "CELLULAR_COMPONENT", 156, 169], ["GR\u03b1", "PROTEIN", 113, 116], ["An adequate initial loading bolus", "TREATMENT", 0, 33], ["prompt elevation in plasma levels", "PROBLEM", 58, 91], ["higher GR\u03b1 saturation in the cytoplasm", "PROBLEM", 106, 144], ["adequate", "OBSERVATION_MODIFIER", 3, 11], ["cell membrane", "OBSERVATION", 156, 169]]], ["In human monocytic cells activated with graded concentrations of LPS and then exposed to graded concentrations of methylprednisolone (Figure 7), reduction in inflammatory cytokine transcription was initially modest, then\u2014after reaching an inflection point\u2014followed by a rapid reduction, likely related to achieving maximal drug receptor saturation and adequate time for a measurable effect (102).", [["monocytic cells", "ANATOMY", 9, 24], ["LPS", "CHEMICAL", 65, 68], ["methylprednisolone", "CHEMICAL", 114, 132], ["methylprednisolone", "CHEMICAL", 114, 132], ["human", "ORGANISM", 3, 8], ["monocytic cells", "CELL", 9, 24], ["LPS", "SIMPLE_CHEMICAL", 65, 68], ["methylprednisolone", "SIMPLE_CHEMICAL", 114, 132], ["human monocytic cells", "CELL_TYPE", 3, 24], ["inflammatory cytokine", "PROTEIN", 158, 179], ["human", "SPECIES", 3, 8], ["human", "SPECIES", 3, 8], ["human monocytic cells", "TREATMENT", 3, 24], ["LPS", "TREATMENT", 65, 68], ["methylprednisolone", "TREATMENT", 114, 132], ["reduction in inflammatory cytokine transcription", "PROBLEM", 145, 193], ["a rapid reduction", "TREATMENT", 268, 285], ["maximal drug receptor saturation", "TREATMENT", 315, 347], ["human monocytic cells", "OBSERVATION", 3, 24], ["inflammatory", "OBSERVATION_MODIFIER", 158, 170], ["cytokine transcription", "OBSERVATION", 171, 193], ["likely related to", "UNCERTAINTY", 287, 304]]], ["To achieve optimal results, the initial loading bolus should be followed by an infusion (daily dose over 24 h) to rapidly achieve a steady state.", [["the initial loading bolus", "TREATMENT", 28, 53]]], ["In patients with septic shock, hydrocortisone administered as an infusion vs. an intermittent bolus was associated with more rapid resolution of shock (310), and fewer hyperglycemic episodes (311, 312).Conclusions and Implications for Glucocorticoid TreatmentIn general, synthetic glucocorticoids are more potent immunoregulators than is cortisol, because they are not subject to endogenous clearance and inhibitors of cortisol activity, including 11\u03b2HSD inactivation.", [["septic shock", "DISEASE", 17, 29], ["hydrocortisone", "CHEMICAL", 31, 45], ["shock", "DISEASE", 145, 150], ["hyperglycemic", "DISEASE", 168, 181], ["glucocorticoids", "CHEMICAL", 281, 296], ["cortisol", "CHEMICAL", 338, 346], ["cortisol", "CHEMICAL", 419, 427], ["hydrocortisone", "CHEMICAL", 31, 45], ["cortisol", "CHEMICAL", 338, 346], ["cortisol", "CHEMICAL", 419, 427], ["patients", "ORGANISM", 3, 11], ["hydrocortisone", "SIMPLE_CHEMICAL", 31, 45], ["Glucocorticoid", "SIMPLE_CHEMICAL", 235, 249], ["glucocorticoids", "SIMPLE_CHEMICAL", 281, 296], ["cortisol", "SIMPLE_CHEMICAL", 338, 346], ["cortisol", "SIMPLE_CHEMICAL", 419, 427], ["\u03b2HSD", "GENE_OR_GENE_PRODUCT", 450, 454], ["patients", "SPECIES", 3, 11], ["septic shock", "PROBLEM", 17, 29], ["hydrocortisone", "TREATMENT", 31, 45], ["an infusion vs", "TREATMENT", 62, 76], ["an intermittent bolus", "TREATMENT", 78, 99], ["shock", "PROBLEM", 145, 150], ["fewer hyperglycemic episodes", "PROBLEM", 162, 190], ["Glucocorticoid Treatment", "TREATMENT", 235, 259], ["synthetic glucocorticoids", "TREATMENT", 271, 296], ["cortisol", "TEST", 338, 346], ["cortisol activity", "TEST", 419, 436], ["HSD inactivation", "PROBLEM", 451, 467], ["septic shock", "OBSERVATION", 17, 29], ["intermittent", "OBSERVATION_MODIFIER", 81, 93], ["shock", "OBSERVATION", 145, 150], ["fewer", "OBSERVATION_MODIFIER", 162, 167], ["hyperglycemic episodes", "OBSERVATION", 168, 190]]], ["Moreover, synthetic glucocorticoids bind the glucocorticoid receptors with higher affinity and remain longer in the cell nucleus, while they bind to mineralocorticoid receptors with lower affinity than do endogenous glucocorticoids, thereby minimizing mineralocorticoid-related side effects (313).", [["cell nucleus", "ANATOMY", 116, 128], ["glucocorticoids", "CHEMICAL", 216, 231], ["glucocorticoids", "SIMPLE_CHEMICAL", 20, 35], ["glucocorticoid receptors", "GENE_OR_GENE_PRODUCT", 45, 69], ["cell nucleus", "CELLULAR_COMPONENT", 116, 128], ["mineralocorticoid receptors", "GENE_OR_GENE_PRODUCT", 149, 176], ["glucocorticoids", "SIMPLE_CHEMICAL", 216, 231], ["mineralocorticoid", "SIMPLE_CHEMICAL", 252, 269], ["glucocorticoid receptors", "PROTEIN", 45, 69], ["mineralocorticoid receptors", "PROTEIN", 149, 176], ["synthetic glucocorticoids bind the glucocorticoid receptors", "TREATMENT", 10, 69], ["higher affinity", "TREATMENT", 75, 90], ["lower affinity", "PROBLEM", 182, 196], ["endogenous glucocorticoids", "TREATMENT", 205, 231], ["cell nucleus", "OBSERVATION", 116, 128], ["endogenous glucocorticoids", "OBSERVATION", 205, 231]]], ["Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids are reviewed in reference (314).", [["glucocorticoids", "CHEMICAL", 67, 82], ["Pharmacokinetics", "TREATMENT", 0, 16], ["pharmacodynamics of systemically administered glucocorticoids", "TREATMENT", 21, 82]]], ["Hydrocortisone and methylprednisolone are the two glucocorticoids most often investigated in critical care RCTs (315).", [["Hydrocortisone", "CHEMICAL", 0, 14], ["methylprednisolone", "CHEMICAL", 19, 37], ["Hydrocortisone", "CHEMICAL", 0, 14], ["methylprednisolone", "CHEMICAL", 19, 37], ["Hydrocortisone", "SIMPLE_CHEMICAL", 0, 14], ["methylprednisolone", "SIMPLE_CHEMICAL", 19, 37], ["Hydrocortisone", "TREATMENT", 0, 14], ["methylprednisolone", "TREATMENT", 19, 37], ["the two glucocorticoids", "TREATMENT", 42, 65]]], ["In the past, different exogenous glucocorticoids were thought to be qualitatively indistinguishable from each other because they act via the same glucocorticoid receptor, however, qualitative differences have been recently discovered, and one glucocorticoid cannot be simply replaced by another (314).", [["glucocorticoids", "SIMPLE_CHEMICAL", 33, 48], ["glucocorticoid receptor", "GENE_OR_GENE_PRODUCT", 146, 169], ["glucocorticoid", "SIMPLE_CHEMICAL", 243, 257], ["glucocorticoid receptor", "PROTEIN", 146, 169], ["different exogenous glucocorticoids", "PROBLEM", 13, 48], ["exogenous glucocorticoids", "OBSERVATION", 23, 48]]], ["While hydrocortisone was initially chosen as the drug of choice for adrenal replacement, methylprednisolone may actually offer unique advantages over hydrocortisone as follows: (i) greater affinity for the glucocorticoid receptor (316); (ii) higher penetration in lung tissue (important for ARDS or pneumonia), and with longer residence time (317\u2013319), (iii) higher potency of genomic activity especially NF-\u03baB inhibitory activity (320); and (iv) higher potency of non-genomic activity (321).", [["adrenal", "ANATOMY", 68, 75], ["lung tissue", "ANATOMY", 264, 275], ["hydrocortisone", "CHEMICAL", 6, 20], ["methylprednisolone", "CHEMICAL", 89, 107], ["hydrocortisone", "CHEMICAL", 150, 164], ["ARDS", "DISEASE", 291, 295], ["pneumonia", "DISEASE", 299, 308], ["hydrocortisone", "CHEMICAL", 6, 20], ["methylprednisolone", "CHEMICAL", 89, 107], ["hydrocortisone", "CHEMICAL", 150, 164], ["hydrocortisone", "SIMPLE_CHEMICAL", 6, 20], ["adrenal", "ORGAN", 68, 75], ["methylprednisolone", "SIMPLE_CHEMICAL", 89, 107], ["hydrocortisone", "SIMPLE_CHEMICAL", 150, 164], ["glucocorticoid receptor", "GENE_OR_GENE_PRODUCT", 206, 229], ["lung tissue", "TISSUE", 264, 275], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 405, 410], ["glucocorticoid receptor", "PROTEIN", 206, 229], ["NF-\u03baB", "PROTEIN", 405, 410], ["hydrocortisone", "TREATMENT", 6, 20], ["adrenal replacement", "TREATMENT", 68, 87], ["methylprednisolone", "TREATMENT", 89, 107], ["unique advantages over hydrocortisone", "TREATMENT", 127, 164], ["the glucocorticoid receptor", "TREATMENT", 202, 229], ["higher penetration in lung tissue", "PROBLEM", 242, 275], ["ARDS", "PROBLEM", 291, 295], ["pneumonia", "PROBLEM", 299, 308], ["genomic activity", "PROBLEM", 377, 393], ["non-genomic activity", "PROBLEM", 465, 485], ["lung tissue", "ANATOMY", 264, 275], ["pneumonia", "OBSERVATION", 299, 308], ["genomic activity", "OBSERVATION", 377, 393]]], ["GR\u03b1 binding affinity, expressed as relative receptor affinity (RRA), correlates with glucocorticoid potency.", [["GR\u03b1", "GENE_OR_GENE_PRODUCT", 0, 3], ["glucocorticoid", "SIMPLE_CHEMICAL", 85, 99], ["GR\u03b1", "PROTEIN", 0, 3], ["RRA", "PROTEIN", 63, 66], ["glucocorticoid potency", "OBSERVATION", 85, 107]]], ["The log RRAs for selected glucocorticoids are 0.95, 1.62, and 2.0 for hydrocortisone, methylprednisolone, and dexamethasone, respectively (316).", [["glucocorticoids", "CHEMICAL", 26, 41], ["hydrocortisone", "CHEMICAL", 70, 84], ["methylprednisolone", "CHEMICAL", 86, 104], ["dexamethasone", "CHEMICAL", 110, 123], ["hydrocortisone", "CHEMICAL", 70, 84], ["methylprednisolone", "CHEMICAL", 86, 104], ["dexamethasone", "CHEMICAL", 110, 123], ["hydrocortisone", "SIMPLE_CHEMICAL", 70, 84], ["methylprednisolone", "SIMPLE_CHEMICAL", 86, 104], ["dexamethasone", "SIMPLE_CHEMICAL", 110, 123], ["The log RRAs", "TEST", 0, 12], ["selected glucocorticoids", "TREATMENT", 17, 41], ["hydrocortisone", "TREATMENT", 70, 84], ["methylprednisolone", "TREATMENT", 86, 104], ["dexamethasone", "TREATMENT", 110, 123]]], ["A comparison study between these three types of glucocorticoids is needed.Conclusions and Implications for Glucocorticoid TreatmentThe suggested mode of administration for septic shock [hydrocortisone <400 mg/day for >3 days (315), or hydrocortisone 50 mg QID for 7 days without tapering] is based in part on an outdated pathophysiological model and a misconception about the risk associated with longer duration of treatment (small) and discontinuation without tapering (high).", [["glucocorticoids", "CHEMICAL", 48, 63], ["septic shock", "DISEASE", 172, 184], ["hydrocortisone", "CHEMICAL", 186, 200], ["hydrocortisone", "CHEMICAL", 235, 249], ["QID", "CHEMICAL", 256, 259], ["hydrocortisone", "CHEMICAL", 186, 200], ["hydrocortisone", "CHEMICAL", 235, 249], ["Glucocorticoid", "SIMPLE_CHEMICAL", 107, 121], ["hydrocortisone", "SIMPLE_CHEMICAL", 186, 200], ["hydrocortisone", "SIMPLE_CHEMICAL", 235, 249], ["A comparison study", "TEST", 0, 18], ["glucocorticoids", "TREATMENT", 48, 63], ["Glucocorticoid Treatment", "TREATMENT", 107, 131], ["septic shock", "TREATMENT", 172, 184], ["hydrocortisone", "TREATMENT", 186, 200], ["hydrocortisone", "TREATMENT", 235, 249], ["treatment (small) and discontinuation", "TREATMENT", 416, 453]]], ["There is some evidence that a treatment duration of 3\u20137 days directed at reducing acuity of illness (transient reduction in systemic inflammation) might shortchange the full beneficial effects of glucocorticoid therapy (322).", [["illness", "DISEASE", 92, 99], ["inflammation", "DISEASE", 133, 145], ["glucocorticoid", "SIMPLE_CHEMICAL", 196, 210], ["a treatment duration", "TREATMENT", 28, 48], ["illness", "PROBLEM", 92, 99], ["systemic inflammation", "PROBLEM", 124, 145], ["glucocorticoid therapy", "TREATMENT", 196, 218], ["reduction", "OBSERVATION_MODIFIER", 111, 120], ["systemic", "OBSERVATION_MODIFIER", 124, 132], ["inflammation", "OBSERVATION", 133, 145]]], ["The impact of a longer duration of treatment on medium- and long-term mortality, as observed in RTCs of patients with Pneumocystis jiroveci pneumonia (323), needs to be investigated.Conclusions and Implications for Glucocorticoid TreatmentWhile glucocorticoids have an important role in supporting homeostatic corrections, this is achieved at the expense of reversible suppression of the HPA axis.", [["Pneumocystis jiroveci pneumonia", "DISEASE", 118, 149], ["patients", "ORGANISM", 104, 112], ["Pneumocystis jiroveci", "ORGANISM", 118, 139], ["Glucocorticoid TreatmentWhile glucocorticoids", "SIMPLE_CHEMICAL", 215, 260], ["patients", "SPECIES", 104, 112], ["Pneumocystis jiroveci", "SPECIES", 118, 139], ["Pneumocystis jiroveci", "SPECIES", 118, 139], ["treatment on medium", "TREATMENT", 35, 54], ["long-term mortality", "TREATMENT", 60, 79], ["Pneumocystis jiroveci pneumonia", "PROBLEM", 118, 149], ["Glucocorticoid TreatmentWhile glucocorticoids", "TREATMENT", 215, 260], ["reversible suppression of the HPA axis", "PROBLEM", 358, 396], ["Pneumocystis jiroveci", "OBSERVATION", 118, 139], ["reversible suppression", "OBSERVATION", 358, 380], ["HPA axis", "OBSERVATION", 388, 396]]], ["In addition, the risk of glucocorticoid treatment-associated adrenal suppression in critically ill patients with dysregulated systemic inflammation is underappreciated.", [["adrenal", "ANATOMY", 61, 68], ["adrenal suppression", "DISEASE", 61, 80], ["critically ill", "DISEASE", 84, 98], ["systemic inflammation", "DISEASE", 126, 147], ["glucocorticoid", "SIMPLE_CHEMICAL", 25, 39], ["adrenal", "ORGAN", 61, 68], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["glucocorticoid treatment", "TREATMENT", 25, 49], ["adrenal suppression", "PROBLEM", 61, 80], ["dysregulated systemic inflammation", "PROBLEM", 113, 147], ["glucocorticoid treatment", "OBSERVATION", 25, 49], ["adrenal", "ANATOMY", 61, 68], ["dysregulated", "OBSERVATION_MODIFIER", 113, 125], ["systemic inflammation", "OBSERVATION", 126, 147]]], ["It has been shown that neither the total or the highest dose, nor the duration of glucocorticoid treatment is a significant predictor of HPA axis recovery (324).", [["glucocorticoid", "SIMPLE_CHEMICAL", 82, 96], ["glucocorticoid treatment", "TREATMENT", 82, 106]]], ["In the recent \u201cReduction in the Use of Corticosteroids in Exacerbated COPD trial\u201d that evaluated prednisone 40 mg daily for 5 or 14 days, adrenal suppression was detected at hospital discharge and at 30 days in 38 and 9% of patients, respectively; no differences were detected between 5 or 14 days of glucocorticoid exposure (325).", [["adrenal", "ANATOMY", 138, 145], ["COPD", "DISEASE", 70, 74], ["prednisone", "CHEMICAL", 97, 107], ["adrenal suppression", "DISEASE", 138, 157], ["prednisone", "CHEMICAL", 97, 107], ["prednisone", "SIMPLE_CHEMICAL", 97, 107], ["adrenal", "ORGAN", 138, 145], ["patients", "ORGANISM", 224, 232], ["glucocorticoid", "SIMPLE_CHEMICAL", 301, 315], ["patients", "SPECIES", 224, 232], ["Corticosteroids", "TREATMENT", 39, 54], ["Exacerbated COPD trial", "TREATMENT", 58, 80], ["prednisone", "TREATMENT", 97, 107], ["adrenal suppression", "PROBLEM", 138, 157], ["glucocorticoid exposure", "TREATMENT", 301, 324], ["Reduction", "OBSERVATION_MODIFIER", 15, 24], ["Exacerbated", "OBSERVATION_MODIFIER", 58, 69], ["COPD", "OBSERVATION", 70, 74], ["adrenal", "ANATOMY", 138, 145]]], ["Similarly to the experimental literature (326, 327), critical care RCTs have shown that abrupt glucocorticoid discontinuation after a 3-to-14 days treatment was rapidly followed by a reconstituted inflammatory response with a clinical relapse in approximately one-third of the patients (233, 322, 328, 329), and increased mortality (329).", [["glucocorticoid", "SIMPLE_CHEMICAL", 95, 109], ["patients", "ORGANISM", 277, 285], ["patients", "SPECIES", 277, 285], ["abrupt glucocorticoid discontinuation", "TREATMENT", 88, 125], ["a reconstituted inflammatory response", "PROBLEM", 181, 218], ["abrupt", "OBSERVATION_MODIFIER", 88, 94], ["glucocorticoid discontinuation", "OBSERVATION", 95, 125], ["inflammatory", "OBSERVATION_MODIFIER", 197, 209], ["increased", "OBSERVATION_MODIFIER", 312, 321], ["mortality", "OBSERVATION_MODIFIER", 322, 331]]], ["In the LaSRS trial (329), discontinuation of study drug 48 h post-extubation was associated with clinical relapse in one-quarter of methylprednisolone-treated patients.", [["methylprednisolone", "CHEMICAL", 132, 150], ["methylprednisolone", "CHEMICAL", 132, 150], ["methylprednisolone", "SIMPLE_CHEMICAL", 132, 150], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 159, 167], ["clinical relapse", "PROBLEM", 97, 113], ["methylprednisolone", "TREATMENT", 132, 150]]], ["These patients were rapidly returned to mechanical ventilation (MV) without re-institution of study treatment, fared poorly, required additional days of MV and had a 9-fold increased risk of 60-day mortality (p = 0.001) in comparison to patients that did not return to MV (330).", [["patients", "ORGANISM", 6, 14], ["patients", "ORGANISM", 237, 245], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 237, 245], ["MV", "SPECIES", 64, 66], ["MV", "SPECIES", 153, 155], ["MV", "SPECIES", 269, 271], ["mechanical ventilation", "TREATMENT", 40, 62], ["study treatment", "TREATMENT", 94, 109], ["MV", "TREATMENT", 153, 155], ["MV", "TEST", 269, 271], ["mechanical ventilation", "OBSERVATION", 40, 62]]], ["Gradual tapering is necessary to preserve the disease improvement achieved during glucocorticoid administration, to sustain continuous resolution and restoration of tissue homeostasis, to achieve gradual recovery of the suppressed HPA axis, to forestall disease relapse from reconstituted systemic inflammation, and finally to comply with the Food and Drug Administration package insert warnings (Reference ID: 3032293) (331).Conclusions and Implications for Glucocorticoid TreatmentWith rapidly expanding knowledge, appreciation of how homeostatic corrections work and how they evolved provides a conceptual framework to understand and appreciate the complex pathobiology of critical illness.", [["tissue", "ANATOMY", 165, 171], ["systemic inflammation", "DISEASE", 289, 310], ["glucocorticoid", "SIMPLE_CHEMICAL", 82, 96], ["tissue", "TISSUE", 165, 171], ["Gradual tapering", "TREATMENT", 0, 16], ["the disease", "PROBLEM", 42, 53], ["glucocorticoid administration", "TREATMENT", 82, 111], ["tissue homeostasis", "PROBLEM", 165, 183], ["the suppressed HPA axis", "PROBLEM", 216, 239], ["forestall disease relapse", "PROBLEM", 244, 269], ["reconstituted systemic inflammation", "PROBLEM", 275, 310], ["Glucocorticoid TreatmentWith", "TREATMENT", 459, 487], ["tapering", "OBSERVATION_MODIFIER", 8, 16], ["disease", "OBSERVATION", 46, 53], ["tissue homeostasis", "OBSERVATION", 165, 183], ["systemic", "OBSERVATION_MODIFIER", 289, 297], ["inflammation", "OBSERVATION", 298, 310]]], ["We have reviewed emerging literature clearly placing the activated GR\u03b1 at the center of the homeostatic corrections in the general adaptation to critical illness.", [["GR\u03b1", "GENE_OR_GENE_PRODUCT", 67, 70], ["GR\u03b1", "PROTEIN", 67, 70], ["homeostatic corrections", "OBSERVATION", 92, 115], ["illness", "OBSERVATION", 154, 161]]], ["Future research directions should include a reassessment of the pharmacological principles that guide glucocorticoid treatment in critical illness and to devise co-interventions to improve cellular responsiveness to glucocorticoids by correcting conditions associated with a reduction in GR\u03b1 and mitochondrial concentration and function.Search MethodologyIn addition to the previously used sources (17), we searched the Google Scholar and PubMed databases, employing the following keywords: \u201cglucocorticoid,\u201d \u201ccorticosteroid,\u201d \u201cglucocorticoid receptor,\u201d \u201cstress response,\u201d \u201cacute phase response,\u201d \u201cregulation,\u201d \u201cresolution,\u201d \u201ccritical illness related corticosteroid insufficiency,\u201d \u201ctreatment,\u201d \u201csystemic inflammation,\u201d \u201cdysregulated\u201d systemic inflammation,\u201d \u201cnuclear factor kappa B,\u201d \u201cevolution,\u201d \u201cendothelium,\u201d \u201cmitochondria,\u201d \u201creactive oxygen species,\u201d ascorbic acid, thiamine, vitamin D, melatonin, \u201cacute,\u201d \u201clong-term,\u201d chronic,\u201d \u201chomeostasis,\u201d \u201callostasis,\u201d \u201ccacostasis,\u201d and terms related to critical illness, sepsis, septic shock, acute respiratory distress syndrome, \u201ccardiac events.\u201d", [["cellular", "ANATOMY", 189, 197], ["mitochondrial", "ANATOMY", 296, 309], ["endothelium", "ANATOMY", 799, 810], ["mitochondria", "ANATOMY", 814, 826], ["respiratory", "ANATOMY", 1045, 1056], ["cardiac", "ANATOMY", 1077, 1084], ["glucocorticoids", "CHEMICAL", 216, 231], ["illness", "DISEASE", 635, 642], ["corticosteroid insufficiency", "DISEASE", 651, 679], ["inflammation", "DISEASE", 705, 717], ["inflammation", "DISEASE", 744, 756], ["oxygen", "CHEMICAL", 839, 845], ["ascorbic acid", "CHEMICAL", 856, 869], ["thiamine", "CHEMICAL", 871, 879], ["vitamin D", "CHEMICAL", 881, 890], ["melatonin", "CHEMICAL", 892, 901], ["cacostasis", "DISEASE", 965, 975], ["critical illness", "DISEASE", 999, 1015], ["sepsis", "DISEASE", 1017, 1023], ["septic shock", "DISEASE", 1025, 1037], ["acute respiratory distress syndrome", "DISEASE", 1039, 1074], ["oxygen", "CHEMICAL", 839, 845], ["ascorbic acid", "CHEMICAL", 856, 869], ["thiamine", "CHEMICAL", 871, 879], ["vitamin D", "CHEMICAL", 881, 890], ["melatonin", "CHEMICAL", 892, 901], ["glucocorticoid", "SIMPLE_CHEMICAL", 102, 116], ["cellular", "CELL", 189, 197], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 288, 291], ["mitochondrial", "CELLULAR_COMPONENT", 296, 309], ["glucocorticoid", "SIMPLE_CHEMICAL", 492, 506], ["corticosteroid", "SIMPLE_CHEMICAL", 510, 524], ["factor kappa B", "GENE_OR_GENE_PRODUCT", 768, 782], ["endothelium", "TISSUE", 799, 810], ["mitochondria", "CELLULAR_COMPONENT", 814, 826], ["reactive oxygen species", "SIMPLE_CHEMICAL", 830, 853], ["ascorbic acid", "SIMPLE_CHEMICAL", 856, 869], ["thiamine", "SIMPLE_CHEMICAL", 871, 879], ["vitamin D", "SIMPLE_CHEMICAL", 881, 890], ["melatonin", "SIMPLE_CHEMICAL", 892, 901], ["cardiac", "ORGAN", 1077, 1084], ["GR\u03b1", "PROTEIN", 288, 291], ["glucocorticoid receptor", "PROTEIN", 528, 551], ["a reassessment", "TEST", 42, 56], ["the pharmacological principles", "TREATMENT", 60, 90], ["glucocorticoid treatment", "TREATMENT", 102, 126], ["critical illness", "PROBLEM", 130, 146], ["co-interventions", "TREATMENT", 161, 177], ["glucocorticoids", "TREATMENT", 216, 231], ["correcting conditions", "PROBLEM", 235, 256], ["a reduction in GR\u03b1", "TREATMENT", 273, 291], ["glucocorticoid", "TREATMENT", 492, 506], ["corticosteroid", "TREATMENT", 510, 524], ["glucocorticoid receptor", "TREATMENT", 528, 551], ["acute phase response", "PROBLEM", 574, 594], ["critical illness", "PROBLEM", 626, 642], ["corticosteroid insufficiency", "PROBLEM", 651, 679], ["treatment", "TREATMENT", 683, 692], ["systemic inflammation", "PROBLEM", 696, 717], ["systemic inflammation", "PROBLEM", 735, 756], ["mitochondria", "PROBLEM", 814, 826], ["reactive oxygen species", "TREATMENT", 830, 853], ["ascorbic acid", "TREATMENT", 856, 869], ["thiamine", "TREATMENT", 871, 879], ["vitamin D", "TREATMENT", 881, 890], ["melatonin", "TREATMENT", 892, 901], ["allostasis", "PROBLEM", 951, 961], ["cacostasis", "PROBLEM", 965, 975], ["critical illness", "PROBLEM", 999, 1015], ["sepsis", "PROBLEM", 1017, 1023], ["septic shock", "PROBLEM", 1025, 1037], ["acute respiratory distress syndrome", "PROBLEM", 1039, 1074], ["\u201ccardiac events", "PROBLEM", 1076, 1091], ["mitochondrial concentration", "OBSERVATION", 296, 323], ["corticosteroid insufficiency", "OBSERVATION", 651, 679], ["systemic", "ANATOMY", 696, 704], ["inflammation", "OBSERVATION", 705, 717], ["systemic", "ANATOMY", 735, 743], ["inflammation", "OBSERVATION", 744, 756], ["reactive", "OBSERVATION_MODIFIER", 830, 838], ["oxygen species", "OBSERVATION", 839, 853], ["acute", "OBSERVATION_MODIFIER", 904, 909], ["chronic", "OBSERVATION_MODIFIER", 925, 932], ["sepsis", "OBSERVATION", 1017, 1023], ["septic shock", "OBSERVATION", 1025, 1037], ["acute", "OBSERVATION_MODIFIER", 1039, 1044], ["respiratory distress", "OBSERVATION", 1045, 1065]]], ["Manual searching of articles, including reference lists of cited publications, was also performed to avoid omissions.Author ContributionsGM conceived and initiated the article and wrote the original draft.", [["GM", "CHEMICAL", 137, 139]]]]}